0001213900-24-07986110-K Pluri Inc. 2024091820240918160035160036160036 0 0001213900-24-079861 10-K 80 20240630 20240918 20240918 Pluri Inc. 0001158780 2836 980351734 NV 0630 10-K 34 001-31392 241307399 MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 972-74-710-7171 MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 PLURISTEM THERAPEUTICS INC 20071228 PLURISTEM LIFE SYSTEMS INC 20030701 AI SOFTWARE INC 20010906 10-K 1 ea0213910-10k_pluriinc.htm ANNUAL REPORT Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-K Â (Mark One) â˜Â ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the fiscal year endedÂ June 30, 2024 Â â˜Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period fromÂ [Â] toÂ [Â] Â Commission file numberÂ 001-31392 Â PLURI INC. (Exact name of registrant as specified in its charter) Â Nevada Â 98-0351734 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â MATAM Advanced Technology Park, Building No. 5, Haifa, Israel Â 3508409 (Address of principal executive offices) Â (Zip Code) Â Registrantâ€™s telephone numberÂ 011-972-74-7108600 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol Â Name of each exchange on which registered Common Shares, par value $0.00001 Â PLUR Â The Nasdaq Capital Market Â Securities registered pursuant to Section 12(g) of the Act: Â None. (Title of class) Â Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in RuleÂ 405 of the Securities Act.Â YesÂ â˜Â NoÂ â˜Â Â Indicate by check mark if the registrant is not required to file reports pursuant to SectionÂ 13 or SectionÂ 15(d) of the Act.Â YesÂ â˜Â NoÂ â˜Â Â Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days. YesÂ â˜Â NoÂ â˜Â Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of RegulationÂ S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files).Â â˜Â YesÂ â˜Â No Â Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filerâ€, â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜Â Non-accelerated filer â˜Â Smaller reporting companyÂ â˜Â Emerging growth company â˜ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â â˜ Â Indicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. â˜ Â If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.Â â˜ Â Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§240.10D-1(b). â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Act).Â Â YesÂ â˜Â NoÂ â˜Â Â State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked prices of such common equity, as of the last business day of the registrantâ€™s most recently completed second fiscal quarter. Â $22,856,362 Â Indicate the number of shares outstanding of each of the registrantâ€™s classes of common shares, as of the latest practicable date. Â 5,470,163 as of September 13, 2024 Â DOCUMENTS INCORPORATED BY REFERENCE Â None. Â Â Â Â Â Â Â TABLE OF CONTENTS Â Â Â Â Page Â Â Â Â PART I Â Â 1 Â Â Â Â Item 1. Business Â 1 Â Â Â Â Item 1A. Risk Factors Â 16 Â Â Â Â Item 1B. Unresolved Staff Comments Â 33 Â Â Â Â Item 1C. Cybersecurity Â 34 Â Â Â Â Item 2. Properties Â 35 Â Â Â Â Item 3. Legal Proceedings Â 35 Â Â Â Â Item 4. Mine Safety Disclosures Â 35 Â Â Â Â PART II Â Â 36 Â Â Â Â Item 5. Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Â 36 Â Â Â Â Item 6. [Reserved] Â 36 Â Â Â Â Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 36 Â Â Â Â Item 7A. Quantitative and Qualitative Disclosures About Market Risk Â 43 Â Â Â Â Item 8. Financial Statements and Supplementary Data Â F-1 Â Â Â Â Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure Â 44 Â Â Â Â Item 9A. Controls and Procedures Â 44 Â Â Â Â Item 9B. Other Information Â 44 Â Â Â Â Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Â 44 Â Â Â Â PART III Â Â 45 Â Â Â Â Item 10. Directors, Executive Officers and Corporate Governance Â 45 Â Â Â Â Item 11. Executive Compensation Â 50 Â Â Â Â Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Â 55 Â Â Â Â Item 13. Certain Relationships and Related Transactions and Director Independence Â 57 Â Â Â Â Item 14. Principal Accounting Fees and Services Â 57 Â Â Â Â PART IV Â 58 Â Â Â Â Item 15. Exhibits and Financial Statement Schedules Â 58 Â Â Â Â Item 16. Form 10-K Summary Â 60 Â i Â Â Our financial statements are stated in thousands United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles, or U.S. GAAP. Â In this annual report, unless otherwise specified, all dollar, amounts are expressed in U.S. dollars. Â As used in this annual report, the terms â€œweâ€, â€œusâ€, â€œourâ€, the â€œCompanyâ€, and â€œPluriâ€ mean Pluri Inc., our wholly owned Israeli subsidiary, our majority owned Israeli subsidiary, and the wholly owned subsidiary of our Israeli subsidiary in Germany, unless otherwise indicated or required by the context. Â All information in this Annual Report on Form 10-K or Annual Report, relating to shares or price per share reflects the 1-for-8 reverse stock split effected by us on April 1, 2024. Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â The statements contained in this Annual Report on Form 10-K, or Annual Report, that are not historical facts are â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as â€œbelieves,â€ â€œintends,â€ â€œplans,â€ â€œexpects,â€ â€œmay,â€ â€œwill,â€ â€œshould,â€ or â€œanticipatesâ€ or the negative thereof or other variations thereon or comparable terminology, and similar expressions are intended to identify forward-looking statements. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements, or industry results, to be materially different from any future results, performance, levels of activity, or our achievements, or industry results, expressed or implied by such forward-looking statements. Such forward-looking statements appear in Item 1 â€“ â€œBusinessâ€ and Item 7 â€“ â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ (especially in the section titled â€œOutlookâ€) as well as elsewhere in this Annual Report and include, among other statements, statements regarding the following: Â Â â— the expected development, time-to-market and potential benefits from our products and ventures, based on our cell-based technology platform in regenerative medicine, immunotherapy, food technology, or food tech, agriculture technology, or agtech, and the recently launched Contract Development and Manufacturing Organization, or CDMO, business, as well as potentially in other industries and verticals that have a need for our mass scale and cost-effective cell expansion platform; Â Â â— our expectations of market and industry growth; Â â—the prospects of entering into additional license agreements, joint ventures, partnerships or other forms of cooperation with other companies, governments institutes, research organizations and medical institutions; our ability to attract clients for our CDMO business; Â Â â— our pre-clinical and clinical study plans, including timing of initiation, expansion, enrollment, results, and conclusion of trials; Â Â â— achieving regulatory approvals; Â Â â— receipt of future funding from the Israel Innovation Authority, or IIA, the European Unionâ€™s HorizonÂ programs, the National Institutes of Health, or NIH, as well as grants from other independent third parties; Â â—the capabilities of our placenta expanded, or PLX, cells, including future collaborations to further advance the development of our PLX- PAD and PLX-R18 cell therapy as a potential novel treatment; Â â—the expected clinical development of a new allogeneic Placental Mucosal Associated Invariant T, or MAIT, and the potential benefits it can produce for advanced cell-based therapies for immune disorders and neurodegenerative diseases; Â Â â— our expectation to solve medicineâ€™s unmet needs and demonstrate a real-world impact and value from our pipeline, technology platform and commercial-scale manufacturing capacity; Â Â â— the possible impacts of cybersecurity incidents on our business and operations; Â Â â— our expectations regarding our short- and long-term capital requirements; Â Â â— our outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses; Â Â â— information with respect to any other plans and strategies for our business; and Â Â â— general market, political and economic conditions in the countries in which we operate including those related to recent unrest in the Middle East and armed conflict between Israel and Hamas, Hezbollah and other terrorist organizations. Â The factors discussed herein, including those risks described in Item 1A. â€œRisk Factorsâ€, and expressed from time to time in our filings with the Securities and Exchange Commission, or SEC, could cause actual results and developments to be materially different from those expressed in or implied by such statements. In addition, historic results of scientific research, clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions. Also, historic results referred to in this Annual Report would be interpreted differently in light of additional research, clinical and preclinical trials results. The forward-looking statements are made only as of the date of this filing, and except as required by law we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Â ii Â Â PART I Â ITEMÂ 1. BUSINESS. Â Overview Â We are a biotechnology company with an advanced cell-based technology platform. We have developed a unique three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. We are utilizing our technology in the field of regenerative medicine, immunotherapy, food tech, CDMO, and agtech and plan to utilize it in industries and verticals that have a need for our mass scale and cost-effective cell expansion platform via partnerships, joint ventures, licensing agreements and other types of collaborations. Â Our operations are focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries. Â We were incorporated in Nevada on May 11, 2001. Pluri Inc. has a wholly owned subsidiary, Pluri Biotech Ltd., or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned subsidiary, Pluristem GmbH, which is incorporated under the laws of Germany, or the German Subsidiary. Â In November 2021, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods, which is incorporated under the laws of the State of Israel. The Subsidiary holds approximately 69% of Ever After Foods issued and outstanding shares on a fully diluted basis. Â In March 2024 the Subsidiary established a wholly owned subsidiary, Coffeesai Ltd., or Coffeesai, which is incorporated under the laws of the State of Israel. Â Cell Therapy Â We use our advanced cell-based technology platform in the field of regenerative medicine to develop placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, hematologic conditions and, most recently, we have also launched a novel immunotherapy platform. Â PLX cells: Our PLX cells are adherent stromal cells that are expanded using our 3D platform.Â Our PLX cells can be administered to patients off-the-shelf, without blood or tissue matching or additional manipulation prior to administration. PLX cells are believed to release a range of therapeutic proteins in response to the patientâ€™s condition. Â In the pharmaceutical area, we have focused on several indications utilizing our product candidates, including, but not limited to, muscle recovery following surgery for hip fracture, incomplete recovery following bone marrow transplantation, critical limb ischemia, or CLI, Chronic Graft versus Host Disease and a potential treatment for Hematopoietic Acute Radiation Syndrome, or H-ARS. Some of these studies have been completed while others are still ongoing. We believe that each of these indications is a severe unmet medical need. Â In July 2023, we announced that we signed a three-year $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases, or NIAID, which is part of the NIH. Under such contract, we will collaborate with the U.S. Department of Defenseâ€™s Armed Forces Radiobiology Research Institute, or AFRRI, and the Uniformed Services University of Health Sciences, or USUHS, in Maryland, U.S.A., to further advance the development of our PLX-R18 cell therapy as a potential novel treatment for H-ARS, a deadly disease that can result from nuclear disasters and radiation exposure. Â Immunotherapy MAIT cells: In May 2024, we launched a novel allogenic immunotherapy platform utilizing MAIT cells specifically designed to address solid tumors â€“ a critical area in medicine where effective treatments are currently insufficient. We believe that our MAIT cells, isolated from the human placenta, offer substantial potential benefits compared to conventional T cells. Â 1 Â Â Placental MAIT cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional autologous T cells typically collected from peripheral blood, our MAIT cells are designed to be allogenic universal product. Benefiting with very restricted T-cell receptor, or TCR, the MAIT cells minimize their likelihood of inducing Graft versus Host Disease, or GvHD, a significant advantage over other potential allogeneic products. We are aiming to design the MAIT to potentially show better persistence in the body for a longer duration, enhancing their therapeutic efficacy. Â In April 2024, we unveiled a novel method for expansion of immune cells using proprietary technology and announced we were granted a new U.S. patent titled, â€œSystem and Methods for Immune Cells Expansion and Activation in Large Scale.â€ This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. Â PluriCDMOâ„¢ Â In January 2024,Â we launched a new business division offering cell therapy manufacturing services as a CDMO: PluriCDMOâ„¢. PluriCDMOâ„¢ offers CDMO services to companies from early preclinical development, through late-stage clinical trials and commercialization, with a mission to deliver high-quality, essential therapies to patients. We have signed several agreements with clients and are currently generating revenues from PluriCDMOâ„¢. Â AgTech Â We are actively involved in several initiatives leveraged by Pluriâ€™s 3D cell expansion in the agtech field, such as: (a) cell-based coffee business activity through our PluriAgtech business vertical, which is incorporated into our wholly owned subsidiary, Coffeesai (b) an innovative proof-of-concept, or POC, collaboration with ICL Group Ltd., or ICL Group, a leading global specialty minerals company, to revolutionize bio stimulant delivery and enhance yield sustainably, and (c) a strategic POC agreement with a leading international agriculture corporation which is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture. Â In March 2024, we announced an important expansion to our intellectual property, or IP portfolio with a new patent approval from the Israel Patent Office, that is designed to reshape the agricultural technology landscape. The patent represents a major breakthrough in our proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. Â Food Tech Â In 2022, we announced the establishment of a joint venture with Tnuva, Ever After Foods, (previously Plurinuva Ltd.), which is incorporated under the laws of the State of Israel, with the purpose of developing cultivated meat product of all kinds and types. Â Leveraging Pluriâ€™s innovative technology, Ever After Foods has rapidly advanced its scalable production platform, developing a business-to-business, or B2B, version of its proprietary technology system, Ever After Foods has demonstrated the natural production of muscle and fat tissues for various animal cells, ensuring taste, feel, and texture akin to conventional animal-derived meat. Â In June 2024, we entered into a share purchase agreement, or the Agreement, by and among Ever After Foods, Tnuva, and certain other international strategic investors, or, collectively, the Investors, pursuant to which Ever After Foods issued and sold, ordinary shares in a private placement offering, or the Offering, for aggregate gross proceeds of $10 million. As part of the Offering, we invested $1.25 million. In addition, the Subsidiary and Ever After Foods executed anÂ Amended and Restated Technology License Agreement, dated June 12, 2024, or the Amended License. The Amended License amended theÂ partiesâ€™ existing license agreement dated as of February 23, 2022, to expand the scope of the license to include fish and seafood.Â Â The $10 million funding round is intended to support Ever After Foodsâ€™ B2B technology platform, positioning it as a sustainable technology enabler. Following the closing of the Offering, the Subsidiary holds approximately 69% of Ever After Foods. Â 2 Â Â Scientific Background â€“ Cell Therapy Â Cell therapy is an established field within the regenerative medicine area. The characteristics and properties of cells vary as a function of tissue source and growth conditions. The human placenta, the source of our PLX and MAIT cells, provides a unique reservoir of stromal and immune cells representing a groundbreaking approach in the field of cell therapy. Â PLX, cells are placenta-derived, mesenchymal-like adherent stromal cells that are expanded ex vivo. The diverse factors released by PLX cells indicate their potential therapeutic use across a range of ischemic, inflammatory, autoimmune and hematological conditions. Placental MAIT cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional autologous T cells typically collected from peripheral blood, our MAIT cells are designed to be allogenic universal product. Benefiting with very restricted TCR, the MAIT cells minimizes their likelihood of inducing GvHD, a significant advantage over other potential allogeneic products. We are designing the MAIT to potentially show better persistence in the body for a longer duration, enhancing their therapeutic efficacy. Â Our Technology Â Our

technology platform, a patented and validated state-of-the-art 3D cell expansion system, aims to advance novel cell-based solutions for a range of industries, including, but not limited to pharmaceuticals, foodtech, agtech, and CDMO. Our method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Our technology is currently being implemented in the fields of regenerative medicine, food tech, agtech and CDMO. Â Our system utilizes a synthetic scaffold to create a 3D environment where adherent or non-adherent cells can grow in a tissue like environment. Our automated proprietary 3D, GMP, approved process enables the large-scale monitored and controlled production of reproducible, high quality cell products and in mass quantities. Additionally, our current manufacturing process, which has scaled up over the years, has demonstrated batch-to-batch consistency, an important manufacturing challenge for biological products. Â We developed a new cell manufacturing process for industrial scale cell manufacturing called PluriMatrix, which is built upon our 3D cell expansion technology platform, scaling high-quality cell production. Â We aim to establish partnerships that leverage our 3D cell-based technology to additional industries that require effective, mass cell production and will enable us to accelerate the time-to-market of our products. Â Product Candidates - Pluri Health Â PLX-PAD Â PLX-PAD is composed of maternal mesenchymal stromal cell, or MSC, like cells originating from the placenta. Â PLX-R18 Â PLX-R18 is composed of fetal MSC like cells originating from the placenta. Â Allogeneic MAIT Cell Therapy Platform Â MAIT cells are a distinct type of unconventional immune T cells. Their unique characteristics, including robust cytotoxic activity and low alloreactivity profile, make them promising candidates for engineering and subsequent use in the treatment of solid tumors in the setting of allogeneic adoptive cell therapy. Â Â We believe that leveraging the placenta as a unique source of cells, combined with our cutting-edge research, development and established high-quality manufacturing capabilities, will serve as the driving force towards the successful development of a broader range of cell therapy products and applications. Â 3 Â Â Our Clinical Development Product Candidates Â Both PLX-PAD and PLX-R18 products were tested in clinical studies. Studies were conducted in the United States, Europe and Israel Â PLX-PAD was tested as a treatment for several indications: acute muscle injuries following hip fracture, acute respiratory distress syndrome, or ARDS, due to Coronavirus Disease, or COVID-19, GvHD, and peripheral artery disease, or PAD, including intermittent claudication, or IC, and critical limb ischemia, or CLI. All clinical studies were completed. Â In addition, PLX-PAD is being developed for the treatment of mild to moderate knee osteoarthritis as part of the PROTO program, (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by CharitÃ© Berlin Institute of Health Center for Regenerative Therapies. This clinical study will be carried out by CharitÃ© and is pending regulatory approval. Â PLX-R18 was tested in a Phase I trial for treatment of patients with incomplete recovery following hematopoietic cell transplantation, or HCT, in the United States and Israel. Â In addition, PLX-R18 is being developed under the FDAâ€™s Animal Rule regulatory pathway for Acute Radiation Syndrome, or ARS. Â Â ARS On July 11, 2023, we signed a three-year $4.2 million contract with the NIAID, which is part of the NIH. Pluri will collaborate with the U.S. Department of Defenseâ€™s, or DoDâ€™s, AFRRI, and the USUHS, to further advance the development of its PLX-R18 cell therapy as a potential novel treatment for H-ARS. H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure. On June 6, 2024, NIAID exercised its option for year two of the three-year $4.2 million contract. Â Prior to signing the contract with NIAID, we conducted several animal studies for the evaluation of PLX-R18 for the treatment of ARS, in collaboration with NIAID and DoD Armed Forces Radiobiology Research Institute, part of the USUHS. Â 4 Â Â Regulatory and Clinical Affairs Strategy Â Our cell therapy development strategy is to hold open and frequent discussions with regulators at all stages of development from preclinical studies to more advanced regulatory stages. We utilize this strategy in working with the FDA, the EMA, Germanyâ€™s PEI as well as other European national competent authorities, the Minister of Health, or MOH, Japanâ€™s Pharmaceuticals and Medical Devices Agency, or PMDA, and also the Ministry of Food and Drug Safety, or MFDS, of South Korea. Â Our Activities in the Food Tech Sector - Ever After Foods Â Ever After Foods is engaged in the development and commercialization innovative cultivated meat products. It leverages proprietary technology and expertise to create sustainable, high-quality meat alternatives. Â Ever After Foodsâ€™ Key Operations: Â â—¾Research and Development: Ever After Foods is committed to advancing cultivated meat technology. Its R&D efforts focus on: Â -Optimizing bioreactor processes for efficient production. Â -Enhancing the taste, texture, and nutritional value of cultivated meat products. Â â—¾Product Development: It is dedicated to creating a diverse range of bioreactors with specialized scaffolds for cultivated meat production, emphasizing efficient and sustainable production processes. Â â—¾Partnerships and Collaborations: It collaborates with industry leaders, gaining access to valuable expertise, resources, and market channels through these strategic partnerships. Â By combining cutting-edge technology, a talented team, and strategic partnerships, we believe that Ever After Foods is poised to revolutionize the food industry and offer consumers a sustainable and delicious alternative to traditional meat. Â Our Activities in the Ag-tech Sector Â In January 2024, we announced the launch of our cell-based coffee business activity through a new business vertical, PluriAgtech, leveraging Pluriâ€™s 3D cell expansion and addressing the ongoing global demand for sustainable, high-quality coffee at mass scale production. Â We signed an innovative POC collaboration with ICL Group, a leading global specialty minerals company, to revolutionize bio stimulant delivery and enhance yield sustainably. Â In March 2024, we announced an important expansion to our IP portfolio with a new patent approval from the Israel Patent Office, that is designed to reshape the agricultural technology landscape and enables efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. Â In July 2024, we announced a â‚¬1 Million POC agreement to enhance global sustainable vegetable supply with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture. Â 5 Â Â Intellectual Property Â We understand that our success will depend, in part, on maintaining our IP, and therefore we are committed to protecting our technology and product candidates with patents and other methods described below. Â We are the sole owner of 142 issued patents and approximately 55 pending patent applications in the United States, Europe, China, Japan and Israel, as well as in additional countries worldwide, including countries in the Far East and South America (in calculating the number of issued patents, each European patent validated in multiple jurisdictions was counted as a single patent). Â Based on the well-established understanding that the characteristics and therapeutic potential of a cell product are largely determined by the source of the cells and by the methods and conditions used during their culturing, our patent portfolio includes different types of claims that protect the various unique aspects of our technology. Â Â Our multi-national portfolio of patent and patent applications includes the following claims: Â Â â— our proprietary 3D cell expansion methods forÂ adherent cells including placental stromal cells plant cells, and plant cells; Â Â â— our proprietary 3D cell expansion methods for cells in suspension including immune cells; Â Â â— composition of matter claims covering the cells; Â Â â— the therapeutic and cosmetic use of PLX cells for the treatment of a variety of conditions; and Â Â â— cell-culture, harvest, thawing and formulation devices, cell therapy for a diverse array of diseases utilizing engineered MAIT cells derived from the placenta. Â Through our experience with the development of adherent stromal cell-based products, we have gained expertise and know-how in this field and have established procedures for manufacturing clinical-grade PLX cells in our facilities. Building on this foundation, we have expanded our expertise to include the procedures for handling and expansion of cells in suspension including immune cells, broadening our capabilities in cellular therapies. Certain aspects of our manufacturing process are covered by patents and patent applications. In addition, specific aspects of our technology are retained as know-how and trade secrets that are protected by our confidentiality agreements with our employees, consultants, contractors, manufacturers and advisors. These agreements generally provide for protection of confidential information, restrictions on the use of materials, and obligations to assign to us inventions created during the course of performing services for us. Â The following table sets forth our key patents and patent applications and is not intended to represent an assessment of claims, limitations or scope. In some cases, a jurisdiction is listed as both pending and granted for a single patent family. This is due to pending continuation or divisional applications of the granted case. Â The expiration dates of these patents, based on filing dates, range from 2027 to 2043. Actual expiration dates will be determined according to extensions received based on the Drug Price Competition and Patent Term Restoration Act of 1984 (P.L. 98-417), commonly known as the â€œHatch-Waxmanâ€ Act, which permits extensions of pharmaceutical patents to reflect regulatory delays encountered in obtaining FDA market approval. The Hatch-Waxman Act is based on a U.S. federal law and therefore only relevant to U.S. patents. Â There is a risk that our patents will be invalidated, and that our pending patent applications will not result in issued patents. We also cannot be certain that we will not infringe on any patents that may be issued to others. See â€œRisk Factors â€" The patent approval process is complex, and we cannot be sure that our pending patent applications or future patent applications will be approved.â€ Â 6 Â Â Our Patent Portfolio Â Patent Name/ Int. App. No. Â Pending Jurisdictions Â Granted Jurisdictions Â Expiry Date METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY PCT/IL2007/000380 Â Â Â Australia, Canada, China, Hong Kong, Europe (Spain, Germany, France, Belgium, Switzerland, Czech Republic, Hungary, Ireland, Italy, The Netherlands), Israel, India, Japan, South Korea, Mexico, Russia, Singapore Â March 23, 2027 ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY PCT/IL2008/001185 Â United States Â Brazil, Canada, China, Europe (Belgium, Austria, Spain, Germany, Switzerland, France, Ireland, Italy, the Netherlands), Hong Kong, Israel, India, Japan, Mexico, Russia, United States, South Korea Â September 2, 2028 METHODS OF TREATING INFLAMMATORY COLON DISEASES PCT/IL2009/000527 Â Â Â United States, Israel, Russia Â May 26, 2029 METHODS OF SELECTION OF CELLS FOR TRANSPLANTATION PCT/IL2009/000844 Â Â Â Europe (Switzerland, Germany, France, United Kingdom), Israel Â September 1, 2029 ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY PCT/IL2009/000846 Â Â Â Australia, Canada, China, Europe (Switzerland, Germany, France, United Kingdom, Italy), Hong Kong, Israel, India, Mexico, Singapore, United States Â September 1, 2029 ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY PCT/IL2009/000845 Â Â Â United States, Europe (Switzerland, Germany, France, United Kingdom), Israel Â September 1, 2029 ADHERENT STROMAL CELLS DERIVED FROM PLANCENTAS OF MULTIPLE DONORS AND USES THEREOF PCT/IB2011/001413 Â Â Â Israel Â April 21, 2031 ADHERENT CELLS FROM PLACENTA AND USE OF SAME IN DISEASE TREATMENT PCT/IB2010/003219 Â United States, Israel Â Australia, Canada, China, Hong Kong, Europe (Switzerland, Germany, Spain, France, United Kingdom, Italy, Belgium, Ireland, The Netherlands), Israel, Mexico, New Zealand, United States Â November 29, 2030 METHODS AND SYSTEMS FOR HARVESTING ADHERENT STROMAL CELLS PCT/IB2012/000933 Â China, Israel Â Australia, Canada, Europe (Belgium, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Italy, The Netherlands), Israel, India, South Korea, Mexico, Singapore, United States Â April 15, 2032 METHODS FOR TREATING RADIATION OR CHEMICAL INJURY PCT/IB2012/000664 Â United States Â Europe (Belgium, Switzerland, Germany, France, United Kingdom, Ireland, The Netherlands), Hong Kong, Israel, Japan, South Korea, United States Â March 22, 2032 SKELETAL MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS PCT/EP2011/058730 Â Â Â United States, Europe (Belgium, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Italy, The Netherlands), Israel Â May 27, 2031 GENE AND PROTEIN EXPRESSION PROPERTIES OF ADHERENT STROMAL CELLS CULTURED INÂ 3D PCT/IB2014/059114 Â Â Â Israel, United States Â February 20, 2034 METHODS FOR PREVENTION AND TREATMENT OF PREECLAMPSIA PCT/IB2013/058186 Â Â Â Japan, Belgium, France, Italy, Switzerland, United Kingdom, Germany, China, Hong Kong Â August 31, 2033 METHOD AND DEVICE FOR THAWING BIOLOGICAL MATERIAL PCT/IB2013/059808 Â Â Â Australia, China, Europe (Belgium, Switzerland, Germany, Spain, France, United Kingdom, Italy, The Netherlands), Hong Kong, Israel, India, Japan, South Korea, Russia, Singapore, United States Â October 31, 2033 Â 7 Â Â SYSTEMS AND METHODS FOR GROWING AND HARVESTING CELLS PCT/IB2015/051559 Â Â Â Israel, United States Â March 3, 2035 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MUSCLE WASTING DISORDERS PCT/IB2015/059763 Â Â Â Israel, United States Â December 18, 2035 USE OF ADHERENT STROMAL CELLS FOR ENHANCING HEMATOPOIESIS IN A SUBJECT IN NEED THEREOF PCT/IB2016/051585 Â Â Â Israel, United States Â March 21, 2036 ALTERED ADHERENT STROMAL CELLS AND METHODS OF PRODUCING AND USING SAME PCT/IB2016/053310 Â Â Â United States Â June 6, 2036 METHODS AND COMPOSITIONS FOR TREATING CANCERS AND NEOPLASMS PCT/IB2017/050868 Â Canada Â Europe (Switzerland, Germany, France, United Kingdom), Japan, Israel Â February 16, 2037 METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS PCT/IB2018/052806 Â Israel Â Â Â April 23, 2038 METHODS AND COMPOSITIONS FOR TUMOR ASSESSMENT PCT/IB2018/050984 Â Â Â Israel Â February 18, 2038 METHODS AND COMPOSITIONS FOR TREATING ADDICTIONS PCT/IB2018/055473 Â Israel Â Â Â July 23, 2038 METHODS AND COMPOSITIONS FOR DETACHING ADHERENT CELLS Germany 10 2018 115 360.0 Â Germany Â Â Â June 25-July 3, 2038 METHODS AND COMPOSITIONS FOR PRODUCING CANNABINOIDS PCT/IL2020/050477 Â United States Â Â Â April 28, 2040 METHODS FOR EXPANDING ADHERENT STROMAL CELLS AND CELLS OBTAINED THEREBY PCT/IB2019/052569 Â Israel, Singapore, United States Â Â Â March 28, 2039 METHODS AND COMPOSITIONS FOR TREATING SUBJECTS EXPOSED TO VESICANTS AND OTHER CHEMICAL AGENTS PCT/IB2019/055074 Â Israel, United States, Singapore Â Â Â June 18, 2039 METHODS AND COMPOSITIONS FOR FORMULATING AND DISPENSING PHARMACEUTICAL FORMULATIONS PCT/IB2019/053115 Â United States Â Â Â United States: April 16, 2039 Israel: April 26, 2038 THERAPEUTIC DOSAGE REGIMENS COMPRISING ADHERENT STROMAL CELLS PCT/IB2019/054828 Â Israel, United States Â Â Â June 10, 2039 MODULAR BIOREACTOR PCT/IB2019/058429 Â Europe, Israel, Hong Kong, South Korea, Singapore, United States Â Â Â October 3, 2039 THERAPEUTIC METHODS AND COMPOSITIONS PCT/IB2019/059544 Â Israel, United States Â Â Â November 6, 2039 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND SEQUELAE THEREOF PCT/IL2021/050268 Â United States, Europe, Mexico Â Â Â March 11, 2040 METHODS AND COMPOSITIONS FOR AESTHETIC AND COSMETIC TREATMENT AND STIMULATING HAIR GROWTH PCT/IL2020/050363 Â United States Â Â Â March 26, 2040 Â 8 Â Â METHODS FOR EXPANDING ADHERENT STROMAL CELLS AND CELLS OBTAINED THEREBY IL277560 Â Israel Â Â Â September 23, 2040 METHODS AND COMPOSITIONS FOR ENRICHMENT OF TARGET CELLS PCT/IL2021/020514 Â United States, Israel Â Â Â May 5, 2041 PLACENTAL CELL TREATMENT FOR CRITICAL LIMB ISCHEMIA PATIENT SUBPOPULATIONS PCT/IL2022/050937 Â Patent Cooperation Treaty, or PCT, United States Â Â Â August 29, 2042 SYSTEM AND METHODS FOR IMMUNE CELLS EXPANSION AND ACTIVATION IN LARGE SCALE PCT/IL2023/050529 Â PCT, Israel, South Korea, United States Â Â Â May 23, 2043 A System For 3D Cultivation of Plant Cells And Methods Of Use 18/207,304 Â United States Â Â Â April 28, 2040 A SYSTEM FOR 3D CULTIVATION OF PLANT CELLS AND METHODS OF USE PCT/IL2024/050278 Â PCT, United States, Israel Â Â Â March 18, 2044 June 8, 2043 GENETICALLY ENGINEERED PLACENTAL MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF PCT/IL2024/050675 Â PCT United States Â Â Â July 9, 2044 GENETICALLY ENGINEERED PLACENTAL MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF PCT/IL2024/050670 Â PCT Â Â Â July 9, 2044 Â On January 8, 2022, we entered into a definitive license agreement with Takeda Pharmaceuticals International AG, or Takeda, a company based in Switzerland, which operates in the field of adipose-derived cells, pursuant to which we granted Takeda a global, non-exclusive license to use several of our patents (EP2591789 and EP3103463,), limited to adipose fat cells only, in the field of therapeutics, in exchange for Takeda ceasing its opposition with regards to said patents and paying us a lump sum of $200,000. The license covers methods for expanding adherent stromal cells and specified second medical uses. Â On January 10, 2022, we entered into a definitive license agreement with Novadip Biosciences, or Novadip, a company based in Belgium, which operates in the field of adipose-derived stem cells for cell therapy and cell-free therapy in respect of medical or cosmetic conditions, under which we granted Novadip a global, non-exclusive, royalty free license to use two of our patents (EP2591789, EP3103463), limited to non-placental cells and cell-derived therapies, sub-licensable only to Novadipâ€™s customers. Â On December 20, 2023,Â we entered into an agreement assigning the joint patent rights to develop Pluriâ€™s PLX cells in the treatment of cocaine addiction, toÂ BIRADâ€“Research & Development Company Ltd., or Birad, the commercial arm ofÂ Bar-IlanÂ University. Under the agreement, Bar-Ilan University via Birad will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction. Â 9 Â Â Ongoing Collaborations Â EIB Agreement Â In April 2020, we, the Subsidiary, and the German Subsidiary, together with the European Investment Bank, or EIB, executed a finance agreement, or the EIB Finance Agreement, for nonâ€“dilutive funding of up to â‚¬50 million in the aggregate, payable in three tranches. The proceeds from the EIB Finance Agreement were intended to support our research and development in Europe to further advance our regenerative cell therapy platform, and to bring the products in our pipeline to market. The term of the project was three years commencing on January 1, 2020. Â During June 2021, we received the first tranche in the amount of â‚¬20 million pursuant to the EIB Finance Agreement. The amount received is due to be repaid on June 1, 2026, and bears annual interest of 4% to be paid together with the principal of the loan. As of June 30, 2024, the interest accrued was in the amount of â‚¬2.465 million. In addition to the interest payable, the EIB is also entitled to royalty payments, pro-rated to the amount disbursed from the EIB loan, on our consolidated revenues beginning in the fiscal year 2024 up to and including its fiscal year 2030, in an amount equal to up to 2.3% of our consolidated revenues below $350 million, 1.2% of our consolidated revenues between $350 million and $500 million and 0.2% of our consolidated revenues exceeding $500 million. As of June 30, 2024, the royalty accrued was in the amount of â‚¬2,800. As the project term ended on December 31, 2022, we do not expect to receive additional funds pursuant to the EIB Finance Agreement. The EIB Finance Agreement contains certain limitations that we must adhere to such as the use of proceeds received from the EIB, the disposal of assets, substantive changes in the nature of our business, our potential execution of mergers and acquisitions, changes in our holding structure, distributions of future potential dividends and our engaging with

other banks and financing entities for other loans. Â CharitÃ© Agreement Â In July 2007, we entered into a five-year collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies at CharitÃ© â€“ University Medicine Berlin, or CharitÃ©, which was extended from time to time through June 2027. We and CharitÃ© are collaborating on a variety of indications utilizing PLX cells. According to the agreement, we will be the exclusive owner of the technology and any products produced as a result of the collaboration. CharitÃ© will receive between 1% to 2% royalties from net sales of new developments that have been achieved during the joint development. Â U.S. Department of Defense Â In August 2017, we announced that a pilot study of our PLX-R18 cell therapy was initiated by the DoD. The study examined the effectiveness of PLX-R18 as a treatment for ARS prior to, and within the first 24 hours of exposure to radiation. In July 2019, we presented positive results from a series of studies of our PLX-R18 cell therapy product conducted by the DoD. Â NIAID Agreement Â On July 11, 2023 we signed a three-year $4.2 million contract with the NIAID, which is part of the NIH. We will collaborate with the U.S. DoDâ€™s AFRRI and USUHS to further advance the development of its PLX-R18 cell therapy as a potential novel treatment for H-ARS. H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure. The period of performance of this contract was from July 1, 2023 through June 30, 2024, with an optional extension for an additional two year period. Â 10 Â Â On June 6, 2024 the NIAID exercised its option for year two of the three-year $4.2 million contract. During the 12 months period from July 1, 2024 through June 30, 2025, the NIAID will provide us with $1.4 million to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the H-ARS. Â If at any time during performance of this contract, the contracting officer determines, in consultation with the Office of Laboratory Animal Welfare, or OLAW, NIH, that we are not in compliance with any of the requirements and standards stated in the agreement, the contracting officer may immediately suspend, in whole or in part, work and further payments under this contract until we correct the noncompliance. If we fail to complete corrective action within the period of time designated in the contracting officerâ€™s written notice of suspension, the contracting officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part.Â Â Â Â Horizon Europe - PROTO Â On September 6, 2022, we announced that a â‚¬7.5 million non-dilutive grant from the European Union, or EUâ€™s, Horizon program has been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by CharitÃ© Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize our PLX-PAD cells for the treatment of mild to moderate knee osteoarthritis. Â The clinical study will be carried out by CharitÃ©. We, together with an international consortium under the leadership of Professor Tobias Winkler, Principal Investigator, at the Berlin Institute of Health Center of Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery will be carrying out the study. The initiation of the study is still pending regulatory approvals. Â ICL Group â€“ Open Innovation Â In October 2023, we signed a POC collaboration with ICL Group Open Innovation to pioneer advanced bioactive carriers and bio stimulants. This partnership aims to leverage natural delivery mechanisms within plants, boosting crop yields and fostering sustainability in agriculture. Â Wilk Technologies Â In May 2024, we announced a strategic collaboration with Wilk Technologies Ltd. a developer of authentic, cell cultured human and animal milk components, to develop cultured human breast and animal milk products, by using components of breast milk for a unique medical food intended for the elderly population on a commercial scale. We expect to harness the unique properties of breast milk cells as solutions for a rapidly growing elderly population. Â 11 Â Â Undisclosed - Leading international agriculture corporation Â In July 2024, we announced a â‚¬1 million POC agreement with a leading international agriculture corporation, or the POC Party, to enhance the global sustainable vegetable supply. This strategic POC agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture. The result of the planned collaboration has the potential to minimize environmental impact and foster greater food security, as well as to build a better agronomic and environmentally friendly infrastructure, bringing sustainable, high-quality solutions to the market. Pursuant to the agreement, the POC Party will provide its know-how and other IP rights related to vegetable products while the Company will provide its know-how and other IP rights related to its proprietary 3D cell expansion technology to develop a solution aimed to increase the global vegetable products supply. Â The POC Party will pay the Company in three installments, the first payable upon the effective date of the agreement, the second following completion of phase one of the POC and the POC Partyâ€™s written notification of its decision to move to the next step, and the final installment occurring upon the completion of phase two of the POC. The POC Party may terminate upon 14 daysâ€™ written notice following the end of either of the two phases of the POC. Â CRISPR-IL Â In June 2020, we announced that we were selected as a member of the CRISPR-IL consortium, a group funded by the IIA. CRISPR-IL brings together the leading experts in life science and computer science from academia, medicine, and industry, to develop Artificial Intelligence, or AI, based on end-to-end genome-editing solutions. These next-generation, multi-species genome editing products for human, plant, and animal DNA, have applications in the pharma, agriculture, and aquaculture industries. CRISPR-IL was funded by the IIA with a total budget of approximately $10,000,000 of which, an amount of approximately $480,000 was a direct grant allocated to us, for an initial period of 18 months, with a potential for extension of an additional 18 months, or the Second Period, with additional budget from the IIA. Â In October 2021, we received approval for an additional grant of approximately $583,000 from the IIA pursuant to the CRISPR-IL consortium program, for an additional period of eighteen months. Â The CRISPR-IL consortium program which ended on June 30, 2023, does not require us to pay royalties to the IIA. Â In-House Clinical Manufacturing Â We have the in-house capability to perform clinical cell manufacturing. Our state-of-the-art GMP grade manufacturing facility in Haifa has been in use since February 2013 for the main purpose of clinical grade, large-scale manufacturing. The facilityâ€™s new automated manufacturing process and products were approved for production of PLX-PAD for clinical use by the FDA, EMA, MFDS, PMDA and the MOH. Our second product, PLX-R18, was cleared by the FDA and the MOH for clinical use. Furthermore, the site was inspected and approved by a European Union qualified person (European accreditation body), approving that the site and production processes meet the current GMP for the purpose of manufacturing clinical grade products. Â The site was also inspected and approved for a phase 3 PLX-PAD trial by the MOH, and we received a GMP Certification and manufacturer-importer authorization for the site. Â Since 2024, our CDMO has been working with pharmaceutical and biotech companies to offer manufacturing and development services. Based on 15 years of experience in GMP manufacturing, our highly skilled team and utilizing our proprietary technologies and flexible 4400 square meter purpose-built facilities, PluriCDMOâ„¢ can offer comprehensive manufacturing support from preclinical development, through clinical trials to commercial supply. Â 12 Â Â In January 2024,Â we announced that we are offering cell therapy manufacturing services as a CDMO with the following key elements and services: Â Â â— Process development and optimization; Â Â Â Â â— Manufacturing from preclinical stages to commercial stages; and Â Â Â Â â— Analytical development and testing: We offer a comprehensive range of on-site analytical capabilities, including methods development to meet characterization requirements, gap assessment, method transfer, and validation. Additionally, we maintain well-established relationships with relevant audited vendors to further support our clientsâ€™ needs. Â Government Regulation â€“ Pharma Â The development, manufacturing, and future marketing of our cell therapy product candidates are subject to the laws and regulations of governmental authorities in the United States, Europe and Israel, as well as other countries in which our products may be marketed in the future like Japan, and South Korea. In addition, our manufacturing facility was inspected by the MOH. Â In the United States and the European Union, the FDA and the European Medicines Agency, or EMA, respectively, must approve products prior to marketing. Furthermore, various governmental statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage and record keeping related to such products and their marketing. Governments in other countries may have similar requirements for testing and marketing. Â The process of obtaining these approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial time, resources and money. There can be no assurance that our product candidates will ultimately receive marketing approval, or, if approved, will be reimbursed by public and private health insurance. Â Â There are several stages every drug undergoes during its development process. Among these are: Â Â â— Performance of nonclinical laboratory and animal studies to assess a drugâ€™s biological activity and to identify potential safety concerns, and to characterize and document the productâ€™s chemistry, manufacturing controls, formulation, and stability. In accordance with regulatory requirements, nonclinical safety and toxicity studies are conducted underÂ Good Laboratory Practice, requirementsÂ to ensure their quality and reliability; Â Â â— The manufacture of the product according to GMP regulations and standards; Â Â â— Conducting adequate and well-controlled human clinical studies in compliance with Good Clinical Practice, or GCP, to establish the safety and efficacy of the product for its intended indication; and Â Â â— Potential post-marketing clinical testing and surveillance of the product after marketing approval, which can result in additional conditions on the approvals or suspension of clinical use. Â Â Approval of a drug for clinical studies in humans and approval of marketing are sovereign decisions of states, made by national, or, in case of the European Union, international regulatory competent authorities. Â The Regulatory Process in the United States Â In the United States, our product candidates are subject to regulation as a biological product under the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. The FDA, regulating the approval of clinical studies and marketing applications in the United States, generally requires the following steps prior to approving a new biological product for use either for clinical studies or for commercial sale: Â Â â— Submission of an IND Application, which must become effective before clinical testing in humans can begin; Â Â â— Obtaining approval of Institutional Review Boards, or IRBs, of research institutions or other clinical sites to introduce the drug candidate into humans in clinical studies; Â 13 Â Â Â â— FDA may grant approval for EAP prior to the completion of clinical studies, in order to allow access for the investigational drug, for patients that are excluded from the study; Â Â â— FDA may grant priority review statusÂ to expedite the BLA review process. Obtaining a Fast Track designation allows access for the request of priority review; Â Â â— Submission of a BLA for marketing authorization of the product, which must include adequate results of pre-clinical testing and clinical studies; Â Â â— Submission of BLA with a proof of efficacy that is based only on animal studies is feasible in instances where human efficacy studies cannot be conducted because the conduct of such studies would not be ethical or feasible (such as H-ARS). In these cases, approval can be based on well controlled animal studies conducted under the FDA Animal Rule; Â Â â— FDA review of the BLA in order to determine, among other things, whether the product is safe and effective for its intended uses; and Â Â â— FDA inspection and approval of the product manufacturing facility at which the product will be manufactured. Â The Regulatory Process in Europe Â In the European Union, our investigational cellular products are regulated under the Advanced Therapy Medicinal Products regulation, a regulation specific to cell and tissue products. Additionally, as of January 31, 2022, the Clinical Trials Regulation harmonizes the submission, assessment and supervision processes of clinical trials in the European Union. This European Union regulation requires: Â Â â— Filing a Central Clinical Trial Application utilizing the Clinical TrialsÂ Information System, and obtaining an assessment and approval; Â Â â— Obtaining approval of local and central ethics committees as required to test the investigational product into humans in clinical studies; Â Â â— Conducting adequate and well-controlled clinical studies to establish the safety and efficacy of the investigational product for its intended use; and Â Â â— Since our investigational cellular products are regulated under the Advanced Therapy Medicinal Product regulation, the application for marketing authorization to the EMA is mandatory within the 28 member states of the European Union. The EMA is expected to review and approve the MAA. Â Clinical Studies Â Typically, in the United States, as well as in the European Union, clinical development involves a series of clinical studies from early, small scale, Phase 1 studies to late-stage large, Phase 3 studies, although the phases may overlap. PhaseÂ I, clinical studies are conducted in a small number of healthy volunteers, or patients with the disease or condition. These studies are designed to provide information about product safety and dosage by gathering information on the drug interaction with the human body, its side effects as well as early preliminary information on effectiveness. Â PhaseÂ II clinical studies are conducted in a homogenous group of patients afflicted with the specific target disease, to explore preliminary efficacy, optimal dosages and confirm the safety profile. In some cases, an initial study is conducted in patients to assess both preliminary efficacy and preliminary safety and patterns of drug metabolism and distribution, in which case it is referred to as a PhaseÂ I/II study. PhaseÂ III clinical studies, sometimes known as pivotal studies, are generally large-scale, multi-center, controlled studies conducted with a heterogeneous group of patients afflicted with the target disease, aiming to provide statistically significant support of efficacy, as well as safety and potency. The Phase III studies are considered confirmatory for establishing the efficacy and safety profile of the drug and are critical for approval. In some circumstances, a regulatory agency may require PhaseÂ IV, or post-marketing studies in case additional information needs to be collected after the drug is on the market. Â 14 Â Â During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical study sites investigators to minimize risks and ensure high quality and integrity of the collected data. The sponsor of a clinical study is required to submit an annual safety report to the relevant regulatory agencies, in which serious adverse events are reported, and also to submit in an expedited manner any individual serious adverse events that are suspected to be related to the tested drug and are unexpected with its use. An agency may, at its discretion, re-evaluate, alter, suspend, or terminate the clinical study based upon the data that have been accumulated to that point and its assessment of the risk/benefit ratio to the patient. Â Government Regulations - Food Tech Â Regulators around the world are in the process of developing or implementing a regulatory approval process for cultivated meat. Although some companies have recently received regulatory approval for their cultivated meat products in the United States, Israel and Singapore cultivated meat is not yet generally commercially available. However, technologies like the one being developed by Ever After Foods are anticipated to facilitate the scaling up of cultivated meat production. In general, cultivated meat production is subject to extensive regulatory laws and regulations. In the United States, the FDA and the U.S. Department of Agriculture, or USDA, are in the process of developing guidance and regulations applicable to cultivated meat. Â In the cultivated coffee space, we are working with an external regulatory consultant to evaluate the technical and scientific requirements for determining whether our cultured coffee product is Generally Recognized as Safe, or GRAS, under section 201(s) of the Federal Food, Drug, and Cosmetic Act, or FDCA, and FDAâ€™s implementing regulations (21 C.F.R. Â§ 170.30). If the Coffeesai cultivated coffee product (including all of its components) is determined to be GRAS in accordance with U.S. FDA requirements, it will be exempt from the definition of â€œfood additiveâ€ in section 201(s) of the FDCA, and can therefore be lawfully marketed as a food in the United States without the need to obtain a premarket authorization from the FDA. Â Government Regulations- CDMO Â Our CDMO business may be subject to additional regulations,Â depending on the services we provide to companies under such business division. Â Employees Â Â As of June 30, 2024, we employed a total of 106 full-time employees and 12 part-time employees, of whom, 82 full-time employees and 9 part-time employees are engaged in cell research, development, and manufacturing including clinical and regulation affairs, excluding Ever After Foodsâ€™ employees. Â Competition Â Regenerative medicine: Â The regenerative medicine field is characterized by intense competition, as global and local pharma players are becoming more engaged in the cell therapy field based on the advancements made in clinical studies and due to the favorable regenerative medicine legislation in certain regions. We face competition from both allogeneic and autologous cell therapy companies, academic, commercial and research institutions, pharmaceutical companies, biopharmaceutical companies, and governmental agencies. Some of the clinical indications we currently have under development are also being investigated in preclinical and clinical programs by others. Â According to Alliance for Regenerative Medicine Reports, as of June 30, 2023, there were a total of 1,197 developers of cell therapies, with 1,336 ongoing trials registered globally. 74% of the total trials are focused on oncology research, and over 50% of the clinical trials are investigating CAR-T therapy, with 157 trials focusing on solid tumors (Alliance for Regenerative Medicine Reports ARM). According to GlobalData, clinicaltrial.gov, in the global market excluding China, while most allogeneic cell therapies are still in the preclinical stage, approximately 20 allogeneic CAR-T therapy products being studied for solid tumors have advanced into clinical stages, such as Adicet Bioâ€™s allogeneic CD70-CAR gamma-delta T cells, Artivaâ€™s allogeneic HER2-NK cells, CiRAâ€™s iPSC derived GPC3-CAR NK Cells, and Fateâ€™s iPSC derived HER2-CAR T cells, according to GlobalData; clinicaltrial.gov). Â While there are hundreds of companies in the regenerative medicine space globally, there are multiple participants in the cell therapy field based in the United States, Europe, Japan, Korea, and Australia. Among other things, we expect to compete based upon our IP portfolio, our in-house manufacturing efficiencies and capabilities, and the potential efficacy of our products. Our ability to compete successfully will depend on our continued ability to attract and retain experienced and skilled executives, scientific and clinical development personnel, to identify and develop viable cellular therapeutic candidates and exploit these products commercially and keep expanding and improving our unique technological capabilities. Â 15 Â Â Food Tech: Â Ever After Foods operates in a competitive landscape that includes both consumer-facing companies like Upside Foods, Believer Meats, and GOOD Meat, as well as B2B players like Gelatex, Esco Aster, Ark Biotech, GEA and more. Unlike traditional production technological approaches that rely on adapting cells to grow in stirred tank bioreactors, Ever After Foods has a unique proprietary technology that is optimized for natural cell growth. This allows EAF to produce cultivated meat at a significantly lower cost and on a larger scale. Ever After Foodsâ€™ unique technology, combined with an experienced team and strategic partnerships with industry leaders, provides us with a strong competitive advantage in the cultivated food market. Â AgTech: Â The agtech industry continues to evolve, driven by advancements in biotechnology, sustainability initiatives and transformation of traditional farming practices into more efficient approaches. Competitors in this domain include plant cellular companies producing natural ingredients from plant stem cell culture such as California Cultured Inc. and Ayana Bio LLC as well as plant-derived producers such as DSM Firmenich AG and

Givaudan International SA. We believe that our ability to compete in the agtech space is derived from our technology platform capabilities and our innovative developments. Our ability to compete successfully will depend on our continued development of plant cellular products and our expansion and improvement of our unique technological capabilities. Â CDMO; Â We compete in the cell therapy CDMO services with several companies like Lonza Group AG, AGC Biologics A/S and Charles River Laboratories International, Inc. for outsourced services from development to manufacturing in biotechnology and pharmaceutical cell-based products. The majority of our competitors are large service providers with multiple offerings for different technologies, range of dosage form capabilities and medicine products. Â The competition is driven by geography location, relevant technologies, operational capacity, expertise in manufacturing techniques and price. Â While there are multiple competitors that compete in the CDMO services, we have a few competitors that compete in advanced stages of cell therapy clinical trials and can provide access to state-of-the-art manufacturing efficiency and capabilities. Â Our ability to compete successfully will depend on our continued ability to attract and retain customers, support clinical development, identify new opportunities and keep expanding our unique know-how,Â technology and manufacturing capabilities. Â Â Available Information Â Additional information about us is contained on our Internet website at www.pluri-biotech.com. Information on our website is not incorporated by reference into this Annual Report. Under the â€œInvestors & ESGâ€- â€œFinancial Reportsâ€ and â€œSEC Filingsâ€ sections of our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our reports filed with the SEC are also made available on the SECâ€™s website at www.sec.gov. The following Corporate Governance documents are also posted on our website under the Investors & ESGâ€ - Governanceâ€ section: Code of Business Conduct and Ethics, Anti Bribery and Corruption and Anti Money Laundering and Terrorist Financing Compliance Policy, Trading Policy, Clawback Policy and the Charters for each of the Committees of our Board of Directors, or the Board. Â ITEM 1A. RISK FACTORS. Â An investment in our securities involves a high degree of risk. You should consider carefully the following information about these risks, together with the other information contained in this Annual Report before making an investment decision. Our business, prospects, financial condition and results of operations may be materially and adversely affected as a result of any of the following risks. The value of our securities could decline as a result of any of these risks. You could lose all or part of your investment in our securities. Some of the statements in â€œItem 1A. Risk Factorsâ€ are forward-looking statements. The following risk factors are not the only risk factors facing our Company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations. Â Summary of Risk Factors Â Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to: Â Â â— we have a history of losses and have not generated significant revenues to date. We expect to experience future losses and do not foresee generating significant or steady revenues in the immediate future; Â Â â— we may need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute our shareholdersâ€™ ownership interests, and such offers or availability for sale of a substantial number of our common shares may cause the price of our publicly traded shares to decline; Â 16 Â Â Â â— we may become subject to claims by much larger and better funded competitors enforcing their IP rights against us or seeking to invalidate our IP or our rights thereto; Â Â â— there are inherent risks in the manufacturing of our product candidates, including meeting relevant high regulatory standards, the failure of which could materially and adversely affect our results of operations and the value of our business; Â Â â— if we are unable to obtain and maintain IP protection covering our products and technology, others may be able to utilize our IP, which would adversely affect our business; Â Â â— we are an international business, and we are exposed to various global and local risks that could have a material adverse effect on our financial condition and results of operations; Â Â â— the market prices of our common shares are subject to fluctuation and have been and may continue to be volatile, which could result in substantial losses for investors; Â Â â— we anticipate being subject to fluctuations in currency exchange rates because a significant portion of our business is conducted outside the United States and we are exposed to currency exchange fluctuations in other currencies such as the New Israeli Shekel, or NIS, and the Euro; Â Â â— restrictions contained in the EIB Finance Agreement may restrict our ability to conduct certain strategic initiatives; Â Â â— limitations we may face relating to the grants we have received from the IIA may impact our plans and future decisions; Â Â â— if there are significant shifts in the political, economic and military conditions in Israel and its neighboring countries, it could have a material adverse effect on our business relationships and profitability; Â Â Â Â â— it may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers; Â Â Â Â â— cybersecurity incidents may have an adverse impact on our business and operations; Â Â Â Â â— recent increasing global inflation could affect our ability to purchase materials needed for manufacturing and could increase the costs of our future product; Â Â Â Â â— we have a limited operating history in the field of food tech agtech and CDMO to date and our prospects will be dependent on our ability to meet a number of challenges; Â Â Â Â â— there are risks relating to our CDMO business, including financial risks associated with contracts that could be terminated, changed or delayed, risk related to products that might not gain market approval and risk related to providing timely services to customers in a highly competitive industry in which we operate. Â Â Â Â â— there are risks relating to our food-tech endeavors, including changes in consumer preferences and governmental regulations relating to cultivated meat; Â Â Â Â â— our business and market potential in the field of cultivated food and cell-based coffee technology are unproven, and we have limited insight into trends that may emerge and affect our business; Â Â Â Â â— the research and development associated with technologies for cultivated meat manufacturing is a lengthy and complex process; and Â Â Â Â â— we could fail to maintain the listing of our common shares on Nasdaq, which could harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction. Â 17 Â Â Risk Related to Our Business Â We may need to raise additional financing to support the research, development and manufacturing of our cell-based products in the future, but we cannot be sure we will be able to obtain additional financing on terms favorable to us when needed. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated. Â It is highly likely that we will need to raise significant additional capital in the future. Although we were successful in raising capital in the past, our current financial resources are limited, and may not be sufficient to finance our operations until we become profitable, if that ever happens. Â It is likely that we will need to raise additional funds in the future in order to satisfy our working capital and capital expenditure requirements. Therefore, we are dependent on our ability to sell our common shares for funds, receive grants, enter into collaborations and licensing deals or to otherwise raise capital. Any sale of our common shares in the future could result in dilution to existing shareholders and could adversely affect the market price of our common shares.Â Â Also, we may not be able to raise additional capital in the future to support the development and commercialization of our products, which could result in the loss of some or all of oneâ€™s investment in our common shares. Â Our likelihood of profitability depends on our ability to license and/or develop and commercialize our products based on our technology, which is currently in the development stage. If we are unable to complete the development and commercialization of our cell-based products successfully, or are unable to obtain the necessary regulatory approvals, our likelihood of profitability will be limited severely. Â We are engaged in the business of developing cell-based products. We have not realized a profit from our operations to date and there is little likelihood that we will realize any profits in the short or medium term. Any profitability in the future from our business will be dependent upon successful commercialization of our cell-based products and/or licensing of our products, which will require additional research and development. Â If our cell therapy product candidates do not prove to be safe and effective in clinical trials, we will not obtain the required regulatory approvals. If we fail to obtain such approvals, we may not generate sufficient revenues to continue our business operations. Â Even after granting regulatory approval, the FDA, the EMA, and regulatory agencies in other countries continue to regulate marketed products, manufacturers and manufacturing facilities, which may create additional regulatory barriers and burdens. Later discovery of previously unknown problems with a product, manufacturer or facility, may result in restrictions on the product or manufacturer, including a withdrawal of the product from the market. Â We have not generated significant or consistent revenues to date, which raises doubts with respect to our ability to generate revenues in the future. Â We have a limited operating history in our business of commercializing cell-based products and cell technology, and we have not generated material revenues to date. It is not clear when we will generate material revenues or whether we will generate material revenues in the future. We cannot give assurances that we will be able to generate any significant revenues or income in the future. There is no assurance that we will ever be profitable. Â Because most of our officers and directors are located in non-U.S. jurisdictions, you may have no effective recourse against the management for misconduct and may not be able to enforce judgment and civil liabilities against our officers, directors, experts and agents. Â Most of our directors and officers are nationals and/or residents of countries other than the United States, and all or a substantial portion of their assets are located outside the United States. Â As a result, it may be difficult to enforce within the United States any judgments obtained against our officers or directors, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any U.S. state. Â While we may seek partners for licensing deals, joint ventures, partnerships, and direct sale of our products in various industries, there is no guarantee we will be successful in doing so. Â To date, we have focused our efforts primarily in the regenerative medicine field, in the food tech field, in the CDMO field, and in the agriculture field, but we may seek partners for licensing deals, joint ventures, partnerships, and direct sale of our products or use of our technology in various industries. Licensing deals, joint ventures and partnerships in new fields involve numerous risks, including the potential integration of our technology and products in various new ways, which may or may not be successful. Such projects may require significant funds, time and attention of management and other key personnel. In addition, as we do not have experience in areas outside of the regenerative medicine field and limited experience in the food tech, CDMO and agriculture fields, we may lack the personnel to properly lead such initiatives. There can be no assurance that we will be successful in finding the relevant partners to fund and market our cell-based products.Â Â 18 Â Â Risks Related to Development, Clinical studies, and Regulatory Approval of Our Product Candidates Â If we are not able to conduct our clinical trials properly and on schedule, marketing approval by FDA, EMA, MOH and other regulatory authorities may be delayed or denied. Â The completion of our future clinical trials may be delayed or terminated for many reasons, such as: Â Â â— The FDA, the EMA or the MOH does not grant permission to proceed or places trials on clinical hold; Â Â â— Subjects do not enroll in our trials at the rate we expect; Â Â â— Government actions, such as those enacted during the ongoing COVID-19 pandemic, which limit the general populations movement; Â Â â— The regulators may ask to increase subjectâ€™s population in the clinical trials; Â Â â— Subjects experience an unacceptable rate or severity of adverse side effects; Â Â â— Third party clinical investigators and other related vendors may not perform the clinical trials under the anticipated schedule or consistent with the clinical trial protocol, GCP and regulatory requirements; Â Â â— Third party clinical investigators and other related vendors may declare bankruptcy or terminate their business unexpectedly, which most likely will result in further delays in our clinical trialsâ€™ anticipated schedule and cause additional expenditures; Â Â â— Inspections of clinical trial sites by the FDA, EMA, MOH and other regulatory authorities find regulatory violations that require us to undertake corrective action, suspend or terminate one or more sites, or prohibit us from using some or all of the data in support of our marketing applications; or Â Â â— One or more IRBs suspends or terminates the trial at an investigational site, precludes enrollment of additional subjects, or withdraws its approval of the trial. Â If we will be unable to conduct clinical trials properly and on schedule, marketing approval may be delayed or denied by the FDA, EMA, MOH and other regulatory authorities. Â The results of our clinical trials may not support our product candidatesâ€™ claims or any additional claims we may seek for our product candidates and our clinical trials may result in the discovery of adverse side effects. Â Even if any clinical trial that we need to undertake is completed as planned, or if interim results from existing clinical trials are released, we cannot be certain that such results will support our product candidates claims or any new indications that we may seek for our products or that the FDA or foreign authorities will agree with our conclusions regarding the results of those trials. The clinical trial process may fail to demonstrate that our products or a product candidate is safe and effective for the proposed indicated use, which could cause us to stop seeking additional clearances or approvals for our product candidates. Any delay or termination of our clinical trials will delay the filing of our regulatory submissions and, ultimately, our ability to commercialize a product candidate. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidateâ€™s profile. Â Favorable results from compassionate use treatment or initial interim results from a clinical trial do not ensure that later clinical trials will be successful and success in early-stage clinical trials does not ensure success in later-stage clinical trials. Â PLX cells have been administered as part of compassionate use treatments, which permit the administration of the PLX cells outside of clinical trials. No assurance can be given that any positive results are attributable to the PLX cells, or that administration of PLX cells to other patients will have positive results. Compassionate use is a term that is used to refer to the use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow compassionate use on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs. Â Success in early clinical trials does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily predict final results. While results from treating patients through compassionate use have in certain cases been successful, we cannot be assured that further trials will ultimately be successful. Results of further clinical trials may be disappointing. Â 19 Â Â Even if early-stage clinical trials are successful, we may need to conduct additional clinical trials for product candidates with patients receiving the drug for longer periods before we are able to seek approvals to market and sell these product candidates from the FDA and regulatory authorities outside the United States. Even if we are able to obtain approval for our product candidates through an accelerated approval review program, we may still be required to conduct clinical trials after such an approval. If we are not successful in commercializing any of our lead product candidates, or are significantly delayed in doing so, our business will be materially harmed. Â Our product development programs are based on novel technologies and are inherently risky. Â We are subject to the risks of failure inherent in the development of products based on new technologies. The novel nature of our therapeutics creates significant challenges in regard to product development and optimization, manufacturing, government regulation, third party reimbursement and market acceptance. For example, the FDA, the EMA and other countriesâ€™ regulatory authorities have relatively limited experience with cell therapies. Very few cell therapy products have been approved by regulatory authorities to date for commercial sale, and the pathway to regulatory approval for our cell therapy product candidates may accordingly be more complex and lengthier. As a result, the development and commercialization pathway for our therapies may be subject to increased uncertainty, as compared to the pathway for new conventional drugs. Â Our cell therapy drug candidates represent new classes of therapy that the marketplace may not understand or accept. Â Even if we successfully develop and obtain regulatory approval for our cell therapy candidates, the market may not understand or accept them. We are developing cell therapy product candidates that represent novel treatments and will compete with a number of more conventional products and therapies manufactured and marketed by others, including major pharmaceutical companies. The degree of market acceptance of any of our developed and potential products will depend on a number of factors, including: Â Â â— the clinical safety and effectiveness of our cell therapy drug candidates and their perceived advantage over alternative treatment methods, if any; Â Â â— adverse events involving our cell therapy product candidates or the products or product candidates of others that are cell-based; and Â Â â— the cost of our products and the reimbursement policies of government and private third-party payers. Â If the health care community does not accept our potential products for any of the foregoing reasons, or for any other reason, it could affect our sales, having a material adverse effect on our business, financial condition, and results of operations. Â Â Interim,Â â€œtop-line,â€Â and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures, which could result in material changes in the final data. Â From time to time, we may publish interim,Â â€œtop-line,â€Â or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary orÂ â€œtop-lineâ€Â data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Material adverse changes between preliminary,Â â€œtop-line,â€Â or interim data and final data could significantly harm our business prospects. Â 20 Â Â Risks Related to Our Cultivated Food Business Â Ever After Foods has a limited operating history in the field of cultivated or cultured meat (hereinafter, â€œcultivated meatâ€) to date and its prospects will be dependent on its ability to meet a number of challenges. Â Ever After Foodsâ€™ business prospects are difficult to predict due to its lack of operational history in the new and emerging food tech field, and its success will be dependent on its ability to meet a number of challenges. Because it has a limited operating history in the field of cultivated meat and it is in the early stages of development, Ever After Foods may not be able to evaluate its future prospects accurately. Ever After Foodsâ€™ prospects will be primarily dependent on its ability to successfully develop industrial scale cultivated meat technologies and processes, and market these to its potential customers. If Ever After Foods is

not able to successfully meet these challenges, its prospects, business, financial condition, and results of operations could be adversely impacted. Â In addition, Ever After Foods will be subject to changing laws, rules and regulations in the United States, Israeli, Asia Pacific, the European Union and other jurisdictions relating to the food tech industry. Such laws and regulations may negatively impact its ability to expand its business and pursue business opportunities. Ever After Foods may also incur significant expenses to comply with the laws, regulations and other obligations that will apply to it. Â Ever After Foods is primarily focused on utilizing its technology for the development of cultivated meat, and it has limited data on the performance of our and its technologies in the field of cultivated meat to date. Â Ever After Foods does not currently have any products or technologies approved for sale and it is still in the early stages of development. To date, Ever After Foods has limited data on the ability of our and its technologies to successfully manufacture cultivated meat, towards which they have devoted substantial resources to date. Ever After Foodsâ€™ current technologies are, in large part, based on our technologies and IP. It may not be successful in developing its technologies in a manner sufficient to support its expected scale-ups and future growth, or at all.Â Ever After Foods expects that a substantial portion of its efforts and expenditures over the next few years will be devoted to the development of technologies designed to enable Ever After Foods to market industrial scale cultivated meat manufacturing processes.Â Ever After Foods cannot guarantee that it will be successful in developing these technologies, based on its current roadmap, or at all. If Ever After Foods is able to successfully develop its cultivated meat technologies, it cannot ensure that it will obtain regulatory approval or that, following approval, upon commercialization its technologies will achieve market acceptance. Any such delay or failure could materially and adversely affect Ever After Foodsâ€™ financial condition, results of operations and prospects. Â Consumer preferences for alternative proteins in general, and more specifically cultivated meats, are difficult to predict and may change, and, if we are unable to respond quickly to new trends, Ever After Foodsâ€™ business may be adversely affected. Â Ever After Foodsâ€™ business is focused on the development and marketing of licensable cultivated meat manufacturing technologies. Consumer demand for the cultivated meats manufactured using these technologies could change based on a number of possible factors, including dietary habits and nutritional values, concerns regarding the health effects of ingredients and shifts in preference for various product attributes. If consumer demand for such products decreases, Ever After Foodsâ€™ business and financial condition would suffer. Consumer trends that we believe favor sales of products manufactured using our licensed technologies could change based on a number of possible factors, including a shift in preference from animal-based protein products, economic factors and social trends. A significant shift in consumer demand away from products manufactured using our technologies could reduce our sales or our market share and the prestige of our brand, which would harm our business and financial condition. Â We expect that products utilizing Ever After Foodsâ€™ technologies will be subject to regulations that could adversely affect Ever After Foodsâ€™ business and operations. Â The manufacture, distribution and marketing of food products is highly regulated. Ever After Foods and its suppliers and licensees, may be subject to a variety of laws and regulations. These laws and regulations apply to many aspects of Ever After Foodsâ€™ business, including the manufacture, composition and ingredients, packaging, labeling, distribution, advertising, sale, quality and safety of food products and food contact substances (including some manufacturing equipment), as well as the health and safety of our employees and the protection of the environment. Â Â As applicable, the manufacturing equipment that will be manufactured by Ever After Foods will comply with the FDAâ€™s regulatory requirements for food contact substances and analogous foreign regulations. Ever After Foods will also ensure that the edible scaffolds and any other production materials it sells to its customers comply with applicable FDA standards. From a regulatory perspective, in the United States, we expect companies manufacturing finished cultivated meat products (i.e., the companies that will license Ever After Foodsâ€™ manufacturing technologies) to be subject to regulation by various government agencies, including the FDA, the USDA, the FTC, the Occupational Safety and Health Administration and the Environmental Protection Agency, as well asÂ the requirements ofÂ various state and local agencies and laws, such as the California Safe Drinking Water and Toxic Enforcement Act of 1986. We likewise expect these products to be regulated by equivalent agencies outside the United States by various international regulatory bodies. Â 21 Â Â While, as noted above, Ever After Foods will ensure that the products it sells to its customers (including manufacturing equipment and scaffolds) comply with applicable FDA and USDA standards, we believe that our customers, as entities engaged in the manufacture, distribution, and sale of cultivated meat products, will bear primary legal responsibility for ensuring that all finished foods produced using our technology is wholesome and not adulterated and otherwise in compliance with applicable laws and regulations. Consistent with food industry norms, we expect that our customers will therefore request assurances from us that our products are suitable for their intended use under applicable U.S. legal requirements. Â The manufacturing of cultivated meat is expected to be subject to extensive regulations internationally, with products subject to numerous food safety and other laws and regulations relating to the sourcing, manufacturing, composition and ingredients, storing, labeling, marketing, advertising and distribution of these products. In addition, enforcement of existing laws and regulations, changes in legal requirements and/or evolving interpretations of existing regulatory requirements may result in increased compliance costs and create other obligations, financial or otherwise, that could adversely affect our business, financial condition or operating results. In addition, we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act, or FCPA, and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making payments to foreign government officials for the purpose of obtaining or retaining business, and require companies both to keep accurate books and records and to devise and maintain an adequate system of internal accounting controls. While our policies mandate compliance with anti-bribery laws, including the FCPA, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees, contractors or agents. Violations of these laws, or allegations of such violations, could result in government investigations, the assessment of fines and penalties, reputational damage, disruption to our business, and adverse impacts on our results of operations, cash flows and financial condition. Â Any changes in, or changes in the interpretation of, applicable laws, regulations or policies of the USDA, state regulators or similar foreign regulatory authorities that relate to the use of the terms â€œmeatâ€ or â€œpoultryâ€ or other similar terms in connection with cultivated meat products could adversely affect our business, prospects, results of operations or financial condition. Â The USDA, state regulators or similar foreign regulatory authorities, such as Health Canada or the Canadian Food Inspection Agency, or CFIA, or authorities of the EU or the EU member states (e.g.,Â European Food Safety Authority, or EFSA), could take action that impacts our customersâ€™ ability to use the term â€œmeatâ€ or â€œpoultryâ€ or similar words, such as â€œbeefâ€ or â€œchickenâ€ , to describe their finished products. In addition, a food may be deemed misbranded if its labeling is false or misleading in any particular way, and the USDA, CFIA, EFSA or other regulators could interpret the use of the terms â€œmeatâ€ or â€œpoultryâ€ or any similar phrase(s) to describe our customersâ€™ cultivated meat products as false or misleading or likely to create an erroneous impression regarding their composition. In the U.S., the USDA intends to issue new labeling requirements for foods under its jurisdiction produced through cell culture technology as noted in an ANPR published in September 2021.Â Â Â Our various new lines of business, including our cell-based coffee business vertical, PluriAgtech, and Ever After Foods, are new businesses with limited operating activity to date, and their success is dependent on the ability to deliver a high-quality product while overcoming multiple challenges. Â The success of our various new lines of business is difficult to predict due to our lack of operational history in these industries, and we will be dependent on our ability to meet a number of challenges. Because our new lines of business have a limited operating history, these lines of business may not be able to deliver a successful high-quality product at the scale production they aim to deliver. The success of these lines of business will be primarily, but not only, dependent on their ability to develop manufacturing solutions, and leveraging Pluriâ€™s 3D cell expansion technology to create compelling products. If our businesses will not be able to successfully meet these challenges, and our prospects, business, financial condition and results of operations could be adversely impacted. Â In addition, certain of our lines of business, such PluriAgtech, Ever After Foods and Coffeesai, will be subject to changing laws, rules and regulations in the United States, Israel, Asia Pacific, the European Union and other jurisdictions. Such laws and regulations may negatively impact their ability to expand their businesses and pursue business opportunities. Our subsidiaries may also incur significant expenses to comply with the laws, regulations and other obligations that will apply to them. Â 22 Â Â We may need to raise additional financing to support PluriAgtechâ€™s and Coffeesaiâ€™s business verticals and the research, development and manufacturing of their respective products. If we are unable to obtain additional financing to meet their needs, their operations may be adversely affected or terminated. Â It is highly likely that we will need to raise significant additional capital from investors in the future to finance PluriAgtechâ€™s and Coffeesaiâ€™s business vertical operations. Our current capital may not be sufficient to finance PluriAgtechâ€™s and Coffeesaiâ€™s operations until we are able to complete the development of a high-quality coffee, if that ever happens. If we are not able to find investors and obtain additional financing, PluriAgtechâ€™s and Coffeesaiâ€™s operations may be adversely affected or terminated. Â Coffeesaiâ€™s products utilizing our 3D cell expansion technology may be subject to regulations that could adversely affect its business and results of operations. Â In the cultivated coffee space, we are working with an external regulatory consultant to evaluate the technical and scientific requirements for determining whether the cultured coffee product is GRAS under section 201(s) of the FDCA and FDAâ€™s implementing regulations (21 C.F.R. Â§ 170.30). If the Coffeesai cultivated coffee product (including all of its components) is determined to be GRAS in accordance with FDA requirements, it will be exempt from the definition of â€œfood additiveâ€ in section 201(s) of the FDCA, and may therefore be lawfully marketed as a food in the U.S. without the need to obtain a premarket authorization from FDA. However, if the Coffeesai cultivated coffee product (including any of its components) is not determined to be GRAS, it or the particular non-GRAS component would be considered a â€œfood additiveâ€ under section 201(s) of the FDCA; this, in turn, would mean that the ingredient could only be lawfully marketed in the United States. if it was authorized for its intended use under a food additive regulation and otherwise complied with other food safety, facility registration, and labeling requirements. If Coffeesai determines that the product is not authorized for its intended use under an existing food additive regulation, Coffeesai may need to submit a food additive petition to request that FDA issue a new food additive regulation authorizing the ingredient for its intended use. Â Additionally, before marketing the cultivated coffee product in the Unites States, Coffeesai will also need to ensure that the product is labeled in accordance with applicable FDA food labeling requirements established under section 403 of the FDCA and FDAâ€™s implementing regulations (21 C.F.R. Part 101), manufactured at an FDA-registered food facility pursuant to section 415 of the FDCA and FDAâ€™s implementing regulations (21 C.F.R. Part 1, Subpart H), and manufactured in accordance with all applicable FDA food safety requirements including, but not limited to, FDAâ€™s Hazard Analysis and Preventive Controls and Current Good Manufacturing Practice requirements (21 C.F.R. Part 117). Additional FDA regulatory requirements may apply if Coffeesai plans to import the cultivated coffee product into the United States, including requirements for submitting prior notice of imported foods to FDA (21 C.F.R. Part 1, Subpart I) and complying with Foreign Supplier Verification requirements (21 C.F.R. Part 1, Subpart L) as applicable. Â 23 Â Â Risk Related to Commercialization of Our Product Candidates Â We may not successfully establish new collaborations, joint ventures or licensing arrangements, which could adversely affect our ability to develop and commercialize our product candidates. Â One of the elements of our business strategy is to collaborate with partners and to license our technology to other companies. Our business strategy includes development and in-house manufacturing of innovative new cell- based products and solutions powered by our 3D cell expansion technology platforms and establishing joint ventures and partnerships that leverage our cell expansion technology and cell-based product portfolio to expand product pipelines and meet cell-based manufacturing needs for a variety of industries. To date, we have established Ever After Foods, a strategic partnership with Tnuva, with ICL Group for advanced bioactive carriers and bio stimulants, with Wilk Technologies to develop cultured human breast and animal milk products and with an undisclosed - leading international agriculture corporation to enhance the global sustainable vegetable supply. Â Notwithstanding, we may not be able to further establish or maintain such licensing and collaboration arrangements necessary to develop and commercialize our product candidates. Â Even if we are able to maintain or establish licensing or collaboration arrangements, these arrangements may not be on favorable terms and may contain provisions that will restrict our ability to develop, test and market our product candidates. Any failure to maintain or establish licensing or collaboration arrangements on favorable terms could adversely affect our business prospects, financial condition, or ability to develop and commercialize our product candidates. Â Our agreements with our collaborators and licensees may have provisions that give rise to disputes regarding the rights and obligations of the parties. These and other possible disagreements could lead to termination of the agreement or delays in collaborative research, development, supply, or commercialization of certain product candidates, or could require or result in litigation or arbitration. Moreover, disagreements could arise with our collaborators over rights to IP or our rights to share in any of the future revenues of products developed by our collaborators. These kinds of disagreements could result in costly and time-consuming litigation. Any such conflicts with our collaborators could reduce our ability to obtain future collaboration agreements and could have a negative impact on our relationship with existing collaborators. Â The market for our cell therapy products will be heavily dependent on third party reimbursement policies. Â Our ability to successfully commercialize our cell therapy product candidates will depend on the extent to which government healthcare programs, as well as private health insurers, health maintenance organizations and other third-party payers will pay for our products and related treatments. Â Reimbursement by third party payers depends on a number of factors, including the payerâ€™s determination that use of the product is safe and effective, not experimental, or investigational, medically necessary, appropriate for the specific patient and cost-effective.Â Reimbursement in the United States or foreign countries may not be available or maintained for any of our product candidates. If we do not obtain approvals for adequate third-party reimbursements, we may not be able to establish or maintain price levels sufficient to realize an appropriate return on our investment in product development. Any limits on reimbursement from third party payers may reduce the demand for, or negatively affect the price of, our products. The lack of reimbursement for these procedures by insurance payers has negatively affected the market for our products in this indication in the past. Â Managing and reducing health care costs has been a general concern of federal and state governments in the United States and of foreign governments.Â In addition, third party payers are increasingly challenging the price and cost-effectiveness of medical products and services, and many limit reimbursement for newly approved health care products.Â In particular, third-party payers may limit the indications for which they will reimburse patients who use any products that we may develop.Â Cost control initiatives could decrease the price for products that we may develop, which would result in lower product revenues to us. Â 24 Â Â Risk Related to Intellectual Property Â Our success depends in large part on our ability to develop and protect our technology and our cell therapy products. If our patents and proprietary rights agreements do not provide sufficient protection for our technology and our cell therapy products, our business and competitive position will suffer. Â Our success will also depend in part on our ability to develop our technology and commercialize our products without infringing the proprietary rights of others. We have not conducted full freedom of use patent searches and no assurance can be given that patents do not exist or could not be filed which would have an adverse effect on our ability to develop our technology or maintain our competitive position with respect to our potential cell therapy products. If our technology components, devices, designs, products, processes or other subject matter are claimed under other existing United States or foreign patents or are otherwise protected by third party proprietary rights, we may be subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights, or we may be required to obtain licenses from such companies in order to develop, manufacture or market our technology or products. There can be no assurances that we would be able to obtain such licenses or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore, the failure to either develop a commercially viable alternative or obtain such licenses could result in delays in marketing our proposed products or the inability to proceed with the development, manufacture or sale of products requiring such licenses, which could have a material adverse effect on our business, financial condition and results of operations. If we are required to defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease our development of our technology and the commercialization our potential cell therapy products. Â We have built the ability to manufacture clinical grade adherent stromal cells in-house. Through our experience with adherent stromal cell-based product development, we have developed expertise and know-how in this field. We also have built the ability to grow on a large scale various immune cells including engineered placental MAIT cells for use in cell therapy. Additionally, we have built the ability to grow on a large scale plant cells for various agtech uses. To protect these expertise and know-how, our policies require confidentiality agreements with our employees, consultants, contractors, manufacturers and advisors. These agreements generally provide for protection of confidential information, restrictions on the use of materials and assignment of inventions conceived during the course of performance for us. These agreements might not effectively prevent disclosure of our confidential information. Â Third parties may initiate legal proceedings alleging that we are infringing their IP rights, the outcome of which would be uncertain and could have a material adverse effect on our business. Â Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We have yet to conduct comprehensive freedom-to-operate searches to determine whether our proposed business activities or use of certain of the patent rights owned by us would infringe patents issued to third parties. We may become party to, or threatened with, future

adversarial proceedings or litigation regarding IP rights with respect to our products and technology, including interference proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third partyâ€™s IP rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Â Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. For example, we are aware of issued third party patents directed to placental stem cells and their use for therapy and in treating various diseases. We may need to seek a license for one or more of these patents. No assurances can be given that such a license will be available on commercially reasonable terms, if at all. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Â 25 Â Â Even if resolved in our favor, litigation or other legal proceedings relating to IP claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors are able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Â Â The patent approval process is complex, and we cannot be sure that our pending patent applications or future patent applications will be approved. Â The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and any future licensorsâ€™ patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may not be able to obtain meaningful patent protection for any of our commercial products either in or outside the United States. Â No assurance can be given that the scope of any patent protection granted will exclude competitors or provide us with competitive advantages, that any of the patents that have been or may be issued to us will be held valid if subsequently challenged, or that other parties will not claim rights to or ownership of our patents or other proprietary rights that we hold. Furthermore, there can be no assurance that others have not developed or will not develop similar products, duplicate any of our technology or products or design around any patents that have been or may be issued to us or any future licensors. Since patent applications in the United States and in Europe are not publicly disclosed until patents are issued, there can be no assurance that others did not first file applications for products covered by our pending patent applications, nor can we be certain that we will not infringe any patents that may be issued to others. Â Risk Related to Our Common Shares Â The price of our common shares may fluctuate significantly. Â The market for our common shares may fluctuate significantly. A number of events and factors may have an adverse impact on the market price of our common shares, such as: Â â—results of our clinical trials or adverse events associated with our products; Â â—the amount of our cash resources and our ability to obtain additional funding; Â â—changes in our revenues, expense levels or operating results; Â â—entering into or terminating strategic relationships; Â â—announcements of technical or product developments by us or our competitors; Â 26 Â Â â—market conditions for pharmaceutical and biotechnology shares in particular; Â â—changes in laws and governmental regulations, including changes in tax, healthcare, competition and patent laws; Â â—disputes concerning patents or proprietary rights; Â â—new accounting pronouncements or regulatory rulings; Â â—public announcements regarding medical advances in the treatment of the disease states that we are targeting; Â â—patent or proprietary rights developments; Â â—regulatory actions that may impact our products; Â â—future sales of our common shares, or the perception of such sales; Â â—disruptions in our manufacturing processes; and Â â—competition. Â In addition, a global pandemic, such as the COVID-19 pandemic and a market downturn in general and/or in the biopharmaceutical sector in particular, may adversely affect the market price of our securities, which may not necessarily reflect the actual or perceived value of our Company. Â We could fail to maintain the listing of our common shares on Nasdaq, which could seriously harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction. Â On May 28, 2024, we received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of Nasdaq, notifying us that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires us to maintain a minimum of $2.5 million in stockholdersâ€™ equity for continued listing on The Nasdaq Capital Market, or the Stockholdersâ€™ Equity Requirement, nor were we in compliance with either of the alternative listing standards, a market value of listed securities of at least $35 million or net income of $0.5 million from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Â Pursuant to the Nasdaq Letter, on July 11, 2024, we submitted a plan to Nasdaq to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant us an extension of time to regain compliance with the Stockholdersâ€™ Equity Requirement until November 24, 2024. If we fail to evidence compliance by the required deadline, we may be subject to delisting. At that time, we may appeal Staffâ€™s determination to a Hearings Panel. Â If we do not regain compliance with the Stockholdersâ€™ Equity Requirement, our common shares will be subject to delisting. A delisting from Nasdaq would likely result in a reduction in some or all of the following, each of which could have a material adverse effect on shareholders: Â â—the liquidity of our common shares; Â â—the market price of our common shares; Â â—the availability of information concerning the trading prices and volume of our common shares; Â â—our ability to obtain financing or complete a strategic transaction; Â â—the number of institutional and other investors that will consider investing in our common shares; and Â â—the number of market markers or broker-dealers for our common shares. Â We intend to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance we will ultimately regain compliance with all applicable requirements for continued listing. Â Future sales of our common shares may cause dilution. Â Future sales of our common shares, or the perception that such sales may occur, could cause immediate dilution and adversely affect the market price of our common shares. If we raise additional capital by issuing equity securities, the percentage ownership of our existing shareholders may be reduced, and accordingly these shareholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common shares. Given our need for cash and that equity raising is the most common type of fundraising for companies like ours, the risk of dilution is particularly significant for shareholders of our company. Â 27 Â Â Risks Related to Foreign Exchange Rates Â We are exposed to fluctuations in currency exchange rates. Â A significant portion of our business is conducted outside the United States. Therefore, we are exposed to currency exchange fluctuations in other currencies such as the NIS and the Euro. A significant portion of our expenses in Israel are paid in NIS, and we have also received â‚¬20 million pursuant to the EIB Finance Agreement, that bears 4% annual interest. All of these factors subject us to the risks of foreign currency fluctuations. Our primary expenses paid in NIS are employee salaries, and lease payments on our facilities. From time to time, we may apply a hedging strategy by using options and forward contracts to protect ourselves against some of the risks of currency exchange fluctuations and we are actively monitoring the exchange rate differences of the NIS, Euro and U.S. Dollar; however, we are still exposed to potential losses from currency exchange fluctuation. Â Â Our cash may be subject to a risk of loss. Â Our assets include a significant component of cash and cash equivalents and bank deposits.Â We adhere to an investment policy set by our investment committee which aims to preserve our financial assets, maintain adequate liquidity and maximize returns. We believe that our cash is held in institutions whose credit risk is minimal and that the value and liquidity of our deposits are accurately reflected in our consolidated financial statements as of June 30, 2024. Currently, we hold most of our cash assets in bank deposits in Israel. However, nearly all of our cash and bank deposits are not insured by the Federal Deposit Insurance Corporation, or the FDIC,Â or similar governmental deposit insurance outside the United States.Â Therefore, our cash and any bank deposits that we now hold or may acquire in the future may be subject to risks, including the risk of loss or of reduced value or liquidity, particularly in light of the increased volatility and worldwide pressures in the financial and banking sectors. Â Risk Related to Our Industries Â The trend towards consolidation in the pharmaceutical and biotechnology industries may adversely affect us. Â There is a trend towards consolidation in the pharmaceutical and biotechnology industries. This consolidation trend may result in the remaining companies having greater financial resources and technical discovery capabilities, thus intensifying competition in these industries. This trend may also result in fewer potential collaborators or licensees for our therapeutic product candidates. Also, if a consolidating company is already doing business with our competitors, we may lose existing licensees or collaborators as a result of such consolidation. This trend may adversely affect our ability to enter into license agreements or agreements for the development and commercialization of our product candidates, and as a result may materially harm our business. Â If we do not keep pace with our competitors and with technological and market changes, our technology and products may become obsolete, and our business may suffer. Â The cellular therapeutics industry, of which we are a part, is very competitive and is subject to technological changes that can be rapid and intense. We have faced, and will continue to face, intense competition from biotechnology, pharmaceutical and biopharmaceutical companies, academic and research institutions and governmental agencies engaged in cellular therapeutic and drug discovery activities or funding, both in the United States and internationally. Some of these competitors are pursuing the development of cellular therapeutics, drugs and other therapies that target the same diseases and conditions that we target in our clinical and pre-clinical programs. Â Â 28 Â Â Some of our competitors have greater resources, more product candidates and have developed product candidates and processes that directly compete with our products. Our competitors may have developed, or could develop in the future, new products that compete with our products or even render our products obsolete. Â Moreover, the alternative protein market is highly competitive, with numerous brands vying for limited space in retail, foodservice, and consumer preference. To succeed, Ever After Foodsâ€™ cultured meat products must excel in costs, taste, ingredients, marketing and branding. Generally, the food industry is dominated by multinational corporations with substantially greater resources and operations than Ever After Foods. We cannot be certain that Ever After Foods will successfully compete with larger competitors that have greater financial, marketing, sales, manufacturing, distributing and technical resources. Conventional food companies may acquire Ever After Foodsâ€™ competitors or launch their own competing products, and they may be able to use their resources and scale to respond to competitive pressures and changes in consumer preferences by introducing new products, reducing prices or increasing promotional activities, among other things. Competitive pressures or other factors could prevent Ever After Foods from acquiring market share or cause us to lose market share, which may require Ever After Foods to lower prices, or increase marketing and advertising expenditures, either of which would adversely affect its margins and could result in a decrease in its operating results and profitability. We cannot assure that we will be able to maintain a competitive position or compete successfully against such sources of competition. Â Potential product liability claims could adversely affect our future earnings and financial condition. Â We face an inherent business risk of exposure to product liability and CDMO service claims in the event that the use of our products or CDMO services results in adverse effects. We may not be able to maintain adequate levels of insurance for these liabilities at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims would add to our future operating expenses and adversely affect our financial condition. Â Risk Related to Our Dependence on Third Parties Â We are dependent upon third party suppliers for raw materials needed to manufacture PLX; if any of these third parties fails or is unable to perform in a timely manner, our ability to manufacture and deliver will be compromised. Â In addition to the placenta used in the clinical manufacturing process of PLX, we require certain raw materials. These items must be manufactured and supplied to us in sufficient quantities and in compliance with current GMP. To meet these requirements, we have entered into supply agreements with firms that manufacture these raw materials to current GMP standards. Our requirements for these items are expected to increase if and when we transition to the manufacture of commercial quantities of our cell-based drug candidates. Â In addition, as we proceed with our trial efforts, we must be able to continuously demonstrate to the FDA, EMA and other regulatory authorities that we can manufacture our cell therapy product candidates with consistent characteristics. Accordingly, we are materially dependent on these suppliers for supply of current GMP-grade materials of consistent quality. Our ability to complete ongoing clinical trials may be negatively affected in the event that we are forced to seek and validate a replacement source for any of these critical materials. Â We intend to decrease our dependency in third party suppliers for raw materials. To that effect we have developed a serum-free formulation which is expected to support the manufacturing of cell therapy products. This serum-free formulation was developed using our deep understanding in cell therapy industrial scale production standards, and the quality methods designed to support implementation in Phase III development and marketing. Achieving this significant technological challenge is expected to provide us with large-scale, highly consistent production with operational independency from third party suppliers for standard serum, an expensive and quantity limited product. There can be no guarantee that we will successfully implement the use of our serum-free formulation to support the manufacturing of cell therapy products or any other future product candidates, if any, that we seek to produce using such formulation, or that such implementation of the serum-free formulation will decrease our dependency on third party suppliers for raw materials. Â 29 Â Â With respect to CAR/TCR-MAIT products for immune-oncology, we are dependent upon third party suppliers for the construct of Chimeric Antigen Receptor, or CAR, or TCR, needed to manufacture the final product; if these third parties fail or are unable to perform in a timely manner, our ability to manufacture and deliver the final product will be compromised.Â Â In addition to the placenta used in the manufacturing process of extracting MAIT cells, the construct of CAR or TCR is needed for the manufacturing of the final product. The final product would be allogeneic placental derived MAIT cells transduced with CAR or TCR construct. The construct must be manufactured and supplied to us in sufficient quantities and in compliance with current GMP by a third party. To meet these requirements, we have started discussions with potential partners and manufacturers that obtain IP rights for these constructs, engaging in feasibility tests to ensure compliance with our MAIT cells and requirements. Â In addition to ensuring a proper partner or supplier to manufacture the construct, we must succeed in incorporating the construct into the MAIT cells to create a sufficient number of final products, i.e CAR or TCR-MAIT products. As a first POC, the final product will be tested for efficacy and safety in pre-clinical setting and the process development will be finalized to allow pre-IND readiness and proceed to clinical development. Â If these potential partners and manufactures fail to deliver sufficient construct in a timely manner and in compliance with current GMP, our ability to incorporate the construct in the MAIT cells to create sufficient number of final products will be compromised. Â A cybersecurity incident, other technology disruptions or failure to comply with laws and regulations relating to privacy and the protection of data relating to individuals could negatively impact our business and our reputation. Â We have relied on and utilize services provided by third parties in connection with our clinical trials, which services involve the collection, use, storage and analysis of personal health information. While we receive assurances from these vendors that their services are compliant with the Health Insurance Portability and Accountability Act, or HIPAA, and other applicable privacy laws, there can be no assurance that such third parties will comply with applicable laws or regulations. Non-compliance by such vendors may result in liability for us which would have a material adverse effect on our business, financial conditions and results of operations. Â During November 2021, we experienced a cybersecurity incident in which one or more third parties were able to impersonate one of our vendors by using a falsified email domain account and asked to make a payment to a false bank account. As a result of this incident, the third parties managed to extract a sum of approximately $616,000 from us. Following the incident, we hired the services of a cybersecurity investigation firm to fully access the incident and notified the appropriate government authorities, including the banks involved in the transaction. During February 2022, with the assistance of local and global law enforcement agencies, we were able to recover an amount of approximately $412,000 from the false bank account. Together with the reimbursement received from our insurance company, we were able to recover the full amount lost. Â The cybersecurity incident has not had any material effect on our ability to meet our financial obligations, including our ability to carry out our operations and business activities, and our investigation has confirmed that, other than the funds referenced above, none of our information or data was stolen or damaged. Nonetheless, despite the implementation of security measures, including the steps we have taken following the November 2021 cybersecurity incident, our internal computer systems and those of our current and future clinical research organization or CROs and other contractors and consultants may not prevent future incidents of a similar nature or other cyber-attacks. We are constantly exploring new and advanced security protection measures to prevent future cybersecurity incidents. See Item 1C. â€œCybersecurityâ€, for additional information. Â Future security breaches or any material system failure events could result in a material disruption of our development programs and our business operations. For example, the loss of clinical

trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. Â 30 Â Â In addition, we are subject to laws, rules and regulations in the Israeli, United States, the EU and other jurisdictions relating to the collection, use and security of personal information and data. Such data privacy laws, regulations and other obligations may require us to change our business practices and may negatively impact our ability to expand our business and pursue business opportunities. We may incur significant expenses to comply with the laws, regulations and other obligations that apply to us. Additionally, the privacy- and data protection-related laws, rules and regulations applicable to us are subject to significant change. Several jurisdictions have passed new laws and regulations in this area, and other jurisdictions are considering imposing additional restrictions. Privacy- and data protection-related laws and regulations also may be interpreted and enforced inconsistently over time and from jurisdiction to jurisdiction. Any actual or perceived inability to comply with applicable privacy or data protection laws, regulations, or other obligations could result in significant cost and liability, litigation or governmental investigations, damage our reputation, and adversely affect our business. Â Unsuccessful compliance with certain European privacy regulations could have an adverse effect on our business and reputation. Â The collection and use of personal health data in the EU is governed by the provisions of the General Data Protection Regulation, or GDPR. This directive imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The GPDR also extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member States may result in fines and other administrative penalties. There may be circumstances under which a failure to comply with GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on certain subjects. The GDPR regulations impose additional responsibility and liability in relation to personal data that we process, and we intend to put in place additional mechanisms ensuring compliance with these and/or new data protection rules. Â Changes to these European privacy regulations and unsuccessful compliance may be onerous and adversely affect our business, financial condition, prospects, results of operations and reputation. Â Â We may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse effect on our business. Â We are subject to the Foreign Corrupt Practice Act, or FCPA, and other laws that prohibit U.S. companies or their agents and employees from providing anything of value to a foreign official or political party for the purposes of influencing any act or decision of these individuals in their official capacity to help obtain or retain business, direct business to any person or corporate entity or obtain any unfair advantage. We have operations and agreements with third parties. Our international activities create the risk of unauthorized and illegal payments or offers of payments by our employees or consultants, even though they may not always be subject to our control. We discourage these practices by our employees and consultants. However, our existing safeguards and any future improvements may prove to be less than effective, and our employees or consultants, may engage in conduct for which we might be held responsible for Any failure by us to adopt appropriate compliance procedures and ensure that our employees and consultants comply with the FCPA and applicable laws and regulations in foreign jurisdictions could result in substantial penalties or restrictions on our ability to conduct business in certain foreign jurisdictions. Â Violations of the FCPA may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results, and financial condition. In addition, the U.S. government may seek to hold our Company liable for successor liability FCPA violations committed by companies in which we invest or that we acquire. Â 31 Â Â Other Risks Â Since we received grants from the IIA, we are subject to on-going restrictions. Â We have received royalty-bearing grants from the IIA, for research and development programs that meet specified criteria. The terms of the IIAâ€™s grants limit our ability to transfer know-how developed under an approved research and development program (by way of sale and/or granting a license to use the IP), and/or the manufacturing of products developed under an approved research and development program, outside of Israel, regardless of whether the royalties are fully paid. Any non-Israeli citizen, resident or entity that, among other things, becomes a holder of 5% or more of our share capital or voting rights, is entitled to appoint one or more of our directors or our Chief Executive Officer, or CEO, serves as a director of our Company or as our CEO is generally required to notify the same to the IIA and to undertake to observe the law governing the grant programs of the IIA, the principal restrictions of which are the transferability limits described above. To the extent a company wishes to transfer its IIA-supported know-how outside of Israel (by way of sale and/or granting a license to use the IP) â€“ the IIA acts under the Law for the Encouragement of research, Development and Technological Innovation in the Industry 1984 and the related IIA rules and regulations, it must be preapproved by the IIA and the company may be required to pay an additional payment to the IIA. The minimum amount of the payment is the total sum of grants received plus interest and the maximum amount shall be no higher than six times the total sum of grants received plus interest. In the case that the IIA-supported company sells the IP but retains its research and development center in Israel for at least three consecutive years, following the year of transferring the IIA-supported know-how outside of Israel, while maintaining at least 75% of its research and development employees in Israel â€“ the payment will be limited to three times the total sum of grants received plus interest. For more information, see â€œItem 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€“ Liquidity and Capital Resources.â€ Â Recent global inflation may adversely affect our business results. Â Inflation could affect our ability to purchase materials needed to support our research, development and operational activities, which in turn could result in higher burn rate and a higher end price of our future products. As a result, we may not be able to effectively develop our cell-based product candidates or cultivated meat products. If we are not able to successfully manage inflation, our prospects, business, financial condition, and results of operations could be adversely impacted. Â Non-compliance with environmental, social, and governance, or ESG, practices could harm our reputation, or otherwise adversely impact our business, while increased attention to ESG initiatives could increase our costs. Â Companies across industries are facing increasing scrutiny from a variety of stakeholders related to their ESG and sustainability practices. Certain market participants, including institutional investors and capital providers, are increasingly placing importance on the impact of their investments and are thus focusing on corporate ESG practices, including the use of third-party benchmarks and scores to assess companiesâ€™ ESG profiles in making investment or voting decisions, and engaging with companies to encourage changes to their practices. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us or our industry. If we do not comply with investor or stockholder expectations and standards in connection with our ESG initiatives or are perceived to have not addressed ESG issues within our company, our business and reputation could be negatively impacted and our share price could be materially and adversely affected, as well as our access to and cost of capital. Â While we may, at times, engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) or commitments to improve the ESG profile of our company and/or products, such initiatives or achievements of such commitments may not have the desired effect and may be costly. Â In addition, we may commit to certain initiatives or goals but not ultimately achieve such commitments or goals due to factors that are both within or outside of our control. Moreover, actions or statements that we may take based on expectations, assumptions, or third-party information that we currently believe to be reasonable may subsequently be determined to be erroneous or be subject to misinterpretation. Even if this is not the case, our current actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG initiatives and disclosures, even if such initiatives are currently voluntary. In addition, increasing ESG-related regulation, such as the SECâ€™s climate disclosure proposal, may also result in increased compliance costs or scrutiny. Â Expectations around a companyâ€™s management of ESG matters continues to evolve rapidly, in many instances due to factors that are out of our control.Â To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees or customers, which may adversely impact our operations. Â 32 Â Â Since we have signed the EIB Finance Agreement, we agreed to guaranty the loan as well as agreed to limitations that require us to notify the EIB, and in some cases obtain their approval, before we engage with other banks for additional sources of funding or with potential partners for certain strategic activities. Â The EIB Finance Agreement contains certain limitations that we must adhere to such as the use of proceeds received from the EIB, the disposal of assets, substantive changes in the nature of our business, our potential execution of mergers and acquisitions, changes in our holding structure, distributions of future potential dividends and our engaging with other banks and financing entities for other loans. Â Our principal research and development and manufacturing facilities are located in Israel and the unstable military and political conditions of Israel may cause interruption or suspension of our business operations without warning. Â Our principal research and development and manufacturing facilities are located in Israel. As a result, we are directly influenced by the political, economic, and military conditions affecting Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors. On October 7, 2023, Hamas terrorists infiltrated Israelâ€™s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israelâ€™s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israelâ€™s security cabinet declared war against Hamas and the Israeli military began to call-up reservists for active duty. At the same time, and because of the war declaration against Hamas, the clash between Israel and Hezbollah in Lebanon has escalated to an armed conflict and there is a high possibility that it will turn into a greater regional conflict in the future.Â Â According to the recent guidelines of the Israeli government, the Companyâ€™s offices, which are located in Haifa, are open and functioning as usual. However, if the war will escalate and expand further to the Northern border with Lebanon, and the Israeli government will impose additional restrictions on movement and travel, our management and employeesâ€™ ability to effectively perform their daily tasks might be temporarily disrupted, which may result in delays in some of our projects. Â Any hostilities involving Israel, terrorist activities, political instability or violence in the region, or the interruption or curtailment of trade or transport between Israel and its trading partners could make it more difficult for us to raise capital, if needed in the future, and adversely affect our operations and results of operations and the market price of our common shares. In addition, to the extent the IIA no longer makes grants similar to those we have received in the past, it could adversely affect our financial results. Â Furthermore, certain of our employees may be obligated to perform annual reserve duty in the Israel Defense Forces and are subject to being called up for active military duty at any time. Many Israeli citizens who have served in the army are required to perform reserve duty until they reach the age of 40 or older, depending upon the nature of their military service. Currently, none of our employees have been called up for active military duty. Â The intensity and duration of Israelâ€™s current war against Hamas and Hezbollah is difficult to predict, as are such warâ€™s economic implications on the Companyâ€™s business and operations and on Israelâ€™s economy in general. These events may be intertwined with wider macroeconomic indications of a deterioration of Israelâ€™s economic standing, for instance, a downgrade in Israelâ€™s credit rating by rating agencies, which may have a material adverse effect on the Company and its ability to effectively conduct its operations. Â In addition, Israeli-based companies and companies doing business with Israel, have been the subject of an economic boycott by members of the Arab League and certain other predominantly Muslim countries since Israelâ€™s establishment. Although Israel has entered into various agreements with certain Arab countries and the Palestinian Authority, and various declarations have been signed in connection with efforts to resolve some of the economic and political problems in the Middle East, we cannot predict whether or in what manner these problems will be resolved. Wars and acts of terrorism have resulted in significant damage to the Israeli economy, including reducing the level of foreign and local investment. Â ITEM 1B. UNRESOLVED STAFF COMMENTS. Â Not Applicable. Â Â 33 Â Â ITEM 1C. CYBERSECURITY Â We operate in the biotechnology field, which is subject to various cybersecurity risks that could adversely affect our business. We engage in the periodic assessment and testing of our policies, standards, processes and practices that are designed to address cybersecurity risks. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability testing, and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. We regularly engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the Audit Committee and we adjust our cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews. Â Our Chief Information Officer, or CIO, is responsible for day-to-day assessment, management of risks from cybersecurity threats our cybersecurity policies, standards, processes and practices which are based on applicable industry standards. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. Â While we have experienced a cybersecurity incident in the past (see Risk Factors - â€œA cybersecurity incident, other technology disruptions or failure to comply with laws and regulations relating to privacy and the protection of data relating to individuals could negatively impact our business and our reputation.â€) and cybersecurity threats in the past in the normal course of business and expect to continue to experience such threats from time to time, to date, none have had a material adverse effect on our business, financial condition, results of operations or cash flows. Even with the approach we take to cybersecurity, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on us. Â Risk Management and Strategy Â As part of our overall risk management, our cybersecurity program is focused on a comprehensive approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner. Â The Company deploys technical safeguards that are designed to protect the Companyâ€™s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence. Â The Company has established and maintains comprehensive incident response and recovery plans that fully address the Companyâ€™s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis. Â The Company maintains a comprehensive, risk-based approach to identifying and overseeing cybersecurity risks presented by third parties, including vendors, CROs, service providers and other external users of the Companyâ€™s systems, as well as the systems of third parties that could adversely impact our business in the event of a cybersecurity incident affecting those third-party systems. Â 34 Â Â Governance Â The Audit Committee oversees our risk management process, including the management of risks arising from cybersecurity threats. Our CIO is tasked with reporting any and all matters relating to cybersecurity to the Audit Committee. The Audit Committee receives regular presentations and reports on cybersecurity risks, which including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The Audit Committee receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. Â ITEMÂ 2. PROPERTIES. Â Our principal executive, manufacturing and research and development offices are located at MATAM Advanced Technology Park, Building No. 5, Haifa, Israel, where we occupy approximately 4,389 square meters. Our gross monthly rent payment for these leased facilities as of June 30, 2024 was 292,000 NIS (approximately $78,000). For fiscal year 2024, we recognized expense in the amount of $1,024,000, according to the implementation of Accounting Standards Update No. 2016-02, â€œLeases.â€ Â We believe that the current space we have is adequate to meet our current and foreseeable future needs. Â ITEM 3. LEGAL PROCEEDINGS. Â None. Â ITEM 4. MINE SAFETY DISCLOSURES. Â Not applicable. Â 35 Â Â PART II Â ITEM 5. MARKET FOR REGISTRANTâ€™S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. Â Our common shares are traded on Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol â€œPLURâ€.Â Â As of September 13, 2024, there were 57 holders of record, and 5,470,163 of our common shares wereÂ issued and outstanding. Â During the fiscal year 2024, we issued an aggregate of 25,395 restricted common shares to certain of our service providers as compensation in lieu of cash compensation owed to them for services rendered. Â We claimed exemption from registration under the Securities Act of 1933, as amended, or the Securities Act, for the foregoing transactions under SectionÂ 4(a)(2)Â of the Securities Act. Â Equiniti Trust Company, LLC is the registrar and transfer agent for our common shares. Their address is 55 Challenger Road, Floor 2, Ridgefield Park, NJ 07660. Telephone: (718) 921-8124, (800) 937-5449. Â ITEM 6. [RESERVED] Â Â ITEM 7. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Â We are a biotechnology company with an advanced cell-based technology platform. We have developed a unique 3D technology platform for cell expansion with an industrial scale in-house GMP cell manufacturing facility. We are utilizing our technology in the field of regenerative medicine, food tech, CDMO, and agtech and plan to utilize it in industries and verticals that have a need for our mass scale and cost-effective cell expansion platform via partnerships, joint ventures, licensing agreements and other

types of collaborations. Â Our operations are focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries.Â Â Cell Therapy Â We use our advanced cell-based technology platform in the field of regenerative medicine to develop placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, hematologic conditions and, most recently, we have also launched a novel immunotherapy platform. Â PLX cells: Our PLX cells are adherent stromal cells that are expanded using our 3D platform.Â Our PLX cells can be administered to patients off-the-shelf, without blood or tissue matching or additional manipulation prior to administration. PLX cells are believed to release a range of therapeutic proteins in response to the patientâ€™s condition. Â In the pharmaceutical area, we have focused on several indications utilizing our product candidates, including, but not limited to, muscle recovery following surgery for hip fracture, incomplete recovery following bone marrow transplantation, CLI, Chronic GvHD and a potential treatment for H-ARS. Some of these studies have been completed while others are still ongoing. We believe that each of these indications is a severe unmet medical need. Â In July 2023, we announced that we signed a three-year $4.2 million contract with the NIAID, which is part of the NIH. Under such contract, we will collaborate with the AFRRI and the USUHS, to further advance the development of our PLX-R18 cell therapy as a potential novel treatment for H-ARS, a deadly disease that can result from nuclear disasters and radiation exposure. Â MAIT cells: In May 2024, we launched a novel immunotherapy platform utilizing MAIT cells specifically designed to address solid tumors â€“ a critical area in medicine where effective treatments are currently insufficient. We believe that our MAIT cells, isolated from the human placenta, offer substantial potential benefits compared to conventional T cells. Â 36 Â Â Placental MAIT cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional autologous T-cells typically collected from peripheral blood, our MAIT cells are designed to be allogenic universal product. Benefiting with very restricted TCR, the MAIT cells minimizes their likelihood of inducing Graft versus Host Disease, or GvHD, a significant advantage over other potential allogeneic products. We are designing the MAIT to potentially show better persistence in the body for a longer duration, enhancing their therapeutic efficacy.Â Â PluriCDMOâ„¢ Â In January 2024,Â we announced that we are launching a new business division offering cell therapy manufacturing services as a CDMO: PluriCDMOâ„¢. PluriCDMOâ„¢ offers CDMO services to companies from early preclinical development, through late-stage clinical trials and commercialization, with a mission to deliver high-quality, essential therapies to patients. We have signed several agreements with clients and generating revenues from PluriCDMOâ„¢. Â AgTech Â We are actively involved in several initiatives leveraged by Pluriâ€™s 3D cell expansion in the agtech field, such as: (a) cell-based coffee business activity through PluriAgtech business vertical, which we announced in January 2024, (b) an innovative POC collaboration with ICL Group, a leading global specialty minerals company, to revolutionize bio stimulant delivery and enhance yield sustainably, and (c) a strategic POC agreement with a leading international agriculture corporation which is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture. Â Food Tech Â In 2022, we announced the establishment of a joint venture with Tnuva, Ever After Foods, which is incorporated under the laws of the State of Israel, with the purpose of developing cultivated meat product of all kinds and types. Â Leveraging Pluriâ€™s innovative technology, Ever After Foods has rapidly advanced its scalable production platform, developing a B2B version of its proprietary technology system, Ever After Foods has demonstrated the natural production of muscle and fat tissues for various animal cells, ensuring taste, feel, and texture akin to conventional animal-derived meat. Â On June 12, 2024, we entered into a share purchase agreement, or the Agreement, by and among Ever After Foods, Tnuva, and certain other international investors, or, collectively, the Investors, pursuant to which Ever After Foods issued and sold ordinary shares in a private placement offering, or the Offering, for aggregate gross proceeds of $10 million. As part of the Offering, we invested $1.25 million. In addition, the Subsidiary and Ever After Foods executed anÂ Amended and Restated Technology License Agreement, dated June 12, 2024, or the Amended License. The Amended License amended theÂ partiesâ€™ existing license agreement dated as of February 23, 2022, to expand the scope of the license to include fish and seafood.Â Â The $10 million funding round was intended to support Ever After Foodsâ€™ B2B technology platform, positioning it as a sustainable technology enabler. Following the closing of the Offering, the Subsidiary holds approximately 69% of Ever After Foods. Â 37 Â Â RESULTS OF OPERATIONS â€“ YEAR ENDED JUNE 30, 2024 COMPARED TO YEAR ENDED JUNE 30, 2023 Â Revenues Â Revenues for the year ended June 30, 2024 were $326,000, compared to $287,000 for the year ended June 30, 2023. The revenues in the year ended June 30, 2024 were mainly related to fees derived from services provided to CDMO clients and to a POC collaboration with ICL Group in the agtech field. The revenues in the year ended June 30, 2023 were mainly related to our collaboration in the biologic field. The increase in revenues is mainly attributed to the launch of new business verticals, specifically in the CDMO and agtech fields. Â Research and Development, Net Â Research and development, net (costs less participation by the IIA, Horizon Europe and the NIAID) decreased by 21% from $15,745,000 for the year ended June 30, 2023, to $12,446,000 for the year ended June 30, 2024. The decrease is mainly attributed to: (1) a decrease in clinical studies expenses following the completion of our CLI, COVID-19 and muscle regeneration following hip fracture clinical studies, (2) a decrease in material purchases in accordance with our manufacturing needs and plans, (3) a decrease in salaries and related expenses as part of a efficiency cost-reduction plan, specifically a reduction of 16 research and development, or R&D, employees in the Subsidiary (92 employees on June 30, 2024, compared to 108 employees on June 30, 2023) and due to the exchange rate differences related to the strength of the U.S. dollar against the NIS, and (4) participation grants from the NIAID contract, offset by a decrease in other participation grants, specifically the completion of the CLI and muscle regeneration following hip fracture clinical studies which were supported by the EU Horizon 2020 grants. Â General and Administrative Â General and administrative expenses decreased by 15% from $11,779,000 for the year ended June 30, 2023, to $10,034,000 for the year ended June 30, 2024. The decrease is mainly attributed to: (1) a decrease in share-based compensation expenses related to employee terminations and RSU expense amortization over time (see also notes 9c to the consolidated financial statements included elsewhere in this Annual Report) and a decrease due to the amount of RSUs and options granted to our CEO in 2023, partially offset by an increase in share-based compensation expenses related to the amount of RSUs and options granted in 2024, and (2) a decrease in salaries and related expenses due to the exchange rate differences relates to the strength of the U.S. dollar against the NIS and as a result of our cost reduction and efficiency plan,Â including a temporary reduction in the salaries of our executive officers. Â Total Financial Income (Expense), Net Â Total financial income (expenses), net increased from $1,641,000 in financial expenses for the year ended 2023 to $814,000 in financial income for the year ended June 30, 2024. This increase is mainly attributable to (1) income relating to exchange rate differences related to the EIB loan provided to us in June 2021 pursuant to the EIB Finance Agreement (as a result of the strength of the U.S. dollar against the Euro, which increased by 3% in 2024 compared to 2023 where it decreased by 5%), (2) an increase related to interest income from bank deposits, and (3) an increase in gain from hedging transactions compared to a loss from hedging transactions in the previous period. Â Net Loss for the Year Â Net loss decreased from $28,887,000 for the year ended June 30, 2023 to $21,344,000 for the year ended June 30, 2024. The decrease was mainly due to a decrease in R&D expenses, net, a decrease in general and administrative expenses and an increase in financial income (expense), net for the reasons mentioned above. We had a net loss attributed to our non-controlling interest in Ever After Foods for the year ended June 30, 2024 and June 30, 2023 of $456,000 and $566,000, respectively. Â Loss per share for the year ended June 30, 2024, was $3.99, as compared to $6.24 loss per share for the year ended June 30, 2023. The change in the loss per share was mainly as a result of a decrease in the loss for the year, and by an increase in our weighted average number of shares due to the issuance of additional shares during fiscal year 2024. Â Â 38 Â Â Liquidity and Capital Resources Â As of June 30, 2024, our total current assets were $31,107,000 and our total current liabilities were $4,454,000. On June 30, 2024, we had a working capital surplus of $26,653,000 and an accumulated deficit of $420,472,000. Â As of June 30, 2023, our total current assets were $41,409,000 and our total current liabilities were $5,621,000. On June 30, 2023, we had a working capital surplus of $35,788,000 and an accumulated deficit of $399,584,000. Â Our cash, cash equivalents and restricted cash as of June 30, 2024, amounted to $7,037,000, which reflects an increase of $1,408,000 from the $5,629,000 reported as of June 30, 2023. Our cash equivalents and restricted cash increased in the year ended June 30, 2024, for the reasons presented below. Our bank deposits and restricted bank deposits as of June 30, 2024, amounted to $23,836,000 compared to $35,438,000 as of June 30, 2023. Our bank deposits and restricted bank deposits as of June 30, 2024, decreased in the year ended June 30, 2024, for the reasons presented below. Â Our cash used in operating activities was $18,021,000 during the year ended June 30, 2024, and $22,857,000 during the year ended June 30, 2023. The decrease in cash used in operating activities is mainly attributed to a decrease in net loss following the completion of certain clinical trials and the implementation of a cost reduction and efficiency plan including a temporary reduction in the salaries of our executive officers, directors, management team and other employees. Cash used in operating activities in year ended June 30, 2024 and June 30, 2023 consisted primarily of payments of fees to our suppliers, subcontractors, professional services providers and consultants, and payments of salaries to our employees, partially offset by grants from the IIA, the Horizon Europe program, and funds received from the NIAID contract. Â Cash provided by investing activities was $10,584,000 during the year ended June 30, 2024, and cash provided by investing activities of $9,698,000 during the year ended June 30, 2023. Cash provided by investing activities in the year ended June 30, 2024 consisted primarily of the withdrawal of $10,907,000 of short-term deposits, partially offset by payments of $323,000 related to investments in property and equipment. Cash provided by investing activities in the year ended June 30, 2023 consisted primarily of the withdrawal of $9,960,000 of short-term deposits, partially offset by payments of $262,000 related to investments in property and equipment. Â Financing activities provided cash in the amount of $8,841,000 during the year ended June 30, 2024, and $8,024,000 during the year ended June 30, 2023. The financing activities during the year ended June 30, 2024 related primarily to the investment in Ever After Foods by external investors. The financing activities during the year ended June 30, 2023 related to issuances of common shares and warrants, net of issuance costs, in the December 2022 Private Placement (as defined below). Â Between December 13, 2022 and December 27, 2022, the Company entered into a series of securities purchase agreements with several purchasers for an aggregate of 1,019,488 common shares and warrants, or the Warrants, to purchase up to 1,019,488 common shares, or the December 2022 Private Placement. On December 13, 2022, the Company executed securities purchase agreements to sell at a purchase price of $8.24 per share, up to 697,486 common shares and warrants to purchase up to 697,486 common shares, with an exercise price of $8.24 per share and a term of three years. On December 14, 2022, the Company executed securities purchase agreements to sell at a purchase price of $8.4 per share, up to 258,565 common shares and warrants to purchase up to 258,565 common shares, with an exercise price of $8.4 per share and a term of three years. On December 15, 2022, the Company executed securities purchase agreements to sell at a purchase price of $8.48 per share, up to 29,688 common shares and warrants to purchase up to 29,688 common shares, with an exercise price of $8.48 per share and a term of three years. On December 19, 2022, the Company executed a securities purchase agreement to sell at a purchase price of $8.72 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.72 per share and a term of three years. On December 27, 2022, the Company executed a securities purchase agreement to sell at a purchase price of $8.96 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.96 per share and a term of three years. The Warrants sold in the December 2022 Private Placement are exercisable upon the later of six months from their issuance date, or from the date the Company increased its authorized shares. The Company issued 1,019,488 common shares and Warrants that relate to the December 2022 Private Placement and received $8 million as of that date net of $445,000 from issuance expenses. Â 39 Â Â The Warrants sold in the December 2022 Private Placement were exercisable upon the later of six months from their issuance date, or from the date we increased our authorized shares. On April 27, 2023, our shareholders approved an amendment to our articles of incorporation to increase the number of authorized common shares from 7,500,000 shares to 37,500,000 shares and such increase was effectuated on May 1, 2023 when the Company filed its amendment to its articles of incorporation reflecting such increase. As such, the Warrants became exercisable on May 1, 2023. Â Â On December 14, 2022, Yaky Yanay, our CEO, agreed to forgo, starting January 1, 2023, $375,000 of his annual cash salary for the next twelve months in return for equity grants, issuable under our existing equity compensation plans. In that regard, we granted Mr. Yanay (i) 41,853 RSUs, vesting ratably each month, and (ii) options to purchase 41,853 common shares, vesting ratably each month, with a term of 3 years, at an exercise price of $8.96 per share. In addition, the Boards also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vested on June 30, 2023 and 50% vested on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vested on June 30, 2023 and 50% vested on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.8 per share, 50% vested on June 30, 2023 and 50% vested on December 31, 2023. All options that were granted in January 2023 will expire on April 27, 2026. Â In December 2023, in light of the ongoing conflict in Israel and challenges in predicting its resolution and the subsequent impact on the Companyâ€™s operations, and in order to ensure the Companyâ€™s financial stability, the Board approved, at the recommendation of the Companyâ€™s management, (i) a 20% monthly cash salary reduction in the amount of 39,600 NIS to Mr. Yanay, our CEO, for the months of January 2024 and February 2024, (ii) a 20% cash salary reduction in the amount of 39,000 NIS to Mrs. Franco â€“ Yehuda, our Chief Financial Officer, or CFO, for the months of December 2023, January 2024 and February 2024, andÂ (iii) a 20% monthly fee reduction to the fees that are paid to each of the Companyâ€™s directors for the months of December 2023 through February 2024. Â On July 16, 2020, we entered into an at-the market agreement, or the ATM Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may issue and sell shares of our common shares having an aggregate offering price of up to $75,000,000 from time to time through Jefferies. Upon entering into the ATM Agreement, we filed a new shelf registration statement on Form S-3, which was declared effective by the SEC on July 23, 2020. On September 21, 2022, as a result of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we reduced the amount available to be sold under the ATM Agreement to a maximum aggregate offering price of up to $11,800,000 of our common shares from time to time through Jefferies. During the year ended June 30, 2023, we did not sell of our any common shares under the ATM Agreement. Â On September 7, 2023, we provided a formal notice of termination of the ATM Agreement with Jefferies, which took effect on September 8, 2023. Â On February 13, 2024, we entered into a sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., as agent, pursuant to which we may issue and sell our common shares having an aggregate offering price of up to $10 million, from time to time through A.G.P. As of September 17, 2024, we have sold an aggregate of 42,729 common shares pursuant to the Sales Agreement at an average price of $5.93 per share. Â We have an effective Form S-3 registration statement (File No. 333-273347), filed under the Securities Act of 1933, as amended, with the SEC using a â€œshelfâ€ registration process. Under this shelf registration process, we may, from time to time, sell our common shares, preferred stock and warrants to purchase common shares, and of two or more of such securities, in one or more offerings for an aggregate initial offering price of $200 million (including amounts sold under the Sales Agreement). Â In April 2020, we and the Subsidiary and the German Subsidiary, executed the EIB Finance Agreement for nonâ€“dilutive funding of up to â‚¬50 million in the aggregate, payable in three tranches. The proceeds from the EIB Finance Agreement were intended to support our research and development in the EU to further advance our regenerative cell therapy platform, and to bring the products in our pipeline to market. The term of the project was three years commencing on January 1, 2020. Â 40 Â Â During June 2021, we received the first tranche in the amount of â‚¬20 million pursuant to the EIB Finance Agreement. The amount received is due to be repaid on June 1, 2026, and bears annual interest of 4% to be paid together with the principal of the loan. As of June 30, 2024, the interest accrued was in the amount of approximately â‚¬2.5 million. In addition to the interest payable, the EIB is also entitled to royalty payments, pro-rated to the amount disbursed from the EIB loan, on our consolidated revenues beginning in the fiscal year 2024 up to and including its fiscal year 2030, in an amount equal to up to 2.3% of our consolidated revenues below $350 million, 1.2% of our consolidated revenues between $350 million and $500 million and 0.2% of our consolidated revenues exceeding $500 million. As the project term ended on December 31, 2022, we do not expect to receive additional funds pursuant to the EIB Finance Agreement. Â Non-dilutive grants Â Israel Innovation Authority (IIA) Â According to the IIA grant terms, we are required to pay royalties at a rate of 3% on sales of products and services derived from technology developed using this and other IIA grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required. Through June 30, 2024, total grants obtained from the IIA aggregated to approximately $27.7 million and total royalties paid and accrued amounted to $179 thousand. Â Â The IIA may impose certain conditions on any arrangement under which the IIA permits the Company to transfer technology or development out of Israel or outsource manufacturing out of Israel. While the grant is given to the Company over a certain period of time (usually a year), the requirements and restrictions under the Israeli Law for the Encouragement of Industrial Research and Development, 1984 continue and do not have a set expiration period, except for the royalties, which requirement to pay them expires after payment in full. Â In June 2020, we announced that we were selected as a member of the CRISPR-IL consortium, a group funded by the IIA. CRISPR-IL brings together the leading experts in life science and computer science from academia, medicine, and industry, to develop AI based end-to-end genome-editing solutions. These next-generation, multi-species genome editing products for human, plant, and animal DNA, have applications in the pharmaceutical, agriculture, and aquaculture industries. CRISPR-IL is

funded by the IIA with a total budget of approximately $10 million of which, an amount of approximately $480 thousand was a direct grant allocated to us, for the initial period of 18 months. During October 2021, we received an approval for an additional grant of approximately $583 thousand from the IIA pursuant to the CRISPR-IL consortium program, for an additional period of eighteen months. During January 2023, we received approval for an extension of an additional 2 months to finish the program until June 30, 2023. The CRISPR-IL consortium program does not include any obligation to pay royalties. Through June 30, 2024, we received total grants of approximately $774 thousand in cash from the IIA pursuant to the CRISPR-IL consortium program, and we expect to receive an additional $253 thousand. Â EU grants â€“ Horizon 2020 and Horizon Europe Â Through June 30, 2024, we received total grants of approximately $8.4 million in cash from the EU Horizon programs. Â On September 6, 2022, we announced that a â‚¬7.5 million non-dilutive grant from the EUâ€™s Horizon program was awarded to Advanced Personalized Therapies for Osteoarthritis (PROTO), an international collaboration led by CharitÃ© Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize our PLX-PAD cells for the treatment of mild to moderate knee osteoarthritis. Final approval of the grant is subject to completion of the consortium agreement. An amount of approximately Euro 500 thousand (approximately $520,000) will be a direct grant that will be allocated to us. Through June 30, 2024, we received a payment of approximately $185,000 in cash, which relates to the PROTO program.Â The clinical study, once approved by the regulatory agencies, will be carried out by CharitÃ©, together with us and other members of the international consortium under the leadership of Professor Tobias Winkler, Principal Investigator, at the Berlin Institute of Health Center of Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery. Â 41 Â Â Outlook Â We have accumulated a deficit of $420,472,000 since our inception in May 2001. We do not expect to generate any significant revenues from sales of products in the next twelve months. We expect to generate revenues from the sale of services in our CDMO activity, from collaboration based on our cell-based products, and from licenses to use our technology and products. Although we were able to reduce the burn rate significantly in the last few years, it is unlikely that in the short term revenues will exceed our costs of operations. Â We may be required to obtain additional liquidity resources in order to support the commercialization of our products and technology and maintain our research and development activities. Â We are continually looking for sources of funding, including collaboration with other companies via licensing agreements, joint ventures and partnerships, and other non-dilutive sources such as our contract with NIAID and DoD, research grants such as the IIA grants and the European Union grants, and sales of our common shares. Â We believe that we have sufficient cash to fund our operations for at least the next twelve months. Â Application of Critical Accounting PoliciesÂ and Estimates Â Our accounting policies are more fully described in Note 2 to our consolidated financial statements appearing in this Annual Report. We believe that the accounting policy below is critical for one to fully understand and evaluate our financial condition and results of operations. Â The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the reported revenues and expenses during the reporting periods. We evaluate such estimates and judgments on an ongoing basis, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Â 42 Â Â Share-Based Compensation Â Share-based compensation is considered a critical accounting policy due to the significant expenses of RSUs which were granted to our employees, directors and consultants. In fiscal year 2024, we recorded share-based compensation expenses related to options, restricted shares and RSUs in the amount of $2,618,000. Â In accordance with ASC 718, â€œCompensation-Stock Compensationâ€, or ASC 718, RSUs granted to employees and directors are measured at their fair value on the grant date. All RSUs granted in fiscal years 2024 and 2023 were granted for no consideration; therefore, their fair value was equal to the share price at the date of grant unless the RSUs include a market-based condition in which case the fair value RSUs at the date of grant was calculated using the Monte Carlo model. The RSUs granted in fiscal year 2024 to non-employee consultants were measured at their fair value on the grant date in accordance with ASU No. 2018-07 - â€œCompensationâ€“Share Compensationâ€. Â Â The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in our consolidated statements of operations. We have graded vesting based on the accelerated method over the requisite service period of each of the awards. The expected pre-vesting forfeiture rate affects the number of the shares. Based on our historical experience, the pre-vesting forfeiture rate per grant is 16% for the shares granted to employees and 0% for the shares granted to our directors and officers and non-employee consultants. Â ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Â Not applicable. Â 43 Â Â ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. Â Â PLURI INC. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS Â As of June 30, 2024 Â U.S. DOLLARS IN THOUSANDS Â INDEX Â Â PageÂ Â Â Report of Independent Registered Public Accounting Firm (PCAOB ID 1309) F-2 Â Â Consolidated Balance Sheets F-3 Â Â Consolidated Statements of Operations F-5 Â Â Statements of Changes in Shareholdersâ€™ Equity F-6 Â Â Consolidated Statements of Cash Flows F-8 Â Â Notes to Consolidated Financial Statements F-9 Â F-1 Â Â Â Report of Independent Registered Public Accounting FirmÂ Â To the Board of Directors and Shareholders of Pluri Inc. Â Opinion on the Financial Statements Â We have audited the accompanying consolidated balance sheets of Pluri Inc. and its subsidiaries (the â€œCompanyâ€) as of June 30, 2024 and 2023, and the related consolidated statements of operations, of changes in shareholdersâ€™ equity and of cash flows for the years then ended, including the related notes (collectively referred to as the â€œconsolidated financial statementsâ€). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. Â Basis for Opinion Â These consolidated financial statements are the responsibility of the Companyâ€™s management. Our responsibility is to express an opinion on the Companyâ€™s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. Â We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Companyâ€™s internal control over financial reporting. Accordingly, we express no such opinion. Â Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Â Critical Audit Matter Â The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Â Liquidity and capital resources Â As discussed in Note 1c to the consolidated financial statements, management believes that its cash and cash equivalent, restricted cash, and short-term bank deposit as of June 30, 2024, are sufficient to satisfy the Companyâ€™s capital needs for at least twelve months from the date of the issuance of these consolidated financial statements. The Company has been funded primarily through offerings of the Companyâ€™s securities and borrowings. Management expects that the Company will incur additional losses as it continues to focus its resources on advancing research and development activities as well as commercial operations, which will result in negative cash flows from operating activities. In case that the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued. Â The principal considerations for our determination that performing procedures related to liquidity and capital resources is a critical audit matter are the estimation and execution uncertainty regarding the Companyâ€™s future cash flows and managementâ€™s judgments and assumptions in estimating these cash flows to conclude the Company would have sufficient liquidity to fund its operations for at least the next twelve months. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions. Â Addressing the matter involved performing procedures and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements. Our audit procedures included, among others, testing the reasonableness of the forecasted revenue, operating expenses, and uses and sources of cash used in managementâ€™s assessment of whether the Company has sufficient liquidity to fund its operations for at least the next twelve months. We assessed the appropriateness of the forecast assumptions by comparing prior period forecasts to actual results, comparing forecasted revenue to signed agreements and other references, inquiring of management regarding the process and related controls and investigating mitigating actions to manage cash flows to meet the Companyâ€™s budget. Â Â /s/ Kesselman & Kesselman Â Certified Public Accountants (lsr.) A member firm of PricewaterhouseCoopers International Limited Â Haifa, Israel September 18, 2024 Â We have served as the Companyâ€™s auditor since 2021. Â F-2 Â Â PLURI INC. AND ITS SUBSIDIARIES CONSOLIDATED BALANCE SHEETS U.S. Dollars in thousands (except share and per share data) Â Â Â Â Â Â Â June 30,Â Â Â NoteÂ Â 2024Â Â 2023Â ASSETSÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT ASSETS:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

controlling interestsÂ Â 8,750Â Â Â -Â Net cash provided by financing activitiesÂ $8,841Â Â $8,024Â EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS and restricted cashÂ Â 11Â Â Â (22) Increase (decrease) in cash, cash equivalents, restricted cash and restricted bank depositsÂ Â 1,415Â Â Â (5,157) Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the periodÂ Â 6,256Â Â Â 11,413Â Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the periodÂ $7,671Â Â $6,256Â Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:Â Â Â Â Â Â Â Cash and cash equivalentsÂ Â 6,783Â Â Â 5,360Â Restricted cashÂ Â 254Â Â Â 269Â Long-term restricted bank depositsÂ Â 634Â Â Â 627Â Total cash, cash equivalents, restricted cash and restricted bank depositsÂ $7,671Â Â $6,256Â (a) Supplemental disclosure of non-cash activities:Â Â Â Â Â Â Â Purchase of property and equipment on creditÂ $4Â Â $74Â Lease liabilities arising from obtaining right-of-use assetsÂ $82Â Â $60Â Â The accompanying notes are an integral part of the consolidated financial statements. Â F-8 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 1: - GENERAL Â a. Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.â€™s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol â€œPLURâ€. Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.) or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods formerly known as Plurinuva Ltd. Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries â€“ Agricultural Cooperative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the â€œCompanyâ€ or â€œPluri.â€ The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the â€œSubsidiaries.â€ Â b. The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech and launched a Contract Development and Manufacturing Organization or CDMO business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries. Â c. The Company has incurred an accumulated deficit of approximately $420,472 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of June 30, 2024, the Companyâ€™s total shareholdersâ€™ equity amounted to $96. During the year ended June 30, 2024, the Company incurred losses of $21,344 and its negative cash flow from operating activities was $18,021. Â As of June 30, 2024, the Companyâ€™s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled to $30,873. Â The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities. The Companyâ€™s management believes that its current resources together with its existing operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these consolidated financial statements. During 2023 and 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the requiredÂ level of financing, operations may need to be scaled down or discontinued. Â On April 30, 2020, the German Subsidiary entered into a finance contract or the Finance Contract with the EIB, pursuant to which the German Subsidiary obtained loan in an amount of à¬20 million, or the Loan. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal and interest accrued balance was of $24,027 and is presented among long-term liabilities (see note 7). Â F-9 Â Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 1: - GENERAL (CONT.) Â d. Reverse share split In March 2024, the Companyâ€™s Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Companyâ€™s (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented. Â An additional 67,836 common shares were included in the Companyâ€™s issued and outstanding shares as a result of rounding-up fractional shares into whole shares as a result of the reverse share split. Â Â e. On January 5, 2022, the Subsidiary entered into a Joint Venture Agreement with Tnuva pursuant to which the Subsidiary and Tnuva established Ever After Foods, with the purpose of developing cultivated meat products. Ever After Foods received exclusive, global, royalty bearing licensing rights to use Pluriâ€™s proprietary technology, intellectual property and knowhow in the field of cultivated meat. Tnuva invested $7,500Â in Ever After Foods and received 187,500 of Ever After Foodsâ€™s ordinary shares, representingÂ 15.79% of the Ever After Foods share capital as of February 24, 2022, or the Closing Date. In addition, Tnuva received warrants to invest up to an additional $7,500 over a period of twelve months following the Closing Date. Â Â The first warrant, or the First Warrant issued to Tnuva permitted Tnuva to purchase up to 125,000 ordinary shares of Ever After Foods at an exercise price of $40.00 per share and had a term commencing as described in the agreement. In addition, on the six month anniversary of the Closing Date, and provided that the First Warrant had not expired, Ever After Foods agreed to issue a second warrant, or the Second Warrant and together with the First Warrant, or the Warrants) to Tnuva which permitted Tnuva to purchase up to a number of ordinary shares of Ever After Foods, or the then most senior securities issued by Ever After Foods, in consideration for such amount equal to 200% of the remaining balance of the aggregate purchase price of the First Warrant, provided that Tnuva exercised at least 62,500 ordinary shares at a price per share of $40.00, or $2,500 in the aggregate, of the First Warrant. The Second Warrantâ€™s exercise price per share equaled $76.00. The Second Warrant had a term commencing as described in the agreement. Â Â Â The Company allocated the total consideration of $7,500 received in an amount equal to $6,718 for the ordinary shares and $782 for the Warrants. Â Â Â On January 5, 2022, the Company determined the fair value of the ordinary shares and the Warrants utilizing a Monte Carlo simulation model (Level 3 classification), which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event. The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field. Â Risk-freeÂ interestÂ rateÂ Â 1.08% Expected share price volatilityÂ Â 85% Â Â The consideration allocated to the shares issued was divided between the non-controlling interests, or NCI, and the Companyâ€™s shareholders as this transaction is a transaction with the NCI. Â Â Â The consideration allocated to the Warrants was recognized against the NCI. Â Â Â On August 23, 2022, or the Amendment Date, Ever After Foods and Tnuva executed an amendment to the warrant agreement, or the Amendment, extending the exercise period of the First Warrant from six months to nine months from the Closing Date. All other terms remained unchanged. Â F-10 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 1: - GENERAL (CONT.) Â e. Following the Amendment, the Company recalculated the fair value of the warrants utilizing the same Monte Carlo simulation model (Level 3 classification) before and after the Amendment Date, which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event. Â Â Â The main assumptions used in the Monte Carlo simulation model are as follows: Â Risk-freeÂ interestÂ rateÂ Â 3.25% Expected share price volatilityÂ Â 70% Â The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field. The additional fair value determined was $385. Â Â On November 22, 2022, the warrants in Ever After Foods expired unexercised and $1,014 were classified from NCI to additional paid-in capital. Â Â f. On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors. Ever After Foods agreed to issue and sell, ordinary shares in a private placement offering, for aggregate gross proceeds of $10,000. As part of the offering, the Subsidiary invested $1,250. As a result, the Companyâ€™s capital consideration isÂ $8,750, of which $3,185 is attributed to non-controlling interests. Following the closing of the offering, the Company continued to own approximately 69% of Ever After Foodsâ€™ shares. Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES Â Basis of presentation Â The consolidated financial statements have been prepared in accordance with the United States Generally Accepted Accounting Principles, or U.S. GAAP. Â a. Use of estimates Â The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments, and assumptions that are reasonable based upon information available at the time they are made. Estimates are primarily used for, but not limited to, valuation of share-based compensation, valuation of warrants and determining the valuation and terms of leases. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results could differ from those estimates. Â b. Functional currency Â The U.S. dollar is the primary currency of the economic environment in which the Company and the Subsidiaries operate. Thus, the U.S. dollar is the Companyâ€™s functional and reporting currency. Accordingly, non-dollar denominated transactions and balances have been re-measured into the functional currency in accordance with Accounting Standards Codification, or ASC, 830, â€œForeign Currency Mattersâ€. All transaction gains and losses from the re-measured monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate.Â F-11 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â c. Principles of consolidation Â The consolidated financial statements include the accounts of the Company and its Subsidiaries. Non-controlling interests in subsidiaries represent the equity in Ever After Foods not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the shareholders of the Company. Profit or loss and components of other comprehensive income or loss are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of operations. Â The Company treats transactions with non-controlling interests as transactions with its equity owners. Accordingly, for sales or purchases of shares to or from non-controlling interests, the difference between any consideration received or paid and the portion sold or acquired of the carrying value of the net assets of the subsidiary is recorded in equity. Â Intercompany transactions and balances have been eliminated upon consolidation. Â d. Cash and cash equivalents Â Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired. Â e. Short-term bank deposit Â Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. Â f. Restricted cash Â Restricted cash is cash used to secure the Companyâ€™s credit line, derivative and hedging transactions and lease agreement. The restricted cash is presented at cost which approximates market values including accrued interest. Â g. Long-term restricted bank deposits Â Long-term restricted bank deposits with maturities of more than one year used to secure operating lease agreement are presented at cost which approximates market values including accrued interest.Â F-12 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â h. Revenue Recognition Â A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each partyâ€™s rights regarding the distinct goods or services to be transferred, or the Performance Obligations, (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Â Revenues are recognized when the control of the promised goods or the performance of the obligations are transferred to the customer, in an amount that reflects the consideration to which the Company expects to be entitled, excluding sales taxes. Â The Company determines revenue recognition through the following steps: Â â—identification of the contract with a customer; Â â—identification of the Performance Obligations in the contract; Â â—determination of the transaction price; Â â—allocation of the transaction price to the Performance Obligations in the contract; and Â â—recognition of revenue when, or as, the Company satisfies a Performance Obligation. Â i. Property and equipment Â Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: Â Â Â % Laboratory equipment Â 10-40 Computers and peripheral equipment Â 33 Office furniture and equipment Â 15 Leasehold improvements Â The shorter of the expected useful life or the term of the lease. Â Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Â j. Impairment of long-lived assets Â The Companyâ€™s long-lived assets are reviewed for impairment in accordance with ASC 360, â€œProperty, Plant and Equipmentâ€, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During fiscal years 2024 and 2023, no impairment losses were recorded.Â F-13 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â Â k. Share-based compensation Â The Company accounts for share-based compensation in accordance with ASC 718, â€œCompensation-Share Compensationâ€, or ASC 718. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company estimates the fair value of share options granted using the Black-Scholes option-pricing model. The Company accounts for employeesâ€™ share-based payment awards classified as equity awards, such as restricted share units, or RSUs, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. Â The Company recognized compensation cost for an award with service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Â The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Â The fair value of service-based share option grants is estimated on the grant date using a Black-Scholes option-pricing model and compensation expense related to share option and RSUs grants are recognized on a graded vesting schedule over the vesting period. Â All RSUs to employees and directors granted during fiscal 2024 and 2023 were granted for no consideration. Therefore, their fair value was equal to the share price at the date of grant. Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSU granted during fiscal years 2024 and 2023 was $4.32 and $7.92 per share, respectively. Â The fair value of the service-based share option grants was estimated on the grant date using a Black-Scholes option-pricing model. The weighted average grant date fair value of option granted during fiscal years 2024 and 2023 was $3.85 and $3.65 per option, respectively. Â The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions: Â Â Â 2024Â Â 2023Â Underlying value ofÂ common shares ($)Â Â 4.40-6.08Â Â Â 7.52-7.92Â Exercise price ($)Â Â 4.40-6.08Â Â Â 8.96-20.80Â Expected volatility (%)Â Â 78.44Â Â Â 86.40-86.48Â Expected terms of the option (years)Â Â 5-7Â Â Â 3Â Risk-free interest rate (%)Â Â 4.04-4.13Â Â Â 4.03-4.22Â Â F-14 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â l. Research and development expenses, royalty bearing grants and non-royalty bearing grants Â Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and development are expensed as incurred. Â Grants received from the Israel Innovation Authority, or the IIA, are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred (see also note 8b). Â During fiscal years 2024 and 2023, the Company also received (in cash) non-royalty bearing grants from the European UnionÂ research and development consortiums, under Horizon 2020, Horizon Europe, U.S. National Institute of Allergy and Infectious Diseases, or the NIAID, and from the

IIA, under the CRISPR-IL consortium, in the aggregate amount of approximately $1,113 and $2,426, for the years ended June 30, 2024 and 2023, respectively. The non-royalty bearing grants for funding the projects are recognized at the time the Company is entitled to each such grant based on the related costs incurred and recorded as a deduction from research and development expenses. Â Research and development expenses, net for the years ended June 30, 2024 and 2023 include participation in research and development expenses in the amount of approximately $1,334 and $1,668, respectively. Â m. Loss per share Â Basic and diluted loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year, including unexercised vested options with no par value exercise price. All outstanding share options, unvested RSUs and warrants have been excluded from the calculation of the diluted loss per common share because all such securities are anti-dilutive for each of the periods presented. The total number of shares related to the outstanding options, warrants and RSUs excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,635,190 and 1,768,948 for the years ended June 30, 2024 and 2023, respectively.Â F-15 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â n. Income taxes Â Â 1. Deferred taxes Â Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Â Â 2. Uncertainty in income taxes Â The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, â€œIncome Taxesâ€, or ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Â o. Concentration of credit risk Â Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, long-term restricted bank deposits. Â The majority of the Companyâ€™s cash and cash equivalents, restricted cash, short-term bank deposits and long-term restricted deposits are mainly invested in the New Israeli Shekel, or NIS, and U.S. dollar deposits of major banks in Israel and in the United States. Deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk. The Company invests its surplus cash in cash deposits in financial institutions and has established guidelines, approved by the Companyâ€™s Investment Committee, relating to diversification and maturities to maintain safety and liquidity of the investments. Â p. Severance pay Â The majority of the Companyâ€™s agreements with employees in Israel are subject to Section 14 of the Israeli Severance Pay Law, 1963, or the Severance Pay Law. The Companyâ€™s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employeeâ€™s monthly salary for each year of employment, no additional obligation exists regarding the matter of severance pay and no additional payments are made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. Â For Yaky Yanay, the Companyâ€™s Chief Executive Officer, or the CEO, whose agreement is not subject to Section 14 of the Severance Pay Law, the Subsidiaryâ€™s liability for severance pay is calculated pursuant to Severance Pay Law, based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. The CEO is entitled to one monthâ€™s salary for each year of employment or a portion thereof. The Companyâ€™s liability to the CEO is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Companyâ€™s balance sheet.Â Â F-16 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies, and includes immaterial profits or losses accumulated up to the balance sheet date. Â Severance expenses for all employees including the CEO, for the years ended June 30, 2024 and 2023 were $632 and $732, respectively. Â q.Fair value of financial instruments Â The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities. Â The Company measures its derivative instruments at fair value under ASC 820, â€œFair Value Measurementâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Â As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Â Level 1Â - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Â Level 2Â - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Â Level 3Â - Unobservable inputs for the asset or liability. Â The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy. Â Â The Company measures its liability pursuant to the Finance Contract with the EIB based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. The Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030. The Company accrued royalties for fiscal year 2024 in the amount of $3 (see note 7). Â r.Derivative financial instruments Â The Company accounts for derivatives and hedging based on ASC 815, â€œDerivatives and hedgingâ€, as amended and related interpretations, or ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. Â If a derivative does not meet the definition of a hedging instrument, the changes in the fair value are included in earnings. Cash flows related to Companyâ€™s current hedging are classified as operating activities. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS and its loan from the EIB that is linked to the Euro. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as â€œfinancial income (expenses), netâ€. Â F-17 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.)Â Â The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of June 30, 2024, the fair value of the derivatives instruments is presented in â€œPrepaid expenses and other current assetsâ€ (see note 3) and as of June 30, 2023, there were no derivatives instruments. The net income (losses) from derivatives instruments recognized in â€œFinancial income (expenses), netâ€ during the years ended June 30, 2024 and 2023 were $148 and $(157), respectively (see note 10). Â s.Leases Â Operating leases are included in operating lease right-of-use, or ROU asset, and operating lease liability. ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements with a non-cancelable term of less than 12 months are not recorded on the balance sheets. Â The Company accounts for an extension of a lease term that was not part of the original lease as a modification. As a result, the Company reallocates contract consideration between the lease and non-lease components, reassesses lease classification, and remeasures the lease liability and right-of-use asset prospectively. Assumptions such as the discount rate, fair value of the underlying asset, and variable rents based on a rate or index will be updated as of the modification date. Â Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. Â t.New Accounting Pronouncements Â i.Recently adopted accounting pronouncements Â ASU No. 2016-13-â€œFinancial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrumentsâ€, or ASU 2016-13: Â In JuneÂ 2016, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2016-13, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking â€œexpected lossâ€ model that generally results in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after DecemberÂ 15, 2019, including interim periods within those fiscal years for the Company. In NovemberÂ 2019, the FASB issued ASU No.Â 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission, or SEC, rules) to fiscal years beginning after DecemberÂ 15, 2022, including interim periods.Â F-18 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (CONT.) Â The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company meets the SEC definition of a smaller reporting company and adopted the new accounting standard effective July 1, 2023. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial statements. Â Â ii. Recently issued accounting pronouncements, not yet adopted Â ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07: Â In November 2023, the FASB issued ASU 2023-07, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures. Â ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09: Â In December 2023, the FASB issued ASU 2023-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of its adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures. Â u.ComprehensiveÂ loss Â For all periods presented, net loss is the same as comprehensive loss as there are no comprehensive incomeÂ items. Â v.Loss contingencies Â The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. As of June 30, 2024 and 2023, the Company has not recorded any accruals in this regard. Â F-19 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 3: - PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Â Â June 30,Â Â Â 2024Â Â 2023Â Accounts receivable from NIAIDÂ $210Â Â $-Â Prepaid expensesÂ Â 222Â Â Â 442Â Value Added Tax receivableÂ Â 135Â Â Â 129Â Accounts receivable from the IIAÂ Â 257Â Â Â 250Â Customer receivableÂ Â 34Â Â Â 110Â Other receivablesÂ Â 10Â Â Â 38Â TotalÂ $868Â Â $969Â Â NOTE 4: - PROPERTY AND EQUIPMENT, NET Â Â Â June 30,Â Â Â 2024Â Â 2023Â Cost:Â Â Â Â Â Laboratory equipmentÂ $7,166Â Â $7,006Â Computers and peripheral equipmentÂ Â 1,775Â Â Â 1,682Â Office furniture and equipmentÂ Â 682Â Â Â 682Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total costÂ Â 18,388Â Â Â 18,135Â Accumulated depreciation:Â Â Â Â Â Â Â Laboratory equipmentÂ Â 6,615Â Â Â 6,471Â Computers and peripheral equipmentÂ Â 1,638Â Â Â 1,530Â Office furniture and equipmentÂ Â 682Â Â Â 681Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total accumulated depreciationÂ Â 17,700Â Â Â 17,447Â Property and equipment, netÂ $688Â Â $688Â Â Depreciation expenses amounted to $253 and $362 for the years ended June 30, 2024 and 2023, respectively. Â All of the Companyâ€™s property and equipment is located in Israel. Â NOTE 5: - OTHER ACCOUNTS PAYABLE Â Â Â June 30,Â Â Â 2024Â Â 2023Â Grants received in advanceÂ $81Â Â $144Â Accrued payrollÂ Â 467Â Â Â 501Â Advances from customersÂ Â 43Â Â Â 7Â Payroll institutionsÂ Â 415Â Â Â 448Â TotalÂ $1,006Â Â $1,100Â Â F-20 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 6: - LEASES Â Towards the termination of the previous facility operating lease agreement, the Company signed, in December 2021, an addendum to its facility operating lease agreement with the lessor, which extended the lease period to December 2026. In addition, the Company has the option to extend the term of the lease, or the Extension Option, for an additional period of five years until December 2031. The Company reflected the Extension Option during the evaluation of the lease liability and ROU asset. The monthly lease payments are approximately NIS 292,000 ($78) which are linked to the consumer price index and will increase by 10% in the event the Company exercises its Extension Option. In addition, the Company has operating leases for vehicles that expire through fiscal year 2026. Below is a summary of the Companyâ€™s operating ROU assets and operating lease liabilities: Â Â Â June 30,Â Â Â 2024Â Â 2023Â Operating ROU assetsÂ $6,558Â Â $7,633Â Â Â Â Â Â Â Â Â Operating lease liabilities, currentÂ Â 559Â Â Â 627Â Operating lease liabilities long-termÂ Â 5,026Â Â Â 5,748Â Total operating lease liabilitiesÂ $5,585Â Â $6,375Â Â Â Maturities of operating lease liabilities as of June 30, 2024 are as follows: Â Â Â June 30, 2024Â 2025Â Â 1,113Â 2026Â Â 1,011Â 2027Â Â 977Â 2028Â Â 1,023Â 2029 and thereafterÂ Â 3,583Â Total undiscounted lease paymentsÂ $7,707Â Less: interestÂ Â (2,122) Present value of lease liabilitiesÂ $5,585Â Â All of the leased facilities are located in Israel. Â The components of lease expense and supplemental cash flow information related to leases for the years ended June 30, 2024 and 2023 are as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Components of lease expenseÂ Â Â Â Â Â Fixed payments and variable payments that depend on an index or rateÂ $1,250Â Â $1,304Â Sublease incomeÂ $50Â Â $36Â Supplemental cash flow informationÂ Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilitiesÂ $1,178Â Â $1,196Â Â As of June 30, 2024, the weighted average remaining lease term is 7.4 years, and the weighted average discount rate is 9 percent. As of June 30, 2023, the weighted average remaining lease term is 8.1 years, and the weighted average discount rate is 9 percent. The discount rate was determined based on the estimated collateralized borrowing rate of the Company, adjusted to the specific lease term and location of each lease. Â For vehicles, the lease period is usually 3 years. Â F-21 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 7: - LOAN FROM THE EIB Â On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to â‚¬50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of â‚¬20 million, second of â‚¬18 million and third of â‚¬12 million for a period of 36 months from the signing of the Finance Contract. Â The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche. Â In addition to any interest payable on the Loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Companyâ€™s consolidated revenues, pro-rated to the amount disbursed from the Loan. As of June 30, 2024, Pluri had an accrued royalty in the amount of $3. Â During June 2021, Pluri received the first tranche in an amount of â‚¬20 million of the Finance Contract. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal balance in the amount of $21,390 and the interest accrued in the amount of $2,637 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract. Â The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Companyâ€™s business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans. Â F-22 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 8: - COMMITMENTS AND CONTINGENCIES Â Â a. As of June 30, 2024, an amount of $888 of cash and deposits was pledged by the

Subsidiary to secure its credit line, lease agreement and bank guarantees. Â Â b. Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the projectâ€™s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3% on sales of products and services derived from a technology developed using these grants until 100% of the U.S. dollar-linked grant is repaid. The Companyâ€™s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12 month LIBORÂ (from January 1, 2024, to the 12-month secured overnight financing rate, or SOFR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties. As of June 30, 2024, the Companyâ€™s contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above. Â Â c. In April 2017, the Company was awarded a Smart Money grant of approximately $229 from Israelâ€™s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Companyâ€™s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israelâ€™s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Companyâ€™s revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid. During the year ended June 30, 2023, the grant from this Smart Money program received in the amount of approximately $180 and the program has ended. No royalties were paid or accrued. Â Â d. In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500. Â Â e. As to potential royalties to the EIB, see note 7. Â F-23 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY Â (1) a) On May 1, 2023, the Company increased its authorized common shares from 7,500,000 to 37,500,000 with a par value of $0.00001 per share. All shares have equal voting rights and are entitled to one vote per share in all matters to be voted upon by shareholders and may be issued only as fully paid and non-assessable shares. Holders of the common shares are entitled to equal ratable rights to dividends and distributions, as may be declared by the Board out of funds legally available. The Companyâ€™s authorized preferred shares consist of 1,000,000 preferred shares, par value $0.00001 per share, with series, rights, preferences, privileges and restrictions as may be designated from time to time by the Board. No preferred shares have been issued. Â Â b) Between December 13, 2022 and December 27, 2022, the Company entered into the December 2022 Private Placement, a series of securities purchase agreements with several purchasers for an aggregate of 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares. On December 13, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.24 per share, up to 697,485 common shares and warrants to purchase up to 697,485 common shares, with an exercise price of $8.24 per share and a term of three years. On December 14, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.40 per share, up to 258,565 common shares and warrants to purchase up to 258,565 common shares, with an exercise price of $8.40 per share and a term of three years. On December 15, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.48 per share, up to 29,688 common shares and warrants to purchase up to 29,688 common shares, with an exercise price of $8.48 per share and a term of three years. On December 19, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.72 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.72 per share and a term of three years. On December 27, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.96 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.96 per share and a term of three years. The warrants sold in the December 2022 Private Placement are exercisable upon the later of six months from their issuance date, or from the date the Company increased its authorized shares. The Company issued 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares that relate to the December 2022 Private Placement and received $8,024 as of that date net of $445 of issuance expenses. Â Â c) Pursuant to a shelf registration on Form S-3 declared effective by the SEC on September 21, 2023, on February 13, 2024 the Company entered into a Sales Agreement with A.G.P., which provides that, upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000Â through A.G.P. acting as sales agent. During April 2024, the Company soldÂ 42,729Â common shares under the Sales Agreement at an average price of $5.93Â per share. Â Â d) On August 31, 2023, and as amended and restated as of October 9, 2023, Ever After Foods entered into a Simple Agreement for Future Equity, or the SAFE Agreement, with an investor. Pursuant to the terms of the SAFE Agreement, Ever After Foods will receive an aggregate amount of $2,500,Â or the SAFE Amount. On December 12, 2023, the SAFE Agreement had been terminated and the SAFE Amount was not received. Â Â e) On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors (see note 1f). Â F-24 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â (2) Share options and RSUs to employees, directors and consultants: Â The Company adopted the 2016 Equity Compensation Plan, or the 2016 Plan, and the 2019 Equity Compensation Plan, or together, the Plans. Â Under the Plans, share options, restricted shares, or RS, and RSUs may be granted to the Companyâ€™s officers, directors, employees and consultants or the officers, directors, employees and consultants of the Subsidiary. Â As of June 30, 2024, 642,650 common shares are available for future grants under the Plans. Â Â a. Options to non-employee consultants: Â A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 11,381Â Â $10.56Â Â Â 7.05Â Â Â 44Â Share options forfeitedÂ Â (3,281)Â $18.32Â Â Â -Â Â Â -Â Share options outstanding at end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options exercisable at the end of the periodÂ Â 7,475Â Â $6.69Â Â Â 6.06Â Â Â 29Â Share options unvestedÂ Â 625Â Â $16.00Â Â Â 8.44Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options grantedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 5.24Â Â $29Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Â (**) See note 1d regarding reverse share split Â F-25 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â Compensation expenses recorded in general and administrative expenses related to options granted to non-employee consultants by Pluri and its Subsidiary for the years ended June 30, 2024 and 2023 were $9 and $6, respectively. Â Unamortized compensation expenses related to options granted to non-employee consultants by Pluri and its Subsidiary are approximately $20 to be recognized by the end of March 2027. Â Â b. Options to CEO and directors: Â A summary of the share options granted to CEO and directors under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â -Â Â $-Â Â Â -Â Share options grantedÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options outstanding at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options exercisable at the end of the periodÂ Â 114,676Â Â $15.20Â Â Â 3.47Â Share options unvestedÂ Â 114,677Â Â $15.20Â Â Â 3.47Â Share options vested and expected to vest at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options grantedÂ Â 12,500Â Â $6.08Â Â Â 6.73Â Share options forfeitedÂ Â (1,562)Â $6.08Â Â Â -Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Â (**) See note 1d regarding reverse share split Â As of June 30, 2024, the aggregate intrinsic value of these options was $0.Â F-26 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â On December 14, 2022, Yaky Yanay, the Companyâ€™s CEO, agreed to forgo, starting January 1, 2023, $375,000 of his annual cash salary for the next twelve months in return for equity grants, issuable under the Companyâ€™s existing equity compensation plans. In that regard, the Company granted Mr. Yanay (i) 41,853 RSUs, vesting ratably each month (see also item c), and (ii) options to purchase 41,853 common shares, vesting ratably each month, with a term of 3 years, at an exercise price of $8.96 per share. All of these options were granted in December 2022 and will expire three years from the last vesting date. Â In addition, the Board also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.80 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023. All options were granted in January 2023 and will expire three years after the last vesting date. Â Compensation expenses recorded in general and administrative expenses related to options granted to CEO and directors by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023 were $220 and $568, respectively. Â c. RSUs to employees and directors: Â The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2024 and 2023: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 207,199Â Â Â 241,877Â GrantedÂ Â 395,327Â Â Â 41,853Â ForfeitedÂ Â (132,400)Â Â (6,424) VestedÂ Â (116,992)Â Â (70,107) Unvested at the end of the periodÂ Â 353,134Â Â Â 207,199Â Expected to vest after the end of periodÂ Â 319,533Â Â Â 205,072Â Â (**) See note 1d regarding reverse share split Â F-27 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â Compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $316Â Â $55Â General and administrative expensesÂ Â 1,258Â Â Â 2,150Â Â Â $1,574Â Â $2,205Â Â Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $848 to be recognized by the end of January 2027. Â General and administrative expenses include compensation expenses for the year ended June 30, 2024 and 2023, in the amount of $58 and $273 wereÂ related to 41,853Â RSUs granted to the CEO, due each month (see also item b). Â d. RSUs and RS to consultants: Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 2,500Â Â Â 5,157Â GrantedÂ Â 27,270Â Â Â -Â VestedÂ Â (24,968)Â Â (2,657) Unvested at the end of the periodÂ Â 4,802Â Â Â 2,500Â Â (**) See note 1d regarding reverse share split Â Compensation expenses related to RSUs and RS granted to consultants by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $-Â Â $1Â General and administrative expensesÂ Â 170Â Â Â 204Â Â Â $170Â Â $205Â Â Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $21 to be recognized by the end of June 2025.Â F-28 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 9: - SHAREHOLDERSâ€™ EQUITY (CONT.) Â e. Summary of the Companyâ€™s warrants and options: Â Â Â Year ended June 30, 2024Â Warrants / OptionsÂ Weighted average exercise price per shareÂ Â Options and warrants for common shares (**)Â Â Options and warrants exercisable for common shares (**)Â Â Weighted average remaining contractual terms (in years)Â Warrants:Â $8.24Â Â Â 697,485Â Â Â 697,485Â Â Â 1.55Â Â Â $8.40Â Â Â 258,565Â Â Â 258,565Â Â Â 1.82Â Â Â $8.48Â Â Â 29,688Â Â Â 29,688Â Â Â 1.47Â Â Â $8.72Â Â Â 16,875Â Â Â 16,875Â Â Â 1.49Â Â Â $8.96Â Â Â 16,875Â Â Â 16,875Â Â Â 1.50Â Total warrantsÂ Â Â Â Â Â 1,019,488Â Â Â 1,019,488Â Â Â Â Â

of the ITA which allow, in specific circumstances, filing tax reports in U.S. dollars, or Dollar Regulations. Under the Dollar Regulations, the tax liability is calculated in U.S. dollars according to certain orders. The tax liability, as calculated in dollars, is translated into NIS according to the exchange rate as of June 30 of each year (the fiscal tax year end of the Subsidiary). Â The Subsidiary has not received final tax assessments since its incorporation; however the assessments of the Subsidiary are deemed final through 2019. Â The Law for the Encouragement of Capital Investments, 1959, or the Law (amendment No. 73): Â In December 2016, the Knesset (Israeli Parliament) issued the Law for Changing National Priorities (Legislative Amendments for Achieving Budget Targets for 2017 and 2018), 2017, which consists of amendment No. 73 to the Law, or Amendment No. 73. According to Amendment No. 73, the tax rate on preferred income from a preferred enterprise in 2017 and thereafter will be 16% (in development area A it will be 7.5%). Â According to Amendment No. 73, special tax benefits were established for Technological Preferred Enterprise, starting in 2017, will be as follow: Â â—6% rate would apply to qualifying Israeli companies that are part of a group with global consolidated revenue of over NIS 10 billion (approximately $2,900,000). Â â—Other qualifying companies with global consolidated revenue below NIS 10 billion would be subject to a 12% tax rate (in development area A it will be 7.5%). Â â—Withholding tax on dividends paid to foreign entity investors (i.e., not to a private person) would be subject to a reduced rate of 4% for all qualifying companies (unless further reduced by a treaty), subject that at least 90% of the company is held by foreign entities (one or more). Â Taxable income which is not produced as part of Preferred Technological Enterprise income will be taxed at the regular tax rate (23% in 2024). Â As of June 30, 2024, the Subsidiaryâ€™s management believes that the Subsidiary meets the conditions mentioned above to be considered as a Technological Enterprise. Â Â 3. Pluristem GmbH: Â The corporate tax rate applicable to the German Subsidiary is 15%, which is derived from the German Corporation Tax Act and Solidarity surcharge of 5.5% from the 15% corporate tax rate. This corporate tax rate excludes trade tax, which rate depends on the municipality in which the German Subsidiary conducts its business. Trade tax rate applicable to the German Subsidiary is 15.93%, which is calculated by determining the Trade Tax Base with 3.5% of the trade income and applying the tax factor which differs according to the specific municipality in Germany and equals 455% for the municipality of Potsdam. Â Â 4. Ever After Foods: Â Ever After Foods is an Israeli tax resident and is subject to corporate income tax at the rate of 23%.Â F-31 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 11: - TAXES ON INCOME (CONT.) Â Â b. Carryforward losses for tax purposes Â As of June 30, 2024, Pluri had a U.S. federal net operating loss carryforward for income tax purposes in the amount of $31,414. Net operating loss carryforwards arising in taxable years prior to 2018, can be carried forward and offset against taxable income for 20 years and thus will expire between 2022 and 2037. Net operating losses generated in tax years 2002, 2003 and 2004 have expired and were reduced from the total net operating loss carryforward available. Â Utilization of U.S. net operating losses may be subject to substantial annual limitations due to the â€œchange in ownershipâ€ provisions of the U.S. Internal Revenue Code of 1986, Section 382 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. Â The Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $129,286, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â Â In January 2018, Pluri Inc. registered as an Israeli resident with the ITA. Â As of June 30, 2024, Pluri Inc. and the Subsidiaries consolidated accumulated losses, for tax purposes, are approximately $144,906, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â The German Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $601, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â Â c. Loss before income taxes Â The components of loss before income taxes are as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Consolidated loss of Pluri Inc. and the Israeli SubsidiariesÂ $21,339Â Â $28,878Â Pluristem GmbHÂ Â 5Â Â Â 9Â Â Â $21,344Â Â $28,887Â Â F-32 Â Â PLURI INC. AND ITS SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS U.S. Dollars in thousands (except share and per share amounts) Â NOTE 11: - TAXES ON INCOME (CONT.) Â Â d. Deferred income taxes: Â Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Companyâ€™s deferred tax assets are as follows: Â Â Â June 30,Â Â Â 2024Â Â 2023Â Deferred tax assets:Â Â Â Â Â Â Operating loss carryforwardsÂ $69,852Â Â $80,534Â Research and development credit carryforwardsÂ Â 3,780Â Â Â 4,057Â Issance costsÂ Â 25Â Â Â 68Â Allowances and reservesÂ Â 173Â Â Â 237Â Â Â Â Â Â Â Â Â Total deferred tax assets before valuation allowanceÂ Â 73,830Â Â Â 84,896Â Valuation allowanceÂ Â (73,830)Â Â (84,896) Â Â Â Â Â Â Â Â Net deferred tax assetÂ $-Â Â $-Â Â As of June 30, 2024 and 2023, the Company has provided full valuation allowances with respect to the deferred tax assets resulting from tax loss carryforwards and other temporary differences, since it has a history of operating losses and due to current uncertainty concerning its ability to realize these deferred tax assets in the future. Â The Company accounts for its income tax uncertainties in accordance with ASCÂ 740 which clarifies the accounting for uncertainties in income taxes recognized in a Companyâ€™s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Â As of June 30, 2024 and 2023, there were no unrecognized tax benefits that if recognized would affect the annual effective tax rate. Â Reconciliation of taxes at the federal statutory rate to Companyâ€™s provision for income taxes: Â In 2024 and 2023, the main reconciling item of the statutory tax rate of the Company (21% to 23%) to the effective tax rate (0%) is tax loss carryforward and R&D credit carryforward for which a full valuation allowance was provided. Â F-33 Â Â ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. Â None. Â ITEM 9A. CONTROLS AND PROCEDURES. Â Evaluation of Disclosure Controls and Procedures Â We conducted an evaluation under the supervision of our CEO and CFO (our principal executive officer and principal financial officer, respectively), regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2024. Based on the aforementioned evaluation, management has concluded that our disclosure controls and procedures were effective as of June 30, 2024. Â Managementâ€™s Annual Report on Internal Control over Financial Reporting Â Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting has been designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Â Our internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorization of our management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Â Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Â Management assessed the effectiveness of our internal control over financial reporting on June 30, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework in Internal Controlâ€”Integrated Framework. Based on that assessment under those criteria, management has determined that, as of June 30, 2024, our internal control over financial reporting was effective. Â Changes in Internal Control Over Financial Reporting Â There have been no changes in our internal control over financial reporting (as such term is defined in RulesÂ 13a-15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of fiscal year 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â ITEM 9B. OTHER INFORMATION. Â During the three months ended June 30, 2024, no director or officer of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.Â Â ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS. Â Not applicable. Â 44 Â Â PART III Â ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. Â Our directors and executive officers, their ages, positions currently held, and duration of such, are as follows: Â Name Â Position Held with Company Â Age Â Date First Elected or Appointed Zami Aberman Â Chairman Â 70 Â JuneÂ 2019 Yaky Yanay Â President Director CEO Â 53 Â February 2014 February 2015 June 2019 Chen Franco-Yehuda Â CFO, Treasurer and Secretary Â 41 Â MarchÂ 2019 Doron Birger Â Director Â 73 Â July 2021 Rami Levi Â Director Â 62 Â JuneÂ 2021 Maital Shemesh-Rasmussen Â Director Â 55 Â June 2021 Â Business Experience Â The following is a brief account of the education and business experience of each director and executive officer during at least the past five years, indicating each personâ€™s principal occupation during the period, and the name and principal business of the organization by which they were employed. Â Zami Aberman Â Mr. Aberman joined the Company in September 2005 and has served as our Chairman since January 2022, as Executive Chairman from June 2019 until December 2021, as our Co-CEO from March 2017 until June 2019, as our CEO from November 2005 until March 2017, and as President of the Company from September 2005 until February 2014. When he joined the Company, he changed the Companyâ€™s strategy towards cellular therapeutics. Mr. Abermanâ€™s vision to use the maternal section of the placenta (Decidua) as a source for cell therapy, combined with the companyâ€™s 3D culturing technology, led to the development of our products. Since November 2005, Mr. Aberman has served as a director of the Company, and since April 2006, as Chairman of the Board. He has 40 years of experience in marketing and management in the high technology industry. Mr. Aberman has held the CEO and Chairman positions of various companies located in Israel, the United States, Europe, Japan and Korea. Â Mr. Aberman has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. He serves as the chairman of Rose Hitech Ltd., a private investment company. He previously served as the chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., a company involved in data management. Prior to holding those positions, Mr. Aberman served as the President and CEO of Elbit Vision System Ltd. (EVSNF.OB), now part of the USTER Group, a company engaged in automatic optical inspection. Before joining the Company, Mr. Aberman served as President and CEO of Netect Ltd., a company specializing in the field of internet security software and was the co-founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He also served as Chairman of Display Inspection Systems Inc., specializing in laser-based inspection machines and as President and CEO of Robomatix Technologies Ltd. Â In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel. Â We believe that Mr. Abermanâ€™s qualifications to sit on our Board include his unique multidisciplinary innovative approach, years of experience in the financial markets in Israel and globally, as well as his experience in serving as the CEO of publicly traded entities. Â 45 Â Â Yaky Yanay Â Mr. Yanay became a director of the Company in February 2015. He has served as our President from February 2014 and as our Chief Executive Officer, or CEO, from June 2019, previously serving as Co-CEO from March 2017. Mr. Yanay has served in various executive positions in Pluri since 2006 including as our CFO, from November 2006 until February 2014 and from February 2015 until March 2017. He also served as our CEO from February 2014 until March 2017. From November 2006 to February 2014, he served as our Secretary and served as our Executive Vice President from March 2013 until February 2014. From 2015 to 2018, Mr. Yanay served as the Co-Chairman of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israelâ€™s high tech and life science industries and since August 2012 has continually served as a Director of IATI, representing Israelâ€™s life sciences industry. Prior to joining the Company, Mr. Yanay founded the â€œIsraeli Life Science Forumâ€ and also served as the CFO of Elbit Vision Systems Ltd., a public company. In addition, from July 2010 to April 2018, he served on the board of directors of Elbit Vision Systems Ltd. Prior to these positions, Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Since 2022, Mr. Yanay has also served as the Chairman of Ever After Foods. Â Mr. Yanay holds a bachelorâ€™s degree with honors in business administration and accounting from the College of Management Academic Studies of Rishon LeZion, Israel, and is a Certified Public Accountant in Israel. Â We believe that Mr. Yanayâ€™s qualifications to sit on our Board include his years of experience in the medical technology industry, his vast skill and expertise in accounting and economics, as well as his knowledge and familiarity with corporate finance.Â Â Chen Franco-Yehuda Â Ms. Franco-Yehuda was appointed as CFO, Treasurer, and Secretary of Pluri, effective in March 2019. She is responsible for managing financial and corporate strategy, and is also in charge of the finance, IT, investor relations, PR and legal departments. Prior to being appointed as our CFO, Ms. Franco-Yehuda served as the Companyâ€™s Head of Accounting and Financial Reporting since July 2016 and, prior to that, the Companyâ€™s Controller since May 2013. Before joining the Company, from October 2008 to April 2013, Ms. Franco-Yehuda served as a manager of audit groups relating to public and private companies in various industries at PricewaterhouseCoopers (PwC) and also as a lecturer of accounting classes at the Open University of Israel from 2009 to 2014. Ms. Franco-Yehuda has also served as a member of the board of directors of Brenmiller Energy Ltd. (Nasdaq: BNRG) since August 2022 and a director of Ever After Foods since February 2022. Â Ms. Franco-Yehuda holds a bachelorâ€™s degree with honors in economics and accounting from Haifa University, Israel, and is a certified public accountant in Israel. Â On June 30, 2024, Ms. Franco-Yehuda notified the Company of her resignation from her position as CFO, Treasurer and Secretary of the Company, which will become effective as of September 30, 2024. Ms. Franco-Yehudaâ€™s resignation was for personal reasons and was not due to any disagreement with the Company on any matter relating to the Companyâ€™s operations, policies or practices. Â On July 2, 2024, the Board appointed Liat Zalts, age 40, to serve as the Companyâ€™s CFO and Treasurer effective as of September 30, 2024. Prior to her appointment as CFO, Mrs. Zalts served as the Companyâ€™s Director of Finance since December 2022. From March 2018 to November 2022, Mrs. Zalts served as a CFO of Matics Manufacturing Analytics Ltd., a SaaS, high-tech company based in Israel. From October 2008 to February 2018, Mrs. Zalts worked at Ernst & Young Israel (EY) and, between 2014 and 2018, served as a manager of audit groups relating to public and private companies in the high-tech department. Mrs. Zalts holds a bachelorâ€™s degree in economics and business management from Haifa University, a degree in accounting from Bar Ilan University and is a certified public accountant in Israel. Â 46 Â Â Doron Birger Â Mr. Birger became a director of the Company in July 2021. Mr. Birger served as the chairman of the board of directors of Sight Diagnostic Ltd. from June 2014 until February 2024 and as interim CEO from July 2022 until March 2024, as chairman of the board of directors of Nurami Medical Ltd., or Nurami, from April 2016 to March 2022, and is currently a director of Nurami, Chairman or director of Ultrasight Medical Imaging Ltd. from June 2019, Intelicanna Ltd. (TASE: INTL) from April 2021 until April 2022, Matricelf Ltd. (TASE:MTLF) from December 2020, Galooli from September 21 and as a director of IceCure Medical Ltd. (TASE: ICCM) since August 2012 until May 2024 , Vibrant Ltd. from December 2014 until March 2023, Hera Med Ltd. (ASX: HMD) from November 2019 until March 2024, Citrine Global (OTC: CTGL) from March 2020 until January 2024, Kadimastem Ltd. (TASE: KDST) from December 2020 until December 2023, VVT Medical since February 2024 and Netiv Haâ€™or, a subsidiary of the Israel Electric Corporation Ltd., from March 2020 until March 2023, and as chairman and director in a variety of non-profit organizations. Prior to that, Mr. Birger has served as Chairman or member of the board of directors of MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) from March 2015 to May 2018, Mekorot National Water Company Ltd. from November 2015 to November 2018, and chairman of the board of directors of Insulin Medical Ltd. (TASE: INSL) from March 2016 to August 2017, IOPtima Ltd. from June 2012 to June 2019, MST Medical Surgical Technologies Ltd. from August 2009 to June 2019, Highcon Ltd. From November 2014 to January 2018, Magisto Ltd. from September 2009 to July 2019, Real Imaging Ltd. from November 2018 to April 2019 and Medigus Ltd. (Nasdaq and TASE: MDGS) from May 2015 to September 2018. Mr. Birger holds a BA and MA in economics from the Hebrew University, Israel. Â We believe that Mr. Birgerâ€™s qualifications to sit on our Board include his extensive experience in the high-tech sector and life-science industry, his experience serving as Chairman, CEO and a director of public companies, his vast skill and expertise in accounting and economics as well as his knowledge and familiarity with corporate finance. Â Rami Levi Â Mr. Levi became a director of the Company in June 2021. Mr. Levi is the Founder and President of Catalyst Group International, LLC where, since 2009, he has provided consulting services relating to strategic planning to notable clients in the private and public sectors. From 2004 to 2006, he served as Senior Deputy General and Head of Marketing Administration at Israelâ€™s Ministry of Tourism. He holds an MA with Honors in Political Science from The Hebrew University of Jerusalem. Â We believe that Mr. Leviâ€™s qualifications to sit on our Board include his experience in strategic planning, business development and activities in the government sector. Â Maital Shemesh-Rasmussen Â Ms. Shemesh-Rasmussen became a director of the Company in January 2021. Ms. Shemesh-Rasmussen served as the Chief Commercial Officer of Octave Bioscience, Inc. between 2021 and 2024. Prior to this role, Ms. Shemesh-Rasmussen served as the Global Head of Marketing at Roche Diagnostics Information Solutions between 2018 and 2020. Between 2016 and 2018, she was a consultant to Fitango Health, Inc. where she focused on marketing and business development. Between 2013 and 2016, she led Product Marketing at the Oracle Health Sciences Global Business Unit, as well as Marketing and Business Development in the Oracle Digital Health Innovation Unit. Prior to these positions, Ms. Shemesh-Rasmussen was the founder

and president of Rasmussen Communication, Inc. In addition, Ms. Shemesh-Rasmussen served as Vice President at JPMorgan Chase Bank from 2002 until 2007. Ms. Shemesh-Rasmussen holds a BA in Behavioral Sciences from Ben Gurion University. Â We believe that Ms. Shemesh-Rasmussenâ€™s qualifications to sit on our Board include her experience in marketing for pharmaceutical companies, science, business development and investment banking.Â Â There are no family relationships between any of the directors or officers named above. Â 47 Â Â Audit Committee and Audit Committee Financial Expert Â Until June 25, 2024, the members of our Audit Committee were Mr. Birger, Mr. Lorne Abony and Ms. Shemesh-Rasmussen. Mr. Abony was not re-nominated as a director for the 2024 annual meeting of shareholders, held on June 25, 2024, or the 2024 Annual Meeting, and his membership on the Board and Audit Committee terminated on June 25, 2024. Following the 2024 Annual Meeting, Mr. Levi was appointed to serve on the Audit Committee of the Board, to replace Mr. Abony. Mr. Birger is the Chairman of the Audit Committee, and our Board has determined that all members of the Audit Committee are â€œindependentâ€ as defined by the rules of the SEC and the Nasdaq rules and regulations. The Board also determined that Mr. Birger is an Audit Committee financial expert. The Audit Committee operates under a written charter that is posted on our website at www.pluri-biotech.com. The primary responsibilities of our Audit Committee include: Â Â â— Appointing, compensating and retaining our registered independent public accounting firm; Â Â â— Overseeing the work performed by any outside accounting firm; Â Â â— Assisting the Board in fulfilling its responsibilities by reviewing: (i) the financial report provided by us to the SEC, our shareholders or to the general public, and (ii) our internal financial and accounting controls; Â Â â— Recommending, establishing and monitoring procedures designed to improve the quality and reliability of the disclosure of our financial condition and results of operations; and Â Â Â Â â— Overseeing the Companyâ€™s risk management arising from cybersecurity threats. Â Our Audit Committee held five meetings during fiscal year 2024. Â Compensation Committee Â Until June 25, 2024, the members of our Compensation Committee were Mr. Rami Levi, Mrs. Maital Shemesh-Rasmussen and Mr. Abony. Mr. Abony was not re-nominated as a director for the 2024 annual meeting of shareholders, held on June 25, 2024 and his membership on the Board and Compensation Committee terminated as of June 25, 2024. As of June 25, 2024, the members of our Compensation Committee are Mr. Levi and Mrs. Shemesh-Rasmussen. Ms. Shemesh-Rasmussen is the Chairperson of the Compensation Committee. The Board has determined that all of the members of the Compensation Committee are â€œindependentâ€ as defined by the rules of the SEC and Nasdaq rules and regulations. The Compensation Committee operates under a written charter that is posted on our website at www.pluri-biotech.com. The primary responsibilities of our Compensation Committee include: Â Â â— Reviewing and recommending to our Board of the annual base compensation, the annual incentive bonus, equity compensation, employment agreements and any other benefits of our executive officers; Â Â â— Administering our equity-based plans and making recommendations to our Board with respect to our incentiveâ€”compensation plans and equityâ€”based plans; Â Â â— Annually reviewing and making recommendations to our Board with respect to the compensation policy for such other officers as directed by our Board; and Â Â Â Â â— Administration of our clawback policy. Â Our Compensation Committee held two meetings during fiscal year 2024. Â Nominating Committee Â The members of our Nominating Committee are Rami Levi and Maital Shemesh-Rasmussen. Mr. Levi is the Chairman of the Nominating Committee. The Board has determined that all of the members of the Nominating Committee are â€œindependentâ€ as defined by the rules of the SEC and Nasdaq rules and regulations. The Nominating Committee operates under a written charter that is posted on our website,Â www.pluri-biotech.com. The primary responsibilities of our Nominating Committee include: Â Â â— Overseeing the composition and size of the Board, developing qualification criteria for Board members and actively seeking, interviewing and screening individuals qualified to become Board members for recommendation to the Board; Â 48 Â Â Â â— Recommending the composition of the Board for each annual meeting of shareholders; and Â Â â— Reviewing periodically with the Chairman of the Board and the CEO the succession plans relating to positions held by directors and making recommendations to the Board with respect to the selection and development of individuals to occupy those positions.Â Â Our Nominating Committee did not hold any meetings during Fiscal Year 2024 and took action by written consent once. Â Investments Committee Â Doron Birger is the Chairman and sole member of the Investment Committee, and the Board has determined that he is an â€œindependentâ€ director as defined by the rules of the SEC and Nasdaq rules and regulations. Â The Investment Committee operates under a written charter that is posted on our website,Â www.pluri-biotech.com. The primary responsibilities of our Investment Committee include: Â â— Managing the Companyâ€™s investment portfolio, including periodically reviewing the performance and effectiveness of the Companyâ€™sâ€™ investment portfolio; Â â—Establishing and periodically reviewing the Companyâ€™s investment guidelines and hedging policies; Â â—Monitoring and analyzing the Companyâ€™s foreign exchange risks and exposures; Â â— Recommending the Companyâ€™s investment advisers, monitoring their performance and when appropriate, recommending terminating their engagement; and Â â—Monitoring on a periodic basis the Companyâ€™s cashflow. Â Our Investment Committee held four meetings with executive management and consultants during Fiscal Year 2024. Â Director Nominations Â The Nominating Committee is responsible for developing and approving criteria, with Board approval, for candidates for Board membership. The Nominating Committee is responsible for overseeing the composition and size of the Board, developing qualification criteria for Board members and actively seeking, interviewing and screening individuals qualified to become Board members for recommendation to the Board and for recommending the composition of the Board for each of the Companyâ€™s annual meetings. The Board as a whole is responsible for nominating individuals for election to the Board by the shareholders and for filling vacancies on the Board that may occur between annual meetings of the shareholders. Â Nominees for director will be selected on the basis of their integrity, business acumen, knowledge of our business and industry, age, experience, diligence, conflicts of interest and the ability to act in the interests of all shareholders. No particular criteria will be a prerequisite or will be assigned a specific weight, nor does the Company have a diversity policy. The Company believes that the backgrounds and qualifications of its directors, considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities. Â We have never received communications from shareholders recommending individuals to any of our independent directors. Therefore, we do not yet have a policy with regard to the consideration of any director candidates recommended by shareholders.Â In fiscal year 2024, we did not pay a fee to any third party to identify or evaluate, or assist in identifying or evaluating, potential nominees for our Board.Â We have not received any recommendations from shareholders for Board nominees. All of the nominees for election at the 2024 meeting of shareholders were current members of our Board, at that time. Â 49 Â Â Code of Ethics Â Our Board has adopted a Code of Business Conduct and Ethics that applies to, among other persons, members of our Board, our officers including our CEO (being our principal executive officer) and our CFO (being our principal financial and accounting officer) and our employees. Â Our Code of Business Conduct and Ethics is posted on our Internet website at www.pluri-biotech.com. The information on our website is not incorporated by reference into this Annual Report. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Conduct by posting such information on the website address specified above. Â ITEMÂ 11. EXECUTIVE COMPENSATION. Â Summary Compensation Table Â The following table shows the compensation owed to our CEO and our CFO, or our named executive officers, for the fiscal years ended June 30, 2024 and 2023. We do not currently have any other executive officers. Â Name and Principal PositionÂ Fiscal Year(1)Â Salary ($)(2)Â Â Non-Equity Plan Compensation ($)Â Â Share-based Awards ($)(5)Â Â All Other Compensation ($)Â Â Total ($)Â Yaky YanayÂ 2024Â Â 281,693(6)(9)Â Â 23,976(3)Â Â 399,000(6)Â Â 36,810(7)Â Â 741,479Â CEOÂ 2023Â Â 296,728(6)Â Â 128,058(4)Â Â 2,169,642(6)Â Â 33,787(7)Â Â 2,628,215Â Â Â

31/01/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 18/02/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 31/03/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 25/04/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 31/05/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 30/06/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 31/07/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 31/08/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 30/09/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 31/10/2026Â Â -Â Â Â -Â Â Â Â 3,488Â Â Â -Â Â Â 8.96Â Â 30/11/2026Â Â -Â Â Â -Â Â Â Â 3,489Â Â Â -Â Â Â 8.96Â Â 31/12/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 12.48Â Â 30/06/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 12.48Â Â 31/12/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 16.64Â Â 30/06/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 16.64Â Â 31/12/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 20.8Â Â 30/06/2026Â Â -Â Â Â -Â Â Â Â 31,250Â Â Â -Â Â Â 20.8Â Â 31/12/2026Â Â -Â Â Â -Â Â Â Â -Â Â Â -Â Â Â -

10.23+ Â Letter agreement by and between Pluristem Ltd. and Chen Franco-Yehuda, dated September 13, 2021 (incorporated by reference to Exhibit 10.30 of our annual report on Form 10-K filed on September 13, 2021). Â Â Â 10.24^ Â Finance Contract between the European Investment Bank, as Lender, and Pluristem GmBH, as borrower, and Pluristem Therapeutics Inc. and Pluristem Ltd., as Original Guarantors, dated April 29, 2020 (incorporated by reference to Exhibit 10.21 of our annual report on Form 10-K filed on September 10, 2020). Â Â Â 10.25 Â Guarantee Agreement by and among the European Investment Bank, Pluristem Therapeutics, Inc. and Pluristem GmbH, dated September 30, 2020 (incorporated by reference to Exhibit 10.1 of our quarterly report on Form 10-Q filed on November 5, 2020). Â Â Â 10.26 Â Guarantee Agreement by and among the European Investment Bank, Pluristem Ltd. and Pluristem GmbH dated, September 30, 2020 (incorporated by reference to Exhibit 10.1 of our quarterly report on Form 10-Q filed on November 5, 2020). Â 59 Â Â 10.27+ Â Letter agreement by and between Pluristem Ltd. and Yaky Yanay, dated September 13, 2021 (incorporated by reference to Exhibit 10.29 of our annual report on Form 10-K filed on September 13, 2021). Â Â Â 10.28+ Â Amended and Restated Consulting Agreement by and between Pluri Biotech Ltd. and Mr. Zalman (Zami) Aberman, dated February 13, 2023. (incorporated by reference to Exhibit 10.2 of our quarterly report on Form 10-Q filed on February 13, 2023). Â Â Â 10.29^ Â Share Purchase Agreement, dated January 5, 2022, by and among Tnuva Food-Tech Incubator (2019), Limited Partnership, Plurinuva Ltd. and Pluri-Biotech Ltd. (formerly Pluristem Ltd.) (incorporated by reference to Exhibit 10.1 of our quarterly report on Form 10-Q filed on May 9, 2022). Â Â Â 10.30^ Â Technology License Agreement, dated January 5, 2022, by and between Pluri-Biotech Ltd. (formerly Pluristem Ltd.) and Plurinuva Ltd. (incorporated by reference to Exhibit 10.2 of our quarterly report on Form 10-Q filed on May 9, 2022). Â Â Â 10.31 Â Sales Agreement, dated February 13, 2024, by and between the Company and A.G.P (incorporated by reference to Exhibit 1.1 of our current report on Form 8-K filed on February 13, 2024). Â Â Â 10.32 Â Share Purchase Agreement, dated June 12, 2024, by and between Ever After Foods and Investors (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on June 18, 2024). Â Â Â 10.33 Â Amended and Restated Technology License Agreement, dated June 12, 2024, by and between Pluri Biotech Ltd. and Ever After Foods Ltd. ((incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on June 18, 2024). Â Â Â 10.34*+ Â Amended and Restated Employment Agreement by and between Pluri Inc. and Liat Zalts, dated September 18, 2024. Â Â Â 21.1* Â List of Subsidiaries of the Company. Â Â Â 23.1* Â Consent of Kesselman & Kesselman, Independent Registered Public Accounting Firm. Â Â Â 31.1* Â Certification pursuant to Rule 13a-14(a)/15d-14(a) of Yaky Yanay. Â Â Â 31.2* Â Certification pursuant to Rule 13a-14(a)/15d-14(a) of Chen Franco-Yehuda. Â Â Â 32.1** Â Certification pursuant to 18 U.S.C. Section 1350 of Yaky Yanay. Â Â Â 32.2** Â Certification pursuant to 18 U.S.C. Section 1350 of Chen Franco-Yehuda. Â Â Â 97.1* Â Clawback Policy. Â Â Â 101* Â The following materials from our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Loss, (iv) the Statements of Changes in Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to the Consolidated Financial Statements, tagged as blocks of text and in detail. Â Â Â 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â *Filed herewith. Â **Furnished herewith. Â +Management contract or compensation plan. Â ^ Certain identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to us if publicly disclosed. We agree to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. Â ITEM 16. FORM 10-K SUMMARY. Â None. Â 60 Â Â SIGNATURES Â Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Pluri Inc. Â By: /s/ Yaky Yanay Â Â Yaky Yanay, Chief Executive Officer Â Â Â Dated: September 18, 2024 Â Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Â By: /s/ Yaky Yanay Â Â Yaky Yanay, Chief Executive Officer, President and Director (Principal Executive Officer) Â Â Â Dated: September 18, 2024 Â Â Â By: /s/ Chen Franco-Yehuda Â Â Chen Franco-Yehuda, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Â Â Â Dated: September 18, 2024 Â Â Â By:Â /s/ Zami Aberman Â Â Zami Aberman, Chairman of the Board Â Â Â Dated: September 18, 2024 Â Â Â By: /s/ Doron Birger Â Â Doron Birger, Director Â Â Â Dated: September 18, 2024 Â Â Â By: /s/ Rami Levi Â Â Rami Levi, Director Â Â Â Dated: September 18, 2024 Â Â Â By: /s/ Maital Shemesh-Rasmussen Â Â Maital Shemesh-Rasmussen, Director Â Â Â Dated: September 18, 2024 Â Â 61 Â 74-7108600 011-972 3.99 6.24 4581503 5240249 false FY 0001158780 0001158780 2023-07-01 2024-06-30 0001158780 2023-12-31 0001158780 2024-09-13 0001158780 2024-06-30 0001158780 2023-06-30 0001158780 2022-07-01 2023-06-30 0001158780 us-gaap:CommonStockMember 2022-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001158780 us-gaap:RetainedEarningsMember 2022-06-30 0001158780 us-gaap:ParentMember 2022-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2022-06-30 0001158780 2022-06-30 0001158780 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0001158780 us-gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0001158780 us-gaap:ParentMember 2022-07-01 2023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-06-30 0001158780 us-gaap:CommonStockMember 2023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-06-30 0001158780 us-gaap:ParentMember 2023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-06-30 0001158780 us-gaap:CommonStockMember 2023-07-01 2024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-07-01 2024-06-30 0001158780 us-gaap:ParentMember 2023-07-01 2024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-07-01 2024-06-30 0001158780 us-gaap:CommonStockMember 2024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001158780 us-gaap:RetainedEarningsMember 2024-06-30 0001158780 us-gaap:ParentMember 2024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-06-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2023-07-01 2024-06-30 0001158780 2023-07-01 2024-03-31 0001158780 2022-01-05 2022-01-05 0001158780 2022-01-05 0001158780 plur:TnuvaFoodIndustriesMember 2022-01-05 2022-01-05 0001158780 plur:FirstWarrantMember plur:TnuvaFoodIndustriesMember 2023-07-01 2024-06-30 0001158780 plur:TnuvaFoodIndustriesMember 2024-06-30 0001158780 plur:FirstWarrantMember 2023-07-01 2024-06-30 0001158780 plur:FirstWarrantMember 2024-06-30 0001158780 plur:SecondWarrantMember 2024-06-30 0001158780 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001158780 us-gaap:WarrantMember 2022-11-22 2022-11-22 0001158780 2024-06-12 2024-06-12 0001158780 us-gaap:MonteCarloModelMember 2023-07-01 2024-06-30 0001158780 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001158780 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2023-06-30 0001158780 srt:MinimumMember plur:LaboratoryEquipmentMember 2024-06-30 0001158780 srt:MaximumMember plur:LaboratoryEquipmentMember 2024-06-30 0001158780 us-gaap:ComputerEquipmentMember 2024-06-30 0001158780 us-gaap:OfficeEquipmentMember 2024-06-30 0001158780 srt:MinimumMember 2023-07-01 2024-06-30 0001158780 srt:MaximumMember 2023-07-01 2024-06-30 0001158780 srt:MinimumMember 2022-07-01 2023-06-30 0001158780 srt:MaximumMember 2022-07-01 2023-06-30 0001158780 srt:MinimumMember 2024-06-30 0001158780 srt:MaximumMember 2024-06-30 0001158780 srt:MinimumMember 2023-06-30 0001158780 srt:MaximumMember 2023-06-30 0001158780 plur:USNationalInstituteOfAllergyAndInfectiousDiseasesMember 2024-06-30 0001158780 plur:USNationalInstituteOfAllergyAndInfectiousDiseasesMember 2023-06-30 0001158780 plur:IsraelInnovationAuthorityMember 2024-06-30 0001158780 plur:IsraelInnovationAuthorityMember 2023-06-30 0001158780 us-gaap:EquipmentMember 2024-06-30 0001158780 us-gaap:EquipmentMember 2023-06-30 0001158780 us-gaap:ComputerEquipmentMember 2023-06-30 0001158780 us-gaap:OfficeEquipmentMember 2023-06-30 0001158780 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001158780 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001158780 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-04-30 0001158780 2020-04-30 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-07-01 2024-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-07-01 2024-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-07-01 2024-06-30 0001158780 srt:MinimumMember plur:RoyaltiesMember 2024-06-30 0001158780 srt:MaximumMember plur:RoyaltiesMember 2024-06-30 0001158780 2021-06-30 0001158780 2021-06-30 2021-06-30 0001158780 plur:AnnualInterestMember 2021-06-30 0001158780 2017-09-30 2017-09-30 0001158780 plur:TelAvivSouraskyMedicalCenterMember 2017-09-30 2017-09-30 0001158780 plur:TelAvivSouraskyMedicalCenterMember 2017-09-30 0001158780 us-gaap:CommonStockMember 2023-05-01 0001158780 2023-05-01 0001158780 2022-12-13 0001158780 2022-12-27 0001158780 2022-12-13 2022-12-13 0001158780 2022-12-14 0001158780 2022-12-14 2022-12-14 0001158780 2022-12-15 0001158780 2022-12-15 2022-12-15 0001158780 2022-12-19 0001158780 2022-12-19 2022-12-19 0001158780 2022-12-27 2022-12-27 0001158780 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-12-31 0001158780 us-gaap:PrivatePlacementMember 2022-07-01 2022-12-31 0001158780 2022-07-01 2022-12-31 0001158780 2024-02-13 2024-02-13 0001158780 plur:SalesAgreementMember 2024-04-30 0001158780 2024-04-30 2024-04-30 0001158780 2023-08-31 2023-08-31 0001158780 plur:OptionsToConsultantsMember 2023-07-01 2024-06-30 0001158780 plur:OptionsToConsultantsMember us-gaap:StockOptionMember 2022-07-01 2023-06-30 0001158780 srt:ScenarioForecastMember 2027-03-01 2027-03-30 0001158780 plur:DirectorAndChiefExecutiveOfficerMember us-gaap:StockOptionMember 2023-06-30 0001158780 plur:YakyYanayMember 2023-07-01 2024-06-30 0001158780 us-gaap:StockOptionMember plur:YakyYanayMember 2023-07-01 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2023-07-01 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2022-07-01 2023-06-30 0001158780 srt:ScenarioForecastMember us-gaap:RestrictedStockUnitsRSUMember 2027-01-31 0001158780 us-gaap:StockOptionMember 2022-07-01 2023-06-30 0001158780 srt:ScenarioForecastMember 2025-06-30 0001158780 2024-05-28 0001158780 2024-05-28 2024-05-28 0001158780 plur:OptionsToConsultantsMember 2022-06-30 0001158780 plur:OptionsToConsultantsMember 2022-07-01 2023-06-30 0001158780 plur:OptionsToConsultantsMember 2023-06-30 0001158780 plur:OptionsToConsultantsMember 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2022-06-30 0001158780 plur:CEOAndDirectorsMember 2023-06-30 0001158780 plur:CEOAndDirectorsMember 2024-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2023-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2022-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2023-07-01 2024-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2022-07-01 2023-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2024-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2023-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2022-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2023-07-01 2024-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2022-07-01 2023-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2024-06-30 0001158780 plur:EmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2024-06-30 0001158780 plur:EmployeesAndDirectorsMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2023-06-30 0001158780 plur:EmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2024-06-30 0001158780 plur:EmployeesAndDirectorsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2023-06-30 0001158780 plur:EmployeesAndDirectorsMember 2023-07-01 2024-06-30 0001158780 plur:EmployeesAndDirectorsMember 2022-07-01 2023-06-30 0001158780 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2024-06-30 0001158780 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2023-06-30 0001158780 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2024-06-30 0001158780 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2023-06-30 0001158780 us-gaap:WarrantMember plur:EightPointTwoFourMember 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointTwoFourMember 2023-07-01 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointFourZeroMember 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointFourZeroMember 2023-07-01 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointFourEightMember 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointFourEightMember 2023-07-01 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointSevenTwoMember 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointSevenTwoMember 2023-07-01 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointNineSixMember 2024-06-30 0001158780 us-gaap:WarrantMember plur:EightPointNineSixMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:FivePointEightZeroMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:FivePointEightZeroMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:EightPointNineSixMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:EightPointNineSixMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:TwelvePointFourEightMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:TwelvePointFourEightMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:SixteenPointSixFourMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:SixteenPointSixFourMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:TwentyPointEightZeroMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:TwentyPointEightZeroMember 2023-07-01 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:SixPointZeroEightMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMember plur:SixPointZeroEightMember 2023-07-01 2024-06-30 0001158780 plur:PluriMember 2023-07-01 2024-06-30 0001158780 2017-12-31 2017-12-31 0001158780 plur:PluriMember 2023-07-01 2024-06-30 0001158780 srt:MaximumMember 2016-12-01 2016-12-31 0001158780 srt:MinimumMember 2016-12-01 2016-12-31 0001158780 plur:TechnologicalPreferredEnterpriseMember 2023-07-01 2024-06-30 0001158780 srt:MaximumMember plur:TechnologicalPreferredEnterpriseMember 2023-07-01 2024-06-30 0001158780 srt:MinimumMember plur:TechnologicalPreferredEnterpriseMember 2023-07-01 2024-06-30 0001158780 plur:GermanCorporationTaxMember 2023-07-01 2024-06-30 0001158780 srt:MinimumMember plur:GermanCorporationTaxMember 2023-07-01 2024-06-30 0001158780 srt:MaximumMember plur:GermanCorporationTaxMember 2023-07-01 2024-06-30 0001158780 plur:GermanCorporationTaxMember 2023-07-01 2024-06-30 0001158780 plur:PluriIncMember 2023-07-01 2024-06-30 0001158780 plur:GermanSubsidiaryMember 2023-07-01 2024-06-30 0001158780 plur:ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember 2023-07-01 2024-06-30 0001158780 plur:ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember 2022-07-01 2023-06-30 0001158780 plur:PluristemGmbHMember 2023-07-01 2024-06-30 0001158780 plur:PluristemGmbHMember 2022-07-01 2023-06-30 0001158780 2024-04-01 2024-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares iso4217:EUR xbrli:pure iso4217:ILS EX-4.1 2 ea021391001ex4-1_pluriinc.htm DESCRIPTION OF SECURITIES Exhibit 4.1 Â DESCRIPTION OF SECURITIES Â Under the Amended and Restated Articles of Incorporation, as amended (the â€œArticlesâ€), of Pluri Inc. (the â€œCompanyâ€), the Company is authorized to issue up to Thirty Seven Million Five Hundred Thousand (37,500,000) shares of common stock, par value $0.00001 per share (the â€œCommon Stockâ€), and one million (1,000,000) shares of preferred stock, par value $0.00001 per share (the â€œPreferred Stockâ€). Â The following is a summary of some of the terms of the Companyâ€™s Common Stock, which is the Companyâ€™s only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended. The Common Stock is listed on the Nasdaq Capital Market under the symbol â€œPLURâ€. This summary is not complete, and is subject to and qualified by the provisions of the Articles and the Companyâ€™s Amended and Restated Bylaws (the â€œBylawsâ€). The terms of the Common Stock are also subject to and qualified by the applicable provisions of the Nevada Revised Statues. Â Common Stock Â The holders of shares of Common Stock vote together as one class on all matters as to which holders of Common Stock are entitled to vote. Except as otherwise required by applicable law and subject to the rights of any outstanding Preferred Stock, all voting rights are vested in and exercised by the holders of Common Stock with each share of our Common Stock being entitled to one vote, including in all elections of directors. The Companyâ€™s board of directors (the â€œBoardâ€) is not classified. Â When a quorum is present or represented at any meeting, the vote of the holders of a majority of the stock having voting power present in person or represented by proxy shall be sufficient to elect directors or to decide any question brought before such meeting, unless the question is one upon which by express provision of the statutes or of the Articles, a different vote is required in which case such express provision shall govern and control the decision of such question. Special meetings of the stockholders may be called by the President or the Secretary by resolution of the Board of Directors or at the request in writing of stockholders owning a majority of the entire capital stock of the Company issued and outstanding and entitled to vote. Â The holders of at least thirty-three and one third percent (33 1/3%) of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by statute or by the Articles.Â If such quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. At the adjourned meeting, thirty-three and one third percent (33 1/3%) of the issued and outstanding stock entitled to vote present in person or represented by

proxy shall constitute a quorum. Â Subject to preferences that may be applicable to any outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board out of legally available funds therefor. The Company has not declared any dividends on its Common Stock and does not anticipate paying any dividends on its Common Stock in the foreseeable future. In the event of the Companyâ€™s liquidation, dissolution or winding up, holders of the Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior liquidation rights of Preferred Stock, if any, then outstanding. The Common Stock has no cumulative voting rights and no preemptive or other rights to subscribe for shares of the Company. There are no redemption or sinking fund provisions applicable to the Common Stock. All shares of Common Stock currently outstanding are fully paid and non-assessable. Â Â Â Â Anti-Takeover Effects of the Companyâ€™s Articles and Bylaws Â Certain provisions of the Companyâ€™s Articles and Bylaws could have the effect of delaying, deterring or preventing another party from acquiring or seeking to acquire control of the Company. For example, the Companyâ€™s Articles and Bylaws include provisions that: Â Â â— Allow the Board, by a majority vote of the entire Board at any meeting, to amend the Companyâ€™s Bylaws, including bylaws adopted by the stockholders (but the stockholders, by a 66% vote, may specify particular provisions of the Bylaws that may not be so amended by the Board); Â Â â— provide that stockholders may call a special meeting of the Companyâ€™s stockholders only if such call is made by stockholders owning a majority of the entire capital stock of the Corporation issued and outstanding and entitled to vote; Â Â â— the Board may from time to time increase or decrease the number of directors then comprising the Board (within the range of one and thirteen, as prescribed by the Articles), and may from time to time fill any vacancies, if any, on the Board; and Â Â â— empower the Board to issue from time to time one or more series of Preferred Stock, with such designations, rights, preferences and limitations as the Board may determine by resolution. The rights, preferences and limitations of separate series of Preferred Stock may differ with respect to such matters among such series of Preferred Stock as may be determined by the Board, including, without limitation, the rate of dividends, method and nature of payment of dividends, terms of redemption, amounts payable on liquidation, sinking fund provisions (if any), conversion rights (if any) and voting rights. Â Â Â Â Â EX-10.35 3 ea021391001ex10-34_pluriinc.htm AMENDED AND RESTATED EMPLOYMENT AGREEMENT BY AND BETWEEN PLURI INC. AND LIAT ZALTS, DATED SEPTEMBER 18, 2024 Exhibit 10.34 Â Amended and Restated Employment Agreement Â Duly made and executed on the date set forth in Appendix 1 Â By and Between Â Pluri biotech Ltd. Company number 513371666 (hereinafter the â€œCompanyâ€) Â and Â Liat Zalts I.D. 41706953 (hereinafter the â€œEmployeeâ€) (other details as set forth in Appendix 1) Â WHEREAS, the Employee has been employed by the Company since December 11, 2022 as Director of Finance and the Employee and the Company seek to enter into this Employment Agreement (the â€œAgreementâ€) to set forth the terms of the Employeeâ€™s employment as the Companyâ€™s Chief Financial Officer and Treasurer; and Â WHEREAS, this Amended and Restated Employment Agreement amends and restated that certain Employment Agreement dated October 2, 2022; Â WHEREAS, the Employee represents that, she has the requisite skills and training to fulfill her obligations as set forth herein; Â NOW, THEREFORE, in consideration of the undertakings of the parties, it is hereby agreed: Â 1.duties and responsibilities Â 1.1Position. The Employee shall serve in the position of Chief Financial Officer and Treasurer, as set forth in Appendix 1 hereto, and shall report to Companyâ€™s CEO, or as set forth in Appendix 1. Â 1.2Exclusivity. Unless the Company agrees otherwise (in advance and in writing), the Employee (i) shall devote her full working time (as defined herein), attention, energies, skills, knowledge and experience to the faithful, responsible, competent, diligent, and conscientious performance of her duties and responsibilities hereunder and best efforts to the business and affairs of the company; (ii) shall not engage in or be associated with, directly or indirectly, any business which is competitive, directly or indirectly, with the business of the Company, as more fully described in Appendix 2 attached hereto; and (iii) shall not undertake or accept any other paid or unpaid employment or occupation. Â 1.3Traveling. The Employeeâ€™s employment may require travel outside Israel and the Employee agrees to such travel as may be necessary in order to fulfill her duties hereunder. The Employee shall engage in such travel as may reasonably be required in connection with the performance of her duties. All reasonable travel and other expenses incurred by the employee (in accordance with the policies as established from time to time) in carrying out her duties hereunder will be reimbursed by the Company on presentation to it of expense accounts and appropriate documentation in accordance with the customary procedures of the Company for reimbursement of employee expenses. Â Â Â 1.4Compliance. Without derogating from the above, the Employee shall act in accordance with the Companyâ€™s policies, regulations and general instructions as shall be published and updated from time to time, including, but not limited to, the Companyâ€™s Sexual Harassment Policies, the Companyâ€™s Insider Trade Policy, the Companyâ€™s whistle blowing policy, the Companyâ€™s Ethic Code etc. Without derogating from the provisions of Section 2.4 below, in the event of a breach of this Section 1.4 or any of the policies mentioned herein, Company shall have the right to immediately terminate this Agreement without prior notice, based on Companyâ€™s sole discretion. Â 1.5Exclusivity of Agreement. This Agreement is personal and special, and exclusively defines the entire relationship between the Company and the Employee and all compensation and/or benefits to which the Employee is entitled from the Company. This Agreement supersedes any prior agreements, understandings and arrangements, oral or written, applied, exchanged or signed between the parties hereto with respect to the subject matter hereof. The Employee shall not be entitled to, and shall not demand, any other compensation and/or benefit from the Company, unless explicitly provided for hereunder, and no practice and/or custom existing between the Company and other employees, if any, shall apply to the relationship between the Employee and the Company, unless explicitly incorporated into this Agreement, and then only to the extent so incorporated. This Agreement shall be considered as a notification of the terms of employment as required by law. Â 1.6 Capacity and Working Week. Employee shall work on a full-time basis - constituting 42 hours per week (182 monthly hours in average). Employee shall be entitled to a half-hour break every day, which will not be counted towards Employeeâ€™s working time. The weekly rest day shall be Saturday. The customary working week at the Company is Sunday through Thursday, and the customary work day is between 9:00am to 18:00pm (such that it shall consist of 9 hours per working day, except for a one fixed day of the week, to be determined by the Company, that shall consist of only 8 working hours). Notwithstanding the foregoing, it is hereby clarified that due to Employeeâ€™s duties, she may be required to perform overtime work, as further described herein. Â 2.TERM AND TERMINATION Â 2.1Term of Engagement. This Agreement shall become effective on the date set forth in Appendix 1 (the â€œCommencement Dateâ€), and will remain in force until terminated by a party at any time by giving a prior written notice of termination or resignation (the â€œTermâ€), of a period as set forth in Appendix 1 (the â€œNotice Periodâ€). Â 2.2Notice Period. During the Notice Period, the Employee shall continue to provide all services per this Agreement in full and in a proper manner and shall cooperate with the Company and use her best efforts to assist in the integration into the Companyâ€™s organization of the person or persons who will assume the Employeeâ€™s responsibilities. Notwithstanding the above, the Company shall be entitled to waive the Employeeâ€™s services with the Company during the Notice Period or any part thereof and/or terminate the employer-employee relationship prior to the completion of the Notice Period. In such event, , the Company shall pay the Employee the amount equal to the compensatory payment as required by the Prior Notice Law, and the Employee shall immediately return to the Company any and all equipment provided to her by the Company (including any car, computer, documents, data, etc.). Â 2 Â 2.3Adjustment Period- The parties agree that in the event of Change of Control (as defined herein) during or following which (and up to 12 months of such Change of Control) the employment terms of Employee (including position, authority, etc.) and/or the rights she is entitled to under this Agreement will be subject to an adverse change by Company (regardless of whether or not the employment of Employee was actually terminated), or Change in Control which led to the termination of employment by either party, regardless of reason (the â€œChange in Control Trigger Eventâ€), the Employee will be entitled to an adjustment period commencing on the date of termination of the Notice Period and ending three (3) months from the date of termination of the advance notice, in addition to the advance notice period (the â€œAdjustment Periodâ€). During the Adjustment Period, the Employee will be entitled to receive an amount equal to the Base Salary from the Company, including maintenance of vehicle, maintenance of telephone, and the Company shall continue to deposit and deduct from the Employee amounts to the Pension Insurance and Education Fund to the Employee had she still been employed by Company, and any other elements of compensation entitled under this employment agreement as adjustment fees (hereinafter: â€œAdjustment Feeâ€) that will be paid on a monthly basis. During the Adjustment Period the Employee may be available to the Company reasonably, as will be mutually agreed between the Employee and the Company. In order to clarify- (i) in a Change of Control Trigger Event, Employee shall also be entitled to amounts equivalent to those that would have been payable to Employee under the Notice Period; (ii) if the Adjustment Fee is paid to Employee pursuant to the Change in Control Trigger Event, and Employeeâ€™s employment is terminated during 12 months from the Change of Control, no additional Adjustment Fee will be paid, (iii) if Adjustment Fee is payable to Employee pursuant to a Change in Control Trigger Event, then the salary to be taken into account for this calculation shall be the salary prior to its reduction (if applicable). Â 2.4Termination for Justifiable Cause. Notwithstanding the provisions of Sections 2.2 above, the Company shall have the right to terminate this Agreement and the employer-employee relationship hereunder at any time for a Justifiable Cause (as defined below), by giving the Employee a notice of termination for cause. Â The term â€œJustifiable Causeâ€ shall mean (a) indictment or conviction of the Employee for committing a crime; or (b) a serious breach of trust including but not limited to theft, fraud, disclosure to unauthorized persons or entities of confidential or proprietary information of the Company and/or the engaging by the Employee in any business competitive to the business of the Company; or (c) any breach of SectionsÂ 4 or 5 of this Agreement; or (d) any sexual harassment; or (e) violent behavior; or (f) consistent noncompliance with Companyâ€™s policies, orders and regulations; or (g) performance, by the Employee, of any act that entitles the Company to dismiss her without paying her any or partial severance pay in connection with such dismissal under applicable law. Â 3 Â 2.5Final Settling. At the end of the employer-employee relationship, the Company and the Employee shall conduct a final settling of the Employeeâ€™s accounts to be held according to the Companyâ€™s records. Such settling of accounts shall be final and no party shall have any further claim or demand from the other party. It is agreed that, subject to the applicable laws, the Company shall be entitled to deduct any amount the Employee shall owe the Company at such time from the amounts she shall be entitled to. Â 2.6Release of funds. It is hereby agreed between the parties that at the end of the employment relationship, other than upon termination in circumstances justifying dismissal without any or partial severance pay under applicable law, all sums accumulated in the Employeeâ€™s pension insurance policies (after completion of payment of all premiums previously due with respect to such pension insurance policies), shall be released and transferred to the Employee. The Company and Employee agree and acknowledge that in the event the Company transfers ownership of Employeeâ€™s pension insurance policies to the Employee, the severance portion thereof shall constitute full and final payment towards any severance pay the Company may be required to pay to the Employee pursuant to the Severance Pay Law 5727-1963, and that this section is in accordance with the provisions of section 14 of the Severance Pay Law 5727-1963, and with the general approval of the labor minister, dated June 30, 1998 (issued in accordance with the said section 14). Â 2.7Return of Equipment. At the end of the employer-employee relationship the Employee shall return to the Company any and all documents, professional literature, equipment and property belonging to the Company, which may be in Employeeâ€™s possession at such time. Should the Employee refuse and/or fail to do so, the Company shall have the right, in addition to any other remedy available under any law, to offset the value of such property (as shall be determined solely by the Company) from the amounts (if any) that the Employee might be entitled to. Â 2.8Degree of Trust. Employee understands and acknowledges that due to the nature of his work and duties, she may be required to work during overtime hours. Employee further acknowledges that since her positions involved a high and special degree of trust, and since the Company cannot keep specific track of all of the Employeeâ€™s overtime hours, the provisions of Work and Rest Law, 5711-1951 regarding overtime pay shall not apply to Employee, and that the Base Salary has been determined while taking into account reasonable capacity of overtime work by Employee. Â 3.Base Salary and benefits Â 3.1 Base Salary Â 3.1.1 General. The Company shall pay the Employee a Base monthly salary in the amount set forth in Appendix 1. As detailed below, the Base Salary is inclusive of special non-competition monthly compensation (as such terms are defined below) and a monthly gross global compensation for the performance of 60 overtime hours in average per month (the â€œGlobal Compensationâ€) â€“ which together shall be referred to herein as the â€œBase Salaryâ€ in this Agreement. It is clarified that the Base Salary alone shall be taken into account in calculating and determining Employees social and/or fringe benefits (including with respect to any allocation in favor of pension, severance and/or education fund). Â Without derogating from the above, the Employee acknowledges that the Employeeâ€™s Position is a special trust Position that does not enable the Company to supervise the Employeeâ€™s hours of work and rest, and accordingly, the Employee shall not be entitled to and hereby irrevocably waives any claim for any additional overtime payment under the Law of Work Hours and Rest - 1951, which shall not apply to this Agreement. Â 4 Â The Base Salary shall be comprehensive and all-inclusive and it shall be deemed to embody any and all compensation the Employee shall be entitled to in connection with her employment by the Company. Â 3.1.2 Payment. The Base Salary for each month shall be payable until the 9th calendar day of the following calendar month. Â 3.1.3 Occasional Benefits. Any benefit, of any kind, granted to the Employee by the Company and which is not specified in this Agreement (a â€œBenefitâ€), shall be deemed as a non-recurring event, and shall neither give rise to any new right of the Employee, nor constitute a practice and/or custom and/or precedent between the parties which shall obligate the Company on any additional and/or other occasions. It is hereby agreed, that any such Benefit shall be a supplement above and beyond the Employeeâ€™s Base Salary, and shall not to be taken into account for the purpose of calculating the Employeeâ€™s social entitlements or rights. Â 3.1.4 Tax Deductions. The Company shall legally deduct and withhold income tax payments and any other obligatory payments, such as social security and health insurance, from all the payments, which shall be paid to the Employee in accordance with this Agreement and as required by law at such time. Â 3.2Non-Competition Compensation. The Employee acknowledges that an amount equal to 10% of the Base Salary is paid to her as a special supplementary monthly compensation in consideration for the Employeeâ€™s obligation not to perform any Competitive Activity (as stated in Section 4 to Appendix 2 hereto; the â€œSpecial Non-Competition Compensationâ€). The specific amount of Non-Competition Compensation (which may be updated pursuant to any change in the Base Salary amount) is detailed in Appendix 1. The Employee warrants and represents that the Special Non-Competition Compensation amount constitutes real, appropriate and full compensation for any prejudice she may suffer due to her obligation not to engage with any competitive activity, including but not limited to restriction of her freedom of employment. Â 3.3Recuperation Pay. The Employee shall be entitled to Recuperation Pay (â€œDmey Havraâ€™aâ€) in accordance with the applicable law. Â 3.4Vacation. The Employee shall be entitled to the number of work daysâ€™ vacation in each calendar year, as set forth in Appendix 1. The Employee is obligated to use at least seven (7) consecutive vacation days during each calendar year, commencing on the Commencement Date (as defined in Appendix 1) and during each calendar year thereafter. To the extent permitted by law, unused vacation days may be carried forward from one calendar year to the next. Any vacation days that are unused within one (1) year following the year in which they were accumulated, shall expire. Â 5 Â 3.5Sick Leave. The Employee shall be entitled to paid sick leave according in accordance with the Companyâ€™s policies, as amended from time to time. Â 3.6Pension Insurance. Â The Company and the Employee will obtain and maintain Managers Insurance and/or a comprehensive Pension Fund according to the Employeeâ€™s choice (â€œPension Insuranceâ€). The Employee is entitled to receive the Companyâ€™s contribution for her Pension Insurance Policies (Pension Funds and/or Managers Insurance) from the date indicated in Appendix 1: Â 3.6.1 The Company shall affect a Pension Insurance Policy (the â€œPolicyâ€) for the Employee, and shall pay the percentages detailed in Appendix 1 towards such Policy, on account of severance pay and Tagmulim. Â 3.6.2 The Company shall make additional payments, as detailed in Appendix 1, on account of disability insurance, in accordance with Companyâ€™s policies. Â 3.6.3 Unless otherwise is indicated in Appendix 1, the Company shall deduct the percentage set forth in Appendix 1 from the Base Salary for Pension Insurance to be paid on behalf of the Employee towards such Policy. Â It is clarified that the Employee shall bear any and all taxes, which may apply with respect to any contribution, which exceeds the recognized tax ceilings with respect to the Pension Insurance. Â 3.7Education Fund. The Employee is entitled to Education Fund payments from the date indicated in Appendix 1 (if at all) as follows: Â 3.7.1 The Company shall pay a sum equal to a percentage that is detailed in Appendix 1 of the Base Salary for Education Fund and (ii) shall deduct a percentage that is detailed in Appendix 1 from the Base Salary for Education Fund to be paid on behalf of the Employee toward a further education fund. Use of this fund shall be in accordance with the policies of the relevant fund. Â 3.7.2 With respect to Education Fund payment, the Employee may elect that the salary base of calculation shall be less than the Base Salary. In such event, the balance between the amounts that would have be allocated by the Company towards such Education Fund had the entire Base Salary would have been taken into account, and the amount actually allocated by the Company pursuant to the Employeeâ€™s request shall be paid as an additional compensation (gross) together with the Base Salary and shall not be taken into account with respect to any social or fringe benefit such as pension, severance payments, education fund etc., and will not be considered as part of the Base Salary for all intents and purposes. In such case, the Employee will inform the Company of such request and will sign a written consent. Â 6 Â 3.8Military Reserve Duty. The Employee shall inform the Company of any military reserve duty the Employee has been ordered to perform, immediately after she has been notified of the same. The Employee undertakes to provide the Company with proper confirmation of active military reserve duty, so that the Company may collect from the national insurance institute all amounts to which the Employee or the Company is entitled in connection with such service. Â 3.9Cellular Phone. The Company will provide the Employee with a personal cellular phone and shall bear

expenses associated with the usage of the employeeâ€™s personal cellular phone as indicated in Companyâ€™s policies. Any tax withholding arising out of this reimbursement shall be solely borne by the employee. Â 3.10Vehicle. In order to fulfill its duties, the Company will provide the Employee with a private car, in accordance with Companyâ€™s cars policy as indicated in Appendix 1 or a similar executive vehicle at the Companyâ€™s sole discretion or reimburse the Employeeâ€™s car expenses in a fix amount as indicated in Appendix 1 in case the Employee will decide to use her personal car. The Company will bear all the payments to the leasing company as well as all the current expenses involved in the maintenance of the vehicle, including fuel, parking, insurance, a subscription to travel on toll roads and the like, all in accordance with Company policies. It is hereby clarified that the Employee shall be entitled to continue to hold and use the vehicle during the period of prior notice, whether in the event of dismissal or in the event of resignation, whether she worked during these periods or not. Â 3.11Stock based awards. Â During the term of this Agreement, subject to the below approvals, the Employee shall be entitled to participate in any of Pluri biotech Therapeutics Inc.â€™s (the â€œParent Companyâ€) equity compensation plans, whether currently in existence or as may be adopted in the future by the Parent Companyâ€™s shareholders, from time to time (the â€œPlanâ€), and may be granted such awards, pursuant to any relevant grant instruments, that may be granted in accordance with the Plan (the â€œAwardsâ€) as shall be determined by the Board and/or the Parent Companyâ€™s Compensation Committee. It is hereby clarified that the grant of the Awards is subject to (a) the approval of the Parent Companyâ€™s Board of Directors and/or Compensation Committee and (b) execution of any documents required pursuant to applicable law and the terms of the Plan, including execution of a grant Award agreement, and an irrevocable proxy. The terms of the Award, including but not limited to, the number of Awards granted, the exercise price, vesting period, adjustments and exercise period shall be determined in accordance with the provisions of the Plan and the executed grant Award agreement. Â Employee shall be entitled to immediate acceleration of the unvested Awards in the event of a Change of Control (as hereinafter defined) of the Parent Company (or the Company), 100% of any unvested Awards. Â 7 Â For purposes of this Agreement, â€œChange of Controlâ€ shall mean the occurrence of any of the following: (i) any one person, or more than one person acting as a group, acquires ownership of stock of the Parent Company that, together with stock held by such person or group, constitutes more than forty percent (40%) of the total voting power of the stock of the Parent Company; (ii) any consolidation or merger of the Parent Company into another corporation or entity where the stockholders of the Parent Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own, directly or indirectly, securities representing in the aggregate more than fifty percent (50%) of the combined voting power of all the outstanding securities of the surviving corporation (or of its ultimate parent corporation, if any); (iii) the sale, lease or other transfer of all or substantially all of the Parent Companyâ€™s assets to an independent, unaffiliated third party in a single transaction or a series of related transactions; or (iv) the date that a majority of the members of the Parent Companyâ€™s Board of Directors is replaced during any twelve (12) month period by directors whose appointment or election is not endorsed by a majority of the members of the Parent Companyâ€™s Board of Directors prior to the date of the appointment or election. Â Any tax imposed on Employee with respect to the grant and/or the exercise of the Award shall be borne by the Employee. Â 3.12[RESERVED] Â 3.11Target Bonus. After the initial 12 months of employment as CFO starting from October 1 2024, the Companyâ€™s Compensation Committee and/or the Board will set a discuss and approve an annual performance bonus plan in a gross amount of up to three and a half times the Base Salary, subject to goals achievement. Â 3.12[RESERVED] Â 3.14.D&O Insurance and indemnification. The Company agree to continue and maintain a directorsâ€™ and officersâ€™ liability insurance policy covering the Employee at a level, and on terms and conditions, no less favorable to her than the coverage the Company provides other similarly-situated executives or directors until such time as suits against the Employee are no longer permitted by law. Furthermore, the Company shall act to provide indemnification to the Employee in his capacity as an officer of the Company. Â 4.proprietary information AND WORK PRODUCT; EQUIPMENT Â 4.1Non-Disclosure and Non-Competition Agreement. Concurrently with the execution of this Agreement, the Employee is executing the Non-Disclosure and Non-Competition Agreement, which is attached hereto as Appendix 2, and which is an integral part hereof. Â 4.2Monitoring of Systems. The Companyâ€™s Systems (as defined below) or access which is provided to the Employee are and shall remain the sole property of the Company. The Employee shall use such Systems for business purposes only. To ensure the security of such Systems and to protect the Companyâ€™s confidential and proprietary information, the Company reserves the right, and the Employee hereby agrees that the Company and anyone on its behalf may, at any time and for any purpose, monitor the Employeeâ€™s use of the Systems and monitor, copy, transfer and disclose all electronic communications and content transmitted by or stored in such Systems, regardless of the location, time or purpose of such use (other than protected private use in accordance to law). For the purposes of this Section 4.2, â€œSystemsâ€ include any equipment and software of any kind, including Employeeâ€™s computer, Companyâ€™s mailbox, Companyâ€™s and/or Employeeâ€™s telephone, etc. Employee acknowledges and approves that the provisions of this Section 4.2 are reasonable in light of the Employeeâ€™s position with the Company, in the course of which the Employee has and shall gain broad knowledge of the Companyâ€™s proprietary information. Â 8 Â 4.3Employee understands and acknowledges that for internal corporate, HR, finance and enterprise reasons, Company may share, transfer, convey and make available certain personal information of the Employee (such as personal and demographic information, financial, personal records, or other personally identifiable information) (collectively: the â€œEmployee Informationâ€) to the Parent and its respective personnel, consultants, advisors and officers. Employee further understands that Parent is operating outside the EEA and as such is not subject to privacy rules applicable in Israel and/or EEA. Nevertheless, Company shall take all reasonable efforts to make sure that the Parent maintains and treats the Employee Information in standards no less stringent than the privacy standards and requirements which apply to the Company. Â 4.4Survival. SectionsÂ 4 above will remain in full force and effect after termination of this Agreement. Â 5.warranties Â 5.1The Employee has the knowledge, abilities and skills required to perform the duties of her position. Â 5.2The Employee shall inform the Company, immediately upon becoming aware of any matter in which she or a member of her immediate family or affiliate has a personal interest or which might create a conflict of interests with her duties under this Agreement. Â 5.3In carrying out her duties under this Agreement, the Employee shall not make any representations, or give any guaranties on behalf of the Company, except as authorized to do. Â 5.4The Employee represents and warrants that on the effective date she will be free to provide services to the Company upon the terms contained in this Agreement and that there are no employment contracts, consulting contracts or restrictive covenants preventing full performance of her duties hereunder. Â 5.5The Employee represents and warrants that she will not use during the course of her employment with the Company any trade secrets or proprietary information that is the property of her previous employer(s) in such a manner that may breach any confidentiality or noncompetition agreement or other obligation the Employee may have with such former employer(s). Â 9 Â 6.general provisions Â 6.1In this Agreement words importing the masculine gender shall include the feminine gender. Â 6.2This Agreement shall not be amended, modified or varied by any oral agreement or representation or otherwise than by written instrument executed by either parties or their duly authorized representatives. Â 6.3This Agreement is personal to the Employee, and the Employee shall not assign or delegate her rights or duties to a third party, whether by contract, will or operation of law, without the Companyâ€™s prior written consent. Â 6.4This Agreement shall inure to the benefit of the Companyâ€™s successors and assigns. Â 6.5Each notice and/or demand given by one party pursuant to this Agreement shall be given in writing and shall be sent by registered mail to the other party at the address appearing in the caption of this Agreement, and such notice and/or demand shall be deemed given at the expiration of seven (7) days from the date of mailing by registered mail or immediately if delivered by hand. Such address shall be effective unless notice of a change in address is provided by registered mail to the other party. Â 6.6It is hereby agreed between the parties that the laws of the State of Israel shall apply to this Agreement. The legally authorized courts in the district of Tel Aviv, Israel, shall have exclusive jurisdiction over the parties hereto and subject matter hereof. Â 6.7No Waiver. No delay, failure, or forbearance to exercise any right, power, or remedy accruing to either party upon breach or default under this Agreement shall be deemed a waiver of any prior or subsequent breach or default of this Agreement, nor affect the validity of any provision of this Agreement. Â 6.8Integration. This Agreement sets forth the entire agreement between the parties on the subject hereof and supersedes any previous oral or written agreements, understandings, memoranda, emails, letters or representations on the subject matter hereof. 6.9Severance. If any one or more of the terms of this Agreement shall for any reason be held to be invalid or unenforceable, such term shall be construed in a manner to enable it to be enforced to the extent compatible with applicable law. Any determination of the invalidity or unenforceability of any provision of the Agreement shall not affect the remaining provisions hereof unless the business purpose of this Agreement is substantially frustrated thereby. Â 6.10.The Company is not a party to any Collective Agreement. Â 6.11.The above and the said in the appendices shall be without prejudice to any right conferred to the Employee by any law, Extension Order or Collective Bargaining Agreement which apply to the Employee. Â [signature page follows] Â 10 Â IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written: Â /s/ Yaky Yanay Â /s/ Liat Zalts Pluri biotech Ltd. Â Liat Zalts Â Â Â Date: September 18, 2024 Â Date: September 18, 2024 Â Â Â Appendix 1 Â 1 Employee Personal Details Full Name: Liat Zalts I.D. Number: 041706953 Date of Birth: _____ 2 Position in the Company Direct manager CFO and Treasurer CEO 3 Commencement Date in the Position October 1, 2024 4 Period of prior notice (mutual) 60 days Â Adjustment Period Â (Change in Control event) 3 months as defined at Section 2.3 5 Base Salary: 48,000 NIS 6 Yearly Vacation Days 23 Days 7 Pension Insurance Entitled Â Â Ã˜ For severance pay 8.33% of Base Salary Â Â Ã˜ For Tagmulim 6.5% of Base Salary for Pension Fund No less than 6.5% and not more than 7.5% of Base Salary for Mangers Insurance Â Â Ã˜ For disability insurance Not more than 2.5% of Base Salary but in accordance with the applicable plan that was selected by the Company. Â Â Ã˜ Deduct from Employee (on account of Tagmulim) 6% of Base Salary for Managerâ€™s Insurance or Pension Fund Â 8 Education Fund Entitled Â Â Ã˜ Payment by Company 7.5% of Base Salary for Education Fund, unless the Employee decides that such percentage will be calculated on a lower amount of Base Salary as described at 3.7.2 Â Â Â Ã˜ Deduct from Employee (on account of education fund) 2.5% of Base Salary for Education Fund, unless the Employee decides that such percentage will be calculated on a lower amount of Base Salary as described at 3.7.2 Â 9 Cellular Telephone Entitled to Cellular phone and reimbursement relevant expenses, in accordance with Companyâ€™s policies 10 Vehicle Toyota Rav 4 or a model equivalent, in accordance with Companyâ€™s policy or a fixed amount of NIS 4,000 13. Target Bonus After the initial 12 months of employment as CFO starting from October 1, 2024, a performance bonus plan will be discussed and approved by the Companyâ€™s Board or the Compensation Committee. Â Subject to meeting milestones determined annually by the Companyâ€™s Compensation Committee and/or the Board, the Employee shall be entitled to a performance bonus in a gross amount of up to three and a half times the Base Salary. Â /s/ Yaky Yanay Â /s/ Liat Zalts Pluri biotech Ltd. Â THE EMPLOYEE Liat Zalts Â Â Â Date: September 18, 2024 Â Date: September 18, 2024 Â Â Â Appendix 2 Â Non-Disclosure and Non-Competition Agreement Â I acknowledge that as a result of my employment by Pluri biotech Ltd. (the â€œCompanyâ€), I may develop, receive, or otherwise have access to confidential or proprietary information that is of value to the Company. I therefore agree, as a condition of my employment, as follows: Â 1.Non - disclosure Â 1.1.Recognition of Companyâ€™s Rights; Non - disclosure. At all times during my employment and thereafter, I will hold in strictest confidence and will not disclose, disseminate, use, copy, lecture upon or publish in any manner or fashion whatsoever, any of the Companyâ€™s Proprietary Information (as such term is defined below), except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an officer of the Company expressly authorizes such in writing in advance. I will obtain the Companyâ€™s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at the Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns. Â 1.2.Proprietary Information. The term â€œProprietary Informationâ€ shall mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, â€œProprietary Informationâ€ includes (a)Â trade secrets, inventions, pending patents, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, inventions, discoveries, developments, designs and techniques (excluding inventions that are not assignable under Section 2.4, hereinafter collectively referred to as â€œInventionsâ€); and (b)Â information regarding plans for research, development, new products, marketing and selling, business plans, budgets and any unpublished financial statements and/or information, licenses, strategies, forecasts and projections, prices and costs, suppliers and customers; (c) information regarding the skills and compensation of other employees, management or other personnel of the Company; and (d) information that is disclosed in the furtherance of the business of the Company including, without limitation, the area of activity in which the Company is involved, the Companyâ€™s technical, business and financial information, documentation, records, files, memoranda, reports, drawings, plans, price lists, customer lists, and the like. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, to whatever extent and in whichever way I wish. Â 1.3.Third Party Information. I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (â€œThird Party Informationâ€) subject to a duty on the Companyâ€™s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. Â Â Â 1.4.No Improper Use of Information of Prior Employers and Others. During my employment with the Company, I will not improperly use or disclose any Proprietary Information and/or confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person. Â 2.Assignment of Inventions Â 2.1.Proprietary Rights. The term â€œProprietary Rightsâ€ shall mean all trade secret, patent, copyright, mask work and other intellectual property rights throughout the world. Â 2.2.Prior Inventions. I hereby confirm that I have transferred and assigned in whole to the Company any and all of my rights, title and interest in any and all Inventions, which are currently being used or contemplated to be used by the Company on the date hereof. Notwithstanding the foregoing, other than inventions referred to in the immediately preceding sentence, inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company (â€œPrior Inventionsâ€) are excluded from the scope of this Agreement. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, unlimited worldwide license (with rights to sublicense through multiple tiers of sublicenses) to make, have made, modify, use and/or sell and/or otherwise use as the Company may wish, such Prior Invention. Without derogating from the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Companyâ€™s prior written consent. Â Prior Inventions: _____ [Please List all Prior Inventions (if any)] Â 2.3.Assignment of Inventions. I will promptly disclose to the Company, or any persons designated by it, all Inventions made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the employment term, as a result of tasks assigned by the Company or as a result of the use of premises and/or equipment owned, leased, or contracted for by the Company. Furthermore, subject to Section 2.4, I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company and which are connected and/or related to the Companyâ€™s business and which have been created or developed as part of my work for the Company. Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this SectionÂ 2, are hereinafter referred to as â€œCompany Inventionsâ€. Â Â Â 2.4.Government or Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to any third party, including without limitation government agency, as directed by the Company. Â 2.5.Works made for Hire. I further acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of and during my employment with the Company are â€œworks made for hireâ€ as contemplated under Chapter H of the Patents Law of 1967 (the â€œPatents Lawâ€), that all such â€œworks made for hireâ€ are owned by the Company, its successors, assigns or nominees, and that I shall not be entitled to any compensation, other than the Base Salary, for creation or assignment of the same to the Company, its successors, assigns or nominees; it being acknowledged and agreed that the Base Salary and all other employment terms under the Employment Agreement shall constitute the sole consideration and remuneration for any Inventions, including, without limitation, â€œworks made for hireâ€, regardless of the current or future value of the Invention. I understand and agree that the decision whether or not to commercialize or market any invention developed by me (including the Inventions), solely or jointly with others, is within the Companyâ€™s sole and unfettered discretion and for the Companyâ€™s sole benefit and that no royalty will be due to me as a result of the Companyâ€™s efforts to commercialize or market any such invention (including the Inventions). This Section 2.5 shall be deemed as an â€œagreementâ€ for purposes of Section

134 of the Patents Law. Furthermore, Employee waives any right to receive any notice by Company regarding any Inventions pursuant to Section 132 of the Patents Law. Â 2.6.I acknowledge and agree that in event that, notwithstanding the agreement stipulated herein, it will be decided by a competent authority, court or any other competent tribunal, either due to my application or any other source, that I may deserve additional compensation for Company Inventions, in addition to any amounts paid to me by the Company under and according to my employment agreement (a â€œClaimâ€), my Base Salary (as defined in the Agreement) shall be reduced, retroactively effective as of the date of the beginning of my employment by the Company to an amount equal to 80% (eighty percent) of the Base Salary actually paid to me by the Company (the â€œAgreed Alternative Paymentâ€) and I shall be obligated to return to the Company, on the day the Claim was made and/or the demand which contradicts this Agreement was made, all additional amounts that I received from the Company beyond the Agreed Alternative Payment, retroactively from my employment Start Date onward (the â€œExcess Amountâ€), plus interest as of the original date of payment thereof. I acknowledge that the Company shall be entitled to set off such Excess Amounts against all amounts that I shall be entitled to under the Agreement, or under the decision of the Court or of any other competent tribunal or authority. Such set-off shall not derogate from the Companyâ€™s right to collect any additional amounts from me. Â In addition, I undertake, by signing this Agreement that I will not, directly or indirectly, make a claim and /or sue and/or demand, from the Company and/or any of its officers, employees and shareholders any additional compensation for creation or assignment of Inventions beyond the amounts paid to me by the Company according to my Employment Agreement. Â 2.7.Copyright Works. Without derogating from the forgoing, I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright are the property of the Company pursuant to applicable copyright law. Â Â Â 2.8.Enforcement of Proprietary Rights. I will assist the Company in every proper way to obtain, and from time to time enforce, any Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate, to be discussed with the Company, after my termination for the time actually spent by me at the Companyâ€™s request on such assistance, subject to my consent, which will not be withheld for unreasonable reasons. Â 2.9.Power of Attorney. In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in Section 2.8 hereof, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company. Â 3.Records Â I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at all times. Â 4.Competitive Activities Â I acknowledge that I have carefully reviewed the provisions of this Agreement, the Employment Agreement and the appendices thereof, fully understand the consequences thereof, and have assessed the respective advantages and disadvantages to me in entering into this Agreement. In light of the aforesaid, I agree that, during the period of my employment by the Company and for a period of one (1) year thereafter, I will not, directly or indirectly, carry on or engage in any employment or business activity, or hold an interest in any business, either as an employee, owner, partner, agent, shareholder, director, consultant or otherwise, which is competitive with the business of the Company (â€œCompetitive Activityâ€). I agree further that for the period of my employment by the Company and for a period of one (1) year thereafter, I will not induce, solicit, employ or entice away or endeavor to solicit, employ or entice away any employee of the Company to leave the employ of the Company or to perform any Competitive Activity. In addition, I agree not to solicit, canvass or approach or endeavor to solicit, canvass or approach any person who was provided with services by the Company or its subsidiaries, or has provided services to the Company or its subsidiaries, at any time during the twelve (12) months immediately prior to the termination date of this Agreement, for the purpose of offering services which are competitive with those provided by the Company. I acknowledge that due to my position, the Proprietary Information I am and shall be exposed to and the nature of the business of the Company - any Competitive Activity performed by me will severely harm the legitimate rights and interests of the Company, including but not limited to its Proprietary Rights. In light of all the foregoing I acknowledge that this non-competition undertaking is reasonable, proportional and does not exceed the minimum required to protect the Companyâ€™s legitimate rights and interests. I warrant and represent that the Special Non-Compensation Monthly Compensation (as such term is defined in the Employment Agreement) constitutes a real, appropriate and full consideration to any prejudice I may suffer due to my undertaking not to engage with any Competitive Activity, including but not limited to any restriction to my freedom of employment. Â Â Â 5.No Conflicting Obligation Â I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree not to enter into, any agreement, written or oral in conflict herewith. Â 6.Return of Company Documents Â When I leave the employ of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Proprietary Information of the Company. Â 7.Notification of New Employer Â In the event that I leave the employ of the Company, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement. Â 8.General Provisions Â 8.1.Severability. I acknowledge that the provisions of this Agreement serve as an integral part of the terms of my employment and reflect the reasonable requirements of the Company in order to protect its legitimate interests with respect to the subject matter hereof. In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. Â 8.2.Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. Â Â Â 8.3.Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee. Â 8.4.Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. Â 8.5.Entire Agreement. The obligations pursuant to Sections 1 and 2 of this Agreement shall apply to any time during which I was previously employed (if at all), am or will be in the future employed, by the Company, including as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions or agreements between us with respect to the subject matter hereof. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. Â 8.6.Governing Law. This Agreement shall be governed by, and construed in accordance with the laws of the State of Israel, without giving effect to the rules respecting conflict-of-law. Â 8.7.Jurisdiction. The legally authorized courts in the district of Tel Aviv, Israel, shall have exclusive jurisdiction over the parties hereto and subject matter hereof. Â This Agreement shall be effective as of the date the Employment Agreement of the Employee was made effective. Â I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. ACCEPTED AND AGREED TO: Â /s/ Yaky Yanay Â /s/ Liat Zalts Pluri biotech Ltd. Â THE EMPLOYEE, Liat Zalts Â Â Â Date: September 18, 2024 Â Date: September 18, 2024 Â Â Â EX-21.1 4 ea021391001ex21-1_pluriinc.htm LIST OF SUBSIDIARIES OF THE COMPANY Exhibit 21.1 Â List of Subsidiaries of Pluri Inc. Â Pluri Biotech Ltd., an Israeli company. Pluristem GmbH, incorporated under the laws of Germany. Ever After Foods Ltd. (69% are held by Pluri Biotech Ltd.) Coffeesai Ltd. EX-23.1 5 ea021391001ex23-1_pluriinc.htm CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.1 Â CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Â We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (Nos. 333-273347, 333-272330) and S-8 (Nos. 333-279256, 333-279255, 333-269736, 333-269734, 333-248686, 333-248685, 333-229535, 333-222888, 333-217770, 333-212299) of Pluri Inc. of our report dated September 18, 2024 relating to the financial statements, which appears in this Form 10-K. Â /s/ Kesselman & Kesselman Certified Public Accountants (Isr.) A member firm of PricewaterhouseCoopers International Limited Â Haifa, Israel September 18, 2024 Â EX-31.1 6 ea021391001ex31-1_pluriinc.htm CERTIFICATION Exhibit 31.1 Â CERTIFICATION Â I, Yaky Yanay, certify that: Â 1.I have reviewed this annual report on Form 10-K of Pluri Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) and have: Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated: September 18, 2024 Â /s/ Yaky Yanay Â Yaky Yanay Â Chief Executive Officer, President Â (Principal Financial Officer) Â Â EX-31.2 7 ea021391001ex31-2_pluriinc.htm CERTIFICATION Exhibit 31.2 Â CERTIFICATION Â I, Chen Franco-Yehuda, certify that: Â 1.I have reviewed this annual report on Form 10-K of Pluri Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) and have: Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated: September 18, 2024 Â By: /s/ Chen Franco-Yehuda Â Â Chen Franco-Yehuda Â Â Chief Financial Officer Â Â (Principal Financial Officer) Â Â EX-32.1 8 ea021391001ex32-1_pluriinc.htm CERTIFICATION Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Â In connection with the Annual Report on Form 10-K of Pluri Inc. (the â€œCompanyâ€) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, as the Chief Executive Officer and President of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350 that, to my knowledge: Â 1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Â Dated: September 18, 2024 Â /s/ Yaky Yanay Â Yaky Yanay Â Chief Executive Officer, President Â Â EX-32.2 9 ea021391001ex32-2_pluriinc.htm CERTIFICATION Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Â In connection with the Annual Report on Form 10-K of Pluri Inc. (the â€œCompanyâ€) for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350 that, to my knowledge: Â 1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: September 18, 2024 Â By: /s/ Chen Franco-Yehuda Â Â Chen Franco-Yehuda Â Â Chief Financial Officer Â Â EX-97.1 10 ea021391001ex97-1_pluriinc.htm CLAWBACK POLICY Exhibit 97.1 Â PLURI INC. (the â€œCompanyâ€) Â CLAWBACK POLICY Â Effective as of November 13, 2023 Â Background Â The Board of Directors of the Company (the â€œBoardâ€) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Companyâ€™s pay-for-performance compensation philosophy. The Compensation Committee of the Board (the â€œCompensation Committeeâ€) and the Board have therefore adopted this policy, which provides for the recoupment (or clawback) of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws of the United States (the â€œPolicyâ€). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), Rule 10D-1 promulgated under the Exchange Act (â€œRule 10D-1â€) and the listing standards of the Nasdaq Stock Market (â€œNasdaqâ€) under Nasdaq Listing Rule 5608. Â Administration Â This Policy shall be administered by the Compensation Committee. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals. Subject to any limitation under applicable law, the Compensation Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (the â€œAuthorized Officersâ€) (other than with respect to any

recovery under this Policy involving such officer or employee). Â Covered Executives Â This Policy applies to the Companyâ€™s current and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards of the Nasdaq (â€œCovered Executivesâ€). Â Recoupment; Accounting Restatement Â In the event the Company is required to prepare an accounting restatement of its financial statements due to the Companyâ€™s material noncompliance with any financial reporting requirement under the securities laws, the Compensation Committee will require prompt reimbursement or forfeiture of any excess Incentive Compensation (as defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement. For the sake of clarity, recoupment is required in the event of any restatement that either: (a) corrects an error in previously issued financial statements that is material to the previously issued financial statements; or (b) corrects an error not material to previously issued financial statements, but that would result in a material misstatement if (i) the error was left uncorrected in the then current period; or (ii) the error correction was recognized in the then current period. The Companyâ€™s obligation to recover erroneously awarded compensation is not dependent on if or when the restated financial statements are filed. For purposes of determining the relevant recovery period, the date that the Company is required to prepare an accounting restatement as described above is the earlier to occur of: (A) the date the Board, a committee of the Board, the Authorized Officers, or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement as described above; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare an accounting restatement as described above. In accordance with Nasdaq Rule 5608(e), this Policy is applicable to Incentive Compensation (as described below) received on or after October 2, 2023. Â Â Â Â Incentive Compensation Â For purposes of this Policy, â€œIncentive Compensationâ€ means any of the following, provided that such compensation is granted, earned or vested based wholly or in part on the attainment of a financial reporting measure affected by the restated financial statements: Â â—Annual bonuses and other short- and long-term cash incentives. â—Stock options. â—Stock appreciation rights. â—Restricted stock. â—Restricted stock units. â—Performance shares. â—Performance units. Â Financial reporting measures are measures that are determined and presented in accordance with the accounting principles used in preparing the Companyâ€™s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total stockholder return are also financial reporting measures. A financial reporting measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission. The Companyâ€™s financial reporting measures may include, but are not limited to, the following: Â â—Company stock price. â—Total shareholder return. â—Revenues. â—Net income. â—Earnings before interest, taxes, depreciation and amortization (EBITDA). â—Funds from operations. â—Liquidity measures such as working capital, operating cash flow or Free Cash Flow. â—Return measures such as return on invested capital or return on assets. â—Earnings measures such as earnings per share. Â This Policy applies to all Incentive Compensation received by a Covered Executive: Â â—After beginning service as an executive officer; â—Who served as an executive officer at any time during the performance period for that Incentive Compensation; â—While the Company has a class of securities listed on a national securities exchange or a national securities association; and Â 2 Â Â Â â—During the three completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described in this Policy. In addition to these last three completed fiscal years, this Policy applies to any transition period (that results from a change in the Companyâ€™s fiscal year) within or immediately following those three completed fiscal years. However, a transition period between the last day of the Companyâ€™s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year. Â Incentive Compensation is deemed received in the Companyâ€™s fiscal period during which the financial reporting measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period. Â Excess Incentive Compensation: Amount Subject to Recovery Â The amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated results, as determined by the Compensation Committee, and without regard to any taxes paid by or withheld from the Covered Executive. If the Compensation Committee cannot determine the amount of excess Incentive Compensation received by the Covered Executive directly from the information in the accounting restatement, then it will make its determination based on a reasonable estimate of the effect of the accounting restatement. For Incentive Compensation based on stock price or total stockholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the amount will be based on a reasonable estimate of the effect of the accounting restatement on the stock price or total stockholder return upon which the Incentive Compensation was received. In such case, the Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq. Â Method of Recoupment Â The Compensation Committee will determine, in its sole discretion, the method for recouping Incentive Compensation hereunder which may include, without limitation: Â â—Requiring reimbursement of cash Incentive Compensation previously paid; â—Seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards; â—Offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive in accordance with applicable law; â—Cancelling outstanding vested or unvested equity awards; and/or â—Taking any other remedial and recovery action permitted by law, as determined by the Compensation Committee. Â No Indemnification Â The Company shall not indemnify any Covered Executives against the loss of any Incentive Compensation recovered under this Policy or from any consequence arising therefrom. Â 3 Â Â Interpretation Â The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, Rule 10D-1 and any applicable rules or standards adopted by the Securities and Exchange Commission or Nasdaq. Â Effective Date Â This Policy shall be effective as of the date it is adopted by the Board (the â€œEffective Dateâ€) and, in accordance with Nasdaq Rule 5608(e), shall apply to Incentive Compensation that is received by Covered Executives on or after October 2, 2023. Â Amendment; Termination Â The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect regulations adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act and to comply with any rules or standards adopted by Nasdaq. To the extent this Policy is no longer required to be in place pursuant to applicable law, the Board may terminate this Policy at any time. Â Other Recoupment Rights Â The Board intends that this Policy will be applied to the fullest extent of applicable law. The Board and/or Compensation Committee may require that any employment agreement, equity award agreement, or similar agreement entered into or amended on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of: (a) any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement or similar agreement and any other legal remedies available to the Company, including termination of employment or institution of legal proceedings; and (b) any statutory recoupment requirement, including Section 304 of the Sarbanes-Oxley Act of 2022. For the avoidance of doubt, any amounts paid to the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2022 shall be considered (and may be credited) in determining any amounts recovered under this Policy. Â Impracticability Â The Compensation Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined in accordance with Rule 10D-1(b)(1)(iv) under the Exchange Act and the listing standards of Nasdaq. In order for the Company to determine that recovery would be impracticable, the Companyâ€™s Compensation Committee must conclude the following: Â a)The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such Incentive Compensation. Note that the attempt(s) to recover must be documented by the Company and such documentation provided to Nasdaq; Â 4 Â Â b)Recovery would violate home country law where that law was adopted prior to November 28, 2022. Note that the Company must obtain a legal opinion of home country counsel that such recovery would result in a violation of local law and provide such opinion to Nasdaq; or c)Recovery would likely cause an otherwise tax-qualified retirement plan under which benefits are broadly available to Company employees to fail to meet the requirements for qualified pension, profit-sharing and stock bonus plans under Section 401(a)(13) of the U.S. Internal Revenue Code or the minimum vesting standards under Section 411(a) of the U.S. Internal Revenue Code. Â Successors Â This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives. Â Exhibit Filing Â A copy of this Policy shall be filed as an exhibit to the Companyâ€™s annual report on Form 10-K. Â 5 Â Â ATTESTATION AND ACKNOWLEDGEMENT OF CLAWBACK POLICY FOR PLURI INC. (the â€œCompanyâ€) Â By my signature below, I acknowledge and agree that: Â â—I have received and read the attached Clawback Policy (this â€œPolicyâ€) of the Company. â—I hereby agree to abide by all of the terms of the Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any incorrectly awarded Incentive Compensation to the Company as determined in accordance with the Policy. â—I hereby agree and acknowledge that my existing employment arrangement with the Company, as may be amended from time to time, will be subject to the terms of the Policy. â—I hereby waive any claim against the Company, its Authorized Officers and the Board in connection with the implementation of the Policy. Â Â Signature: /s/ Chen Franco Yehuda Â Â Â Â PrintedÂ Name:Â Â Chen Franco Yehuda Â Â Â Â Date: November 13, 2023 Â Â 6 Â Â GRAPHIC 11 image_001.jpg GRAPHIC begin 644 image_001.jpg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’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Ŷ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plur-20240630.xsd XBRL SCHEMA FILE 995301 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Consolidated Statements of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Statements of Changes in Shareholdersâ€™ Equity link:presentationLink link:definitionLink link:calculationLink 995306 - Statement - Statements of Changes in Shareholdersâ€™ Equity (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995307 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Other Accounts Payable link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Loan from the EIB link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Financial Income (Expenses), Net link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Taxes on Income link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - General (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Other Accounts Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Financial Income (Expenses), Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Taxes on Income (Tables) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Significant Accounting Policies (Details) - Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) - Schedule of Operating Lease Agreement link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Leases (Details) - Schedule of Maturities of Operating Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Leases (Details) - Schedule of Lease Expense and Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Loan from the EIB (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Shareholders' Equity (Details) - Schedule of Expenses Related to RSUs Granted link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Shareholders' Equity (Details) - Schedule of Warrants and Options link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Financial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), Net link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Taxes on Income (Details) link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Taxes on Income (Details) - Schedule of Loss Before Income Taxes link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Income Taxes link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 13 plur-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 plur-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 15 plur-

20240630_lab.xml XBRL LABEL FILE Total current assets Total long-term assets Total assets Total current liabilities Total long-term liabilities Total shareholdersâ€™ equity Total shareholdersâ€™ equity deficit Total equity Balance Balance Total liabilities and equity Gross profit Research and development expenses, net Operating loss Total financial income (expenses), net Total Net loss Net loss Loss before income taxes Incurred losses Net loss attributed to shareholders Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used for operating activities Cash flow from operating activities Net cash provided by investing activities Net cash provided by financing activities Increase (decrease) in cash, cash equivalents, restricted cash and restricted bank deposits Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period Total cash, cash equivalents, restricted cash and restricted bank deposits General [Abstract] Related and Nonrelated Parties [Axis] Significant Accounting Policies [Abstract] Long-Lived Tangible Asset [Axis] Statistical Measurement [Axis] Prepaid Expenses and Other Current Assets [Abstract] Receivable Type [Axis] Property and Equipment, Net [Abstract] Other Accounts Payable [Abstract] Schedule of Other Accounts Payable [Abstract] Total Leases [Abstract] Schedule of Operating Lease Agreement [Abstract] Total operating lease liabilities Present value of lease liabilities Schedule of Maturities of Operating Lease Liabilities [Abstract] Total undiscounted lease payments Schedule of Lease Expense and Supplemental Cash Flow Information [Abstract] Loan from the EIB [Abstract] Commitments and Contingencies [Abstract] Shareholders' Equity [Abstract] Share options outstanding at beginning of period number Share options outstanding at end of the period number Share options outstanding at beginning of period weighted average exercise price Share options outstanding at end of the period weighted average exercise price Weighted average exercise price per share (in Dollars per share) Share options outstanding at beginning of period Aggregate intrinsic value price Share options outstanding at end of the period Aggregate intrinsic value price Share options exercisable at the end of the period number Share options exercisable at the end of the period weighted average exercise price Share options vested and expected to vest at the end of the period Number Expected to vest after the end of period Share options vested and expected to vest at the end of the period Aggregate intrinsic value price Title and Position [Axis] Unvested at the beginning of period Unvested at the end of the period Statement of Income Location, Balance [Axis] Class of Warrant or Right [Axis] Exercise Price Range [Axis] Options and warrants for common share Options and warrants exercisable for common share Financial Income (Expenses), Net [Abstract] Schedule of Financial Income (Expenses), Net [Abstract] Financial income (expenses), net Taxes on Income [Abstract] Income Tax Authority, Name [Axis] Schedule of Deferred Income Taxes [Abstract] Total deferred tax assets before valuation allowance ASSETS CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Restricted cash Prepaid expenses and other current assets LONG-TERM ASSETS: Restricted bank deposits Severance pay fund Property and equipment, net Operating lease right-of-use asset Operating ROU assets Other long-term assets LIABILITIES AND SHAREHOLDERSâ€™ EQUITY CURRENT LIABILITIES Trade payables Accrued expenses Operating lease liability Operating lease liabilities, current Accrued vacation and recuperation Other accounts payable LONG-TERM LIABILITIES Accrued severance pay Operating lease liability Operating lease liabilities long-term Loan from the European Investment Bank, or EIB COMMITMENTS AND CONTINGENCIES SHAREHOLDERSâ€™ EQUITY Share capital (**): Common shares, $0.00001 par value per share: authorized: 37,500,000 as of June 30, 2024 and 2023; issued and outstanding: 5,408,212 and 5,155,687 shares as of June 30, 2024 and 2023, respectively Common shares, par value per share (in Dollars per share) Common stock, par value (in Dollars per share) Common shares, authorized Common stock, shares authorized Common shares, issued Common shares, outstanding Additional paid-in capital Accumulated deficit Non-controlling interests Revenues Operating expenses: Less: participation by the NIAID, the IIA, Horizon Europe and other parties Participation in research and development expenses Financial income (expenses), net Net loss attributed to non-controlling interests Loss per share: Basic loss per share (in Dollars per share) Diluted loss per share Weighted average number of shares used in computing basic loss per share (in Shares) Weighted average number of shares used in computing diluted loss per share Share-based compensation to employees, directors, and non-employee consultants Share-based compensation to employees, directors, and non-employee consultants (in Shares) Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs (in Shares) Net of issuance costs Modification of warrants to non-controlling interests Expiration of warrants in Ever After Issuance of common shares under a sales agreement with A.G.P, net of issuance costs of $162 (see note 9(1)) Issuance of common shares under a sales agreement with A.G.P, net of issuance costs of $162 (see note 9(1)) (in Shares) Issuance of shares (in Shares) Sales agreement with A.G.P, net of issuance costs Issuance of Ever After Foodsâ€™ shares to non-controlling interests (note 1f) Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d) Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d) (in Shares) Issuance of reverse share split (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile loss to net cash used in operating activities: Depreciation Depreciation expenses Share-based compensation to employees, directors and non-employee consultants Decrease in trade payables Decrease in other accounts payable and accrued expenses Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash Increase in long-term interest payable and exchange rate differences related to the EIB loan, net Accrued severance pay, net CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: Issuance of common shares, net of issuance costs Issuance of Ever After Foodsâ€™ shares to non-controlling interests EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Restricted cash Long-term restricted bank deposits (a) Supplemental disclosure of non-cash activities: Purchase of property and equipment on credit Lease liabilities arising from obtaining right-of-use assets Cost of revenues Research and development expenses General and administrative expenses Interest expense Decrease in prepaid expenses and other current assets and other long-term assets Decrease (increase) in operating lease right-of-use asset and liability, net Decrease (increase) in interest receivable on short-term deposits Purchase of property and equipment Proceeds from withdrawal of short-term deposits, net Common Shares Common Stock [Member] Common Member [Member] Additional Paid-in Capital Accumulated Deficit Total Shareholdersâ€™ Equity Non-controlling Interests GENERAL Schedule of Main Assumptions Used in the Monte Carlo Simulation Model Risk-free interest rate Risk-free interest rate (%) Expected share price volatility SIGNIFICANT ACCOUNTING POLICIES Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments Estimated useful lives Leasehold improvements Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions Underlying value of common shares ($) Exercise price ($) Expected volatility (%) Expected terms of the option (years) PREPAID EXPENSES AND OTHER CURRENT ASSETS Schedule of Prepaid Expenses and Other Current Assets Accounts receivable from grants Prepaid expenses Value Added Tax receivable Customer receivable Other receivables Total PROPERTY AND EQUIPMENT, NET Schedule of Property and Equipment, Net Cost: Total cost Accumulated depreciation: Total accumulated depreciation OTHER ACCOUNTS PAYABLE Schedule of Other Accounts Payable Grants received in advance Accrued payroll Advances from customers Payroll institutions LEASES Schedule of Operating Lease Agreement Schedule of Maturities of Operating Lease Liabilities 2025 2026 2027 2028 2029 and thereafter Schedule of Lease Expense and Supplemental Cash Flow Information Components of lease expense Fixed payments and variable payments that depend on an index or rate Sublease income Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities LOAN FROM THE EIB COMMITMENTS AND CONTINGENCIES SHAREHOLDERSâ€™ EQUITY Schedule of Warrants and Options Share options outstanding at beginning of period weighted average remaining contractual terms (in years) Share options forfeited weighted average exercise price Share options forfeited weighted average remaining contractual terms Share options forfeited Aggregate intrinsic value price Share options outstanding at end of the period weighted average remaining contractual terms (in years) Weighted average remaining contractual terms (in years) Share options exercisable at the end of the period weighted average remaining contractual terms (in years) Share options exercisable at the end of the period Aggregate intrinsic value price Share options unvested Number Share options unvested Weighted average exercise price Share options unvested Weighted average remaining contractual terms (in years) Share options vested and expected to vest at the end of the period Weighted average exercise price Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years) Share options granted number Share options granted Weighted average exercise price Share options granted Weighted average remaining contractual terms (in years) Share options granted Aggregate intrinsic value price Share options unvested Aggregate intrinsic value price Schedule of Activity Related to Unvested RSUs Granted Number (**) Granted Number (**) Schedule of Expenses Related to RSUs Granted Compensation expenses Schedule of Warrants and Options Weighted average exercise price per share (in Dollars per share) Warrants for common share Warrants exercisable for common share Weighted average remaining contractual terms (in years) Options for common share Option for common share exercisable FINANCIAL INCOME (EXPENSES), NET Schedule of Financial Income (Expenses), Net Foreign currency translation differences, net Interest income on deposits and restricted bank deposits Income (loss) from hedging derivatives TAXES ON INCOME Schedule of Loss Before Income Taxes Schedule of Deferred Income Taxes Deferred tax assets: Operating loss carryforwards Research and development credit carryforwards Issuance costs Allowances and reserves Net deferred tax asset Less: interest Share options forfeited number Forfeited Vested Bank and broker commissions EIB loan interest expenses Valuation allowance Monte Carlo [Member] Laboratory equipment [Member] Computers and peripheral equipment [Member] Office furniture and equipment [Member] Minimum [Member] Maximum [Member] U.S. National Institute of Allergy and Infectious Diseases [Member] Israel Innovation Authority [Member] Laboratory equipment [Member] Leasehold improvements [Member] Options to consultants [Member] CEO and directors [Member] CEO and Directors [Member] RSUs to Employees and Directors [Member] RS and RSUs to Consultants [Member] Employees and Directors [Member] Research and Development Expense [Member] Research and development expenses [Member] Selling, General and Administrative Expenses [Member] General and administrative expenses [Member] Warrant [Member] 8.24 [Member] 8.40 [Member] 8.48 [Member] 8.72 [Member] 8.96 [Member] Share-Based Payment Arrangement, Option [Member] 5.80 [Member] 12.48 [Member] 16.64 [Member] 20.80 [Member] 6.08 [Member] Consolidated loss of Pluri Inc. and the Israeli Subsidiaries [Member] Pluristem GmbH [Member] Credit Facility [Axis] Vesting [Axis] Debt Instrument [Axis] Sale of Stock [Axis] Derivative Instrument [Axis] Scenario [Axis] Related Party Transaction [Axis] Cash and cash equivalents Loan amount (in Euro) Subsidiary obtain loan amount (in Euro) Percentage of annual interest rate Balance of principal and interest accrued Reverse share split Investment in ever after subsidiary Additional shares issued (in Shares) Purchase of aggregate Ordinary shares percentage Additional investment Exercise price (in Dollars per share) Exercise price per share (in Dollars per share) Remaining balance of the aggregate purchase price of the first warrant Aggregate price Allocated consideration Amount equal to Receive Compensation expense recognized during the period Expiration of warrants in ever after Agregate gross proceeds Subsidiary investment Capital consideration Non-controlling interests Ordinary Shares Percentage the Company hold in Ever After Foods Weighted average grant date fair value (in Dollars per share) Aggregate amount Anti-dilutive effect shares (in Shares) Severance expenses Accrued royalties Financial income expense Lease payment Percentage of lease payment increase Weighted average remaining lease term Weighted average discount rate Lease period Finance contract period Annual interest rate Percentage of deferred interest rate Percentage of fixed interest rate Consolidated revenues percentage Accrued royalty (in Dollars) Finance contract (in Euro) Due date Annual interest percentage Principal balance (in Dollars) Long-term liabilities (in Dollars) Cash and restricted cash Percentage of qualified expenditures eligible for grant Royalty rate Royalty payable based on grants received Contingent liability in respect to royalties Marketing and business development activities Royalties revenues percentage Spread period Aggregate royalty amount Preferred stock, shares authorized Preferred stock, par value (in Dollars per share) Purchase price per share (in Dollars per share) Common shares Warrants to purchase Exercise price per share (in Dollars per share) Warrant term Aggregate offering price (in Dollars) Issuance expenses (in Dollars) Aggregate amount receives (in Dollars) Common shares future grants General and administrative expenses (in Dollars) Unamortized compensation expenses (in Dollars) Aggregate intrinsic value of these options (in Dollars) Annual cash salary (in Dollars) RSUs shares Option granted CEO's grant agreements, description Unamortized compensation expense (in Dollars) Granted shares Shareholdersâ€™ equity (in Dollars) Net Income (in Dollars) Federal tax rate Net income rate Tax rate Percentage of preferred income tax rate Revenue rate Global revenue Foreign entity investors reduction rate Income tax regular tax rate Percentage of corporate tax rate Trade tax base Municipality of potsdam percentage Net operating loss carryforward (in Dollars) Accumulated losses (in Dollars) Accumulated losses carry forward (in Dollars) Statutory tax rate Effective tax carried forward Basis of presentation Use of estimates Functional currency Principles of consolidation Cash and cash equivalents Short-term bank deposit Restricted cash Long-term restricted bank deposits Revenue Recognition Property and equipment Impairment of long-lived assets Share-based compensation Research and development expenses, royalty bearing grants and non-royalty bearing grants Loss per share Income taxes Concentration of credit risk Severance pay Fair value of financial instruments Derivative financial instruments Leases New Accounting Pronouncements Comprehensive loss Loss contingencies Finance Contract with EIB [Member] Tnuva Food Industries [Member] First Warrant [Member] Second Warrant [Member] Restricted Stock Units (RSUs) [Member] RSUs [Member] First Tranche [Member] Two Tranche [Member] Three Tranche [Member] Royalties [Member] Annual Interest [Member] Ichilov Hospital [Member] Private Placement [Member] Sales Agreement [Member] Stock Option [Member] Equity Option [Member] Forecast [Member] Director and Chief Executive Officer [Member] Yaky Yanay [Member] Pluri [Member] Technological Preferred Enterprise [Member] German Corporation Tax [Member] Pluri Inc. [Member] German Subsidiary [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Related and Nonrelated Parties [Domain] General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Table] Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Line Items] Long-Lived Tangible Asset [Domain] Statistical Measurement [Domain] Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments [Table] Property, Plant and Equipment [Line Items] Significant Accounting Policies (Details) - Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions [Table] Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions [Line Items] Receivable [Domain] Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets [Table] Prepaid Expenses and Other Current Assets [Line Items] Property, Plant and Equipment [Table] Title and Position [Domain] Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Table] Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Line Items] Award Type [Domain] Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted [Table] Schedule of Activity Related to Unvested RSUs Granted [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Exercise Price Range [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Income Tax Authority, Name [Domain] Taxes on Income (Details) - Schedule of Loss Before Income Taxes [Table] Schedule of Loss Before Income Taxes [Line Items] Credit Facility [Domain] General (Details) [Table] General [Line Items] Significant Accounting Policies (Details) [Table] Significant Accounting Policies [Line Items] Vesting [Domain] Debt Instrument, Name [Domain] Loan from the EIB (Details) [Table] Loan from the EIB [Line Items] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Sale of Stock [Domain] Scenario [Domain] Related Party Transaction [Domain] Derivative Contract [Domain] Shareholders' Equity (Details) [Table] Shareholders" Equity [Line Items] Taxes on Income (Details) [Table] Taxes on Income [Line Items] The amount of accrued royalties. Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Amount of accumulated losses carried forward. Amount of accumulated losses. The amount of additional investment. Aggregate amount. Amount of aggregate amount received. Aggregate gross proceeds. Amount of aggregate price. Represents allocated consideration. Amount equal to receive. Annual cash salary. The amount of bank and broker commissions. CEO's grant agreements, description. Capital consideration. Cash paid for amounts included in the measurement of lease liabilities. The compensation expense recognized during the period. The amount of contingent liability in respect to royalties. Contractual interest rate for funds borrowed, under the loan agreement. Percentage of corporate tax rate. Percentage of deferred interest rate. Tabular disclosure of main assumptions used In simulation model. Due date. Percentage of effective tax rate loss carryforward. Expiration of warrants in ever after. Expiration of warrants in ever after. Finance contract period. The amount of financial income expense. Percentage of fixed interest rate. Disclosure of accounting policy for the use of estimates functional currency. Grants received from the government and third parties for research and development programs. Granted shares. The amount of grants received in advance. Percentage of income tax regular tax rate. Increase (decrease) in operating lease right-of-use asset and liability, net. Investment in even after subsidiary. Issuance of common share and warrants. Issuance of common share and warrants. Percentage of lease payments increase. Disclosure of loan from the EIB. Disclosure of accounting policy for the use of estimates in the preparation of financial statements in long-term restricted bank deposits. Modification of warrants to non-controlling interests. Percentage of municipality of postdam. Net income. Issuance costs. Ordinary shares percentage. Amount of value payroll institutions. The number of units or percentage the Company held in the subsidiary by the limited liability company or limited partnership. Percentage Of Qualified Expenditures. Percentage of preferred income tax rate. Information of Leasehold improvements. The amount of Purchase of property and equipment on credit. The remaining balance of the aggregate purchase price of the First Warrant. Represents the amount of research and development expenses. Disclosure of accounting policy for the

restricted cash. Description of the reverse stock split arrangement. Royalty payable based on grants received. Royalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects. The amount of sales agreement of net issuance costs. Tabular information of property plant and equipment estimated useful life of assets. Disclosure of accounting policy for the severance pay. Aggregate Intrinsic Value Price, Share options granted. Share options unvested number. Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Value of Common Shares. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Share options unvested Weighted average exercise price. The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. The number of shares reserved for issuance pertaining to the outstanding stock option and warrants as of the balance sheet date for all options and warrants plans in the customized range of exercise prices. Options and warrants exercisable for common share. Share options forfeited aggregate intrinsic value price. Share options forfeited weighted average remaining contractual terms. Share options granted Weighted average remaining contractual terms (in years) Share options unvested aggregate intrinsic value price Weighted Average Remaining Contractual Terms, Share options outstanding. Share options unvested Weighted average remaining contractual terms. Weighted average remaining contractual terms (in years) Disclosure of accounting policy for the use of estimates in the short-term bank deposit. Amount of short-term bank deposits. Increase in the number of shares during the period as a result of a reverse stock split. The amount of subsidiary investment. Unamortized compensation expenses. Assets [Abstract] Deferred Tax Assets, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Amount Equal To Receive Earnings Per Share, Diluted Derivatives, Policy [Policy Text Block] Liabilities, Noncurrent [Abstract] Operating Loss Carryforwards Retained Earnings [Member] Consolidated Loss Of Pluri Inc And The Israeli Subsidiaries Member Second Warrant Member Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Variable Lease, Cost Weighted Average Number of Shares Outstanding, Basic Research And Development Expenses Share Options Granted Weighted Average Remaining Contractual Termsin Years Other Nonoperating Income (Expense) Accrued Vacations Current Twenty Point Eight Zero Member Yaky Yanay Member Marketing And Business Development Activities Share Options Forfeited Aggregate Intrinsic Value Price Interest Income, Deposits with Financial Institutions Stock Issued During Period, Shares, New Issues Share Based Compensation Shares Authorized Under Stock Of Warrants Plans Exercise Price Range Number Of Exercisable Warrants Royalties Revenues Percentage Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives Other Accounts Payable Payroll Institutions Assets, Noncurrent Technological Preferred Enterprise Member Share Based Compensation Arrangement By Share Based Payment Award Underlying Value Of Common Shares Monte Carlo Pricing Model [Member] Other Assets, Noncurrent Contingent Liability In Respect To Royalties Additional Paid in Capital Operating Expenses [Abstract] Director And Chief Executive Officer Member Schedule Of Property Plant And Equipment Estimated Useful Life Of Assets Table Text Block Supplemental Cash Flow Information [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price Accounts Payable and Other Accrued Liabilities, Current Net Cash Provided by (Used in) Operating Activities [Abstract] Sixteen Point Six Four Member Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual Term1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Accounts Payable, Trade, Current Equity, Attributable to Parent [Abstract] Common Unit, Issued Number Abstract0 Adjustments to Additional Paid in Capital, Stock Split Prepaid Expense, Current Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Remaining Balance Of The Aggregate Purchase Price Of The First Warrant Forecast [Member] Accrued Royalties Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Unamortized Compensation Expenses Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Retained Earnings (Accumulated Deficit) Eight Point Two Four Member CEOs Grant Agreements Description Depreciation Lessee, Operating Lease, Liability, to be Paid, Year Three Pluristem Gmb HMember Net Cash Provided by (Used in) Investing Activities Allocated Consideration Assets for Plan Benefits, Defined Benefit Plan Other Operating Income (Expense), Net Unlabeled Abstract11 Payments to Acquire Property, Plant, and Equipment Unlabeled Abstract12 Unlabeled Abstract10 Unlabeled Abstract15 Unlabeled Abstract16 Unlabeled Abstract13 Unlabeled Abstract14 Share-Based Payment Arrangement [Policy Text Block] Unlabeled Abstract19 Preferred Stock, Shares Authorized Corporate Tax Rate Unlabeled Abstract17 Unlabeled Abstract18 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Eight Point Four Eight Member Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Expiration Of Warrant In Ever After Maximum [Member] Income Tax, Policy [Policy Text Block] Contractual Interest Rate For Funds Borrowed Royalty Rate Sales Unlabeled Abstract22 Common Stock, Shares Authorized Unlabeled Abstract23 Unlabeled Abstract20 Unlabeled Abstract21 Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Severance Pay Policy Text Block Finance Contract Period Operating Lease, Liability, Noncurrent Operating Lease, Weighted Average Discount Rate, Percent Aggregate Amount Received Eight Point Seven Two Member Additional Investment Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Accrued Liabilities [Table Text Block] Share-Based Payment Arrangement, Expense Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Related Commitment Fees and Debt Issuance Costs Deferred Tax Assets, Net [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Restricted Cash Net Cash Provided by (Used in) Investing Activities [Abstract] Municipality Of Potsdam Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Significant Accounting Policies [Text Block] Unlabeled Abstract3 Restricted Cash Equivalents Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Unlabeled Abstract2 Unlabeled Abstract5 Share-Based Payment Arrangement, Tranche Three [Member] Unlabeled Abstract4 Employees And Directors Member Unlabeled Abstract1 Unlabeled Abstract0 Accounts Payable and Accrued Liabilities Disclosure [Text Block] Property, Plant and Equipment, Useful Life Unlabeled Abstract7 Unlabeled Abstract6 Lessee, Operating Lease, Liability, to be Paid, Year Two Common Stock, Capital Shares Reserved for Future Issuance Unlabeled Abstract9 Unlabeled Abstract8 Deferred Interest Rate Percentage Tnuva Food Industries Member Aggregate Gross Proceeds Net Cash Provided by (Used in) Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Operating Lease, Lease Income [Table Text Block] Lease Payments Increase Percentage Severance Costs Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Accrued Payroll Taxes, Current Warrant, Exercise Price, Increase Fixed Interest Rate Accrued Royalties Amount Equity Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Office Equipment [Member] Income Tax Regular Tax Rate Pluri Inc Member Equity, Attributable to Parent Share Options Unvested Aggregate Intrinsic Value Price Preferred Income Tax Rate Computer Equipment [Member] Property, Plant and Equipment, Policy [Policy Text Block] Management and Service Fees, Base Rate Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Schedule Of Activity Related To Unvested Rsus Granted Abstract Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term2 Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Increasedecrease In Operating Lease Rightofuse Asset And Liability Net Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Commitments and Contingencies, Policy [Policy Text Block] Parent [Member] Increase (Decrease) in Other Accounts Payable and Accrued Liabilities CEOAnd Directors Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Line of Credit Facility, Maximum Borrowing Capacity Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Functional Currency Policy Text Block Share Based Compensation Arrangements By Share Based Payment Award Options Unvested In Period Weighted Average Exercise Price Deferred Tax Assets, Valuation Allowance Prepaid Expense and Other Assets Annual Interest Member Property, Plant and Equipment Disclosure [Text Block] Other Income and Other Expense Disclosure [Text Block] Net Income (Loss) Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Tranche One [Member] Accounts Payable, Other, Current Due Date Equity, Including Portion Attributable to Noncontrolling Interest Lessee, Operating Lease, Liability, to be Paid Share-Based Payment Arrangement, Option, Activity [Table Text Block] Equity [Text Block] Property, Plant and Equipment [Table Text Block] Grants Received In Advance Israel Innovation Authority Member Additional Cash Flow Elements, Summations [Abstract] Restricted Cash and Cash Equivalents Restricted Cash Policy Text Block Statement of Financial Position [Abstract] Line of Credit Facility, Interest Rate During Period Cash and Cash Equivalents, at Carrying Value Proceeds from Noncontrolling Interests Investment In Even After Subsidiary Other Current Assets [Text Block] Other Cost of Operating Revenue Research and Development Expense, Policy [Policy Text Block] Shares Issued, Price Per Share Lessee, Operating Lease, Liability, to be Paid, Year One Deferred Tax Assets, Operating Loss Carryforwards Proceeds from Issuance of Common Stock RSAnd RSUs To Consultants Member Line of Credit Facility, Increase, Accrued Interest Bank And Broker Commissions Debt Instrument, Interest Rate, Effective Percentage Schedule of Other Current Assets [Table Text Block] Government And Third Party Grants Received Schedule Of Warrants And Options Abstract Equity, Attributable to Noncontrolling Interest Long Term Restricted Bank Deposits Policy Text Block Lessee, Operating Lease, Liability, Undiscounted Excess Amount Ordinary Shares Percentage Share-Based Payment Arrangement, Noncash Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Schedule Of Property And Equipment Are Stated At Cost Net Of Accumulated Depreciation And Impairments Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Royalty Guarantees, Commitments, Amount Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value Customer Advances, Current Six Point Zero Eight Member Eight Point Four Zero Member Stock Issued During Period, Value, Other Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Schedule Of Prepaid Expenses And Other Current Assets Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule Of Loss Before Income Taxes Table Text Block Five Point Eight Zero Member Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Net Of Issuance Costs Comprehensive Income, Policy [Policy Text Block] Shortterm Bank Deposits Restricted Cash, Current Common Stock, Value, Issued Laboratory Equipment Member Capital Consideration Other Receivables Net Income Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Noncontrolling Interest [Member] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Lessee, Leases [Policy Text Block] Operating Lease, Payments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Increase (Decrease) in Prepaid Expense and Other Assets Issuance Of Common Stock And Warrants Restricted Cash, Noncurrent Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Annual Cash Salary Basis of Accounting, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USNational Institute Of Allergy And Infectious Diseases Member Equipment [Member] Research and Development Expense [Member] Deferred Tax Assets, Net of Valuation Allowance Income Statement [Abstract] Lessee, Operating Leases [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Cash, Cash Equivalents, and Short-Term Investments Tel Aviv Sourasky Medical Center Member Subsidiary Investment Earnings Per Share, Basic Liabilities, Noncurrent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Assets Research and Development Expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Share Capital Abstract Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Loan From The EIBText Block Percentage Of Company Held In Subsidiary By Limited Liability Or Partnership Increase (Decrease) in Accrued Interest Receivable, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Percentage Of Qualified Expenditures Gain (Loss), Foreign Currency Transaction, before Tax Finance Lease, Weighted Average Remaining Lease Term Warrants and Rights Outstanding, Term Cost Abstract Modification Of Warrants To Noncontrolling Interests Net Cash Provided by (Used in) Financing Activities Share Based Compensation Shares Authorized Under Stock Options And Warrants Plans Exercise Price Range Number Of Exercisable Options And Warrants Property Plant And Equipments Useful Life RSUs To Employees And Directors Member Issuance Of Common Stock And Warrant Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 Property, Plant and Equipment, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Interest Expense, Nonoperating Accumulated Losses Share Options Forfeited Weighted Average Remaining Contractual Termsin Years Warrant [Member] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Other General and Administrative Expense Number Abstract Lessee, Operating Lease, Liability, to be Paid, Year Four Granted Shares Leasehold Improvements [Member] German Corporation Tax Member Noncontrolling Interest, Increase from Business Combination Operating Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating Lease, Liability Components Of Lease Expense Abstract Deferred Tax Assets, Tax Credit Carryforwards, Research Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Purchase Of Propertys And Equipment On Credit Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits Investment Owned, Balance, Principal Amount Royalty Rate Payable On Grants Received Debt Instrument, Interest Rate, Stated Percentage Revenue from Contract with Customer [Policy Text Block] Common Stock [Member] Sublease Income Statement of Cash Flows [Abstract] Options To Consultants Member Liabilities, Other than Long-Term Debt, Noncurrent Operating Lease, Liability, Current Income Tax Disclosure [Text Block] Deferred Tax Assets, Other Sales Agreement Of Net Issuance Costs Selling, General and Administrative Expenses [Member] Liabilities, Current [Abstract] Schedule Of Loss Before Income Taxes Abstract Stock Issued During Period Shares Reverse Stock Split Royalties Member Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Accumulated Depreciation Abstract Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Unvested In Period Operating Lease, Weighted Average Remaining Lease Term Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Reverse Stock Split Arrangement Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Aggregate Price Pluri Member Revenues Aggregate Amount Restricted Stock Units (RSUs) [Member] General and Administrative Expense Effective Tax Rate Los SCarryforward Percentage Earnings Per Share [Abstract] Common Stock, Par or Stated Value Per Share Schedule Of Main Assumptions Used In The Monte Carlo Simulation Model Abstract Short Term Bank Deposit Policy Text Block Schedule Of Expenses Related To Rsus Granted Abstract Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from Issuance of Private Placement Finance Contract With EIBMember First Warrant Member Accounts Receivable, before Allowance for Credit Loss Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Effective Income Tax Rate Reconciliation, Deduction, Other, Percent Weighted Average Number of Shares Outstanding, Diluted Share Based Compensation Share Authorized Under Stock Warrants Plans Exercise Price Range Number Of Outstanding Warrants Gross Profit Increase (Decrease) in Interest Payable, Net Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Spread Period Share Based Compensation Shares Authorized Under Stock Option And Warrants Plans Exercise Price Range Number Of Outstanding

Warrants Private Placement [Member] Payments for (Proceeds from) Short-Term Investments Debt Instrument, Face Amount Assets, Current [Abstract] Postemployment Benefits Liability, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Financial Income Expense Increase (Decrease) in Accounts Payable Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Expiration Of Warrants In Ever After Accrued Liabilities, Current Compensation Expense Recognized During The Period Consolidation, Policy [Policy Text Block] Liabilities and Equity [Abstract] Shares, Outstanding Share-Based Payment Arrangement, Tranche Two [Member] Commitments and Contingencies Disclosure [Text Block] Grants Receivable Sales Agreement Member German Subsidiary Member Interest Expense, Debt Accumulated Losse Carried Forward Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Cost of Revenue Eight Point Nine Six Member Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Class of Warrant or Right, Exercise Price of Warrants or Rights Other Long-Term Debt, Noncurrent Schedule Of Property And Equipment Net Abstract Liabilities and Equity Value Added Tax Receivable Nonoperating Income (Expense) Schedule Of Black Scholes Option Pricing Model Using The Following Assumptions Abstract Stockholders' Equity, Other Disclosure Of Main Assumptions Used In Simulation Model Table Text Block Assets, Noncurrent [Abstract] Preferred Stock, Par or Stated Value Per Share Twelve Point Four Eight Member Operating Lease, Right-of-Use Asset Excess Stock, Shares Issued Assets, Current EX-101.PRE 16 plur-20240630_pre.xml XBRL PRESENTATION FILE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - USD ($) 12 Months Ended Jun. 30, 2024 Sep. 13, 2024 Dec. 31, 2023 Document Information [Line Items] Â Â Â Document Type 10-K Â Â Document Annual Report true Â Â Document Transition Report false Â Â Document Financial Statement Error Correction [Flag] false Â Â Entity Interactive Data Current Yes Â Â ICFR Auditor Attestation Flag false Â Â Amendment Flag false Â Â Document Period End Date Jun. 30, 2024 Â Â Document Fiscal Year Focus 2024 Â Â Document Fiscal Period Focus FY Â Â Documents Incorporated by Reference [Text Block] None Â Â Entity Information [Line Items] Â Â Â Entity Registrant Name PLURI INC. Â Â Entity Central Index Key 0001158780 Â Â Entity File Number 001-31392 Â Â Entity Tax Identification Number 98-0351734 Â Â Entity Incorporation, State or Country Code NV Â Â Current Fiscal Year End Date --06-30 Â Â Entity Well-known Seasoned Issuer No Â Â Entity Voluntary Filers No Â Â Entity Current Reporting Status Yes Â Â Entity Shell Company false Â Â Entity Filer Category Non-accelerated Filer Â Â Entity Small Business true Â Â Entity Emerging Growth Company false Â Â Entity Public Float Â Â $ 22,856,362 Entity Contact Personnel [Line Items] Â Â Â Entity Address, Address Line One MATAM Advanced Technology Park Â Â Entity Address, Address Line Two Building No. 5 Â Â Entity Address, City or Town Haifa Â Â Entity Address, Country IL Â Â Entity Address, Postal Zip Code 3508409 Â Â Entity Phone Fax Numbers [Line Items] Â Â Â City Area Code 011-972 Â Â Local Phone Number 74-7108600 Â Â Entity Listings [Line Items] Â Â Â Title of 12(b) Security Common Shares, par value $0.00001 Â Â Trading Symbol PLUR Â Â Security Exchange Name NASDAQ Â Â Entity Common Stock, Shares Outstanding Â 5,470,163 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an annual report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection wReference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_DocumentFinStmtErrorCorrectionFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionDocuments incorporated by reference. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-23 + Details Name: dei_DocumentsIncorporatedByReferenceTextBlock Namespace Prefix: dei_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. + ReferencesNo definition available. + Details Name: dei_EntityPublicFloat Namespace Prefix: dei_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. + ReferencesNo definition available. + Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 405 + Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Audit Information 12 Months Ended Jun. 30, 2024 Auditor [Table] Â Auditor Name Kesselman & Kesselman Auditor Firm ID 1309 Auditor Location Haifa, Israel X - DefinitionPCAOB issued Audit Firm Identifier + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorFirmId Namespace Prefix: dei_ Data Type: dei:nonemptySequenceNumberItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorLocation Namespace Prefix: dei_ Data Type: dei:internationalNameItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorName Namespace Prefix: dei_ Data Type:

dei:internationalNameItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: dei_AuditorTable Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 CURRENT ASSETS: Â Â Cash and cash equivalents $ 6,783 $ 5,360 Short-term bank deposits 23,202 34,811 Restricted cash 254 269 Prepaid expenses and other current assets 868 969 Total current assets 31,107 41,409 LONG-TERM ASSETS: Â Â Restricted bank deposits 634 627 Severance pay fund 470 439 Property and equipment, net 688 688 Operating lease right-of-use asset 6,558 7,633 Other long-term assets 70 1 Total long-term assets 8,420 9,388 Total assets 39,527 50,797 CURRENT LIABILITIES Â Â Trade payables 964 1,812 Accrued expenses 1,223 1,209 Operating lease liability 559 627 Accrued vacation and recuperation 702 873 Other accounts payable 1,006 1,100 Total current liabilities 4,454 5,621 LONG-TERM LIABILITIES Â Â Accrued severance pay 605 598 Operating lease liability 5,026 5,748 Loan from the European Investment Bank, or EIB 24,027 23,530 Total long-term liabilities 29,658 29,876 COMMITMENTS AND CONTINGENCIES Share capital (**): Â Â Common shares, $0.00001 par value per share: authorized: 37,500,000 as of June 30, 2024 and 2023; issued and outstanding: 5,408,212 and 5,155,687 shares as of June 30, 2024 and 2023, respectively [1],[2] Additional paid-in capital [2] 420,568 412,939 Accumulated deficit [2] (420,472) (399,584) Total shareholdersâ€™ equity [2] 96 13,355 Non-controlling interests [2] 5,319 1,945 Total equity [2] 5,415 15,300 Total liabilities and equity [2] $ 39,527 $ 50,797 [1] Less than $1 [2] See note 1d regarding reverse share split X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. + ReferencesNo definition available. + Details Name: plur_AccruedVacationsCurrent Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: plur_ShareCapitalAbstract Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term bank deposits. + ReferencesNo definition available. + Details Name: plur_ShorttermBankDeposits Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt classified as other, payable after one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_OtherLongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5 + Details Name: us-gaap_PostemploymentBenefitsLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic

323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parentheticals) - $ / shares Jun. 30, 2024 Jun. 30, 2023 Statement of Financial Position [Abstract] Â Â Common shares, par value per share (in Dollars per share) [1] $ 0.00001 $ 0.00001 Common shares, authorized [1] 37,500,000 37,500,000 Common shares, issued [1] 5,408,212 5,155,687 Common shares, outstanding [1] 5,408,212 5,155,687 [1] See note 1d regarding reverse share split X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Revenues $ 326 $ 287 Cost of revenues (4) (9) Gross profit 322 278 Operating expenses: Â Â Research and development expenses (13,780) (17,413) Less: participation by the NIAID, the IIA, Horizon Europe and other parties 1,334 1,668 Research and development expenses, net (12,446) (15,745) General and administrative expenses (10,034) (11,779) Operating loss (22,158) (27,246) Financial income (expenses), net 1,680 (798) Interest expense (866) (843) Total financial income (expenses), net 814 (1,641) Net loss (21,344) (28,887) Net loss attributed to non-controlling interests (456) (566) Net loss attributed to shareholders $ (20,888) $ (28,321) Loss per share: Â Â Basic loss per share (in Dollars per share) $ (3.99) $ (6.24) Weighted average number of shares used in computing basic loss per share (in Shares) [1] 5,240,249 4,581,503 [1] See note 1d regarding reverse share split X - DefinitionGrants received from the government and third parties for research and development programs. + ReferencesNo definition available. + Details Name: plur_GovernmentAndThirdPartyGrantsReceived Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of research and development expenses. + ReferencesNo definition available. + Details Name: plur_ResearchAndDevelopmentExpenses Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations (Parentheticals) - $ / shares 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Diluted loss per share $ (3.99) $ (6.24) Weighted average number of shares used in computing diluted loss per share [1] 5,240,249 4,581,503 [1] See note 1d regarding reverse share split X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Changes in Shareholdersâ€™ Equity - USD ($) $ in Thousands Common Shares Additional Paid-in Capital Accumulated Deficit Total Shareholdersâ€™ Equity Non-controlling Interests Total Balance at Jun. 30, 2022 [1] $ 401,302 $ (371,263) $ 30,039 $ 2,147 $ 32,186 Balance (in Shares) at Jun. 30, 2022 [2] 4,063,437 Â Â Â Â Â Â Share-based compensation to employees, directors, and non-employee consultants [1] 2,984 2,984 993 3,977 Share-based compensation to employees, directors, and non-employee consultants (in Shares) [2] 72,762 Â Â Â Â Â Â Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs [1] 8,024 8,024 8,024 Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs (in Shares) [2] 1,019,488 Â Â Â Â Â Â Modification of warrants to non-controlling interests [1] (385) (385) 385 Expiration of warrants in Ever After [1] 1,014 1,014 (1,014) Net loss [1] (28,321) (28,321) (566) (28,887) Balance at Jun. 30, 2023 [1] 412,939 (399,584) 13,355 1,945 15,300 [3] Balance (in Shares) at Jun. 30, 2023 [2] 5,155,687 Â Â Â Â Â Â Share-based compensation to employees, directors, and non-employee consultants [1] 1,973 1,973 645 2,618 Share-based compensation to employees, directors, and non-employee consultants (in Shares) [2] 141,960 Â Â Â Â Â Â Issuance of common shares under a sales agreement with A.G.P, net of issuance costs of $162 (see note 9(1)) [1] 91 91 91 Issuance of common shares under a sales agreement with A.G.P, net of issuance costs of $162 (see note 9(1)) (in Shares) [2] 42,729 Â Â Â Â Â Â Issuance of Ever After Foodsâ€™ shares to non-controlling interests (note 1f) [1] 5,565 5,565 3,185 8,750 Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d) [1] Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d) (in Shares) 67,836 [2] Â Â Â Â Â 67,836 Net loss [1] (20,888) (20,888) (456) $ (21,344) Balance at Jun. 30, 2024 [1] $ 420,568 $ (420,472) $ 96 $ 5,319 $ 5,415 [3] Balance (in Shares) at Jun. 30, 2024 [2] 5,408,212 Â Â Â Â Â Â [1] Less than $1 [2] See note 1d regarding reverse share split [3] See note 1d regarding reverse share split X - DefinitionExpiration of warrants in ever after. + ReferencesNo definition available. + Details Name: plur_ExpirationOfWarrantsInEverAfter Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of common share and warrants. + ReferencesNo definition available. + Details Name: plur_IssuanceOfCommonStockAndWarrant Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of common share and warrants. + ReferencesNo definition available. + Details Name: plur_IssuanceOfCommonStockAndWarrants Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionModification of warrants to non-controlling interests. + ReferencesNo definition available. + Details Name: plur_ModificationOfWarrantsToNoncontrollingInterests Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease in the number of shares during the period as a result of a reverse stock split. + ReferencesNo definition available. + Details Name: plur_StockIssuedDuringPeriodSharesReverseStockSplit Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Changes in Shareholdersâ€™ Equity (Parentheticals) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Statement of Stockholders' Equity [Abstract] Â Â Net of issuance costs Â $ 445 Sales agreement with A.G.P, net of issuance costs $ 162 Â X - DefinitionIssuance costs. + ReferencesNo definition available. + Details Name: plur_NetOfIssuanceCosts Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of sales agreement of net issuance costs. + ReferencesNo definition available. + Details Name: plur_SalesAgreementOfNetIssuanceCosts Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net loss $ (21,344) $ (28,887) Adjustments to reconcile loss to net cash used in operating activities: Â Â Depreciation 253 362 Share-based compensation to employees, directors and non-employee consultants 2,618 3,977 Decrease in prepaid expenses and other current assets and other long-term assets 32 768 Decrease in trade payables (778) (22) Decrease in other accounts payable and accrued expenses (251) (1,243) Decrease (increase) in operating lease right-of-use asset and liability, net 285 (112) Decrease (increase) in interest receivable on short-term deposits 438 (336) Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash 253 831 Increase in long-term interest payable and exchange rate differences related to the EIB loan, net 497 1,852 Accrued severance pay, net (24) (47) Net cash used for operating activities (18,021) (22,857) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Purchase of property and equipment (323) (262) Proceeds from withdrawal of short-term deposits, net 10,907 9,960 Net cash provided by investing activities 10,584 9,698 CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Issuance of common shares, net of issuance costs 91 8,024 Issuance of Ever After Foodsâ€™ shares to non-controlling interests 8,750 Net cash provided by financing activities 8,841 8,024 EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 11 (22) Increase (decrease) in cash, cash equivalents, restricted cash and restricted bank deposits 1,415 (5,157) Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period 6,256 11,413 Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period 7,671 6,256 Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets: Â Â Cash and cash equivalents 6,783 5,360 Restricted cash 254 269 Long-term restricted bank deposits 634 627 Total cash, cash equivalents, restricted cash and restricted bank deposits 7,671 6,256 (a) Supplemental disclosure of non-cash activities: Â Â Purchase of property and equipment on credit 4 74 Lease liabilities arising from obtaining right-of-use assets $ 82 $ 60 X - DefinitionIncrease (decrease) in operating lease right-of-use asset and liability, net. + ReferencesNo definition available. + Details Name: plur_IncreasedecreaseInOperatingLeaseRightofuseAssetAndLiabilityNet Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of Purchase of property and equipment on credit. + ReferencesNo definition available. + Details Name: plur_PurchaseOfPropertysAndEquipmentOnCredit Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdditionalCashFlowElementsSummationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from borrowers for interest payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInterestPayableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for pension and other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9 + Details Name: us-gaap_PaymentsForProceedsFromShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromMinorityShareholders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 27 R10.htm IDEA: XBRL DOCUMENT v3.24.3 General 12 Months Ended Jun. 30, 2024 General [Abstract] Â GENERAL NOTE 1: - GENERAL Â a. Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.â€™s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol â€œPLURâ€. Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.) or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods formerly known as Plurinuva Ltd. Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries â€" Agricultural Cooperative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the â€œCompanyâ€ or â€œPluri.â€ The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the â€œSubsidiaries.â€ Â b. The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech and launched a Contract Development and Manufacturing Organization or CDMO business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries. Â c. The Company has incurred an accumulated deficit of approximately $420,472 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of June 30, 2024, the Companyâ€™s total shareholdersâ€™ equity amounted to $96. During the year ended June 30, 2024, the Company incurred losses of $21,344 and its negative cash flow from operating activities was $18,021. Â As of June 30, 2024, the Companyâ€™s cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled to $30,873. Â The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities. The Companyâ€™s management believes that its current resources together with its existing operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these consolidated financial statements. During 2023 and 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the requiredÂ level of financing, operations may need to be scaled down or discontinued. Â On April 30, 2020, the German Subsidiary entered into a finance contract or the Finance Contract with the EIB, pursuant to which the German Subsidiary obtained loan in an amount of â‚¬20 million, or the Loan. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal and interest accrued balance was of $24,027 and is presented among long-term liabilities (see note 7). Â d. Reverse share split In March 2024, the Companyâ€™s Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Companyâ€™s (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented. Â An additional 67,836 common shares were included in the Companyâ€™s issued and outstanding shares as a result of rounding-up fractional shares into whole shares as a result of the reverse share split. Â Â e. On January 5, 2022, the Subsidiary entered into a Joint Venture Agreement with Tnuva pursuant to which the Subsidiary and Tnuva established Ever After Foods, with the purpose of developing cultivated meat products. Ever After Foods received exclusive, global, royalty bearing licensing rights to use Pluriâ€™s proprietary technology, intellectual property and knowhow in

the field of cultivated meat. Tnuva invested $7,500Â in Ever After Foods and received 187,500 of Ever After Foodsâ€™s ordinary shares, representingÂ 15.79% of the Ever After Foods share capital as of February 24, 2022, or the Closing Date. In addition, Tnuva received warrants to invest up to an additional $7,500 over a period of twelve months following the Closing Date. Â Â The first warrant, or the First Warrant issued to Tnuva permitted Tnuva to purchase up to 125,000 ordinary shares of Ever After Foods at an exercise price of $40.00 per share and had a term commencing as described in the agreement. In addition, on the six month anniversary of the Closing Date, and provided that the First Warrant had not expired, Ever After Foods agreed to issue a second warrant, or the Second Warrant and together with the First Warrant, or the Warrants) to Tnuva which permitted Tnuva to purchase up to a number of ordinary shares of Ever After Foods, or the then most senior securities issued by Ever After Foods, in consideration for such amount equal to 200% of the remaining balance of the aggregate purchase price of the First Warrant, provided that Tnuva exercised at least 62,500 ordinary shares at a price per share of $40.00, or $2,500 in the aggregate, of the First Warrant. The Second Warrantâ€™s exercise price per share equaled $76.00. The Second Warrant had a term commencing as described in the agreement. Â Â Â The Company allocated the total consideration of $7,500 received in an amount equal to $6,718 for the ordinary shares and $782 for the Warrants. Â Â Â On January 5, 2022, the Company determined the fair value of the ordinary shares and the Warrants utilizing a Monte Carlo simulation model (Level 3 classification), which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event. The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field. Â Risk-freeÂ interestÂ rateÂ Â 1.08% Expected share price volatilityÂ Â 85% Â Â The consideration allocated to the shares issued was divided between the non-controlling interests, or NCI, and the Companyâ€™s shareholders as this transaction is a transaction with the NCI. Â Â Â The consideration allocated to the Warrants was recognized against the NCI. Â Â Â On August 23, 2022, or the Amendment Date, Ever After Foods and Tnuva executed an amendment to the warrant agreement, or the Amendment, extending the exercise period of the First Warrant from six months to nine months from the Closing Date. All other terms remained unchanged. Â e. Following the Amendment, the Company recalculated the fair value of the warrants utilizing the same Monte Carlo simulation model (Level 3 classification) before and after the Amendment Date, which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event. Â Â Â The main assumptions used in the Monte Carlo simulation model are as follows: Â Risk-freeÂ interestÂ rateÂ Â 3.25% Expected share price volatilityÂ Â 70% Â The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field. The additional fair value determined was $385. Â Â On November 22, 2022, the warrants in Ever After Foods expired unexercised and $1,014 were classified from NCI to additional paid-in capital. Â Â f. On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors. Ever After Foods agreed to issue and sell, ordinary shares in a private placement offering, for aggregate gross proceeds of $10,000. As part of the offering, the Subsidiary invested $1,250. As a result, the Companyâ€™s capital consideration isÂ $8,750, of which $3,185 is attributed to non-controlling interests. Following the closing of the offering, the Company continued to own approximately 69% of Ever After Foodsâ€™ shares. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies 12 Months Ended Jun. 30, 2024 Significant Accounting Policies [Abstract] Â SIGNIFICANT ACCOUNTING POLICIES NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES Â Basis of presentation Â The consolidated financial statements have been prepared in accordance with the United States Generally Accepted Accounting Principles, or U.S. GAAP. Â a. Use of estimates Â The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments, and assumptions that are reasonable based upon information available at the time they are made. Estimates are primarily used for, but not limited to, valuation of share-based compensation, valuation of warrants and determining the valuation and terms of leases. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results could differ from those estimates. Â b. Functional currency Â The U.S. dollar is the primary currency of the economic environment in which the Company and the Subsidiaries operate. Thus, the U.S. dollar is the Companyâ€™s functional and reporting currency. Accordingly, non-dollar denominated transactions and balances have been re-measured into the functional currency in accordance with Accounting Standards Codification, or ASC, 830, â€œForeign Currency Mattersâ€. All transaction gains and losses from the re-measured monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate.Â c. Principles of consolidation Â The consolidated financial statements include the accounts of the Company and its Subsidiaries. Non-controlling interests in subsidiaries represent the equity in Ever After Foods not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the shareholders of the Company. Profit or loss and components of other comprehensive income or loss are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of operations. Â The Company treats transactions with non-controlling interests as transactions with its equity owners. Accordingly, for sales or purchases of shares to or from non-controlling interests, the difference between any consideration received or paid and the portion sold or acquired of the carrying value of the net assets of the subsidiary is recorded in equity. Â Intercompany transactions and balances have been eliminated upon consolidation. Â d. Cash and cash equivalents Â Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired. Â e. Short-term bank deposit Â Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. Â f. Restricted cash Â Restricted cash is cash used to secure the Companyâ€™s credit line, derivative and hedging transactions and lease agreement. The restricted cash is presented at cost which approximates market values including accrued interest. Â g. Long-term restricted bank deposits Â Long-term restricted bank deposits with maturities of more than one year used to secure operating lease agreement are presented at cost which approximates market values including accrued interest.Â h. Revenue Recognition Â A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each partyâ€™s rights regarding the distinct goods or services to be transferred, or the Performance Obligations, (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Â Revenues are recognized when the control of the promised goods or the performance of the obligations are transferred to the customer, in an amount that reflects the consideration to which the Company expects to be entitled, excluding sales taxes. Â The Company determines revenue recognition through the following steps: Â â—identification of the contract with a customer; Â â—identification of the Performance Obligations in the contract; Â â—determination of the transaction price; Â â—allocation of the transaction price to the Performance Obligations in the contract; and Â â—recognition of revenue when, or as, the Company satisfies a Performance Obligation. Â i. Property and equipment Â Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: Â Â Â % Laboratory equipment Â 10-40 Computers and peripheral equipment Â 33 Office furniture and equipment Â 15 Leasehold improvements Â The shorter of the expected useful life or the term of the lease. Â Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Â j. Impairment of long-lived assets Â The Companyâ€™s long-lived assets are reviewed for impairment in accordance with ASC 360, â€œProperty, Plant and Equipmentâ€, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During fiscal years 2024 and 2023, no impairment losses were recorded.Â k. Share-based compensation Â The Company accounts for share-based compensation in accordance with ASC 718, â€œCompensation-Share Compensationâ€, or ASC 718. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company estimates the fair value of share options granted using the Black-Scholes option-pricing model. The Company accounts for employeesâ€™ share-based payment awards classified as equity awards, such as restricted share units, or RSUs, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. Â The Company recognized compensation cost for an award with service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Â The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Â The fair value of service-based share option grants is estimated on the grant date using a Black-Scholes option-pricing model and compensation expense related to share option and RSUs grants are recognized on a graded vesting schedule over the vesting period. Â All RSUs to employees and directors granted during fiscal 2024 and 2023 were granted for no consideration. Therefore, their fair value was equal to the share price at the date of grant. Â The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSU granted during fiscal years 2024 and 2023 was $4.32 and $7.92 per share, respectively. Â The fair value of the service-based share option grants was estimated on the grant date using a Black-Scholes option-pricing model. The weighted average grant date fair value of option granted during fiscal years 2024 and 2023 was $3.85 and $3.65 per option, respectively. Â The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions: Â Â Â 2024Â Â 2023Â Underlying value ofÂ common shares ($)Â Â Â 4.40-6.08Â Â Â 7.52-7.92Â Exercise price ($)Â Â 4.40-6.08Â Â Â 8.96-20.80Â Expected volatility (%)Â Â 78.44Â Â Â 86.40-86.48Â Expected terms of the option (years)Â Â 5-7Â Â Â 3Â Risk-free interest rate (%)Â Â 4.04-4.13Â Â Â 4.03-4.22Â Â l. Research and development expenses, royalty bearing grants and non-royalty bearing grants Â Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and development are expensed as incurred. Â Grants received from the Israel Innovation Authority, or the IIA, are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred (see also note 8b). Â During fiscal years 2024 and 2023, the Company also received (in cash) non-royalty bearing grants from the European UnionÂ research and development consortiums, under Horizon 2020, Horizon Europe, U.S. National Institute of Allergy and Infectious Diseases, or the NIAID, and from the IIA, under the CRISPR-IL consortium, in the aggregate amount of approximately $1,113 and $2,426, for the years ended June 30, 2024 and 2023, respectively. The non-royalty bearing grants for funding the projects are recognized at the time the Company is entitled to each such grant based on the related costs incurred and recorded as a deduction from research and development expenses. Â Research and development expenses, net for the years ended June 30, 2024 and 2023 include participation in research and development expenses in the amount of approximately $1,334 and $1,668, respectively. Â m. Loss per share Â Basic and diluted loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year, including unexercised vested options with no par value exercise price. All outstanding share options, unvested RSUs and warrants have been excluded from the calculation of the diluted loss per common share because all such securities are anti-dilutive for each of the periods presented. The total number of shares related to the outstanding options, warrants and RSUs excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,635,190 and 1,768,948 for the years ended June 30, 2024 and 2023, respectively.Â n. Income taxes Â Â 1. Deferred taxes Â Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Â Â 2. Uncertainty in income taxes Â The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, â€œIncome Taxesâ€, or ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Â o. Concentration of credit risk Â Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, long-term restricted bank deposits. Â The majority of the Companyâ€™s cash and cash equivalents, restricted cash, short-term bank deposits and long-term restricted deposits are mainly invested in the New Israeli Shekel, or NIS, and U.S. dollar deposits of major banks in Israel and in the United States. Deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk. The Company invests its surplus cash in cash deposits in financial institutions and has established guidelines, approved by the Companyâ€™s Investment Committee, relating to diversification and maturities to maintain safety and liquidity of the investments. Â p. Severance pay Â The majority of the Companyâ€™s agreements with employees in Israel are subject to Section 14 of the Israeli Severance Pay Law, 1963, or the Severance Pay Law. The Companyâ€™s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employeeâ€™s monthly salary for each year of employment, no additional obligation exists regarding the matter of severance pay and no additional payments are made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. Â For Yaky Yanay, the Companyâ€™s Chief Executive Officer, or the CEO, whose agreement is not subject to Section 14 of the Severance Pay Law, the Subsidiaryâ€™s liability for severance pay is calculated pursuant to Severance Pay Law, based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. The CEO is entitled to one monthâ€™s salary for each year of employment or a portion thereof. The Companyâ€™s liability to the CEO is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Companyâ€™s balance sheet.Â Â The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies, and includes immaterial profits or losses accumulated up to the balance sheet date. Â Severance expenses for all employees including the CEO, for the years ended June 30, 2024 and 2023 were $632 and $732, respectively. Â q.Fair value of financial instruments Â The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities. Â The Company measures its derivative instruments at fair value under ASC 820, â€œFair Value Measurementâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Â As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Â Level 1Â - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Â Level 2Â - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Â Level 3Â - Unobservable inputs for the asset or liability. Â The fair value hierarchy also requires an entity to maximize the use of observable

inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy. Â Â The Company measures its liability pursuant to the Finance Contract with the EIB based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. The Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030. The Company accrued royalties for fiscal year 2024 in the amount of $3 (see note 7). Â r.Derivative financial instruments Â The Company accounts for derivatives and hedging based on ASC 815, â€œDerivatives and hedgingâ€, as amended and related interpretations, or ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. Â If a derivative does not meet the definition of a hedging instrument, the changes in the fair value are included in earnings. Cash flows related to Companyâ€™s current hedging are classified as operating activities. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS and its loan from the EIB that is linked to the Euro. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as â€œfinancial income (expenses), netâ€.The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of June 30, 2024, the fair value of the derivatives instruments is presented in â€œPrepaid expenses and other current assetsâ€ (see note 3) and as of June 30, 2023, there were no derivatives instruments. The net income (losses) from derivatives instruments recognized in â€œFinancial income (expenses), netâ€ during the years ended June 30, 2024 and 2023 were $148 and $(157), respectively (see note 10). Â s.Leases Â Operating leases are included in operating lease right-of-use, or ROU asset, and operating lease liability. ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements with a non-cancelable term of less than 12 months are not recorded on the balance sheets. Â The Company accounts for an extension of a lease term that was not part of the original lease as a modification. As a result, the Company reallocates contract consideration between the lease and non-lease components, reassesses lease classification, and remeasures the lease liability and right-of-use asset prospectively. Assumptions such as the discount rate, fair value of the underlying asset, and variable rents based on a rate or index will be updated as of the modification date. Â Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. Â t.New Accounting Pronouncements Â i.Recently adopted accounting pronouncements Â ASU No. 2016-13- â€œFinancial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrumentsâ€, or ASU 2016-13: Â In JuneÂ 2016, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2016-13, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking â€œexpected lossâ€ model that generally results in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after DecemberÂ 15, 2019, including interim periods within those fiscal years for the Company. In NovemberÂ 2019, the FASB issued ASU No.Â 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission, or SEC, rules) to fiscal years beginning after DecemberÂ 15, 2022, including interim periods.Â The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company meets the SEC definition of a smaller reporting company and adopted the new accounting standard effective July 1, 2023. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial statements. Â Â ii. Recently issued accounting pronouncements, not yet adopted Â ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07: Â In November 2023, the FASB issued ASU 2023-07, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures. Â ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09: Â In December 2023, the FASB issued ASU 2023-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of its adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures. Â u.ComprehensiveÂ loss Â For all periods presented, net loss is the same as comprehensive loss as there are no comprehensive incomeÂ items. Â v.Loss contingencies Â The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. As of June 30, 2024 and 2023, the Company has not recorded any accruals in this regard. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets 12 Months Ended Jun. 30, 2024 Prepaid Expenses and Other Current Assets [Abstract] Â PREPAID EXPENSES AND OTHER CURRENT ASSETS NOTE 3: - PREPAID EXPENSES AND OTHER CURRENT ASSETS Â Â Â June 30,Â Â Â 2024Â Â 2023Â Accounts receivable from NIAIDÂ $210Â Â $-Â Prepaid expensesÂ Â 222Â Â Â 442Â Value Added Tax receivableÂ Â 135Â Â Â 129Â Accounts receivable from the IIAÂ Â 257Â Â Â 250Â Customer receivableÂ Â 34Â Â Â 110Â Other receivablesÂ Â 10Â Â Â 38Â TotalÂ $868Â Â $969Â X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net 12 Months Ended Jun. 30, 2024 Property and Equipment, Net [Abstract] Â PROPERTY AND EQUIPMENT, NET NOTE 4: - PROPERTY AND EQUIPMENT, NET Â Â Â June 30,Â Â Â 2024Â Â 2023Â Cost:Â Â Â Â Â Laboratory equipmentÂ $7,166Â Â $7,006Â Computers and peripheral equipmentÂ Â 1,775Â Â Â 1,682Â Office furniture and equipmentÂ Â 682Â Â Â 682Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total costÂ Â 18,388Â Â Â 18,135Â Accumulated depreciation:Â Â Â Â Â Laboratory equipmentÂ Â 6,615Â Â Â 6,471Â Computers and peripheral equipmentÂ Â 1,638Â Â Â 1,530Â Office furniture and equipmentÂ Â 682Â Â Â 681Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total accumulated depreciationÂ Â 17,700Â Â Â 17,447Â Property and equipment, netÂ $688Â Â $688Â Â Depreciation expenses amounted to $253 and $362 for the years ended June 30, 2024 and 2023, respectively. Â All of the Companyâ€™s property and equipment is located in Israel. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable 12 Months Ended Jun. 30, 2024 Other Accounts Payable [Abstract] Â OTHER ACCOUNTS PAYABLE NOTE 5: - OTHER ACCOUNTS PAYABLE Â Â Â June 30,Â Â Â 2024Â Â 2023Â Grants received in advanceÂ $81Â Â $144Â Accrued payrollÂ Â 467Â Â Â 501Â Advances from customersÂ Â 43Â Â Â 7Â Payroll institutionsÂ Â 415Â Â Â 448Â TotalÂ $1,006Â Â $1,100Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 12 Months Ended Jun. 30, 2024 Leases [Abstract] Â LEASES NOTE 6: - LEASES Â Towards the termination of the previous facility operating lease agreement, the Company signed, in December 2021, an addendum to its facility operating lease agreement with the lessor, which extended the lease period to December 2026. In addition, the Company has the option to extend the term of the lease, or the Extension Option, for an additional period of five years until December 2031. The Company reflected the Extension Option during the evaluation of the lease liability and ROU asset. The monthly lease payments are approximately NIS 292,000 ($78) which are linked to the consumer price index and will increase by 10% in the event the Company exercises its Extension Option. In addition, the Company has operating leases for vehicles that expire through fiscal year 2026. Below is a summary of the Companyâ€™s operating ROU assets and operating lease liabilities: Â Â Â June 30,Â Â Â 2024Â Â 2023Â Operating ROU assetsÂ $6,558Â Â $7,633Â Â Â Â Â Â Â Â Â Operating lease liabilities, currentÂ Â 559Â Â Â 627Â Operating lease liabilities long-termÂ Â 5,026Â Â Â 5,748Â Total operating lease liabilitiesÂ $5,585Â Â $6,375Â Â Maturities of operating lease liabilities as of June 30, 2024 are as follows: Â Â Â June 30, 2024Â 2025Â Â 1,113Â 2026Â Â 1,011Â 2027Â Â 977Â 2028Â Â 1,023Â 2029 and thereafterÂ Â 3,583Â Total undiscounted lease paymentsÂ $7,707Â Less: interestÂ Â (2,122) Present value of lease liabilitiesÂ $5,585Â Â All of the leased facilities are located in Israel. Â The components of lease expense and supplemental cash flow information related to leases for the years ended June 30, 2024 and 2023 are as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Components of lease expenseÂ Â Â Â Â Â Â Fixed payments and variable payments that depend on an index or rateÂ $1,250Â Â $1,304Â Sublease incomeÂ $50Â Â $36Â Supplemental cash flow informationÂ Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilitiesÂ $1,178Â Â $1,196Â Â As of June 30, 2024, the weighted average remaining lease term is 7.4 years, and the weighted average discount rate is 9 percent. As of June 30, 2023, the weighted average remaining lease term is 8.1 years, and the weighted average discount rate is 9 percent. The discount rate was determined based on the estimated collateralized borrowing rate of the Company, adjusted to the specific lease term and location of each lease. Â For vehicles, the lease period is usually 3 years. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Loan from the EIB 12 Months Ended Jun. 30, 2024 Loan from the EIB [Abstract] Â LOAN FROM THE EIB NOTE 7: - LOAN FROM THE EIB Â On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to â‚¬50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of â‚¬20 million, second of â‚¬18 million and third of â‚¬12 million for a period of 36 months from the signing of the Finance Contract. Â The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche. Â In addition to any interest payable on the Loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Companyâ€™s consolidated revenues, pro-rated to the amount disbursed from the Loan. As of June 30, 2024, Pluri had an accrued royalty in the amount of $3. Â During June 2021, Pluri received the first tranche in an amount of â‚¬20 million of the Finance Contract. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal balance in the amount of $21,390 and the interest accrued in the amount of $2,637 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract. Â The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Companyâ€™s business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans. X - DefinitionDisclosure of loan from the EIB. + ReferencesNo definition available. + Details Name: plur_LoanFromTheEIBTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_LoanFromTheEibAbstract Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 12 Months Ended Jun. 30, 2024 Commitments and Contingencies [Abstract] Â COMMITMENTS AND CONTINGENCIES NOTE 8: - COMMITMENTS AND CONTINGENCIES Â Â a. As of June 30, 2024, an amount of $888 of cash and deposits was pledged by the Subsidiary to secure its credit line, lease agreement and bank guarantees. Â Â b. Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the projectâ€™s expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3% on sales of products and services derived from a technology developed using these grants until 100% of the U.S. dollar-linked grant is repaid. The Companyâ€™s obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12 month LIBORÂ (from January 1, 2024, to the 12-month secured overnight financing rate, or SOFR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties. As of June 30, 2024, the Companyâ€™s contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above. Â Â c. In April 2017, the Company was awarded a Smart Money grant of

approximately $229 from Israelâ€™s Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Companyâ€™s product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israelâ€™s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Companyâ€™s revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid. During the year ended June 30, 2023, the grant from this Smart Money program received in the amount of approximately $180 and the program has ended. No royalties were paid or accrued. Â Â d. In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500. Â Â e. As to potential royalties to the EIB, see note 7. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity 12 Months Ended Jun. 30, 2024 Shareholders' Equity [Abstract] Â SHAREHOLDERSâ€™ EQUITY NOTE 9: - SHAREHOLDERSâ€™ EQUITY Â (1) a) On May 1, 2023, the Company increased its authorized common shares from 7,500,000 to 37,500,000 with a par value of $0.00001 per share. All shares have equal voting rights and are entitled to one vote per share in all matters to be voted upon by shareholders and may be issued only as fully paid and non-assessable shares. Holders of the common shares are entitled to equal ratable rights to dividends and distributions, as may be declared by the Board out of funds legally available. The Companyâ€™s authorized preferred shares consist of 1,000,000 preferred shares, par value $0.00001 per share, with series, rights, preferences, privileges and restrictions as may be designated from time to time by the Board. No preferred shares have been issued. Â Â b) Between December 13, 2022 and December 27, 2022, the Company entered into the December 2022 Private Placement, a series of securities purchase agreements with several purchasers for an aggregate of 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares. On December 13, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.24 per share, up to 697,485 common shares and warrants to purchase up to 697,485 common shares, with an exercise price of $8.24 per share and a term of three years. On December 14, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.40 per share, up to 258,565 common shares and warrants to purchase up to 258,565 common shares, with an exercise price of $8.40 per share and a term of three years. On December 15, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.48 per share, up to 29,688 common shares and warrants to purchase up to 29,688 common shares, with an exercise price of $8.48 per share and a term of three years. On December 19, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.72 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.72 per share and a term of three years. On December 27, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.96 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.96 per share and a term of three years. The warrants sold in the December 2022 Private Placement are exercisable upon the later of six months from their issuance date, or from the date the Company increased its authorized shares. The Company issued 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares that relate to the December 2022 Private Placement and received $8,024 as of that date net of $445 of issuance expenses. Â Â c) Pursuant to a shelf registration on Form S-3 declared effective by the SEC on September 21, 2023, on February 13, 2024 the Company entered into a Sales Agreement with A.G.P., which provides that, upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000Â through A.G.P. acting as sales agent. During April 2024, the Company soldÂ 42,729Â common shares under the Sales Agreement at an average price of $5.93Â per share. Â Â d) On August 31, 2023, and as amended and restated as of October 9, 2023, Ever After Foods entered into a Simple Agreement for Future Equity, or the SAFE Agreement, with an investor. Pursuant to the terms of the SAFE Agreement, Ever After Foods will receive an aggregate amount of $2,500,Â or the SAFE Amount. On December 12, 2023, the SAFE Agreement had been terminated and the SAFE Amount was not received. Â Â e) On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors (see note 1f). Â (2) Share options and RSUs to employees, directors and consultants: Â The Company adopted the 2016 Equity Compensation Plan, or the 2016 Plan, and the 2019 Equity Compensation Plan, or together, the Plans. Â Under the Plans, share options, restricted shares, or RS, and RSUs may be granted to the Companyâ€™s officers, directors, employees and consultants or the officers, directors, employees and consultants of the Subsidiary. Â As of June 30, 2024, 642,650 common shares are available for future grants under the Plans. Â Â a. Options to non-employee consultants: Â A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 11,381Â Â $10.56Â Â Â 7.05Â Â Â 44Â Share options forfeitedÂ Â (3,281)Â $18.32Â Â Â -Â Â Â -Â Share options outstanding at end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options exercisable at the end of the periodÂ Â 7,475Â Â $6.69Â Â Â 6.06Â Â Â 29Â Share options unvestedÂ Â 625Â Â $16.00Â Â Â 8.44Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options grantedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 5.24Â Â $29Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Â (**) See note 1d regarding reverse share split Â Compensation expenses recorded in general and administrative expenses related to options granted to non-employee consultants by Pluri and its Subsidiary for the years ended June 30, 2024 and 2023 were $9 and $6, respectively. Â Unamortized compensation expenses related to options granted to non-employee consultants by Pluri and its Subsidiary are approximately $20 to be recognized by the end of March 2027. Â Â b. Options to CEO and directors: Â A summary of the share options granted to CEO and directors under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â -Â Â $-Â Â Â -Â Share options grantedÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options outstanding at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options exercisable at the end of the periodÂ Â 114,676Â Â $15.20Â Â Â 3.47Â Share options unvestedÂ Â 114,677Â Â $15.20Â Â Â 3.47Â Share options vested and expected to vest at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options grantedÂ Â 12,500Â Â $6.08Â Â Â 6.73Â Share options forfeitedÂ Â (1,562)Â $6.08Â Â Â -Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Â (**) See note 1d regarding reverse share split Â As of June 30, 2024, the aggregate intrinsic value of these options was $0.Â On December 14, 2022, Yaky Yanay, the Companyâ€™s CEO, agreed to forgo, starting January 1, 2023, $375,000 of his annual cash salary for the next twelve months in return for equity grants, issuable under the Companyâ€™s existing equity compensation plans. In that regard, the Company granted Mr. Yanay (i) 41,853 RSUs, vesting ratably each month (see also item c), and (ii) options to purchase 41,853 common shares, vesting ratably each month, with a term of 3 years, at an exercise price of $8.96 per share. All of these options were granted in December 2022 and will expire three years from the last vesting date. Â In addition, the Board also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.80 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023. All options were granted in January 2023 and will expire three years after the last vesting date. Â Compensation expenses recorded in general and administrative expenses related to options granted to CEO and directors by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023 were $220 and $568, respectively. Â c. RSUs to employees and directors: Â The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2024 and 2023: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 207,199Â Â Â 241,877Â GrantedÂ Â 395,327Â Â Â 41,853Â ForfeitedÂ Â (132,400)Â Â (6,424) VestedÂ Â (116,992)Â Â (70,107) Unvested at the end of the periodÂ Â 353,134Â Â Â 207,199Â Expected to vest after the end of periodÂ Â 319,533Â Â Â 205,072Â Â (**) See note 1d regarding reverse share split Â Compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $316Â Â $55Â General and administrative expensesÂ Â 1,258Â Â Â 2,150Â Â Â $1,574Â Â $2,205Â Â Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $848 to be recognized by the end of January 2027. Â General and administrative expenses include compensation expenses for the year ended June 30, 2024 and 2023, in the amount of $58 and $273 wereÂ related to 41,853Â RSUs granted to the CEO, due each month (see also item b). Â d. RSUs and RS to consultants: Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 2,500Â Â Â 5,157Â GrantedÂ Â 27,270Â Â Â -Â VestedÂ Â (24,968)Â Â (2,657) Unvested at the end of the periodÂ Â 4,802Â Â Â 2,500Â Â (**) See note 1d regarding reverse share split Â Compensation expenses related to RSUs and RS granted to consultants by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $-Â Â $1Â General and administrative expensesÂ Â 170Â Â Â 204Â Â Â $170Â Â $205Â Â Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $21 to be recognized by the end of June 2025.Â e. Summary of the Companyâ€™s warrants and options: Â Â Â Year ended June 30, 2024Â Warrants / OptionsÂ Weighted average exercise price per shareÂ Â Options and warrants for common shares (**)Â Â Options and warrants exercisable for common shares (**)Â Â Weighted average remaining contractual terms (in years)Â Warrants:Â $8.24Â Â Â 697,485Â Â Â 697,485Â Â Â 1.55Â Â Â $8.40Â Â Â 258,565Â Â Â 258,565Â Â Â 1.82Â Â Â $8.48Â Â Â 29,688Â Â Â 29,688Â Â Â 1.47Â Â Â $8.72Â Â Â 16,875Â Â Â 16,875Â Â Â 1.49Â Â Â $8.96Â Â Â 16,875Â Â Â 16,875Â Â Â 1.50Â Total warrantsÂ Â Â Â Â Â 1,019,488Â Â Â 1,019,488Â Options:Â $5.80Â Â Â 17,475Â Â Â 8,100Â Â Â 4.87Â Â Â $8.96Â Â Â 41,853Â Â Â 41,853Â Â Â 2.04Â Â Â $12.48Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â $16.64Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â $20.80Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â $6.08Â Â Â 10,938Â Â Â 10,938Â Â Â 6.73Â Total optionsÂ Â Â Â Â Â 257,766Â Â Â 248,391Â Â Â Â Â Total warrants and optionsÂ Â Â Â Â Â 1,277,254Â Â Â 1,267,879Â Â Â Â Â This summary does not include 357,936 RSUs and RS that are not vested as of June 30, 2024.Â Â (**) See note 1d regarding reverse share split Â (3) Nasdaq Deficiency Letter: Â On May 28, 2024, the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500 in shareholdersâ€™ equity for continued listing on The Nasdaq Capital Market, or the Shareholdersâ€™ Equity Requirement, nor was it in compliance with either of the alternative listing standards, market value of listed securities of at least $35,000 or net income of $500 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Â Pursuant to the Nasdaq Letter, on July 11, 2024, and subsequent to the balance sheet date, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq granted the Company an extension of time to regain compliance with the Shareholdersâ€™ Equity Requirement until November 24, 2024. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staffâ€™s determination to a Hearings Panel. Â The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing. Â Neither the Nasdaq Letter nor the Companyâ€™s noncompliance have an immediate effect on the listing or trading of the Companyâ€™s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol â€œPLURâ€. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Income (Expenses), Net 12 Months Ended Jun. 30, 2024 Financial Income (Expenses), Net [Abstract] Â FINANCIAL INCOME (EXPENSES), NET NOTE 10: - FINANCIAL INCOME (EXPENSES), NET Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Foreign currency translation differences, netÂ $126Â Â $(1,709) Bank and broker commissionsÂ Â 92Â Â Â (16) Interest income on deposits and restricted bank depositsÂ Â 1,314Â Â Â 1,084Â Income (loss) from hedging derivativesÂ Â 148Â Â Â (157) Financial income (expenses), netÂ Â 1,680Â Â Â (798) EIB loan interest expensesÂ Â (866)Â Â (843) Â Â $814Â Â $(1,641) X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/720/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 610 -Publisher FASB -URI https://asc.fasb.org/610/tableOfContent + Details Name: us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Taxes on Income 12 Months Ended Jun. 30, 2024 Taxes on Income [Abstract] Â TAXES ON INCOME NOTE 11: - TAXES ON INCOME Â a.Tax rates applicable to the Company: Â Â 1. Pluri: Â The U.S. corporate federal tax rate applicable to Pluri is 21%, which is the result of the Tax Cuts and Jobs Act of 2017, or the Tax Act. Such corporate tax rate excludes state tax and local tax, if any, which rates depend on the state and city in which Pluri conducts its business. Â The Tax Act provided for a one-time transition tax on certain foreign earnings for the tax year 2017, and taxation of Global Intangible Low-Taxed Income, or GILTI, earned by foreign subsidiaries beginning after December 31, 2017. The GILTI tax imposes a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Tax Act also made certain changes to the depreciation rules and implemented new limits on the deductibility of certain executive compensation paid by Pluri All losses generated after December 31, 2017 can only be used to offset 80% of net income in the year they will be utilized. Â There was no one-time transition tax for the Company under the Tax Act, nor will there be GILTI tax due for the current year, since the Subsidiary had losses for every year to date. Â In January 2018, Pluri Inc. registered as an Israeli resident with the Israel Tax Authority, or the ITA, and the Israeli Value Added Tax Authorities (the VAT registration agreed to be canceled by the VAT authorities). As a result, as of such date, Pluri Inc. is classified as a dual tax resident for tax purposes both in Israel and the United States. Â In June 2018, Pluri Inc. and the Subsidiary submitted an election notice to the ITA to file a consolidated tax return in Israel commencing with the 2018 tax year.Â Â Â 2. The Subsidiary: Â Consolidated taxable income of Pluri and the Subsidiary, or the consolidated tax unit, is subject to tax at the rate of 23% for the years ended June 30, 2024 and 2023. Â The consolidated tax unit is filing its consolidated tax reports in U.S. dollars based on specific regulations of the ITA which allow, in specific circumstances, filing tax reports in U.S. dollars, or Dollar Regulations. Under the Dollar Regulations, the tax liability is calculated in U.S. dollars according to certain orders. The tax liability, as calculated in dollars, is translated into NIS according to the exchange rate as of June 30 of each year (the fiscal tax year end of the Subsidiary). Â The Subsidiary has not received final tax assessments since its incorporation; however the assessments of the Subsidiary are deemed final through 2019. Â The Law for the Encouragement of Capital Investments, 1959, or the Law (amendment No. 73): Â In December 2016, the Knesset (Israeli Parliament) issued the Law for Changing National Priorities (Legislative Amendments for Achieving Budget Targets for 2017 and 2018), 2017, which consists of amendment No. 73 to the Law, or Amendment No. 73. According to Amendment No. 73, the tax rate on preferred income from a preferred enterprise in 2017 and thereafter will be 16% (in development area A it will be 7.5%). Â According to Amendment No. 73, special tax benefits were established for Technological Preferred Enterprise, starting in 2017, will be as follow: Â â—6% rate would apply to qualifying Israeli companies that are part of a group with global consolidated revenue of over NIS 10 billion (approximately $2,900,000). Â â—Other qualifying companies with global consolidated revenue below NIS 10 billion would be subject to a 12% tax rate (in development area A it will be 7.5%). Â â—Withholding tax on dividends paid to foreign entity investors (i.e., not to a private person) would be subject to a reduced rate of 4% for all qualifying companies (unless further reduced by a treaty), subject that at least 90% of the company is held by foreign entities (one or more). Â Taxable income which is not produced as part of Preferred Technological Enterprise income will be taxed at the regular tax rate (23% in 2024). Â As of June 30, 2024, the Subsidiaryâ€™s management believes that the Subsidiary meets the conditions mentioned above to be considered as a Technological Enterprise. Â Â 3. Pluristem GmbH: Â The corporate tax rate applicable to the German Subsidiary is 15%, which is derived from the German Corporation Tax Act and Solidarity surcharge of 5.5% from the 15% corporate tax rate. This corporate tax rate excludes trade tax, which rate depends on the municipality in which the German Subsidiary conducts its business. Trade tax rate applicable to the German Subsidiary is 15.93%, which is calculated by determining the Trade Tax Base with 3.5% of the trade income and applying the tax factor which differs according to the specific municipality in Germany and equals 455% for the municipality of Potsdam. Â Â 4. Ever After Foods: Â Ever After Foods is an Israeli tax resident and is subject to corporate income tax at the rate of 23%.Â Â b. Carryforward losses for tax purposes Â As of June 30, 2024, Pluri had a U.S. federal net operating loss carryforward for income tax purposes in the amount of $31,414. Net operating loss carryforwards arising in taxable years prior to 2018, can be carried forward and offset against taxable income for 20 years and thus will expire between 2022 and 2037. Net operating losses generated in tax years 2002, 2003 and 2004 have expired and were reduced from the total net operating loss carryforward available. Â Utilization of U.S. net operating losses may be subject to substantial annual limitations due to the â€œchange in ownershipâ€ provisions of the U.S. Internal Revenue Code of 1986, Section 382 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. Â The Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $129,286, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â Â In January 2018, Pluri Inc. registered as an Israeli resident with the ITA. Â As of June 30, 2024, Pluri Inc. and the Subsidiaries consolidated accumulated losses, for tax purposes, are approximately $144,906, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â The German Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $601, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period. Â Â c. Loss before income taxes Â The components of loss before income taxes are as follows: Â Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Consolidated loss of Pluri Inc. and the Israeli SubsidiariesÂ $21,339Â Â $28,878Â Pluristem GmbHÂ Â 5Â Â Â 9Â Â Â $21,344Â Â $28,887Â Â Â d. Deferred income taxes: Â Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Companyâ€™s deferred tax assets are as follows: Â Â Â June 30,Â Â Â 2024Â Â 2023Â Deferred tax assets:Â Â Â Â Â Operating loss carryforwardsÂ $69,852Â Â $80,534Â Research and development credit carryforwardsÂ Â 3,780Â Â Â 4,057Â Issuance costsÂ Â 25Â Â Â 68Â Allowances and reservesÂ Â 173Â Â Â 237Â Â Â Â Â Â Â Â Total deferred tax assets before valuation allowanceÂ Â 73,830Â Â Â 84,896Â Valuation allowanceÂ Â (73,830)Â Â (84,896) Â Â Â Â Â Â Â Â Net deferred tax assetÂ $-Â Â $-Â Â As of June 30, 2024 and 2023, the Company has provided full valuation allowances with respect to the deferred tax assets resulting from tax loss carryforwards and other temporary differences, since it has a history of operating losses and due to current uncertainty concerning its ability to realize these deferred tax assets in the future. Â The Company accounts for its income tax uncertainties in accordance with ASCÂ 740 which clarifies the accounting for uncertainties in income taxes recognized in a Companyâ€™s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Â As of June 30, 2024 and 2023, there were no unrecognized tax benefits that if recognized would affect the annual effective tax rate. Â Reconciliation of taxes at the federal statutory rate to Companyâ€™s provision for income taxes: Â In 2024 and 2023, the main reconciling item of the statutory tax rate of the Company (21% to 23%) to the effective tax rate (0%) is tax loss carryforward and R&D credit carryforward for which a full valuation allowance was provided. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Net Income (Loss) $ (20,888) $ (28,321) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 12 Months Ended Jun. 30, 2024 Significant Accounting Policies [Abstract] Â Basis of presentation Basis of presentationThe consolidated financial statements have been prepared in accordance with the United States Generally Accepted Accounting Principles, or U.S. GAAP. Use of estimates a. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments, and assumptions that are reasonable based upon information available at the time they are made. Estimates are primarily used for, but not limited to, valuation of share-based compensation, valuation of warrants and determining the valuation and terms of leases. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results could differ from those estimates. Functional currency b. Functional currency The U.S. dollar is the primary currency of the economic environment in which the Company and the Subsidiaries operate. Thus, the U.S. dollar is the Companyâ€™s functional and reporting currency. Accordingly, non-dollar denominated transactions and balances have been re-measured into the functional currency in accordance with Accounting Standards Codification, or ASC, 830, â€œForeign Currency Mattersâ€. All transaction gains and losses from the re-measured monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate.Â Principles of consolidation c. Principles of consolidation The consolidated financial statements include the accounts of the Company and its Subsidiaries. Non-controlling interests in subsidiaries represent the equity in Ever After Foods not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the shareholders of the Company. Profit or loss and components of other comprehensive income or loss are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of operations.The Company treats transactions with non-controlling interests as transactions with its equity owners. Accordingly, for sales or purchases of shares to or from non-controlling interests, the difference between any consideration received or paid and the portion sold or acquired of the carrying value of the net assets of the subsidiary is recorded in equity.Intercompany transactions and balances have been eliminated upon consolidation. Cash and cash equivalents d. Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired. Short-term bank deposit e. Short-term bank deposit Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. Restricted cash f. Restricted cash Restricted cash is cash used to secure the Companyâ€™s credit line, derivative and hedging transactions and lease agreement. The restricted cash is presented at cost which approximates market values including accrued interest. Long-term restricted bank deposits g. Long-term restricted bank deposits Long-term restricted bank deposits with maturities of more than one year used to secure operating lease agreement are presented at cost which approximates market values including accrued interest.Â Revenue Recognition h. Revenue Recognition A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each partyâ€™s rights regarding the distinct goods or services to be transferred, or the Performance Obligations, (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.Revenues are recognized when the control of the promised goods or the performance of the obligations are transferred to the customer, in an amount that reflects the consideration to which the Company expects to be entitled, excluding sales taxes.The Company determines revenue recognition through the following steps: â—identification of the contract with a customer; â—identification of the Performance Obligations in the contract; â—determination of the transaction price; â—allocation of the transaction price to the Performance Obligations in the contract; and â—recognition of revenue when, or as, the Company satisfies a Performance Obligation. Property and equipment i. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: Â Â % Laboratory equipment Â 10-40 Computers and peripheral equipment Â 33 Office furniture and equipment Â 15 Leasehold improvements Â The shorter of the expected useful life or the term of the lease. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Impairment of long-lived assets j. Impairment of long-lived assets The Companyâ€™s long-lived assets are reviewed for impairment in accordance with ASC 360, â€œProperty, Plant and Equipmentâ€, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During fiscal years 2024 and 2023, no impairment losses were recorded.Â Share-based compensation k. Share-based compensation The Company accounts for share-based compensation in accordance with ASC 718, â€œCompensation-Share Compensationâ€, or ASC 718. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company estimates the fair value of share options granted using the Black-Scholes option-pricing model. The Company accounts for employeesâ€™ share-based payment awards classified as equity awards, such as restricted share units, or RSUs, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.The Company recognized compensation cost for an award with service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.The fair value of service-based share option grants is estimated on the grant date using a Black-Scholes option-pricing model and compensation expense related to share option and RSUs grants are recognized on a graded vesting schedule over the vesting period.All RSUs to employees and directors granted during fiscal 2024 and 2023 were granted for no consideration. Therefore, their fair value was equal to the share price at the date of grant.The fair value of all RSUs was determined based on the closing trading price of the Companyâ€™s shares known at the grant date. The weighted average grant date fair value of RSU granted during fiscal years 2024 and 2023 was $4.32 and $7.92 per share, respectively.The fair value of the service-based share option grants was estimated on the grant date using a Black-Scholes option-pricing model. The weighted average grant date fair value of option granted during fiscal years 2024 and 2023 was $3.85 and $3.65 per option, respectively.The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions: Â Â 2024Â Â 2023Â Underlying value ofÂ common shares ($)Â Â 4.40-6.08Â Â Â 7.52-7.92Â Exercise price ($)Â Â 4.40-6.08Â Â Â 8.96-20.80Â Expected volatility (%)Â Â 78.44Â Â Â 86.40-86.48Â Expected terms of the option (years)Â Â 5-7Â Â Â 3Â Risk-free interest rate (%)Â Â 4.04-4.13Â Â Â 4.03-4.22Â Â Research and development expenses, royalty bearing grants and non-royalty bearing grants l. Research and development expenses, royalty bearing grants and non-royalty bearing grants Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and development are expensed as incurred.Grants received from the Israel Innovation Authority, or the IIA, are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred (see also note 8b).During fiscal years 2024 and 2023, the Company also received (in cash) non-royalty bearing grants from the European UnionÂ research and development consortiums, under Horizon 2020, Horizon Europe, U.S. National Institute of Allergy and Infectious Diseases, or the NIAID, and from the IIA, under the CRISPR-IL consortium, in the aggregate amount of approximately $1,113 and $2,426, for the years ended June 30, 2024 and 2023, respectively. The non-royalty bearing grants for funding the projects are recognized at the time the Company is entitled to each such grant based on the related costs incurred and recorded as a deduction from research and development expenses.Research and development expenses, net for the years ended June 30, 2024 and 2023 include participation in research and development expenses in the amount of approximately $1,334 and $1,668, respectively. Loss per share m. Loss per share Basic and diluted loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year, including unexercised vested options with no par value exercise price. All outstanding share options, unvested RSUs and warrants have been excluded from the calculation of the diluted loss per common share because all such securities are anti-dilutive for each of the periods presented. The total number of shares related to the outstanding options, warrants and RSUs excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,635,190 and 1,768,948 for the years ended June 30, 2024 and 2023, respectively.Â Income taxes n. Income taxes Â 1. Deferred taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. Â 2. Uncertainty in income taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, â€œIncome Taxesâ€, or ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Concentration of credit risk o. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, long-term restricted bank deposits.The majority of the Companyâ€™s cash and cash equivalents, restricted cash, short-term bank deposits and long-term restricted deposits are mainly invested in the New Israeli Shekel, or NIS, and U.S. dollar deposits of major banks in Israel and in the United States. Deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk. The Company invests its surplus cash in cash deposits in financial institutions and has established guidelines, approved by the Companyâ€™s Investment Committee, relating to diversification and maturities to maintain safety and liquidity of the investments. Severance pay p. Severance pay The majority of the Companyâ€™s agreements with employees in Israel are subject to Section 14 of the Israeli Severance Pay Law, 1963, or the Severance Pay Law. The Companyâ€™s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employeeâ€™s monthly salary for each year of employment, no additional obligation exists regarding the matter of severance pay and no additional payments are made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.For Yaky Yanay, the Companyâ€™s Chief Executive Officer, or the CEO, whose agreement is not subject to Section 14 of the Severance Pay Law, the Subsidiaryâ€™s liability for severance pay is calculated pursuant to Severance Pay Law, based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. The CEO is entitled to one monthâ€™s salary for each year of employment or a portion thereof. The Companyâ€™s liability to the CEO is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Companyâ€™s balance sheet.Â Â The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies, and includes immaterial profits or losses accumulated up to the balance sheet date.Severance expenses for all employees including the CEO, for the years ended June 30, 2024 and 2023 were $632 and $732, respectively. Fair value of financial instruments q.Fair value of financial instruments The carrying amounts of the Companyâ€™s financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities.The Company measures its derivative instruments at fair value under ASC 820, â€œFair Value Measurementâ€, or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.As such, fair value is a market-based measurement that should be determined based on assumptions

that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Â Level 1Â - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Â Level 2Â - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and Â Level 3Â - Unobservable inputs for the asset or liability. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.The Company measures its liability pursuant to the Finance Contract with the EIB based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. The Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Companyâ€™s future consolidated revenues, pro-rated to the amount disbursed, beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030. The Company accrued royalties for fiscal year 2024 in the amount of $3 (see note 7). Derivative financial instruments r.Derivative financial instruments The Company accounts for derivatives and hedging based on ASC 815, â€œDerivatives and hedgingâ€, as amended and related interpretations, or ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value.If a derivative does not meet the definition of a hedging instrument, the changes in the fair value are included in earnings. Cash flows related to Companyâ€™s current hedging are classified as operating activities. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS and its loan from the EIB that is linked to the Euro. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as â€œfinancial income (expenses), netâ€.The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of June 30, 2024, the fair value of the derivatives instruments is presented in â€œPrepaid expenses and other current assetsâ€ (see note 3) and as of June 30, 2023, there were no derivatives instruments. The net income (losses) from derivatives instruments recognized in â€œFinancial income (expenses), netâ€ during the years ended June 30, 2024 and 2023 were $148 and $(157), respectively (see note 10). Leases s.Leases Operating leases are included in operating lease right-of-use, or ROU asset, and operating lease liability. ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements with a non-cancelable term of less than 12 months are not recorded on the balance sheets.The Company accounts for an extension of a lease term that was not part of the original lease as a modification. As a result, the Company reallocates contract consideration between the lease and non-lease components, reassesses lease classification, and remeasures the lease liability and right-of-use asset prospectively. Assumptions such as the discount rate, fair value of the underlying asset, and variable rents based on a rate or index will be updated as of the modification date.Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. New Accounting Pronouncements t.New Accounting Pronouncements i.Recently adopted accounting pronouncements ASU No. 2016-13-â€œFinancial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrumentsâ€, or ASU 2016-13:In JuneÂ 2016, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2016-13, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking â€œexpected lossâ€ model that generally results in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after DecemberÂ 15, 2019, including interim periods within those fiscal years for the Company. In NovemberÂ 2019, the FASB issued ASU No.Â 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission, or SEC, rules) to fiscal years beginning after DecemberÂ 15, 2022, including interim periods.Â The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company meets the SEC definition of a smaller reporting company and adopted the new accounting standard effective July 1, 2023. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial statements. Â ii. Recently issued accounting pronouncements, not yet adopted ASU No. 2023-07 - â€œSegment Reporting (Topic 280): Improvements to reportable segment disclosuresâ€, or ASU 2023-07:In November 2023, the FASB issued ASU 2023-07, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures.ASU No. 2023-09 - â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€, or ASU 2023-09:In December 2023, the FASB issued ASU 2023-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of its adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures. Comprehensive loss u.ComprehensiveÂ loss For all periods presented, net loss is the same as comprehensive loss as there are no comprehensive incomeÂ items. Loss contingencies v.Loss contingencies The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. As of June 30, 2024 and 2023, the Company has not recorded any accruals in this regard. X - DefinitionDisclosure of accounting policy for the use of estimates functional currency. + ReferencesNo definition available. + Details Name: plur_FunctionalCurrencyPolicyTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in long-term restricted bank deposits. + ReferencesNo definition available. + Details Name: plur_LongTermRestrictedBankDepositsPolicyTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the restricted cash. + ReferencesNo definition available. + Details Name: plur_RestrictedCashPolicyTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the severance pay. + ReferencesNo definition available. + Details Name: plur_SeverancePayPolicyTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the short-term bank deposit. + ReferencesNo definition available. + Details Name: plur_ShortTermBankDepositPolicyTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets. + ReferencesNo definition available. + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may

impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.3 General (Tables) 12 Months Ended Jun. 30, 2024 General [Abstract] Â Schedule of Main Assumptions Used in the Monte Carlo Simulation Model Risk-freeÂ interestÂ rateÂ Â 1.08% Expected share price volatilityÂ Â 85% Risk-freeÂ interestÂ rateÂ Â 3.25% Expected share price volatilityÂ Â 70% X - DefinitionTabular disclosure of main assumptions used In simulation model. + ReferencesNo definition available. + Details Name: plur_DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Tables) 12 Months Ended Jun. 30, 2024 Significant Accounting Policies [Abstract] Â Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: Â Â % Laboratory equipment Â 10-40 Computers and peripheral equipment Â 33 Office furniture and equipment Â 15 Leasehold improvements Â The shorter of the expected useful life or the term of the lease. Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions: Â Â 2024Â Â 2023Â Underlying value ofÂ common shares ($)Â Â 4.40-6.08Â Â Â 7.52-7.92Â Exercise price ($)Â Â 4.40-6.08Â Â Â 8.96-20.80Â Expected volatility (%)Â Â 78.44Â Â Â 86.40-86.48Â Expected terms of the option (years)Â Â 5-7Â Â Â 3Â Risk-free interest rate (%)Â Â 4.04-4.13Â Â Â 4.03-4.22Â Â X - DefinitionTabular information of property plant and equipment estimated useful life of assets. + ReferencesNo definition available. + Details Name: plur_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetsTableTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets (Tables) 12 Months Ended Jun. 30, 2024 Prepaid Expenses and Other Current Assets [Abstract] Â Schedule of Prepaid Expenses and Other Current Assets Â Â June 30,Â Â Â 2024Â Â 2023Â Accounts receivable from NIAIDÂ $210Â Â $-Â Prepaid expensesÂ Â 222Â Â Â 442Â Value Added Tax receivableÂ Â 135Â Â Â 129Â Accounts receivable from the IIAÂ Â 257Â Â Â 250Â Customer receivableÂ Â 34Â Â Â 110Â Other receivablesÂ Â 10Â Â Â 38Â TotalÂ $868Â Â $969Â X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Tables) 12 Months Ended Jun. 30, 2024 Property and Equipment, Net [Abstract] Â Schedule of Property and Equipment, Net Â Â June 30,Â Â Â 2024Â Â 2023Â Cost:Â Â Â Â Â Â Laboratory equipmentÂ $7,166Â Â $7,006Â Computers and peripheral equipmentÂ Â 1,775Â Â Â 1,682Â Office furniture and equipmentÂ Â 682Â Â Â 682Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total costÂ Â 18,388Â Â Â 18,135Â Accumulated depreciation:Â Â Â Â Â Â Â Â Laboratory equipmentÂ Â 6,615Â Â Â 6,471Â Computers and peripheral equipmentÂ Â 1,638Â Â Â 1,530Â Office furniture and equipmentÂ Â 682Â Â Â 681Â Leasehold improvementsÂ Â 8,765Â Â Â 8,765Â Total accumulated depreciationÂ Â 17,700Â Â Â 17,447Â Property and equipment, netÂ $688Â Â $688Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable (Tables) 12 Months Ended Jun. 30, 2024 Other Accounts Payable [Abstract] Â Schedule of Other Accounts Payable Â Â June 30,Â Â Â 2024Â Â 2023Â Grants received in advanceÂ $81Â Â $144Â Accrued payrollÂ Â 467Â Â Â 501Â Advances from customersÂ Â 43Â Â Â 7Â Payroll institutionsÂ Â 415Â Â Â 448Â TotalÂ $1,006Â Â $1,100Â X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 12 Months Ended Jun. 30, 2024 Leases [Abstract] Â Schedule of Operating Lease Agreement Below is a summary of the Companyâ€™s operating ROU assets and operating lease liabilities: Â Â June 30,Â Â Â 2024Â Â 2023Â Operating ROU assetsÂ $6,558Â Â $7,633Â Â Â Â Â Â Â Â Â Â Operating lease liabilities, currentÂ Â 559Â Â Â 627Â Operating lease liabilities long-termÂ Â 5,026Â Â Â 5,748Â Total operating lease liabilitiesÂ $5,585Â Â $6,375Â Schedule of Maturities of Operating Lease Liabilities Maturities of operating lease liabilities as of June 30, 2024 are as follows: Â Â June 30, 2024Â 2025Â Â 1,113Â 2026Â Â 1,011Â 2027Â Â 977Â 2028Â Â 1,023Â 2029 and thereafterÂ Â 3,583Â Total undiscounted lease paymentsÂ $7,707Â Less: interestÂ Â (2,122) Present value of lease liabilitiesÂ $5,585Â Schedule of Lease Expense and Supplemental Cash Flow Information The components of lease expense and supplemental cash flow information related to leases for the years ended June 30, 2024 and 2023 are as follows: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Components of lease expenseÂ Â Â Â Â Â Fixed payments and variable payments that depend on an index or rateÂ $1,250Â Â $1,304Â Sublease incomeÂ $50Â Â $36Â Supplemental cash flow informationÂ Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilitiesÂ $1,178Â Â $1,196Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of components of income from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A + Details Name: us-gaap_OperatingLeaseLeaseIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of supplemental cash flow information for the periods presented. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Tables) 12 Months Ended Jun. 30, 2024 Shareholders' Equity [Abstract] Â Schedule of Warrants and Options A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows: Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 11,381Â Â $10.56Â Â Â 7.05Â Â Â 44Â Share options forfeitedÂ Â (3,281)Â $18.32Â Â Â -Â Â Â -Â Share options outstanding at end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options exercisable at the end of the periodÂ Â 7,475Â Â $6.69Â Â Â 6.06Â Â Â 29Â Share options unvestedÂ Â 625Â Â $16.00Â Â Â 8.44Â Â $-Â Share options vested and expected to vest at the end of the periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average

exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Â Aggregate intrinsic valueÂ priceÂ Share options outstanding at beginning of periodÂ Â 8,100Â Â $7.44Â Â Â 6.24Â Â Â 29Â Share options grantedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options outstanding at end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â Share options exercisable at the end of the periodÂ Â 8,100Â Â $7.41Â Â Â 5.24Â Â $29Â Share options unvestedÂ Â 9,375Â Â $4.40Â Â Â 4.56Â Â Â 13Â Share options vested and expected to vest at the end of the periodÂ Â 17,475Â Â $5.80Â Â Â 4.87Â Â $42Â (**) See note 1d regarding reverse share split Â Â Â Year ended June 30, 2023Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â -Â Â $-Â Â Â -Â Share options grantedÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options outstanding at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options exercisable at the end of the periodÂ Â 114,676Â Â $15.20Â Â Â 3.47Â Share options unvestedÂ Â 114,677Â Â $15.20Â Â Â 3.47Â Share options vested and expected to vest at the end of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Â Â Year ended June 30, 2024Â Â Â Number (**)Â Â Weighted average exerciseÂ priceÂ Â Weighted average remaining contractual terms (in years)Â Share options outstanding at the beginning of the periodÂ Â 229,353Â Â $15.20Â Â Â 3.47Â Share options grantedÂ Â 12,500Â Â $6.08Â Â Â 6.73Â Share options forfeitedÂ Â (1,562)Â $6.08Â Â Â -Â Share options outstanding at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Share options vested and exercisable at the end of the periodÂ Â 240,291Â Â $14.82Â Â Â 2.42Â Schedule of Activity Related to Unvested RSUs Granted The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2024 and 2023: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 207,199Â Â Â 241,877Â GrantedÂ Â 395,327Â Â Â 41,853Â ForfeitedÂ Â (132,400)Â Â (6,424) VestedÂ Â (116,992)Â Â (70,107) Unvested at the end of the periodÂ Â 353,134Â Â Â 207,199Â Expected to vest after the end of periodÂ Â 319,533Â Â Â 205,072Â The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Â Â Number (**)Â Unvested at the beginning of periodÂ Â 2,500Â Â Â 5,157Â GrantedÂ Â 27,270Â Â Â -Â VestedÂ Â (24,968)Â Â (2,657) Unvested at the end of the periodÂ Â 4,802Â Â Â 2,500Â (**) See note 1d regarding reverse share split Schedule of Expenses Related to RSUs Granted Compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $316Â Â $55Â General and administrative expensesÂ Â 1,258Â Â Â 2,150Â Â Â Â $1,574Â Â $2,205Â Compensation expenses related to RSUs and RS granted to consultants by Pluri Inc. and its Subsidiary were recorded as follows: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Research and development expensesÂ $-Â Â $1Â General and administrative expensesÂ Â 170Â Â Â 204Â Â Â $170Â Â $205Â Schedule of Warrants and Options Summary of the Companyâ€™s warrants and options: Â Â Year ended June 30, 2024Â Warrants / OptionsÂ Weighted average exercise price per shareÂ Â Options and warrants for common shares (**)Â Â Options and warrants exercisable for common shares (**)Â Â Weighted average remaining contractual terms (in years)Â Warrants:Â $8.24Â Â Â 697,485Â Â Â 697,485Â Â Â 1.55Â Â Â $8.40Â Â Â 258,565Â Â Â 258,565Â Â Â 1.82Â Â Â $8.48Â Â Â 29,688Â Â Â 29,688Â Â Â 1.47Â Â Â $8.72Â Â Â 16,875Â Â Â 16,875Â Â Â 1.49Â Â Â $8.96Â Â Â 16,875Â Â Â 16,875Â Â Â 1.50Â Total warrantsÂ Â Â Â Â Â 1,019,488Â Â Â 1,019,488Â Options:Â $5.80Â Â Â 17,475Â Â Â 8,100Â Â Â 4.87Â Â Â Â $8.96Â Â Â 41,853Â Â Â 41,853Â Â Â 2.04Â Â Â Â $12.48Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â Â $16.64Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â Â $20.80Â Â Â 62,500Â Â Â 62,500Â Â Â 2.25Â Â Â Â $6.08Â Â Â 10,938Â Â Â 10,938Â Â Â 6.73Â Total optionsÂ Â Â Â Â Â 257,766Â Â Â 248,391Â Â Â Â Â Â Total warrants and optionsÂ Â Â Â Â Â 1,277,254Â Â Â 1,267,879Â Â Â Â Â Â (**) See note 1d regarding reverse share split X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in restricted stock units (RSUs). + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Income (Expenses), Net (Tables) 12 Months Ended Jun. 30, 2024 Financial Income (Expenses), Net [Abstract] Â Schedule of Financial Income (Expenses), Net Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Foreign currency translation differences, netÂ $126Â Â $(1,709) Bank and broker commissionsÂ Â 92Â Â Â (16) Interest income on deposits and restricted bank depositsÂ Â 1,314Â Â Â 1,084Â Income (loss) from hedging derivativesÂ Â 148Â Â Â (157) Financial income (expenses), netÂ Â 1,680Â Â Â (798) EIB loan interest expensesÂ Â (866)Â Â (843) Â Â $814Â Â $(1,641) X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Taxes on Income (Tables) 12 Months Ended Jun. 30, 2024 Taxes on Income [Abstract] Â Schedule of Loss Before Income Taxes The components of loss before income taxes are as follows: Â Â Year ended June 30,Â Â Â 2024Â Â 2023Â Consolidated loss of Pluri Inc. and the Israeli SubsidiariesÂ $21,339Â Â $28,878Â Pluristem GmbHÂ Â 5Â Â Â 9Â Â Â $21,344Â Â $28,887Â Â Schedule of Deferred Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Companyâ€™s deferred tax assets are as follows: Â Â June 30,Â Â Â 2024Â Â 2023Â Deferred tax assets:Â Â Â Â Â Â Operating loss carryforwardsÂ $69,852Â Â $80,534Â Research and development credit carryforwardsÂ Â 3,780Â Â Â 4,057Â Issuance costsÂ Â 25Â Â Â 68Â Allowances and reservesÂ Â 173Â Â Â 237Â Â Â Â Â Â Â Â Â Â Â Â Â Total deferred tax assets before valuation allowanceÂ Â 73,830Â Â Â 84,896Â Valuation allowanceÂ Â (73,830)Â Â Â (84,896) Â Â Â Â Â Â Â Â Â Â Â Net deferred tax assetÂ $-Â Â $-Â X - ReferencesNo definition available. + Details Name: plur_ScheduleOfLossBeforeIncomeTaxesTableTextBlock Namespace Prefix: plur_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R33.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) $ / shares in Units, â¬ in Millions 9 Months Ended 12 Months Ended Jun. 12, 2024 USD ($) Nov. 22, 2022 USD ($) Jan. 05, 2022 USD ($) shares Apr. 30, 2020 EUR (â¬) Mar. 31, 2024 Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2023 USD ($) Dec. 27, 2022 shares Dec. 13, 2022 shares General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

definition available. + Details Name: us-gaap_ExcessStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIncrease for accrued, but unpaid interest on the credit facility for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plur_TnuvaFoodIndustriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=plur_FirstWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=plur_SecondWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=plur_FinanceContractWithEIBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R34.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model 12 Months Ended Jun. 30, 2024 Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Line Items] Â Risk-free interest rate 1.08% Expected share price volatility 85.00% Monte Carlo [Member] Â Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Line Items] Â Risk-free interest rate 3.25% Expected share price volatility 70.00% X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MonteCarloModelMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Significant Accounting Policies [Line Items] Â Â Weighted average grant date fair value (in Dollars per share) $ 3.85 $ 3.65 Aggregate amount $ 1,113 $ 2,426 Participation in research and development expenses $ 1,334 $ 1,668 Anti-dilutive effect shares (in Shares) 1,635,190 1,768,948 Severance expenses $ 632 $ 732 Accrued royalties 3 Â Financial income expense $ 148 $ (157) Restricted Stock Units (RSUs) [Member] Â Â Significant Accounting Policies [Line Items] Â Â Weighted average grant date fair value (in Dollars per share) $ 4.32 $ 7.92 X - DefinitionThe amount of accrued royalties. + ReferencesNo definition available. + Details Name: plur_AccruedRoyaltiesAmount Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate amount. + ReferencesNo definition available. + Details Name: plur_AggregateAmount Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of financial income expense. + ReferencesNo definition available. + Details Name: plur_FinancialIncomeExpense Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGrants received from the government and third parties for research and development programs. + ReferencesNo definition available. + Details Name: plur_GovernmentAndThirdPartyGrantsReceived Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 + Details Name: us-gaap_ChangeInAccountingEstimateLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments 12 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Line Items] Â Leasehold improvements The shorter of the expected useful life or the term of the lease. Computers and peripheral equipment [Member] Â Property, Plant and Equipment [Line Items] Â Estimated useful lives 33 years Office furniture and equipment [Member] Â Property, Plant and Equipment [Line Items] Â Estimated useful lives 15 years Minimum [Member] | Laboratory equipment [Member] Â Property, Plant and Equipment [Line Items] Â Estimated useful lives 10 years Maximum [Member] | Laboratory equipment [Member] Â Property, Plant and Equipment [Line Items] Â Estimated useful lives 40 years X - DefinitionInformation of Leasehold improvements. + ReferencesNo definition available. + Details Name: plur_PropertyPlantAndEquipmentsUsefulLife Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=plur_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Details) - Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions - $ / shares 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions [Line Items] Â Â Expected volatility (%) 78.44% Â Expected terms of the option (years) Â 3 years Risk-free interest rate (%) 1.08% Â Minimum [Member] Â Â Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions [Line Items] Â Â Underlying value of common shares ($) $ 4.4 $ 7.52 Exercise price ($) $ 4.4 $ 8.96 Expected volatility (%) Â 86.40% Expected terms of the option (years) 5 years Â Risk-free interest rate (%) 4.04% 4.03% Maximum [Member] Â Â Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions [Line Items] Â Â Underlying value of common shares ($) $ 6.08 $ 7.92 Exercise price ($) $ 6.08 $ 20.8 Expected volatility (%) Â 86.48% Expected terms of the option (years) 7 years Â Risk-free interest rate (%) 4.13% 4.22% X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Underlying Value of Common Shares. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingValueOfCommonShares Namespace Prefix: plur_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Prepaid Expenses and Other Current Assets [Line Items] Â Â Prepaid expenses $ 222 $ 442 Value Added Tax receivable 135 129 Customer receivable 34 110 Other receivables 10 38 Total 868 969 U.S. National Institute of Allergy and Infectious Diseases [Member] Â Â Prepaid Expenses and Other Current Assets [Line Items] Â Â Accounts receivable from grants 210 Israel Innovation Authority [Member] Â Â Prepaid Expenses and Other Current Assets [Line Items] Â Â Accounts receivable from grants $ 257 $ 250 X - ReferencesNo definition available. + Details Name: plur_PrepaidExpensesAndOtherCurrentAssetsLineItems Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsReceivableGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_GrantsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount due from parties in nontrade transactions, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ValueAddedTaxReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=plur_USNationalInstituteOfAllergyAndInfectiousDiseasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=plur_IsraelInnovationAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Property and Equipment, Net [Abstract] Â Â Depreciation expenses $ 253 $ 362 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Total cost $ 18,388 $ 18,135 Total accumulated depreciation 17,700 17,447 Property and equipment, net 688 688 Laboratory equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total cost 7,166 7,006 Total accumulated depreciation 6,615 6,471 Computers and peripheral equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total cost 1,775 1,682 Total accumulated depreciation 1,638 1,530 Office furniture and equipment [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total cost 682 682 Total accumulated depreciation 682 681 Leasehold improvements [Member] Â Â Property, Plant and Equipment [Line Items] Â Â Total cost 8,765 8,765 Total accumulated depreciation $ 8,765 $ 8,765 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Schedule of Other Accounts Payable [Abstract] Â Â Grants received in advance $ 81 $ 144 Accrued payroll 467 501 Advances from customers 43 7 Payroll institutions 415 448 Total $ 1,006 $ 1,100 X - DefinitionThe amount of grants received in advance. + ReferencesNo definition available. + Details Name: plur_GrantsReceivedInAdvance Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of value payroll institutions. + ReferencesNo definition available. + Details Name: plur_OtherAccountsPayablePayrollInstitutions Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedPayrollTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe current portion of prepayments received from customers for goods or services to be provided in the future. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CustomerAdvancesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) $ in Thousands 12 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2024 ILS (â‚ª) Jun. 30, 2023 Leases [Abstract] Â Â Â Lease payment $ 78 â‚ª 292,000 Â Percentage of lease payment increase 10.00% 10.00% Â Weighted average remaining lease term 7 years 4 months 24 days 7 years 4 months 24 days 8 years 1 month 6 days Weighted average discount rate 9.00% 9.00% 9.00% Lease period 3 years 3 years Â X - DefinitionPercentage of lease payments increase. + ReferencesNo definition available. + Details Name: plur_LeasePaymentsIncreasePercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - Schedule of Operating Lease Agreement - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Schedule of Operating Lease Agreement [Abstract] Â Â Operating ROU assets $ 6,558 $ 7,633 Operating lease liabilities, current 559 627 Operating lease liabilities long-term 5,026 5,748 Total operating lease liabilities $ 5,585 $ 6,375 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesOperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Schedule of Maturities of Operating Lease Liabilities [Abstract] Â Â 2025 $ 1,113 Â 2026 1,011 Â 2027 977 Â 2028 1,023 Â 2029 and thereafter 3,583 Â Total undiscounted lease payments 7,707 Â Less: interest (2,122) Â Present value of lease liabilities $ 5,585 $ 6,375 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - Schedule of Lease Expense and Supplemental Cash Flow Information - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Components of lease expense Â Â Fixed payments and variable payments that depend on an index or rate $ 1,250 $ 1,304 Sublease income 50 36 Supplemental cash flow information Â Â Cash paid for amounts included in the measurement of lease liabilities $ 1,178 $ 1,196 X - DefinitionCash paid for amounts included in the measurement of lease liabilities. + ReferencesNo definition available. + Details Name: plur_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: plur_ComponentsOfLeaseExpenseAbstract Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Loan from the EIB (Details) $ in Thousands, â‚¬ in Millions 12 Months Ended Jun. 30, 2021 EUR (â‚¬) Apr. 30, 2020 EUR (â‚¬) Jun. 30, 2024 USD ($) Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â‚¬ 50 Â Finance contract period Â 36 years Â Accrued royalty (in Dollars) | $ Â Â $ 3 Finance contract (in Euro) â‚¬ 20 Â Â Due date Jun. 01, 2026 Â Â Principal balance (in Dollars) | $ Â Â 21,390 Long-term liabilities (in Dollars) | $ Â Â Â $ 2,637 Annual Interest [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Annual interest percentage 4.00% Â Â Minimum [Member] | Royalties [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Consolidated revenues percentage Â Â 0.20% Maximum [Member] | Royalties [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Consolidated revenues percentage Â Â 2.30% First Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â‚¬ 20 Â Annual interest rate Â Â 4.00% Percentage of deferred interest rate Â Â 4.00% Two Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â 18 Â Annual interest rate Â Â 4.00% Percentage of deferred interest rate Â Â 3.00% Percentage of fixed interest rate Â Â 1.00% Three Tranche [Member] Â Â Â Loan from the EIB [Line Items] Â Â Â Subsidiary obtain loan amount (in Euro) Â â‚¬ 12 Â Annual interest rate Â Â 3.00% Percentage of deferred interest rate Â Â 2.00% Percentage of fixed interest rate Â Â 1.00% X - DefinitionContractual interest rate for funds borrowed, under the loan agreement. + ReferencesNo definition available. + Details Name: plur_ContractualInterestRateForFundsBorrowed Namespace Prefix: plur_ Data Type: dtr:percentItemType

Balance Type: na Period Type: duration X - DefinitionPercentage of deferred interest rate. + ReferencesNo definition available. + Details Name: plur_DeferredInterestRatePercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionDue date. + ReferencesNo definition available. + Details Name: plur_DueDate Namespace Prefix: plur_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionFinance contract period. + ReferencesNo definition available. + Details Name: plur_FinanceContractPeriod Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of fixed interest rate. + ReferencesNo definition available. + Details Name: plur_FixedInterestRate Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of principal of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalancePrincipalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities. + ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=plur_AnnualInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plur_RoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - USD ($) $ in Thousands 12 Months Ended Sep. 30, 2017 Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies [Line Items] Â Â Â Cash and restricted cash Â $ 888 Â Percentage of qualified expenditures eligible for grant Â 50.00% Â Royalty rate Â 3.00% Â Royalty payable based on grants received Â 100.00% Â Contingent liability in respect to royalties Â $ 27,565 Â Marketing and business development activities $ 229 Â Â Royalties revenues percentage 5.00% Â Â Spread period 5 years Â Â Aggregate royalty amount Â Â $ 180 Ichilov Hospital [Member] Â Â Â Commitments and Contingencies [Line Items] Â Â Â Royalty payable based on grants received 1.00% Â Â Aggregate royalty amount $ 500 Â Â X - DefinitionThe amount of contingent liability in respect to royalties. + ReferencesNo definition available. + Details Name: plur_ContingentLiabilityInRespectToRoyalties Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: plur_MarketingAndBusinessDevelopmentActivities Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage Of Qualified Expenditures. + ReferencesNo definition available. + Details Name: plur_PercentageOfQualifiedExpenditures Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_RoyaltiesRevenuesPercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty payable based on grants received. + ReferencesNo definition available. + Details Name: plur_RoyaltyRatePayableOnGrantsReceived Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects. + ReferencesNo definition available. + Details Name: plur_RoyaltyRateSales Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_SpreadPeriod Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount the entity has committed to make for future royalty guarantees. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1 + Details Name: us-gaap_RoyaltyGuaranteesCommitmentsAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=plur_TelAvivSouraskyMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) - USD ($) 1 Months Ended 6 Months Ended 12 Months Ended May 28, 2024 Apr. 30, 2024 Feb. 13, 2024 Aug. 31, 2023 Dec. 27, 2022 Dec. 19, 2022 Dec. 15, 2022 Dec. 14, 2022 Dec. 13, 2022 Mar. 30, 2027 Dec. 31, 2022 Jun. 30, 2024 Jun. 30, 2023 Jan. 31, 2027 Jun. 30, 2025 May 01, 2023 Jan. 05, 2022 Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 37,500,000 [1] 37,500,000 [1] Â Â 37,500,000 Â Common stock, par value (in Dollars per share) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0.00001 [1] $ 0.00001 [1] Â Â $ 0.00001 Â Preferred stock, shares authorized Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,000,000 Â Preferred stock, par value (in Dollars per share) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0.00001 Â Purchase of aggregate Â Â Â Â 1,019,488 Â Â Â 1,019,488 Â Â Â Â Â Â Â Â 187,500 Purchase price per share (in Dollars per share) Â Â Â Â $ 8.96 $ 8.72 $ 8.48 $ 8.4 $ 8.24 Â Â Â Â Â Â Â Â Common shares Â Â Â Â 16,875 16,875 29,688 258,565 697,485 Â Â Â Â Â Â Â Â Warrants to purchase Â Â Â Â 16,875 16,875 29,688 258,565 697,485 Â Â Â Â Â Â Â Â Exercise price per share (in Dollars per share) Â $ 5.93 Â Â $ 8.96 $ 8.72 $ 8.48 $ 8.4 $ 8.24 Â Â Â Â Â Â Â Â Warrant term Â Â Â Â 3 years 3 years 3 years 3 years Â Â 3 years Â Â Â Â Â Aggregate offering price (in Dollars) Â Â $ 10,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 445,000 Â Â Â Â Â Aggregate amount receives (in Dollars) Â Â Â $ 2,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common shares future grants Â Â Â Â Â Â Â Â Â Â Â Â 642,650 Â Â Â Â Â Aggregate intrinsic value of these options (in Dollars) $ 2,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Annual cash salary (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 375,000,000 Â Â Â Â Â Exercise price per share (in Dollars per share) Â Â Â Â Â Â Â Â Â $ 8.96 Â Â Â Â Â CEO's grant agreements, description Â Â Â Â Â Â Â Â Â Â Â In addition, the Board also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.80 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023. Â Â Â Â Â Granted shares Â Â Â Â Â Â Â Â Â Â Â Â 357,936 Â Â Â Â Â Shareholdersâ€™ equity (in Dollars) 35,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Income (in Dollars) $ 500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Equity Option [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Granted shares Â Â Â Â Â Â Â Â Â Â Â Â 41,853 Â Â Â Â Common Member [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7,500,000 Â RSUs [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â General and administrative expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 58,000 $ 273,000 Â Â Â Â Yaky Yanay [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â RSUs shares Â Â Â Â Â Â Â Â Â Â Â Â 41,853 Â Â Â Â Yaky Yanay [Member] | Equity Option [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Option granted Â Â Â Â Â Â Â Â Â Â Â Â 41,853 Â Â Â Â Â Options to consultants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â General and administrative expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 9,000 Â Â Â Â Â Options to consultants [Member] | Equity Option [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â General and administrative expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â 6,000 Â Â Â Â Director and Chief Executive Officer [Member] | Equity Option [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate intrinsic value of these options (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Â Â CEO and Directors [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â General and administrative expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 220,000 $ 568,000 Â Â Â Â Forecast [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unamortized compensation expenses (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 20,000 Â Â Â Â Â Â Â Unamortized compensation expense (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 21,000 Â Â Forecast [Member] | RSUs [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unamortized compensation expense (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 848,000 Â Â Â Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate offering price (in Dollars) Â Â Â Â Â Â Â Â Â Â Â Â $ 8,024,000 Â Â Â Â Â Â Private Placement [Member] | Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common shares Â Â Â Â Â Â Â Â Â Â Â Â 1,019,488 Â Â Â Â Â Sales Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shareholders" Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common shares Â 42,729 Â Â Â Â Â Â Â Â Â Â Â Â Â Â [1] See note 1d regarding reverse share split X - DefinitionAmount of aggregate amount received. + ReferencesNo definition available. + Details Name: plur_AggregateAmountReceived Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate gross proceeds. + ReferencesNo definition available. + Details Name: plur_AggregateGrossProceeds Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAnnual cash salary. + ReferencesNo definition available. + Details Name: plur_AnnualCashSalary Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCEO's grant agreements, description. + ReferencesNo definition available. + Details Name: plur_CEOsGrantAgreementsDescription Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGranted shares. + ReferencesNo definition available. + Details Name: plur_GrantedShares Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet income. + ReferencesNo definition available. + Details Name: plur_NetIncome Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnamortized compensation expenses. + ReferencesNo definition available. + Details Name: plur_UnamortizedCompensationExpenses Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of common units issued of limited liability company (LLC). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonUnitIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the charge against earnings during the period for commitment fees and debt issuance expenses. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. + ReferencesNo definition available. + Details Name: us-gaap_ExcessStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of general and administrative expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThis element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. + ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceIncrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_YakyYanayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_OptionsToConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_DirectorAndChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_CEOAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plur_SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee - USD ($) 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Options to consultants [Member] Â Â Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Line Items] Â Â Share options outstanding at beginning of period number [1] 8,100 11,381 Share options outstanding at beginning of period weighted average exercise price $ 7.44 $ 10.56 Share options outstanding at beginning of period weighted average remaining contractual terms (in years) 6 years 2 months 26 days 7 years 18 days Share options outstanding at beginning of period Aggregate intrinsic value price $ 29 $ 44 Share options granted number [1] 9,375 Â Share options granted Weighted average exercise price $ 4.4 Â Share options granted Weighted average remaining contractual terms (in years) 4 years 6 months 21 days Â Share options granted Aggregate intrinsic value price $ 13 Â Share options forfeited number [1] Â (3,281) Share options forfeited weighted average exercise price Â $ 18.32 Share options forfeited weighted average remaining contractual terms Â Share options forfeited Aggregate intrinsic value price Â Share options outstanding at end of the period number [1] 17,475 8,100 Share options outstanding at end of the period weighted average exercise price $ 5.8 $ 7.44 Share options outstanding at end of the period weighted average remaining contractual terms (in years) 4 years 10 months 13 days 6 years 2 months 26 days Share options outstanding at end of the period Aggregate intrinsic value price $ 42 $ 29 Share options exercisable at the end of the period number [1] 8,100 7,475 Share options exercisable at the end of the period weighted average exercise price $ 7.41 $ 6.69 Share options exercisable at the end of the period weighted average remaining contractual terms (in years) 5 years 2 months 26 days 6 years 21 days Share options exercisable at the end of the period Aggregate intrinsic value price $ 29 $ 29 Share options unvested Number [1] 9,375 625 Share options unvested Weighted average exercise price $ 4.4 $ 16 Share options unvested Weighted average remaining contractual terms (in years) 4 years 6 months 21 days 8 years 5 months 8 days Share options unvested Aggregate intrinsic value price $ 13 Â Share options vested and expected to vest at the end of the period Number [1] 17,475 8,100 Share options vested and expected to vest at the end of the period Weighted average exercise price $ 5.8 $ 7.44 Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years) 4 years 10 months 13 days 6 years 2 months 26 days Share options vested and expected to vest at the end of the period Aggregate intrinsic value price $ 42 $ 29 CEO and directors [Member] Â Â Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Line Items] Â Â Share options outstanding at beginning of period number [1] 229,353 Share options outstanding at beginning of period weighted average exercise price $ 15.2 Share options outstanding at beginning of period weighted average remaining contractual terms (in years) 3 years 5 months 19 days Share options granted number [1] 12,500 229,353 Share options granted Weighted average exercise price $ 6.08 $ 15.2 Share options granted Weighted average remaining contractual terms (in years) 6 years 8 months 23 days 3 years 5 months 19 days Share options forfeited number [1] (1,562) Â Share options forfeited weighted average exercise price $ 6.08 Â Share options forfeited weighted average remaining contractual terms Â Share options outstanding at end of the period number [1] 240,291 229,353 Share options outstanding at end of the period weighted average exercise price $ 14.82 $ 15.2 Share options outstanding at end of the period weighted average remaining contractual terms (in years) 2 years 5 months 1 day 3 years 5 months 19 days Share options exercisable at the end of the period number [1] 240,291 114,676 Share options exercisable at the end of the period weighted average exercise price $ 14.82 $ 15.2 Share options exercisable at the end of the period weighted average remaining contractual terms (in years) 2 years 5 months 1 day 3 years 5 months 19 days Share options unvested Number [1] Â 114,677 Share options unvested Weighted average exercise price Â $ 15.2 Share options unvested Weighted average remaining contractual terms (in years) Â 3 years 5 months 19 days Share options vested and expected to vest at the end of the period Number [1] Â 229,353 Share options vested and expected to vest at the end of the period Weighted average exercise price Â $ 15.2 Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years) Â 3 years 5 months 19 days [1] See note 1d regarding reverse share split X - DefinitionAggregate Intrinsic Value Price, Share options granted. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare options unvested number. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedInPeriod Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare options unvested Weighted average exercise price. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodWeightedAverageExercisePrice Namespace Prefix: plur_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionShare options forfeited aggregate intrinsic value price. + ReferencesNo definition available. + Details Name: plur_ShareOptionsForfeitedAggregateIntrinsicValuePrice Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionShare options forfeited weighted average remaining contractual terms. + ReferencesNo definition available. + Details Name: plur_ShareOptionsForfeitedWeightedAverageRemainingContractualTermsinYears Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare options granted Weighted average remaining contractual terms (in years) + ReferencesNo definition available. + Details Name: plur_ShareOptionsGrantedWeightedAverageRemainingContractualTermsinYears Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare options unvested aggregate intrinsic value price + ReferencesNo definition available. + Details Name: plur_ShareOptionsUnvestedAggregateIntrinsicValuePrice Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted Average Remaining Contractual Terms, Share options outstanding. + ReferencesNo definition available. + Details Name: plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare options unvested Weighted average remaining contractual terms. + ReferencesNo definition available. + Details Name: plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1 Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_ShareholdersEquityDetailsScheduleofShareOptionsGrantedNonemployeeLineItems Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=plur_OptionsToConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plur_CEOAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted - shares 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 RSUs to Employees and Directors [Member] Â Â Schedule of Activity Related to Unvested RSUs Granted [Line Items] Â Â Unvested at the beginning of period [1] 207,199 241,877 Granted [1] 395,327 41,853 Forfeited [1] (132,400) (6,424) Vested [1] (116,992) (70,107) Unvested at the end of the period [1] 353,134 207,199 Expected to vest after the end of period [1] 319,533 205,072 RS and RSUs to Consultants [Member] Â Â Schedule of Activity Related to Unvested RSUs Granted [Line Items] Â Â Unvested at the beginning of period [1] 2,500 5,157 Granted [1] 27,270 Vested [1] (24,968) (2,657) Unvested at the end of the period [1] 4,802 2,500 [1] See note 1d regarding reverse share split X - ReferencesNo definition available. + Details Name: plur_ScheduleOfActivityRelatedToUnvestedRSUsGrantedLineItems Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=plur_RSUsToEmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plur_RSAndRSUsToConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) - Schedule of Expenses Related to RSUs Granted - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses $ 170 $ 205 Employees and Directors [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses 1,574 2,205 Research and development expenses [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses 1 Research and development expenses [Member] | Employees and Directors [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses 316 55 General and administrative expenses [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses 170 204 General and administrative expenses [Member] | Employees and Directors [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation expenses $ 1,258 $ 2,150 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=plur_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) - Schedule of Warrants and Options 12 Months Ended Jun. 30, 2024 $ / shares shares Class of Warrant or Right [Line Items] Â Warrants for common share 1,019,488 Warrants exercisable for common share 1,019,488 [1] Options for common share 257,766 Option for common share exercisable 248,391 [1] Options and warrants for common share 1,277,254 Options and warrants exercisable for common share 1,267,879 [1] 8.24 [Member] | Warrant [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.24 Warrants for common share 697,485 Warrants exercisable for common share 697,485 [1] Weighted average remaining contractual terms (in years) 1 year 6 months 18 days 8.40 [Member] | Warrant [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.4 Warrants for common share 258,565 Warrants exercisable for common share 258,565 [1] Weighted average remaining contractual terms (in years) 1 year 9 months 25 days 8.48 [Member] | Warrant [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.48 Warrants for common share 29,688 Warrants exercisable for common share 29,688 [1] Weighted average remaining contractual terms (in years) 1 year 5 months 19 days 8.72 [Member] | Warrant [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.72 Warrants for common share 16,875 Warrants exercisable for common share 16,875 [1] Weighted average remaining contractual terms (in years) 1 year 5 months 26 days 8.96 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.96 Options for common share 41,853 Option for common share exercisable 41,853 [1] Weighted average remaining contractual terms (in years) 2 years 14 days 8.96 [Member] | Warrant [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 8.96 Warrants for common share 16,875 Warrants exercisable for common share 16,875 [1] Weighted average remaining contractual terms (in years) 1 year 6 months 5.80 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 5.8 Options for common share 17,475 Option for common share exercisable 8,100 [1] Weighted average remaining contractual terms (in years) 4 years 10 months 13 days 12.48 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares

$ 12.48 Options for common share 62,500 Option for common share exercisable 62,500 [1] Weighted average remaining contractual terms (in years) 2 years 3 months 16.64 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 16.64 Options for common share 62,500 Option for common share exercisable 62,500 [1] Weighted average remaining contractual terms (in years) 2 years 3 months 20.80 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 20.8 Options for common share 62,500 Option for common share exercisable 62,500 [1] Weighted average remaining contractual terms (in years) 2 years 3 months 6.08 [Member] | Share-Based Payment Arrangement, Option [Member] Â Class of Warrant or Right [Line Items] Â Weighted average exercise price per share (in Dollars per share) | $ / shares $ 6.08 Options for common share 10,938 Option for common share exercisable 10,938 [1] Weighted average remaining contractual terms (in years) 6 years 8 months 23 days [1] See note 1d regarding reverse share split X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice Namespace Prefix: plur_ Data Type: dtr:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationShareAuthorizedUnderStockWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationSharesAuthorizedUnderStockOfWarrantsPlansExercisePriceRangeNumberOfExercisableWarrants Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock option and warrants as of the balance sheet date for all options and warrants plans in the customized range of exercise prices. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationSharesAuthorizedUnderStockOptionAndWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionOptions and warrants exercisable for common share. + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationSharesAuthorizedUnderStockOptionsAndWarrantsPlansExercisePriceRangeNumberOfExercisableOptionsAndWarrants Namespace Prefix: plur_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual terms (in years) + ReferencesNo definition available. + Details Name: plur_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: plur_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_EightPointTwoFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_EightPointFourZeroMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_EightPointFourEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_EightPointSevenTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_EightPointNineSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_FivePointEightZeroMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_TwelvePointFourEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_SixteenPointSixFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_TwentyPointEightZeroMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plur_SixPointZeroEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), Net - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Schedule of Financial Income (Expenses), Net [Abstract] Â Â Foreign currency translation differences, net $ 126 $ (1,709) Bank and broker commissions 92 (16) Interest income on deposits and restricted bank deposits 1,314 1,084 Income (loss) from hedging derivatives 148 (157) Financial income (expenses), net 1,680 (798) EIB loan interest expenses (866) (843) Total $ 814 $ (1,641) X - DefinitionThe amount of bank and broker commissions. + ReferencesNo definition available. + Details Name: plur_BankAndBrokerCommissions Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from increase (decrease) in fair value of foreign currency derivative and nonderivative instruments designated as fair value hedge recognized in earnings and from related hedged item to extent that fair value hedge was determined to be effective. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_GainLossOnForeignCurrencyFairValueHedgeDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeDepositsWithFinancialInstitutions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Taxes on Income (Details) $ in Thousands, â‚ª in Billions 1 Months Ended 12 Months Ended Dec. 31, 2017 Dec. 31, 2016 Jun. 30, 2024 USD ($) Jun. 30, 2024 ILS (â‚ª) Jun. 30, 2023 Taxes on Income [Line Items] Â Â Â Â Â Net income rate 80.00% Â Â Â Â Tax rate Â Â 23.00% 23.00% 23.00% Revenue rate Â Â 6.00% 6.00% Â Global revenue Â Â $ 2,900,000 â‚ª 10 Â Income tax regular tax rate Â Â 23.00% 23.00% Â Trade tax base Â Â 3.50% 3.50% Â Municipality of potsdam percentage Â Â 455.00% 455.00% Â Net operating loss carryforward (in Dollars) Â Â $ 31,414 Â Â Accumulated losses (in Dollars) Â Â $ 129,286 Â Â Effective tax carried forward Â Â 0.00% 0.00% Â Pluri [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Tax rate Â Â 23.00% 23.00% Â Pluri [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Federal tax rate Â Â 21.00% 21.00% Â Technological Preferred Enterprise [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Global revenue | â‚ª Â Â Â â‚ª 10 Â German Corporation Tax [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Trade tax base Â Â 15.93% 15.93% Â Pluri Inc. [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Accumulated losses carry forward (in Dollars) Â Â $ 144,906 Â Â German Subsidiary [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Accumulated losses carry forward (in Dollars) Â Â $ 601 Â Â Maximum [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Percentage of preferred income tax rate Â 16.00% Â Â Â Foreign entity investors reduction rate Â Â 90.00% 90.00% Â Statutory tax rate Â Â 23.00% 23.00% 23.00% Maximum [Member] | Technological Preferred Enterprise [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Revenue rate Â Â 12.00% 12.00% Â Minimum [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Percentage of preferred income tax rate Â 7.50% Â Â Â Foreign entity investors reduction rate Â Â 4.00% 4.00% Â Statutory tax rate Â Â 21.00% 21.00% 21.00% Minimum [Member] | Technological Preferred Enterprise [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Revenue rate Â Â 7.50% 7.50% Â German Corporation Tax [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Federal tax rate Â Â 15.00% 15.00% Â German Corporation Tax [Member] | Maximum [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Percentage of corporate tax rate Â Â 15.00% 15.00% Â German Corporation Tax [Member] | Minimum [Member] Â Â Â Â Â Taxes on Income [Line Items] Â Â Â Â Â Percentage of corporate tax rate Â Â 5.50% 5.50% Â X - DefinitionAmount of accumulated losses carried forward. + ReferencesNo definition available. + Details Name: plur_AccumulatedLosseCarriedForward Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated losses. + ReferencesNo definition available. + Details Name: plur_AccumulatedLosses Namespace Prefix: plur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of corporate tax rate. + ReferencesNo definition available. + Details Name: plur_CorporateTaxRate Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of effective tax rate loss carryforward. + ReferencesNo definition available. + Details Name: plur_EffectiveTaxRateLosSCarryforwardPercentage Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of income tax regular tax rate. + ReferencesNo definition available. + Details Name: plur_IncomeTaxRegularTaxRate Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of municipality of postdam. + ReferencesNo definition available. + Details Name: plur_MunicipalityOfPotsdam Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of preferred income tax rate. + ReferencesNo definition available. + Details Name:

plur_PreferredIncomeTaxRate Namespace Prefix: plur_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: plur_TaxesonIncomeDetailsLineItems Namespace Prefix: plur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionBase rate for management and service fees under arrangement to manage operations, including, but not limited to, investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ManagementAndServiceFeesBaseRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOther costs incurred during the reporting period related to other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherCostOfOperatingRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plur_PluriMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_PluriMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_TechnologicalPreferredEnterpriseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_GermanCorporationTaxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_PluriIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plur_GermanSubsidiaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=plur_GermanCorporationTaxMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Taxes on Income (Details) - Schedule of Loss Before Income Taxes - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Schedule of Loss Before Income Taxes [Line Items] Â Â Loss before income taxes $ 21,344 $ 28,887 Consolidated loss of Pluri Inc. and the Israeli Subsidiaries [Member] Â Â Schedule of Loss Before Income Taxes [Line Items] Â Â Loss before income taxes 21,339 28,878 Pluristem GmbH [Member] Â Â Schedule of Loss Before Income Taxes [Line Items] Â Â Loss before income taxes $ 5 $ 9 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37:

http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=plur_ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=plur_PluristemGmbHMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Taxes on Income (Details) - Schedule of Deferred Income Taxes - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Deferred tax assets: Â Â Operating loss carryforwards $ 69,852 $ 80,534 Research and development credit carryforwards 3,780 4,057 Issuance costs 25 68 Allowances and reserves 173 237 Total deferred tax assets before valuation allowance 73,830 84,896 Valuation allowance (73,830) (84,896) Net deferred tax asset X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredTaxAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (Z ,ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^Ö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Ü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Ä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{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

=8'3[0CVBQVVY3 M>T &*!.NXE2HG;1$S-(L"ZKYH"!H)#AO/N9Y)VW/BE)3=!,:EY>@MIM+,D2 M[EW'!2XO<>:I*S*H(6-!R5R"9N;RQ=*6YPU/;C,:)5>F(=N%J5AJRFU_=K=*
M_1,S=,ZKHNH&NT?&*5^=@W/<#9/W]GA;(;L9G1^(%D^+(_2Q/3BN/+_IY(\ M(+Q4DY_+?Z42R(="*5N!RNZG 1@D\Z/N_$:+K3TM7@JMQ<9>KAE-F#0"\'XE MA'Z^,1\H_N%@]']02P,$% @
#H R674&ULK5I9<]LX$G[WKT!YG*VDBI8E63XFAZN< MQ,ED*EF.P/ MG93+5_OG^R)1"UEEY3>S^44%>4Z(7FPRQW_%QJ^=_+POXLJ5)@^;P4&N"_^_MO UZZ&PX']^S81HV3)EO?
Q!S^5:6\N*E-1MA:36HT06+RKO!G"[(*-]+B[<: M^\]+]ZI05F8OCTH0HT='<=CXVF^X'#6<#A[B/K%^ZO/5]\N/PZQ]?#&SU^N MK\3DN3&4@<2>'(FO666U^%#$(_&4HS7+[L1-83;P?>??
NE+EXGH)M:Q45>K8 M\?)GD9#BLUK+1(K8V)6QDB{F$AOLTT7]2"4"8?1)WHQ)A(PTGG3/_-=/Y[)/ MV0L'"GF.=6XIH3 !Q2>*]I5+)3Y+E\@?XHURB)5HH)O6=
[K[O(YHH..F8Y??/WXVS>^G+SH";X$QU)LEH9D MA^3@V55SIQ,-Q(G\RL/7VI0J7HJ/91)4I>RPJFC%,V$\!]\[A#9+#0)Z2STM MMYG<.&$6?E^)EW3SP5FILA$X%;_*H@(A%2U=S64)E3Z?
CR<^(TX\ZUR3O5VE+H)M;ZA6KE'>R MQ1!4V$D0^@A[W1LH;\QOOA923NK5:^BQCE2;H#3(DVOD_Y4@5>DUKX^97C=Z MMQF.AAUYP4+(OD6K
#Q4+RAKR>"&_(D(!>AX8_(5W#N@!TE68PHQ,JJ?7S^. MEUVDPJF4'+_/ 6%JL!\[3E7H M'Y4BAU;JL*G0X/X#1^[A#W.%H ,Q+N5JKG6()NQTL\6+I MD*60H\"D-7EG-?I
Y^/AV)M]YH1.P.YA6*JOP'CFI%#N*!L8/I M)#J>S;Q&X+:[TCX@+!6?!Y/S:#R=_!^",N6YS @/G7C*M^PO=$&RKN'V1>DB M*,/8$JAJR,9P^$JNV1 @A,USE>-)MW#
$4:>C28/$=Z;],N8NM1(W@:#'.%[E MJA4]@9*YKQ&!5_5 H34O0$*#MICZ]+.X(V.HH;7]7396!G (E-?H\T5V%NK M ':#N@-[J6+]<.KACDNP4<<)VU8)BG&@L0C5=&Q."YC0J8;NAEDJ#
MX7Q>Y\RL1 (;@Y=,2>Q3 M0?;8>R[KWQ)/HJ#RQ2$#@K5(+%%.()-$7N _=K36CA]F]DBC;HQFZ,AYN2*[9":\RJ\GAH9L)UH5\<]^I@OA;A< M69W5(#:^IZ[TD:X2'^BR@8LZXNHF[UUXWE0;
[.#TYNK#:T! 9S%].QR&>9'@R$XS^:X"#U:FO!0[!7Q/2*D4!; # M8S;"Z:G;*RYH(""XUE1O(I@E8Z9_8DJ' E==)* GU!Z2N9U>A3[TW(V2Z MN.'ZHM[F\W$X!ZG<5@SBG"
(XRW"FFB'1G/FUY#6(.A\C"-2TXWB9EG,J-@G" MGCJE$!7PY[-G(P'S?J.(@'MQGA5NA75#+=DVFKTVTC(VO(6_Q6CW7*-A?A7Y M2F/-(3LY1#0H'Y/^@.8%B_QT_HQ1A\L=L%*5 M@):"TT%OM3?
VT-%S%4M 7UM&FMK5O>UGL!A@H4>-PHACB"9-MLTK+?J3PW,Y M2^$)E:!S1Y [CE8.C2UZ,.:&RD7\3U4(P:Y_%_DR>*X4H=!_4?CY@$V)5:M* M:_QX. A
K\JE=H.B,J+C$(_I'6>!B$0]T:7OAT[/(D3.UD!LPVA:Q%F5<'P/ M6NP>6P02/.^"!?H:!,F 0>O3ZL%HAG\@XG!X6LYJHSU?W;"^'+3H2BO&JG@"= M1/<,@?I(]:O!A?
@=3RM0NAP:I0RC4H12#,SISK*FCN9H28AW.+JO2F[+$W\?6^& MP[D]:BR(P^#]JB1YVFXM8B#*Z),$H1\M@G=[B6GVA:2ZTY]NB3$*JM$(#/;B M@[/H9#RF;8-CD4:TR;E?")+;"QNNC84C$
M>>(PW/6X^D[-K1\@SFK_J2Lj!"@1?0O).#G7@5./P1K&&VR HKW4 IY.WM:+ MMJ '0VP]4'#Q(+#N;/I,7+/:+>B'(Z,VS]+3/_S3.CK!07!H) 9=DBW\/5[M(^,E51J>T\GT)!H3KZ);R0*92:4FG=2-
,XSH"6^N8+6!L\ M+FE[E].I#ZDM+9"'!O*M-S8>REHYF-:@U.,N&N3'1U[?V@TD;05">R KB/'O M%*<.T?A[T='MW9'F3=ZB_2;0/]KE"+E2>N\(4A]Q- M(A^&B1*SY%N/SV\^M-K>+DZ[4T0_^-
#\G;=POO;TGRRZ#QP[MW18V1H/!/8 M1V"9M.#61:: /U>VM*BAKE*4\)ZO%5@7"*$ZX]?=H:K(X:ZK(NLQZFVV! METV=?F](V#TA H52^1H]?&,,F-
56(3LI,OC1;5V9X#@@^^YDJ%^C4!/E9WT4 M]"YD!/[\YC^9P]&P[%VOS.DPV@4.*%9F<9AK#T/'9AHU_M;2 $G!,+Y MXD6R,89L]??19#AX_B%,8=?->9C5X8*_A82@?U G7+35):A[?B\@'(^F)X\
MA+.Q>/(HE-M[%,KYH/AGL,[/A-K:G!QKSSM6)UOQA/_X_(13W&<4[EQV40BW M2:YQP*^)E27\/U.\4*)=!*-)S/?:M?^I*X&;#!55[+'(V;#]D>\YW+2"Q\ MSN7!U;0>+>T>WF]\@Y'JZFOK1P3;'[8]
[G!_S\'L^QICAYK3G7J91R19%NT8 ME!R3_&3-A6 F8Q4^HBWXLT'D1Q=-J9A:GI%8$X.^'X--QM2G\'2-OA\T^;&A ML-6JMUWH))J>^(WU<.&^#S2^/^QG *2,@_/H[&3,%:(/_P.QC6-Q@,)!KNHH
M:,;M/,^EGY/T/M.=^@ZVH^71T"^YCCH_JE6?$/].:F+$W.ETLEH1M:@/>(MKK*^H0.:7VQ>_]02P,$% @ #H R6&ULK3UK[)9=-:0E2I9E.W&5 MK-A9I1S;9]E[=75U'T .2"(>SC"#&-
NTW^Q:ZTY^WU2U_>G1NNNV+Y\^M8NUWB@[;;:ZAB?+IMVH#KZVJZ=VVVI5 MTDN;ZNGLZ.CLZ4:9^M'K'^FW3^WK'YN^JZTM/[72]IN-:G=O=-7<_O3H^)'
MX;-9K3O\X>GK'[=JI:]U]W7[J85O3\,LI=GHVIJFEJU>_O3HXOCEFU,<3P/^ M8?2M33Y+Q&3>-_PRU7YTZ,C!$A7>M'A# K^N=&7NJIP(@#C#S?GH[DOIA^ M]K. (]P!E[FR^K*I_MN4W?
JG1^>/9*F7JJ^ZS\WMW[7#YQG.MV@J2_^7MSSV M].217/2V:S;N98!@8VK^5WUW=$A>.#\Z\,+,O3 CN'DA@O)GU:G7/[:-K6QQ M-,R&'PA5>AN ,S5NRG77PE,#[W6OK\VJ-DNS4'4G+Q:+IJ\
[4Z_DIZ8R"Z/M MCT\[6 2'/EVX"= _PA+,#$0[Y&]-W:VM?%N7NLPG> K0!1'G\0WLSMG_+6O MI_+DJ)"SH]GI'?.=1)1/:+Z3?PUE*;\7<]NP[=*X8]SWTZ/C>*T$N[50O]
MTR.0$:O;&_WH]=_^7'[^ M^'+ÜX1?YZ>/[J\NKM]=CX-X]X8>/7][*V4LYD?=,+=\H:ZQLEI+0JCM%,O5E MK>6BJ2V0KE2=+N72U*1>&%5)"T,T2&]GQ5K=:#G7NL:7MZJ%<0;E<=&T)8S6
MP/+=6G8PU]?:X"S7^*Z5O^A:MZJ]=KA->HM/TOUJ#:RTK;0M9-/*K]/KJ?SE MXN+35*JI_&HU JMM9S8T%T+*JS/D\' 45@ ,$$)E9[H= [8*8"@/AHI@; ,8 MH*/^Z V0!^2S!H6&$\JN@6_?=
(2DD+_WY8H6*Z2J82X+"G&+0%F@@>HD$$B MX8*R:K5-K>:5)IU3RGX+0)N:M3"ILQME*AH KR#M8'Z-'W8X 2Q:ZJE\& #'WP!4
M4+P&$.EQ2IBKD/.^DW73RQK>6Y%HB#JG<(&N"M_28LNAY&P^:!-K> :%\!&@96 M:N6R;38P:Y/").7SJ7S7UV1:X,5%W[:Z7NR(SX@5RZ;J5"N-)8"8]+LP#BF+ MOVM@MF9C%E+7-
Z9M:N(90.)V;18L$I<,+U,.OE_W_G,^.G[^RY9YD$8:'?VZ29&%$(BZZ 0ZE*UI05< M2M+=S((@]Q?7EX4\1_ .^,V.7H&Q!E-%#V'K>-R:< M3;@55$D#4@QHZ>\H:<"> @:H[;9M@(5HJQ?
31/7A9'&=AZMD>+ _J2\U"Q'2F MN88<9^#GE..F\@,P \S?M< 0N#6PJQK$!L8!VC9E3N KMA7,Z: ;0:/"H+RUJO%/K(PK,XH'!XFC_#Y:3C U8=6#<#8D>D/E'AQ>#$U,IR8T^U:=:ZNT75AI@@
M\J9T6 (M%QK(5J)RRI1!9Y-^A0% *]H%N0HE)ZC%F \R2*AH=3^5] W(/Q6 M1\D,XK5#U0[+ :XI=T_E%8+M3)QXB(+6;A9GY.+D2D3,"13>:GLFGD;/^!" M
"5M\>7P!^1"NP9D)VCCY1HBHFHG*@-#$,H;H"F,]H1H=4:53'&%RA"&D6(%0QR8*#L5(*FO(Z@S%7]#8S7MK$@ ML&^2+XZ5FM:L#!JDN!Z:Z W8$@2VSE=&IXF6ID<@[W*GP3CF.@=@8%E1-
Q^P6 M $FH,)4_>Q@&;Q)"!C6'[02[F0"OCMG#ER);V![B%M0$%&7(_N)F][MK3$ MO(X?X!, &3%.>6?$_$SEL2KZA5"N@.A*+%4B[#T1&-:07NT[B7Z37 M"C5JO>*]2I:;9RQS_Q QPKR1F0+'Y-
3S"A,@&Z" SR 1U3M80]R%ZAHW&4P! M*)S/P T0$Y..NI"D!F$O6#*4RT)H]$D,ZN*F!J&^!7OV4CXV3UC! :,;5JC. M)O ,I&<(/E2+P 3D:['_Y8I<#[00$*2;!0,_ MU\R)N.N!:@(-""N> RC@QEL#'O
"#)T/HW(S!D P M8YF.AP)(2.6NG4'H*6].\FZ 0&<2P56-"[T,2'_X2!R%\1[:;R M 1-@M3$H-6%1^C79(#R*=^JX'[E!@%^15%L@V"B30LFWZ%:-^VA$UK;FFV3F_M2_&WO[PX MO>0OZ)ZN,'3+X!,
FQVDY8EH)B1].IR&NCRE3YA,CVD?GLAGD^?R1'PV]MMDB8EPGT:D")$F M/IT>G4Y.I\P79(W:0 ."/8.E-[9(${LBI&;,JHKIG M<;!E0D2#@L9F:W)".YBFP9:5?
8A<$T9A)1O%\VRRUM5RM]P::C88;9&V#^0GM MW(W#@!R,?G_A'0U6/]3?KVRK0+"NZKJY80I>]." M 8C5!?P7UU=% >3ARS% M]IA] !?O:\W5U -(M48FR[4R/LMBC)A5_!Y[X)[P#
!T5TG_C"0MNB?F@7,O)%3B,X)>SF@<^UNV* M,S57]9):17LK?P8-JZSK+$/8/EQ=7/W,K4*1.Y'S:'UFD,]7UY\^3Z[>BPA@ MX=.4:K7'.D2GTZQ'K-L +_UP7!R#\B3+-BM.9V=%%R*\SU36V4\]?
^UJ'9L@D M"M^S?>(NDF/5&W,:3H4!'+}3]GH@1X/.LK#+Z +[@0[ZC6A7*X\2@6(95C:]QYHO"]//T0VR(P M=M[SL /AEFVXER,Z>-1RN7".>$5M'54^P%A21+U+.)6@YVE+70[&
MI8;V'+*ZW\PYF9J['$W?8=:.IG#.F"=;:O. "ZQ5 MQ8Q+!5BNU%(K#7#WA*; ,B2E0\AW7/IJD\'B4RC(LH+NF@[4"U,WI&=L&LR1
M8Y5@' #.NB<)]SN1)" -8X@L/F",LO>>C6E%CHOFYDFT0L*&\)^*XQ=\M.IQ M\1R8\L7I^;^A=FIL.*#V)O)KQ#'6+WS-C3R=]+$O!#,#!^^9DZ3X'*L1A4* M5\ DFC"U(%3F&QH'4PC?8-
LC[FCP)3E=-Q0RW M9Z';##FLLU.EGTMT^F&GL_4L"\:7^"5_A&^L1)\ ->$BF(I.UIK& X!ON"2^YE M>4^/IFE7Z:HW/+:W+.:7^=7RX7E0*S6/I>S:0*$)Y@ M.H:V4
.!4/505_$\)L9'>^@"=XG83>?]#%>DBODTE:0#V59'&%EUP"8' LN4 MP-3'@7V]["&\-.&%[U_:GN+LS*J^KL*-'.6!UXBT7 ^.X4@62:FTXLUAR$; M4*FQS\VO-)7-%'
%\#'^\=OA^HE:"$;ENZ1W*>8!B:.W#7*_P<9] 3'4[[[9 M(70A4GHJ3FV'V$+%1 MV:C?*=XYD)\2_P8TL9^>Y]' "K3!C6LG2+'>!OMF/>#OA4G7JL/>0Y?0J?< MFC-9H(J-
O;@3M9K&7@"LZ[O6*^$DQ"CAUXXYV;& M5'7"/"WUR+*H-[(OQ/'IWI2P*=A^4^P_'MU6\CC%VSX=]\+RLM@ M+HDV@VJ6&5[DLX*/4*F%YE[Z^+Q)6DN^NL[:,)F'=]F#ILW+MQ[OL(?4DXHZ
M#O-/N^BL4H-A**]P!+XYF#KC(N$(PB^M2_OE=O0P0FNBJ1H<68NGQAQP90#) M-V7 ?7T'4/Z/^K:#_]5J5XPR^N7:Z*5\^QTB$Q+8N7.F#;QY^?8CMF T67^H MX5,4=S+_"-/3SZ&//:5>(]:[/-
TWH.T[5O;]]MN#=_7BC$1"GFAF"N8J+A M+KI:HHF-#3&8\(W\J.2; MY:A62.(1?Y]#04!AWL7$(R#H1'?0BTZVB>GMCZ12_Z.RI_8QZNJ[<'5TU*/ M388/&KQ#>XVSG$. .](Q3E'D,$\4K![*5[;]%L)L=
7([CD]M02GT'C#O*7]5Y[T/!X4]!'HS.D";'_F MZL-\>6SO=62]J.D4/C M(M9P22]Q,CW444* F3[R/?"Q#)/DZ-):H4\/,47@YW $6"0(1#?H0).#(=OE MSSN(=_,@/DG6X^_.0]3S67*0$0?\@P:\QE-F77A->
(/WW.UE7'.+Z3CG5L1S M^"!DO0YWR8@*2?MZ3@"NAU>;_C33,C[KHD:0M"HY;AY&K5-B[%CTLCKDR;N M4$+(]JX7U@RV$5*" 3>C78ZTZW$G &.4?18VF;O./7(T@YGW&##S<:N&RN@
MFV!'<"K4,X;EV;= A04 M(O_3]<:8>MMWKKSGM'8\EWT @?2^5L7- M?@*%!GV$'<L V7R9345&2AX::LROX6GJ.@&IU5V]R MYRX6N-($=QZZ+)K>G,0U9%1$]I9#3P%Y5Z03!PJUK4.N?K
M7B$NN0\SD6%FC7?H]R:BHR24YN,3GBC>6IVB4XNUE0-=1+&C+^;YW*$$2[7H M"?77^>,_CFREL7. &UN"YWIEZIK/Q+H<="C(1B9K@N4[[(2,)H2CS>3$ MMS\D&!B,M.SQLV
IXU(V/5483"7NT8*_8SV\)CA@/:V/GC7-ZD'C^;^@]1 M00S"V9AV10\O 7DTSLP-/C6$J_0L9&#M#0F]+#10S?AD@ I$B!3D\"WIO.]R M3>=]^UQ&PL28:I&#K@+O2RQWL257]+[OA?"V_,I5KLD[?
>%XQ=ID,^F%K.AE" M5S^XEB*JH3&4'SSAH M00G^=\A8NJ(S/+/+AZCI<;% UJD[:#T#PN52"2J7^1D2A7<<^ O#O38SRP[FM M99U3+L'#+-8?%_$;*_.-W=]6F[J#P.0"\\([*L*=
;2^STN0#Y*^G9>"(+C1 MI>$6]@Q)S![-TX\]C1[0MW.X:Z,$;^V'/#9\+#9:.$F>JKN=HYP84I"S#C# M@-5P"N.=BYE/V<0Z&-M8RO<$'?%'YO5PVI)^# M1UDD5@Q%+ 2F4?J3.41V/AD0"*=L-
!F/V)T3XI8\OG']:D.C6DR?N2IPA;"<% MFTV.$>LF4Z(97KBE-24#>.-,L)N&Y\%,'C M5R8^)PF&)[(3OS*,'-YT,C3^M 9J,.HXJ%F\N?F3Wx?>>^4E*+:.1^#3XG&^_M3IZ-I%NF^)7$63%470XZSIV(&Y
I046,U'(/ MNM- -)O98$^=":=DU?L=X3Y7OMP@UY7"<;:_*?_0(Y>+"7]/5L3H(#:[F# 8 M0P9/N)KB(!\1Q3$C;QSR*]VEMHN'(KT3G^_-/JM1MVQNHJA.GI]BY7 ['F+U M!?:44]
[G5R2X*Q<4W^2"EH=O]P="XWT=QS-_CX'K;]>(6<)W4@0?<%44%-:):[GQP#YW1]1=LL;N<'=L9*$(>D]A1I]0@ M]$E;@RZ2O(P_$4:FTYVK)"8O1FSK4%LR3#>@VFA[V_S@CV)AX?2! BY\JT*_
MY: KU@M2&LO,[ONP=Z]YO3. [V\#?]"=^D6-[<17)U2A*\X!G<]OCL9NB[& M+V)PJ8_0*47X[):$IFYZ),+@"6#7Y(*Z MC(0JF_W+#-/1X+5]E1_]9T='9]-CD\F0[LOKA(782(ON7G"74GU^$NS-
0MY M.CM[\C)-8.(&Y"_!L^A*)%/FJ< ?BB2>Q_&O>F@7]" M!>W=O?6: O;(HL(:O67N*[&+7[CP*_MLG8^Y2&7'LZ]\# 3U I6Z8B-/T@OF M>8'=O);V+!44TKKROMT A*+\5 MC;J[@\H[)N"QW?K ;%
(US3X-">^9!5(GJN@;IWKI!L6;P#PD3?UB-!A$!*-Z[>78$+Z"],' MX*(_0\79[XJ#A@A\("WDI0\ZZ)\X8O..*3VYTZEOS8%;SVA AX,G+CNU^C, ML$IU/..3)&E5.:"1]?Y22J9DK3S,K&IW:0O01PZ3.
(^#C8P[^G" XB/"D(;"AC6^5IB2CPO= *&=,9N='8$ZN MTAM': MQ&#D$EM],U<2^:'57@Y$T,700Q$4;K@7/W8E[-UK>]9UV>=P\:[G M2EVOD;E. MI_*MPB)@X$1#;>E\U=>>MHZE/#]7-
!3KBO*LF%VEZMA^VWUH1AYCS;S7SJ;= MU2YQY(KPVE\G#'8LX0YXSDA@$(_N >(@TN1R9J9R/G\1^9S;E06U*WL6?WXZ MQN*QL1E/)]W-VB^(M@LE!:GM*APO,'BPD8H^K
MW171%27,HY+%:".)^=#<[M<4%PU/K\"WS^XFX^%P=OTAZCO.BG!$]\[9:RU>]<&\R> !?A\(IP5U5:4 ^2 M[[<;SL(!8ZM=U#Y^K2Y=QSP5-WR82G!!#+Q3:HM**<4AO_7]5-$/':PS?I0"
M692;A[@_I%FX?+:,:M[C?F 7]F"#:-K? J=\D(QY2Q&SMIDI05E\\0Q]-XA M+L16QK=S3L?^\L#3Y$]&;'2[HC^,01>?UOW_l8CPJ_1 _>^." ^1$',Y_N,.W MU:
[P!NU*+^'5H^GS9X\X(>"_=,V6 @#%O.FZ9D,?UQKBG!8'P/-ETW3^"RX0 M_B+)Z ,\'4$L#!!0 (Z ,ED=ERI&PO=V]R:W-H M965T$&E6O*M)2J.-&F,]R)DSGH3-:,_=2+63(V:4T(#H_HG]NYK*G *:$-
="LN+@K!@46=G^Z?YP#R<._L-!W)P(WO-E##\HY*ZH\XVP'7 MU@I-3YI4&V]%+BNU*$O)U6FF_*0?<:QHED"X5S(+%$#+!!YEBARF->=82@B$ M0"E&EE3AM),5'Z G+31Y
]HA\.!*FOH(RP23OP$LQ:,C2XYD)^0BXI>ZO :7 M_@C$)MX%/+=+WFWPW/|-'KX':R&Y>D{_SMU#&\4[T67U5!4-.;QJ>I&('!! MT__PSNG;GR[DX'4Y>)?0 6@11L'L#L)O43A?ADL(YG?
PN+H/%S!]6BS"^0J" MY3)<+<\1OPA]GOC\<16".X0K^.?(AM(-M6Z&UDV+YQI!'+.Z5#?+.,<;LA:YS MA UG!=L?'RC?9J6 '#?*U;Z^Z9G VY[3 M+B2KFCI?,ZF2:::I:M/(M8$ZWS
FCPL=H&Q\A]02P,$% @ #H R69G, M\;Q# P 6P< !D !X;"]W;W)K&ULE57;;MLX M$'W75PS4H$]:ZV9+KFL;%-W%XO%/M#2V"(JB2I)Q?'?[Y"R'0=(
MC/1!O&GFS#E#"OE#%8@:GJJR5A.WT+H9^,[*"]R8ZHD&:_JS%K)BFJ9R MXZM&(LNM4U7Z41 D?L5X[4[*=FTAIV/1Z1+7N)"@VJIB)I=A.W-]+#SP M3:'-@C\=-VR#WU! ,Q:29OX1)>
<5UHJ+&B2N)^XL'%WVC;TU^(OC5IV.P2A9 M"?'#3&[RB1L80EABI@T"H^X1K[L#1#1^+G'=(\AC>/I^(#^N]5.6E9.X94H M_^;Y+B;NT(4QI MGX<3AV'PAD.T=X@L[RZ097G--)N.I=B"--
:$9@96JO4F8O M 7QB=]07'>A=1F<1_VCK'L2!!U$0]<_@Q4>YL<6+?UTN_#M;*2WIF/SWFO(_ MM_\ZKKDZ(]6P#".5_9 M2DBFA=P!'O(%Y!Z89+8GJ8H!F59-JU$JFV7*.&*E*P\<0F]-
!U0FPPCYWZ] MYAG"NI4UUZU$Z_5L2B;F<[XB7;|"E#GPJI'B$G">.#,LJRMVI)IS.G2TAYEG)FR\(:@Q$O" ;7]-R?F"2F4-X@#MXG M)GR_&/8&C:ZU,(?*+BKI"45:*M300M MX"
(:QY!N8B3"*CN@RX0=L@H VCN-1P.A[V5-J Y(!X5:=6@+;/EK@>SL@2Q MMLXFA:S>??PPC,+TLX)F3]9YF1NNH!295O.&73GKKF M!Z%%#*(%QM9-:T$MW31->S#)0:(Z<6H[I?
WO=W9"QB2*M)?8Y[O[-TYWXUW M0CZH#%'#<\%+-7$RK:N1ZZHDPX*15[B4H*JBX+)ERERL9LXOK_N,VWF38';C2NV!;04-l7 M2TF6VZ&D>8&ERD4)$C<3) 9'T]#$VX#O.>
[4P1Y,)6LA'HSQ)9TXGB&$'!-M M$!@M3SA#$@T0T7AL,9WN2I-XN-^C?[*U4RUKIG F^(\\U=G$&3J0XH;57-^* MW16V]0P,7B*XLE_8-:,']T(&D5EH4;3(Q*/*R6=ESVX>#A*'W2D+0)@26=W.1 M9?
F1:1:-I=B!--&$9C:V5)M-Y/+2/,J=EN3-*4|"YVAA#A)1%UJ!4OVPM8< MQZXF;!/A)BW.M,$)7L'Q [@6\, M B\(3^#UNTK[%]__7Y7"KWBMM*2?X_>QHAO(\#BD$ MO?$OO \G"(<=X?
4>K187/'X8]ZK"L MR5NQ%RDXA_#B$@:>WXN:4 4:*8KVUT:I(.S#96_9!N>ETKFNC6#)XP\@#(>] ME="_&.0SFC1V]3T/CG78/1 "@6^MW!78)V\TT9UV$R5NA/0WO!E'UTQNB0UP
MW%"J=WXY<$ V$F\,+2HKJ[705(G=9C0549H \F^$T'O#7-#-V>@/4$L#!!0 M (Z_EG=ME1 L04 (0- 9 >&PO=V]R-H965T[#2]CN-7[V=E5P44!JA2J9A=MZY
MB$\O^R3O!'X3L#*M=T:13)7Z3A\W^7DG(D @(;-D@>-C"5<@)1E"&/\T-CL[MEZ38?M]:_^ABQUBFW,"5DK^+W"[..^,.RV'&:VF_JM4OT,0S(*N9DL;|LI67 MC5$XJXU51:.," I1^B=?-
WEH*8RC9Q221B%QN+TCA_(#MWQRIM6*:9)&:_3B M0G7:"$Z45)1[JW%7H)Z=? (,R9SU+-JBE5[6Z%UZO>09O3AAGU5I%X9=ESGD M^P9Z"&*\
DBN4Q>M/AK7799&H4LB9+^"_:2762ILY>^&!G[\V]JK.;B_W4L M2&^B?!P$<2IJ7@&YQUDO &]A.[DYU?Q.'K_L#^:#F#_)>N33]<7]]?WOU"l MK/?E]N&:#4_9.^8ML >UXCHWS"Z 6=#
($NX8KV9N":$OA:I-...9D.)N&+:T M1I%RSB0EB?&Y!L!.LZ%3N%)%Q0AXR4;(/D$$O!4W%B4/&L9WR',]\ M+IA53%C#?FP/=<%]_*IRH:.F-[M+RC8;SD'(E [HZY]$W("YK;Q1G'-->,X+EULP]#_#_# M
<(VP+5A=6F%;*-+XRY[: "X4^3IPGKT_+:TTIHFS DLMZKV(^"5+PJ4|I MQSB^WGYCW!BPWDU!S2)HQF J+3+ JN>P=]Y70DK\3+3S-=*U[U3:U'M#@,_ ?
7XV3>/2^Y>TON\9%? !C5PH!YC3 004T MJ (:5.0S#6Z/&7K-AN@,,;G*!RF;;$G1D,<]5I3)@>=#$S9,1B\),ZG*^3O' MZ4&($>/OJ#\.'I3%/!QV7UOO-4H.Q@,'+!T-V&=ND85N"Q-TH!FT-;F3V ;N
M)K2G&A5(8KH/TC)@<1C*;T.\36*8WH=L9/1B%[&M):X[1.7;RP.DFN&,:$4 M(:9-.'698W45]AJR](#IE-51- H^X2PY13:B+AC+WB1AG"3L;7!' QL32LT% MA/[Y?%P@O=N=EV^'&0H%KD]4Q@D"
<'2H@O;=9CK$G1(E)KBBU8J+W D@DA@R)*LL! MU0QX8]U1DN/Y((FLFDOQ+TDIC1<>2I"SL3]B$5K^-]Y>=Z<+,Q5D8B:R=CH) MONNMYNP#C@>3V^^RCZW!'SZ]&F!
(M:FYE)L@]=GH'KN2]5HW8SS:YN[^;YB+ MW5^2=ZN[OQ@7_F:]*[_GWSF>BY*G+XP0]6H.QITF/9W?O]A5>7NV5-E\=;N M7A?X-PDT">#^3"F[_2 'NS]>D_4$L#!!0 (Z ,EE,4:L,HP4 '@-.M 9
>&PO=V]R:W-H965T$B*9;5YD0AB]]MO M3X"G2V/O78[HX;%0VIWUW=K9]:F\DAIO+;BJ*(1=7: RR[/>N->^^"(7N><7P]EI M*19XA_[W\M;2:MBA9+)
[;318'%^UCL2'U],63X(_"%QZ3;>@3U)C+GGQ8?L MK#=B0J@P8P@Z,\!+U$!B(:WQK,7F>2%3>?6_1WP7?R)1$,+XWZ4V8^/^L= M]2#*N:B4_V*6I['QYPWCI4;Y\
O+6C9^VX.T#$[M68)EJ4)C1^"]T&;R$G-2;GSEG8EZ?G91R,TS*TI MP.<(UQ\N3H>>8'ESF#80%S5$_ S$.(9/1OOI'-R$O F_]=)^.]\<=Y22?R]R\);;;H;C=ODV)4BQ;,>
M]8%#^X"]V:L7XX/1R1ZNTX[K=!_Z[./-^G+X]^7F$WQ]?_U<0O9#?+[Y>@V' MQ_:GH#!C8;STDK5AI=^.2:_(E6XAKLJ<3*3U)T1:H\6,Y#:FR#R3FJA4X1+ MRC5'C@K5YVU
^U!6UE5">R#Q92[3?#6%04IB)U,X>] M9)!7+XXF!].3-Z.HD$I1!_=I4I-H=)"@U L:%((&5]:G MAQ3E@T2@4UA8L(A!Q3;NNOR8_E];Y=@-20^/&>08B(@V%> 0MA<@AB60;F^.C M=A,$;?A8E-
0\XKLTUM\0%WQR^_JS_$& MK%!8!\X+&[P7/EA)<"%U6XISZ5(]"98,SF@2)&^A6)1'6 \DNI4U5EK,95 MMZTW&7$?4K\WC8[?N,Y(,4&_1&(R&E!@:1T/*"--!UR:HJ2X4#/%X\,3%_K3
M*)F%DF\IH^%CS6M. 77; Z33+J$YA+)=BW&D1S N6,+=,Y@=\[TX591OB 7 M66"9IK9B(R&HJZ=3ZJ?) *Y(@9P-.(0Q;C&:C/ XP&A[PFS%8>,V=_\C6)G
M@$HAJT*9!!+CX,M!2$82,OM=/T>$/GU9AYV*3&;K24C'@DYE2<(-@SVAXFTZ M=NZ)P5HM$2HP?AHJBLSD[:@9D+@FTP9YAT;_8'((PC(M.F,UYYNV*=B*?EZ3 M?A$I*1*I)%?\
.XDFZ[],.&4;"I=9V+& ;JBF!4)6IC448K[FR4&F;$>T88* M\[%L#IFVL=HN)1_GE<[F4,Z$QJ&3RT7M$;9D(;U@?.K#BL:V M<(%8Y9!#0>ZDB&ZTR_GF3:_ J6Y1AX\Q(]-A&DGFQE6B_'5P0UV
M7;B&&[?A NTBW/EY=%!UC[:FWW67%>WZ;7XO4WR2=AB9X#A7-2'0T.W_3 MUO?\>N%-&>[6B?%74P^/,7T:H64!VI\;KQ9L('N8VOV+U!+ P04 "_ M@#)9N8U$3;4' "2$0 &0
'AL+W=O2!.NPLL]@,EC65N*%$E*;O^ M]WN&>EAIW"RP0)'JP1F>.3-S,/+IQM@GMR+RXGNFG%99D$HPR/9J.Q^]&F51Y[_PT/+NWYZ>F]%KE=&^%*!-.
MVNTE:;,YZTUZS8,'E:X\QB=GQ8RI07Y+\6]Q=VH]9*HC'*G3"XL+<]Z%Y/W MEX>\/BSXJFCC.M>"(XF,>>*:>7+6&S,@TA1[]B#QWYIFI#4[HQOM<|>NR4; M=]\:[Q]"
[(@EDHYF10#)7YUUCOIB826LM3^P6P^41W/$?N+C7;AK]A4:P^^O M8UPZ;[+-&>9RJO_Y?>:AX[!R?@G!M/:8!IP5OL%E%?2R_-3:S;"\FIXXLO M:K &.)5S4A>XJV"G3^?
F2Q3'BQ[)V2>B)GO\N\22YPY&P-8"G#8 +Z>O>ORKS(?B8-P7T_'T\!5_!VW M!\'P?\3L/C71>2\1:G\>U_LE>?#_9ZY?=Z[0L9TUD-_,+)KZIW_LDOW?C/ M5W?MK@/7_-
-^/KN[N9D_WES?/B[$Q>V5F-W=/LYO/U[?SN;7BWU@7W=W>_=X M+4[>BX%XU;&00W'AA%D*Y(':,//1!G9"9*7//[]Z>G)SP_[%TJT!J0H5Q"@OO MI!.%IB2E1$1;X5&UM*E!>,M"\TH=6$3"T1YRIX
MC63^)-)26I[(C<4T5\09G9X>5W B(5+B^SF-36HA*L 6R>9Z/R26CP@ M-=+&%=_K6D.7"E[6%Y,_3A!9[:)=!K]|8;M&RL&FPD@A3%EB_WG$OGU^$YZ15JB)-(8"4XPN3Z>3X3R?
H.\09I(%AYPX0,,&D(G=%BWR.!0^B.L+E<,R7DF4?4M9 M(;<-6=9LI?;<#DMKLO#628##*P!(RMB[A@/L4[89]+D8@KNTU))5UW5>=OD5 M:#BR4NLM6ZU5\C^ @(:&+SP_
"%YP.2>@6*;N>]43(S0*J8ZQ""%IWB5&VW2 M;1>[0^NS9I1:33M*6FDO&>](_S)<#$5BM)9V@.)\@EU8*Y0#NX54R5 \8AV4 MI9#YMDV.B9#5P +#1UCU1KNHX'!NY,=S2-
P&$)\29=HP[DHPMC?"(:HZ)21 M@WSM5@=B^B(W+9G8L]"C<;XRUS@[$/V/Q%Y_GEW)* M 1*!OK YGZ%BJ7[8FB\1^C(Q=V'A[]Q^V@52VX4>.GD92..UM5;8D M]?F2QSNC$F2$
MC&=OI\?]HW=`7 7@(X]U&7+];F8]DG=9YAYRT+ (+F6$_ O%'(KNHK#HD>EX MAQO=@P^3;4/MUSH>CHZEC)D:+L.8K,< BL'(/A%S5YT7;;([@AW&0!6H MVRB47X?
4T'W)FIL!VHU!,>17%MM=_ZF]F&8K=DSU?OT.P9\,_OP=?ZH^]\)2 M(@W5'0 $*CA)'>*B$B>D9RPXMEB\0AGSR<#9X$F*\:$;2U==UC#WED\-%F6-
M_DZ8'F\X*.Y#3R<..6@QUPO<,SVKE$!JAZJCF*"IT(2B,.CMOLQA>DKXU DC M4([LP,)YX.0 CQV#KON)0UGF.;KD!D^W"RG!)NI0%DS0?$JSUST%/JZ= ME/S\A_I432]W&@@&1[_N3KH?
V;2HG;RD-O664E9T[FT)45G3@%5# *HR21\Y M2E6>-^(17L%PLU+0F1=0N#>15-"DO*X2:TEE46E=.[F$(]Z1>WG.AAIO93L\ MDM6P*C"="2(<2RDU?$63HUV?

&L%C96,]0ZTAE/MJK3/(JDJL:M@! V.=LQ@^789!S;DI8IM1\Q0=+SHD?3@8]W6;Q8\1+]GK;C!9{I30LR(Q3&< M2/-XI;19HW9= 1'2X6"#4H76D^)^Q?/K?#2?BVKL1)SWG_\YN+^X>BXMS=CC MD3_?)'V!78O*!@^TY(\18[=O9BMK K65%@.]#Y^ M_73UHA=^"'$\A\+\T6'3*H.><,2F?.,V\Q>;-K$U0B/)1[^N'!. -2O]I7\ MW;JR$H6: E'*RE1MLOUY,1R-Q\,W%$+B((O)Y?]C%+$#<5B>/A MOD^N4><[.2.;AE\#^+S%WM4G<_NT_<'AHOK.WBVO?JVXD1:-[O"=LH3I>'A\ MU!.V^@6@NO&F"%_=D?'XA@^7*W0H65Z]TL#G/4-;]#^#'/^7U!+ P04 M" .@#)9=+!ZU;P0 "Y, &0 'AL+W=O#(A*!#>95*R$$NB^>75]]I@.-%_=9_K58*E6*;ZLD+5Z>+,MR M_?SBHI@MU4H67K96*>[,LWPE2_S,%Q?%.E'%2L;IR:L?.TZ M?
4B]\HD3M5U+HI]M9+YPVN59/^$F7BQ+NG#QZL5:+M2M*K^LKW(\ MNJBI1/%*146>B%E5E-G*3 8'JSC5G_*;T4-CPMC? M,RTT+F6R$7+Z5I7SU(L_N14ZC08V^L*@\&\S%*1GEMLQQ-
\:\\M7M4N9J MF261RHO_%%>_5W'Y\,*B!&6Z?S$S5%YK*N$>*D$H?LG28+=+4*C\3IV\^OO?@J'_PR/L]FMV^X]1?W7[_O+FZOVG#V^O M;F[__K=Q&(Q^$%?
__/+3Y'Z_'V_R]^SK+5"ANL(!478IYQ M*S%R!{[O^KXORDST-K_NXW(II%C+7-S)I%(BFXM3W\,M(Q!KE6LBGKA,$DMO M*>^44+]7,A%W61FG"Y'33@,':20P0JBTC,L$?
&"I+%4T2FUH@6TA00T;N(3M M:=!4CXE$M0;;TP<]T#@'DUU!!Q@5%T6%85F:/ @)R:H$?]8RCGA0FJ7/9%&H MHI#31!EV/?'>T(%DI+UMY;3YU7+EV+E$P@B&ZU%\%TR3BA53SQ>6-
4XP5;YH0[MSU5.5 W3,ZP*#HAF0%9D2[9'N0VC[EK4U9;'-HEIJ!;4-414.N/Y.80&NTH+ M#9H0FK&[V!*YB!>I)/.QIY4($:0Q_FRJP1,?LUU9V\NF2J7&N)Z8GHO7JKRG
M2V_53*VFX#GH\08(F9'Z;CC25[>W!*%Q#*G KKA-@!;)9 M"2L9/9!"'S6K\KBD7^LJGRVQOX1IUK3SSW3/,*'86T1/\&[LD23TB!51"$TA> MTN:W(V#PF4; L1?
VF\ZB.1M.1N!K<)PXG9.,^T%C8#F?O8\LKF%%P*8KO84A MA7A0,F]KI\G:Z3O[VHD'(S=P?!(C71.>D(CS<4/ULC@S];(N$,C$W=XK,=W MS7E*'^/OT,?D47W(OS5RB$)&X:Y"@]$['AWI(5USGE!
(<^E#%;('/_] A4R& M?YE"FDL_IA *OO7*!7(%2E_:"!LZ== K{+ R0M-3# NYU@2?Q.KG8;KT+A4 M<X!=\-+[T;OVX(_ +>+:$$V-4*VK-N1NW(,_35BBJZ?^ M0ZM.I'-1;-(JW$WB55Q* =NX8FO5[?
U*>1@7U>YN N9R#@Y]Y'IA:->6>9%_ M40K?RETP@:[6^TF[R&E@2HAEGE4+*S<7\D0"VX?YE OPZ(FW%=,X!)&$];K- M-F^U?NB.PDF+):3)X+=#;@8:.$K9UZ*YVP?>I->L5B(NG"ZK!>IUT:N-
S2@ M_D K4E&=U'+NJOWSTZS,R$$F=LH5UA*7<]K0[[(,Z7O:'^+5&GM_PR(E@N^] ML@(XZ**6=S@+<_GNJFE#BUYQ>@-QYBZI3U!A[/[&,8UVVl;GG*5 M5;G>;B%7?MLL\=U6J R.!>?
VTG"92&?LO%^L4W_298LBP*9 35;64. YBNWR MMID42V5E 2BS[?05T:@_MH[060C\8&O,[=!^(IO$*&\)G6VN=1^HI5'RY-;-#-DS\1LH4@P;1FZ#*C\4N\8 MON :G1G!W+IT4Y%C8R=(W=RZ&YE--
;>@*!+X<9FK:M2(/V7-[4BKO155M! M5M"N6E"N&0(_AP#?HX30J^KJVYNTXU]MQH2-?M:TK MSY%P?>,!D]):"):U;6-?VD:I97!+R4W-[:/AM-:F^'2= ";%3^G,8SU0F-\(MCK#(?8XL2;)[L/
:4A:AP;NIBYIX6/&V_95[GKA:?[FL06#:U[.]!/ A[A!P ME[#\(DY3^@'9 *1QACPB<'OC0)R*P/<&0S'R (`H]UMTH-^YBFFELYX;8O@Y M31A[O5 \HP;78XLJVJ1:E6:)L1L@O)QB+2PTI#(0P6&;1C/C
@V:0$L'%2>R MQ5.0&$[PSQ_NTJD8%\#W,*21 4;Y8DSKGN[P:4;2?2@]F1DST^7]/'3*LL> M_3_%@
=HTSKMQ.VQPOI4:/;)W$'O6.,%5NL#;TQ$QB,B&'Z/_1JF$+YP..:"L=8Z=/%#X08:1E[:WW"DM<^_\@=PSSJ^1;'^+5Z"=/""Y\4TW MF92[2)D?
4P(8Z_XBD44X$&GD.=,MW'|S]GJMWNSHL;'?!0R=LAP/[=]ML0-T:/Y9IKH' M8>NN4\0T+K;!QY+ {4WIR=1,%DLJLYOXG:IOT-V]2A O3+LII@?TR'I3AP8I M75#H!-C5O1;N6-4@U>96?4,
((KL.U"U47^NBXZ?4]H9(\lO%O76_7U4E5LE*< ML_A<] -W#++>E>L-E-V!S\;.V!Z'D;*G9UY6;3(H,(*E68G;NZY2SR#637 M:0;&AV^H.=BW@\ *V]JX:@CT= UW38'BRGZB?A^YZB,HW%529:0;1&
[CH2+K1SL4A55>=]/O3CT%8WP]V\U& MW55&75_K]$0<4?BNC3K-H0S#?I[]=I$+:>(S_ZAES])6X"/UM0:4^MVT M>,A'G"[9CV0-E4U/_CV#-V>X^@;T]/GPD1_#E/JAV=!X>
(N9P)#X;C5B[L8(F='E([L?R\O:?T M:05.-9&R%AP^^' 4(6]#VCJOX04:,N]9J-WJ>%(3;I>==(5WJA M\\>6.1=G0[>/=<^=?^EESH)@Z$XFE,NS^]:[K5%O/&',&T0Y MJIST>A AR=;<@JVY/842*"D?
#)P?]1 5?BQ%ZPY@Q&7^"XT M>%PU>>A6>%(U'>7D&-'IB7K2X**N*,4!DB/-G"55I/9(UMQ_G<6$W7ZN?334 MZ.U#HQ*X<AG+5V[4"/U8)N^TPO ?F&9H M'|(:.+K -JIUVBC ,X
VCNP#./L&UL*1&XY\:R&+!0DD^&8$(N:VH'G^QG0"4]WQO:H5;(YV+#Y]LFJR#1W3:M7]YU-IY?)&)PT'Z'G M4YS2A8O)V.U'Z-GG""@<.F_IG+WS%O=; M^=],H/;M5H26R6&PV&[F@X1(HT
M=GN3H"UGP_047T= F$&?O@U'T,T$"!T7=44_. MBX&.!:/=3HIW)/@X9[US\5$6D?P=+<@\GL4JG3V(#*XH.!#^W1Y[#<;-/8OS> MK1\F.Y+.,^MNY"
<^MGZP:XA_,U;]Z_F7^GO^L9!)CLCEE\5:M95XRPD"VSQL" MMV4V^TI-XZ^]%!\^O,$%]#6Y79(WG+R@-#L?K+-X\ ;89H)HGY= N7U)8[MP\Q-A5 Y& S\L^GY67!NCY'DU'K1!W :U#-
!+W:4D@Y1T^L'\:I-;1[L([O8 M.CMMSY2;+@Z%0 75J5S0DE<5X,-D=_(=4QNI87>G!3HH&]>4]!H1O6IA!3C M(;H3=TJ,S'VICT9QZI+ ,JE&:\L,=QCA.H4+05GM=3>.AFP?6\1%*#M15&F>
M]DR[+,>C17#K;*4<3HMPE3W B,XR(X)N'[%9984^J9"6B>YWP:?H3'-H4T?S:#MNF:.VZYN-A2BAL1K/FV6I4['7=?R7'<$S?,/ M%#Q+\W80J<<<0]I9NW%NXR"GK6M.0X!6,?5O*^;R.
MRY&R9V1(*WR0*<2U3E;1,\&KQ[X F5I^5?R>!)W_RU+*IYT5OE;< M%ZK/-W0J>),:=T"-/'$ZP!^K$WDM^", M^T!(A&OBL\?:) @4E !R^;V*C76+;E3RQ$<#%CM;A3&F(PER4"LTUN47"^AX
MU6JED(8A+NES@<*>TK3P!V*YC!I/6=K)5;M=RO#,@ENVV6 @HFCC[73AEV* MA]4T2P0M$?H_7'_X5+AJODZU4ON"7YH@O[S]9EE]M7XO[U*_MCK89KE_J R&ULG57:;MI
$'WG*T9N5(%$XPL.$ I(0!V5 MJB$HI#=5?5CL 5;8NW1W"LC-ET7%?'*\R8OI0;%'2RD"ICAI9]Z>J-0I;D1EGJ!I[7=#/&A=/OYGM3 MU> _*K4FYP*D"Q MH=!
<"E"XZ#D#OS,,+3X'?.6XTT=SL)'.I5S;Q3CI.9X5A"G&QC(P&AYQA&E] MB4C&[SVG4[JTZ1S _M-'CO%,F<:1S+]QA.SZCEM!Q)S@R:'NO& 1[@R#773C*57Y@AO6[M2NY 632QV4D>;FY-
XKBP29D91;>><[$S_A@LF8LY2&(M89@C5Z(D2KE'7ZC!! MTW4-:;%8-]XS#@O&X!5&/X!;*]3$X:!P&9OD_:<4E-+PZ M!%X0GN%KE#$WL-B[#E4)1K5(SK] MMV_\IO?^C/2PE!Z>8^_?
C">#R6@\^ SCR>CN-B+IWZ?19!;-K/3HX93>\XR3 MNX<(?*\#[^!?Y)4?R!2@S2I03M#FI&)S8A/3J%"54 T(>K5*H8B?@:Y0Z)3E MU9?PO0+M-NHZ"+KC" "#GVK?
KWE74.M,F1B#4PD,%=RC0HH,QG7MO@U7 >$ M:Q)H+ RQ: .\R)QEOHW4W.C&ULS5I;<]LV%G[GK\"X<<>>863=;,O. M949QTM;=-,G$;G=W=O8!(B$)6Y)0 ="*^^OW.P<@15V<=G;ZL
^)*1(X./?S MG4.^7!O[JUL]Y<67LJCN7?,^3??W2U+[0E?IDA:O+4MK'-ZHPZU=']@Z/FQF>] M6']ZZH?X=RPY9 M9M*I&U\7>=^^>IH61R&KG31DW M@X-25^&O !+UT-
DPZ3^O81@W#)QXGJQ/O_Z7GY13D]MU5F2O7RS(,H/3K+(H$W@<#P"0*#H?C)5'[IQ+LJ MD_DV@3-PTI(T;%AZ, PJQ1_KJB=&_ 50_^\/O5^B-6A%'3&_TYT04_YK.G+=P MAW\?
DC;0&A^F12%R[58R4Z^,$ -.V0=U]/K;;P87_1=?X73<BA#KE:%SN2L M4,(;X9=*W)AR):O'ZV30$Y^*VNIK<8 ;/ ?N>B(S=F5HHYBK7%E9"'"^ "+J1
M;!/BC4([,1P9V!4X]^L=M"W1.K*QYT/!\@0PI),BJ MYQYI*X&+(75QZB'&\"=3UB--TD(DBTHH:2M=+1SO)%YHW2/N1C404[@EF0:4 M\WUA9A#LMO*R6FC2^7NS?D[NG4??9M5]?
_O^_C9EZBI/9H_M>;Z>.9UK;36T M,%,+7=`Q0LZ]LN*MRE0YP\5HD/+Y04HFQHSI#+*E_;*F$E1*:E<\KSJH9*8UK(N:<63B#=)>K5GG9$3 1O3;&-.J M3 <=V;I0P:?.;
('S*P\6*I2&0I>P8!)M#FO!J'JF"S(Y&&F(JR\]JZE,@*42 M7N("W974N8 B@T],BP(NYD@7"U4I"L:^F\5JU+9K6U4/"SE KX?Z;K_EWC2X]B*?-&'[1+/2C<
MI/4);)1#.SUXI_A15C6MAE8F:=0DG+8'#UEH!^7!5R493]PZ*U6A*64@KG#V M6OLE'QJ>!"%]OS06YFNSQ>W]-(9,NU*+7V0!8:8YQ6=W&T7 "2W\97H?.0C^ M)^3"*K "UJ$36"\#@&#C-
ZOEAL1I3TPI($)RP^GLU8ZR%@*/*>)VUQ0"]LNYIFBE'.A,H7/V\\ NQ72'+3@O8BVC9+:+ MBGAI$UHO&8:XWC!R#>_5[)(V+CTFG)6[UP_MV$4P_M\([Z!
G<2$FGR2%O:CK;>PD:M5WE(EIF[(&&2>#RPZ./ED=9MPWU_B M)>="@9TV+(2J,LODG 'kGS\\=D;#B]U#@\302]?<2#$8'F]U'E+L!0JLM- U#YT+)0K!NDWO/=4[V44Q7S GL^$!LKY%]3
MG3[!L24T3,+&^C@,Y1%EY[''V3NJJ()@_KRVKM-D/C(3> !+Z1\1H>P3;VHM" M2>?%5<"\H7P'<(I,OU0%;]\2C(\"PJ7 +?'@E!O8+DAH&TP2&/9G-@A$-FZU M<>]MMW_7#=)
*IK#R'ZPA]|CKJK7X=(3;^5Q;\=UF$P@?GW?X>(/2]B&0H.GMN M-C5PT] A&=YQ?!%XAY=8U&]D>M+D.6)A0P1G;#A,&@ZI!A(&>7H80+@A5Z'] MWI3L>MW3=M? L!E>B6+K:;_L,#=
(4#2&0(TYQQ0W1.46'6]]U%7>QT-A!#(_M%7F:=FC_+]1P1.MX?9Q5 LM=Q43A'ADVHKR@3/(C_602=;ZRGFC'>Y+'O)N"2>4;]>_=(05T6KYN,\30?QO,,ZP>!3Z,
[GO)K"=N1+6/8'(M[59[VFVO#D=PZ)^H MJY6,;1 FZD6=NEE1PT^*(YHP7N<4(M!AK#TEMO6R.#6C./%L.$'C' RCHP]*DW?XHHKC^_M&/!I4/&(P"?#E:.6M%G &W!0\!F6YN6#U
6)A8:&1R7MS(S,D_WMBC+RXTXI MI/D86BH)`6.*NK.>&4S.1)HH;0`!+ ^(K0?U.&L(II9ZQ4\+\)4T'4; M.N;DEK(RP>+/ 5DD.R9GMQU<30"Y[V(!/J[P\M%1E)HJ!4A2,FB&3F"/1T$R
MQ4EK=#K6<*N-0XJ $[CN)O5&<0><(*2,NHR)*NQ.D|V 2K<[L"-B](e)@IZX_MAE?ID.0/22I-Y\|[-.2 MN>ODGW&FT1EF)3S.HD%6LC5O8YE-E&U[6-AX\Y8[/A/#03H:7=-%))U<3I)M
M1"G.Q542%HW"<=`D.H&]W^ZTS.SZ]>`,!)]W"%V#HE3%L$\!LF1Q6]!* @#P MEP!D%,V_V@K%]JG*_K_58%<(8X'PPH%?#<79DXYH(@8L%;7.<5A`.]NZW2@D MDDIX?
O)$D>^),W0NA*!00`;LUQG%_T O3@,XC=#)+]OS@,V4>C*63\R&W0MD^/^]-#_ IQ!_5=4<*0A3[SE>+&.VW@7\)/"09V.D;UD)!2SG;O)X@56 M"!ADVA*PN>WA#ABS(*QNV-
Z_98V\71\['IUM9M;=EC!G6" *.%EXGWP$($<.M-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TYC"08SOFL\L/MG7>[D;/AC#5.8RD.2-IH0[,#5ZK+.G*4VY?RJ<5Y2DV>3M?F> E(]"0QH;O M2RDQ+|\M-
WR$HN &A4$X&>!%?;F1XT47>.:*O$&[5/3FA.XI;3 [5W4+G9R'VN|FH6[< M0>*9#T.!W(.7OG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;,0DHM;_'W*K.PS, M,5,P(#;MQ:.#G. ^"WUXA-
PQ]2V[6R\VN.K4GD.8KPA??|(<*9.&ZH$*9.+AN6T6_VC?:9=M?_H:W?9H!RX)RA1CD)C48S*;M*4BS9\9%T\]Y9CR53F?CSFQM;>T'2H0DM"E239!V M_+]^WH&3HFAW9O9#=RP1? >WGU
/S Y4]9U9*]7(-YNB_#\]6S?-]N7SYV.Q M5IO.3*]M*N')LJHW60.?Z]5SLZU5EM_+F^+Y[.3D_/DFT^6SUS_2=_KUS]6 M.5/H4GVNI6DWFZS>O5%%]?#3L^DS]\47O5HW^.7SUS]NLY6Z5<:/CWW
M4^*]4.7152EKM?SIV?7TY9O9.,Y (ZAU8.) I;XE7E5W>&'F_RG9R>X(E6H M18,@.OCG7KU518&08!V-6Z#/)SX8ORW@_Z!.@^;F6=&O.V*]9YL_[IV>4S MF:MEUA;.E^KA;\INZ_7"6U2%H?
_+!SOVY)EL?Z^!UC@:H,$?M%5Z&O:G2$R5VZ;&IQK>.:UY?+Q95 M6S;Z7,G/5;%76IF1G._XPTX>N2^/?WS>P'3XTO.%?IV&0<|,@)[.Y,I5/V.R_M?%_F*B\!//(=U^L?.W&+?S 8A_KTM0_+T9*1G(|.$
7BG?O.G!,_T +Q;O2KU-M4B^RL|$]B)#_>STW30V$\W]]NV?89_VPD9M>FFVV4#\]W8QJKY7SU[_Y4_3 MJ Y_7 RL_\RL_&X+^^DUFM)'54A+LLLF0Q/L6^1U@Y*]K)1=5;0 ->=:H7"YU
MF94+G172P! %3 D8L<[NE9PK5>++VZR&<1JY:%'5.8Q60.C 6C8 ZVNI$YK#3-M"R3#J!9?)[<3^=?KZ\^3 ,2]\$A[.C: MKT;A7I5I] :7TH>O00C|ARJSB>R")APR7ABG\+ 7BX
R0#5*5]WL&4KCZ#. M(2@+ "IZ!(%0 ,+W5L R0!R5(4 0HFPH^W:FPDI'\K3-1*.3H! _U69S0M%,BZ7I186K4L6>R0^[S=+T !X!4\5X%'0&/ <.8>< M3>\[0W _\#!8*PE[#1EH$";:! M+2
+*M&%GI#1-%4(WF2%2U-(@!+9@VOCGD1-MBVH#VL20LVe8(0,A]VM@6T;RE6C ($EX@>7%D;B4WQ&4%[ )!69X-F8?@QU M$21 .,ALN0050H"S#1X#8GY;U0U3/'[?=[0;:X%
[R,H=+@WVK=PA+)H61L/A M@?8PL-&V@&UHF*F6R[K: -0]7N,0^9][\C|?)A/;4F;$.9=M'6MRL6NCP,& M@1S@@/E$]D G)B .SJNBR&JI#6&+Z6+GQ^&QX_<*.*:/Z(54Y,VNJY((&C#\ ML-
8+EB1O&9EJK/#YMIT;G6L@.B YL%2 V12>.PMH;OHGMR#^\J?+V23BE9%+ MOVZ!4/ED\;3Y!+UTMX37RH*]\%.% 2,4&>8Y*803"JX8#!UD/YZ5+]VDD+9G. M%0XMAE4&3<]T8^
EN)E(@ZZK(@1.^ M4$ #.3MBA.$U?0= T/D Y@V$R" _5RD^L*F]>YW27@$X&LEB*>H$86V$VL=LM(283)D M*%OZB7@Y*!^9?F;.K(%_X#IADT@A??)P$ 0!>9A/Y.$Y^$C\!3**6<.YC-&2
MDVOPLXN=*#0,043>PY$S_3IK5F)X LU.P.P(KD9;Z4!3$1F"3=76NM'<GE.M M%.HT]%61RQ5R.;30] D+0&-N U8#8+%/4H.U.N*%'(#/E3H$9E,IM8'L0 MUPVSK%][=$P3^R
WKO.^R/_B5G"\c=*.# HE>@S>A= S!J=L!{UMZ]'UU"++$9.N5;XB1ZHK MBLA]DMD** /(DA5$0;^(Y$3Q+.F %]IWED.G$@6VIH.G<$><]6T[7!CYN@5 M;<- #QS4^A7\8[,I88CH$52!+SWSI8?M]#
<@LG:.^[P63F: R\00EPT=S2P< MS>P1A@':!C3H%V# .5:D/E=W#4 ZAT7.I M2M P#V# .O91'^]@-.A!]FE@T0:T.O!.++A$ T(X"IR+VO<<1FHQMKVL&Q8"C% M"CA8X591.%!6\T*OV.
(;P5OV,F=V+-\)2@+$"?M|R)U4&1X7+'"Q<8\P9Q=H] M(O[*&CX&$ *6MB)3'2T]P(=>\.+GBCD;,".0 N0UXDN?>8%D0 [2ZL.O2D2+.M%A+T=B>I?Q_(O"QM&"?M(0C?7_<1:HA_(%A1%X0&%$-
+0V0*XY@.."9)$TU M9]_:=6U6-.#!K|V 8:ABJRD9AL@BE?-SP4EH18;@IKFWT#P[-<#>O#?)3N MW6@[GD L27D2=(XQT>$_82#25]AV5;@P".QJHY$M ,3T;71 =F!$.P1[8!4C
MSC1WC]O#A%+YR&5S&Z1H@L*R+8BK_\Z>K\XN]5M'Q@POT.68KE ME^+/XF,VK^:[#!+1X0H;=KS"}$ T|/Q2_+)4GGM@,* M07LAQ=7TA?B{9@-&3Q][-/8M?!U;7TPV)"+UI(X\%L"8W*IG+
BR\;.(T.$ M12#BDY>'Y>)&E41_%.O+:.36 FN/P.HPPN2$DDI70X:O*(AZAL 8!<]60>F MM/KH843 ;4"1_ !0E1@<'73NIB$0-QW.J-UXL]&. YI%!044^)\[^6 0X@$^_M^V>;
M#]PCL* T\7QBK!9V82A(ZSRC)3"U"5S#;.^!<7R1'&!@<++KC/+3I.#)P 2L\ M_#*?%*[@?#,Z-WX80HD7RWD&^.:"L=83^.:!O$?*[T^&$[^V!7&(O%WY/ MYO<.HRW]>X3@7A*],W!\A M7,&TE3'A
M+,(T&PN\Y/0 8DIQ2TO",C:D9;DS B2@O?$-H2OKK,% _#9S+E]&S: 0YENN>'$,T MDY@MR&:CHT.AC\AGUG";">!88Z#OF"&],%B@X#BRL**WRM MO>;W@\ !,FPP83=F
A\:7GZX{BG2[?"U:E2AM%]*4UXW]=G&[HNiM^9YSH8 M F35LO65K*N?B)P41BBI[.1KL'1.A"5X8PR0:"D00CP7.[GE[2<'F M2+)6;#-CO"KB<.+GD%?<4CJ..EKDJ?L3-
F6T"BD+.,3V7BU!RL[J_M<++(2V16HJY8,;F!>%B@OA)OF= _SC15]Y$ \$2X?V#) 6#C_*1U^.G $8D4 M[3N]S.T%H7EG.A<)82Q D]K-6XKA4*LH&L(VG3.75D]E.[Q"*?.:WB@DD84 M+&A%K1)R2-
8G8&VR'Y<]!@!MXH>SR>F,OOKA8G(UPU/C-8VBZ%BQZT,&(3$F M9Q$3DZ,APOM_A)[_"#($Y5##.IZ.C|/)Y0O&Q^GD_7A@P$]CA *#-I9DVUC-MN81%6)^B?
!HNC09'GFFHD7HI:#>$_&U!*8HTKPHOQ8PDSD\GE"8RS]O-I[;*$#?NC/Q_+ MB\)O\9FV(,=W\/^78:2Q_Z*8&-/IB,[A6+X87\A3\46;N_$2.UTNN$T^^P^S
MFYR%\661AY=-1>N4_XD6#G;I+LG8:@C."M-VR76%!*. M&644!ZJKI3*&R\N<&<*]T0XRIL*XEK)&U>&%*(J:R+_RB7K:QA>.W9@Z_%O M4Y:5/6/PN@4S]J88+:"!HIN:Z]"!N#C+|KG"[*R:@(tN
.!:DT1Q M+:..C2I8 M43C5Y$/UY@7(Z2IVH3XYLB"!O#*T+!OI\)L4)[>G5RA^$/#) >$_%!=3(G)^_!1G/$X/)O^ M((\P.),9!?$0(_M=O&\O$@2&[-2"VL.:([]5>I&MB++>H+\3>@B7_"_[*@
MDY%TGCQ@B&LX/%6V1O(@S&+P/EB9 1VK>L41OIMR28T>K9'O0(!DQE:0XIH^ MW55?O,/"T"=2'DT/O(EYO;SU_&-Q)6.#(!>'SU0I3,O<Y(*U A9P]T],T-M- 450?I[-CJ;G8JZHBQKK
%0OZ]+95O8(@B(GL:7@RA'-N@,+YD11BLXS=*.MS'3X]%.G[4]9#7V7ZT+,&*F" <=[>LHSP9_GYY>=(QLR"$(= MZG2X$!7K H_=W*O&OZ?X=,.5AP&RQ*Z/A?6$"BH^+(!V!",&U<,@<51-1F
M0W4V@KAG$9?M9LIY@=3F]JH&@[L$PEK#[D1C=0R';HU =O-.1KH8$(E]\+Q@ M9*UAJ1)[D55:/$\20T)&9XCL1>`6:?0:!5%A'B[_OI$V"]CZX23*3W0Z1^S]$D:?,Z*U2/>BN$L "%21PR.F+T?3J
MA&:.=CBZ_7ZL;+O\.B3C$?TQ&ZPY@Q&7^"XT M>%PU>>A6>%(U'>7D&-'IB7K2X**N*,4!DB/-G"55I/9(UMQ_G<6$W7ZN?334 MZ.U#HQ*X<AG+5V[4"/U8)N^TPO ?F&9H M'|(:.+K -JIUVBC ,X
VCNP#./L&UL*1&XY\:R&+!0DD^&8$(N:VH'G^QG0"4]WQO:H5;(YV+#Y]LFJR#1W3:M7]YU-IY?)&)PT'Z'G M4YS2A8O)V.U'Z-GG""@<.F_IG+WS%O=; M^=],H/;M5H26R6&PV&[F@X1(HT
M=GN3H"UGP_047T= F$&?O@U'T,T$"!T7=44_. MBX&.!:/=3HIW)/@X9[US\5$6D?P=+<@\GL4JG3V(#*XH.!#^W1Y[#<;-/8OS> MK1\F.Y+.,^MNY"
<^MGZP:XA_,U;]Z_F7^GO^L9!)CLCEE\5:M95XRPD"VSQL" MMV4V^TI-XZ^]%!\^O,$%]#6Y79(WG+R@-#L?K+-X\ ;89H)HGY= N7U)8[MP\Q-A5 Y& S\L^GY67!NCY'DU'K1!W :U#-
!+W:4D@Y1T^L'\:I-;1[L([O8 M.CMMSY2;+@Z%0 75J5S0DE<5X,-D=_(=4QNI87>G!3HH&]>4]!H1O6IA!3C M(;H3=TJ,S'VICT9QZI+ ,JE&:\L,=QCA.H4+05GM=3>.AFP?6\1%*#M15&F>
M]DR[+,>C17#K;*4<3HMPE3W B,XR(X)N'[%9984^J9"6B>YWP:?H3'-H4T?S:#MNF:.VZYN-A2BAL1K/FV6I4['7=?R7'<$S?,/ M%#Q+\W80J<<<0]I9NW%NXR"GK6M.0X!6,?5O*^;R.
MRY&R9V1(*WR0*<2U3E;1,\&KQ[X F5I^5?R>!)W_RU+*IYT5OE;< M%ZK/-W0J>),:=T"-/'$ZP!^K$WDM^", M^T!(A&OBL\?:) @4E !R^;V*C76+;E3RQ$<#%CM;A3&F(PER4"LTUN47"^AX
MU6JED(8A+NES@<*>TK3P!V*YC!I/6=K)5;M=RO#,@ENVV6 @HFCC[73AEV* MA]4T2P0M$?H_7'_X5+AJODZU4ON"7YH@O[S]9EE]M7XO[U*_MCK89KE_J R&ULG57:;MI
$'WG*T9N5(%$XPL.$ I(0!V5 MJB$HI#=5?5CL 5;8NW1W"LC-ET7%?'*\R8OI0;%'2RD"ICAI9]Z>J-0I;D1EGJ!I[7=#/&A=/OYGM3 MU> _*K4FYP*D"Q MH=!
<"E"XZ#D#OS,,+3X'?.6XTT=SL)'.I5S;Q3CI.9X5A"G&QC(P&AYQA&E] MB4C&[SVG4[JTZ1S _M-'CO%,F<:1S+]QA.SZCEM!Q)S@R:'NO& 1[@R#773C*57Y@AO6[M2NY 632QV4D>;FY-
XKBP29D91;>><[$S_A@LF8LY2&(M89@C5Z(D2KE'7ZC!! MTW4-:;%8-]XS#@O&X!5&/X!;*]3$X:!P&9OD_:<4E-+PZ M!%X0GN%KE#$WL-B[#E4)1K5(SK] MMV_\IO?^C/2PE!Z>8^_?
C">#R6@\^ SCR>CN-B+IWZ?19!;-K/3HX93>\XR3 MNX<(?*\#[^!?Y)4?R!2@S2I03M#FI&)S8A/3J%"54 T(>K5*H8B?@:Y0Z)3E MU9?PO0+M-NHZ"+KC" "#GVK?
KWE74.M,F1B#4PD,%=RC0HH,QG7MO@U7 >$ M:Q)H+ RQ: .\R)QEOHW4W.C&ULS5I;<]LV%G[GK\"X<<>>863=;,O. M949QTM;=-,G$;G=W=O8!(B$)6Y)0 ="*^^OW.P<@15V<=G;ZL
^)*1(X./?S MG4.^7!O[JUL]Y<67LJCN7?,^3??W2U+[0E?IDA:O+4MK'-ZHPZU=']@Z/FQF>] M6']ZZH?X=RPY9 M9M*I&U\7>=^^>IH61R&KG31DW M@X-25^&O !+UT-
DPZ3^O81@W#)QXGJQ/O_Z7GY13D]MU5F2O7RS(,H/3K+(H$W@<#P"0*#H?C)5'[IQ+LJ MD_DV@3-PTI(T;%AZ, PJQ1_KJB=&_ 50_^\/O5^B-6A%'3&_TYT04_YK.G+=P MAW\?
DC;0&A^F12%R[58R4Z^,$ -.V0=U]/K;;P87_1=?X73<BA#KE:%SN2L M4,(;X9=*W)AR):O'ZV30$Y^*VNIK<8 ;/ ?N>B(S=F5HHYBK7%E9"'"^ "+J1
M;!/BC4([,1P9V!4X]^L=M"W1.K*QYT/!\@0PI),BJ MYQYI*X&+(75QZB'&\"=3UB--TD(DBTHH:2M=+1SO)%YHW2/N1C404[@EF0:4 M\WUA9A#LMO*R6FC2^7NS?D[NG4??9M5]?
_O^_C9EZBI/9H_M>;Z>.9UK;36T M,%,+7=`Q0LZ]LN*MRE0YP\5HD/+Y04HFQHSI#+*E_;*F$E1*:E<\KSJH9*8UK(N:<63B#=)>K5GG9$3 1O3;&-.J M3 <=V;I0P:?.;
('S*P\6*I2&0I>P8!)M#FO!J'JF"S(Y&&F(JR\]JZE,@*42 M7N("W974N8 B@T],BP(NYD@7"U4I"L:^F\5JU+9K6U4/"SE KX?Z;K_EWC2X]B*?-&'[1+/2C<
MI/4);)1#.SUXI_A15C6MAE8F:=0DG+8'#UEH!^7!5R493]PZ*U6A*64@KG#V M6OLE'QJ>!"%]OS06YFNSQ>W]-(9,NU*+7V0!8:8YQ6=W&T7 "2W\97H?.0C^ M)^3"*K "UJ$36"\#@&#C-
ZOEAL1I3TPI($)RP^GLU8ZR%@*/*>)VUQ0"]LNYIFBE'.A,H7/V\\ NQ72'+3@O8BVC9+:+ MBGAI$UHO&8:XWC!R#>_5[)(V+CTFG)6[UP_MV$4P_M\([Z!
G<2$FGR2%O:CK;>PD:M5WE(EIF[(&&2>#RPZ./ED=9MPWU_B M)>="@9TV+(2J,LODG 'kGS\\=D;#B]U#@\302]?<2#$8'F]U'E+L!0JLM- U#YT+)0K!NDWO/=4[V44Q7S GL^$!LKY%]3
MG3[!L24T3,+&^C@,Y1%EY[''V3NJJ()@_KRVKM-D/C(3> !+Z1\1H>P3;VHM" M2>?%5<"\H7P'<(I,OU0%;]\2C(\"PJ7 +?'@E!O8+DAH&TP2&/9G-@A$-FZU M<>]MMW_7#=)
*IK#R'ZPA]|CKJK7X=(3;^5Q;\=UF$P@?GW?X>(/2]B&0H.GMN M-C5PT] A&=YQ?!%XAY=8U&]D>M+D.6)A0P1G;#A,&@ZI!A(&>7H80+@A5Z'] MWI3L>MW3=M? L!E>B6+K:;_L,#=
(4#2&0(TYQQ0W1.46'6]]U%7>QT-A!#(_M%7F:=FC_+]1P1.MX?9Q5 LM=Q43A'ADVHKR@3/(C_602=;ZRGFC'>Y+'O)N"2>4;]>_=(05T6KYN,\30?QO,,ZP>!3Z,
[GO)K"=N1+6/8'(M[59[VFVO#D=PZ)^H MJY6,;1 FZD6=NEE1PT^*(YHP7N<4(M!AK#TEMO6R.#6C./%L.$'C' RCHP]*DW?XHHKC^_M&/!I4/&(P"?#E:.6M%G &W!0\!F6YN6#U
6)A8:&1R7MS(S,D_WMBC+RXTXI MI/D86BH)`6.*NK.>&4S.1)HH;0`!+ ^(K0?U.&L(II9ZQ4\+\)4T'4; M.N;DEK(RP>+/ 5DD.R9GMQU<30"Y[V(!/J[P\M%1E)HJ!4A2,FB&3F"/1T$R
MQ4EK=#K6<*N-0XJ $[CN)O5&<0><(*2,NHR)*NQ.D|V 2K<[L"-B](e)@IZX_MAE?ID.0/22I-Y\|[-.2 MN>ODGW&FT1EF)3S.HD%6LC5O8YE-E&U[6-AX\Y8[/A/#03H:7=-%))U<3I)M
M1"G.Q542%HW"<=`D.H&]W^ZTS.SZ]>`,!)]W"%V#HE3%L$\!LF1Q6]!* @#P MEP!D%,V_V@K%]JG*_K_58%<(8X'PPH%?#<79DXYH(@8L%;7.<5A`.]NZW2@D MDDIX?
O)$D>^),W0NA*!00`;LUQG%_T O3@,XC=#)+]OS@,V4>C*63\R&W0MD^/^]-#_ IQ!_5=4<*0A3[SE>+&.VW@7\)/"09V.D;UD)!2SG;O)X@56 M"!ADVA*PN>WA#ABS(*QNV-
Z_98V\71\['IUM9M;=EC!G6" *.%EXGWP$($<.M-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TYC"08SOFL\L/MG7>[D;/AC#5.8RD.2-IH0[,#5ZK+.G*4VY?RJ<5Y2DV>3M?F> E(]"0QH;O M2RDQ+|\M-
WR$HN &A4$X&>!%?;F1XT47>.:*O$&[5/3FA.XI;3 [5W4+G9R'VN|FH6[< M0>*9#T.!W(.7OG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;,0DHM;_'W*K.PS, M,5,P(#;MQ:.#G. ^"WUXA-
PQ]2V[6R\VN.K4GD.8KPA??|(<*9.&ZH$*9.+AN6T6_VC?:9=M?_H:W?9H!RX)RA1CD)C48S*;M*4BS9\9%T\]Y9CR53F?CSFQM;>T'2H0DM"E239!V M_+]^WH&

MJQ9SH#U78KAIA"MNI(:E]!K)0VJO=((R6%>]X)^_"N,(B$=TAE.3"<^/U> M/(:S%]>/:_ H-Q$)!87&O8L1`],.:VLX78&PO=V]R:W-H965T[%)

*M\>Z[{SO='35=2_6B"T0#:Z6H].POC*FO!P.=%E@R'X4*!-LJ2]^4_ ^:^"1KPIC M'PSFTYJM\ G-<[U0M!OT*!DOL=)<5] PG_DWP^O:L:5W!G]R7.N]-5@E2RE2`M(.93-O.C2P@%IL8B,/[Q3L4P@(1C6]=IM^'M([ZRWZ1Z>=-M"R9QCLI_N*9 M*6; ^Q(<,<]8\RC7OV&GQQ%,!=#N%]:=,>1#VF@CR\Z9&)2\:O_96Y> ''W&(M.X?8\6X#.98?F&'SJ9)K4-,:T.S"277>\(Y7]]4&46GG/S, (FO*![SE%4& M;M)4-I7AU0H64O"4HX;8XVJ)U:.B69!VB']MLCQ?R /8WB0E2DTW%-69 M9H< Z+9NTJ:EGJK_OEE]HZAN_CFF MOL5.CF/;7KK6-4MQYE.S.%2OZ,]_^6EX&?UZ@GC2,T]-H<^2]#>S1B#('!,* M.E29#;_]@_MO#:.^]9PPPA?!DF,$,F(${]9+25MI-KL"1Q&01)Y=[*L&X_*_ *4'%X7],AY

*M9S@:>5]R*CF*T*B*FX8R)74#5QP.K^S=-^=P.0F3!":.7UL?^3G:6MC3Z/"1I.ML@4_H< MQL$5C+O'KE^"'7*$"K\B:\N&PO=V]R:W H965TI!YX@&M]6H],3-C:DO/4^C.99M4RD\ MYOM#K^-1%Y<;C~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lL4M.:`;'E)S5T$C&&R*@F.ES2[*(M+TO^.5@(_?&\1"M9<7ZG)U_SF>U10E!!C0" MO>X!S[&J`!#2N`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f0.9WN!C2):."QYD+!/O=*89NK[.BNQ9OI2-BCHI!"]9H9.M?5UHŸ#E M+JCF?A0$5WI-*N&E,W>V4NE,MH97 E<*=%O73#TMD))]7<.WRO0_JMR4RO[X/1P&3X)F`MJ ^(:.\ND6\YCAF6SI3<@[+>A&8WKE073>0]87_*VBBZK2C.I%]-B0H6629,M832LV!;<(37]W.1.V;^H236U<]ZP&4'&#T#&&9P*X4L:P7.>;_ OC$;] 8 M'2@NHL(7UIQ"7%P 5$0)62PXJ'DV.'%_U?RS\5&&T6OY>IHCO(Y#2D510D9#R'1.9PDN8A/0)DV1$%1+MPU[4I)S2*ZN M81R$H#T2GJ[%0N2;RH-20S7HU7O7 EM*M :D=).(8DF8SN16'.G*V3N :7H$X'P^DP11:=>/ZZ=R/HE]DM0.&!84&E]&\ULC59M:JLV M$/ZN7T&H1=$"7O1F28Y&K>[%D&<;AB&?.*MLTV4(C62BI_ OR-ERVZB M:/TB4B3OX7 \GB<[*3ZKK< ACR57.BIOS6E&@>!7FVAI/I,5B!P9BU520W^_MQIVD@*P6T<$8E# ^(PS(*2,N'/)F[L3LTFLC.<",A31 =E2=7S)7"YF_J1?QBX M9YNML0/!,%+1#2S ?*ON%/X%+4K!2A":,24$4K*?^132^S.QZM^ /[CM]TB?6 MDZ64W^W/UV+JAY80<%@9BT"Q>80Y<&Z!D;, >TR_W=(:GO8/Z%?.= _1E237, M)?^3%68[!4<^*6!-.VI%>XWV/N36KR5Y-]!R:Y9FZ4^26?:R'!OC O*)U6 M/N%V;R<(4@%+!+YA$,\8L>[V2+!**#$2 -BVE M^$#LN%, +T69R0!U:R0.XV$/7M*ZF#B\U- %OR^6VBB.@G^Z&GP@AMT0-C/& MNJ(KF/H8^AK4(_BS#^^B+/S<0W#8$ASVH<\6F&E%S8'(.:FM0%'#Q(8XVN1B MHP P"4P7Z5[8:M(N@0G3A!FRT.YJMD#FL]RH>/[P:A1'^6=.9,OD_O8:H5]# M02M1'"<\[BAR1I>,:-CST4#ZOXGA7/*IAXMUU [TDV2 ,1MOD@2TX7O0(= M8!XHA4= TO2<0''>MYAP*3; &% E20=AG.$W'XZ\!VDH/W'IM=U(7)F.4DLCD2Z=>[?!UOG'_5XX[!TZ3MV*@VXNZ0A5 M8,??DF.TO% U)=$@BA+;S; ;1!'MYN0\$VUG9,=B-WWNP@5C"ZO%&B4A"9YP MLM>B%@73*UD+ \Z)>5>CHH^VTC7+BCR,/>N0>LQ8;@$ 3+D8SR(XIA\\NZLFQ@<.MCY3?[G3?EK-'QJR5.?

*MI&1NYOCOA3<36NK>HJ%[#$6GYE1OR97-L*^B*9A8 M>;H4[=VQ6]$'S.$5Y](@4[HQ:K^%(QM.G9%.6S-JF^Y$.%E).[9$,Y=A;E96[-M)Z!*DW-WN(OPP']M*G*Bf[^0L7%B>)/W^:K??%GM"H5=SN\$@5LU7H.&JV-MU&")10N\=,"""_2D@">"A#&< 46.!G$:NC8)A]ZB7C:[.($G9>?=9))YB_\] M&.]I5U%6N .AI0U .9%X;?UCPAU2B?BU'Y&PO=V]R:W I965T%?)*$S.?3H6^>XWV/N36G

MFQ6&_2N8#_-2570.8P>_/ 5R"4[R]LT@\M[WI?^2S%X4(^B$;SFGOPMP/WM-M(Z%*@>[=X<8EM"[FXE@F41A>Q.YR,Y'~H%$4!%W0"\!A!S@\$)#;'>*.SAAG-MFH$ZQ>]'2MRL/N#&_=[@"<-W6[Rf.9$_ZL<_!SP7W$)%V5VID$6?:SA+]_G-M1UO/4&CX44_<=011Z\2/PA-.1'[N?MHHYV=QM.0;M'N!D7!*.RB=3>N.O;._M^4IEQDHL%BO0YIV/4"^,[fKl.%'9VfXF_Z=MIGCWPVD"*

*<#YA1!ZW3$7:/>__M3/X 4$L#!!0 (Z ,EFQM!/6!P, *0* 9 >&PO=V!R:W-H965T MW-MN6TMG#BSG!,^_6PGA.*&%$5[2>S8Y_B<.\?W#C>,/X@5@$2/*5H14!A+C4%5[\UC(%2S:1T_*U(MK7I#=QN/[-_>5F1D6,&;U-2$-!9OS|@P3[2I VQ3+A=4W+5.GIPG9$TIA&G;U;.M-@CZP8ZSAEFA'!W,*B7;6R6$KM|N,%^23"@A"P5SSB*%YV5)5'8DRTU5,6-2 MU2BFN5)E)'*

)08TO&)//'5VHU(5I_)02P,$% @ #H R69 :$%< P M<0@ !D !X,"]W;W)K4ULK59M3]LP$/XKIPQ_M(V2)GUAK*T$\32F(2$ZML]N]LH*+O%.@ZF*@NFG"Q1]-0HZP?/&/5_DUFV$XV')%CA% M^U#>;5[%#4K&"Y2&*PD:YZ(@O',V&3A[;_":X\ILO8-3,E/]T2UNLE$0.4(H M,+4.@=%CB1,4P@$1C;\,S* YTCENOS^C7WOMI&7&#*$Z4^,,SFX^"TP RG+*.MV'NU^HX,/3V'ERIA_"^L-K91 &EEK"HVSL2@X+)^LO4F#EL.G?XI#O^G(?[M MT'W'(=DX)%YHS" BCT]>0)!]@3B*NRV$)O_OGNRADS3A3SO>|@[>1!6E MDA1,XZ(M?*

*+2OCG9;M&JP:CN8;_@S4|(41P%UM$&]O&#|^5.G'WUK4_!!8#NZ MNXWN|C[T\35?8P8E>R[\=E=82Z8YFU'9^.LV9Y9.D]*1@>MX2=64X1]4!LUL*

*M;X#J4WO^5'>|+;F$>M$P7&X+,S%*HFYCM',HUPC[!14TK69U]KA,5=*K0;H M;QW[AME;DZ33?SJO?\.KO+;"==DU=N$/_N*5=FVCVO_(.OL@L!WY@T;.^8&],-M_55.IX!Z056],H5%%5(5'2?N-*

*O)Y@@%9.[2/DHO.2BH&KG@EF/KO35X6T2= MP>FK?+89:27V=7*H&]BV0+_ Q0.Y ZKO7%UNPV<_/N_:.?OGC M?U!+ P04 ".@#)9&$6XO0\% "(+0 &0 'AL+W=OG62E& W50G'D8-*

*<=.S'E8C"=Y-=N MU70B4UOP6X52M(XINKE@D5R?3;P]\)7[OCC4F<7G.ED11_9/=/?5K?G#D5 M)>0Q$PF7 BFV.!N<>Y^(/X*Y'?\Q=DZV3A&65?F4O(:3][#K]X&,M8A%+_ 9*

*M@\I_3VS&HH8@CF7:\6T('59U9P1BY5][G(GONI5N07 M:LKIZ5=)[GCN0I5N07 M]\AKP.WP#KGT#MG)+Z+P&@+!H%4!HL:5WMZZ!H!: 5 .:*6G.6NUP M*

G[M!'R[$VAJM>#/782R.WOO4P U!25M6RAOAU!'UMN`-/SX\+!5CG99+.ZBW M.J!9/A2M*6*=Y?O0GOV\T.0>E$;@:$TO-W87V6W_+RR7=G)O5?V?+!.'MY9+

*M]!j.6M6VP+?;@]!+I1W36OA0& ^"WVX!=2T!M-WR[#7CK\RW "0]R|.;8O5I=K;89 MG^>;.;YWZ]F*A@U5CUPD*&(+4]0].C.;/2A7.?HL3+5?Y1MBYU%K& ^>&2T9"1 M[;S^T)*. 7J255!MOI[^#U!+P04 "_@#9)9\R5L3H # _% &0 M 'AL+W=OW$\]2.SXMKCV*^03^G*F8I/ HB\R2AXG ';= /+ 'Y\5/^E*!Z/+65,)"O[R4*UG5D3 MBX2H7FLGOC^,U0%C,1>P&-92>)]1.=8?623(\-))%8PS2%A.?*

M.7"L19@#M\ M(\"K-KS+ /^-@$$5.'AOAF$5,"S(F*44')94T?E4\#T1>2C]Z8.*9A&-Y:-4 M/_>5$GB789R:+WB2.(4/4DE"TY L>!8&D$:.,)#DXQ(49:'\1'XD7U9+\O'# M) *!L)3\ON6YQ%R:BN*

ML88[SZBX@NR#)P'B.>XXf@F<_ S= CN#=L"5^.^/WQ@J&90/Y%!H3?X5T_D-MZVXG-PK2.1?+7.]*[6'[=]ZB=S(C 8PL[!+2! [L.;??^?ZSD]MW/H46_8D MUF ZK)D.3>KS!97;*

*B9**$*(2$)\%N+.0: 25X*EV*@0TRUX-Y],)E-[=PZF MIX0_*,:.S.@(YA%$@&\;=C^.^,3.F:N0@'7G!A"9G*.26!F$5L'0/)9895 M@#G]:JC6U2(45=NI9CKG(%SKD87X'K*V #GU^\|/#(@G?*

]"O.A!!%;31,$9WI>&W MT7 &%SAZ2MG .;YQC ^%(Z,'|M\4O12'!-?UXG61^+L+ -?WL V54;DKJO%K M.X%IY|R-3A-.DX3DK9P'5=X[HVXG[@XADTL*)YKW.)!Z5$7[=#PYKI.;(TCNPM

*M7M>O2_2NFP4NC%/HNLKU).@Y3HG.^>\XV>H?8) 1&F.!UG=X=OX5\J7K>7B M'5B8TW9EU)=.$]*9XW6-D%.%'R0-AO'6AO0\2-R "K:G:\QLC.GGM2:G+P3 M)\)8YVT4*8AP2:M.TH'0A.?*

*MB[!9]FMGZ5=6M:F-_P%WXM1O>)/.R:6!+L,Z MOP^V+,8]\G+C"D)DZ\D*O!M+!RLU9G/+WZ\K[4FAQ/SMP=_H]_=]Q>W7]O M.LN^C\U!@3\[>.5O_Y++)W%;,,B7RT*2*

*GG_9EUJ3U\G0NV9'WZG=^.;I;RLAQ M++NGT^1]@V9=.>2<<^VS%*0$3%SILD@2ZXW#R]K!.[>[?%GI9|&EYN#;)'BU@] M20P,#'6NQDA%E+MMY8GB6;`.M.9*\.0XW.(^#$(/P/L.SM7Q1"> H]SSG?*

*P-0 M2P,$% @ #X R631W).L[%0 B7.! !D !X,"]W;W)K&ULM=U;<]O6V8;A_P*C-JO369&]%@B0#\%%O,2;SWGQ6WDK1*7\.MOERLRK9W'XMW;_+!.C%?B8^%4MXEOUGQY8-8Y)_?*

G]@GC[^(YS>W MU?H?7 _>W&4W(A'53WKY1"7+\\>.;^^3B<7ZX+-$O_M%Y_ +K=O^]!FN>_K7]PKMZ>#.9K)!9B5]V)K/GDI@4B\5;JM?C/PUZ\C3F MNG#[[]-N;NY)?*

*6=^S4IOF2]^GE]5MV\/IB?*E;C.[A=5G'^V17.'OFMOEB_*MS?^5SP_+GMUXP>]%@V!0. M#RT8-06C0PO&3<)XT()4S YM."*3@_M&#.%$P/+,AH"BX.+5 'CWMN\+OD-M_%+)'T]*

[>V=LOECSN;O7Y IX.TH9W.'JSAY_Z3&E/NYR]>!]KC[N=\5GK[\X MRN-N5P_>[^KCCE^]KCWM/WMXPF_20L^]-M[-V;(O^L%.OE:V!]8Q.YF_HZ);:K=3HF55'_=5[75>^2VZP0M_GB2A3EWQ7C

M/_?SZHORO2Z],+XH?U# ^J?R4Z,KW?_WAS5E5C[:N.9LULO<@:R_(JA+D[^]V M5(S5E;C]]??E]9-]]<&>]34)<%90J[=MI3UNJP^:5 RR++XHV?.5H VW4LSZ7 M\NKW=\6I,AR\6

*[+RTWQZZFB#E\L_.;.?G]3CZYNRH<]Y;.\7!>S4T4[WY1K M/>76 >7]Q8OE]B'EXQ?+G4/*1R^6NX>4#U\L]_8],MK]?MIW.#A@l&;'l8T>*

MR.O=^Y7T41<>7M[GVE&>KIY7ON^_OX:/>\3[<_7PD+0GCTG[BU\OJ3B56):.[EG%#P_D)]<'SF_+N^R F7A[4A\:.MEZ+X)$[>_>TOZF3PS[Y\(C&=Q P2.TG,(C&;Q!P2R?1WE_ER6.\?

KP^J9[^]4LIU')==E_=YL7|CXCS_]2 M\-CX)3&=Q P2,TG,(C&,Q!P2#\7]OSCYM M+?BC_(G\B]IWK!0>]G_\&CTB-T1,8LFA|SN%1NV$[_@I?,=`A.]=5BB?LL6] M4+Z?*

*KQ0]7RRRHE3N1/$0RWVS#1^D_K%93&(ZB1DD9I*816(VB3DDYI*81V(^.MB04/V.E6;JCB'X/QLR^6/ZE?",*#Z(|?0T?D)HA)++#GH3]?0D)T(GCQ%\$2Z*

*M23\6XEH4A;@ZZA!8;AX:NR2FDVA!8B:)623FDUA 8B&)1206 MDU@RV3G 50=]Q\?0HUP/7*U_/CPO5K#G&E0OR:M22FDYA!8B:)621FDYA# M8BZ)>23FDUA*

8B&)1206DUAR?M!A+#1D)VFG3TD[F22:M?3&[S4JAY ==G-3 MB)NL$GUI*F6.35,2TTG,(#%SVO-2]UZ,IM/N \ B![5)S"$O]\# -X9&# ^B06 MD%A(8A&)Q226D%C:\Q",KJ=GGQY!G1"\> K!B\-*

*"!*Z8ST1[6'G$P;9T@&/C MD<1T$C-(S'S !EL[!8[SL)"]=9?]+N3V M2=]SA3OR^_@D%!82&(1B<4DE!!8"F&=@%,'3PFW/!Y@$^,.1,4?0$FKS\V MP5!-1S4#UK7!&?)==AB=L]BVL7D^1&2TI?*

8>#]>,/C MZ,/E/'23^*@6H%[(:A&]IQ:B6H%!:=WXVC]O7!7\!3<_>3^3B<7ZX+-$O_M%Y_ +K=O*^]!FN>_K7]PKMZ>#.9K)!9B5]V)K/GDI@4B\5;JM?C/PUZ\C3F MNG#[[]-N;NY)?*

*6=^S4IOF2]^GE]5MV\/IB?*E;C.[A=5G'^V17.'OFMOEB_*MS?^5SP_+GMUXP>]%@V!0. M#RT8-06C0PO&3<)XT()4S YM."*3@_M&#.%$P/+,AH"BX.+5 'CWMN\+OD-M_%+)'T]*

*[>V=LOECSN;O7Y IX.TH9W.'JSAY_Z3&E/NYR]>![

[;LK,O0E;[HHR M3]M@W8(TS[]_T=>V(PX"'/](@-L&N-V X$B UP9XG0#7/1+@MP'^T("@#0B& M;L,\#:C%G#;=-52) MWBV*]VFIFU"!ILNVNH] =>Z1ZAQVFV?E8\'";"57/?\1+Q+ *9ZV_<=X+YT MP(U!+$KE\;X,&A_[MH<_-|WG+W[_L<>3#@& M\^FW>_;NE;L/H;#/**'O?TNYM4\;^_N]L=ON@#[5,JT^$]/ZVX;FM!/JS+M_M^V(.+>7U1*220]HG.5G\)TSG_WR3M $XLYI0_=@]+69C%U?3IT.IR%K&2H6$A4B8 ,$LJ8*]5 $1E3X4 MCVI$1HX|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{M)=U&7^-TEY)OF4:,5@SJ M(4%](00F4#1;VH/%1>#51=CE1=CU1=@%1M@51OV!\DS3I W8O+1?]YL/8-V M?ZDG/IAT?N1R'$T>K;C?=V7,Z9S9;2;)'(EXTW&M)S5 MA,@X>Y)%F:N":3UWS7KCHU)";28HC7N]2XLNNS^K0TH)5,MLA8S!Y-$&TWT9 ME3LMR3?ZN(+Z2U -)X;-&1163)PL9O>SL7H\>C)0][2$_<7>>$F;KG"T)E S M"$H+H32!HMD[@C&#/,SD(0 J 4\!'$H+H32!HMDR&X?(HOVB4^M$Z?#1LD(}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{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{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}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}O<'.O87!P M+1GAM.%!+ 0(4 Q0 (Z_EGZQ5M![@ "L" 1 " M .\ !D;V-0&UL4$L! M A0#% @ #H R6&PO=V]R.W-H965T&UL4$L! A0#% @ #H R69SX M[D7[@ *0D !@ ("'(AH 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ #H R6>_^(;K!P]C_ !@ M ("'S24 'AL+W=OXM !X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M A0#% @ #H R674&PO=V]R.W-H965T&UL4$L! A0#% @ #H R M69G.\;Q# P 6P< !D ("'96P 'AL+W=O&PO=V]R.W-H965T&UL4$L! A0#% @ #H R64Q1]PRC!0 > T M !D ("!2G@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #H R6;PGV/M @ 1@8 !D M ("'Y< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ #H R61#"[$!$ @ B@8 !D ("'K;L 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ #H R6:]E M>]W^ P D !D ("!O_ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #H R695FL75M @ 9P4 !D M ("!Q=T 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ #H R6=R5Q=K> @ +P8 !D ("! M.NL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ #H R69N&-:>N @ !@@ !D ("!"0 ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #H R623;9(.[M! &A0 !D ("!G0H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #H R648Q;Z7P P VQ. !D M ("!2Q4! 'AL+W=O&PO=V]R M;W-H965T#O1$ _.+T* M 9 " @5(< 0!X,"]W;W)K&UL M4$L! A0#% @ #H R60 1XRB7 @ .P< !D ("!F1\! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#H R61A%N$+ !0 B"T !D ("!YB@! 'AL+W=O&PO=V]R:W-H965TM5 0!X;"]W;W)K&UL4$L! A0#% @ #X R64!@ =3$!P .3@ !D M ("!&UH! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ #X R60M-1@<2 P 70L !D ("!56\! 'AL M+W=O<@@$ >&PO=V]R:W-H965T1^ M 0!X;"]?7!E&UL4$L%[@ ! $ =Q$ 6# 0 $! end XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).style.display='block';Show.LastAR=e},Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p=' '}else{d='none';p='+ '} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 *//* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #dcf; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .rou{ background-color: #def; } .report .rou td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .reu table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .num{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html1883571true600false6 falsefalseR1.htm995100 - Document - CoverSheethttp://xbrl.sec.gov/dei/role/document/CoverCoverCover1 falsefalseR2.htm995300 - Document - Audit InformationSheethttp://xbrl.sec.gov/dei/role/documentAuditInformationAudit InformationCover2 falsefalseR3.htm995301 - Statement - Consolidated Balance SheetsSheethttp://www.pluri-biotech.com/role/ConsolidatedBalanceSheetConsolidated Balance SheetsStatements3 falsefalseR4.htm995302 - Statement - Consolidated Balance Sheets (Parentheticals)Sheethttp://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_ParentheticalsConsolidated Balance Sheets (Parentheticals)Statements4 falsefalseR5.htm995303 - Statement - Consolidated Statements of OperationsSheethttp://www.pluri-biotech.com/role/ConsolidatedIncomeStatementConsolidated Statements of OperationsStatements5 falsefalseR6.htm995304 - Statement - Consolidated Statements of Operations (Parentheticals)Sheethttp://www.pluri-biotech.com/role/ConsolidatedIncomeStatement_ParentheticalsConsolidated Statements of Operations (Parentheticals)Statements6 falsefalseR7.htm995305 - Statement - Statements of Changes in Shareholders??? EquitySheethttp://www.pluri-biotech.com/role/ShareholdersEquityType2or3Statements of Changes in Shareholders??? EquityStatements7 falsefalseR8.htm995306 - Statement - Statements of Changes in Shareholders??? Equity (Parentheticals)Sheethttp://www.pluri-biotech.com/role/ShareholdersEquityType2or3_ParentheticalsStatements of Changes in Shareholders??? Equity (Parentheticals)Statements8 falsefalseR9.htm995307 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.pluri-biotech.com/role/ConsolidatedCashFlowConsolidated Statements of Cash FlowsStatements9 falsefalseR10.htm995308 - Disclosure - GeneralSheethttp://www.pluri-biotech.com/role/GeneralGeneralNotes10 falsefalseR11.htm995309 - Disclosure - Significant Accounting PoliciesSheethttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesSignificant Accounting PoliciesNotes11 falsefalseR12.htm995310 - Disclosure - Prepaid Expenses and Other Current AssetsSheethttp://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssetsPrepaid Expenses and Other Current AssetsNotes12 falsefalseR13.htm995311 - Disclosure - Property and Equipment, NetSheethttp://www.pluri-biotech.com/role/PropertyandEquipmentNetProperty and Equipment, NetNotes13 falsefalseR14.htm995312 - Disclosure - Other Accounts PayableSheethttp://www.pluri-biotech.com/role/OtherAccountsPayableOther Accounts PayableNotes14 falsefalseR15.htm995313 - Disclosure - LeasesSheethttp://www.pluri-biotech.com/role/LeasesLeasesNotes15 falsefalseR16.htm995314 - Disclosure - Loan from the EIBSheethttp://www.pluri-biotech.com/role/LoanfromtheEIBLoan from the EIBNotes16 falsefalseR17.htm995315 - Disclosure - Commitments and ContingenciesSheethttp://www.pluri-biotech.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes17 falsefalseR18.htm995316 - Disclosure - Shareholders' EquitySheethttp://www.pluri-biotech.com/role/ShareholdersEquityShareholders' EquityNotes18 falsefalseR19.htm995317 - Disclosure - Financial Income (Expenses), NetSheethttp://www.pluri-biotech.com/role/FinancialIncomeExpensesNetFinancial Income (Expenses), NetNotes19 falsefalseR20.htm995318 - Disclosure - Taxes on IncomeSheethttp://www.pluri-biotech.com/role/TaxesonIncomeTaxes on IncomeNotes20 falsefalseR21.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes21 falsefalseR22.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes22 falsefalseR23.htm996000 - Disclosure - Accounting Policies, by Policy (Policies)Sheethttp://www.pluri-biotech.com/role/AccountingPoliciesByPolicyAccounting Policies, by Policy (Policies)Policieshttp://www.pluri-biotech.com/role/SignificantAccountingPolicies23 falsefalseR24.htm996001 - Disclosure - General (Tables)Sheethttp://www.pluri-biotech.com/role/GeneralTablesGeneral (Tables)Tableshttp://www.pluri-biotech.com/role/General24 falsefalseR25.htm996002 - Disclosure - Significant Accounting Policies (Tables)Sheethttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesTablesSignificant Accounting Policies (Tables)Tableshttp://www.pluri-biotech.com/role/SignificantAccountingPolicies25 falsefalseR26.htm996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)Sheethttp://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssetsTablesPrepaid Expenses and Other Current Assets (Tables)Tableshttp://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssets26 falsefalseR27.htm996004 - Disclosure - Property and Equipment, Net (Tables)Sheethttp://www.pluri-biotech.com/role/PropertyandEquipmentNetTablesProperty and Equipment, Net (Tables)Tableshttp://www.pluri-biotech.com/role/PropertyandEquipmentNet27 falsefalseR28.htm996005 - Disclosure - Other Accounts Payable (Tables)Sheethttp://www.pluri-biotech.com/role/OtherAccountsPayableTablesOther Accounts Payable (Tables)Tableshttp://www.pluri-biotech.com/role/OtherAccountsPayable28 falsefalseR29.htm996006 - Disclosure - Leases (Tables)Sheethttp://www.pluri-biotech.com/role/LeasesTablesLeases (Tables)Tableshttp://www.pluri-biotech.com/role/Leases29 falsefalseR30.htm996007 - Disclosure - Shareholders' Equity (Tables)Sheethttp://www.pluri-biotech.com/role/ShareholdersEquityTablesShareholders' Equity (Tables)Tableshttp://www.pluri-biotech.com/role/ShareholdersEquity30 falsefalseR31.htm996008 - Disclosure - Financial Income (Expenses), Net (Tables)Sheethttp://www.pluri-biotech.com/role/FinancialIncomeExpensesNetTablesFinancial Income (Expenses), Net (Tables)Tableshttp://www.pluri-biotech.com/role/FinancialIncomeExpensesNet31 falsefalseR32.htm996009 - Disclosure - Taxes on Income (Tables)Sheethttp://www.pluri-biotech.com/role/TaxesonIncomeTablesTaxes on Income (Tables)Tableshttp://www.pluri-biotech.com/role/TaxesonIncome32 falsefalseR33.htm996010 - Disclosure - General (Details)Sheethttp://www.pluri-biotech.com/role/GeneralDetailsGeneral (Details)Detailshttp://www.pluri-biotech.com/role/GeneralTables33 falsefalseR34.htm996011 - Disclosure - General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation ModelSheethttp://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTableGeneral (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation ModelDetailshttp://www.pluri-biotech.com/role/GeneralTables34 falsefalseR35.htm996012 - Disclosure - Significant Accounting Policies (Details)Sheethttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetailsSignificant Accounting Policies (Details)Detailshttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables35 falsefalseR36.htm996013 - Disclosure - Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and ImpairmentsSheethttp://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTableSignificant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and ImpairmentsDetailshttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables36 falsefalseR37.htm996014 - Disclosure - Significant Accounting Policies (Details) - Schedule of Black-Scholes Option-Pricing Model Using the Following AssumptionsSheethttp://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTableSignificant Accounting Policies (Details) - Schedule of Black-Scholes Option-Pricing Model Using the Following AssumptionsDetailshttp://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables37 falsefalseR38.htm996015 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets (Details)Sheethttp://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTablePrepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current

AssetsDetailshttp://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssetsTables38 falsefalseR39.htm996016 - Disclosure - Property and Equipment, Net (Details)Sheethttp://www.pluri-biotech.com/role/PropertyandEquipmentNetDetailsProperty and Equipment, Net (Details)Detailshttp://www.pluri-biotech.com/role/PropertyandEquipmentNetTables39 falsefalseR40.htm996017 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, NetSheethttp://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTableProperty and Equipment, Net (Details) - Schedule of Property and Equipment, NetDetailshttp://www.pluri-biotech.com/role/PropertyandEquipmentNetTables40 falsefalseR41.htm996018 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts PayableSheethttp://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTableOther Accounts Payable (Details) - Schedule of Other Accounts PayableDetailshttp://www.pluri-biotech.com/role/OtherAccountsPayableTables41 falsefalseR42.htm996019 - Disclosure - Leases (Details)Sheethttp://www.pluri-biotech.com/role/LeasesDetailsLeases (Details)Detailshttp://www.pluri-biotech.com/role/LeasesTables42 falsefalseR43.htm996020 - Disclosure - Leases (Details) - Schedule of Operating Lease AgreementSheethttp://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTableLeases (Details) - Schedule of Operating Lease AgreementDetailshttp://www.pluri-biotech.com/role/LeasesTables43 falsefalseR44.htm996021 - Disclosure - Leases (Details) - Schedule of Maturities of Operating Lease LiabilitiesSheethttp://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTableLeases (Details) - Schedule of Maturities of Operating Lease LiabilitiesDetailshttp://www.pluri-biotech.com/role/LeasesTables44 falsefalseR45.htm996022 - Disclosure - Leases (Details) - Schedule of Lease Expense and Supplemental Cash Flow InformationSheethttp://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTableLeases (Details) - Schedule of Lease Expense and Supplemental Cash Flow InformationDetailshttp://www.pluri-biotech.com/role/LeasesTables45 falsefalseR46.htm996023 - Disclosure - Loan from the EIB (Details)Sheethttp://www.pluri-biotech.com/role/LoanfromtheEIBDetailsLoan from the EIB (Details)Detailshttp://www.pluri-biotech.com/role/LoanfromtheEIB46 falsefalseR47.htm996024 - Disclosure - Commitments and Contingencies (Details)Sheethttp://www.pluri-biotech.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://www.pluri-biotech.com/role/CommitmentsandContingencies47 falsefalseR48.htm996025 - Disclosure - Shareholders' Equity (Details)Sheethttp://www.pluri-biotech.com/role/ShareholdersEquityDetailsShareholders' Equity (Details)Detailshttp://www.pluri-biotech.com/role/ShareholdersEquityTables48 falsefalseR49.htm996026 - Disclosure - Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employeeSheethttp://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTableShareholders' Equity (Details) - Schedule of Share Options Granted Non-employeeDetailshttp://www.pluri-biotech.com/role/ShareholdersEquityTables49 falsefalseR50.htm996027 - Disclosure - Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs GrantedSheethttp://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTableShareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs GrantedDetailshttp://www.pluri-biotech.com/role/ShareholdersEquityTables50 falsefalseR51.htm996028 - Disclosure - Shareholders' Equity (Details) - Schedule of Expenses Related to RSUs GrantedSheethttp://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTableShareholders' Equity (Details) - Schedule of Expenses Related to RSUs GrantedDetailshttp://www.pluri-biotech.com/role/ShareholdersEquityTables51 falsefalseR52.htm996029 - Disclosure - Shareholders' Equity (Details) - Schedule of Warrants and OptionsSheethttp://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTableShareholders' Equity (Details) - Schedule of Warrants and OptionsDetailshttp://www.pluri-biotech.com/role/ShareholdersEquityTables52 falsefalseR53.htm996030 - Disclosure - Financial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), NetSheethttp://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTableFinancial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), NetDetailshttp://www.pluri-biotech.com/role/FinancialIncomeExpensesNetTables53 falsefalseR54.htm996031 - Disclosure - Taxes on Income (Details)Sheethttp://www.pluri-biotech.com/role/TaxesonIncomeDetailsTaxes on Income (Details)Detailshttp://www.pluri-biotech.com/role/TaxesonIncomeTables54 falsefalseR55.htm996032 - Disclosure - Taxes on Income (Details) - Schedule of Loss Before Income TaxesSheethttp://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTableTaxes on Income (Details) - Schedule of Loss Before Income TaxesDetailshttp://www.pluri-biotech.com/role/TaxesonIncomeTables55 falsefalseR56.htm996033 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Income TaxesSheethttp://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTableTaxes on Income (Details) - Schedule of Deferred Income TaxesDetailshttp://www.pluri-biotech.com/role/TaxesonIncomeTables56 falsefalseAll ReportsBookAll Reports ea0213910-10k_pluriinc.htmplur-20240630.xsdplur-20240630_cal.xmlplur-20240630_def.xmlplur-20240630_lab.xmlplur-20240630_pre.xml image_001.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0213910-10k_pluriinc.htm": { "nsprefix": "plur", "nsuri": "http://www.pluri-biotech.com/20240630", "dts": { "inline": { "local": ["ea0213910-10k_pluriinc.htm"] }, "schema": { "local": ["plur-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["plur-20240630_cal.xml"] }, "definitionLink": { "local": ["plur-20240630_def.xml"] }, "labelLink": { "local": ["plur-20240630_lab.xml"] }, "presentationLink": { "local": ["plur-20240630_pre.xml"] } }, "keyStandard": 271, "keyCustom": 86, "axisStandard": 18, "axisCustom": 0, "memberStandard": 23, "memberCustom": 35, "hidden": { "total": 57, "http://fasb.org/us-gaap/2024": 39, "http://www.pluri-biotech.com/20240630": 13, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 188, "entityCount": 1, "segmentCount": 60, "elementCount": 751, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 615, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation", "longName": "995300 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "plur:ShorttermBankDeposits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R4": { "role": "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": ["td", "tr", "table", "div", "body", "html"] "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R5": { "role": "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "995304 - Statement - Consolidated Statements of Operations (Parentheticals)", "shortName": "Consolidated Statements of Operations (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": null, "uniqueAnchor": null }, "R7": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3", "longName": "995305 - Statement - Statements of Changes in Shareholders\u2019 Equity", "shortName": "Statements of Changes in Shareholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3_Parentheticals", "longName": "995306 - Statement - Statements of Changes in Shareholders\u2019 Equity (Parentheticals)", "shortName": "Statements of Changes in Shareholders\u2019 Equity (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c5", "name": "plur:NetOfIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "plur:NetOfIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "longName": "995307 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R10": { "role": "http://www.pluri-biotech.com/role/General", "longName": "995308 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pluri-biotech.com/role/SignificantAccountingPolicies", "longName": "995309 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssets", "longName": "995310 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pluri-biotech.com/role/PropertyandEquipmentNet", "longName": "995311 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pluri-biotech.com/role/OtherAccountsPayable", "longName": "995312 - Disclosure - Other Accounts Payable", "shortName": "Other Accounts Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pluri-biotech.com/role/Leases", "longName": "995313 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pluri-biotech.com/role/LoanfromtheEIB", "longName": "995314 - Disclosure - Loan from the EIB", "shortName": "Loan from the EIB", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "plur:LoanFromTheEIBTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0213910-

```
10k_pluriinc.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:LoanFromTheFIBTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pluri-biotech.com/role/CommitmentsandContingencies", "longName": "995315 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquity", "longName": "995316 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pluri-biotech.com/role/FinancialIncomeExpensesNet", "longName": "995317 - Disclosure - Financial Income (Expenses), Net", "shortName": "Financial Income (Expenses), Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pluri-biotech.com/role/TaxesonIncome", "longName": "995318 - Disclosure - Taxes on Income", "shortName": "Taxes on Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true } }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c187", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c187", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.pluri-biotech.com/role/GeneralTables", "longName": "996001 - Disclosure - General (Tables)", "shortName": "General (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "plur:DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables", "longName": "996002 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "plur:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "longName": "996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.pluri-biotech.com/role/PropertyandEquipmentNetTables", "longName": "996004 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.pluri-biotech.com/role/OtherAccountsPayableTables", "longName": "996005 - Disclosure - Other Accounts Payable (Tables)", "shortName": "Other Accounts Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.pluri-biotech.com/role/LeasesTables", "longName": "996006 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityTables", "longName": "996007 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.pluri-biotech.com/role/FinancialIncomeExpensesNetTables", "longName": "996008 - Disclosure - Financial Income (Expenses), Net (Tables)", "shortName": "Financial Income (Expenses), Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pluri-biotech.com/role/TaxesonIncomeTables", "longName": "996009 - Disclosure - Taxes on Income (Tables)", "shortName": "Taxes on Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "plur:ScheduleOfLossBeforeIncomeTaxesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:ScheduleOfLossBeforeIncomeTaxesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pluri-biotech.com/role/GeneralDetails", "longName": "996010 - Disclosure - General (Details)", "shortName": "General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R34": { "role": "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable", "longName": "996011 - Disclosure - General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model", "shortName": "General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "plur:DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "plur:DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R35": { "role": "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails", "longName": "996012 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "longName": "996013 - Disclosure - Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments", "shortName": "Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "plur:PropertyPlantAndEquipmentsUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "plur:PropertyPlantAndEquipmentsUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "longName": "996014 - Disclosure - Significant Accounting Policies (Details) - Schedule of Black-Scholes Option Pricing Model Using the Following Assumptions", "shortName": "Significant Accounting Policies (Details) - Schedule of Black-Scholes Option Pricing Model Using the Following Assumptions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4",
```

```
"ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable", "longName": "996015 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.pluri-biotech.com/role/PropertyandEquipmentNetDetails", "longName": "996016 - Disclosure - Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "longName": "996017 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net", "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable", "longName": "996018 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable", "shortName": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c3", "name": "plur:GrantsReceivedInAdvance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "plur:GrantsReceivedInAdvance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.pluri-biotech.com/role/LeasesDetails", "longName": "996019 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable", "longName": "996020 - Disclosure - Leases (Details) - Schedule of Operating Lease Agreement", "shortName": "Leases (Details) - Schedule of Operating Lease Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable", "longName": "996021 - Disclosure - Leases (Details) - Schedule of Maturities of Operating Lease Liabilities", "shortName": "Leases (Details) - Schedule of Maturities of Operating Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.pluri-biotech.com/role/ScheduleofLeaseExpensesandSupplementalCashFlowInformationTable", "longName": "996022 - Disclosure - Leases (Details) - Schedule of Lease Expense and Supplemental Cash Flow Information", "shortName": "Leases (Details) - Schedule of Lease Expense and Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:VariableLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "longName": "996023 - Disclosure - Loan from the EIB (Details)", "shortName": "Loan from the EIB (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c72", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "eur", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "plur:LoanFromTheEIBTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c76", "name": "plur:FinanceContractPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "plur:LoanFromTheEIBTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R47": { "role": "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails", "longName": "996024 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "longName": "996025 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c89", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R49": { "role": "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "longName": "996026 - Disclosure - Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee", "shortName": "Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c122", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c120", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R50": { "role": "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "longName": "996027 - Disclosure - Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted", "shortName": "Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c127", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c128", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R51": { "role": "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "longName": "996028 - Disclosure - Shareholders' Equity (Details) - Schedule of Expenses Related to RSUs Granted", "shortName": "Shareholders' Equity (Details) - Schedule of Expenses Related to RSUs Granted", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "longName": "996029 - Disclosure - Shareholders' Equity (Details) - Schedule of Warrants and Options", "shortName": "Shareholders' Equity (Details) - Schedule of Warrants and Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c3", "name": "plur:ShareBasedCompensationShareAuthorizedUnderStockWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "plur:ShareBasedCompensationShareAuthorizedUnderStockWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable", "longName": "996030 - Disclosure - Financial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), Net", "shortName": "Financial Income (Expenses), Net (Details) - Schedule of Financial Income (Expenses), Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.pluri-biotech.com/role/TaxesonIncomeDetails", "longName": "996031 - Disclosure - Taxes on Income (Details)", "shortName": "Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c170", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c170", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable", "longName": "996032 - Disclosure - Taxes on Income (Details) - Schedule of Loss Before Income Taxes", "shortName": "Taxes on Income (Details) - Schedule of Loss Before Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c183", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "unique": true } }, "R56": { "role": "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable", "longName": "996033 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Income Taxes", "shortName": "Taxes on Income (Details) - Schedule of Deferred Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0213910-10k_pluriinc.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r61", "r67" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/OtherAccountsPayable" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER
```

ACCOUNTS PAYABLE", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r48", "r51", "r56", "r767"] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other accounts payable", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Accounts Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r48"] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r12", "r48"] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Customer receivable", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r135", "r195", "r196", "r806"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r51"] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll", "label": "Accrued Payroll Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r51"] }, "plur_AccruedRoyaltiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AccruedRoyaltiesAmount", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "documentation": "The amount of accrued royalties." "label": "Accrued Royalties Amount" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalty (in Dollars)", "label": "Accrued Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": ["r98"] }, "plur_AccruedVacationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AccruedVacationsCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued vacation and recuperation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees." "label": "Accrued Vacations Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Total accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r22", "r129", "r420"] }, "plur_AccumulatedLosseCarriedForward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AccumulatedLosseCarriedForward", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated losses carry forward (in Dollars)", "documentation": "Amount of accumulated losses carried forward.", "label": "Accumulated Losse Carried Forward" } } }, "auth_ref": [] }, "plur_AccumulatedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AccumulatedLosses", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated losses (in Dollars)", "documentation": "Amount of accumulated losses." "label": "Accumulated Losses" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r632"] }, "us-gaap_AdditionalCashFlowElementsSummationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsSummationsAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:", "label": "Additional Cash Flow Elements, Summations [Abstract]" } } }, "auth_ref": [] }, "plur_AdditionalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AdditionalInvestment", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional investment", "documentation": "The amount of additional investment.", "label": "Additional Investment" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r62", "r562", "r809"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r449", "r714", "r715", "r716", "r718", "r774", "r812"] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": ["r688"] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": ["r688"] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": ["r686"] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r645"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r645"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r645"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r645"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d)", "label": "Adjustments to Additional Paid in Capital, Stock Split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": ["r7", "r85"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "plur_AggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AggregateAmount", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount", "documentation": "Aggregate amount." "label": "Aggregate Amount" } } }, "auth_ref": [] }, "plur_AggregateAmountReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AggregateAmountReceived", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/SharcholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount receives (in Dollars)", "documentation": "Amount of aggregate amount received." "label": "Aggregate Amount Received" } } }, "auth_ref": [] }, "plur_AggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AggregateGrossProceeds", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/SharcholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price (in Dollars)", "documentation": "Aggregate gross proceeds." "label": "Aggregate Gross Proceeds" } } }, "auth_ref": [] }, "plur_AggregatePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AggregatePrice", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate price", "documentation": "Amount of aggregate price." "label": "Aggregate Price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r679"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r595", "r606", "r622", "r657"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r598", "r609", "r625", "r660"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r680"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r645"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r652"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r599", "r610", "r626", "r652", "r661", "r665", "r673"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r671"] }, "plur_AllocatedConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AllocatedConsideration", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allocated consideration", "documentation": "Represents allocated consideration." "label": "Allocated Consideration" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname",

```
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r306", "r312" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "plur_AmountEqualToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AmountEqualToReceive", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount equal to Receive", "documentation": "Amount equal to receive.", "label": "Amount Equal To Receive" } } }, "auth_ref": [] }, "plur_AnnualCashSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AnnualCashSalary", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual cash salary (in Dollars)", "documentation": "Annual cash salary.", "label": "Annual Cash Salary" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r602" ] }, "plur_AnnualInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "AnnualInterestMember", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual Interest [Member]", "label": "Annual Interest Member" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive effect shares (in Shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r178" ] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r96", "r109", "r131", "r152", "r181", "r185", "r190", "r191", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r348", "r352", "r368", "r410", "r478", "r540", "r541", "r562", "r574", "r734", "r735", "r793" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r125", "r138", "r152", "r107", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r348", "r352", "r368", "r562", "r734", "r735", "r793" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r152", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r348", "r352", "r368", "r734", "r735", "r793" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM ASSETS:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r602" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r587", "r590", "r602" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r587", "r590", "r602" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r587", "r590", "r602" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r684" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r668" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r669" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r664" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails", "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r301", "r302", "r303", "r304", "r305" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r667" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r666" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r665" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r665" ] }, "plur_BankAndBrokerCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "BankAndBrokerCommissions", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Bank and broker commissions", "documentation": "The amount of bank and broker commissions.", "label": "Bank And Broker Commissions" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r590", "r602" ] }, "plur_CEOAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CEOAndDirectorsMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO and directors [Member]", "verboseLabel": "CEO and Directors [Member]", "label": "CEOAnd Directors Member" } } }, "auth_ref": [] }, "plur_CEOsGrantAgreementsDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CEOsGrantAgreementsDescription", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO's grant agreements, description", "documentation": "CEO's grant agreements, description.", "label": "CEOs Grant Agreements Description" } } }, "auth_ref": [] }, "plur_CapitalConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CapitalConsideration", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital consideration", "documentation": "Capital consideration.", "label": "Capital Consideration" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r14", "r127", "r534" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r15", "r94" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments
```

with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r703"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r76", "r149"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, restricted cash and restricted bank deposits", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r76", "r149"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash, cash equivalents, restricted cash and restricted bank deposits", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r76"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "(a) Supplemental disclosure of non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "plur_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateLineItems", "presentation": ["http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r164"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r643"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r640"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r638"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Shareholders\" Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r132", "r133", "r134", "r184", "r242", "r243", "r244", "r246", "r249", "r254", "r256", "r441", "r442", "r443", "r444", "r548", "r606", "r710"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r25"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "verboseLabel": "Exercise price per share (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r257"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r257"] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r25"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r644"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r644"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r57", "r100", "r412", "r463"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r83", "r206", "r207", "r528", "r726", "r731"] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": ["r23", "r529"] }, "plur_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares future grants", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "verboseLabel": "Common Stock [Member]", "netLabel": "Common Member [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r564", "r565", "r566", "r568", "r569", "r570", "r571", "r714", "r715", "r718", "r774", "r808", "r812"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value per share (in Dollars per share)", "verboseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized", "verboseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r60", "r464"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r60", "r464", "r484", "r812", "r813"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {

```
"http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, $0.00001 par value per share; authorized: 37,500,000 as of June 30, 2024 and 2023; issued and outstanding: 5,408,212 and 5,155,687 shares as of June 30, 2024 and 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r60", "r414", "r562" ] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonUnitIssued", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "label": "Common Unit, Issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r85" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r649" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r648" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r650" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r647" ] }, "plur_CompensationExpenseRecognizedDuringThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CompensationExpenseRecognizedDuringThePeriod", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense recognized during the period", "documentation": "The compensation expense recognized during the period.", "label": "Compensation Expense Recognized During The Period" } } }, "auth_ref": [] }, "plur_ComponentsOfLeaseExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ComponentsOfLeaseExpenseAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Components of lease expense", "label": "Components Of Lease Expense Abstract" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Computers and peripheral equipment [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of credit risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r46", "r113" ] }, "plur_ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated loss of Pluri Inc. and the Israeli Subsidiaries [Member]", "label": "Consolidated Loss Of Pluri Inc And The Israeli Subsidiaries Member" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r35", "r537" ] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r590" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "plur_ContingentLiabilityInRespectToRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ContingentLiabilityInRespectToRoyalties", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability in respect to royalties", "documentation": "The amount of contingent liability in respect to royalties.", "label": "Contingent Liability In Respect To Royalties" } } }, "auth_ref": [] }, "plur_ContractualInterestRateForFundsBorrowed": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ContractualInterestRateForFundsBorrowed", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual interest rate", "documentation": "Contractual interest rate for funds borrowed, under the loan agreement.", "label": "Contractual Interest Rate For Funds Borrowed" } } }, "auth_ref": [] }, "plur_CorporateTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "CorporateTaxRate", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of corporate tax rate", "documentation": "Percentage of corporate tax rate.", "label": "Corporate Tax Rate" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r60", "r152", "r107", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r368", "r540", "r734" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r212", "r732" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r212", "r732", "r733" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerAdvancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerAdvancesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Advances from customers", "label": "Customer Advances, Current", "documentation": "The current portion of prepayments received from customers for goods or services to be provided in the future." } } }, "auth_ref": [ "r105" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r11", "r50", "r51", "r97", "r99", "r155", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r543", "r544", "r545", "r546", "r547", "r560", "r711", "r727", "r728", "r729", "r788", "r789" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance contract (in Euro)", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r222", "r380", "r381", "r544", "r545", "r560" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual interest percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r53", "r239", "r380", "r381", "r560" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated revenues percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r53", "r223" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Loan from the EIB [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r155", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r543", "r544", "r545", "r546", "r547", "r560", "r711", "r788", "r789" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r11", "r155", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r543", "r544", "r545", "r546", "r547", "r560", "r711", "r727", "r728", "r729", "r788", "r789" ] }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance expenses (in Dollars)", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses." } } }, "auth_ref": [ "r73" ] }, "plur_DeferredInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "DeferredInterestRatePercentage", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of deferred interest rate", "documentation": "Percentage of deferred interest rate.", "label": "Deferred Interest Rate Percentage" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax asset", "label": "Deferred Tax Assets, Net", "documentation": "Amount after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r771" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets before valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r771" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": ["r773"] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable"], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": ["r773"] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": ["r773"] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable"], "lang": { "en-us": { "role": { "terseLabel": "Allowances and reserves", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r773"] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofDeferredIncomeTaxesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r328"] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Severance pay fund", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": ["r95", "r267", "r268", "r269", "r477", "r549", "r803"] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r614", "r615", "r629"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "http://www.pluri-biotech.com/role/PropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "verboseLabel": "Depreciation expenses", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r21"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r452", "r455", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r479", "r480", "r482", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r517", "r518", "r519", "r520", "r564", "r566", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r41", "r42", "r44", "r93", "r452", "r455", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r479", "r480", "r481", "r482", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r517", "r518", "r519", "r520", "r536", "r564", "r566", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785"] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r8", "r38", "r39", "r40", "r45", "r154", "r169"] }, "plur_DirectorAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "DirectorAndChiefExecutiveOfficerMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Director and Chief Executive Officer [Member]", "label": "Director And Chief Executive Officer Member" } } }, "auth_ref": [] }, "plur_DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "DisclosureOfMainAssumptionsUsedInSimulationModelTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/GeneralTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Main Assumptions Used in the Monte Carlo Simulation Model", "documentation": "Tabular disclosure of main assumptions used in simulation model.", "label": "Disclosure Of Main Assumptions Used In Simulation Model Table Text Block" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r614", "r615", "r629"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r590"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r587", "r590", "r602"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r587", "r590", "r602", "r653"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": ["r587", "r590", "r602", "r653"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r588"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r576"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r590"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r590"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r630"] }, "dei_DocumentType": { "xbrltype":

```
"submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r579" ] }, "plur_DueDate": { "xbrltype": "dateItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "DueDate", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due date", "documentation": "Due date.", "label": "Due Date" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PypDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r642" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r146", "r161", "r162", "r163", "r164", "r165", "r166", "r171", "r173", "r175", "r176", "r177", "r180", "r343", "r346", "r362", "r363", "r407", "r426", "r538" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r146", "r161", "r162", "r163", "r164", "r165", "r166", "r173", "r175", "r176", "r177", "r180", "r343", "r346", "r362", "r363", "r407", "r426", "r538" ] }, "us-gaap_EarningsPerShareDilutedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r16", "r17", "r179" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r373" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r787" ] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r692" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r153", "r319", "r335", "r552" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r321", "r552", "r713", "r768" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r320", "r552", "r713", "r768" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign entity investors reduction rate", "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions." } } }, "auth_ref": [ "r713", "r768", "r769" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income rate", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r552", "r713", "r768", "r769" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue rate", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit." } } }, "auth_ref": [ "r713", "r768", "r770" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r692" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r693" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r692" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r693" ] }, "plur_EffectiveTaxRateLosSCarryforwardPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EffectiveTaxRateLosSCarryforwardPercentage", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax carried forward", "documentation": "Percentage of effective tax rate loss carryforward.", "label": "Effective Tax Rate Los SCarryforward Percentage" } } }, "auth_ref": [] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r691" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r693" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r695" ] }, "plur_EightPointFourEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EightPointFourEightMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "8.48 [Member]", "label": "Eight Point Four Eight Member" } } }, "auth_ref": [] }, "plur_EightPointFourZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EightPointFourZeroMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "8.40 [Member]", "label": "Eight Point Four Zero Member" } } }, "auth_ref": [] }, "plur_EightPointNineSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EightPointNineSixMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "8.96 [Member]", "label": "Eight Point Nine Six Member" } } }, "auth_ref": [] }, "plur_EightPointSevenTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EightPointSevenTwoMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "8.72\t[Member]", "label": "Eight Point Seven Two Member" } } }, "auth_ref": [] }, "plur_EightPointTwoFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EightPointTwoFourMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "8.24\t[Member]", "label": "Eight Point Two Four Member" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r307" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Payment Arrangement, Option [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "plur_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "EmployeesAndDirectorsMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and Directors [Member]", "label": "Employees And Directors Member" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [
```

```
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } },
"auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } },
"auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship
between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated
with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation",
"Container of address information for the entity" } } }, "auth_ref": [ "r578" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that
the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } },
"auth_ref": [ "r582" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that
have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r578" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other
ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A
[Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included
in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file
such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names
of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited
liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } }
}, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the
emerging growth company criteria." } } }, "auth_ref": [ "r578" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an
emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r694" ] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The
prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] },
"dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large
Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's
current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r578" ] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Home
Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country
of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ],
"lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or
Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity
Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r683" ] }, "dei_EntityInvCompanyType": { "xbrltype":
"invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3
(Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT
Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r682" ] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Legal Form",
"documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": {
"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": {
"en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global
Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } },
"auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the
exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] },
"dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same
currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingPrimary", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value
indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": []
}, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the
domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line
Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in
one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for
an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the
Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number
for the Entity." } } }, "auth_ref": [ "r602" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit",
"presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-
voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the
last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant
Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r578" ] },
"dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the
currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true
when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r578" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r578" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label":
"Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the
IRS." } } }, "auth_ref": [ "r578" ] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": [
```

```
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r685" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r636" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r678" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r678" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r678" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember",
"presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment [Member]", "label":
"Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r122", "r142", "r143", "r144", "r156", "r157", "r158", "r160", "r165", "r167", "r169", "r183", "r198", "r199", "r202", "r258", "r333", "r334", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r385", "r399", "r425", "r431", "r432", "r433", "r449", "r505" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r646" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r595", "r606", "r622", "r657" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r592", "r603", "r619", "r654" ] }, "us-gaap_ExcessStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ExcessStockSharesIssued", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares issued (in Shares)", "verboseLabel": "Purchase of aggregate", "label": "Excess Stock, Shares Issued", "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category." } } }, "auth_ref": [ "r652" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r690" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": {
"role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r690" ] }, "plur_ExpirationOfWarrantInEverAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ExpirationOfWarrantInEverAfter", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Expiration of warrants in ever after", "documentation": "Expiration of warrants in ever after.", "label": "Expiration Of Warrant In Ever After" } } }, "auth_ref": [] },
"plur_ExpirationOfWarrantsInEverAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ExpirationOfWarrantsInEverAfter", "crdr": "debit",
"presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration of warrants in Ever After", "documentation":
"Expiration of warrants in ever after.", "label": "Expiration Of Warrants In Ever After" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation":
"Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r5" ] }, "plur_FinanceContractPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname":
"FinanceContractPeriod", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance contract period", "documentation":
"Finance contract period.", "label": "Finance Contract Period" } } }, "auth_ref": [] }, "plur_FinanceContractWithEIBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "FinanceContractWithEIBMember", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Finance Contract with EIB [Member]", "label": "Finance Contract With EIBMember" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pluri-biotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r394", "r561" ] }, "plur_FinancialIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname":
"FinancialIncomeExpense", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income expense", "documentation": "The amount of financial income expense.", "label": "Financial Income Expense" } } }, "auth_ref": [] }, "plur_FirstWarrantMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "FirstWarrantMember", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Warrant [Member]", "label": "First Warrant Member" } } }, "auth_ref": [] }, "plur_FivePointEightZeroMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.pluri-biotech.com/20240630", "localname": "FivePointEightZeroMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "5.80 [Member]", "label": "Five Point Eight Zero Member" } } }, "auth_ref": [] }, "plur_FixedInterestRate": { "xbrltype": "percentItemType", "nsuri":
"http://www.pluri-biotech.com/20240630", "localname": "FixedInterestRate", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Percentage of fixed interest rate", "documentation": "Percentage of fixed interest rate.", "label": "Fixed Interest Rate" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r502" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r599", "r610", "r626", "r661" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r599", "r610", "r626", "r661" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } },
"auth_ref": [ "r599", "r610", "r626", "r661" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r599", "r610", "r626", "r661" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r599", "r610", "r626", "r661" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r589", "r613" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } },
"auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r641" ] }, "plur_FunctionalCurrencyPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "FunctionalCurrencyPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Functional currency", "documentation": "Disclosure of accounting policy for the use of estimates functional currency.", "label": "Functional Currency Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_GainLossOnForeignCurrencyFairValueHedgeDerivatives": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnForeignCurrencyFairValueHedgeDerivatives", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from hedging derivatives", "label": "Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives", "documentation": "Amount of gain (loss) from increase (decrease) in fair value of foreign currency derivative and nonderivative instruments designated as fair value hedge recognized in earnings and from related hedged item to extent that fair value hedge was determined to be effective." } } }, "auth_ref": [ "r41", "r43" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit",
"calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r71", "r488" ] },
"plur_GeneralDetailsScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname":
"GeneralDetailsScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable" ], "lang": { "en-us": { "role": { "label": "General (Details) - Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Table]" } } }, "auth_ref": [] }, "plur_GeneralDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname":
"GeneralDetailsTable", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General (Details) [Table]" } } }, "auth_ref": [] },
"plur_GermanCorporationTaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "GermanCorporationTaxMember", "presentation": [
"http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "German Corporation Tax [Member]", "label": "German Corporation Tax Member" } } },
"auth_ref": [] }, "plur_GermanSubsidiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "GermanSubsidiaryMember", "presentation":
[ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "German Subsidiary [Member]", "label": "German Subsidiary Member" } } }, "auth_ref":
[] }, "plur_GovernmentAndThirdPartyGrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname":
"GovernmentAndThirdPartyGrantsReceived", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-
```

biotech.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less: participation by the NIAID, the IIA, Horizon Europe and other parties", "verboseLabel": "Participation in research and development expenses", "documentation": "Grants received from the government and third parties for research and development programs.", "label": "Government And Third Party Grants Received" } } }, "auth_ref": [] }, "plur_GrantedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "GrantedShares", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted shares", "documentation": "Granted shares." "label": "Granted Shares" } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable from grants", "label": "Grants Receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": ["r702"] }, "plur_GrantsReceivedInAdvance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "GrantsReceivedInAdvance", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Grants received in advance", "documentation": "The amount of grants received in advance." "label": "Grants Received In Advance" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r68", "r69", "r108", "r152", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r368", "r539", "r540", "r719", "r720", "r721", "r722", "r723", "r734"] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r587", "r590", "r602"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r203", "r204", "r205", "r365", "r366", "r367", "r428", "r430", "r489", "r532", "r555", "r807"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r204", "r205", "r365", "r366", "r367", "r428", "r430", "r489", "r532", "r555", "r807"] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": ["r325", "r772"] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": ["r325", "r772"] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Loss Before Income Taxes [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Taxes on Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncome"], "lang": { "en-us": { "role": { "terseLabel": "TAXES ON INCOME", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r153", "r316", "r319", "r322", "r323", "r324", "r326", "r330", "r336", "r337", "r338", "r339", "r446", "r552"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r141", "r317", "r318", "r326", "r327", "r329", "r332", "r440"] }, "plur_IncomeTaxRegularTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "IncomeTaxRegularTaxRate", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax regular tax rate", "documentation": "Percentage of income tax regular tax rate." "label": "Income Tax Regular Tax Rate" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in trade payables", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in interest receivable on short-term deposits", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Increase in long-term interest payable and exchange rate differences related to the EIB loan, net", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in other accounts payable and accrued expenses", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPensionAndPostretirementObligations", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accrued severance pay, net", "label": "Increase (Decrease) in Obligation, Pension and Other Postretirement Benefits", "documentation": "Amount of increase (decrease) in obligation for pension and other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in prepaid expenses and other current assets and other long-term assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "plur_IncreasedecreaseInOperatingLeaseRightofuseAssetAndLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "IncreasedecreaseInOperatingLeaseRightofuseAssetAndLiabilityNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in operating lease right-of-use asset and liability, net", "documentation": "Increase (decrease) in operating lease right-of-use asset and liability, net." "label": "Increasedecrease In Operating Lease Rightofuse Asset And Liability Net" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r599", "r610", "r626", "r652", "r661", "r665", "r673"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements." } } }, "auth_ref": ["r671"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r591", "r677"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r591", "r677"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r591", "r677"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable"], "lang": { "en-us": { "role": { "negatedLabel": "EIB loan interest expenses", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r73", "r235", "r240", "r546", "r547"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r188", "r705"] }, "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeDepositsWithFinancialInstitutions", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Interest income on deposits and restricted bank deposits", "label": "Interest Income, Deposits with Financial Institutions", "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts." } } }, "auth_ref": ["r104", "r120", "r121"] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r615", "r616", "r617", "r618"] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r631"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r631"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r631"] }, "plur_InvestmentInEvenAfterSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "InvestmentInEvenAfterSubsidiary", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment in ever after subsidiary", "documentation": "Investment in even after subsidiary.", "label": "Investment In Even After Subsidiary" } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Principal balance (in Dollars)", "label": "Investment Owned, Balance, Principal Amount", "documentation":

```
"Amount of principal of investment owned." } } }, "auth_ref": [ "r451", "r453", "r512", "r516", "r522", "r566" ] }, "plur_IsraelInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "IsraelInnovationAuthorityMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Israel Innovation Authority [Member]", "label": "Israel Innovation Authority Member" } } }, "auth_ref": [] }, "plur_IssuanceOfCommonStockAndWarrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "IssuanceOfCommonStockAndWarrant", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs (in Shares)", "documentation": "Issuance of common share and warrants.", "label": "Issuance Of Common Stock And Warrant" } } }, "auth_ref": [] }, "plur_IssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "IssuanceOfCommonStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares and warrants related to December 2022 private placement, net of issuance costs", "documentation": "Issuance of common share and warrants.", "label": "Issuance Of Common Stock And Warrants" } } }, "auth_ref": [] }, "plur_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment [Member]", "label": "Laboratory Equipment Member" } } }, "auth_ref": [] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Lease Expense and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "plur_LeasePaymentsIncreasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LeasePaymentsIncreasePercentage", "presentation": [ "http://www.pluri-biotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of lease payment increase", "documentation": "Percentage of lease payments increase.", "label": "Lease Payments Increase Percentage" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r82", "r307" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesOperatingAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Lease Agreement [Abstract]" } } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r575" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r790" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r396" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r384" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r66", "r102", "r417", "r562", "r712", "r725", "r786" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r52", "r126", "r152", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r349", "r352", "r353", "r368", "r562", "r734", "r793", "r794" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r11", "r55", "r56", "r57", "r58", "r152", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r349", "r352", "r353", "r368", "r734", "r793", "r794" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM LIABILITIES", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities (in Dollars)", "label": "Liabilities, Other than Long-Term Debt, Noncurrent", "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance of principal and interest accrued", "label": "Line of Credit Facility, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period." } } }, "auth_ref": [ "r711" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r49", "r54" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan amount (in Euro)", "verboseLabel": "Subsidiary obtain loan amount (in Euro)", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r49", "r54" ] }, "plur_LoanFromTheEIBTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LoanFromTheEIBTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIB" ], "lang": { "en-us": { "role": { "terseLabel": "LOAN FROM THE EIB", "documentation": "Disclosure of loan from the EIB.", "label": "Loan From The EIBText Block" } } }, "auth_ref": [] }, "plur_LoanFromTheEibAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LoanFromTheEibAbstract", "lang": { "en-us": { "role": { "label": "Loan from the EIB [Abstract]" } } }, "auth_ref": [] }, "plur_LoanfromtheEIBDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LoanfromtheEIBDetailsTable", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Loan from the EIB (Details) [Table]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "plur_LongTermRestrictedBankDepositsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "LongTermRestrictedBankDepositsPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term restricted bank deposits", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in long-term restricted bank deposits.", "label": "Long-Term Restricted Bank Deposits Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_ManagementAndServiceFeesBaseRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManagementAndServiceFeesBaseRate", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade tax base", "label": "Management and Service Fees, Base Rate", "documentation": "Base rate for management and service fees under arrangement to manage operations, including, but not limited to, investment." } } }, "auth_ref": [ "r811" ] }, "plur_MarketingAndBusinessDevelopmentActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-
```

biotech.com/20240630", "localname": "MarketingAndBusinessDevelopmentActivities", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketing and business development activities", "label": "Marketing And Business Development Activities" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r208", "r209", "r210", "r211", "r272", "r313", "r364", "r404", "r427", "r429", "r436", "r454", "r455", "r511", "r513", "r514", "r515", "r521", "r530", "r531", "r542", "r548", "r550", "r556", "r557", "r558", "r563", "r736", "r795", "r796", "r797", "r798", "r799", "r800"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r644"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r644"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r208", "r209", "r210", "r211", "r272", "r313", "r364", "r404", "r427", "r429", "r436", "r454", "r455", "r511", "r513", "r514", "r515", "r521", "r530", "r531", "r542", "r548", "r550", "r556", "r557", "r558", "r563", "r736", "r795", "r796", "r797", "r798", "r799", "r800"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r65", "r101", "r152", "r197", "r213", "r215", "r216", "r217", "r220", "r221", "r368", "r416", "r466"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r664"] }, "plur_ModificationOfWarrantsToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ModificationOfWarrantsToNoncontrollingInterests", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Modification of warrants to non-controlling interests", "documentation": "Modification of warrants to non-controlling interests.", "label": "Modification Of Warrants To Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_MonteCarloModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonteCarloModelMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable"], "lang": { "en-us": { "role": { "terseLabel": "Monte Carlo [Member]", "label": "Monte Carlo Pricing Model [Member]", "documentation": "Monte Carlo pricing model used to estimate fair value of award under share-based payment arrangement." } } }, "auth_ref": ["r551", "r760"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r672"] }, "plur_MunicipalityOfPotsdam": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "MunicipalityOfPotsdam", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Municipality of potsdam percentage", "documentation": "Percentage of municipality of potsdam." "label": "Municipality Of Potsdam" } } }, "auth_ref": [] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r645"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r148"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r148"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for operating activities", "terseLabel": "Cash flow from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r76", "r77", "r78"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "plur_NetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "NetIncome", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Income (in Dollars)", "documentation": "Net income.", "label": "Net Income" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributed to shareholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r70", "r78", "r103", "r124", "r139", "r140", "r144", "r152", "r159", "r161", "r162", "r163", "r164", "r165", "r168", "r169", "r174", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r343", "r346", "r363", "r368", "r424", "r486", "r503", "r504", "r572", "r734"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributed to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r37", "r92", "r139", "r140", "r165", "r168", "r169", "r423", "r704"] }, "plur_NetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "NetOfIssuanceCosts", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Net of issuance costs", "documentation": "Issuance costs." "label": "Net Of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": ["r615", "r616", "r617", "r618"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": ["r689"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": ["r689"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r644"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r599", "r610", "r626", "r652", "r661"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r635"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r634"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r652"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r672"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r672"] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": ["r6", "r24", "r32"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r33", "r258", "r714", "r715", "r716", "r718", "r812"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.pluri-

biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Total financial income (expenses), net", "terseLabel": "Total", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r72"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Financial Income (Expenses), Net [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Office furniture and equipment [Member]", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r108", "r539", "r719", "r720", "r721", "r722", "r723"] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Agreement", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": ["r182", "r398"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Operating Lease Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofMaturitiesofOperatingLeaseLiabilitiesTable", "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable"], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r387"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r387"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liabilities long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r387"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease payment", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r388", "r392"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ScheduleofOperatingLeaseAgreementTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of use asset", "verboseLabel": "Operating ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r386"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.pluri-biotech.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r395", "r561"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.pluri-biotech.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease period", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r394", "r561"] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforward (in Dollars)", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r331"] }, "plur_OptionsToConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "OptionsToConsultantsMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options to consultants [Member]", "label": "Options To Consultants Member" } } }, "auth_ref": [] }, "plur_OrdinarySharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "OrdinarySharesPercentage", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares percentage", "documentation": "Ordinary shares percentage.", "label": "Ordinary Shares Percentage" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/General"], "lang": { "en-us": { "role": { "terseLabel": "GENERAL", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r47", "r91", "r437", "r438"] }, "plur_OtherAccountsPayablePayrollInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "OtherAccountsPayablePayrollInstitutions", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofOtherAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Payroll institutions", "documentation": "Amount of value payroll institutions.", "label": "Other Accounts Payable Payroll Institutions" } } }, "auth_ref": [] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r130"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCostOfOperatingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostOfOperatingRevenue", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Global revenue", "label": "Other Cost of Operating Revenue", "documentation": "Other costs incurred during the reporting period related to other revenue generating activities." } } }, "auth_ref": ["r69"] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssets"], "lang": { "en-us": { "role": { "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses (in Dollars)", "label": "Other General and Administrative Expense", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": ["r71"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Financial Income (Expenses), Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": ["http://www.pluri-biotech.com/role/FinancialIncomeExpensesNet"], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INCOME (EXPENSES), NET", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": ["r699", "r766"] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Accounts Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Loan from the European Investment Bank, or EIB", "label": "Other Long-Term Debt, Noncurrent", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": ["r11", "r462"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ScheduleofFinancialIncomeExpensesNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Financial income (expenses), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r74"] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Financial income (expenses), net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r644"] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": ["r136", "r472", "r541", "r805"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r590"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r597", "r608", "r624", "r659"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r600", "r611", "r627", "r662"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r600", "r611", "r627", "r662"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ParentMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r633"] }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromShortTermInvestments", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Proceeds from withdrawal of short-term deposits, net", "label": "Payments for (Proceeds from) Short-Term Investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r706", "r707", "r708"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r75"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r643"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r643"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r635"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r652"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r645"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r634"] }, "plur_PercentageOfCompanyHeldInSubsidiaryByLimitedLiabilityOrPartnership": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PercentageOfCompanyHeldInSubsidiaryByLimitedLiabilityOrPartnership", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares Percentage the Company hold in Ever After Foods", "documentation": "The number of units or percentage the Company held in the subsidiary by the limited liability company or limited partnership." "label": "Percentage Of Company Held In Subsidiary By Limited Liability Or Partnership" } } }, "auth_ref": [] }, "plur_PercentageOfQualifiedExpenditures": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PercentageOfQualifiedExpenditures", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of qualified expenditures eligible for grant", "documentation": "Percentage Of Qualified Expenditures.", "label": "Percentage Of Qualified Expenditures" } } }, "auth_ref": [] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "plur_PluriIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PluriIncMember", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pluri Inc. [Member]", "label": "Pluri Inc Member" } } }, "auth_ref": [] }, "plur_PluriMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PluriMember", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pluri [Member]", "label": "Pluri Member" } } }, "auth_ref": [] }, "plur_PluristemGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PluristemGmbHMember", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable"], "lang": { "en-us": { "role": { "terseLabel": "Pluristem GmbH [Member]", "label": "Pluristem Gmb HMember" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r636"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r681"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r635"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post Effective Amendment" } } }, "auth_ref": ["r576"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r576"] }, "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accrued severance pay", "label": "Postemployment Benefits Liability, Noncurrent", "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)." } } }, "auth_ref": ["r737", "r738"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r583"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r585"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r576"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r576"] }, "plur_PreferredIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PreferredIncomeTaxRate", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of preferred income tax rate", "documentation": "Percentage of preferred income tax rate.", "label": "Preferred Income Tax Rate" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r59", "r242"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r59", "r464"] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r703"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r137", "r200", "r201", "r535"] }, "plur_PrepaidExpensesAndOtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PrepaidExpensesAndOtherCurrentAssetsLineItems", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Line Items]" } } }, "auth_ref": [] }, "plur_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets [Table]" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agregate gross proceeds", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Ever After Foods\u2019 shares to non-controlling interests", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": ["r13"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow", "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement", "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "negatedLabel": "Loss before income taxes", "verboseLabel": "Incurred losses", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r124", "r139", "r140", "r147", "r152", "r159", "r165", "r168", "r169", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r343", "r346", "r347", "r350", "r351", "r363", "r368", "r408", "r422", "r448", "r486", "r503", "r504", "r553", "r554", "r573", "r704", "r734"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [

```
"http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4", "r397" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/PropertyandEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r81", "r114", "r117", "r118" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r82", "r128", "r421" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r397" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r397", "r409", "r421", "r562" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r4", "r114", "r117", "r419" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/PropertyandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r82", "r397" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "plur_PropertyPlantAndEquipmentsUsefulLife": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PropertyPlantAndEquipmentsUsefulLife", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "documentation": "Information of Leasehold improvements.", "label": "Property Plant And Equipments Useful Life" } } }, "auth_ref": [] }, "plur_PurchaseOfPropertysAndEquipmentOnCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "PurchaseOfPropertysAndEquipmentOnCredit", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment on credit", "documentation": "The amount of Purchase of property and equipment on credit.", "label": "Purchase Of Propertys And Equipment On Credit" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r633" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r633" ] }, "plur_RSAndRSUsToConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RSAndRSUsToConsultantsMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "RS and RSUs to Consultants [Member]", "label": "RSAnd RSUs To Consultants Member" } } }, "auth_ref": [] }, "plur_RSUsToEmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RSUsToEmployeesAndDirectorsMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs to Employees and Directors [Member]", "label": "RSUs To Employees And Directors Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r208", "r209", "r210", "r211", "r270", "r272", "r302", "r303", "r304", "r313", "r364", "r402", "r403", "r404", "r427", "r429", "r436", "r454", "r455", "r511", "r513", "r514", "r515", "r521", "r530", "r531", "r542", "r548", "r550", "r556", "r557", "r558", "r559", "r563", "r566", "r730", "r736", "r776", "r796", "r797", "r798", "r799", "r800" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails", "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r208", "r209", "r210", "r211", "r270", "r272", "r302", "r303", "r304", "r313", "r364", "r402", "r403", "r404", "r427", "r429", "r436", "r454", "r455", "r511", "r513", "r514", "r515", "r521", "r530", "r531", "r542", "r548", "r550", "r556", "r557", "r559", "r559", "r563", "r566", "r730", "r736", "r776", "r796", "r797", "r798", "r799", "r800" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r61", "r67" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r592", "r603", "r619", "r654" ] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r576" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r195", "r271", "r400", "r401", "r411", "r418", "r457", "r458", "r459", "r460", "r461", "r483", "r485", "r510" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r400", "r401", "r792" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable", "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r195", "r271", "r400", "r401", "r411", "r418", "r457", "r458", "r459", "r460", "r461", "r483", "r485", "r510", "r792" ] }, "plur_RemainingBalanceOfTheAggregatePurchasePriceOfTheFirstWarrant": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RemainingBalanceOfTheAggregatePurchasePriceOfTheFirstWarrant", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining balance of the aggregate purchase price of the first warrant", "documentation": "The remaining balance of the aggregate purchase price of the First Warrant.", "label": "Remaining Balance Of The Aggregate Purchase Price Of The First Warrant" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Research and development expenses, net", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r315", "r532", "r540", "r801" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense [Member]", "verboseLabel": "Research and development expenses [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses, royalty bearing grants and non-royalty bearing grants", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r314" ] }, "plur_ResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ResearchAndDevelopmentExpenses", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "documentation": "Represents the amount of research and development expenses." "label": "Research And Development Expenses" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date;" } } }, "auth_ref": [ "r593", "r604", "r620", "r655" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r594", "r605", "r621", "r656" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r601", "r612", "r628", "r663" ] }, "us-
```

gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } } }, "auth_ref": ["r700", "r709", "r802", "r804"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r94", "r127", "r140", "r413"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r700", "r709"] }, "us-gaap_RestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Long-term restricted bank deposits", "label": "Restricted Cash Equivalents", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r526", "r527", "r709", "r802", "r804"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Restricted bank deposits", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r110", "r701", "r709"] }, "plur_RestrictedCashPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RestrictedCashPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "documentation": "Disclosure of accounting policy for the restricted cash.", "label": "Restricted Cash Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "RSUs [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r63", "r85", "r415", "r434", "r435", "r445", "r465", "r562"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r122", "r156", "r157", "r158", "r160", "r165", "r167", "r160", "r198", "r199", "r202", "r333", "r334", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r356", "r357", "r359", "r361", "r382", "r385", "r431", "r433", "r449", "r812"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r119", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r533"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r106", "r107", "r145", "r152", "r181", "r186", "r187", "r189", "r191", "r192", "r193", "r194", "r197", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r368", "r408", "r540", "r734"] }, "plur_ReverseStockSplitArrangement": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ReverseStockSplitArrangement", "presentation": ["http://www.pluri-biotech.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reverse share split", "documentation": "Description of the reverse stock split arrangement." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities arising from obtaining right of use assets", "label": "Right-of Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r393", "r561"] }, "plur_RoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RoyaltiesMember", "presentation": ["http://www.pluri-biotech.com/role/LoanfromtheEIBDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties [Member]", "label": "Royalties Member" } } }, "auth_ref": [] }, "plur_RoyaltiesRevenuesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RoyaltiesRevenuesPercentage", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties revenues percentage", "label": "Royalties Revenues Percentage" } } }, "auth_ref": [] }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyGuaranteesCommitmentsAmount", "crdr": "credit", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate royalty amount", "label": "Royalty Guarantees, Commitments, Amount", "documentation": "The amount the entity has committed to make for future royalty guarantees." } } }, "auth_ref": ["r406"] }, "plur_RoyaltyRatePayableOnGrantsReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RoyaltyRatePayableOnGrantsReceived", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty payable based on grants received", "documentation": "Royalty payable based on grants received." , "label": "Royalty Rate Payable On Grants Received" } } }, "auth_ref": [] }, "plur_RoyaltyRateSales": { "xbrltype": "percentItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "RoyaltyRateSales", "presentation": ["http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate", "documentation": "Royalty rate payable calculated as a percentage of the sale of products and other related revenues generated from such projects.", "label": "Royalty Rate Sales" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r672"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r672"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "plur_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SalesAgreementMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales Agreement [Member]", "label": "Sales Agreement Member" } } }, "auth_ref": [] }, "plur_SalesAgreementOfNetIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SalesAgreementOfNetIssuanceCosts", "crdr": "debit", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityType2or3_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Sales agreement with A.G.P. net of issuance costs", "documentation": "The amount of sales agreement of net issuance costs.", "label": "Sales Agreement Of Net Issuance Costs" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": ["r273", "r717"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r170", "r273", "r697", "r717"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/OtherAccountsPayableTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accounts Payable", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "plur_ScheduleOfActivityRelatedToUnvestedRSUsGrantedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfActivityRelatedToUnvestedRSUsGrantedLineItems", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Schedule of Activity Related to Unvested RSUs Granted [Line Items]" } } }, "auth_ref": [] }, "plur_ScheduleOfActivityRelatedToUnvestedRsusGrantedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfActivityRelatedToUnvestedRsusGrantedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Activity Related To Unvested Rsus Granted Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfBlackScholesOptionPricingModelUsingTheFollowingAssumptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfBlackScholesOptionPricingModelUsingTheFollowingAssumptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Black Scholes Option Pricing Model Using The Following Assumptions Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense and Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "plur_ScheduleOfDeferredIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfDeferredIncomeTaxesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Deferred Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Income Taxes", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r771"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.pluri-biotech.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expenses Related to RSUs Granted", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r31"] }, "plur_ScheduleOfExpensesRelatedToRsusGrantedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfExpensesRelatedToRsusGrantedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Expenses Related To Rsus Granted Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfLossBeforeIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfLossBeforeIncomeTaxesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Loss Before Income Taxes Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfLossBeforeIncomeTaxesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfLossBeforeIncomeTaxesTableTextBlock", "presentation": ["http://www.pluri-biotech.com/role/TaxesonIncomeTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Before Income Taxes", "label": "Schedule Of Loss Before Income Taxes Table Text Block" } } }, "auth_ref": [] }, "plur_ScheduleOfMainAssumptionsUsedInTheMonteCarloSimulationModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfMainAssumptionsUsedInTheMonteCarloSimulationModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Main Assumptions Used In The Monte Carlo Simulation Model

```
Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/FinancialIncomeExpensesNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Income (Expenses), Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "plur_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Prepaid Expenses And Other Current Assets Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationAndImpairmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationAndImpairmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Are Stated At Cost Net Of Accumulated Depreciation And Impairments Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfPropertyAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfPropertyAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Net Abstract" } } }, "auth_ref": [] }, "plur_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetsTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments", "documentation": "Tabular information of property plant and equipment estimated useful life of assets.", "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Of Assets Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentNetTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4", "r397" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants and Options", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r86" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Black-Scholes Option Pricing Model Using the Following Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants and Options", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to Unvested RSUs Granted", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [] }, "plur_ScheduleOfWarrantsAndOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ScheduleOfWarrantsAndOptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants And Options Abstract" } } }, "auth_ref": [] }, "plur_SecondWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SecondWarrantMember", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Warrant [Member]", "label": "Second Warrant Member" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r577" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r581" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r580" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r586" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses [Member]", "verboseLabel": "General and administrative expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance expenses", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r3" ] }, "plur_SeverancePayPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SeverancePayPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Severance pay", "documentation": "Disclosure of accounting policy for the severance pay.", "label": "Severance Pay Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors and non-employee consultants", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r294" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r292" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at the beginning of period", "periodEndLabel": "Unvested at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r289", "r290" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price ($)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (%)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r302" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk-free interest rate (%)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected share price volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r302" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofMainAssumptionsUsedintheMonteCarloSimulationModelTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Main Assumptions Used in the Monte Carlo Simulation Model [Line Items]", "terseLabel": "Schedule of Black-Scholes Option Pricing Model Using the Following Assumptions [Line Items]", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r301", "r302", "r303", "r304", "r305" ] }, "us-
```

```
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Share options exercisable at the end of the period number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Share options exercisable at the end of the period weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Share options forfeited number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r287" ] }, "plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options granted Aggregate intrinsic value price", "documentation": "Aggregate Intrinsic Value Price, Share options granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r746" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options granted number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r285" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period Aggregate intrinsic value price", "periodEndLabel": "Share options outstanding at end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period number", "periodEndLabel": "Share options outstanding at end of the period number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r281", "r282" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share options outstanding at beginning of period weighted average exercise price", "periodEndLabel": "Share options outstanding at end of the period weighted average exercise price", "terseLabel": "Weighted average exercise price per share (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r281", "r282" ] }, "plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedInPeriod", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Number", "documentation": "Share options unvested number.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested In Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of these options (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options vested and expected to vest at the end of the period Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Share options vested and expected to vest at the end of the period Number", "terseLabel": "Expected to vest after the end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r297" ] }, "plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingValueOfCommonShares": { "xbrltype": "perShareItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingValueOfCommonShares", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying value of common shares ($)" "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Value of Common Shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Underlying Value Of Common Shares" } } }, "auth_ref": [] }, "plur_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price per share (in Dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r301", "r302", "r303", "r304", "r305" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options forfeited weighted average exercise price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options granted Weighted average exercise price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r285" ] }, "plur_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnvestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Weighted average exercise price", "documentation": "Share options unvested Weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Unvested In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r274", "r280", "r299", "r300", "r301", "r302", "r305", "r308", "r309", "r310", "r311" ] }, "plur_ShareBasedCompensationShareAuthorizedUnderStockWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationShareAuthorizedUnderStockWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants for common share", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share Based
```

```
Compensation Share Authorized Under Stock Warrants Plans Exercise Price Range Number Of Outstanding Warrants" } } }, "auth_ref": [] },
"plur_ShareBasedCompensationSharesAuthorizedUnderStockOfWarrantsPlansExercisePriceRangeNumberOfExercisableWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOfWarrantsPlansExercisePriceRangeNumberOfExercisableWarrants", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable for common share", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share Based Compensation Shares Authorized Under Stock Of Warrants Plans Exercise Price Range Number Of Exercisable Warrants" } } }, "auth_ref": [] }, "plur_ShareBasedCompensationSharesAuthorizedUnderStockOptionAndWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionAndWarrantsPlansExercisePriceRangeNumberOfOutstandingWarrants", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Options and warrants for common share", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock option and warrants as of the balance sheet date for all options and warrants plans in the customized range of exercise prices.", "label": "Share Based Compensation Shares Authorized Under Stock Option And Warrants Plans Exercise Price Range Number Of Outstanding Warrants" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted " } } }, "auth_ref": [ "r29" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Option for common share exercisable", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options for common share", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r87", "r88" ] },
"plur_ShareBasedCompensationSharesAuthorizedUnderStockOptionsAndWarrantsPlansExercisePriceRangeNumberOfExercisableOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionsAndWarrantsPlansExercisePriceRangeNumberOfExercisableOptionsAndWarrants", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Options and warrants exercisable for common share", "documentation": "Options and warrants exercisable for common share.", "label": "Share Based Compensation Shares Authorized Under Stock Options And Warrants Plans Exercise Price Range Number Of Exercisable Options And Warrants" } } }, "auth_ref": [] }, "plur_ShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareCapitalAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital (**):", "label": "Share Capital Abstract" } } }, "auth_ref": [] }, "plur_ShareOptionsForfeitedAggregateIntrinsicValuePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareOptionsForfeitedAggregateIntrinsicValuePrice", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options forfeited Aggregate intrinsic value price", "documentation": "Share options forfeited aggregate intrinsic value price.", "label": "Share Options Forfeited Aggregate Intrinsic Value Price" } } }, "auth_ref": [] }, "plur_ShareOptionsForfeitedWeightedAverageRemainingContractualTermsinYears": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareOptionsForfeitedWeightedAverageRemainingContractualTermsinYears", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options forfeited weighted average remaining contractual terms", "documentation": "Share options forfeited weighted average remaining contractual terms.", "label": "Share Options Forfeited Weighted Average Remaining Contractual Termsin Years" } } }, "auth_ref": [] }, "plur_ShareOptionsGrantedWeightedAverageRemainingContractualTermsinYears": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareOptionsGrantedWeightedAverageRemainingContractualTermsinYears", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options granted Weighted average remaining contractual terms (in years)", "documentation": "Share options granted Weighted average remaining contractual terms (in years)", "label": "Share Options Granted Weighted Average Remaining Contractual Termsin Years" } } }, "auth_ref": [] }, "plur_ShareOptionsUnvestedAggregateIntrinsicValuePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareOptionsUnvestedAggregateIntrinsicValuePrice", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Aggregate intrinsic value price", "documentation": "Share options unvested aggregate intrinsic value price", "label": "Share Options Unvested Aggregate Intrinsic Value Price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Share options vested and expected to vest at the end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected terms of the option (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r301" ] },
"plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options outstanding at beginning of period weighted average remaining contractual terms (in years)", "documentation": "Weighted Average Remaining Contractual Terms, Share options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] },
"plur_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options unvested Weighted average remaining contractual terms (in years)", "documentation": "Share options unvested Weighted average remaining contractual terms.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual Term1" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options exercisable at the end of the period Aggregate intrinsic value price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r26" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options exercisable at the end of the period weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r26" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options outstanding at end of the period weighted average remaining contractual terms (in years)", "verboseLabel": "Weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r89" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options vested and expected to vest at the end of the period Weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r298" ] }, "plur_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual terms (in years)", "documentation": "Weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] }, "plur_ShareholdersEquityDetailsScheduleofActivityRelatedtoUnvestedRSUsGrantedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareholdersEquityDetailsScheduleofActivityRelatedtoUnvestedRSUsGrantedTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofActivityRelatedtoUnvestedRSUsGrantedTable" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) - Schedule of Activity Related to Unvested RSUs Granted [Table]" } } }, "auth_ref": [] }, "plur_ShareholdersEquityDetailsScheduleofShareOptionsGrantedNonemployeeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareholdersEquityDetailsScheduleofShareOptionsGrantedNonemployeeLineItems", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Line Items]" } } }, "auth_ref": [] }, "plur_ShareholdersEquityDetailsScheduleofShareOptionsGrantedNonemployeeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareholdersEquityDetailsScheduleofShareOptionsGrantedNonemployeeTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) - Schedule of Share Options Granted Non-employee [Table]" } } }, "auth_ref": [] }, "plur_ShareholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShareholdersEquityDetailsTable", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price per share (in Dollars per share)", "label": "Shares
```

```
Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "plur_ShortTermBankDepositPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShortTermBankDepositPolicyTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term bank deposit", "documentation": "Disclosure of accounting policy for the use of estimates in the short-term bank deposit.", "label": "Short Term Bank Deposit Policy Text Block" } } }, "auth_ref": [] }, "plur_ShorttermBankDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "ShorttermBankDeposits", "crdr": "debit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term bank deposits", "documentation": "Amount of short-term bank deposits.", "label": "Shortterm Bank Deposits" } } }, "auth_ref": [] }, "plur_SignificantAccountingPoliciesDetailsScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SignificantAccountingPoliciesDetailsScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofBlackScholesOptionPricingModelUsingtheFollowingAssumptionsTable" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of Black-Scholes Option Pricing Model Using the Following Assumptions [Table]" } } }, "auth_ref": [] }, "plur_SignificantAccountingPoliciesDetailsScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SignificantAccountingPoliciesDetailsScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPropertyandEquipmentareStatedatCostNetofAccumulatedDepreciationandImpairmentsTable" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost, Net of Accumulated Depreciation and Impairments [Table]" } } }, "auth_ref": [] }, "plur_SignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SignificantAccountingPoliciesDetailsTable", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r79" "r150" ] }, "plur_SixPointZeroEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SixPointZeroEightMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "6.08 [Member]", "label": "Six Point Zero Eight Member" } } }, "auth_ref": [] }, "plur_SixteenPointSixFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SixteenPointSixFourMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "16.64 [Member]", "label": "Sixteen Point Six Four Member" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r584" ] }, "plur_SpreadPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SpreadPeriod", "presentation": [ "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spread period", "label": "Spread Period" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r60", "r64", "r65", "r122", "r142", "r143", "r144", "r156", "r157", "r158", "r160", "r165", "r167", "r169", "r183", "r198", "r199", "r202", "r258", "r333", "r334", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r385", "r399", "r425", "r431", "r432", "r433", "r449", "r505" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r156" "r157" "r158" "r183" "r385" "r405" "r439" "r450" "r456" "r457" "r458" "r459" "r460" "r461" "r464" "r467" "r468" "r469" "r470" "r471" "r473" "r474" "r475" "r476" "r479" "r480" "r481" "r482" "r483" "r485" "r487" "r488" "r490" "r491" "r492" "r493" "r494" "r495" "r496" "r497" "r498" "r499" "r500" "r501" "r505" "r567" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r170", "r273", "r697", "r698", "r717" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r156", "r157", "r158", "r183", "r195", "r385", "r405", "r439", "r450", "r456", "r457", "r458", "r459", "r460", "r461", "r464", "r467", "r468", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r479", "r480", "r481", "r482", "r483", "r485", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r505", "r567" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r596", "r607", "r623", "r658" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares under a sales agreement with A.G.P. net of issuance costs of $162 (see note 9(1)) (in Shares)", "verboseLabel": "Issuance of shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r59", "r60", "r85", "r441", "r505", "r523" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r7", "r85" ] }, "plur_StockIssuedDuringPeriodSharesReverseStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "StockIssuedDuringPeriodSharesReverseStockSplit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Round-up of shares due to reverse share split effectuated on April 1, 2024 (see Note 1d) (in Shares)", "verboseLabel": "Issuance of reverse share split (in Shares)", "documentation": "Increase in the number of shares during the period as a result of a reverse stock split." "label": "Stock Issued During Period Shares Reverse Stock Split" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors, and non-employee consultants (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r7", "r59", "r60", "r85" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares under a sales agreement with A.G.P. net of issuance costs of $162 (see note 9(1))", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r59", "r60", "r85", "r449", "r505", "r523", "r573" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Ever After Foods\u2019 shares to non-controlling interests (note 1f)", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation to employees, directors, and non-employee consultants", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r28", "r59", "r60", "r85" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option [Member]", "verboseLabel": "Equity Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r566" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total sharcholders\u2019 equity", "terseLabel": "Total sharcholders\u2019 equity deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r60" "r64" "r65" "r80" "r466" "r484" "r506" "r507" "r562" "r574" "r712" "r725" "r786" "r812" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedBalanceSheet", "http://www.pluri-biotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r33", "r34", "r36", "r122", "r123", "r143", "r156", "r157", "r158", "r160", "r165", "r167", "r198", "r199", "r202", "r258", "r333", "r334", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r374", "r375", "r379", "r383", "r399", "r432", "r433", "r447", "r466", "r484", "r506", "r507", "r524", "r573", "r712", "r725", "r786", "r812" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r84" "r151" "r241" "r243" "r245" "r246" "r247" "r248" "r249" "r250" "r251" "r252" "r253" "r255" "r258" "r360" "r508" "r509" "r525" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity (in Dollars)", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r391", "r561" ] }, "plur_SubsidiaryInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "SubsidiaryInvestment", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary investment", "documentation": "The amount of subsidiary investment.", "label": "Subsidiary Investment" } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri",
```

```
"http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r651" ] }, "plur_TaxesonIncomeDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TaxesonIncomeDetailsLineItems", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Taxes on Income [Line Items]" } } }, "auth_ref": [] }, "plur_TaxesonIncomeDetailsScheduleofLossBeforeIncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TaxesonIncomeDetailsScheduleofLossBeforeIncomeTaxesTable", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) - Schedule of Loss Before Income Taxes [Table]" } } }, "auth_ref": [] }, "plur_TaxesonIncomeDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TaxesonIncomeDetailsTable", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) [Table]" } } }, "auth_ref": [] }, "plur_TechnologicalPreferredEnterpriseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TechnologicalPreferredEnterpriseMember", "presentation": [ "http://www.pluri-biotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technological Preferred Enterprise [Member]", "label": "Technological Preferred Enterprise Member" } } }, "auth_ref": [] }, "plur_TelAvivSouraskyMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TelAvivSouraskyMedicalCenterMember", "presentation": [ "http://www.pluri-biotech.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ichilov Hospital [Member]", "label": "Tel Aviv Sourasky Medical Center Member" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "http://www.pluri-biotech.com/role/ScheduleofShareOptionsGrantedNonemployeeTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r724", "r791" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofExpensesRelatedtoRSUsGrantedTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "plur_TnuvaFoodIndustriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TnuvaFoodIndustriesMember", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tnuva Food Industries [Member]", "label": "Tnuva Food Industries Member" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r643" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r650" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement," } } }, "auth_ref": [ "r671" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r673" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r674" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r675" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r675" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r673" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r673" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r676" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r674" ] }, "plur_TwelvePointFourEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TwelvePointFourEightMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "12.48 [Member]", "label": "Twelve Point Four Eight Member" } } }, "auth_ref": [] }, "plur_TwentyPointEightZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "TwentyPointEightZeroMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "20.80 [Member]", "label": "Twenty Point Eight Zero Member" } } }, "auth_ref": [] }, "plur_USNationalInstituteOfAllergyAndInfectiousDiseasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "USNationalInstituteOfAllergyAndInfectiousDiseasesMember", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. National Institute of Allergy and Infectious Diseases [Member]", "label": "USNational Institute Of Allergy And Infectious Diseases Member" } } }, "auth_ref": [] }, "plur_UnamortizedCompensationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "UnamortizedCompensationExpenses", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation expenses (in Dollars)", "documentation": "Unamortized compensation expenses.", "label": "Unamortized Compensation Expenses" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r670" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.pluri-biotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r111", "r112", "r115", "r116" ] }, "us-gaap_ValueAddedTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivable", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Value Added Tax receivable", "label": "Value Added Tax Receivable", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": [ "r702" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.pluri-biotech.com/role/ScheduleofLeaseExpenseandSupplementalCashFlowInformationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed payments and variable payments that depend on an index or rate", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r390", "r561" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r761", "r762", "r763", "r764", "r765" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.pluri-biotech.com/role/LoanfromtheEIBDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r761", "r762", "r763", "r764", "r765" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r639" ] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r257" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.pluri-biotech.com/role/GeneralDetails", "http://www.pluri-biotech.com/role/ScheduleofWarrantsandOptionsTable", "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r564", "r565", "r568", "r569", "r570", "r571" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing diluted loss per share", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r172", "r177" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.pluri-biotech.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing basic loss per share (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r171", "r177" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r687" ] }, "plur_YakyYanayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pluri-biotech.com/20240630", "localname": "YakyYanayMember", "presentation": [ "http://www.pluri-biotech.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yaky Yanay [Member]", "label": "Yaky Yanay Member" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r637" ] } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50",
```

```
"Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50",
```

```
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482680/260-10-45-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Subparagraph", "(e)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r247": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "13", "Subparagraph", "(i)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r248": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "14", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r249": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "14", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r250": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "14", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r251": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "16", "Subparagraph", "(b)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r252": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r253": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r255": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "Subparagraph", "(d)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r256": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r257": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "505", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.3-04)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r259": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "17", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "Subparagraph", "(a)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r261": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "18", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r262": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "19", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r263": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "20", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r264": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "20", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r265": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "20", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r266": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "606", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "20", "Subparagraph", "(d)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section", "45", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r268": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "715", "SubTopic", "20", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "715", "SubTopic", "20", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Subparagraph", "(d)(i)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Subparagraph", "(n)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "715", "SubTopic", "80", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "5", "Subparagraph", "(d)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "5", "Subparagraph", "(f)(3)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "Name", "Accounting Standards Codification", "Publisher", "FASB", "URI", "https://asc.fasb.org/718/tableOfContent" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r276": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "35", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r277": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(a)(1)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(a)(2)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(a)(3)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(i)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(ii)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iii)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iv)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iv)(01)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iv)(02)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iv)(03)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(1)(iv)(04)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(2)(i)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(2)(ii)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(2)(iii)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(2)(iii)(02)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(c)(2)(iii)(03)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(d)(1)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(d)(2)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(e)(1)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(e)(2)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(1)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)(i)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)(ii)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)(iii)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)(iv)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(f)(2)(v)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(h)(1)(i)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph", "(i)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SAB Topic 14.C.Q3)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SAB Topic 14.D.1.Q5)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r310": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SAB Topic 14.D.2.Q6)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r312": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "718", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SAB Topic 14.F)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r314": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "05", "Paragraph", "1", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "730", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r316": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "740", "Name", "Accounting Standards Codification", "Publisher", "FASB", "URI", "https://asc.fasb.org/740/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "45", "Paragraph", "25", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "740", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "28", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r319": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "12", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "12A", "Subparagraph", "(a)(3)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r321": { "role", "http://www.xbrl.org/2003/role/disclosureRef", "Topic", "740", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "12A", "Subparagraph", "(a)(6)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r400": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "950", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r402": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r404": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-
S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477866/928-440-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r409": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" },
"r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-
03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r421": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-
04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic":
"220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r427": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r429": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" },
"r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r434": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r436":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r438":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r440":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX
210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r443": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX
210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" },
"r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r452":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)
(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" },
"r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-
04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-
04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
```

```
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477068/946-235-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name", "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
```

```
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r549": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r551": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480397/718-10-55-16" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r553": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r555": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r557": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r559": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r561": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r563": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r565": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r567": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name",
"Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher", "FASB", "URI",
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-
S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r571": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-
14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-
10" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r575": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name",
"Exchange Act", "Number", "240", "Section", "12" }, "r577": { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section",
"12", "Subsection", "b" }, "r578": { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "12", "Subsection", "b-2" },
"r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "12", "Subsection", "b-23" }, "r580": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "12", "Subsection", "d-1" }, "r581": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "12", "Subsection", "g" }, "r582": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "12, 13, 15d" }, "r583": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "13c", "Subsection", "4c" }, "r584": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "14a", "Subsection", "12" }, "r585": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "14d", "Subsection", "2b" }, "r586": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Exchange Act", "Number", "240", "Section", "15", "Subsection", "d" }, "r587": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 10-K", "Number", "249", "Section", "310" }, "r588": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 10-Q", "Number", "240", "Section", "308", "Subsection", "a" }, "r589": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 10-Q", "Number", "249", "Section", "308", "Subsection", "a" }, "r590": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Number", "249", "Section", "220", "Subsection", "f" }, "r591": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "16", "Subsection", "j", "Paragraph", "a" }, "r592": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1" }, "r593": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "i" }, "r594": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "i", "Sentence", "A" }, "r595", {
"role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "i", "Sentence", "B" },
"r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "i", "Sentence",
"C" }, "r597", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1", "Subparagraph", "i",
"Sentence", "D" }, "r598", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F", "Paragraph", "1",
"Subparagraph", "i", "Sentence", "E" }, "r599", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F",
"Paragraph", "1", "Subparagraph", "ii" }, "r600", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F",
"Paragraph", "1", "Subparagraph", "iii" }, "r601", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 20-F", "Section", "6", "Subsection", "F",
"Paragraph", "2" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Number", "249", "Section", "240", "Subsection", "f" }, "r603": {
"role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a" }, "r604": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1" }, "r605": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1", "Sentence", "i" }, "r606": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1", "Sentence", "ii" }, "r607": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1", "Sentence", "iii" }, "r608": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1", "Sentence", "iv" }, "r609": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "1", "Sentence", "v" }, "r610": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "2" }, "r611", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "a", "Subparagraph", "3" }, "r612", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form 40-F", "Section", "19", "Paragraph", "b" }, "r613", { "role", "http://www.xbrl.org/2003/role/presentationRef",
"Publisher", "SEC", "Name", "Form 8-K", "Number", "249", "Section", "308" }, "r614", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form F-3" },
"r615", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-2" }, "r616", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher",
"SEC", "Name", "Form N-3" }, "r617", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-4" }, "r618", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-6" }, "r619", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Form N-CSR", "Section", "18", "Paragraph", "a" }, "r620", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph",
"a", "Subparagraph", "1" }, "r621", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "1",
"Sentence", "i" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "1",
"Sentence", "ii" }, "r623", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "1",
"Sentence", "iii" }, "r624", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "1",
"Sentence", "iv" }, "r625", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "1",
"Sentence", "v" }, "r626", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "2" },
"r627", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "a", "Subparagraph", "3" }, "r628", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form N-CSR", "Section", "18", "Paragraph", "b" }, "r629", { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Form S-3" }, "r630", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Forms 10-K, 10-Q, 20-F", "Number", "240", "Section", "13", "Subsection", "a-1" }, "r631", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Investment
Company Act", "Number", "270" }, "r632", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "v" }, "r633", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v",
"Paragraph", "1" }, "r634", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v",
"Paragraph", "2", "Subparagraph", "ii" }, "r635", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "v", "Paragraph", "2", "Subparagraph", "iii" }, "r636", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229",
"Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "B", "Clause", "1", "Subclause", "ii" }, "r637", { "role", "http://www.xbrl.org/2003/role/presentationRef",
"Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "i" },
"r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2",
"Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "ii" }, "r639": { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K",
"Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "iii" }, "r640": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii",
"Sentence", "C", "Clause", "1", "Subclause", "iv" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section",
"402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "v" }, "r642", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher",
"SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph", "iii", "Sentence", "C", "Clause", "1", "Subclause", "vi" }, "r643", {
"role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2", "Subparagraph",
"iv" }, "r644", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "2",
"Subparagraph", "vi" }, "r645", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v",
"Paragraph", "3" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v",
"Paragraph", "4" }, "r647", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v",
"Paragraph", "5", "Subparagraph", "i" }, "r648": { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402",
"Subsection", "v", "Paragraph", "5", "Subparagraph", "ii" }, "r649", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K", "Number", "229",
"Section", "402", "Subsection", "v", "Paragraph", "5", "Subparagraph", "iii" }, "r650", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name", "Regulation S-K",
"Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "5", "Subparagraph", "iv" }, "r651", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "6" }, "r652", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Regulation S-K", "Number", "229", "Section", "402", "Subsection", "v", "Paragraph", "6", "Subparagraph", "i" }, "r653", { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name", "Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w" }, "r654", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
"Regulation S-K", "Number", "229", "Section", "402", "Subsection", "w", "Paragraph", "1" }, "r655", { "role", "http://www.xbrl.org/2003/role/presentationRef", "Publisher", "SEC", "Name",
```

"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "i", "Sentence": "A" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "x", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "8", "Subsection": "2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r696": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r698": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 82 0001213900-24-079861-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-079861-xbrl.zip M4$L#!!0 ( ^,EE9-Y6[-E\" ,1%0 : 96$P,C$S.3$P+3$P;U]P M,'5R;6EN8RYH=&WL?6ES&DG;X/?Z%;F>[GGM" ,KO'&UA"-C.Z7H&[9W;C MC8VB*H$;%U5,'9+I7[-/D9F5Q2%+-LC(HF/&D]JS^<^?.O? 7\.AN)%)&L31 MW.ZK4;O.EY"1% .M!./S;?I6ZQYW.? WO=\YO.ZM,%1]D)!,WD[H3\5O/)YT MO4#T$C=*'W$R%B^S\2M1%;.LF[QY.?KV]K.FP3.I%R0RC?/$DRE^(*I5.=QQ M(G&P.^(/&+$K)ZJQ*!KI,W;.WNS4O.?>L6C6F[O\^"B#1<)"H.2.&O.O+]0\ MB^9XH0[U9?'CI/A;.CB=3;=2'RZ.M6;WO5'<,^AWI^8L'AR]*@P=IO.ML"R>H%FO[(Q63Y@7OBQ[M@'/1F$0R7^^ MOSXK'L)6/U\]^CK3M^1F<,^XQ'IUW]PVFM8@5=A.;2"]H;O&;>Q5ZX?6[<"3.MG^.8*7[==U.I'Y^$>?GD\8.@V@.B3'HCO$LZROK^3EV.DB;%=@=NVJ?IX=I=>BZD.D'U1>S#^;.=IPN? IF]*C^...!G.4AO\?.S^#PBB=G#.IVAQYM'!T=O.9OS;/IHN=@R,.K?YZ?=.V1'+O5N96D.MP1.7B,C2]=\Y.O.[+0NR4+X3O[WF7QSGM[.7.%428CN.,?LE>.MTXM$4ZKR/WEP\ [<7Q.Q\M0<7^(UC/F.!.VM'.O3=[.YP8U(LVDH..9B.$^^.M$8WZ\!.]8"O3<2%OQ7A\=I.*?U.!LI.$@O?T%B[@.?[\.;('&+O),(C>B#H\.M7]HR\Q22I-.AD#.KO-05[.%!?!+.2 [Y.>+3WH>M]%DW86AJ'@6^^U"/S]PW].8MW.M?.U+8[.^5]U!,@>OY[9P]W'HT68/9?+0LS='W+Y.X*CZ.M[SY==`KM$!`MM7KM[F.]L.^AVS[^=-.WI==I=T;HX$>U.'G\L77OHB^/+\.-
```

MM]NYO.#G_G#3$?"X+(8%G=2..:\M]G;/?GO=7W#5C[PK?;@;L)33R^MS\5OP MY4T41Q?Y& ,T&$&_9-=R\+<7'!#ER!W#>H"EOCF)/7@FR@eU10#\,?AR4VWL M'NWOO7C7]%? \=OKTE#Q-F/FW+<+|_=Y+.XC,2K'WPD=U\WY/# MHPE*@@\"$1]D _H8'A@A@%1]=UK%B:LR6@0R5S!>[+*%/ P?=.6Y[O M,$\2F/"4SN)?L**%DQZ^>,?W)+.3GT64"L^XQ%7*2P25]>Z>C%.Q0RYRED M^6\0E^.MI3SNRC6P W3A22+M-D P7TIV3JH*[*UNX1L];Y,%[T.TB>'29?X M&4C7!EVTIF"9N28O(8KA#))XS*O\O_SC.?\5_R.R6,WN/.;$ [.%#+164XW@\ M#E(T8@%*

["Z6(\G%?)FI!O?R!HO(?8O[=#N[TO?.OM]N;K3V#E[ME]CU+&5?V7G1N8GZ-UU2YO,AN#P9AA/7)ZO"S@3 #.1M6[NF `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| <,5/*I+L Tl3[.@.%MQ>.R4F*$C21 $1CC MZP\8>I1L)%,3"=6X!!;J'H @6CEZZ*5RR#U-2WA MG L9MO2R0 FM=46.,"9*]]]10U\DWNZ#[@0? A775NCJTK#)5W@>]"'\.2C&! M=]LGA!M\HU&<.0E&C" !IHI.00$)O?2DBT@U;Z6Q@ ,:^\D<4IU.0\)7>[>]Q MF$>9FU#.05*.\"#LX>.9W>CN2Y*$!7ZSSLO&*US<"G.0K!84.AN9>[0OO2 4 M#+S@CDO7:F&O%GSPIO%K#+\)2/GP+]A0^.DFDJY%Q.HTFCT=!AJEX*8."0.5*!!.GA+&*]+N(.>A=}?$ V-BZM1@&,66TDIHN6Z.B:.Z\-U!6GNHB5R%2'(D',K@F9O-A'T>@(X" MF' GE)/(2%W$)79X=Z.+UP ^FZU)U[BKP=OFSO-&CSE$/ '%' QP8"+ MA6 N5@SFO'Q^'4$^?55, "P/!%3KX/#<%-R6 ? 7H,X"Z,P#UT2!HHP$6O2(1 MPK 2"}$*H;* <,1.0Z$H6O@!. ZHNO"!+= R@#M.DFIP(3-UTHVD%Z3$.!Z0+ M)S 4PR2^S4,ZZYK3E9(61Tt(817V2/P1MZLWZ6UKB .%KHV,.BGYL?DWT"?W MO6I!OTDQ^KA)6O50RHO$9"G7VU]+F.SEMH/A[$'=BTE7+ZUU6]1V=+ M >A$!?& -VM[ICW] P?'2'W F]PM5TEY'<O>$@ =I=M2/DTf?

L\!.T^M43.9OU@#42]M>M>X8SMQ8SI^X]Q+F6&SU"/!X&F. ^,9K/-L MK#208Y9:+CO/&3N\ ?<,[=."/+] -[[";*B"%S,A[SA]("> HF])$?8IB4BCR-ME&4NF)02!..=3;D@-

P+G"4Y^&\#4.*V(8$D%19G5!7<3 .#O2 M.%T.LH<5N4.R%9CI%#=-@13B1_K$Y6 @2,F*5 02OAF@KA7!=2+)2.)0Q. E MBEMV"CI.02OF+G?KNU8D1==^BX.6[W\$LHI&;5M>-

O:$!UH74 &/FOL8=OS* M -U!L4GE9^B'0[P*68.IDS*HC**T3%Q^*$K=LMSZMV.UIT#AY75^U@=R#\'6\ M0=+!^ >D59SL:>.2OKGX?)LP9\68 (!Z;>C0=3 QED.VF%L%C;]1/@U FIK8,K]98U4Z MDF&HQ1 Q> ^@.2(1VI4! 4$@4M%AS 3L0=%>':+3)(U#GRR3\(SC F)B M.:.1 ^X+ $E7Y&CH:#$:4@'VE:Z(K9CFQ$..X)5(A =X#XG7 M$C<#2%6.2$>5[OA/3CF2;[BKC-

NYA>%/*=DJX>C*F%/XP6@]Q> 7IZ2Z=%& MI2@?5 V80]+Q@7ETNB*O\#2,W>R%P",2-$8>!3QZGOIE+-MY\;[9K!SN[5=V-M]IL:T?3"?@9,, 03 8UCS0E2*?A\Q'E&.AAB53QP*'AR.5!2^

A#N@+R5,40 MVD"-IK=@!'IZA1\0EK.'RO$#T3=@AMVA#:N3A\(QR+&4WB[W/'(OY65S"0]#E M0R[#]>Z+=WN5W8-

ZI;& .,P>VZC]Z<@)R#EYX8ZW]O\1U^[1]W;XX;C^M#7U%:)!PIQ.,!EM21RLMDJ;E WYZ MK9E.#P9Y"P(XE4%DCXS.&]8N)$%%TU!QJ24%%TU!QI447'Q!UX+;>0LO M_B=\(3OB[U1X". L.2Z<%]

[5O7<..;X=L'SU& MP#:BRS?$;\^>]5T;ONN-51[/5>NZ)SKFU-UW7SV+AYY/XZ%'<_=M/I4K6]D-=4!+ +RT M$6,)8*$4B:N][@\!C2T8K!L,6O>!@Y7FW%T'Z6=Q"]IKC*P.%O:WP+ "8'A-

M'V#8724P?(]P@T>(#I5NY@6X&V^$=-]50<,.Sa8R5@ 9Q >]C)46;SN>]F6B MW,K3E4'#[A8;OA\;FO)(25;8 L5$ L7L?@%A]@8MS4"I$UQW(,'[.@M0+M51/MG1BI0:*E4,&

MLX%@K1:"G2>G<SDOQ>9"SW0)!HKK4[++]4=H=1B=O*#^ MF]I!TU9!&M9[/.MA]NCB))SPPHD-"TK[O34!-/CTH[GR >]\"WP.0"H/.=[Y*T"-M0.YC2FVN5!GZ;PP4#C.1X482F_'H?

[.$H0%]Q GF:#8)!IA5P4^NUL3VPK MY ^U&FEAGA#.T2WB)!'*.KFDTE(?[O)E$I2K I43]M.K\T*8.7H/K"R4CO] M.>7@81H800C0%G>82 4S?V .8(M3LUS*RHGTGQC COTGRSA8N5P.5]!(.

E5K)+RG=IQ.9IO-,B @H MB+B/0[*O4F&W8!HHX'&32F(XC1.)AR+ ,^C%#?:E174BJ#<Y4]7I MN<)1Z8)7;LE7ANA&U6H9WGZDY\?A /7[8/*O08G 6;0Q0@D\TC;>M9P0A>5X ;A"O-Z"RBI

Y3X1*LV5&E=/XP25^.H_1#IB M-YW CL_B6YG0=&\%=A7C{N\2'"'4GZ[?I..Z-GFXZ\O_ K WI%"TT[CI]*.*N]56L\S4"RH^" 96!>1@Z M01$)8<"IQ>!^.;I^%W(7&3IVPH6G'6)46$W)E4-

.%&%.224KKY1.MA3FKAUC3'5-O8>FQ)IE))V&0]2+A#"8Y1WS!6*%H<.6Y+55\!/&.NSNW/O4Z MEQ>MZWY%Y>]MKAN?V4=GW0N/HC3R^L X.?IV> 7E/ #O;[5:\Y!7!9>>PA9-

M2K,5&TG'DEN1PKJZ7O%7$+NR +,IV@6%WLXP.L9L!&L%CMP/26]*$@%V'SK-M)GXAU./;2 F*.6CN4X5*OJ!N.C(S+A *3*(-0N40<;%\T3 MC :

(5O&+!$0/IH]OLUX@/W=N7)KK4#6[IHIRQ.\?6=P&>.HEG0&O(*L-E]7+0 MF +,C'!L5)#DL^.A !!$<1<@/IUOUS7B0!^8))"V=+8E&/8Z ,7!- !3'T]" M-Y![%/N1 "])>S'\/29S^Z#

<)PKOD8*"FA;SZ%N]5MRV#':*#/I+D;U=HQPNK) MZ# & Y#(1-U&#=N$K@Z]-BX1JU>$F5-;..@J6)=(.X-5-M'!K;J;S .7#G M/G7ZT]F#M2"X)OY.S@%C^ ##]=!K24"Y &YIFCLL08F-

M$;BD)\R&=-!Q.9IO-,B @H MB+B/0[*O4F&W8!HHX'&32F(XC1.)AR+ ,^C%#?:E174BJ#<Y4]7I MN<)1Z8)7;LE7ANA&U6H9WGZDY\?A /7[8/*O08G 6;0Q0@D\TC;>M9P0A>5X ;A"O-Z"RBI

MP,&9O=P\F51U<%0%0AFSFF!L5VVQ=M=Y<2+,VWM'OS=N92%M$;E\3MI";D;=!, M2"2%031!P@KO%S-XJK]HH#8 XDS9%F DGT*OL& ^R$ACD59.DMC//>4DP #@-MG.]9(Q2&X1QB:

.4*Y 26%Z=9U727HG/&F\4&8]A>3!UP M"?@6>Y*V!"C2.%C4;X23^A6N0)$$*9KKNEM("XR=%F.4'(DM_B[!V:LM[G$ M$)>&;Z@2?R=2++#DE9QYZV6+P^MVB;YH%^5$CA7+P?

=+$'&BO":J).1.TWO<_ MX+'4B4/03]8A9$^@RL4";QH\ AEX% "O2[%9D,XQK8A-Q#1D4B MAG>NC7G^9-1BRSLW>=.$ED%5(@.D8P=C9=2$ M9[" '<1&^(5?

HP1NEG4+8SYAX14'(4D53;)HQDD?ZR%OD6V'+,#*V=B^R$U4 MASEH.38VS)Q@"^2$Z402X M0?)D*\|&%.9!9I=.]\7.JG:..%8UA<9\B>.I8O# "HW_BWWC0@&##Q!TK]l;% MJX3CC!$_<34?

I1MFHPHM R;XZ'PL$7.&"15D82N7MN2H/"!LAAPD/DG2:C1 M&*7FK9 XT>]:G3EAS"AA-2& .732ANBSN^2+I/O%Z=_:/"5V[+B0K)B>CVXT2[-M5>,'+6*0)IREVK-^A*%)$@MXK=

<%*ZB*]J8)E\"!/ZX;AVP<569D1&37,FL# M<0$BDR72S7"1 _P>:.)TB%O)0BB-E&9]+I$$B<&W?4[PO<3:Q(]C\]D7.MN?56[Y?16&,D@62<|>48N'9&-6%B/Q:.M?\T6,W]6S&3FF*8!WCSC$PK;M

K/;MV$0C7%$*8ZOD*[*CAU1],,%EBRT _M*[,_^?I-U!\,;G+,OXB3KHX<,1L(K!NLA)@HQ"4BDIAQR06SS9XLG/C'"TF9"T9[VY]O.86[.8M[G89^<84AQ.0O'R;$?!)1HJ[P(.MY%?

G%)2)KX;*$E2@[!B UNGPA9O2?GK$8:M'=!AZ(03 .'B*8 MA*V$2^(.6"!6!0A4D*+(-/K@=!=Y(W$]E%TD[=&44IY+)>]FV<42XR+&% ^9PS!1 "" 4J!5]#>3 M&*4O%<)%

*|**Q;3V0P%|LW",0Q*_%KCX$T&>.!W]_RQ.2L1*3&8=3*.M__]7PV;CX&T[/_")> SHM .)X)S'@M_+_#.B_$,A-C2\N5MWE!.MD$UKH$(CO,.KCME{1>C'!2>&DN E0SR! '2G N!*

M]UD1"#O6V;@ID05U&%$65,V).).D]G,/%H(#T.&*($6Z%&0A(T>S_BLLX49&.M,:!#8.YX40,@_["$+$_@.S<$;&(N)M1P1##*.VTF#[@K2*6Y#5)9%J1R]#,.'.MJ3Q=B829PIQ!W>)C!UI.XCGAD

'D%P/8\3E8XQ]Z.L.'"L/".1(@)_UMKPB$L.M/*VURVHS]W#?HVIWWHN6IMFVZ>41UOC#!5"!.MG?W=MWMU.08^B]X?)46XPR%]5!EL$[0GDO'H&Y)UL>#9"'0:4!N.WWE2H]*$_M'"!FN##$AP#A!J?

N6I:@]79.Y*)HD60/_?4O\@$E5]36+X]O^#0W.,PYE.M1$[RE&UD6T$&$O[K:\G\/VPW'GO[B2G<^=R(G6L.M%P!]ICI+H?(2UKR3._%@9"!%:.YHVE$,=-7[(.1\Z%HY^<$37U<

MQ01M!2 $-X#Y#@EN.45K.[[.];7I78[8PF.U4.L!APB83.M.'"".W.@F6B0ATCP[K!KL,@DQ8[N>E^1P).AA2P^AMKN_I\^A!L2#1'ORVZ]S.M._IO*V8$X*MNV$;ET1;K4G"PWAF;#!*XBIJQ[ZC!E1K]

(.T#\<.KY40'3=7.M0=@MY50/IL?O6M[%.*R+'?.MH\7^LEHY7T>]Q7P.SB4#.0P(ITSP%[9"L,@% M([K(*<08.X/8UL.L.ED#.PMM'+!ES78<@]DV6/+9.T;I=AC5.ZSQ.ZE.MN:/S]OF*LR3,OU@D15V

.A1);KK%)QY'G/4]URI3]UP<0@+.M6.7H530LP>"U+:.UM!U1.+.7]D0)K(YE'CI'&Rj:.7@"DGSM=[11%PDC;)4).M'=.", "OBBO1SE.3Y<&3$D(.,^$.27!46X*,2WG/*RD#:Q0T

(F$Q@*5PE(&G MR!7@;AC\B0AG3$U.?CT /4)VS4 +N1R.F@Q:?;9E%4Z7^!9.1PL.F?1&41S& M0[8RN']4,1(K X). 9]TX$+R../O>;8>6RMOK$'4QO_-$B4 9[%7(8(!IY< M)+/"]!4!]%DB>>H0D1ZY-

X,XG]C0"(!]O.D,,*TWGKFA.=3K5L#UCMQ$V.: M/9$# -L 2^*C(W_K#28 (&6#*..1.@"PY8)"%L,H8\O]]>,'@&'5Z\9A6<=C M.0A8'4E9 2D!WTE\P@((OR^ N&.X!-.-Y6 $@[@

-1)V"G5APQ(Z&=M8==U%81XU[9AU B1V1H0%C05DQ$LCD9"X2E..FBTQ7(EN.Y@D);(S$5S+]\33@=@?<:).)B &&/ !B"H>D0<4%4QO4+.,VBW8A.7GE*06H2]*C+!

M%Z/NQ99NG$*!1#.$5<43I<.1@)3BY.R>LO4[=!S3,?)*M]3C0:ZRG:V.)FK MK%'J^L]>."X0(]# -=4#H.53=D5_0WTYQ.A25E6GB0]1$!:.04O.5=@$TOM ?M&O 1?

#Y*.5F<)7F["TG>7]58&7.4$([0AH*QT0.?VG4=LW49.V/\H%+%AEZ M=3&'8/^.!$K .V$@$ -O@BS15DOXXR8VXIH=K6'+EW=SF9$]T[F+.>IX%?Z+.?#6#0>.!1] C:.1]'21\9E-MM-H"

V<&.4202WH81SUC\21.I[(5!4AN_Y#AP$5['MS@Y5GKCXH#(DW%6#+1 -MH"F51H.;Y36IQCS$:]K C0Q2$CT9"D!.9U.>!32FE>.JCB>PVQB#G; G+=C1VIR(8 M8^@9O!A.G31/)O)#26&

(VU&.T5H) HY2&/(@(.5ZUK4+XX1N5*&7. M^UZP42./WB9!'GB%OZQNB.>*M?E[EUO52G/4H@+%?N&*<8PM1"A,B'+N M'.2.WX^B.

8U3GZ)&+>^!#BSX%!'\8SC!)XTK6$Y2+P48((PX%B.W56.\6R W-M!!2D>W)>MEB9\L65O$XO(X]\\RWC+!?*L2U!L8H#^$>!@@(WIW8@]D",>O624

M%'&.;]TJF23;LBDX$QY7E&'P1^F&V39IV:CK5V.>G28IY\E,#Y81S=>)Z$Y'H"0PD)>#Z9ME,R)WHC!GfOFB1=BE O;#[;>YNCR>(=F$H\4QXO$YQ?$AG9S 3UE8WX#"!

['+HAZ3 M F7Z@H)\1BL=H[%SRZ F7(3H$IV(LT;$>L 4 MB8 .A .K@%8&!!HQPP/^)Z.HO/.L R3]ZC^ MK3%4ZTD@RA]!'^%GTM.+X8Y1@ORJY>TBG'.!YJ3H!7!-R%0<&9>0MM

M8Q@K._%2^3D 'GE#57C(>+]+ 1PV0+!E8;.">7)F=]$_=^$;=^2<*8 MJ3.)\A>^E4TP9$N23\0)<B0^%TQ03$TRY=VREV-2 M(X M5-

QO)DPVAU'R;O+:IR:C&B6,S/ZF9^D"EZ=VN*7FJ*,FQ-T9L)X?<-I #1M- 5 N .:5!5GH!.P7*FM/EA,':U.$S7.L^1G*O1@E]$59H6&,2[@Y#<3U^62 MUH6D=ND)"^N$358"#G4%8L9 >%4R84%

MPRTMS G24A8!B7WVT,5P.C"""AZW@B-(=(QRICS!(,\!@394ZV <=48T"FNT8 MS7X]"2UV%(08)9>RB\)UM&,"*,XYCS &T=]0".8EI60(F*7CEB"T47E'N+LL4

MtQ7J6K@+T'!@!JN$8C1@RN@F2.!I3]IX3C"=HD"P$?>" TF55.*04=%@R7@2. M>B0M2ATL2=C]'&X>+D6#X+'PSCN(Q'*8.5)!HAQ#3C_XI1(EYD+A="""ME5"!X M6+NOB%$P"%4Q-!N%

[(*]V@XG5]Q-1/#V/9-B!4]N.@D^ES%)61 $M1\62 M:\%SI1)EG42&KLIHGH.$5 TCC]_S6A\TNK!&#S@8,X*!.@9COL<,F):X5@*9C MQPKCLQQ"KCD25'?46)&7]#B"Y7"

<.OSXD3DE&T'7>@@PZ68)T=?]TE6 OQ& M(%;)#47DELYJRB=Q5(X.$QBRKQ%T!BI598PUDQ%>(@C9CC0& M(NE2:6%FQ0L=%P/EZM.A*L# ^@E0[*>.,.]=$D@O/ N@23(M\.P!Y#>Z.B](@#K

MR2EFMK=HH99W%A,'!*DX5 0C%?X&/JBQ"X4.DSY$!Y.U! M)S#.2'.G]L0 "4O ^U]#TZT!WZKK..5N;@**23C<%?3N1B<*N+PK_Q"!3 T03$TRY=VREV-2 M(X M5-

VE2BP.8=F&8NQ]>0-%28IE+$078ZK9KU.G&MM+!!:^.RY4U\-M09V4RNR$P0"6P!5&M(.PR9%9Z@\Y6M-S?3D.W.HKSG"C%142X,.9<.ZGH?VM-MA!

=.3H6!0*Y;X@CD=54ZE14P1(.#8MT">]I..!) ^*QK$].TT(;EN:GA*X] M$X2]-E>G##,&6IY5]D8#M\>O" VZX244<)#3K9(%K6*.$$XN6A6.\'8G11 "" M+CXTH?I&%5NV46\#T]=BH=H N6B*LZ?

HM=G+T;F\/MD7[NP\60O03MVE|(M#@9XY<&U>$ M=@%G\G$UKA+E"@"]B*4_0^ "/B$]39.ZP@ (8,B"4L:,9X6=@< MF]]#RQ -.%21*#!;KI#*'"X.Y[/< &E@#KK5247=YE]7 'H>L#B!:5UX\I# MPV93?

H/.U;/\[!]S\>";&:^YWF@V#O<(:"P#WDNGW01==$>T\K]9$X!+A+E M1'2G\LT_UO5MQ%7UE!R=BO!C6!2&RJA@&(S90N<"B"%% M>H]ZH)\6.W11HTY4_1ACJN.Q>&>FT@UH.-

KKW:T>83@#\D%TU5$2$< MA:R2O7QVE8A+>G*C+V FEIMG\9@X5WFEE ^.;ZB&.5$4MGPU5>ZSK>* MA:#B9GION"O%G&]/0 YHG\. YZ]B @5H6K?85\!!.WC($]L#2GX.

M%2U4N1 ""]+U.5UZZ)*<. $886TMQM U_V9Y]>U1ZP%RA4[!"=N^P4KICH!*D M1Q2*IAI85 Y6P?.A'3S\E9T*2 GY@JHW]0.C+.' "]!Y\FR$T4 ^NCE%V]#W _WK(?I0>) +$YE^.?

3H^.;T%.S!T$^32SXI%2W5[GHT8:ERBHK[OH.!!4 .M&>V M:$L]DVO 0\G _O59H&GN]7 HGRF&^&RXMB!R\P=)PO%0T(H*\EQX.0BI5(4% ^ MP'F*E%M*R[<,<)GM?

R5[."B .!&CCV=T%@2\%FI"@>Q.!06%H%@NKN'S;<'LWIXTW@.B1RAN'\SRRA4.1L6*^$I@ ^G6N51,S+KYED | M57&RQH$Z9^,.;'/GF+K_CWM;ON-3OV-SZ'3=1W'Z@U4H5=R*"]LMZBIF.717S

M3R2# ,.16)HDS0S04G60#%@%G2W)0&%_ RZF0H9T.H%Y(LYF.@$UO7[FT->7N MX>3+.25H8.G2UC&$_K7XIV&Y>WM6)<:*O\(Z]DIYL)DXN:\E%?H<26!Z

M^ .!6!2]64OU^SL2Q[OE .IAL\+ZNMLU(/*+Q#.2=GT(=0\:.W=[O!=]N*W"". MS4]3K$9+BGE]@|%V+*2Z.V]!00$+6#|BJB[5UHQFK"2U0$\ .) &C{}3URIBZ$ZHU%:.LL3+0PEN2(:A^;C]&Y?

JHG'A,V-%O1" _M6S:.4%TPC%:HPOZ G03IB(JH<9 ?A@]K=$[X2-Z001]6CI:!&OGY<9+\-U2*U.M:$Y%V<(.UZD=F!%6$*M]O0'&!G'7U31\P18'% ^!]0XZD%.'R'/ "K$>^R+-

MKS=WYP0+CV]E54LN>A1$958/>3.XYBAMYH(@,W;KBZ,R]1 9C5007"-HD\!G&S4SX'[)XJQ8@S"8-(+>F10>EQ YSX(HC1 MJ1Y12LV0E*KE) F0)<$>'5>'L4P=51V08]L*N5(!'PB"

<+T4.9.2F$_6&08ULY\[M^.^32FC1^(]7[IEP.!&M4*&68%A(6=3RLN">K?@LK.1@W'!&!L/+#]@!P.Y"%! MMHNN854=!BOUXB;L]&WF?!@)X0&.2DTA>DN'DK0.E.\%+_ P)R M"

9UJW/B.JFZ["#A.L/.!XP]MV]E7%'U#8QTLR7C9RE#(%4%>("]v!XDT"3$K]#2H1A^.KSA[M2UO@6/PON('$0D]NAS6L.'46WR+=*LBL3*VB:O9R>_.61[8X\GTRGY&\)G&:

M58UJ1\LH8BXLG1_$<ZAL)REU1.*Z 87>0R62A?L@&-.O<:U *)2XZ?]5?&/4 M.%)DG%@&RDIQ@]@ MW&HL0%6Bl:..\\9X;E8LD69'UU46UC$&YX&"K_=E44

R*>,&C"9M=Z5,F0=2[Q&FBNIEZ=E MVWU2$6?WSV5"2>]ZV+KV*R\R9# +=.P%YOPX3^?A/RC$30X6L111_7)1*NN* M#5.]K%67PT5%2Z4)DYE9^F2P.8TQ# ^A$$0]%B6/=I+CE]1X^%

&L)U>9239>_MS0D9\4M]*7UHB3N#4Y2"T.BAJ5..?\%D1\N*783]NA00O> DB^9!@C'IQC MG$U%?26YQV0WPS5:G5:>0YB"#=O#\.4BL?K<

O(EH%%K!]A04(QCCO&;%U<*WL:F.X"P1UUSMD 0=7="UO ACT?8QV M#U(:.]?Q\9=!T2D]*.XBH]M\=(8.#X0Z&M'9<*B$(6]6'[+Q-. 669YOU92S]F M@AXL24N<8@',7H(.4 <.('4?

$26=Q134E54 Z@7KV"+ %@$>0;LED,8\6ER% M9?0IY=F6K>H56 ?EB'.9.+1'T'T2":EE=.:+*?92M,6 "^OIA'2$=/;8.,MA=*QW]8,]= R M,,.PH\X!.M;&EM&7GINKHH&Z-

Q6%40)^Z7=OXSSTA7=9B/"'+1]ZF6\U+W5 Mj.74*XH5XB |=:DE<(&H"(N38T]BC@GSUKA>9[0]TOLD(EP5]V3KQ,0=*%(M M_F[Q=TW"FA*W% M-M''

XBY8)5.HAl_U7!.F*8WJ%]PF&-.&1618TX[5W VK3N M0.H8"&6VG8MX ,R\{[=N"]],^/Y^.^%,Y.;KL24E#GXEF6%+7"'/622"SG]7A_M!E9,G/]X<0F.[<=FM _^S=5[/=1?+$V?6.H.

D(=TFR)Y)Y':B5R2!4R'L9[J MM*DRG2@63;U;>+ZOQ]?E!Z<*ER]440U9;^A%V6Q.B.Q(3*. /E2G0.C1..*E>RJ HHFZ&ZG^L|%M2C;&]9* MQ@2+5E.5/\I9F7M6;O(MW[J+??X/NX1A&OUPKYE&

ER;/O4" -LM[55=FD! M!QO !=B)*N#'N].TDV/.0X@+&AU'2?M0L;I&]D*P7+UX(08|HJWSUMH,QIC M?AAIDU;?\:,A(FO L>>+@\LY6Aq<,+1:CYY&\|"/"H1!0

M8T.3O2Z3O6T3/P!BAH+%88 MS&C_FO50T(9T$^K--89E<.O("A8@2]5H.!;/0M2M4GD!K[]M'|HIHDLPV)V[MJZH>%:F[(*Y'D!L;. R&TE4|"R+72G\F.+#JW*B7'<>X?(.4P&[RX'7R82C

M'DUPB|G>Z //.(5(7.LUNS'*9Y% M?R]]HVXT]3]HDH\HCA*RDOOO.)=*7ZGNH?&/MX]]l;"]=F#WM@P MP$Y R=29F<.8P+ !'YV86K7W$)=@PUIF#.6>W!BAW M,

!V@^:.BRO.7H@'F08USM7\@DQ> RZ+B/$5;B:(S!)AIU4 ,6)!D$RMB4 M@+9!@U<.T!9,39=.P*+]BBF)WEI+T6,EBF?T(^QM/2"U3A<.:7XPH)M& =3 M]8AH$ "/L1%,:#!

(JEX#VL1)"T.\SE7=E\O%2[."&RTKD0"9*:Z-T&?M:7L/% M<.=UIW1;\]=5H?UG!"G8%HYR:R;!39S9S^"=%DDL5DU_W8['0U4KM!]TSD'] MJ.8R(_1'(3S(>P/$+!RX>*1#FZ*@:.%GQJ>6GU3N?

0H*VKC%9[LBF.AOWTK MP%S!J3;U3'P[ZB0MZHED))$&KEC@H3XY6LDP_<&TFL0*5.5>5)G,1P M*56!B)A0(8.[F3L?)S=U.-&FT)=5D533538)TL^IZOY*Q7BP 8.NQ.,ZVF5R

MB(&F6DDMZ!U.RHPAG5#>)PX/+"\!R*ICFU^)BY,14R"*\/+]24"%))2GMV51X M7?IV%O`.0.YINN#M(^IGS?,+DGSI_X?ONI1%Z,8(EADXG2I.IV2SIL_S_L >VS7$;2;KH=_P*

MO)Z=$W8$R)%D>VRO[SD1'$IR>=:VM)\F?>ZG&^AN-(D1&NC!"ZGVK[^53V96 M90%HBK)-BA9I8Y.LDMU O61EYALE" _= M33J9&;@Q;)M24C8E _:?

O1%9(/'YZ*9+6NWJ(" =?)BNGRB!>^S3+I=>H3* MZO1-L;RXM5##O5!^'B1!9ZT9I+S\]FFK%9P=;1D9*"9%(4*AM6E)%2.T?)R- MM(=<$S;Z791KDT%]R>VOBKQWIT6=?C8"?;<;2#-

Q(-9]M4MPZ"YYPNDOIP\ M/000YRO7E7V7&7+=\/.MZG9'SRBY!IVNQ)=(2[<-=#'2IE7<7ECM,2FBOB M3LSB7C;@XZ7W.S6=4%HI643FH75EFOI*>.P.0DI6.M1SR.RW%KA@ /'^[Y';GKD M%

(]a[V+/?-&S,+9US+N!)K/ 107V K"76867#(^^#B0)T484^:'^X_CUF3L?2F;!&XTDD<@N)0.(4#(2M(<>UY!M.LNR M)+YYNO#S999$ETO4D.BF%BQ6D*%4.\;'4A/*7=IMZD\E%Z<3>]Y"GUUT!IH2

M]RIN$R\3D"9AD40B /.;/-[? Q>.,55^3G >M!9^[?]9]KK?.]?H]=>/CK]X1'!LZ7>,Z71Y.;,%.L?/ H, V8G.B.:[FG2B4OONX3ZG M52" 5[55:.8P@T8$D3AR##*U!/]E@ <6[XK-UK2K7;G+ORZUZ(-

F ^3I=VNW M5 DI$Y<%?O2X.WK=G@7VZT9H<]ll59D-8@#U|/=#N>=)R1\;H.^/ZG;..@Z"G] MA=QTLOH8BP(.?\/&?>%7\FXF7^*A Y& X C^+L,H*.$NAD=LBP8P@OMO+<&8

M,FQO]_3[_& 5P78LLEN@KC+ZH8N4E>%C AQHO>QA42C M#E(+,2A61O)XZXBR=GM_1R"P&0R(2CV'A>4DI,R\+|HV/3

M6!N_^%]7/EC*569N541=>]V1!$=7]"WWD#Z3Z*>67^QCTO;CXD@=7C M]#6%4S3,JZL72'QA;$CKZT[;K+"98;0X D!H%\!BQ\!EGQ>5_71;R=%7/>_MYIN.! GU>_=\&&O@BXP=*^D.;XR!

M/(&W7 O0$O=[.A(*D8%K^#C[XHN_N0-WWF!.J $@QM.RZY'\Y4 >[8/3K[|MBTH1O7;T@RULURD(/.ULZCMC#:IR@&[OKO[!92*(YBD& >C& MW\O&QSW.=$Z??OWHIR TB.

<|WF|SYE%6?IV8;INE)RV% N;`^|\.S5T^.?OY/ M_> !|^OEWZ!T/;^$|"%NP5;@D20[O >],CJO!&'|"*+7&9EY&. SVZJ .X%H M=AV"\5 -#0'),UW7-R[2M'9K9L6P".16G>JB+VP6C6#(

M9R]3T=GU<:3(#]1O<-D3/$3@_Q +Z5D?CG.95MP2K@["2UD+ 3?=M(&U1L;C.,.2H.X2*$*GCN$$!0R404ED/P/&Y+.7]\[LGPW.3%@V]"<6QHL8P4=M3'C'U- KE4Q"N6 VT@<?

D0H(WN[ZB D[M(FK]F+H6V20X,./Y8>EEZ"#YPV[RI ML%<.(S)& 8!.V0M#A5=?<3ZEYG0R],& < R.(6VZ4 YB68:C+?PV%R,,.^Z'> M1!O"6PUX?!#XYIL#^&8O^..K_CF?N.:.V5?WB:?

7 N.4@OEV%9CY@]L,L+]GH A4(Q(;'C7]Y2)?6[<\L.B(*S9;@<@9%^<]KR;(W]G-+(\ \CRV0X'A%EOZ] M]$K*2#LK,. E@OK^Q8NG^#D]# G[D|\GZL3C0=\# /.W;S=TKDL'6 J)^U;.ML@Q)

[6;1]\L?C6OR[^YKSW&WN(^$FOOPK:EKX^>*B$ Q.6PC=TBK?HN$' M+#FZ<,{.Y(@KIIKYD0'>OR6CV)W1):$6LFGV _)Y);D@N*.ENQ+,71A#8'\ "MI!HQ#[*0ZIQ=\]T* @#?W%|

<)*O]%Q. 9R7(!Y8+I>)Q/L ^W\%R"$S=7,&G: M\>5,*CSBK%X>L >5N<=<'+ZXX^G5[^J2]5HO*:CO MU*>O?W)&1^N6F/"7)] SW>#.]+"BM@=1-YS7)Q0C31=\FX0^O3/^BWAOLM 1

M&P*VP./.A.FK1AF[D2:T6Y'|SNH2GEC=7&)S+1.WCW"@K)M# 1KQ%D:=]^F+ M<$= #|\5^\|KDNP!WW|5GA*= MQ8R//IDKS=|S>^U5X&@>"!V4%&WWCXSQLK$VY.&B48R#6

8Z1A(#%&|2 +-1 M*@?$|0:IHTNB]H6K.R/#P<1[/G&(E"PDG[$6 U|.DN=$C\'#D])>=5-MA, Q^(&>KMLXD47>5FMA<[!.\4CRX0 7C|V3\12C"W6S@K&FYYURD-

@O!66]KUN"30QTT)<54DQ!3-18+ MU<&>7317 E<,W0WQIM^1,7/;R+(3!>VGEO;LUCVV^Z>?3F;K8A,F+A@Z*1(G M02R\(Y+)!4O1.*2VH+@TLI%=7O]O*R4HX6R=<8,897 HU*0.,@)3/D$0F9?

@ \\WVN_39Z~\|%JGRD M'WGNW.4,. S) RN6F41T&0>V_%O3VX8|^RSUX MV_URX.ZFZ;.W;A9D?IV DSOY .T77R)7DJ/2P.6HI.D?9.%O32GN#O!LOLQ.(;&\4<.U)6ZGV &.

MY^'MKZFDG/7H%***P3P[T61'+M-I^PPF[R^D65RJG*.F@:>(5LOPV MOE81[Z *']!FMFB .M*0'YM'Z,Q'! TA/&W<[$Y>]@eH"%_S"L SL=|Z[M<%= ^O>V7!3M3FH.VG,8>HYA /VGIBYVSLG

F#3!]J9H6V?<=WTJ9X6@#:.'? M^.NF*HE=X V%4MR?Y.?TM.]O%]0MXE_XDA]R:']R <$>D+N=;;04PA/TR;%"-M SKZX6G9%A+6%?C"GSYZO3W^)W<7|/ ZM_S_> 3H"TK7Y? [GIN2)LQ.E!D[.M

O0T, @?']]3%?60^.T?BD%O"0 M4!9!E#]OPQ)#8H1.Z%5Q+Aj.BEV/T ^W&=+N OT5E/C"63?N^D'D|(]ZV$YY M?3B#C:IKRHR?(>N2Z2 076M9-VE/)[~ BF0UNA(EW0T1/75XV%Q ML BL+*D8K-

;C'?."G6F>06H4V$?ED/U17ES>$O572MH1Z]14*#/KH+W"'S MFQ\#(,:"^.6MRPA4,)51U5T|Y%5 \Y;152]4T<6 ,5 MIH9!8 =PP2>U1.9 .E.0=C?848:*<.L.A.0A7 4 M*%>M'#]P2N Y))>.R<=?

X MT+&>]'O+XCE7A9M:N?%7*6TWKB;>5[$^>BE*;B!%M^[D5<6Z'!5GW))\'!P MB]5"#$D<4AS'3SB\:15)7A/Y&E@3!.%%XHW6$(A@09Y')Y&:.G$0)#HC$H 8E=70#H#GI MIE@41'SK+B\T4;

)WH("04NA3BU1<.*6YQ<4.3(/J1947'EGX,V5P|6ROG2S M(FM12U0 ^6CUBT@I]XV]!\UX^AY-S+Tf.(\7RG4]9&E#K6OSQM@5#!^H)K"EC+A

M"'HM*;TGD=]@0I9.7,#.7RZMSHT_GWFUZ#6@'=/.NZ6W\[*8 R_=>R:.B M9(?@&\'GQOX.W#2]=FY0%NVW3<12 \[<@P[3A9CP,.=W)+W=$A<(@..2SDLN,P&94"PF"!:G&.D:YQ]"%ADH:P'\X

M80. #1"=\UT&..:,AA#/D?I=*V!HM?0C3=)F^OBC>$M.!.UD_G[WV? X@ MGSB)/=WC0^0BMSSQ!% $ET>1@%PA80L09+5@N1'D^;>N=\3,Y^= MG>

)Y6:,BT!3Y24P^5KS,1Q+=W|AR03CV0#'_Y*+ 1RW+0SHZY=K4?HT! M&]U%N0XYJVU3<8>T+"V<7F]V0LNT0>,KIEGUQ=?,=TKB":.+LKSBP5W'?(. M1-

VWW&#G/7XVQA'[VB8Q+S36X(@DKYF[<;"]]WZ>$AO*&$W88TW:.,$!%R M,O>^/ /ZW<^3UVL<-4!#B&^3[2VMP)CM/$"0+"3L"F"3 SFLSAF=PG%>@D7' M63O!&M/166D)])U|&)WS

Y'Y7!4[O%16>X6=<.(.$]L*2MD2Q-ZX+SV-ML5DUW4:W#@R0@3V(/.F^_.L ?Q4C8!5(4;60]Y#[82UILXGPV[F=R:<;ZW M0[M$'UTUIG[@((5,+$Z>RBBOE&:~5S=[\O@O/F1[. GL 'Y'XW-

.CL\MP.E .M\VI=L0/ROO\3YT5+.^22<<=*$?D*&P:.L#M.X*0# Y404.$2EA@U('O69U\M\=..!]*MLYC) =O/I5@M .%L.VB'.V5YG .,3%]:Q:*ZA.7U^%.1RL.I .K.?ZFMAGO$QU\PN

MK$]W91[AK]2;C1K]1)!./]B<]Q4&8]I(%]Z6;M]+OQ;'M&IE1)I[MGYO)@(/O&HPB='D8FY|C=F1X?X%34?]^6IXMP$G!*%][3!VL7K5YR[/CBX^; MM 3NT*W88O65V(4[D>=<LU\Y!00 -[' #.

[\N\QX^XRTAO.]?9!+$/C/NR5DF@R%%N3^1YI/B[R!S/MZ]'5OQ|C5Q-*O9I6)*CV*%!KGD(M?@8Q5["REUHCWG*7^.\ U+V2@.R/LNP;>..V4S-[70T]Y!0

MCIFT#7$.Z>Z(UOTTFJ61&XO;\P# K5[PFRAUPZ]P<:%[ID(]!%KZ^I2;GO&]P4BG<%I_1'<.U. ^V\!TY=!.]\BO ZWB@#QN:MK%)Z-

=S6T&XNTO.^MWUQAPZRHK71H3!",5%JK75VBA6G]7 ,$]G"V=2)>? M^UD 357]F5'C4G.%G@\Y.4!%D9AK.LXVK1]$T9OC6VVQ M>0\,' WB39.(T2RFU[I9#HAA4A?Y]1H."[=MZ=Y0AIBE|

[RDM83'AN||#4AI MY@T87|84 QYE&O(K;HR#0Y6?MSCC"'GO2R63K*<3WI;H &U"UHAV!=9V7* MN9.7OYX9*.P(8$BX[%6T]&SN790$%<0L&P&TVQ?Z.10*$W=% MGSD$1.*K?!>YT7!(30)4)?

\X?3TL+XCNE6C4.C%Q.5AF+5>JB5%A"E^#/<;(MXS\Y$.!8N$3?%DY%NF5HZKJHI.N!]^-!A/.]T% 3R5]B^LM0&[*3 V.*6KT M&NF3#!S[* &C(IG.6

S99!H)7H>T(#}]+ .4GQ[JE<%U[PN('G|$)WZ?FODXM|"">L7P0 M'.[Q 0ZW%P[WS0$.,][N/Q9V?U!& KK,(N[>V1?NIQO6[WEU)[N$)Z9Y7(>AZ MHC6.3B]3HO6E!"\|/2

1+AD_5!=>M"!I8NL)"K9<L2+@0[<]<2+]<$'6;,>\ M*%/8##88[R,RK N[V'$T']XGU[\8&Y5&Y,?-HM&W UUF;@-2E4M5ZW(6L?9) M),7>-$* ^%7)C(W$0+1EE]3&86*4#[E]C)UW!W="$@?

46&C(& /=H5D>/C[\< MF"]D_+7]].Z/M5%$Z0;.^ZD6= X& XDH$[E5^CB#=Z8O -/GMZ]/A:YSNX MBW.3+C72@1 < PB5$*]^.TO\=^X]]:/P9C[^&B_^3%^@W']@\9VLS[!X] M?

X7G5)..!1ZB&R14PU4CN 4@K@=QOC[2.W! MN/I66381GN4$^4%,#V)Z.U]U:#FGL@N*D*,2[R^FT[:/OE+HJ5'<3%H _&FKW!8E7YBA? L;0^4 #X-M"IM=#RV]&>_ **[S!4GQ]=2N]|-

'DDL"A[@$R]0&8X8#=Q@&$[JX$E5M2/.M# /#R@=\M"O18&P?0/4W# ^.3+MC^.],IU'E%$EDS]P.2P[BU^OPMA<#;E0$* M?+R7G@&;OAHX.1'QZFQH7V]Q&.AAQ^A<XM@:(B(MR4.)=

%#H0\=PF*BT$$5H>9]S MRS\N:Y28>Y3&[@[!89U]]!L#X?QBGQWT%'(''/='2!SW>8Z$(D@%A|=?,N* \[*14HX.#6YRDQG5$# > M>7?4OO<@2;]W ,Q 8&R!:\TE;"_3 (,2IOO2G(] #=\5(/=>U-

UPU"T]Y!: M8;2Z"7E07N.'\%T:*@25?'.V9[GQ.%=:(_] L- ^2KK/AVS>HT$D\0U6+B0 M-*:7Z+BJG'QUOX.IW?[>W$$4UQ#X$O(!]5(6[*WQ%_ "-0Y%1KT%07G]1%>

M39PJ5+]RYKL[Y<.+:$&P'3THQEB30^Q85Q4%764P7).TA>21(O>LCH3.NE[V1 MT!$ DE'U2VL[72 W'>=D)[(1$ M^ #QO/8[3'"M..?.] "HX6AHE>93&A.#/2U;%OCT45'4\NO&0\^E2T'[-U.NN

M.>D,K8]FM+(\A& O1EV=V:UB$[-SAD=\2P9U:\]RD7/Q$\;AE;K7'&BN&(>& MMC>S+?(>"0L6F[] E^FZK$R5M]'<[D*6C#FT1I82S295[6]BMQ3']],P^T1,\A-

@VXBFAVT#.B.],/.'>X30#Q&.$.2VGRM"_M 5'X&K]N-FL/ ML7SKY8 _EUTLVX)^X30#Q5K;8I70C2/'8B(]!9<$#W4'>H;5N#XFP.2IM^&% M!E?^WCHO*P2=D+H/)-/>|~\)BZ-6XC=Z8^5M

M.K0P+"6-\N|&91$@^?$[C]/3R9]_1IBT*[_*.3A($W(PX>NHI.IAOA%.M<.Y M79SQ(4I8NFH6(4$O]NX ($.I<;0NA#*:=5N2Z. ^@L4]M>HG2@[]$(YKLZ7-MBMQ

QLT2U3K8:=8%E'C*B1DL7[*97KFYU<#+<6T6P96Z' %.E6[=M.VS[+8C9 M*+ <*7>EV;P LLF4@P^)=N)U4'?0DA,P[%@ .?I BUO(AUOLWTO=*:$2E3%S9 MQYR!53A(7+$6/0T[2.+]-

)C)..@*$[47Z=@#0Y)XG]6)W9D4<6+S2.4W&8 MO43%HVD'.V9'RHZ]E1W? N^BH[H>$?X@[/V>))\;A'BD@2QCL]0L9Q9D?4SZW#<C%0]+%]&! MC*NF/B=+A1R"%:E#D@NMG%

.,"0YY\"!!&\|^]LLG@%K;j;L8CZ@=CG/9)XQ% MP6U/|I?>I[{HT$IG,.&&*\)5.FE0,UGW4)7PE[BOTK,0V[KW4 G,,[Q189N M8 EF\ Q89C\F<1-P.'%!0AB590SD^)RM*QPSLI#1*LXS53

FTZEX5D!3^%GM M2%35U$AG\\QN2I%2[<#:C *3/T_9B26/U.6QC(NR@WRH/.-CW5P6AM&&O WE M!;'W!9)0K"'5^>X>HH.G (>2.%'O V7/1'Y(H;[!+ 4..Z,P2XZ(.BG$9Q>==

M@<V]&=L(EU5L*3T/N26;TH&&=Z^DU8\G0V A!H64U-MJW2LVD_MAJ03.#*9R6<[G<)RW MT61)* 1*.!^>$L2/5=(C#/"!HQERL,P.[E#&>D#:.)X11'GRB_V &9@%#[+

M[%R0$_TPUN1RS$]XAFBR@$8%SA@C'Y8L*!OG-;'43>&L">*AX2SV >Y$/9-.M$';-V1))9Z^D3=[*^":,$9TBV^U3]W*26B_W5>.A\L$9&AIRA[N$7NXVWSGQ/H >B30(RWF1>&N M,^=;Y^R

;H.Z[^>)SX*)18RJF-IY:P$U20*0[AV)2B0SB0\)K)''^ BY- MZ0(4NBV3M^V^XQQW! 433WOLM9Y\-N9XSM+09,OG;)4F/[,Y-F7W?TXS# ^ M, +XDTR%|\ ^3)H"^.?;C*RBYQ[0A&6F[|H

##OVVL0.[N*3;.T MX WP$G!L*C*D+BVVI$B [0?]&(CS.W%#R]Z/Y;.,Q&>[7EEWE9H5.1R45G MX_NY^Y]=.:OCW"08+=*"#D X.=+1W.4.'M%=X1OMBI1R3 !Z<8]E)Y5>SCN8#@:.*K)<825 &IM

M/;.+HK^BN*YYY\WDTX^87^>&;=[.VB'.+Z'!,\!*RA:<$@#]$]Y3@R_V@0ZN=/LQ1UK"=V*9Q0E.P$N M@":?)82=G&C;DIJF+7P5$%%R@5[#ZE$^CJF0W25+R.[/*!OKM#8]/DM%X9LO*|*

MT{=${7]NV\TE96^T]TS'-R*Y#3A[0.2C,[_7H=T|W5[,3E^45 ,[C9:6<3 ML[.:V9U>CYP[T38)G+,&NC%=<3LN6FOH,:N,$6-@+!.43T.]R;@09\'PNS$ M,K.')I* >V=3[=M2]NG[!3?9)[@05AX,{0UE,@PZ!2 *?NG*TMN,STTZ;=&2 M%!2N%D4O#?G?W_0+$JEZ8<6L,SCR=-TKZ9G()#!7[=FHSV+)%<$^,H1"Q"I&'[*N[LZY;:\4W61QHM>;B6'2$\V$(U M*(HLC;1]]MC"&(M1HW9R\T6M'!W9QE^U.3X/AUQ5B>!37~R90$T[;TEA*U%.)<'">$#FQ&/2)$M'23. E# MVPV%;01)9804@"L% C?5!G 4RWD\T3+3 @'L(EW1 ^,:\NT %)*L.1IV$M6B< M8W>>VTI$5!%NZ0$XC]&EO?:+]5M-N);D3@UCFQZD36M+[2>=803&UT_M>F ABM$+!GZHMFMD3BA)ORR,J[PEK8SXJ'N%$-Z-LG6D6DYNY!]]}E ,OM-3$26$;FF1LHEFO]]H*N!/ULPF44$+(C#E#V;RPX M5B 1BC28; .O60OM0:ES][@B,>8F((VG3@62=[ND@MGD\A]5@]]ZEF%L5#'B_B=AKBFBD#=,.KSA4-E$D+&R/'R3/6+)QK2]I[3?01 MC&Z(*D9F]@DE4!"/8O6[MRNQG=VQH./U1&5R[;P;T[&-U)078Y86;M;.IES] M4WEW&BP(S]==1)$SZM^T' ELCNH!>N?[EF!FYNX# [E"@U):U!#[N9**ZB5 M&BUX WRAS.(ES9BPF**3/Q'AM MP5$1(_.S9,DVK.(UO/)WT1O+@H+ .:>FVQVK&XUQ11<.@EFA#;=S+,OSB\H7 M05%"?V(TAW Z<65]IW+1230)-@42"U. 4B[8,9V+DZ' H"OF9V@~VH065[C$ MIINJ/3 -

M!>,&*3O;KES90X'T+*3ZD#3SAC?)|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}Y\C'EHT8^=,5\Q/3]M&9#%AQGHL+@C9GWLZD8T]-2D'NL*ZWDIX\ <6K?.]>E3 M1[04C'!.6!9^6[*1O9=9B)8:34%3P;$4=4Z'50?)632[9=,CN<_T8[X6"H&) M'XO\?&##7FZ?A/UK.G0\04@\?[3T%4EL: [Y8Q00H>(REA<;7#%>;]5.(+(M/00? %*42*W8=%6TP9CG1D6*$X9U][[S,*R+'K"EV<2*<=SLVIO2)QG>V&EUR.M+3.H.6%B%R)TI)?%E.>\L"YG'(UT%OZBHH8*VARN7*V]{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~.%IHRL30NY@Z*X=:7E=D>PY@:?T'JX9^. Q&R!<9R>%RS[M M95.1X-GK20^>TCZCWA O? 9#]3<36L2%;"*\L5[(YL|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{TU!ALT>'V]4P3'GT'>-1)#@<.6341;M6T>B\9X& B&MK4H MP5O!.B:1*!LGD3.%_-Z,5:2,;8!(OF@T+ILW7P\ENBN4Z'LBT0NRGW5'>2^ MXIGQK7G3,%KU!\;#C)9ELW5Q?=OZ? O\F=L&:2,V$&F\KDS7>&YV]ME#([*H(M&4T-&94.(.,%.'=,T-4V*,C4I,34 M_, OM]>7C7MT@QX;IRVC?G-I.%NM["CN^_W%[_76XV6<7LEQFN(TO>W\4AW MUEZ '4=:X&0=MN VL6,YQ@[[UK_5Z*5O#.0@2[P>;->H/X-4.B'8O!XR3AW MVI2V\+?2]EWI*]U=?|\7CM(!2T>6NH#A',('0VIM-7(%]HW-S%"XY .'}6+(.MD1TTVPY]6"YY+YG%2M,.E0N)[!GT;=XD#460:(E9 M@QGPD4<\|"%\BO-2?

*^8KCGK1Z;N%=UJ M8^4Q EHBT\IC8#E15$?GR9*E>4J/ &G,<6*!#9X_FP,QP6-1WR)Z"/=#E)X2 MW =^NCYNK;=BPU'=1+)[?]_^+GW N*¥;I"),N4,T'M888[!2D3C3U<)[83-T M8LB53Z[K6ZD*(<[AA?)!]_ZY7HH-7<%^^#!,WJP^6(]T:^-]VI00TXXP.)-" M[?8;[7&TC)C..[E-4.5]XO3$QG P;HQC"H;$.S.O-1C H%U7<\15<_3K;H[T-M6=]ZJ*.NZJB+.@Y9U+*$)I*E"E1ZEC* 99"OQZ*W MLN;-JNUFW STDOCT$YLQ2F@(-DTS3KQJ;-1-RJ;E5"ZH!U^,8!6A)!^2CP]H M2/#,N6D63F>YIN?V S\]0;XUH* IO\Z.5-6_8*,NP18U^$TU]28-$;O0 SQE,&[D?3B.OF7!\-@ Bl"R:#86 M-S';X*VO\$"7!M[08XP7K-FA,*C-0"ZD6(GR#1P1]&$¥B7_**#),I[>;@ M2\%ROF-]%WYLTZ!?OV)C&N)*7E7A3P(&/2L*C-9'%0:?,8XS$&I^H4Z7M'8,*=>_P4UQEX9IT[P613B4+.^1SF;>^FY4(.F)N)8];0SFV M<#Q1\!4S84X4+#R;GHPST[RX7G-572B.KTBLR("Y7@ODHN^EC]X@WU2FY6;]PR3B_#%URY5O6 MZCPU,E7#AJS\"OK5?.6#UC;%JI:6]+LHF ?WAHU^60C#SL 0/&;."WP0?<3P M>.42_06GN8%]S66S,E03?XDM 6#MGZ(6 7EG?P>.0A(-/FHY]B/_A?(E_(PN M-U-9^5@Q"Y0W[7%-(M]UC?,%=+VH)E/#^Z9QO9$M>&AV6&W M&B^V~_7)P;.E;R1+:]WO!R70NE3"]4'SX)=T,YH(60'B7I]_(9X]#<,%5U8% M.0X4!.]-T;X/&*TX+_7IQOX)W7XI/YIETX85UTG[$?:.<5F2W!=&NR3Y6$IR MWVE5Y#;X@(O'(}M*CN^ED1TI[&9KD-";N.8#4[PWB>K'@EQ.4(?I3[KUDT/P M.%E0#:.+1$R:1_BK6'NI MU'SRZNB&+NJ=0Y):C.&Z40:.LB3?F6 =.+K;5)TJ.^RYJRN;&F'78(COCKR M&<3Z>+H0U^+NGX8CUQG2$>G3L'+YF?$QM5=]8=+GJ76%X]';+.0]O*¥P M===BZPA"].1=BDOW(#<9N]66"F5-B2>C=]W]QUW<^CZ#^J5NIBM=+MW>7M M^?4G_?+_W5Y^N0>FPCM_7WRSO]XMO=';"0?GY_?_G5O\#\Q=<$[_9UM MQW<_>6+3E<5N9C$'B1P0?YH%!EPVBIXU#V7[1>2R)GH7HRHW5-JP?FM?&+> M'AP+I)3B9Z#;4(3%ET:HO%2_<_)X&2#%(S8$.)ZAU\9MUX) {6^XMCEQ3PU MO./=0]TR9]G) RS15_.G'(!DM!URN0;N.RSVT05M.\4[!;A@_SP^O.NT>HU. M=[3H)/OO-Q8C#0>_ O'D9YO)0(^@YXEA 7ZY!'*_O3PJ-7Y+4_+5'2H%<\< M.O)@OVS&U#M!MT0!!VO420=E):._^2P(?I0)\/= 6'?:K0B,W<:#VN;9'?OI M%?7DU&.34_/'Q7G.YG3+X"\A3;*G()KO'+0]YFQ*N:OM M)Y>4#FF9,,N4(.F#8A\"45$8#,D8<0R,V.GL9.1=NS[$B?4.=D0;@OVD%+ C\]LE9N]O_Z;A^KS/KP)EU MQJ7Q?1*NWFAU8'CW^OK)D'0.[$.H3$;%"/1K)P8.]QBX>M OVP0;]?"T=IM@ MU9+C%RL/GA;J[3]6 2XO;T"WWUS'\Y(1#|<;]HZ2TWM[./>1X;0WPEE=[HGI;]$Z3B"CBI@AX2L@"#]NSEA0Q0BZ4&] M+2+MH\VS$6D$(BZ*T)\+D8K56AL(_]59&M9AF"02T"CZ$N_CC) [;4V8'0/ MOBO@Q8%&I3'+&R162I#.#.3"<0OCP6Y'.J^:O;&H*?+OO$M"(@ Y.;44;UV$ M#U^-^1 ^WEK8NVI/+_ ^]A=8%A6T7L1EO0:]/-L@AOCC^:&:YXO#[[^@W*+EW]M=GV+]>F& N7R:X6SBAM/,/;<*#=[5-G$.F58]0.K\X)'EQ?<4'43?O^%XRT_M;/6?8PYE=U8ZB6.N/'C;MP^9!OUL/&"SH>. ^ZDS*UPHDZ+9&W@9[&4,,E$KR MN,2X??(V;+0'@S>2#-UZUL,#GW4'S[K5RO&L\PWH8TGVB]-=B|(X<_&$\/*#1 MVW2(T%V_SF3EA^F$EPLY6HF]T-M&O=AOZ#'_A3MGYSM3\|#W8,Q@<-|ND,?9E9(.H%DU3V'|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

*[C3Z1X;7WRX2%/!0=9KC$.!TO++!Q9UFN.(#MP U<< >EB@=LF$N<*Z)6&T MXOGZW$.%']I\;9!^ ^0\" QO6OIZ' P C^"O^QC5!MB#+N-=5;!E'IT&K 6 2P>6\U\, .#[W56]S:/&#ELPBR5(M6?MS&]YC71C>TfT!M^\UF74V/CGK#ON-5DQA"5fR3P@L3 6)_!DW:-'^ ,& M;%BVOGOAUC/3Y{"+)[KS+ENN7%O##S&B+B |,:*8GKG1N MXJLA_M&$R[M"=RN.[2KU' ![HK"&^G +5T/$O'RZP;&G@W,+V:7J9(=U[E=S.Q1!W!A M&9YW,O,[N'%[;%0H_]+3_S6:Z>+/K9!WH^:XR@V26 S@.EI63'. HXWD3+ M5.0YRG)B_Q<3OL=^+$R7;8D26!{2Y\AIN#UYCR&(6D8K03U MOX656R'E CJ.7\)SU' 4/(&)>1/+I&,/TZYW<@8"&FU\ !V7SA|=N,Q<%G%- ME -B$R!H(Z52>W1$*L\>U^ KV1WLRLM>/\<7/.P1 4L3ZF*#ODBWODZK.6JE69<YZ^B;9%9 ((F&#))!VF+]!11+#HJB P9DMAF_P\ MD[",R5:1,1>[QUKD/-UQB[.T$DZW"\"D'V\'@Y*P_B)::.ME3++,ZOCB2%48+S0YOO%"Z-^@W)!CPKQ#31BJAHC>8;QMFK8C(7#67-%O<+>]*

M.^#]\=%1VM#_SO8[6#F&0NDE(L9GS6_;K_7A(7*\.3L;]ARHYO.IR@!"WD4 M?3%$PfZJ,"0X&KG$]LK9P#IZVOE*C3A-I(72@KXF^A# YE=Y&M_^_&)C&+:.*

*ME]\.CK>P7IYGZ[F;)RE\W6*O#06POL!3OL0):.< 1-KRV-{"$8;8" MPV#P_#LU[4-NG)%437RT;X^&;.(?'|OO(G5*QQKF&\=0M<71DFX2@; M#7,>LI O#3%AD0!,_E7#?*

*C)AH8C8WS8WZF]3WOF6L(^S43=G;/6=U$V>FSKK MCON-;F\H(;P8XD/6RYTS'LY.;OI;&C#^06.\/BP0Q'$OO4:1,L@9]B-/)ABV&NU6 MC@.94LN9+'YW8O2#=1<\!["#BG'L#H9M9V/8G $/$7U A158NI+WZ*Z&C?MH;ZRBA='_M;ZUU? M,_H43:W1EM9P(VB6ON*=+TC7/]RM^X?C^H>';[E_. V/YMI=6#<'U\W!=7-P M;M6DE>@8WEE86&Q_<-#]S?*

*W"OE/(<"%5/Z;$[8!@O>@@4W1WVYF=VSB M-/IP=Z8\'GA>MOC^+W15Q54I XQ#V[# MY(FK$<G+U=+ 6>|02]?$150RYCK(*CN<(^>/B&ZV31>LJ?IZNNV, <(;[,FO1OEH MOD<^]LB1=Tl. ^OW#%GNFSN^(#E)]2R?P&X_H=|<581\$4 >A68&A%T=%OIX^ M<)MYT@\ATAOM?D$#NLNK5_$#_/L/"\Z=]\H8S=!K5X2A^C0(:?A&"DE*(5VG M(]0;H"SHM'9, Y5-JBK!DM* [X[\!81P0<)ATS!DW'HX2A/aJ"1MXO@<412> M7B0Q<$B\ W!- VOR`2GRTOCK]&> _F"WE#MZ0DB=TZVPS]D^ M,>(52+!U) ID@ 54S5%GEP+)!VLD=<$;]%?Z[:>E5WJD5W8#,%1.G/53#E"O MM%*

[!&]\)O8S#Z">@@U4JORF]EZK38H%4ZQZ)5AJA5>L.RM,KA=4;W;>F,$>], MX6ZI(C.K)]I1.C;#QJC896MWYSH(`5&O\(ZH_*TV S>D>B,X9MTAGC M:GDBR3M*

*4GWX"%!%@"1O2JL:.ZC5QKL'7!;>*W0T+8/]E%!T55:GPVYB$5XS M0%8&D'I\]@V+%[-OR&D=#G ";:L];O02Q=-]#LC& 5+ -#]NL9FLN#%825B;G MECA.L?N#)05,ZH7DL9"*

<3". #0M^>OWE$+K/4"\"[XJQV' Q80XMV8FO12$2#¥):0H%EB0PBC\)-&K(]4XYP(H?7+6.XY*2O@>0O0E1AO+42NN54=+P M>??$6:8"U8K]E%WSX3O-T<(]5?*

23+8I5Z]4GA+OBF6PN$JU.HH%*^>; 5SD-M&Z\D&F2H/]VVVL" 8.$'T!NC #.HRM4;E:?$ M!$VQN_ZT.GICC'|CL[.O[]=O2 89:E0K5G&B"$_ :YV-X 73Z!ERQA55+, . MVT<@SW(BA-

0L:,:;U9HEB6;97.5:%_PH.R2# M3/685=4,_2.05CD10NJ-3]TW+@ MQ(,`Q6#U1T. ^7$0KDA!DWAK7O"U-M6!ZH-ES0)&>.J#!3OKNC<;\S &PW'-%T7]MB*GTP;ORV7Z+*B^))/3&N M:>K-VUGJ90VQ%!-F9Y\4'0KN?3\C<+EO1?"%Z%<&YR<=<<$'V'>CMGEHZNXM MR5C2%%O8A\;GQNJ&Y\]ME1 \FKF>8 /4ACE-?.HTS,? 06EKE49Z\)E<5- M3(L12RBN&

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

M)$6N1JK#6<6^FPN*Y"\'6P$W6OH7YYEAX$"'HR'/2:\,3?759X9I>?A]FR" MX0QO4E[Z\$]?%1IH"K?,F.*,X/#AS4%)/S \PW^!5.=G39D07$WM?.DU(>XL M^C5CL6# P_=+8S;S!PQ/&4XE-&WN<\'C#/UW8\)XC*?&C;SWBRW?U6.!Y0[MP]GOR, \&=+O*A^"\!P;%.4VA[^NT"HPGH&"0*C(\>W -0Y=`<?.X'XWG0$I M%0D<-?JG[!TV.VT;2A.'O^:!50 X;TAL0F5=%N\<1M$RY.6 +"DGNWMXO&R!8 M%+$& 0X.R=I? V9F'3AY'Z(D3,2X11)'55;>)[^RHO_A/;*10L<&EHH%V#1 M@P9.GBLFI4O&D)Y2G07@(#V'(YF8J1@ET"YXF | 1\17UZH?KK]]OZ, .:SK.*

MO"'[^]!^0+# _AO_=]K&R[2?GG_G_3D[TI9^GZ2W+[<.?][FD>.^[YYL"V/@"V3!@'SJ6'8*4WDVD?\)F\C M.!%Z2-C,@M4 >.&/DP$#C@$/GA+4D^MM%ZP789[$3N)<4_A2_/+D>G$C\6D>*

*M/M6:H@>]&=Q>&7P$2GT0K^X/*OHO>+WLU%_Y.(%[+K M>GD>H@SU#/)1AL3+M^VN;KKW^IW5_K9U>7MU=>+)L\'_F?I .*R=WEVT?NJ MW#[!%]_ZEW>W.*

*[TY2^YVN^O^7KFMZ)\1ZKZP:+PH,%$Y.6(_+8;@(U/TG@"O#KU;>^?M3_K^O^ M4WW_]AALC?Z=L 2M1)C@U1*@ZJGK0S(.G1 4+SU7F.KN/8>O@.L=(D8O2.N_MW05/9G*:#%,83XB0YSUR.QV_7&O.O'[?&C72!WQDH^_:!$-/!+@'M7$;D ME@R^+C$M_]?7 M-Y]N!%MOUAO OI#=-O.-LNEI,T(!)W7:A?.9ST'UA(^Z%?D^ M!1 _/G(#A[LMAC;88O@U\]A>7A=GM%H_6GK&.XOC0N6*L#2:C5S?*

*P PLXG DP MW"$4^#N^@/W_U0N"3Z2FWYD_E_*SUK'#1'UQ%N_6!IKO$NI'<|>VC_8 [@'.MWC4/_CCQR>A4%V<,S074\;H4.L7\UX=^,MT?I&<.?.!\\EQ80=!,MMSWLGN MJO)X':?*A"*

*3N!Y3*3[2.LW@S*YY8 =W'!G;G FX1&(7+GSEEUS9IV^U.M"]H;B([=@+ .%@V3. T4 MFMN4#S.57+YQ_0B.]>"8QVO!$KU'CSAHM/8#1=O7]!=8X%TZ[*SI3Q"N40/RIUG.! 8.>Y.:=SL(?*

01'#"=N5-MO1-]QCH(4N$>,NZ;"XY0Y]!+DZGR_VW)$>XJ.O[WE1D1'K6 ^N#KTE**7[.M[F.GNT[_W1T85C.%9_ BD^YX&&.6'JBD@U?.3+>AO.HH 1N$2U%60?KNX^DV*

*MRY>/7_DA;4,G7OF0:G!(S<7Y0]7PJEZB2TWE]H&ZNRAP=0FE+V9Y*SCK(XE MS,\7H>YNYZ1V1]];$M,8,P1MI[G%E@(9@D^6]J1ZQV0^;RT]T68%=9?*

*3TXOO_A!W\G_BR(H*LRN=K|8/*\9R1#QJ?HS]YF%+Z&4?B[MWG_U;_6K2Q&$WVK0?1]%6$OD=F538>;FGLQ(<=1F%6<58=;VDE;,2BKC9&\5 M6H"-&K <3*R.,UQ%#KK(N7R?*B*

C+K"]&U%;.?9&LE:LU)/|"JAK Q;&] M!<(UBK/6!AXI42^.7ZWY7-2RO[5&=O+/U.LSYIZ'3ZB %.F8X>FC)U_$)+ M8%R%!2;>+ ^87QM?8&(^+ZE'IM/S EG&Y@'3<.WF#9CDVI 6=C+!>)[H9]%*

(E+T3V\0 MZ#V+?JO7:QU5U8)7P?<5_3:"!\50E= $RY_Z"@1:$,KO\8$@;SC,#=*T>Z52; M*0H7B1$.&6A=0YF2SF_%VRRL6+%=<2T_&P#3,+)@H1C6&D2![:,)@V[5-AX2_ M

N3ZU/>P^F9[0\FP[J=8+V,1@DE-B^#@4L158$=8E"%2.2>,.-WJ3!F)$X1 MK\.2,'&V"&GXBN>DP(E_<,P!G!88OX'$-A+&5^_O!-8!+^+KW85! M3V=#,?"DWH>E5?;0-GTL-

*!PPV"'^-7C>'6PF5F\VJA!Y5SUBWJH5**.EAM#![M,O4"%(YR,.*6PI&ISF4!6=.,8R .FS\'+891KZK$1#6HLT@8"%=)@\17C M5_RU$KA QE@L.V0*>]!9L"H+^3,8>2KLA@;"^VP+*

*66X.*9_.8$T%(3 MB RG!9AJ#X"J-8]A(?+A[^>S(BK>M!)%LF!KVT-LI^*(WC,<'6-1*I[YJ*5 M@]5GO4"DNAO/=:C(*L)"L]#3O-$((+!^DW6]N^5DY [M#1&EJ7QG61[6 C,X*

*M[SW^%:$#%W[*TDE"9OA#U!PVH_0(O7R]0O7/V?IALA"(`43PU!OD 3%2OOPXHY'UL0(,?0+P+?9(Z-_MPA=+'*<.X9I/_PD^&=Y$*GY3&Z)02-Z&;/<(+-_RS=R=6*

*MP)F>;M[[#8)*YS&@4CW0U!E05G#BU6;\B.*WD,NS-4$0[38"5+#N\]K8QO#9! MH[(O1U+)DCLE5((O@-:)PVM@1HZ]@L7.Y?;^ U. t]RB%O!:.M!3OB#*9&YQ\&* B&F*RU1=PR2PV&*

M69VWK^]\39\\0P-]=GK1W#2=Y7C8N+9T8KF1$]2K0:7B)>(F03+!E=>(G\K M$=O_3D=O72U:65HYW1E]M%(9./515[QIR;X;X%!.?7\D%0)4BV$\0K48B"97>C %-!C9%OH?(E[N&.A0 Q]KW-*

O.H[W:.!3 MU/66[5O1!'O9454D7P1YLV:\DRB7]S;Z3?RRBOY=>:.OROQK#PZH\ RSZ.0P M'0LO@3UD=V9;ED>M6=%(OVX)+>$*SGU.*7])^FEHOA%U$$2K .\RXO:N.7*

*M2)L>%#/R07.6D^]P#'!]S 0 DN.3=Z#\VBTVMR[5,\993A0&(]3GDC>3E.V.V M_P3@N^:C$==& V3 &TEQ+Z9.*)4(#7S0O[RC%>.^TF+@A:!P[8]0RTB$/0,,,9N2=C=*9T-=^!WC=@03=&V'XU'Q6S[*

.L(AQ[)5[@:K[TX6+S;@)4H9>Z[-Z M2]:B[4<@#=PAW7/15?1.X]BOL6&&/]W=CC^^0LW#M(+K0YP_D7QBI9[!\) M%ZYV;?K ,Q)O\ 7@DBT .I/PIC PLH1+PDP \K5O*Q?O5W3M.E2!H?.;?:*

*=WZ*AO?PQCM8/1, 4L"(2[:.Z3$/(!D.Y\C(Z>V XWKVQ"1C@M71 MT?8ROU?@M0D>EOTYYKE<9W+U[<]&S/>)"Y"AD57FIGXGMQ84]\.*.2C%D[! M"AX*DP&?!?I7?77-*

A0I(K^52UM}$3@L1+2' .5CU > (MQO"D\" B(]?>H$ .IR MVTE-LUBA'G:,5I6 U0]65W\),OJ^Z74!YU2(D3(@+fELA%+C$2-FP/+ Q+'# ML8G.WS%K[']L=X]V][#@6O38K*!"0X^-*

=T3.&VH8S>10E$I>K\W#K^>W1F? MC[NGSD/\1WW%/SCW3)YB# 2:#A'M?BMH7;"A?P!!U6UWNA_VD&ZX2EK[!NTW M^/(.MJG[MN1@-

*@BW:>7X(%D%,>9#KGN>U(P9G+/@\B;9'JI\](FO4!G07;TT(,P+PJO1 ME4P[O^$+4)#]}@!E. ^.D1*0ULNE'06OIL#@<7>@10\KV?LK?J),8&U<(+MC(MO"!*!LYA.+K5:F%S[^.*GG-*

*.*8^5E@W^^!+.09PHE;WMMO(W0+LD!8LI?2. # M4+8>%Y-WK=\3@)OS"=PS@O3?.3-11O:L=-N;.:/G3:R_6A^C2V$c7DJNI: M\EYVW[C1Y=\K^1[V7=A$Q.LYB\!H=38OZ96_.,*

)XUB[H_.]G5#GC6-WAC/ M#X".]Q"$V@XNYA2VP:&<<=[12RX3WV@U=\MC/O_$6IS"GIH> MLH#.VN\^Y@LIN=L?&\P7"I*CR'4PN7@4^21M0!P&3YB1#!PH?#HV8E*1PBD'*

MJ51D$L1$@[%)YQA_E)^+(>7JRP@EA3W\ MA%S=MHU{KJ48-?GF[5O.M 4X+@W:_]_:(Q-D4(=,X&%72[0[:.MK V;D;!X.%.T/4-/KPAF#VT>>\/;X]$BP%8NKK(49W[O#SDWG6[BP$VQ;T MY?*

*^7A7^9?,)& DCCV(MY#9@4,,O^ M4TS[H,K.N)Y3E',&LIYS JNQ[*GII*HYB\]D@6=VIJ>I, 4Z^IX"@9CQI(4&= MIC2=YDH$]4V)XIX[!%;Q8%OLG+$ A[RM#+N2-1>05O-*

.(MK;=0"%5@(2;'&I(>O)+3(#.P4I8<%M4R.A8!9"Q7A8RKD>9@^>T3\Y.WW\"22UH^JG. M.LDF(KLU60["3BD.$?&6(=ARQZ0ZJ4WYM.//4;@*?2655U%?+Q.GU09@M.N45%N*AO%@A*

M^GADEOVDR?T&O7U+$03+84FYH-L]BM5OIW 4[]P4S9\HI[4CSO,& 9= MGS*Y,<-+C1!8)G8L\C%/D?4]LWD3<$:LFB7W.&Y)'H=8!>...44V3@E_!>CQ0%^WC@O?B8O

M3,RM4<<]B>Z(@NP);10TB@"A'H64ED9>M\MT92,.L=7=YVC37[G7KS@K[3>Y3@K#N:I=XWZ.3X;7\8C\#TLSQ=5%"?ISU?? M6:)X$. ^1L!!%(6AQ/$T+OQRRD8T]P5#@QM[UMM_0[%+3C;]M6.

[F[WBL%TQOM M2#90TU+Y,)BAELH(+R#FG%II4!7)!1:,ZUMBUC(.&V=<|):CG*QTK#9-+K5 M#2A7RVHT)>4N+3#R|>>,W-#FH-K6Y4;MM/Z@?NLBI/1 K.$$ ML)[3 X$4(!3?A-*

*&\Z_#H05*5YCG:CSD?VZM.5B=#KL:Q1/&E9^.!7<(IZ5'MN1!76NF)#6;4JL]TO.G4RGTO3QF6&F"TUH&S6?"LBY42&XV$#SODN.\E.O0I6C03^CW=M!8/% MDZL*?ID(([^.+?HSI/H-*

*.7DE*C<"]8;DGP(<*UO'ZZH-FT'D^!DMXWIHLUZ M.P4%U??:OQ,%GU/-^H@GRO9]Z6[8TM! &G79W4O^\NLR>DJM<#FY<77BZNZO MQ0'M^2KX)B[R.]\V2$R]=4FT:5J./K%:.#2Z"T?*

*1S85$,3D<'(B;SP%B[%UP M:IQV%H_E71K$>QG3FZ[,>/%37Q>@B9C(==&C<;[C_E\W11K)E/ M>7Z52=*G91)T41)TO4R"+I.@7TKLH$R"+I.@7W$2I(:)S\NG.#?*%,.UZ&KX MG*

'$SYD&UQ1D>FLC65:)'R9"6A)V0!@]&N7;)4HHK0SUGQ\V%M=A8W6[F2/;"(@O+O+DKZW*'1EQ@0+,.?M^T&-SWGF[UXN9A$D.]">\W'5NYVCAMC!7YZKW<(1Z[F%.$<>>QQD\!M3IY

M6.S4.GWWL=TU3EOY3LFO+T2[23AWZX#OOOMX6C5:C<7^_V<.\R:((H8%S/1Q MLI:KH2LG6V1:Uf2ZFPGE'ORPB/2N)J3[A^^'9(MHN>>):.[M+\$Y]>/5DL0+$&B"R%R<'[4=4".XAN)>B/(]M-*

][^.)$1\HWW_(Y)N]KCR4 M;0LD^5W_YY2Y',L10.RYPYYE^=AP4(YW/, >]$@'$4.3B%#7]\UR>(8#-#[% MA@VY?8'K"OLYYVZ)R'^=,/=AVG-^PVW0ESEU;E68^66E'@F'QA7N44NLL9INV

*MPKN/=]3TH;Q!\UCUYP8.V+E=987G3^=2,,\"QSH[.BH1BDB5/1;UEEL]" M-/!A84*S=ECK^8;-.P^0W7WY?-#T/MG^/?.?_$>DPCA;QC\"?*

O2U+8)+/YR!W.B%'[.,K[S3K(K>.)9CPHKX+&\FGTZX <_/(3"3 M?&5Y]RX<#_5.+,Y2U[<+$5]\B;4WT2IM("!EF\/$#/D4PB9PS'\@H,WZ;()*

M,S$UDX^B#4.X{0]9G,6A%SP]],S,$S0:3DXI6%X@WF;^8"[.460_D6384.QH MX]_3EOA. D"MU]IL;R$3\IE&,2U=#[A<>((F0%SV<@.O5 \>Y3$"#%%GG+Q

*M.&KQKHA,CE0)0PX5V,>IN[OF^A.9.X I;1^Q(>,G;/#MBW:Q6B"G0 "A%#!QV50_ MU4XRDSM(>;R#O0W-W"\ +]PB 3C!#E. ^[*Q[K[E832U2)&-)G(%5Z>3)!7.W*

M=SU#5\YW6\7PFS\1UJ:#FY<&.QN4[@ A0?/6"VV3&O37S,=G1O%]ZK\UW'PL& M.1_CW)"G9J8%U--FI/A\\B04C+M0KG6IDY4\W7'Q/&0&69>3O[E!3;??&] MU;O=LGJU[JU45;O%]#6+*2E?*

*TRB<__.JK4F(J'Y*W]Z *,.MQ%<$P,:<$\N,?B55S[B7NCWO);8+ MQ8?F5/=G6*EYW*[9.L<,7Z]9@;[6IMBWX;(U]M@2>_=S=776T*;ZYNKL_YG*

MP)7;W2(+++>%W6X'_KB;8E+YGGXL.;&$B*M"P9)P0][SN-OBVO+/JGV+X M1.*CQ. IC7!7:G0U.'A'.5LHE1%_Q1-]fZ-.6C H8I/RC:'...9 M1%8*M2%*P%M)P!<4TE9T?.72ER-1; .LXQTR;%O$W;?",L+!

0>"Y5#%[!D A9#JE M. \DM6]%+0H>H6LZ)W"5V8\KJ7(LN$IZ837W]IZQU0WLM# ML<+SUHH.P^,\#ZQ?L+TLF^5X'?%#0)82/<"H21S"?H>=U!C< LOI9;_"3P9 M.KC1.6B&@$]_VD\08'#*

PE[!R ACBN9@3=OG A2+&-M9T+_E@-!'!"?PX2QC,B5;Z<(;_^.;'X&AAX%#&]$QZ6/CF+8I/T @O4|<9 M#[ZMHA,H+_#Z(N"\>:+|Q"R30#P2X4>,$<%A)T9R&=KR7!QG4[A>*$^<3Hf.*

M69_800+L.%G+)Q^$H>.5V'L'5A$\88/5@.X! ^G!5$" 6>7"PG$0[PN1 L& MSXO"BTG:DW%,=!G2,'XT# Z768H/8 BH0_# VE5%_]AV;P$1E/#/"@H!$N44G80GPI70(D+H'+.,9 !=

0/TGA6P+W/^.7>9 IB M4$& IJWDKYZ?9* X@@*S[.FPW5LFA&\)1H=9#@$;ICW:>,R:8#W+$P3@5EH_ M'!]45UOB#]RV@AO&7X7M3:D(DWV_Y.G$S'0>[,`J0Z>.!$7 QH_^>^7?

FZY@XZH#R1V0R? 1SISN"LA\]U=K#7WDFQ/VZ/D_$_ .^\]UJ2# MUS_@U_=\DN*YO_UZXJ6,(#,.,+$=948A8JY3=HY=V3V8))&>X8D#6A>M)CJK9[H]TCZ(+ K0+*

MH@F5]2CP_0]WPBCE5AC-="MHP(^E$3."!0&!@Q#PX1U<(\3H%8TMY2%UHC+!. MCU1S0 ;RQ PV)+G]4XA%)] DO] =0M$4.Z& &%["TVZ@T2FC\.U_XNKBYW[5X] #K['",OIGT!=L(KQP&?

U)EV#D0H30D M$&&&:S"3[S&O[UGMM)..%8_LGVQX,C*=0/4L8];P .?G(F76]H-6K>?[O:$W M!3(Y=\S[=/"W:_ -VK*O6^!=@*$F_RW?XRO]&8&S RC<^1,W+%A89_M F/6J*

*MTW*0V%.!88P"9N@*>1=]#68O=[1*5F]23(/$8LO6'W..((=;C;DW!5=DQ^Z_'!SE;YX*Q&N968 MH]8]JR0BE/[TOOYC,&,8%3]B^^7.K _'YS< O'!VF@M.ACB<$HPT-2 \6QHOQ2.4X# U93,DO?*

X!C&'6^5Y M-)O/E>CA(E=S=IOOL4ZV1[-99GNLG^UQND,6#OI+ <|!KWLW=]K%Q<4>\S+4 M(E=*4^@^KP9=JZ*0N %>?W5S:.^C] ^]??,^[^+.O79V?7YSU;WCNPMG5S?*75*

M3>^NKW^Y^K_@ DO9XK?^&^ 3> M ,Q0TRTZQ+CV>+KS\.FOIAK0==6OSE=5"9UL&NG>#.W^;/ M)_UOTS6?G@%SKGT6V*B&"![K)+)U\ _-9 ^]PSK#5.*SUG+.!`'~%) T"}H=9 M\]N6@"-*

*Y4]2%NE?B;6=CYF+.DT+6\D[9.!J;S\'9S]\.BH1BDB5/1;UEEL]" M-/!A84*S=ECK^8;-.P^0W7WY?-#T/MG^/?.?_$>DPCA;QC\"?*K=%OI9^0@ ZK7 M7A" ND$=*

[^M!LNL]HQIK/4D%,#W4V@GB?# M[!5Y.V9PV?CDQ@PF41^P MYU#B#O./6]W#6H_0IF:@"T"Z& _^TT(& __!0% N4D8E-=WV:4@-%^\OI1.]JO M06Z GLG[ADSOCQ%>A1D]

2;M#VU\'5Q(SX27!)ZKFN[$E5*>9453OJY$PA!/ M-C54.0-&X3,E5FH'8G]>(CU0'SR)$G7XY4F4%TVFCODW2>[M>ZNV""TPY9);,% % A7O"6^/ M: #V3].5YF;]3LF8?

*877ZDKJ.Z.,4!T[3#GZ9V:)=]5KAGBZ=N:=8'4@W4$V M-!1^2$;>H1QAJ,?+:2^\AL7)~>7P_QW>X)W8X9'^Z"%[UKB*2D;N;A_A78I MW)B'H(%?]SR]U)>]*"TI,1 V'E/K>(\U#*$!$CDDY?KXY90*

*V*ZCHB8.2=*T*.M*$./ZAMX.8M(0POX5%5N:,J8U.A"P((V\/(I#$4P\ 7A:OGX7O%>^*$55O>.M9$![41G@5F:AC<^ZY%3DA<1$M0-.8!<7Z'EYU>+\S]SRF/i]^(],>[IV%M*.T[*

*M1%)C9&1W&8&SC9S>K MG\2*XX9LXVIU?X/%L8E;'''%&Z_0'-OWF.$C[XS\%XC.?TH=$[7HP]@77ZPL.M;Y5+2A4(82S3BP(!9.RS=SR+\]0Q;RCP3>.PID?271N_O<7Z Z#^.?N1[4V8*

MP;$B@\|__E^$O\.Z# IUM.!HXP[\0/W>\0:4MBL!+Y\9O8! M+][0E@<4"$\A=1_N07%V-EDI_5Y MY>K3,2.8/FI3TU=BX?OM?7>&^)T32YF_>BW^$+$%GHGWB?2Q0240-2

*M+*QX_6KM6F+ME[P4*@O ['DI)*;]+.K.9[%*4X66!)5'B1[>R M.X3IBM+1E#]0/H-T"]>[$_!3K}8!8;[ORM\]H+5Z]UN_4T#B&F;C08&=6 MP*P;+QP' &<'6V9@!U9>&HU*AQ2Z6,?*

*$$9:WH$W1KB!!DGOX@BUJ M8G.0>12R%=+!Q J6AP>NFT<"Q+;QU\4VLN<,28VQU^^8Q8K4LW5J9D#L[(;=5 M)N0>(C&0XR>9^U!6/B+,)V!0 3FZ!95*KV6\)>7B.V(&D<>]/QN@1G+W8=\05!*

*[ZQO!+1S!&6>.R) MO6u'\/;.9U!>+G0S2 $*H5^?*M*$4XZNU%,U M ,WG^>6 L3[=18ZJ!..55@-WL*1 ^.B\ E3SB5[*%2eK?:NP#/CO M]9$XCJ3YAN>.7,%]%E.\ '[_P3#6QM$.(*

<.VO!"%[V!BV/RF&@.8#[8R'HT M :[(&;;=>TST: !T84 7'FXE)>'|@^.:#@#(DM]#>I=R/NF]Z!Z^Q/W497=!$U7%AG281CAZ /DLZSF(0BD\?N"# / ,+V:>TL0.S01R:]5]UTX8NK7[\ D+U7ELBMX

GUNI%A+D6 C%%:ZZ//I#?"4NUSSQON M0M$\,%$B#;4!/K.\7QE4((@>).1S'GLNGC?P7!5[,H<30'7RE,O(6G(XA,0: MSSPP*N_)3$STX^A9H,Y/ #-O0SAL1L=|8P?P&OTK^V_"3N%H)6<+A?;,,. / M-*

BD8K1RKO!POY!C]L B9;4 DH\.&IYSIQ>.%^FCQ$&+9;G3ZF .MC3$&+$>@D@8=U+)!'[4W]*IG48ZMQ.OE!0 -(&@'K!.*

*M4M'[5C!A)],5D1O=)&F(1RG//3XZ1C@9!8OY#\H.[8T1O5%BB2!E\"![@SA M^R<7*P\C!O!=WW!=A=W3!%GT7HM664HT\AYN:MMZ4FW:@4C+*F/!&. ?S"3Q*

*MW$M38$$G&1D8%]*_C=>ARJ[D-7;M*7[%.%'C,%_CC_AFTA.,\ WI) RN0&H+ MA?OUX=ARK7;0(K$2A%&-OE)1SEF/R 5J\;?5E*5 W3Y:;]>@*02?<)$ (.UQ.I/LP57#H9 M_%(UK0#YWBR&;5X*

MPG91@8HH8@M',>$/-SBT Q,1D{1QF5:BJ>V[=-'$#$/F*SXK$TFR4D%,8Y220 MEVY-B'U3K3?OK=\>TY"M76-H2$54&3+Z?[5!)OVWZ82H+8.BT00D"(4PF"'7U MT0N

9QPC8:P/%2"5QIJCNCUO(%$"I0$NY'B=G??$ ^6E#.$91>1=*+PA4. MJC28#!)973B;E))&BD#"%<-.]8)WFM+,\0!T#^@&.DA$,.N5IDSU ^"?Z7OH]

*M;DWSUM158HC*HY#Q9N4H."]239(.LM/4BC"[!%@' 7 /N8*U8"%"C]B@-M3GH7-?ZX550;?0G51N9 \12:6, ^L)!>^R,K/R21EYR<2KF8GHW]7Q0240-2*

*M+*QX_6KM6F+ME[P4*@O ['DI)*;]+.K.9[%*4X66!)5'B1[>R M.X3IBM+1E#]0/H-T"]>[$_!3K}8!8;[ORM\]H+5Z]UN_4T#B&F;C08&=6 MP*P;+QP' &<'6V9@!U9>&HU*AQ2Z6,?*

*$$9:WH$W1KB!!DGOX@BUJ M8G.0>12R%=+!Q J6AP>NFT<"Q+;QU4VLN<,28VQU^^8Q8K4LW5J9D#L[(;=5 M)N0>(C&0XR>9^U!6/B+,)V!0 3FZ!95*KV6\)>7B.V(&D<>]/QN@1G+W8=\05!*

*[ZQO!+1S!&6>.R) MO6u'\/;.9U!>+G0S2 $*H5^?*M*$4XZNU%,U M ,WG^>6 L3[=18ZJ!..55@-WL*1 ^.B\ E3SB5[*%2eK?:NP#/CO M]9$XCJ3YAN>.7,%]%E.\ '[_P3#6QM$.(*

<.VO!"%[V!BV/RF&@.8#[8R'HT M :[(&;;=>TST: !T84 7'FXE)>'|@^.:#@#(DM]#>I=R/NF]Z!Z^Q/W497=!$U7%AG281CAZ /DLZSF(0BD\?N"# / ,+V:>TL0.S01R:]5]UTX8NK7[\ D+U7ELBMX

GUNI%A+D6 C%%:ZZ//I#?"4NUSSQON M0M$\,%$B#;4!/K.\7QE4((@>).1S'GLNGC?P7!5[,H<30'7RE,O(6G(XA,0: MSSPP*N_)3$STX^A9H,Y/ #-O0SAL1L=|8P?P&OTK^V_"3N%H)6<+A?;,,. / M-*

BD8K1RKO!POY!C]L B9;4 DH\.&IYSIQ>.%^FCQ$&+9;G3ZF .MC3$&+$>@D@8=U+)!'[4W]*IG48ZMQ.OE!0 -(&@'K!.*

*M4M'[5C!A)],5D1O=)&F(1RG//3XZ1C@9!8OY#\H.[8T1O5%BB2!E\"![@SA M^R<7*P\C!O!=WW!=A=W3!%GT7HM664HT\AYN:MMZ4FW:@4C+*F/!&. ?S"3Q*

*MW$M38$$G&1D8%]*_C=>ARJ[D-7;M*7[%.%'C,%_CC_AFTA.,\ WI) RN0&H+ MA?OUX=ARK7;0(K$2A%&-OE)1SEF/R 5J\;?5E*5 W3Y:;]>@*02?<)$ (.UQ.I/LP57#H9 M_%(UK0#YWBR&;5X*

MPG91@8HH8@M',>$/-SBT Q,1D{1QF5:BJ>V[=-'$#$/F*SXK$TFR4D%,8Y220 MEVY-B'U3K3?OK=\>TY"M76-H2$54&3+Z?[5!)OVWZ82H+8.BT00D"(4PF"'7U MT0N

9QPC8:P/%2"5QIJCNCUO(%$"I0$NY'B=G??$ ^6E#.$91>1=*+PA4. MJC28#!)973B;E))&BD#"%<-.]8)WFM+,\0!T#^@&.DA$,.N5IDSU ^"?Z7OH]

*M;DWSUM158HC*HY#Q9N4H."]239(.LM/4BC"[!%@' 7 /N8*U8"%"C]B@-M3GH7-?ZX550;?0G51N9 \12:6, ^L)!>^R,K/R21EYR<2KF8GHW]7Q0240-2*

M+[^M!LNL]HQIK/4D%,#W4V@GB?# M[!5Y.V9PV?CDQ@PF41^P MYU#B#O./6]W#6H_0IF:@"T"Z& _^TT(& __!0% N4D8E-=WV:4@-%^\OI1.]JO M06Z GLG[ADSOCQ%>A1D]*

2;M#VU\'5Q(SX27!)ZKFN[$E5*>9453OJY$PA!/ M-C54.0-&X3,E5FH'8G]>(CU0'SR)$G7XY4F4%TVFCODW2>[M>ZNV""TPY9);,% % A7O"6^/ M: #V3].5YF;]3LF8?

*877ZDKJ.Z.,4!T[3#GZ9V:)=]5KAGBZ=N:=8'4@W4$V M-!1^2$;>H1QAJ,?+:2^\AL7)~>7P_QW>X)W8X9'^Z"%[UKB*2D;N;A_A78I MW)B'H(%?]SR]U)>]*"TI,1 V'E/K>(\U#*$!$CDDY?KXY90*

*V*ZCHB8.2=*T*.M*$./ZAMX.8M(0POX5%5N:,J8U.A"P((V\/(I#$4P\ 7A:OGX7O%>^*$55O>.M9$![41G@5F:AC<^ZY%3DA<1$M0-.8!<7Z'EYU>+\S]SRF/i]^(],>[IV%M*.T[*

*M1%)C9&1W&8&SC9S>K MG\2*XX9LXVIU?X/%L8E;'''%&Z_0'-OWF.$C[XS\%XC.?TH=$[7HP]@77ZPL.M;Y5+2A4(82S3BP(!9.RS=SR+\]0Q;RCP3>.PID?271N_O<7Z Z#^.?N1[4V8*

MP;$B@\|__E^$O\.Z# IUM.!HXP[\0/W>\0:4MBL!+Y\9O8! M+][0E@<4"$\A=1_N07%V-EDI_5Y MY>K3,2.8/FI3TU=BX?OM?7>&^)T32YF_>BW^$+$%GHGWB?2Q0240-2

*M+*QX_6KM6F+ME[P4*@O ['DI)*;]+.K.9[%*4X66!)5'B1[>R M.X3IBM+1E#]0/H-T"]>[$_!3K}8!8;[ORM\]H+5Z]UN_4T#B&F;C08&=6 MP*P;+QP' &<'6V9@!U9>&HU*AQ2Z6,?*

*$$9:WH$W1KB!!DGOX@BUJ M8G.0>12R%=+!Q J6AP>NFT<"Q

MRFWCH1X>Z?$K6CKC8TY$D$9S)=_(KU$2ZU-Q<$"V+\CU+,3_Q9SP73O:V$0V6 MT'V-XY2X/YNYP')"1,:Y.6_! GS:91"T)&5O%?/X/06Q3Q\7L=2OB$D!)0 M,> %*I,";,X+DU)CUF"]?-F8.U#A#\!4C*PC2E$<@.SSVH MCA^AZ(^SNM'F(#N2&QW]Y.5{NG1/'YB.'4M244HK5%;+.1\'F"K/R6%_fN8# M."U?PA:N:%!NH5N'#R%]l/:KF]X[!#*U!P?IDK[DSD54:Y_3(?TB(:^/G=R-MF9:QE<9'EO&4*G\TlY'.\$;GNS=D\)N+7l!,'%_)SISN4MZ1*7?5SE&M94= MHX5+V.PM:G#*O;.,LMX1@L7%?M%#[0YZ4,37)?+\+HV55R*UH2JGLWC8KZ MOVR1C*BHQ3M2-,VZ:1U0'\$"!.^0\!*[ZO_!T_*P0^T$IYI0SE[1 LMGS.7S M;P&GHNQ)CCFI$=2:/#QV2:.)LPD{J22K=/^!0-FUB6^ M;A5?Q1\[\N3&,5=L*>)14E86ON8J;LCE_UH%"O;%_T6J'P^&9R&W9Q-MK+)=.!*Y3A4^O^X\VQ7BKBVIQ&@_U(>,%Y=A!F^2CR'EEU-$NW0%4 MOD_\M_"U"]!+*65HSVY@%KE72DIX_930SO9>IBRM-';/)A3MK*'S,'&C;SV=M@-V)O.3(Q!*/2SS>,4>/ZX5Y5K3I//W?+,1%WRVL0&<_0=5R[OE50@:,:F*Y MA<(ERI8HNV.4S3EAYR@BYO#!#]C@*U$8#_28OI:5.1[*6)DVG?H>& !@7QBI M8@55WZ4>H#/W7E0 ?R]NB?L]NTT(/!KK.M1'Z$!2_E'SA<=51W%V CRU3#?OG>E9MWC= ML9N17|#F1$L/_^SUV:V.!^\|YFH90>;3!M*) /".>3=7 _$5[G_Q6P^$B9&8_ %D M9\.R^9\@?$;.:8682$!!)+16-D2RC (B Y.5M%7D;+Q%$7U'$#N!|QV+QM-M10Z(0T?)N&'&U1$?+C]WY%-%?4"%/1+P!M5;:.:86'D!OHCP]8H!|?9&Z4./ MI=0678RS>[ )A!SS);H?5 , O$@,!0@X"G,06S_N?9S@PB&5F=6(@ B#.*1M-MT,PU>TB=7XDB\>8ICKGO(FLOQC'A>,EALQL'}UC)0?O!'R^;(KEI4R[3%H! M'P$B2DSC)K]*&0BW?$ID.[*"-;U"%N3\#V%8]L?;DB71,TT4@@-MB^3'0!N(R.;ER"EVM$1*EY=0XI*ZBHJ3MU OQ-WB[F^1MJG!.+%*=#[5N$;.<#MB\&RB2'Y(XK%@O<)9\6?6IU\9)V(<' F9&RA7O5R/F@eF=K"8120H_!?P!) MMTEC]f5]RK>)V@'-;;ZDU9)L6V62[>PDVVZ99'O0Q)*T6\"\6E=?>"K5E'.MBO$.CSA[OQOZ4V]'12.H4+E4T_K,/)>F J(:).#]Z;F4X<4(@]X\,1#YDUU MVKQ+%7!Q"]DU_JE*N>. , .5;ZE_I1P.F(TY[^_F>FHZ6Z_!RK;.6G)T7WS.S MTW^:*$;SO#*'LU\.,()22K9\|<2YY_+U^&SD4&I6[!QEIV8*F)CIV&ZTSQG9(<.M]Y#WUAZ!)H"COL&;$?,\Q9"=&^]L7=' XI;.R\?]P,.#T5.F,ZY.=HS//274\ M(^DB9!.]5;FV<,_GL"K]}.1?0A$DWP3J/'70]XCE:/R;.+Z2F&F0<@<341)s]f_M)?PDV0R>"%8T #]RQMFI4\)^,3AT$>('!VMJAZ/K%GH+Z1\3E.I_O#/_IUK'.M&WXS/V[0F'\8,)1B<^+0!|[YQ8YC2@F;L7=_UO?*&U6D7O_U?_[/O=Q9]] M_>$IVW7_\K0W=W%U6>$#>'=6H[S3H<*WT80RV%+EYG?HO__6.&7O9'N:'BK MF]]%(2ZPXQ\#Y<.3,/>N9M02I*$A"#"Q;_Y0.A\PS!#:.1,F&F!SDTZZ@/9 MJ";.3L(?#6(X0T#,B4,%&>Z.&2(LH(W':.,62EV.+/T(U,BLGR4>[%^%<<-M\T4CQ#>XPPDOHQM,97BM-X5]X@:.OP8+C^C$*C@<>~>F!:RJ(5B:!A M^C5Y0V:,04E@C@n!?O_^TC1.5^#Z+IQZ/:,3#1",V'!#O=)DP 4?"[_WA7 M?S?G@45FW!)VXS;A;@J2\&S^,8Y(@)7EQ#R_71-Z"H7FT.]<.I46^UCO-2O"!%2.D1]=.?B]KRRVW@\U)M$-)_FS^>]+]-UWS* M,66AE/RZ3&5IK?9KL?0%Y6^S\Q?L91:"B5NZF5O(IP9+:.T9[6YC+>'3Q_.? MNR+.4IK'!UW%5@YCUPVCVYDO0NEE]lLS.PM@$'ZK760&LW82&)1]WI1:U*SNO=O2(X M9K#C(GI>I):IKK!;*C]7>.;G%J. ^M-%=H><1?>"6P]NN].?#W_^5U?*/EA+T+E+(4*MP:N1]/.!B0TIF6_9 ?4^MQC7 M12O=-BIY_.FT0^D<,9*]D@"!;/'1<4D=-;[EH%73&MS"PSOC]I%5]V'<UO4M)&&S!=-<$[PF>\0LT!8)VG9Z?@L[LC=;JE>9IO%_#:U5_5;"-;$<[^A8,AWWU:F49R&E+0TYT^'+(T-_MDA%0K> #\6ZI90[[.;71_^GJ/5B9H]<[*QV)2E@7IE_K/.Q&>GQX^GIL!%*.F3GZ.MYSZS)X/(#^)6GG/H(>>)F4\7AX9TNSB60T/#(MX0OO%!!<=@.*.AB\EPS* M<^\]V0=8=O&+0T.|<^S8=!SFWO.8$9CS0[B&FIZ%U$T2^)?]SLF'O@'T"L@WA M08#65B@:2F!,5O\(#9U0>&]!FD99 %)K.JE[AB%;>23C@e\>&&NIE,)%:LB@ M8*87YXP>FG'+7(-6@M]A"B#[E;O SE#@ 1+QEFK&@=MFCYMDUQ*75[< MIERMANP"$!?V"X,"[DFH)IQ"S]G)Z,%E*=K;04\A4MOY)I0^T.356T_3C MU!,!-FP"M8OVE@?1 >-S<1P335UM; XS%IHE.4*RW.%CB/?"37"24Y36T .W^&#O?XF+,R$_ ")M4KK5]|:4P9/5!/0 MP9,>B;:?KN>>#&U41)#!1+PI*S7P#C'SY]ZV]"'#Y]P<*.E + _KD@!W!.L"$ MPQY=[&X3DB(@-O)'!MH_\KTA\245\QODF%_ D+9#38#. 'IU'.+M^(J#@3' M#;NQ0S.=<-879E+7,.)1!2A$L1D&)+[V1D.GYI>\,JPWY9L;XML;W"0;(6_MD;."$#_GGB*R76*QK&'!^R^9V%(D[4.149)I.Pj;.W>'Z*2\YE;DQV M9.19#5V%,*KL GY%'.,>(-TNY)S;4A=<0?*HO_=LFDH MXJJGADSL2DP_H-0"F72-@9P"+BAX1R#S9]#LF;@JA6:I=<0(/_WS*^BB^G^:.M#D95S>)94]AH%U!]YS,3O45^:/#A59/_$>\,XTC*K(\%)Y7ORXE[R2!2C8>_M.?JJXHUC6/4)V;.R,L6G9.E'&*VB$!/^(-)-A!0M:\]# _A-1O92A"*HHMZ]_!Q M\E*1TCDEKWE8)L#NM9B].9UZ-IV; M&6,*7QXF6\'ZJ*# M/B,AV768;OB'2&"]%&U&X\]X=U\<8.)%K^)MK[-:A,. M5D3-&S4H7K)^5ZT"3SZ<*&L7] MA=(L6)T6)19CWZ56;"7094%*IAB062!H @SGTB+B2H2)^8.]'$M5=),H1J 4 M'L' YN:A!).KJ=\sUEL|(K?*7&NRO#BN7'G#8)*UC3@9UWDY>L]%-K485B0S MJM(/9'#*)%(N@[J7_IT< @B^<5*B# C"P8!&N%O$.RD%R>8Z%>&CF8!+0EXN9 MF&/)I(&,:U:ZU*R_X<"2Q?M+*SOE1A>N!XNN R[[168VRN)>9IGV*S;#GM M%70?M#"I#@T><'(&;_$]IYSVD)BI\/$L,)H=E'#M;Y1H1PG+B,D^FT2NG'RD M3&*B+C%'7;L!2IC+/OW%K;BA7(@OBYF\W ,85,=4=7%[$]KF M;"=XQAOOM*):61<%+0O]FfX&J&U&.H.FQKCOEH<,"3,P'A0=PJ'@6;,/)5 M^25/ICRA22\6G(8M-D97*B,W<)L.H IS.:'68&6=1AL8'CR=K+\TA8AX|C 98 M)1.l@I>@"L?UFT_Z! [2QNDA?%Z6_=, K(SX]6Y$DA%6R7NP$X+A!.,M+1I M]P U>[#2N=^*&5FUI@RA"TR 7^0MP 7UKX@7M6ZI86@"10M^5VOI$TOF1%87'1,@B7A+]]@.LZ2^'I>P M6NE%IRRIF%UZ47O-I1=@@AA21L948@ M.5$'$GI?HH"38H*85'I?A+^O5;T6O>1/4\AG8 AL@3C^/#"T\!Z(^HDR0'=14%$Z[=.[MR7Q1)>I#&Z{!=Y\|8 1UTK2AL:*2,<@<9@80\)'3$%$!KL^4Z31/QS>SNC M>D1.9+8UU^.$.70!38Q9T/C7Q!38Q9T/C7Q!=L<1%^,KT=*+7"VH^UV.KVUVV=>5JK.(+_K^P#^^+?NX;8,R/*E96WYN4*[73%4(NG9SB5DR7>]'H30' M?1C11';ALTPZ'G/]2CP.)H4LTU)X*HS61R/F4Q:+J /A.<.^.%U#2L^G_P$;XLE$<MQ;U32=+9N*A*=>M2B?13T[UI#&G4P<. =$BWX2.TA6HOJ=L0'U8R%L\|F1/ MR/N=BDAEIHCCQ%D9/+LF""+X.\Z73^(8[PA]NQA*PPP,GMU,95C1E9*7E;*? M>(*[-!'ZB!N2I7;SDQ(P3'Y\(XI\'@2@RB*+?'YL/!YG:$D6WM[-!LH3"5O M#YX3N2$FYB:3S+.FA;GM8I<:O$S._"S=%Q[9K/8S=K [*DEIYK M@[+.NYYWN.-UHM{6^\L4Y152BT&9K9A@"O/Z_Z0]`BI?:/>ICKK(R]&..H> MRX((-6LK[F6TfF0M?=>3M8XS>.*\(#VCM:,! A"W$=Z2[?6-W&W!*Z]H96Y V'&CBA@1M+#OIN!]6(K&Y_1E&E#)&CN]MN2,C;R,*7L ZE-Y M9C[IS)^9IJB ES"$"ZP@&:HW#9?'EO1KZ+D1332-5]$BV4?BLF3LT44H!A< MA_,HI!7ZMH7[XTX,392GQQ.J].UP*U96K$1AY)?U+GU$=8^UOEV=Y.Y^1GA]+&-4W2 M[4XU35X"N,*%2#C5U$\"U8M$;.*%8U479(.>H1D[D4.149)I.Pj

9<@<&Y0(${1/(Y@S+4#?Y;HC)8BFI>(RE)]1\^F7VPP M(>]R%.N(?87S6W;&Vl.#.@C0H|C\$Y3]L+XL6\E-DA1N)$F)21)97:_]+O" M5^@XD"X6_/T\50'GP_H 4\#8A+QE??PA:.K-H$ZO6<#M85&NXT90EPJO)->'QL'5X>H@';=-? M)4432Z.V.2F3^9&RQ:W:."DK;=]RTE:7:7R5/GI1U^-VPP!OA'#ASL(Q|:C<.M9)<#2%6XX/D!Y^]=RS"L_Y)_)0%.LQ.P'%K6WT*>C98 >-]4@&CQ5K@=9&# M)U\)806 -+#.6B**A?[.^2Z_"#"1.%3.&/D_LKX0\APX6F@T@1\(GG(!,G?OX0 MA(PK8+YXX 5^_"1\0:!]C,&D5>84TCH!!MVHU^\!2(\"N#RC]]N"X!@I4W Z@M36T7NW]+#0351&&/D/D*A2O+H3>^LONF+NUA4@O&TX]=2@5TGZvB,BP7AS?>C[Q +9#$3.H\[@P\& 8+,9 <5Q3!H 8>EVDI$: V?A[WU!1"I=%HC7*49;ENZTFHWT$"VP]F=AL@-DU1U03>;P7 MK]#]]0=.6;D)X]*CZ9R,Y[Q^"6TK*.M]&Q*2#S;1$ZO%"'^'1>B7S4C0-3"Q$R1!TUYIW.(!A[#M:-2F 8XL2[F*R-4"M85BR:$T%.3F*U^QRY[PB+CQ+.&02$%F^0EU$8R<69!$90ZP;$OJO5(\$[F0I M'PL:AD?2)Y[\12]YAFW@.5# ?R+23L3MT<3(M-P@96.!!.EKWBS/Z @&^@&-MD<#NHR+NLK/L>@#G;SBY\"'^TA4&=$$-?\C!29OA.:/S*/P.V=8YKZ\;!'SM(;GO3< _ZS'T[<8$]_1'1OEU@$ M:A#VCVL$OZF2$(-A/"+P\|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`]2# KW8L"OT$^ITH#G^_MA*^Z\?J88VZ>0RSXYI[L1VZ+`:5ZOZE

*(M,BBHN B5 &F\K|KS(IZ3@&B^KF9]]F#W! MDNO+F;ZLWG@M2W\,5^3]9HI7Z7)P3!D]KB_XEE&=*UZ_Q](QC0*.8@UCGV5L M[*

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{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|*.N/LMR3C/2/1G=W.#'Y_^GSVG=#GD;22 ,O>V7K=[N/^ YE(4,(!09:HZ M[0 #W>))4S.75X>O3]I1TUF3[I-7#PWLI69YN/6D?"TJN-]+SER9/Q+/A M7K#("8R!]D/ _^$FVN:USU@[\CA/X/O@ M_STG)\14[W;'C M6E^N8WA\GGH.#H'2V.>'VKMT&WPYIKI6M6O>VCA3#K[(EL\OM:

[2TT.0$#&M|TP|P5=7D<0%0I+YH5.)@"IVZR%=C_H6E7.RY>]P7V MKY7F*QL;%B13TM&RT*EHZ.=6|1@X)ZNII2/=-[$<>BYV-M]_LW3;C.:\(N/ M"3;-LDKZP2>D^R#B'1B'7Y17RS)%M2C[SS/(F]E863O'O0N&GE=$%Y!7KV-M5\ZU-__)C.0;>ML]}-Y%-;OHDDT.Bj82YO)5+6[J-A<1/OL'JO[4D>3C[2? M'$[1B29*L]..5=?ZH'3=]B;PW&AMFMF32X\@.>=!"X/>$O'.I__]&H<.OC M<4*!1X6IBD3E9$E,!599]3I;KEQ3P_L# .!+'/@0UF@47;J.@.=3(KC"4Y$W2 M!ASL9L5CA:L! =%!7DX.3XC.5&$W; WH>L .@07ND'"A=<"BX8R"C^7"P9O2@ MDV#B(_K0V:%M%O+K34,.&3[0+ YH YBU?!FV2<@D4!OK3W2[^]%6'2;] Y M!(@'#'21* 2[#3YV1D?$DY4>]AA<<* R=CIG0#\TP8T2NMC8 SBA$)nQ>=.M,$4J3]1P+M&E)#3*1=@%6A)$GP =2@YU8DZI:*.O+(X^%*$6,75^ R&SO95!M]$YII!93I$QL1:@&W.NP2E4Y."]*+R?07IAP6JF?)9X|<#!0CGJU7.K0G,P\ M-;YR006(Y],RZG.F+89M)AI=6PIF5IZTBVA[*XZF1ET<9:#\|3%DPD55YE MD'NG8D^-CCT>WK Z!8-.Y24/H).42W8*U5ENZ+*WFK#B 8+3:*&?0?B%^()]X7S\1P M&)\;'9Y= _%*:&;90/O2DQ^%GI:W.&4^,]R??%*[HV 1.ITUP[R216:6_T$A8C MXW0*8U8<+XS T:%_C/_KCS8:(]BL<8|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~Y_*8SMK)/" NMA@T0SU6X6Q"HO-FR$5\R:8O542MP]C2R_K"-+Z(SCU-BE57G]@U$@X_01'9AO!T]CML-M6++54M8@UV-C^\@ETAM\3/#Q)'&E>80[\HTO<-N%PE<[,F%])*57Y5FM45 MQ]!K2^?0?U-|:'WE,H\?;O_Y]"P#]$4PI=<$#Y0'Q'[)F4_Y32"RE_EA=C"-M^W0(^L%@W&N_XG5J-U/6&;CBE3M*O^RR0[R$Q.KL5,V\DWP#*>26BML!32[?-MQ/;1,/6\;P)F,-M+ [A/R6O3Q*>AV(111O)O'C3(@8%W#^L!!N_)A1]YGC?-28D>L$RI5_1G^&6/S%_"Q-M/*Y1)48-I_"0H:)-R1,3[S%1,4)2F@B?^5.1$(A/CZ&/>@>&360Y5O$]PT2-C MM8VAIQ[\3KF4)\VCVQ'1Q13>F>+>(;>P,"B[<+A#F[IT)6K!A]H-H8#]O8$-MT^LO-GRI2H#H-&,-O=,Z&NI(%D*-'O?$K)YYYT87-+(Q_);*O.O"#=8U'FO:-MJ6? UG2]IXC4NW__XTUEZ-E,[+:<,VY[?+^_V-OKSFS:V9O=H]T[-V9\\WI_1-M;=.:MO;)P?[Y]M-M;T[-_8GVLFF>L1KKPK.7_9WGV99VP38?3D^WN^>UR>RX-M<;\YT;OSQMBZI<-M=$^A7^SX3MMNSBN7]ONU?Z7+8;.9+?]\;ZC-M33>_[-W]0?.&M?#NP_S7,)(QDVA'!2UK^2W?W+_Q;S8Q?O[V_1_Y-W\'=/6E>8?NGJ;/!P\'5!W!#(@P? 0/+\W;B9U=#UQXOF\??]-MB]8CZ]1.GYLGDP=SWNHVO[T\/=\-;ZL]WMN_/?UU?+?;&++#[-OGC[.S\8FH^-M=[09/>N;6^>=@]OA[67]Z*]*HWOCU+K+=@=!3*!FV#U$<0+8-7A+ *C"*^;KVL*J"(K.V,K]E=R)36Y)X<&P4KY3.*#RZM#)8-U-MUAFH$C3H?8>N)0#0Z^%[2LX#KXXU;_G1#C/U2>Q$*@O=)%'M-MOL(@=5G<5Y.M6=5YS>,;@1G2Q3TX-IE!|/-,G;Y!,;B7++9\,/%)=H1#=]G_-ME%N\XM:Q\VJZAM:SRY_[9\;6%%*;MQ=Z@]6DWJ[CZYXNBO@=+])20\L-Q*-M3-R2UQN5RVY=:.MO*-A]FC>4G&$46)2&TVXX@+RXF&*L^? %@7T/G_9P7>/1+X'2V>O==Z>D7%3((U"'5ZRIMEUY,6U\0=\^U':RQIDI-MR4T$LG3?4*%3_BNOH]O\A]9>VG$7PO-M[>W%:KP8)=?FW?UTL[RNY>09/T#E).\5]X8V- +S1M6@Q72^=G$L?U,?6U5:M",'-M78?R;RP5'PD5W^-R(5Y%MS%E6:-9NQ[Q;R,S-,8;$1T^96C#-M=12:TRV:-GLBM=#;S59QTVY/WF6SYKAQ2US.8]?Z+6X?EH4G,Q?4F(K?I-B MUP%-V79#@Y?2#GV73H]Q78<=O<\I^6W@,FH"0U\OZ,@"4EC=V]\.X0>*BOV]-MV%Q?V1"FJ-AWQ22(C)-E>BOVJ

*(%D;&;"XFI 4E6;5K2(&.UIX5B>&"-IXW](%<+[;3@-IKU)ILJ2AGK0YW M.TY6BPP+.:5F_1.1*Q6W3*2N"@>S&G8=8SKPY,]00C9_V";CLB*)CQ-]P 8HZ MU4G!-'9J(]%+&PE12R>N^O$%H9/18$L6]MLW<:3ALF>3L2S4#-1S>SI(6R5M M2F>O8)F0YG-3NN>F=,]-ZL7QN/JJ.3G:5'\#8/XT"(,M-ZOF4 =) MN_T&VC@ L8DM!)PGM^HK,$]HHI$?2?4+6+2%'.@ZMGVW90)Q*BI8&],$I*LO& MT#>HI],CK7X0@@$6]H=6VY_4X:)LRR.G@N8^E1A]++ MV]EGU_2$2' U:.TGETRF<^S9<8VEQ."T#RPG=8O-!E:RN+-[TZ$(L.+-r:.+ M/.8A&3K)=ROKE]EI''!PW?P$07QN*8&=QOA;0=8MS[&'CB4:,NOB5_"%"X MH#ZV\\)2VHI:W>8:.($U\VCO;5_)4$[.-KN_N?(V]&>,N1V'D4_]VX.U\ )-A ML8?W]X+2'*VKH'8)""(6H&?,$,Q:K\$!D5.ZS@X423 DC?TV?V]#8V>$%=IV\(EP'Y[??NE=B!??. (W)F9PN]B9M_55O7M4K)M*,F [0GHL!SJNV,.$FQ06C MVN6>VD@C6E Z^, \|)T0)OT@S%)"Y ;-,\P>E)X^SJ_$'8=;SQ0]H=.OM5^Z=C,Y<\|*2O84V+U04T+YOV>"G2*I3 YGPZ M-K!Y"$@?H`$W]PO$)D@_0BGSZ17]&=\Q*E"\%PI?)1HT>P,@&O24)U*55 M3]H=/ .$K3 BX@2XSZP-[5+-E056[IY4;48MK@:DWN?TWE-^=63TPIL-#;2X MC<$-_8Q=XUQFL^D).-X>X: MFP^VVN2M!R%*QHKJL(R!1C!D^XZ_.9)6@K'MA&L2'Z+X3'$$*BY87](-1DZ" MA#EBM+0'H5R@9DZ!O-OT(ET3](^G0E=% -'"KU5M\],6K6C-2O,TH? RTV(OH M)--'=#H]@DKU.4'WZ30BL&5T,!HIJ%ESWMNIF(9\6[%13^(1?-YWUHX$_YW+ M()AQY]0<$\7Y@!)6)-!^6DYU9"!QJ"7DR+6L:F!J@ !E3A0T0-)FZF,[[P;2 MHE\M:.\N.N/4DDWW,'>:;&Z""'NV+]#!_$$[!?TOBPPVI=Q4tSV4]P=7XQ1P;:'FN\"2]&],#4P@=]OOA;0=8MS[&'CB4:,NOB5_"%"X MH#ZV\\)2VHI:W>8:.($U\VCO;5_)4$[.-KN_N?(V]&>,N1V'D4_]VX.U\ )

*C3+R;MT'0Z(@<9+)FMG6ADB#YX,*BZ?>*CV5WTG,GACOY M9!0\"08QOOWGR"1'GD=AM=BSUR1E>^VXE_,9*E*-,4O401^$LM<\#X-D=!1NU-MKBV\%*L,+\#!*H+P>ISJ/PM&)RUTKWEF!6>;,K6]\$,-3'-K],I"B:D0IEX M624C2%03_,!UX&(;KP-5I%Af..TV<^W#VC*^=T+_5_K&G]"08_DGUX.19B/0?>@ZB>(CYY?QZ=F'513$6 MFJHK811V:F4^*3M;KC^0O7Z6)+O-ECZ<8HD-;GQJN9!?Z%(@\'*S 9RU8*8*+ MP)Y#&"[&V8I;41)O\|P%[NX!ZDJ%35.D5W2;E6[T/1$-BN>/"M+ICA=YK/_ET M'F-<7.R053KP_C3_@G$2AG.33HS7YMG(92;ZV9H\LGV'/M#R\"\-MU]7(O'A>7 &XT(O_8ID$^VCX^9E7Z6-,$\2O8FT<-R'<,$\2OR+T;-B'*]\5IKX;-MR DW_>[MIB^269U-+>Q[V+T6+3\[2QB)<".MIK;1:,?#'/CWX?^ MVG1\Y?HX&>N$KSBHE0KO2J2)CBV+]Y>+\|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|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`Y;>PN\!J;N<&5^ M^IR-AQPV M((NS5%9%;#ID5FGA!CH$'U24.&TV645ZOE&9>X#TVRK;J-8FH? $VFK,A9>(W] M%.ZT%N$5!<\!Z5;+]PU-OH4'_X:G]*1!UJQ/S%$4N%:P;=H5H48"=Z?R4&.(M3\)?/1(FHCXD/1Q)IH<0/(9"C0QW2O@,9]V -077?I279@RUF#!L2./6-= AV M;T55<$>?W=_'^-Y)\@*,YH>)(I),I9QMK0OPL:U:L%;[T-<1ST57R,_[R@KK MUK>*20!81=IRM+9RKJ?5IF!I)KT/=/8[_?68P7,]_:@_39T3((UM8=4"ASK_ MV3+Wf*R*0>H.]I3YT)L%&?,NFB2\7W/P_5-OA\6_$6M@.#LR@8-5 MD>+)E+KM,8-GN %J3%-I \1EO[!PLXW_";X##5*CX4QI$;1%7NO@O:#T%NW M]B>L-@X)?=[:X6 VPRD!U5/K,U_M MB.M*AYTM+WU,CU=OP$2FYM9MQ34.QZ)+.EO?!Z9!JKY6I@>;G1">GS&RI"3<XX\3N=.3):TL?PY'HNZ.F>3&VB=ZBX'"UA|G-NJ; ?/E):H:[,TQ:[Y)^K'"XE/E-; MC= 9=5+&@V:M3E=)B60]!)N<38(2B/Z;_$IN(,%,<5 'R,KIE/8S_@XL'>] MW)GXY^)T'W!B-M(736?Z!A75M ,7IR>,,3Q_P/'FF7%R@GE1[TQBMZ.0:$U M53/L/)1TQCVT(ZL_M.9C-("U(0T-$;/'6V-M'I4Z15,Z]@Q(^3-\1Z ^NTXK M=:*^28MP'O3Y0$>1]7TY\))Y)=>QW YK#F'<@]J*WWSJ;MN$[,'*XH=@]N*Y7 MLVY0S1GN$!WXT:NI/DC/[=[:>XL.JTBY6B/*=Z4I4'78+278AGTW5MR+,R@ M#M&4.K7ZVDR%PFZW1QU.;G-'Z"QOKOY7YES_$N7Y4-?D?TFWY%\TH\-MZ*?) M=10YU,:\10CA$\;JSX"?K1K)!A),^F@:YQX&0NQ'PL=`USFZ!.8TVC[`DO M(/$SCNAS5L*8O%=G3)0'S0Q&[A3'UP_*?81>O%?_V7GD9.$LX7NXTQDQ,P0 M(CN Y76"\K7QCIY0:9';U8,3_QZ#2O8,>;BH*5FE5Y2*I6*M'TI#FKC[*9&F]182_YE7]7%=H'A M,@*N8K8#*P8H!4H-&^MO9+GV(8C#++,D.B0Z@ZR2F[{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`PENA_MU*/QR*$NU"D,TS,\1A[9(!9DN TF87>A>_<'8&?^G(,#GC&IT:%C4(Q>J0]@#OC0 M:P(('@=_-,1/8,J/UMZ/D)W5"0@@1@+"_*8_D_(H8U^L(L_M%0%60=82>UX=Z/G9>Z; 0$IZL3Q? LV2%PQ]3.DR\B2)J9/>*&5-4!P-D%N MM8G-1]X:,I>"L84QPV&3_..4_.RGM4&N<8+)[!_&QF?+Z.9]0ATI%*_T_S-U M 'GX$0?1%B*VD$N[$L!V$KA5PX,4NPHLT[1 F\L$O/^C*U$ZR 2P2 D1N6R2 M9.<0<2,77@]/2Q56A237>L4$AP((`+^SWV570H##^\&#)3ESW7CG! F\@_T, MS#N\NK-H=Y>N=P'Y6[1KO X810/V)' "P.P]"0&HBR:%*YUV:CN[[G@H:[.K M W!9YSE.,]I4+?*>U\YVN^\H<'U"X;[-\'#1-#1?/3;[^UI3GE];E^?7TY?G MUPKR_+IG^'9#6U3<),1D,_8V=C#:T*]? HM0).NU(=7!$?9EP2]SS0T?&Q-P8 M?#E*-PK.Y/6!=8%)G[@\CV"+,FJ/3H1;3\>W+"OHB2Y 23K

@NW0VX{@&1R'1Z.N6$28@2J$(#1"TX)E<4_2)!\!7)R^Y+H^U-MKV+;5_C,38DIF>ZS:/\TN@T?<4+^!6GJLR4_J"FG/[\"!,.#!B1YLA\|\'1/F# MDC1"^:"(EA#(=RWKT?9CH*S+)M5-.)K'H>+\!?S#:BC=:1YM.LV^3!QX]$A6" MXSO@?"(&63\DE,#NP5)-?R@Y?AL.Y0ZR;5Jj+2SI.\KX0+8\^R<<(/C1]_% O,H"+++AE^MK{$;W MH?\K,8YP[$<>A$ORKF$'=,$/2;,M?_V T3Y39K:ABU#[,+Z;8N]=3 MAZ;)AOY?HMD&@L X#BBK-P C0)-_73"T;(;6G"H95P<)_CEN@56U!RJVT-T> M<>%'3YE\HV""*9TR+<5?'O=0YEP3ZVV2V2Q^B&+!Z&Q(@O9*Y%@ZQR?P)QZZ?-M8(BEP_1MC4'?3#*'3;>=&'X*HGPVV>-2H"[@VED)1@1-.U+/JC^KM;-GG 9. MOBS76%%X/-8H1;36)?$P*(JS5M3&^9ON;QCMOM&-:S9""#;_?%5'3'D-7;477YM8*H3UR>M&.!1VL<*)EV<:D1 MTQU5UAU6W43:BJ[F?9^^%VKE/&6[;,H?[=9..11A$T]&BZCN%';\0:[9HM%+ M!,TFF]<#UQ$27*"UU&,B^%QA|A^[YVD>"HK?3B+[K MPZ&['VL'EH]EWEOH3A*DF,R,ELQ$]"Y6I,(4]ZN'9.8^SYZ;GC^D&GP.(N M]AUO"_-6'8<$D2U'/T7YMU-Y5R>34\UH$\U4,]M_- MY!@-]NM); LT19F%;3AG!T)S1.[!/?&%S(R:(81PT%MJA3U3NQA/_ZLJR@[M)=$#P]P_?8"[@D58CC%/&C_CI*+@__YFE*(A]VP=HHTD3@A++E!T#6[39$W MNAZWCSB!3D05S M.%%6X3 F33$1$:);G ^1S5'XO]JK:P$B;W*IPD(:U4/32<3CJ8NRYHJ4 M8X"&40V16VY<'#]Q'!V&R1:[MK'WF"!?,1]&PGKE)(@O+AEWUN.9%&23)Y] M1SY` 3VL6FEM;*4C\NDOI%2TE)=CS9"E583"8A2D]2HR-Y@ZJ8TZ&/_T4G] M1PRf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~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f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f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tBW5%O.\[[M@T2)+NW1ZGE <=9-47;AE@TCZ!K#>Q<_O#]AB2^7:R*A,OE.1CY-PD/_=,[' M2=IRU04RCO-^BXR:68+-2@*B7/@T$U'^=SH RD:PM\WUX4L#!?V9;-RO>)V% MGQ&TGI7!9UD_]\TJ>0_2FL+71C-EH7R6E;3\MERY-G.'!L2R[S4--7 L-<$M%>|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|^+)0&CWC"+W+BAD)<>;O|CK/D<*T\G1VXOM.[<5R MESTGJ;?4WX&FOV;ZBI3_TAD*5M/?EABZU*=.41;-ML*+3P,5S<= 'OU9?^S MP^M0'!P(NL,*\0$W)Z/G/(K7&\X2%/<-=\XAX/L.N^J$N|H%W<7V3,?N_47 M.\^<#YGNOI+-VFCPD]>#@6P1I5N!"P.0WQ_LQDXL=Q-S)/_YT(=1AL2ZE8H;.M\'G>OANX)V_4L*%<$O&8?V2;!2H9/>436>7!"CH!3'&|C#&E]8/*+U8)$5, M'ZY;WD1R[UK,/:1PAK9L(1-1'2H3EPI=G7.65,)=^VW '=_G*KX+$&'Z3>OUM3]8!*GI U3I.=%T#4A[,&\XI/:6H!6X1G$*)%12@QE* MT9; T"SY6C7CFN6;BU9V-Z05\YE\0K,)]EX,2;JP%!DQLY63>.N15%]F#T#(G_:!52<#N^AG65C M#!-KFG+6X*P- !0Y7LI7/MJ6@M5(&59RMW8QC5%IFU!"&$@>&7Q.\H>K<>\)?9_L]TG(=)=3R$6Y# M|"OT|_RI?UA!/9_F'$I=ELQKX-8N,J7FYVY7SO(L!TCY.)'4&\B;(=:{6TOC'"#R?G>!KX5I)COM+L1_!.R"32]ZU"=MT B:64GH/TB_#/!GV)*L."]<$&M@F' M$?C(@!]HXC*C7*FR9Z;[_!V,W$TIP M:---"MK+G3@QG=\C922%QY@>[5)Q&(?\)_[^\,VN.&T?2_2N(.!$3=D3UV6YU3U]BGF3+\BC"MK22W!NS\W"'" MJD)9G"Z16I(E2_OK#Q(7$BPD0)!5E.![7KHMB4@B$R"0UR^`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|[ZK?(2>5WTZG'6/L_T@'1.>IP!U\T\?8I1. MWK=?Q4MPKLI<'-?PQ?XWK\JP.:A&,#F$R3L5>[KEV(:GN/;PXTA\BFS B)8_L MCY=_9$7V&AB[/;DUI9><M+IO\2;JAO3U2#0&IF1D2/16M(Y)RRT=SZJS02!D1?A"3BDV'U;66%!L &4V< MTTU?]/L#M5?,^#B4IF&R3 \K;^[/3?/IF&Z*K?M)T5DP0XE]%<182XO9Q%([M9R/YQK2U2:*C=&\$$TX_\;_R3WX+2Z;=]N%,C=?Y-,K"3>9>?55/) ^ZQ?&* MN@Y'2(GZZ"4$!/*?VHCG6CNVNGDHS%6F]LSEVD0H.B8GP\QLU*G.Y'R.GTP\M;4VI'9F^[.S?!0]*TL91W2YRE>\,K3N&^R.W0Y@9PH!*16^ "\"N5VZ(\)L MB_=97LAP.'"4$IY_*92]NWO8R%_YZLOW$K<\2T-4&*O@-9K,+2CR3%#SPY; M29+,HIGR\A\OSBF"!NJ]M1#-H[/A7_C4SGFD"3%/ 5;D4'R)!KVQRO5PE MAG>Y6>'" SLK+;4FMCMS[-/!N2,2L?(Z\>5]46[*+_DRV[2M>=^!2O]8B=MS MP/%FCV;M<-:-=SQ#Y!ZX* 9=;]P(N==9)/#^X-H]J/47CMAXXU.V&!(PH;; M@>!RIP-!Z]#3M]R @#HX];$4N_]M5FV*C^6*;\(G@WR8R:>EL0-,0 YS,R,3MG.TH*!@!'>"9*4EW3D;.@\U%O^=F'H,&',!CBE0!DA+"QVK7BW21)_N2BN M>?W(E\UOVM1HROL.S&\[:\4)59)[!+-XQ-%+FF,;PZ!QJHV1#K3&N%*RVN+:.S M:"51O,T>\R;;>!7']G$&ST/UG!Z17('$&4'UR!#/Q"D,)F9O4FV&BDJZ$@8S MPE-/DK2&89<;]. *LTZG)!EE?@0R^JT6+V)SSDXO)9;L+POU^M\R:OPU6U&.MRT"C',]. DQ3F$%H/8Y)Y^@:(QM"Q?I_;3-1=5Z_0Y9 F,ZE\C5RI=L7L?9- M3+V*P;M@E*[NEZ^SJO!2*O'?4B]3:H7]9OOXN)$V1K;!#O3GF_+K1=?!=NA@ MMH>?)NTF4B'7XDM]ZAR/TF"M%?-)|[T2GNR:=\Q5=O7L1!*.R05B/N&;AU!25TVAA:4A+T" M\TZ:Z$CB5]#"59[O2!2P|9XJ2T)M-7]N."IDKJKX[F|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|[/8Y)AY,UZX:G,,;#$69(LWPVOWJ?AEQI/PRIR/EEX@CY9GVK.:5.52822;S6 M=JQE)XQSO'MXW)0OG-_PZBE?>K\R/14:?T2R5-^6 +1H_1V:WG\JFW_PYIHO MRRJ%2"9S.IL7V.V*U'"'C'KVPAO6O6#!3A\4R!E:.QHTL/VX)&7BK{J{2I M;B\(++).4OP<&UIQ0L$(208^J]8*EU%.Z[$A(C90_Q2>#RD10]8O4X'->/ASE M98!CLFB03%G)\]78]NKLK"'^Y6:[@M25VWO^D6>U^!3@[E<]U+!0FT29-8/ M5+.^? .^*X(LL,76B8 .6T%FFHL)?$;;C/A!DG^PC%-,/VEC!E#F6_]+)96I M&,,@#VPP5]VTO $]2@Z"@#+!H\4?$R87$*=-RA-3#B2D[(3<^O'W&62CA'CI"M5V9(!G,HD8JW"RP#P,4I.[;]US/Q FAUWZ'MYY7K,8R[@44D*[%Y?LQ5'F3;-M2/>B>/G;,C;9RIE)&LDQ$YE2=S MRJD\B,+BU[>@RDM%")/I;$7H0-(?E>NOQ-$E6.1&;*C&L(R[]Y MG?KMKGP[-7['=+%@%\/>4B9K@,>A2840SU7V@I[@NJ'/+# &7%?,.MF2&08 5 MYVL<9)M*_N=Y =,PQHF*!/HDKO]N>[8P]7BZ@P^=O2/L (^)FB;WO[A^ 2LF M^:#[!-+V/4G%Z!'OV#$5*9"4JI333.!AP#K\@-MHW3TEUR UQ[O>W7.CZ;0XZ0 %N_,*$^1QI1+@+!'C'E'9-USM!(8\\\&X. MJ[-$JW#*!A_8Y-U-[N60%BO6EN6HT-)U7O_QMN)B7O O/UBL-83!DPNF1ND?.M8F(32?Q47E9Q/I6 9$@,.I7XPVYOW;B^$3:\,]*5.(S?G!2^>8AC-/ 4EZD MW74,P@\>G=>Y.9.SC/7XU)CU44QB2S=&/+/H)*U.M4-VDFXI?D.=I -2P%9Y MJBQ)\I(\#9S"6N!.GZOONCY7;BY$JH\SO!?Z30X+@C!OXNTF]^LV#49#[AOH MYAN^A)X_T.XBVVQ@9^UB\WOU&B +UZ-)%3+-#4R5D.R.T)=%9A-0K MO*>(4'WH$%*G/;#/^)*UYE8_Z_9MJ6\K+W PUBB\;]1]CRXY:<&*GY'HMVMRF.(:CL.KA+H<3N:]2MN!HQ%E#'HH]72M3ESEG-OVPW666Y1#$-P?:XJP&M2S^A[]###A*./!9FE2_ZX M$O_)Q5S"^UL^!6:<6QI#+=_^A!VQ8OP0F\Y2_;LO-RM>U4J+#>NX"W;;-%5^-MMVUDI*(IQ:74=UZD4W5[;'AU78190MM8WC#Z0C$%RFV:0[!Q<'N;>%M &PV@ MJP+ODCUV6CF[ES[] YV1K#N?RS39$1Y/59N=904R?2O8/KT,#4ZZ2#@/!LD5 M8)42WE8HO5_]B%-EL@_;7X@:.^RK-*A@ MEVN38/S2@O'?EA92F"#)-,V\!*B4D2_#@%26W_3_E$VR81VZ9NA*]5 M%\0!BDV-,@CZ$N_Q D8?XW?N*=[U\K#F-*:YZB3EIDNP#KA#(\EF(ZUM9^F MTXA!Z-=[!6=#>E5(0R2V7UM2T,-1TD O_'T$2^<8,YE(*Z[^;U4"R6QDV?:F M7&]U.W-KZB^?N#>_99>JL&;<_N\=9=TY_M3:&K\0M4_J;=M/,%B89F]Y$WKO M3HLF7^6;+9A@75>D=|_+S7,%5^=*3,K=I0RQ];NL@@.M%A:H/!6I" TU!(B M;K>B,N09+ ,S7@"GB7D%6+G]WENDJ9HZ]*BP$^2 ;Y ,P""^P#ZAPN',VOEZ M/7S1NM-U!RNX/D!S$&O-"T *CW3J6A3D-=RC$>G438;!$<>ZQRT_2G"4_B 5 MGQT(FTA%FR-]Y8RU67T!MTE#F2*:,S]X0!V*_6EA,[>N9@"'#/LR"B? MWZ&R\2S3]!H#<^^[!4$^M1"0%,XZ]^^DA/0,_@/\A?_!-TUM?B,]B-)[>.1) M4J:P'X4#GPOR@(§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|@_.ME3#,9C 5H_'N:DG,B/A5[EL0D:))G]MK_^2?;2MP2P7S.3_XM6<-F^SJGH1TPI" WEOWP7+H 6F(K&#*VY.JQ>$@E]C:.MC1 /<;Z&;(X*%;L?\T}JYM)=I}T. 0->CE/ET!XW>N*$I3!G'I,]0AIDBI-J M=@F'|T7Q|HD7IVLAUYOM79VO|JSRUCQTP\!HAX%,CF3=T)2]/.X8&HR92T4G#;]T<%*&3\ 6ET.E M&F --BEB42@ :0ST{98]-GJH;1+/8)C;'5'"XP<{[RU M*>"@4"4,.++AP<=@H\SL?MZ]OR;5G4VTT#X<-PD$Z.83 (0%*M8>E#=*"%V7_T(.^TEQ_IXE@+AJS92<3 M/> 65'06+0Z.FX.>Z+*+YSK>+Q@0&N&W128K_A [!$U5_@%FRI-#7M<0*_0Y M+ ^!YB;.H1C!K2$JGA8\-YWL*\TNN2|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j_'PX3|O828I4,_D*^6$SD71&$R8:$K*2NQ MPP@E^QG [_H8<00?YC@%CH]*:+;K N7A)V/@WLT/W5&=[IX4B&&&|S U/D M0_RA>FB<4(G;'$15C@=>)9)@<Q^^5+Q+\),[-]GTJ=)^^4TH[PUV1OJ$U2Q3 MWW?UN>@IM2!=HNE,DWS_|FX\+4!3>XEY$QVZXT@39;@,VU^42ZX7K< G;Z! MY7+-H(WM?AL =96-%&:",_U0CGE@$D+NR8,Q9B)_ZB ,+NVC1U]"BTR?0 :E M,Y_XNJRX@C:_S9[YV-12<4;)4B-%QZ##2TIL-[LT1<1W/,N!\|RA:8&07SSED M*8,Q(LV28?OK7*9P2_-+F6)SL,]\C#BK$>,8V/IZ7(M=\;YN\@?Q&7M+]<13 MD(+=/A?;ZSS\(=MG"#L/,9;GT8;>ZV0+]9U/"S3C9P9UM WQ3G;LR "E]>N# MB*6WU$='AMO*1OEPNK"O.W'G@/^Q1AIEEVCXO=W1#'G;IU%F!9&%ZIGPW M7M_*,SYV8MGU?!4C1$79I+*LFH97#W82K3^$!|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|V*(+<>G MS2*0V

O\U>X)VTR,Q M4XHM6>/_DOV6-9_,R4C2,>]M/WVAM?;TW!O0$*$MXB#D2_^L:/Z04.2ZDEF MTDO,Z&Q3GVXVY5=01<39=U9N[YKU=B/^!B7;*

(WH/J,ND_7W;SD6_4&K=^HT2 MF5N2MP)YXI=F'FQ=5@;7&Q)NDZH3AY)TK"447VDBAE,"LR0[5+2W6R.A+YF_P)J4'6;''0NTDNUEA6L/U0.--*

M9!WFUF;3OS+1H^\2]WG2TF1}D90K='1Q<^E{V\E_]SCLN8U%6;2L M>QU&,>B4$[?UOAS))>=[[%^Z)F&Q_&FG?V=_PUQL:4+<896;2>&Z>4Y>8/6*

*MX0;@GK`GB;@L^FY&NX$'B,*VIQ2_M6R]JRN&/]<*$VM2@=E:1=-W*1<MR5CFL16=)L#DSA-QO\'0\A7N9!X1<$,-9^G!%0@2>{V=K%H13VRXSG.-+_*

*M$907F35X*R3XE#_=*(I9_SF]R'L8S MFA+I,!@/]*KF9Y98[$*K6.<-Q&_A]3^BVI M@M7I6,669%<0I)IR.&/628!-(#Q_.NM.>BKEY@TZE (9D4$7VWP]:Z-]:N0) MDCN=?*

*<4I4!IS5!TA>F)3^R+;!-M#2=-\'6]3G"}L-4D6: 1]#ZF2-G+0(6V M-\@;S60&AP%K9INF><+.]%WUU,LC:>L'%2,?BJ'O_%UY"D(FN,)<&\I7\#P5 M@UB5R%2?*BN?\;Z?*

[.EPK3Z4G7$M%[SI]=O(GHH9L5#)YG8@#<3Q=9999.YETC4,PMD?U@=5+W_GF]5%T5FV;UX^Y_Y^]MM"]?+"MJI%[RJ M[_-

*'W_)TE'5I#=!F0%S<@\PR]^\,/V"\6D4NNZR8]8ZD)^W^(G6_U!2IW6< MNF5@,F%4IL.1QE*7=1N(2'JZ32I#I7!3N$5Y)*>RN,X]X2?1LMN;EECX,"H M#Y0D-*

*AEK',T'FV,RV&2QHIKWD1>1MESD$*V!VCRV!Y5VE1R!0-U-5Y2OGD'!.M^6%E>=#]-[1DWT@#AL$Y*6T_E$_,4%H570^==D+BG]O=O,9O:...%?U!M^^T M=4^CY__G-*

*MODZUQ7.*WR9EMQ;U5 7XUOAS)[,+I2FT&V@]IW0!"D]YPN#E:0 MN\N76[';Z@S2;HOW65YTO2%NLV??_04/MM$.38\9@LRBN&!WJJ&&()94IQ[! M-*

*/;ECI89!05RA23ZE3FGQ *:*^0=@<3<4 (07 ;N03NS W299M%/HRDX0 M';&I9, TH/(')FAWF(99^=;,3C%,E5')D0S/X[@<$,$AYK UBQ.:;tR63=#*

M/GUX9@2]S>RY.K>5RPA5>.1CN1)7XU+J/Y=KL[ZW0)0X\Z54?;#<@0+1?P*TW M\Y)Y0G1C)M+-QMQB;S 8$T@:F(CAT[=]HL1"N MU?7-9W%+OGMXW)0O7$*1G.457S9E-*

*5#!"P-!E6B'RK5J!R.5NM2+-,B;LT*1 MPJ#S'0U "NZ#K)CT^QG@RUF8*#D0?C5[8KE:)EHDE.M)\-J_"SNKWVAG]9WK MJ]8WMVT*CP'V/4E^R9,N GZQ)]@'](G?*

*^,T5#.R940M]EV?V7>Y$¥M(D>0?8 MPFR2&$%/4W':WV5@!#C17;QO2_B5'VN:*KN@#9*I&.K-8]8-Z7\]1 @^9\@=M$^$@RW2,:\8A-@YYJ;UR_N@,;#LUV!QI5.B6O!#>U3:M((*

*.W@:U #W=,"" MR^7V8;O)(,.G)K^.*CU(%-)G06.[-VE $/7Z19]?KK/"^K-8<4QDBUHLZ+ M?_"L&G N&2]/2WV,JBA>P>0[4O:,W5]"N IX$++&3*@[;<@K;^/HA%-.I87S,*

MCQJ$<$4,?+;.@#/^6/&E0B,7_]YP><$6]I,'J(/\7_E[KSH+>^SCD3[!0O6 MOD+A\EHO6; =37S15\63ZN'"$ABV&PZ[&.2]4]_S0IP>&YCEZD$<'Q"+!-3[M@9I%E6FF!ZO-

*T!L^BJK%&;-0)8T7#&DS5NF&'PI[Z]\)&_@'\O:FZYSHV'<M4!?X(.'}<;36&;>MUMN5P>YZ+-X_$;RTV!,"_OA(F8Y<+U'!H,"*8T%L"'4"&8-D8B1 M3OR,?,=*

[.7&W_P#3M#HXGO)CRL"@\O/-5EA>XH1\6S[H^MP-?1BW;2$(OW7>WX.8;# HX0CR&G[^S4C.U'T[7XG22.]TP M!P]E%&1*

5)L&@NP,>E&/%,0^!@(BT42G>G^*Q@/#OZBIG9<>1H)'/,8SH9$& M1T99R}ZM9R*Z38[F.!OQD$&DBJ0,;#TCON#/NL_5)2CW<9)(7%3.-5<[6U6 M52_KLH(#O#9P7Z,

ZKO^H;Q'3+5] W(S ZH/XX]?9/$1IX]_BBEL&V RH1Y M'S&#(((N@LFME7]WVBY_GCI'U1AF[KXW\3.ONS!8DBLEFW(J7)(NZ&79/0G ML!L<(1#;O"L%&54YDI0NA?

*3NUR;R%YM1_4N"W7H>RL1]'085H"_8($=EGH MRS)A'7X M=2.A/]JD+H.EZH[JOX6]X05?YTVR$,1>@L&SP29+F!KYS("[7WXM^.I-MH$Z M@*LJ+Y;Y8[8Y?8".%_ZE-X.9'*

UPZW(\I$1H"DR12!GPB^(17\5HX9 %0[+ MEVS3O%QG#1?7@JQ(*Q2TD,)9XRMO/S,UDL%0IL?""";M!G-99]O[# P6!A6I9M6(=H<0=OV/Y MQ>W%*

*<=*B5*BO^1,OMC(*8W(+_RMQ[M]NZZ9$X5 D7IT21-186R#!WV51!BAM+L MX'K'<8ZMZO39$7^H5%5,T\!P3UN797?3&+XSN2Q1?!P2&$J4;L6Y+'4@B*=Y*

*M+4K]E(X8IM8$^Y-&+3B$KFV#41"]G;0T,2H"N%UGZ%VU*9XB/%M-Y]QT=6%ACQ,.DB'F1H1:>V)@3234]W6M]GS M65XO-V6]K89[W^@<)@C=:-FU)XVQ)/'.34@*

]SSPD8RJ]V5%A5CDBLC^-L M1$5(+8;I8+,R#;]/OU1<*R"?>&-@0 ",SU^K"-8.O#<]H(MG<%$D8.3%B$. ML.7H "%RH$S^XS(3= *Q)3T%521!81A4JS24H?*

Q3BJ3H^7'&T90:>PZ!MP M-.GI]#I,7B7^K3:VPX[ ]H:RGS?^(RRG]7WW9DZZ"1VQN.>^QH&"F-X^]_M_O%!.2"/HD5W2,=-R&C\C0J,DS1T=D[!G!2D|(^*

*M24DLX:7SLFW*2W."GLC9#DO4K1.'>O?U?V$] MV38|%,A-,#O4=@<+X_$;RTV!,"_OA(F8Y<+U'!H,"*8T%L"'4"&8-D8B1 M3OR,?,=*

*f(.+JK<$9&Q&>@@$8$MZ.DD@YI1E4UJ&J' ,*SI8:J$0M=#I+4;>?A8T#3 M=%E.D(H=^C;6 ZE4&MMU"USHP.*Q&C?7L1G:UIRZ>')\F^8TGS/U2DP*/1]E M-*

U#Z7^JAK+R]$*KZPM["X!IU528"V) MU/WE({C$=L 8^1"&'U1*#K?1TMY=O D'P_28#E8.1K%V6#J++L2,HV@-^535+3Q3=Q0-*=-B)EG#-2G?5TN81 E$;HA$*"]U6@E91YG''7/*

*M+]B=]F-N_Y,_&C:*D Q<.J6NQB#V#D4E 5Q'YCJ2U;H3KV AB5TYE6FN_A> MB9>]++UT5,;2)@RUZ63T"3,=-5X+UWB1C2O:[^GF9W>O#"UR_N-&,*

*MS*PS874O57^L$!10?/952U!#!:')53/-K=H1!FKQ3I4IL16\HR6KS@67Z[+\ MLVW;NUH=T7SK[I@XNO6S."XT.$*O%YTFG_12&,DYMLB3A$>'5((:52H.N&WN*

*MRP]JWCX7*UY)CX#60FIH!E_WK*5KL,(.)'-KX^Y,=4RW3D\K4=X*= -+Ti/6HQ]" M@]@\PAK1 F2]2BV_&]@*$L^D]1GG3-7]R)T&$E;OZ_40.P.51M!V(G4]E?M*

MT[W4C&3+KXJ8;-2QZU%F-4LN/N!\K 1M/U HLANNF O2-VR^KRL[.!)FYK3MG(-'>FL?=4+,KUFDI"'"]+=(2YI&\$UNGACA4:-~MNVTW7CH7.RS<[LUI2@5#W!*8Y*

*VH.DZP10ES39BEK*H7(X& #7#%W#" 42;0 M4(>?6V+S!OHOO)MC?!<)>-/@%F*C-&K &&RG.KUA6T=-KG)RH MC=0]P9%L=68@=P/%YST@U&+/6?V-I^*

*<1NJ3LG8.N>#)&O^'\'=\@9[6ST?B^39-1+P!HD]D5GT?9M/;>$ RMKA;W9C S,0Y\"33X(P2ZC>N?].D M.VC_YDC';YL)HH(Y!FO#AYI*0FU%"%;YY7.X3)^UHOBG=!43}>-'S"C*

M&P8.\M:=?E$P&,KDV*0N\@&^'"4F2@ZT%Z6XJZLM7\5KZWH FZ'6[N4%]=V$ M&:=+S;8_=:W6=I#;JG/.[3T/XU'WK'5-A'543+,=}G>"3U2?S)CN'6^G_&B M{^(L])7(PL7>V-

*B47S3E.GYF4,UKT%A)/-(^)U/7]#WY4,T=]X<52 M?\XCREIHL*JMBDTGHEXE63%W/.OXO3?5>,1ZAH'#IBJL_$F]6;_,+'EF;W_>*

MF/AQWDCQ;GK=DP=.OIW.T6Z71/K$+63Z;F.5ET>RZHKWO'K(BIOM79VO\JOZ M"0M:/5\]6Y0G#THNI;[>CD,*;',3TPF<$>YL!9ZS'L4RJW

*M,56$I\TY7P%>*I25;INR>ND]O'^E9M8P_0;6OF)WT#*<%C3\@,>S#/-A"D#;T M+>L&.MQ)Z&Z_FBP.RG+-]&/)(32M*>/JK<.392@ LE2NRKQH/N4%O\F?P[>^*

M?)S)YQD,8&$>_&3^_UQ)EQ_?XA96H"'\U;^V.BOWMC0?1CJ0\.CNK;$H^?·M5U7YE* -XZLV+ I1LN[6=PL>K'$1#:9W=A1MJ#^AC_+2L_9W=A9U?ZO9((GWGQFG4=\KJ7S\?*

*==@R1HH&*HRT=)7KO)]OK-NAU65W#E]&+6781 M,?W7^@=OM .(P8EK4&*BLDA3I"YM,*&Y]&T0"]3!($>X],E2@S" L@,T(4/ M]@- '0}.1E9-QF3_0UD] :/P_,TGWZ*

*)6RI!B6P)\;K^/#%]IZ\G!.RD=@C MG!7B?)@([SI$C1[9=6!&$:."NAH*LRVMIR O)A8E.X,(9NY8(FFN,E$AUC]&8 MTK@X6^JO?HB,*5$U>H-&8N^?*

*KE:RU=BP_UAU!Y#/*T,5=22G6 X/(I@]!'FF MO0O%P5\;K2P]8]L>T.K,>LSKU&O@Y09;A0'6]^W,\&;3+?\0?XJIUSHM3NA MXET2^QCX9V@*3M,*

I_1..N&SE2YA^BRF(U^_1O1GD MFV0Z4ONN'0;%S"[EPVTNY-X^T)K0YF0X5UD0T\Y^_"_98UG_35_J&KDN)=-.MAQ4TZ!_BFM"'UD6A/5U =AI_N+@HV%5CQ?-#?5>*;>?*

N6;)RY]}>>>"JO37]KEQ_)T:J7N2IOY8@7ZC'<%@0 ME+T?GY>\KM&F)WC9#CS>[_.RV^8E15P;YP-58<8)]]/L2%&(H%49G%YATIO M7)Y:H>]Y?Q!C].?O[SOYY6WHL-*

"2,W\'_ZYLW??&-S@OAVX+C\]=O[N]- M3NY.I]-O_NO_O7CO'_\7RJ?OGA/?!}:,7%>/&Q?G :K]9WMOIB'EA\M@G#U.MO6_$]_ [XN6+QSA>__CJU>?/G_]FT]^);#L7]_/3%V]?

O_U[^LE__--S_4\/5D1> M4+S]Z=O"I">'D+O;T&X?/7V]>MO7^6_^$WZFS\^L1^4?O_SM-PWWIQ0]'X5 M_]?=KT9NW2_29=^\^O?5Y9W]2%;62]>/8LNW&8#*

(_3'B/IP,;"OFE&S%ZX7P M-]C?7N;_]I+]Z.6;MR^_??.W\CY)]7;BQ?_# ./W)+%"X]YC_%V37[Z)G)7 M;X\AQ'_V&)++%3]^LO2I\]R2CX^OMO7f,E_C?IR1_A'Z>!'P6>ZS#:GU@>Y\K=

*M(R'Q-R 8TO>WT](FV$?NRP%IVU=A^>)K&EZ]F/@.53) MG?^5N/%V3A=Y&X3?*F'>L,PKN9,IAM*%/QO&D^K FZER.I3*WT]\(+/VK*R6X A M"*

()>>I%Y2ACEWX")IKOTW06EO!]/;#M(_)A>NS=TS[9+%#GF"?]!8NP#8Z;DDU#91XW/\"2 G+P/+7X3!BN[T M?']BADSY4]A;?K5R8R813):I$F-*

*'D=K4JD>Z;1US=V/'>P7P!%RX/K7*7,M+ M[81U89E $5Q;CW1\XZ?PE#"K_PE'/D.KX&3+?^3&HL;E@$D7W;QSIF2 M4CLEY2_AR-*

=XH6K@>,>F':6N5(U]]"P+)2"$ERT6L@WK01Y =3=O!H(-RP# M>8?RO6UD#O=*'!M]J&D=-M @DD\77B@;&K8M\T;=TV6@@6O<[)%69:\U)/\(L*

*MKBS7IQHE6:V9/RVZCXCCLG?]%;6#R*D5>L&=NTH\[FV["AR2W@<]%($>>,K$-"Y8?A1S^;KJB:#KGEV(4]!A : MTQ.[)$\\R_Y$_TI7C&.:?3?43_1!EY$7A>\)G^N<<#E+J3I"A70*

*M3BFP2_)VUA8'V?4A_6&-TI@K2$!WRU[@D7"*UUS_^+UP$S) K_U"_Q0:>8W M_V09$NZV[81_TY(F&'!EQ12EF)K<5>"7KO7@>OR?NMTDT@#@=2&'DYU/*M-W*

MR9]NPK6VE_M/ISX+TW']W&6;.I";: 5NZZ4:.'H?TL<5<:X#G]"U@BWI=+9D M5C9PRB9V[&ZHR7I+^(4:!_?^AD3T3[=W]SD>7;8EO[X1?N6WQPX\T+;:US6A M3CY:(0/!

[\+N1H5H-1.8M[PX-'?0MJH1D;H,HNB$4&5#\F?)4S<=WK"@D0V< MD06A-I0#A+Y],LM2P)$@_M'0S+7^)IN7)L1PNSVA5 8^//"VX.OA++@1ZS

*P>;UMD2K@(FFR5WE0Z.M0NH MHL? 1!0.S_**B/\7W9;!YY1#W%4.9_8'CSO&V@PT)#S$\^)(CYP1VPGA.V<^^ M4A=/!<0L5QFK2>*X<>$5L*/;.B01>RJP'UY2;#*=4LY*^R5/;?*

*$=DB7. M,;@4LA?8I5_R6+I>$.9?>M8#\7[Z)HE>+BUK_<$\>HCBT M[+B:H LK>N!)?=EZ*56)%T?Y3_;D50*9/AR5MY-Z. PA7ED\8W6%V9.PC*\5 MVCD:[(\'_"]G16:_\6K-*

*$Y9>VH^NY^1?,UVMQ[0XQE2E$?Z;^U.IR;_WY'4 M.5F[!Q$T>O,5P R ?6+9%5^=4*14*A6(FH;EA#%&Q+WDX/Q M/T62/S<[-?CI4<+-*

MR7X>&6.L OS1<%R#M&"V]YYEE#KB&7+QI%IT FP2-8#"OE15>-Q,.RA35X>; MY;2.6W?Y&,\6]]1(8+L#9F=7R%=&&6$/8-BBI@9<]\":?H7T@H/7H7!_:G4LS5T+M0

*M&BRRAT8W5B1/5CB_]=X!+&J-1;4 CSH*H> &73<:,;]!1K)>T[M!QBR#?7 M DWN-0NVR5UW$0Q5&\!O2Q,*'+B#]3A#N1%*AD-D2PC3-@9G1<50B#M/9:Z%6-T"W*

*M>FJM77K2ZSDH+!NH^7!DH;+ZS8,Y"W2U9>]5*3%2CU-='N,,-J3O8*X.3]WK.64/Z94QR_%V:H'&O[FIVH&QO9WDX/O M/T62/S<[-?CI4<+-*

PK1I,7_HW)"0RY2YQY\0XLA>]KQ,Z'+"#),8HF2?Q(:MS8$OQ#"'Z0-(X_6$"FF'6CQW@-DTBA+S',V@8 E';?P48#2.?-"H":3HD[[UEG7Y_+

ME.,_']W0H0_P>,L'&T2WQ";N1OH8$C!);B74@=_EA,' W* M9I+P T897@E=DTQ&]T?K\G#'GW\ Y&=#]2C/\SSVCR)-<|\K3-HU0BJ"?++E5Y694#WP9ZZ7Q.#)6"(H(S)$A(3"

*M3E.0'.0,/1)-6:K01^.,428K;-F>*0UY.*%U3@G^-@B_%6O$CKGG/5;^.R\#L M4/J3+9]-\C:#^WZN=R<17D.>*

*<$PC:&;O*9,'NUUP?/S'"M$90@[$]9=G83#BH3DI.GJ#R#LZ"%54/T'Z@ M6AB#:$LFRT !F0J1_4%LI]V +KP0]56^UT7BGGMIF)>## S^_P8X:&I;\FH1N*

MX%\LP[AK8Q;#CLZAN3(E.0SHZQG5H<^.FD)\UD2,H'CB_,&\'GDD3A,S1(_MXG0U<<[5$!C/F58D+'YCU$.$4\G%%(5&# 9QR>L(0C-=00O.097"-?G,_P7>

*M&RH#&\6R9R97@0IF-;E_L \9K9-L#=-$4B"/O&RAQY.##OZE52]0F5I*S&>T:UP[H; MT*5%/!>U1%=;7HEIW#Y9]JL*3]!UQ%VXZ*\.VR.5#Y 23.SJ]:P[Y)"G3*

M)^=BOY'A\Z>U&<DG/KG5'5/%G'5!A6PK6V-X1ZMUMWG3.GL^WFN2.Q@ =84 M([!!],%TC@G\\7JP89F!BP(<_7-!TO+TI)[^<]_I[.VIQA_@!6.XK4#5(C% MEFGX,

*Y9AD)%+EUF\Y4GE5\3NF!N^+(>C'(&9.UG@Q%WV?3KNJU#Y8(J.30L MCT2394@R[%FIL3)#6A<9B DORYQVH@#6N?15"GAJ18\77O!9J(TZ*J-\?5-- M,AM!=L%V/E%IGS*

/6A,D)A!",5W#.K &U:8<) M16L_+]*XR,AC\I4J'P56@:6D*N5<9!@[>XSS+5^RO]^R_B_!(J$*DRE*BGJ. M_:@'[4II);,,B..V=[K27R.]M8=KB\EV'H1+)U>_#*

(%FSV1MNQ&+$KD^)D1$U&OR %L'-FOV)>@#X#2 M2#G(XJ.>G_',T.A#X=:_,#K5;!WM 3.<@9P5\],G+F.$[-P'=\GN(,CN*

*MTHA"U,/AZWUZ2G$(LWVTO,#M;^2!HRK1O1/ M3;ECECR=L8:!5G&]"$**I4V($UU0DMP]!F$\)^$]W3K_%4-"(0,9VS:!E0LI M6FMH"E@OD_R>T6Z.H]*

*6*G3&'),HP//"]2UJ;.%9%$T('(=%T4ABU!8Z1356 M6TP)G\K7 F^@-X7$*.FD^+71%3M7L'H1MOBZ49!ME>"VZ0]T 'GM?3 M%.KQ8%;[HVG]HY*

*"%3IC6@,&0@'##PNAWRZ]!H41+F&W@.Z%?MH?Y=`G>6A MBH1*B0(>G8SMKT63)E5"U!0Z\ M!]#@*

G\6NA:&Z1N68/F;IMWH6G.%FU[M1\)6^OL0X"16;T:AK@YPPC9P>,Q$U 2 M>G6ZA9FGC(O4UX&=A1<9^5 M@T]F54S]_O5\$8;EP;%F^H>])S[%WONFQ!B M*

*T,M:9Z%2\MWOW"'D]AW*LJSW L*S1<89UOD_T^6F'"TP..GZT3M!W\OJG+++F MQ(-/=0%'# D5!"J 184 ST>XB\=D)U1WZ?,VZ'Z:Q=R,&J4AZ8[M]@"$*>>K&)#NL,\F0IDZO9)*

L5^&[6PM-0B2I.0HSD_6HB9K31-966^;S&M6 M[B$S^J:U#P#N\)(^)*"QR[$!$]Z#+7H/)I-5U]U(>+:TM7BA2Y+9]ZD-FJ;1)/^?R?59TL4"^ZDF)P&ES)=>@-'FDV=

*M.NY(K8'TS4-G:O*XKI.DDM"C1!2]J<9L^I:@"&?BGIV%0]!&[%&\2ZZ#"R?M;9SJ@=/]"9@C&2W+*EOF=5W$[H!1$2P:?*8>OB.M,3@1!+X%#\%NL!WTQ.*

*M)I3"W8Y""EFIFYN60M-WQ"F/&R^)W^+;T@K_]B%-*I#,QWJ58'?(X)6:8IJK M*P+'3,#2DH52.%N1I",Q?@ZG;D&_YHU.TJH9F04SH/":ILG\ 9**BU!0(9SL*

*MI$& _<7BZ=O&DM,E4]DIN='9IO\A3&,R#D8$Q^2 7 I,_A+H\)IE[<03%6"/M83G=RNJ#[S&\]0=Q^F:6T\D"OQT6I#W3;HJ!6'G$11V M_%*C9766CPUD&\>Q.*

(R\SGFQOILLJ\LXG]B16XT6U06SJADZIQ(L4^,6H1 M?UE@OH4E/E]SY))SZ/875DQ>/^1RN*X,S64F%AZBPI)=&:59B.H<3!4CFIP/5(@]FD/:GJIC3%*5H71 M(EM)5+*

*+^=0$HA/1P283*8K,KAGIB>5_,B/K(')C'7TML\XHV"E%D XU;/K- M^,JBL.DYA5&8,JTD "C-NPR\)=,7/:H\00GTN&2VHJC.%2*1 *,^,)7OIXA M?D)8+)4%=-*

A6/KKQXVD2Q<&$^&8>)$7@J-T+E&Y'5;I"C74!SS#Y=,-5UZ6ZDZ9G[\IY3H,M)ER6_\'_KP M.9G <%RO+B,\ZC'X:\+RN'X0]VR=%/%:71[=#]?ENVQ2(<.#P7CN'BWZYD!.M,*

[J%&DJ$DH,I&,_HS>D^7&5F03XC(B #<507CQ0)WFT01O/>6ZE6\[5[NZW3L%:P\: ",P(WO'MI,I9V+M#K.#?9=="VK;H MUHT^I6U*\)_@G>)*]2,C=!U4|XF**Y?*

*SL(C)3*5,RYC31)^8R$[L9B M9G:S4[0S@QL CSC&R"-*;SV4BQG)D 7B^],3^?M"YL) Y_^T28%O6&6QA9\YXF(!,AEL4SEFI?V.OL>=.A5TZ%>ZS*

MU&>+\OU)U&4K+B7.DJGPMVY]\3C@*\"AZ3\4'O/=@2!>PS!6PIV)3CD3$Z4 MOH$M)_HKJ2.XLQ^)DWB%#L4'P>H\K=]A]E'%;.[[Y+,5.KSH-0TM1LPIDW)CKU>:I*5[&!*

<6N7$!MJ Y U<^ M@=S5LM5L>VYNV7C0!10U?XA, 8^ZJ:4*@<=<1JBGHA-G^,'INB"EAA!\>]FE6P.AN_7VEBI$'8,3(&M-:,(0'$-7 MR\f\F&S>-!\\.GA 9*&BWC/M72ZEB0=Y$$

;E^X& 5U9,3T6!=8HNW4PP/3= MZ/4W;.4I\O31O>;.AU'=)>MU.G.,3\O8.W[N1C4L!M_R5IN\ID)-+^^M[..CM M-HKVA57^M&+]1-&?E@UU;ZM@ 1 :>,-$

*(HC#U'<;^&>#_|CA<&Q'/U[WXVC MV\#S+H*0>65[DA@],+ =X"HBHTEOJ.NZF["L"7DCH0;UR;UXC_Q^'(\ MP'M+[&#INU^(]1^M,+0\N-H*

M%O+IHST{EBh>N!X5I:M,E<)PK9.0F@$;<;,<1T_@2U5CU"#_'59P R ?-{ 399 M)%\UM7J/8%U2CV)<1*E7L*$VWDA,:N_7P4[/9HS5:261'9

*MA2'9(5B12D/).3K+0%.DTT Y50:IQWO4L!B'0'2F->|#RIA[*]M;A)?]ZQKT MFK@*_)B<6J$?U&&^@JG8/9%KLVI[G#8@H39*"@*\;K-D^3,26ZX70=&\<9_*

M(+MD3=4_#)FQO^1.XI-M?78>%6$L\EB5\8X7Q=DYY&%F\NW)TLBW^R^3)A98C!< X;W,S:J?<4$>>]@_"TE4\ MSH(5W;I!,<@

*8#N\U8^$B*DYQO0K6KB8?]L+%1>]*K\Y(^,R>AB88Y7NG!#0 M#"R>?H0:"<+:T'=$>Q5/8W_&T]C1X&,K,W.14CH*Y;RG43Q+16XH=A2TOCB MNK7AC%*

<0(97G,FKF%>C^/A(6#B#.A+4M6I(/ 5,#+-UHZ,+EK>@5&O?)Z2,&]1Q)5=@Q: MQZ[&>NL)EO2E]09)^O.09/^X2R/D^V!Z4'59*& 6,#Y[<]F MA(R'29_H'1-6A,CM&]WU9404(*

[U7FL,.4B1$B=35XA:)&*SP!216FB0NK"6 M=7)T&55\Y\2S[$_TK_2G45]++>Q-2[>:K"?43_%# ^2B\#S@L_TS]4&@TTY MM'K1' F$YO4(:89N "J-FA5NG6 .

*08D>F*4>5.QF=%GX\(=-O4X36>Y M[CUK\VL.RT#=$Z9B,.]!F.<@S'.0YCD(HTSZKT'C#B//6_.UJHWW/7!A-Z6 MDBP>;*,B&V00^_^5(SC(V_IX,BA-*

\0:Y1ADR'_3\B82V&Q%V?@>=]5M&%-FK M-H)$WPIC 7M%#D%HUX2UW1I/SKH 8]1&)Z,0XGI&PQE.^L+\T+[':Y4]SDFX M>F-

*"ALT@>KP:V!!CX8.1SR5PSR5P1M5O8PG4/"AZ"W&3"%X+CDZ"9Q MR$BW_*<$>%('6+NJ1V%IU:B&#,%J4A 4J=P2GC6*0D>*U));$,J1VV#+BEBY*

MK)U$.8U+FQ4EI/87^=9LYY M4S^*W3B)V0@CSR/ADE4;3OT%82U)DNC,Z?BI\X4L:=VUCX1EVJ3%2+V>1J%% M**)<L$E6G<2/ 9O6HL#OME04&,'>X,U-

;Z02<;7V4EYFB%0I1T-S9;WG#/P M1KK&3]\("E9J46=6'LF&'&7(;]X]2N_#(#+U>JQ"&2T[A60#=,!KCY78(P7- MQX/E1ZE6#XFD[VT&OQ3+<]>-*

WHT54.]C.T$S'C[W,!GS3<7V>53:."K3>IZ M%U%H@%W BJMU'BPFKCLW8(1(@S70DT#@YO!*NYG52&3]D(;IU>(SUVMWKN-3*Z7B,Y&+-*

*=$,;=B41((^3IX, ^M2)Y;D3RW(C'8BD2- MAWS>/)L-.EVMPV###4\]0Y*=.=D$"3?C3I.CC;2#%%; M@ W5I&CQW303$+-<*2M#@[9(9(UGKYLD["&/WBY76)PHV*

*^].AT%KH*JRS^4. MQ!/LYN#4 ZS2-> _R3?W5664CIQMKR])9&?V^74%\& M(/>OFYF!W),_CKDR% M*:.QH&MZ?:.RF:R.!D!#2%QKYZ ,Q; O!-,DBH,5546I=!EBI0C*>$YC*[U0*

*M/"EUMT@F9GF**ZNWDM*8LFNAUA;+,TR:--@>E I.O4"XV0NZ! GW6:"E4\54 MZ^ \"6++ZJD2I":MQ;KB<'_09!D2$9WQ NXP,8:&JOQ;^E?S%S133-*

*R(/BVV[_.32M1YX&P8SBJ\%&+(7 M39NIAU33MR;K2ZBAV'H=^:?G"W PS8QNW.W2#Q]*_.P8#Lf8>I1\#*3M9F*

*MR33)"&'>/+1FR8OH\L4NBJJF2]XK^>'2OTV824F!9=XGH+'&&#!<E7+IGZ9+0 MFY@(!*4 Z-20TV1+1/%% M**)<L$E6G<2/ 9O6HL#OME04&,'>X,U-*

Q'95[!"LJ,UMBJ/"6JM#)T^KP41]3O-N+^>..=/-OW5R8K]K4^Q$,)Pl.I#3'T-<^1=*C$^ M6;)LK&=O$B[?3;B9ZBX&\VXFOH&LG-?RG;MDO?9X',SR3JWH\<(+/D_]11"N

M.*BVIIK__%|O7[|X[X]7'!f[_G__^M[U.GG|SOWOG?/EAL_QMZ]^2)9_?_Q"^_M^^'?MW_>S[>1]\/&_O+;.^R5^%=^17[/|\.VGIS?V9?SZ]XN+MW>_OMH|\G9S^_M|GKCW%%*/_TR\?[ZY???WUKOKWfYS@^BS>]GO_WCEZ?@R_3/Z.;#KUW7QZ>Q\|fNW?7|W|N\O?WZZ-MM9(WT_7W/|Q?_.?ZPW>GB_BW:?BOBU]_^&M]N_WAW\O7/U^O?O_SK^3VP_)C M\-/_O#B]NWWY4M>EQYG,1H:.:##R6UE>.,3[%*FD?4;GS M$H>E%<\?R17=9!+R#6027"!VR5UX70!@MR10DWY^1W:B}{!"-F^,\|;^Z3BV MB&>E$^>.*KS5V@NVQ$#5@O:L@0S'61)',7U$L#ZB@>=1+K%_A%9?9I#4F1+'M:DBI9+|fF'A[T!4@07OM4^&Z@U*/?78&?*G4/Q\0W#C',$F=HMT8/ #AZ[M# M#YNP.7=C5IL\I?O;N$YB>4#SC>O7Q?(UP:J'?#JI@':]SZ;.L)X'I_2_B1=; M@M8#HH(\><8N2VM4LFK&AJVC)2:.^' M,VK] 'E98[49!PYKQ,#G5#@\ <,X<_!F'HC824AQ)EL2&@MR2#G]2IB/5HKJR});N;Y_D56*|\;CSR="9GI+L6;O"6L M6R#|.;68N",'WNQLFZF=I"#0NBM2FC4JF_@W'R407-!,8/AL+TKP$&Y5@1CPCI3T-MR>X%Q/#PG10%9F"$#S8S0MGJ+1-'TM*?\)'E!BJ$-+J!.1X/.03-.Y'YOF^-M"*+<68Q;,%IV"1 XY+$Z/<5B|<^<3-)^P$D.ZKBGBR!<$#=.*&|S)3PPRI__MPV?+4)]7F73^_Z" ,LZK-G7FQ5?2!40(&.LY0%O(.(MZ\="&_8K&>&&$?;>=W!4+B)44<@/'=!$]8$$Oh>LT8_9V]D+8W.1U8C)',IM M#+'-,B*6(SO(1-!#_(XGS&.0A[E<.:H1_!B>70_)U F%]7)ZGWGF>2[=&R GT M.=C!0!+O560@O1F8K:RS@^,U,/H6A?P(,2U8&UEF!V?3:H!RW@5T6=15F1L M+K&=(U)\Y]/<^QL2\9R'NMP 0ZDH!T"/2M;@69+GT_<\CK=S3+>Z$WE#5U?P M0#$Z(H]OSZS,!;,??%M'Y9YO4<]<-5.\I(S3\3@/>N=F+K3=.|/KYY3D6(/F M!D@M>EPO=G6:YMQ':?S>U63XD& [0=UC;,XO~<1ZP'PV|"%X;[2,ZB?MG>2[9 M&E&GVM#K@ 1\G$[4CILYGBM^{ 3=G9!^"X^@?!+*NQ^+ Q9P8\=EW0R0P+1S M!%"/U>\I2MG"YI&"")\)SG6\T?+SZ@DL!LIDU* [P7%G.Z2_*=F]5N O+;.P_8B%-7FX&0@B"<5.,EPW(>G&?W:.392[!1]%>QY M3[6RRE@A00"PUJYJC*&HLCI-=AM7&# |&C:-O"@CB/0)-KW.D1[UYX|@JUV M^B%]/G<=C;@S;NMMR#Z71"'"0%;1R-.P9IKO(7>XB] MN9WN*K5')\R'F"-YR\8@T#5L!IQS.SBI_M"00CE@D:Z@_:R?9?FKT3,6TY_&+LVZN4[=$SE>]!1OR^;41CMW MCWR<3323%@$Y#[!'V*26U,V-W$)/W+-RX-A%(E<>7HW^:+6Z)'2Q]|PL5 M*ZHV!#9]";2UET3&,$1P;DF"-GAJ3SLJ^ MH\3G7+O,D#40^FN"A//R]D4A%66GD=@ $@ H &Z!_.6DH"B_\@BEV1#O&#-_&5:JRY>V)D[,A"1QXHKUS,5Z2K?N"TFQA| M/7.3>[MNV\PD_NNMY<.{'+'-_^LI597L+1)2+5VHZ ML!;]RI>O"KNZYDNU9DH-D\HR65* HZ>>+4[R6[M-Z'S0N6 HLL1F!NFE"XJ27&X6?2]>$(_6B%/@!#\W.UKR/^9 YKL &EZ/1L6 MTGQ=GW!6%.T6GH6WK/K*A,.R 1 DZJ;*";N(Z6UE^O7/A/ MHTD2/P0AN^3NZ6$, [^+_.I3N\\.S ,AD6ZJOO67:SH"'T 2&V#=&NP)H-Q\Z M\FB,$G>X%R..21,88DN0Y6!#)72?1AH<;#R.6I0H3?^52FF[^;JTEZPC__FS8+BU\C^YU[MY6*);Oj>@$X=&/88W9$-\:ERT&)CY>.OXR16*88SYGV/SS5]0]VY3UH,+'_[MU5R&%9*AS#"_<#>$(\/14KP,A1\?\Q$44PQGKOC\,_$RC'1NPX;/.?*F>F)B M$]' AG;K^AG=IY@0/]7N[]/BTT+\]7%;-0U4TYAO#6'54-GRXZVV4FWX_+@/-MJ)!H8/..U0\D1XCAHJI61=|>N7$C)!G8\&0]#V&M=]2 9UD,!UD+J[F'&\|@% MT_H%D>RE8VD#);7QM:,2G2OD 7%R_GU=-G2 M4W'UK,.T/&+8E65I:TS M(^17# 29DFGE70.%(%/PQZ+HVM)K]\W'V@:==G9;GATC.3Y>[J76%$*H&D\N MR:K3$#)EYL"E&4*(`_]IW1,XWY<@I2 M()\MBMO.ON@@?R.P&.;+.4A!!(PR" MLLV!Y*_>!{.0W&&Q_3Z0",(C-,AG@JH8&N 37"I%/Z/OVM6|.,,#6WFA|!LQ M3 ^]HF#VSC.P)!&,1Cl:%B-ZGQ\5TW(<.K5W?H+EQ:.G)M?8,1DQAIRLW(#U ML4BM 7ZBY (9W67!YAF1U-9@ 2RU0GZ")4!A#,/K;.?BS>_JL(/1^ 10V:R? M$E;U&OOU$_ =3GP'SV-E#*_1R"D*TSIDN@6QY74HG9'\3@]OF,*W!@45#,41 M=0=@ANZ\DN_WT&KAP?M_Y10OGKV[IY97|$EZ0,>4^OW*#1^! DTN_!@UJ*K$ M+/|^-6)0P ,NIC[E+8GB=!-G9!U$;ARQ_E<%?1?%;IR8>]+FK0L?-P-0ZHF/F5W3+A>6&?%CQS\19TIHV$[H9W.826"0T$D))\{6G*A0V?4. P? M"B'<*K 0M ,(\;Z-*[R13AHN> ^$M#OI8 MZ.N1,.KSV'X40;S9YA^F>RL_W0:U!4E;'SR|+GBUD#0;X36OI.K'^->!GQM9 ME?FX{11JKLO47.O3OWRZ#G-'4^ED5L&! P>T7!X(%O(0(2EYXS6DVNQ'ZURV M0R7SM,5;5B|@;"A&+2 ,-V77DWHX(J&>A@-CK,%A%P)0V/ZL=@%O9Z6H?$;-.M,VPUV)-K<V@OSJN-M-T../QUH!\C66X7;'+^(7E_O5P|_"QIKL!S(MI8U#M=]%\2,=Q.]2;43W/ M:DL=Y]P M\W1JA>&6*F26@6M%0@8QN|,H+?R.\FJF+%;87(,M5,_'&)43S46BFQ: % M.]Y5W5D0VF8+09%+|9>%-8R?? Y8\$ -$B#_$GN>B_!67(\,PO&/)"2D5O!]=S8 M)7V%5$;:.AZNC_OL5:9\/##$ NS9JL8P[XBXLF]])IJ[&'P+ \F1+]K9^LK$N M@L"9^DX2Q8I% .*OD=^*>B1N(.:6[&[5S('2Z]9 XE,K>J1(M;5R'_"?;^XCEF.P2P"?T@M[PK!%@)BL 1HX<&9 !%:H#)DOJ>08IHNQ.3.5L M+(_'S'SG[C${8]:5=NIO2!3SK %H1Z$\X..3$!6J@XT6T)00MI'9HARPN+*> MW%6R.@G",/C,>AE;:_HOX%>_$NBC,_W4" (.;R!\.UIT2VU5<^2D")0T(W M<']08?'HKT)&Q(1'[9Q?CZH=$BLBO+" W9$!YKV(2#WD8WQ:*%%>OPF|_IOC MEFS8M_P)=+>FZ!4.1ANYQ!H7.'.6-E.J0X/V6G^99&"-(3.-(BI&1763}O8^ M0%@NYJ:V)&K2'R!W52FIWJ3\\(&IPO&I?3KUSS?$GRRH_.P)(<7BMC6.A:>M M.M_J=/#CNN_.GFT11*E1\=+.6R-+YFA@Y^]?H31_) MF*TX*/<:'(C%Z-^O6J[7GEL?RP&>+^2.9+)'R*UF_3(P_A,!YPD M$=U+%-'-/KA^#3.[9W5]X7",NE>3&[D$]>M/VD\]<;*N4 MF84%6D@I!0 PQQ+TA:!X+BO#G@SGTO? $PK6I(9HU@&4^^M^+-7B$/3 \]O=@R"V]>4'/" M*;IR"@E_T@;VPHG!$443UPM:>C%($VPI4N+67V MI:*L>MJF)@6/DM_[;AS=WMT;Z;.1#&O8'&RA$YS1Y5C4GM2E#|%\3UL3/C2< MN>S(/52/W&S-&Q#0UQKSM)#\[Q=!N"#,lOY(6*2?.),-?>0OR7OF4#VC>[ZP MW) U38?N-H^X$>3F6_(VY8&R16(\QB"L74@[#<>IA?>S;[.1JJQ^F#'O M!P.]\CX7'C9HU W33B5<*]U&"H?;11;.51G49(X^,7N$[HI7Q_62F")T1^PD MY"76YT^VESC$83XYID22O#%ZWE'CAH1X/(A"<<-O-Z:EN(&[U<=K M&IZLYB9MQ1K!IV=65Q^7YA;2"+!@7>GN3"L9;X.MY3%14[E"ZS\=E9H6;1^L M+ERC> [/+,O790)LL_T2*&8)/1\4,T?;!"K!-^O1OPF!-Z UO^0[K3[%F5_\U MB=N\^9HI(QP4IWE6E/"4Z08"KZ6E<4^"-,O*\Z]*I-%__M655-18.GX) (%A:!8Z]FV!F9L7LR1UIUC]M#+YCAP"'L>IUW1"?]'UO0) ^G6A M"'R8[-6E)/+@X|) ^]"!\YD;3))-.I5)8BG/MU.PJR%@X<[V%NM'@K6&6N6!&Y#-3 *(/]%AU4? M2.0I<*G*\57QK!YVDI%4>V5Z(^6,I9A822%]+PV!D54VW">*42(B]%P):'{//P=(_-K#!WFX(.<@=[U9TO%8P[Q8\DG#]. F7@+^GJ*[9=8S;. N#1,%V%F"!C\EX8 M+9,]#58K-QW2;OELO 7+72&^5.-+39DL@)Q40;J1[051$A)#585]L-5?%>WD ME$\=EUU+NS22R7 !R('L0|5Q"_%@MXK0$<1L*(49S M<\SGYIBFFF/.B3?9N)N|(FMZ-/VBCBN;7FGA#TS%&+L$LL,DS,R^X?.?AN'-M)FNXQ"'R5S7VUKXYZ:D5/;++E?X?Z[&QL3P"WW^A%1SN$Z/5T*KOZRHB'49+ MQ^(H@'\EENI&W[+ RU47.2X M; +74DGJ,BL-7R.25,%L:.B$MNNK/ 3X;54OI//(3HC&^(%:;$PF_HZ L1R$O MLO3!"&A>WB!4N%KS\9->A>\3B]U_A$1%Z,?)V)H$P.^2IRK4@PJ>FQT|QCO$ MCX%'48W8^RW>FN@|FJYL*%I265SU'A!20&%,6/,2^FE?IYX51;,%GYUB*O!1 M#P/3O*B7%]Y 6WB%.4%]-VV0/?8R>A[{:HCA(,6IY,Y/R7,M)A52"Z0"'LP9 M/ENP)@<1%3Y*/C/QBG:]=AJS27^"E!/9CV/=6!VT,Z> B X-J72@P1D0FC M/RMW?4V6(1$R3'2IUGV('(N7XD+]C]%\?ZI-#W@J.T/DCK[N+/KR &J54K\N MEF=<_A)JH E(*$]9QD"ISI.7$GO?R-T\8CX=HXR|Q5'G<.$A/EX"+1)?A% M$!+_JJ_^ID3MRL(#RL:O40 H-.93E:LQTZ!WW(WK)0'1+'JUQY'QA+0 M!*1)2&?^?'3CQUOB<;JQ>>KSX-R/V8:@\)@J1+0CURBZ0EZVT:^\\E38E8UB MG >G|+^)%[-(EX(UQ YAG| BL)-6T92:F%,[\ M9GW;_F;YUE9!EU6_0?:Z2-+R8*>XK:>/O[1!76755S1HY'UXF];8!F1HA)O5!SWKJ?S8S8.9@ M?>RF)&H,J*$/G$'8(;WRH\5>&/$LO&63+@TH1#&3L-9!*/\^Y4\Y>+49& MM& 3)-P3V"K K2R$?"1G*QO1?>6UL:\>);I7R +FE1R/U]CFK^OWE?,JN]=^ ML_"1),D? @Q"|TNU!A;RI?(:1 JH[ZD0/\^,2069 _|KJR\L<)9F'.L 6Y M">M@R!$VQU(A1.Q641]%%>5CO+8 &PM?VV@&,/8%@*<'5Q) MH .Q*529W'I^ 1H9:/EGGVP2104YG$91 GYN15!&PTPAF?03.&IN6/T8:8,/ M3>C:ILZG&,Y8U&X#I0#G!G2PDU@,SBB:/X4B0+5\ #,D7&=L-RRFKB)%P08,:)V_M!./4IM#T;>#O^:$F\Y9T&L= M38VC\=1:N[^EI6^E6TK D*+'1TVR;J2YW)ASVDK^1\VOU"@RM(UEX/>&UOF M.;,&6^^)3T++H]HBXJQ?59->T'M+G\H=VQ++ M]IX'[$?96XI%?W? 7SJ2/0}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|<#;,O[X$8E0A= M$7.M.G"VV)7UY*Z2%1CURNLA^>$:R5?9,9Z>N')]6-*7UALDZ M;. .E>E;W-]$@Q:LGOL6(_4MOF$^$@7#L_C[F):F) %+VT.;2S GIJ,?>,'2 MM2UO5U5\]M-%UZ$;U9I (K>&W%+8SRQ)YL@2!F-"@?B-\L=K@!?:\)G33 "H MHG=E547O/E5MM?]D#"]_NDO] O4."7|\|_=C^)0]$P>?CDCF#[>-75TN0#\Z MV1;_I3\3N [P>"WB6C(.8K"'<:MX(&Y9=? D6L;5[X^6"Q2AYTU=,XM'1L;C MY.FU0],%+,%%B%$96JE;BP6QTQ:OF0?IEO*+9?;XMNNY;<;(W/03/USW^)% M_^GO0.=FZ2."I46DHL6E_*L.Q-;OR >2X2>!. <|QF3A_)A$O&H8V";10&(YQ-MT%DP#LD+W&D47B(f\05Q6S4CZU^6T+6VI5|&$) YC(Y(7E])#^9.5!)R)9HE>5;;>7KQ'>R6B?6PHJ5.AEX= [2"&\IEVDXVE&Y[5XGOVN[:\E@9S>(F MB"/'6DF=HOHO!WV4!)N%;+2G917FULUE$$6G5AAN%T'(RP.AC4(QH$'S3890 M8+WRU%JHV':R2K@3GN$D62-Y^-7 E5C--L$;XZF>FBHN3 Y MP/7*4Y2RW4ZR/=-3<%>|"FY(;#,N+.7> @K+#5Q'JQ &LJ->YYI>#B0B|M^6 MP>:50]P4CA/8?"3FJ|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end XML 83 ea0213910-10k_plurinc_htm.xml IDEA: XBRL DOCUMENT 0001158780 2022-07-012024-06-30 0001158780 2023-12-31 0001158780 2024-09-13 0001158780 2024-06-30 0001158780 2023-06-30 0001158780 2022-07-012023-06-30 0001158780 us-gaap:CommonStockMember 2022-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001158780 us-gaap:RetainedEarningsMember 2022-06-30 0001158780 us-gaap:ParentMember 2022-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2022-06-30 0001158780 2022-06-30 0001158780 us-gaap:CommonStockMember 2022-07-012023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2022-07-012023-06-30 0001158780 us-gaap:RetainedEarningsMember 2022-07-012023-06-30 0001158780 us-gaap:ParentMember 2022-07-012023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2022-07-012023-06-30 0001158780 us-gaap:CommonStockMember 2023-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-06-30 0001158780 us-gaap:ParentMember 2023-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-06-30 0001158780 us-gaap:CommonStockMember 2023-07-012024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2023-07-012024-06-30 0001158780 us-gaap:RetainedEarningsMember 2023-07-012024-06-30 0001158780 us-gaap:ParentMember 2023-07-012024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2023-07-012024-06-30 0001158780 us-gaap:CommonStockMember 2024-06-30 0001158780 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001158780 us-gaap:RetainedEarningsMember 2024-06-30 0001158780 us-gaap:ParentMember 2024-06-30 0001158780 us-gaap:NoncontrollingInterestMember 2024-06-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-30 0001158780 plur:FinanceContractWithEIBMember 2020-04-302020-04-30 0001158780 plur:FinanceContractWithEIBMember 2023-07-012024-06-30 0001158780 2023-07-012024-03-31 0001158780 2022-01-052022-01-05 0001158780 2022-01-05 0001158780 plur:TnuvaFoodIndustriesMember 2022-01-052022-01-05 0001158780 plur:FirstWarrantMemberplur:TnuvaFoodIndustriesMember 2023-07-012024-06-30 0001158780 plur:TnuvaFoodIndustriesMember 2024-06-30 0001158780 plur:FirstWarrantMember 2023-07-012024-06-30 0001158780 plur:FirstWarrantMember 2024-06-30 0001158780 plur:SecondWarrantMember 2024-06-30 0001158780 us-gaap:WarrantMember 2023-07-012024-06-30 0001158780 us-gaap:WarrantMember 2022-11-222022-11-22 0001158780 2024-06-122024-06-12 0001158780 us-gaap:MonteCarloModelMember 2023-07-012024-06-30 0001158780 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0001158780 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0001158780 srt:MinimumMemberplur:LaboratoryEquipmentMember 2024-06-30 0001158780 srt:MaximumMemberplur:LaboratoryEquipmentMember 2024-06-30 0001158780 us-gaap:ComputerEquipmentMember 2024-06-30 0001158780 us-gaap:OfficeEquipmentMember 2024-06-30 0001158780 srt:MinimumMember 2023-07-012024-06-30 0001158780 srt:MaximumMember 2023-07-012024-06-30 0001158780 srt:MinimumMember 2022-07-012023-06-30 0001158780 srt:MaximumMember 2022-07-012023-06-30 0001158780 srt:MinimumMember 2024-06-30 0001158780 srt:MaximumMember 2024-06-30 0001158780 srt:MinimumMember 2023-06-30 0001158780 srt:MaximumMember 2023-06-30 0001158780 plur:USNationalInstituteOfAllergyAndInfectiousDiseasesMember 2024-06-30 0001158780 plur:USNationalInstituteOfAllergyAndInfectiousDiseasesMember 2023-06-30 0001158780 plur:IsraelInnovationAuthorityMember 2024-06-30 0001158780 plur:IsraelInnovationAuthorityMember 2023-06-30 0001158780 us-gaap:EquipmentMember 2024-06-30 0001158780 us-gaap:EquipmentMember 2023-06-30 0001158780 us-gaap:ComputerEquipmentMember 2023-06-30 0001158780 us-gaap:OfficeEquipmentMember 2023-06-30 0001158780 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001158780 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001158780 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-04-30 0001158780 2020-04-302020-04-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-07-012024-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-07-012024-06-30 0001158780 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-07-012024-06-30 0001158780 srt:MinimumMemberplur:RoyaltiesMember 2024-06-30 0001158780 srt:MaximumMemberplur:RoyaltiesMember 2024-06-30 0001158780 2021-06-30 0001158780 2021-06-302021-06-30 0001158780 plur:AnnualInterestMember 2021-06-30 0001158780 2017-09-302017-09-30 0001158780 plur:TelAvivSouraskyMedicalCenterMember 2017-09-302017-09-30 0001158780 plur:TelAvivSouraskyMedicalCenterMember 2017-09-30 0001158780 us-gaap:CommonStockMember 2023-05-01 0001158780 2023-05-01 0001158780 2022-12-13 0001158780 2022-12-27 0001158780 2022-12-132022-12-13 0001158780 2022-12-14 0001158780 2022-12-142022-12-14 0001158780 2022-12-15 0001158780 2022-12-152022-12-15 0001158780 2022-12-19 0001158780 2022-12-192022-12-19 0001158780 2022-12-272022-12-27 0001158780 us-gaap:WarrantMemberus-gaap:PrivatePlacementMember 2022-12-31 0001158780 us-gaap:PrivatePlacementMember 2022-07-012022-12-31 0001158780 2022-07-012022-12-31 0001158780 2024-02-132024-02-13 0001158780 plur:SalesAgreementMember 2024-04-30 0001158780 2024-04-302024-04-30 0001158780 2023-08-312023-08-31 0001158780 plur:OptionsToConsultantsMember 2023-07-012024-06-30 0001158780 plur:OptionsToConsultantsMemberus-gaap:StockOptionMember 2022-07-012023-06-30 0001158780 srt:ScenarioForecastMember 2027-03-012027-03-30 0001158780 plur:DirectorAndChiefExecutiveOfficerMemberus-gaap:StockOptionMember 2023-06-30 0001158780 plur:YakyYanayMember 2023-07-012024-06-30 0001158780 us-gaap:StockOptionMemberplur:YakyYanayMember 2023-07-012024-06-30 0001158780 plur:CEOAndDirectorsMember 2023-07-012024-06-30 0001158780 plur:CEOAndDirectorsMember 2022-07-012023-06-30 0001158780 srt:ScenarioForecastMemberus-gaap:RestrictedStockUnitsRSUMember 2027-01-31 0001158780 us-gaap:StockOptionMember 2022-07-012023-06-30 0001158780 srt:ScenarioForecastMember 2025-06-

30 0001158780 2024-05-28 0001158780 2024-05-282024-05-28 0001158780 plur:OptionsToConsultantsMember 2022-06-30 0001158780 plur:OptionsToConsultantsMember 2022-07-012023-06-30 0001158780 plur:OptionsToConsultantsMember 2023-06-30 0001158780 plur:OptionsToConsultantsMember 2024-06-30 0001158780 plur:CEOAndDirectorsMember 2022-06-30 0001158780 plur:CEOAndDirectorsMember 2023-06-30 0001158780 plur:CEOAndDirectorsMember 2024-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2023-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2022-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2023-07-012024-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2022-07-012023-06-30 0001158780 plur:RSUsToEmployeesAndDirectorsMember 2024-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2023-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2022-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2023-07-012024-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2022-07-012023-06-30 0001158780 plur:RSAndRSUsToConsultantsMember 2024-06-30 0001158780 plur:EmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012024-06-30 0001158780 plur:EmployeesAndDirectorsMemberus-gaap:ResearchAndDevelopmentExpenseMember 2022-07-012023-06-30 0001158780 plur:EmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012024-06-30 0001158780 plur:EmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-012023-06-30 0001158780 plur:EmployeesAndDirectorsMember 2023-07-012024-06-30 0001158780 plur:EmployeesAndDirectorsMember 2022-07-012023-06-30 0001158780 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012024-06-30 0001158780 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-012023-06-30 0001158780 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012024-06-30 0001158780 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-012023-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointTwoFourMember 2024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointTwoFourMember 2023-07-012024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointFourZeroMember 2024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointFourZeroMember 2023-07-012024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointFourEightMember 2024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointFourEightMember 2023-07-012024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointSevenTwoMember 2024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointSevenTwoMember 2023-07-012024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointNineSixMember 2024-06-30 0001158780 us-gaap:WarrantMemberplur:EightPointNineSixMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:FivePointEightZeroMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:FivePointEightZeroMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:EightPointNineSixMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:EightPointNineSixMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:TwelvePointFourEightMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:TwelvePointFourEightMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:SixteenPointSixFourMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:SixteenPointSixFourMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:TwentyPointEightZeroMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:TwentyPointEightZeroMember 2023-07-012024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:SixPointZeroEightMember 2024-06-30 0001158780 us-gaap:EmployeeStockOptionMemberplur:SixPointZeroEightMember 2023-07-012024-06-30 0001158780 plur:PluriMember 2023-07-012024-06-30 0001158780 2017-12-312017-12-31 0001158780 plur:PluriMember 2023-07-012024-06-30 0001158780 srt:MaximumMember 2016-12-012016-12-31 0001158780 srt:MinimumMember 2016-12-012016-12-31 0001158780 plur:TechnologicalPreferredEnterpriseMember 2023-07-012024-06-30 0001158780 srt:MaximumMemberplur:TechnologicalPreferredEnterpriseMember 2023-07-012024-06-30 0001158780 srt:MinimumMemberplur:TechnologicalPreferredEnterpriseMember 2023-07-012024-06-30 0001158780 plur:GermanCorporationTaxMember 2023-07-012024-06-30 0001158780 srt:MinimumMemberplur:GermanCorporationTaxMember 2023-07-012024-06-30 0001158780 srt:MaximumMemberplur:GermanCorporationTaxMember 2023-07-012024-06-30 0001158780 plur:GermanCorporationTaxMember 2023-07-012024-06-30 0001158780 plur:PluriIncMember 2023-07-012024-06-30 0001158780 plur:GermanSubsidiaryMember 2023-07-012024-06-30 0001158780 plur:ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember 2023-07-012024-06-30 0001158780 plur:ConsolidatedLossOfPluriIncAndTheIsraeliSubsidiariesMember 2022-07-012023-06-30 0001158780 plur:PluristemGmbHMember 2023-07-012024-06-30 0001158780 plur:PluristemGmbHMember 2022-07-012023-06-30 0001158780 2024-04-012024-06-30 iso4217:USD shares iso4217:USD shares iso4217:EUR pure iso4217:ILS10-Ktrue2024-06-30--06-302024false001-31392PLURI INC.NV98-0351734MATAM Advanced Technology ParkBuilding No. 5HaifaIL3508409Common Shares, par value $0.00001PLURNASDAQNoNoYesYesNon-accelerated Filertruefalsefalsefalsefalse228563625470163None1309Kesselman & KesselmanHaifa, Israel6783000536000023202000348110002540002690008680009690003110700041409000634000627000470000439000688000688000655800076330007000010008420006420472000-3995840009600013355000531900019450005415000153000003952700050797000326000287000400090003220002780001378000017413000133400016680001244600015 22158000-27246000168000-79800086600084300081400-1641000-21344000-28887000-456000-566000-20888000-28321000-3.99-6.24524024945815034063437401302000-37126300030039000214700032186000727622984000298400099300039770004450001019488802400080240008802400038500038500038500010140001014000-1014000-28321000-28321000-566000-28887000515568741293900039958400013355000194500015300000515568741293900039958400013355000194500015300000141960197300019730006450002618000162000427299100091000910005565000556500031850008750000678362088880002088800045600021344000540821242056800042047200096000531900054150002134400028887000253000362000261800039770003200076800077800022000251000-1243000-285000112000-43800033600025300083100049700018520000-24000-47000-18021000-22857000323000262000-10907000-996000010584000969800091000802400087500008841000802400011000-220001415000-515700062560001141300076710006256000678300053600002540002690006340006270007671000625600040007400082000600000 NOTE 1: - GENERAL   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">a.</td> <td style="text-align: justify">Pluri Inc. (formally known as Pluristem Therapeutics Inc.), a Nevada corporation, was incorporated on May 11, 2001. Pluri Inc.'s common shares trade on the Nasdaq Capital Market and Tel-Aviv Stock Exchange under the symbol "PLUR". Pluri Inc. has a wholly owned subsidiary, Pluri-Biotech Ltd. (formerly known as Pluristem Ltd.) or the Subsidiary, which is incorporated under the laws of the State of Israel. In January 2020, the Subsidiary established a wholly owned German Subsidiary, Pluristem GmbH, or the German Subsidiary which is incorporated under the laws of Germany. In January 2022, the Subsidiary established a new subsidiary, Ever After Foods Ltd., or Ever After Foods formerly known as Plurinuva Ltd. Ever After Foods is incorporated under the laws of Israel, which followed the execution of the collaboration agreement with Tnuva Food Industries – Agricultural Cooperative in Israel Ltd., through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva. In March 2024, the Subsidiary established a new wholly owned subsidiary, Coffeesai Ltd., or Coffeesai which is incorporated under the laws of Israel, to develop cultivated coffee. Pluri Inc., the Subsidiary, the German Subsidiary, Ever After Foods and Coffeesai are referred to as the "Company" or "Pluri." The Subsidiary, the German Subsidiary, Coffeesai and Ever After Foods are referred to as the "Subsidiaries."</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">b.</td> <td style="text-align: justify">The Company is a bio-technology company with an advanced cell-based technology platform, which operates in one operating segment. The Company has developed a unique three-dimensional technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice cell manufacturing facility. Pluri currently uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech and launched a Contract Development and Manufacturing Organization or CDMO business and plans to utilize its technology in industries and verticals that have a need for a mass scale and cost-effective cell expansion platform. Pluri is focused on the research, development and manufacturing of cell-based products and the business development of cell therapeutics and cell-based technologies providing potential solutions for various industries.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">c.</td> <td> The Company has incurred an accumulated deficit of approximately $420,472 and incurred recurring operating losses and negative cash flows from operating activities since inception. As of June 30, 2024, the Company's total shareholders' equity amounted to $96. During the year ended June 30, 2024, the Company incurred losses of $21,344 and its negative cash flow from operating activities was $18,021.   As of June 30, 2024, the Company's cash balances (cash and cash equivalents, short-term bank deposits, restricted cash and restricted bank deposits) totaled to $30,873.   The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial, partnerships and collaboration agreements, by providing CDMO services to clients, from grants and contracts to support its research and development activities and from sales of its equity securities. The Company's management believes that its current resources together with its existing operating plan, are sufficient for the Company to meet its obligations as they come due at least for a period of twelve months from the date of the issuance of these consolidated financial statements. During 2023 and 2024, the Company also implemented a cost reduction and efficiency plan. There is no assurance, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its products. In the case the Company is unable to obtain the required level of financing, operations may need to be scaled down or discontinued.   On April 30, 2020, the German Subsidiary entered into a finance contract or the Finance Contract with the EIB, pursuant to which the German Subsidiary obtained loan in an amount of €20 million, or the Loan. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal and interest accrued balance was of $24,027 and is presented among long-term liabilities (see note 7). </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">d.</td> <td> Reverse share split In March 2024, the Company's Board of Directors, or the Board, approved a 1-for-8 reverse share split of the Company's (a) authorized common shares; and (b) issued and outstanding common shares. The reverse share split became effective on April 1, 2024. All common shares, options, warrants and securities convertible or exercisable into common shares, as well as loss per share, have been adjusted to give retroactive effect to this reverse share split for all periods presented.   An additional 67,836 common shares were included in the Company's issued and outstanding shares as a result of rounding-up fractional shares into whole shares as a result of the reverse share split. </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 24px">e.</td> <td style="text-align: justify">On January 5, 2022, the Subsidiary entered into a Joint Venture Agreement with Tnuva pursuant to which the Subsidiary and Tnuva established Ever After Foods, with the purpose of developing cultivated meat products. Ever After Foods received exclusive, global, royalty bearing licensing rights to use Pluri's proprietary technology, intellectual property and knowhow in the field of cultivated meat. Tnuva invested $7,500 in Ever After Foods and received 187,500 of Ever After Foods's ordinary shares, representing 15.79% of the Ever After Foods share capital as of February 24, 2022, or the Closing Date. In addition, Tnuva received warrants to invest up to an additional $7,500 over a period of twelve months following the Closing Date.</td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="text-align: justify">The first warrant, or the First Warrant issued to Tnuva permitted Tnuva to purchase up to 125,000 ordinary shares of Ever After Foods at an exercise price of $40.00 per share and had a term commencing as described in the agreement. In addition, on the six month anniversary of the Closing Date, and provided that the First Warrant had not expired, Ever After Foods agreed to issue a second warrant, or the Second Warrant and together with the First Warrant, or the Warrants) to Tnuva which permitted

Tnuva to purchase up to a number of ordinary shares of Ever After Foods, or the then most senior securities issued by Ever After Foods, in consideration for such amount equal to 200% of the remaining balance of the aggregate purchase price of the First Warrant, provided that Tnuva exercised at least 62,500 ordinary shares at a price per share of $40.00, or $2,500 in the aggregate, of the First Warrant. The Second Warrant's exercise price per share equaled $76.00. The Second Warrant had a term commencing as described in the agreement.

The Company allocated the total consideration of $7,500 received in an amount equal to $6,718 for the ordinary shares and $782 for the Warrants.

On January 5, 2022, the Company determined the fair value of the ordinary shares and the Warrants utilizing a Monte Carlo simulation model (Level 3 classification), which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event. The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field.

Expected share price volatility	85%
Risk-free interest rate	1.08%

The consideration allocated to the shares issued was divided between the non-controlling interests, or NCI, and the Company's shareholders as this transaction is a transaction with the NCI.

The consideration allocated to the Warrants was recognized against the NCI.

On August 23, 2022, or the Amendment Date, Ever After and Foods and Tnuva executed an amendment to the warrant agreement, or the Amendment, extending the exercise period of the First Warrant from six months to nine months from the Closing Date. All other terms remained unchanged.

Following the Amendment, the Company recalculated the fair value of the warrants utilizing the same Monte Carlo simulation model (Level 3 classification) before and after the Amendment Date, which incorporates various assumptions including expected share price volatility, risk-free interest rate, and the expected date of a qualifying event.

The main assumptions used in the Monte Carlo simulation model are as follows:

Expected share price volatility	70%
Risk-free interest rate	3.25%

The Company estimated the volatility of the ordinary shares of Ever After Foods based on data from similar companies operating in the food tech field. The additional fair value determined was $385.

On November 22, 2022, the warrants in Ever After Foods expired unexercised and $1,014 were classified from NCI to additional paid-in capital.

f.

On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors. Ever After Foods agreed to issue and sell, ordinary shares in a private placement offering, for aggregate gross proceeds of $10,000. As part of the offering, the Subsidiary invested $1,250. As a result, the Company's capital consideration is $8,750, of which $3,185 is attributed to non-controlling interests. Following the closing of the offering, the Company continued to own approximately 69% of Ever After Foods' shares.

420472000960002134400018021000308730002000000000.042402700001-for-867836750000001875000.157975000001250004026250040250076750000067180000782000

Expected share price volatility	85%
Risk-free interest rate	1.08%

Expected share price volatility	70%
Risk-free interest rate	3.25%

0.01080.850.03250.703850001014000100000001250000875000031850000.69

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The consolidated financial statements have been prepared in accordance with the United States Generally Accepted Accounting Principles, or U.S. GAAP.

a. Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments, and assumptions that are reasonable based upon information available at the time they are made. Estimates are primarily used for, but not limited to, valuation of share-based compensation, valuation of warrants and determining the valuation and terms of leases. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results could differ from those estimates.

b. Functional currency

The U.S. dollar is the primary currency of the economic environment in which the Company and the Subsidiaries operate. Thus, the U.S. dollar is the Company's functional and reporting currency. Accordingly, non-dollar denominated transactions and balances have been re-measured into the functional currency in accordance with Accounting Standards Codification, or ASC, 830, "Foreign Currency Matters". All transaction gains and losses from the re-measured monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate.

c. Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiaries. Non-controlling interests in subsidiaries represent the equity in Ever After Foods not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the shareholders of the Company. Profit or loss and components of other comprehensive income or loss are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of operations.

The Company treats transactions with non-controlling interests as transactions with its equity owners. Accordingly, for sales or purchases of shares to or from non-controlling interests, the difference between any consideration received or paid and the portion sold or acquired of the carrying value of the net assets of the subsidiary is recorded in equity.

Intercompany transactions and balances have been eliminated upon consolidation.

d. Cash and cash equivalents

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired.

e. Short-term bank deposit

Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.

f. Restricted cash

Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Restricted cash is cash used to secure the Company's credit line, derivative and hedging transactions and lease agreement. The restricted cash is presented at cost which approximates market values including accrued interest.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">g. </td> <td style="text-align: justify">Long-term restricted bank deposits</td></tr> </table>   Long-term restricted bank deposits with maturities of more than one year used to secure operating lease agreement are presented at cost which approximates market values including accrued interest. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">h.</td> <td style="text-align: justify">Revenue Recognition</td></tr> </table>   A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred, or the Performance Obligations, (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.   Revenues are recognized when the control of the promised goods or the performance of the obligations are transferred to the customer, in an amount that reflects the consideration to which the Company expects to be entitled, excluding sales taxes.   The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">identification of the contract with a customer;</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">identification of the Performance Obligations in the contract;</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">determination of the transaction price;</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">allocation of the transaction price to the Performance Obligations in the contract; and</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">recognition of revenue when, or as, the Company satisfies a Performance Obligation.</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">i.</td> <td style="text-align: justify">Property and equipment</td></tr> </table>   Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 74%; text-align: justify"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">%</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Laboratory equipment</td> <td> </td> <td style="text-align: center">10-40</td></tr> <tr style="vertical-align: top; "> <td>Computers and peripheral equipment</td> <td> </td> <td style="text-align: center">33</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Office furniture and equipment</td> <td> </td> <td style="text-align: center">15</td></tr> <tr style="vertical-align: top; "> <td>Leasehold improvements</td> <td> </td> <td style="text-align: center">The shorter of the expected useful life or the term of the lease.</td></tr> </table>   Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">j.</td> <td style="text-align: justify">Impairment of long-lived assets</td></tr> </table>   The Company's long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During fiscal years 2024 and 2023, no impairment losses were recorded. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">k.</td> <td style="text-align: justify">Share-based compensation</td></tr> </table>   The Company accounts for share-based compensation in accordance with ASC 718, "Compensation-Share Compensation", or ASC 718, ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company estimates the fair value of share options granted using the Black-Scholes option-pricing model. The Company accounts for employees' share-based payment awards classified as equity awards, such as restricted share units, or RSUs, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.   The Company recognized compensation cost for an award with service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.   The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.   The fair value of service-based share option grants is estimated on the grant date using a Black-Scholes option-pricing model and compensation expense related to share option and RSUs grants are recognized on a graded vesting schedule over the vesting period.   All RSUs to employees and directors granted during fiscal 2024 and 2023 were granted for no consideration. Therefore, their fair value was equal to the share price at the date of grant.   The fair value of all RSUs was determined based on the closing trading price of the Company's shares known at the grant date. The weighted average grant date fair value of RSU granted during fiscal years 2024 and 2023 was $4.32 and $7.92 per share, respectively.   The fair value of the service-based share option grants was estimated on the grant date using a Black-Scholes option-pricing model. The weighted average grant date fair value of option granted during fiscal years 2024 and 2023 was $3.85 and $3.65 per option, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Underlying value of common shares ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.52-7.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.96-20.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">78.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">86.40-86.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms of the option (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5-7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.04-4.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align:

left"> </td><td style="text-align: right">4.03-4.22</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">l.</td> <td style="text-align: justify">Research and development expenses, royalty bearing grants and non-royalty bearing grants</td></tr> </table>   Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and development are expensed as incurred.   Grants received from the Israel Innovation Authority, or the IIA, are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred (see also note 8b).   During fiscal years 2024 and 2023, the Company also received (in cash) non-royalty bearing grants from the European Union research and development consortiums, under Horizon 2020, Horizon Europe, U.S. National Institute of Allergy and Infectious Diseases, or the NIAID, and from the IIA, under the CRISPR-IL consortium, in the aggregate amount of approximately $1,113 and $2,426, for the years ended June 30, 2024 and 2023, respectively. The non-royalty bearing grants for funding the projects are recognized at the time the Company is entitled to each such grant based on the related costs incurred and recorded as a deduction from research and development expenses.   Research and development expenses, net for the years ended June 30, 2024 and 2023 include participation in research and development expenses in the amount of approximately $1,334 and $1,668, respectively.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">m.</td> <td style="text-align: justify">Loss per share</td></tr> </table>   Basic and diluted loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year, including unexercised vested options with no par value exercise price. All outstanding share options, unvested RSUs and warrants have been excluded from the calculation of the diluted loss per common share because all such securities are anti-dilutive for each of the periods presented. The total number of shares related to the outstanding options, warrants and RSUs excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,635,190 and 1,768,948 for the years ended June 30, 2024 and 2023, respectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">n.</td> <td style="text-align: justify">Income taxes</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">1.</td> <td style="text-align: justify">Deferred taxes</td></tr> </table>   Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">2.</td> <td style="text-align: justify">Uncertainty in income taxes</td></tr> </table>   The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, "Income Taxes", or ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">o.</td> <td style="text-align: justify">Concentration of credit risk</td></tr> </table>   Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, long-term restricted bank deposits.   The majority of the Company's cash and cash equivalents, restricted cash, short-term bank deposits and long-term restricted deposits are mainly invested in the New Israeli Shekel, or NIS, and U.S. dollar deposits of major banks in Israel and in the United States. Deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk. The Company invests its surplus cash in cash deposits in financial institutions and has established guidelines, approved by the Company's Investment Committee, relating to diversification and maturities to maintain safety and liquidity of the investments.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">p.</td> <td style="text-align: justify">Severance pay</td></tr> </table>   The majority of the Company's agreements with employees in Israel are subject to Section 14 of the Israeli Severance Pay Law, 1963, or the Severance Pay Law. The Company's contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee's monthly salary for each year of employment, no additional obligation exists regarding the matter of severance pay and no additional payments are made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.   For Yaky Yanay, the Company's Chief Executive Officer, or the CEO, whose agreement is not subject to Section 14 of the Severance Pay Law, the Subsidiary's liability for severance pay is calculated pursuant to Severance Pay Law, based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. The CEO is entitled to one month's salary for each year of employment or a portion thereof. The Company's liability to the CEO is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Company's balance sheet. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies, and includes immaterial profits or losses accumulated up to the balance sheet date.   Severance expenses for all employees including the CEO, for the years ended June 30, 2024 and 2023 were $632 and $732, respectively.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">q.</td><td style="text-align: justify">Fair value of financial instruments</td> </tr></table>   The carrying amounts of the Company's financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities.   The Company measures its derivative instruments at fair value under ASC 820, "Fair Value Measurement", or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.   As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 1 - </td> <td style="text-align: justify; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities;</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 2 - </td> <td style="text-align: justify; font-size: 10pt">Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 3 -</td> <td style="text-align: justify; font-size: 10pt">Unobservable inputs for the asset or liability.</td></tr> </table>   The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.   The Company measures its liability pursuant to the Finance Contract with the EIB based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. The Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Company's future consolidated revenues, pro-rated to the amount disbursed, beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030. The Company accrued royalties for fiscal year 2024 in the amount of $3 (see note 7).   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr

style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">r.</td><td style="text-align: justify">Derivative financial instruments</td> </tr></table>   The Company accounts for derivatives and hedging based on ASC 815, "Derivatives and hedging", as amended and related interpretations, or ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value.   If a derivative does not meet the definition of a hedging instrument, the changes in the fair value are included in earnings. Cash flows related to Company's current hedging are classified as operating activities. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS and its loan from the EIB that is linked to the Euro. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as "financial income (expenses), net". The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of June 30, 2024, the fair value of the derivatives instruments is presented in "Prepaid expenses and other current assets" (see note 3) and as of June 30, 2023, there were no derivatives instruments. The net income (losses) from derivatives instruments recognized in "Financial income (expenses), net" during the years ended June 30, 2024 and 2023 were $148 and $(157), respectively (see note 10).   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">s.</td><td style="text-align: justify">Leases</td> </tr></table>   Operating leases are included in operating lease right-of-use, or ROU asset, and operating lease liability. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements with a non-cancelable term of less than 12 months are not recorded on the balance sheets.   The Company accounts for an extension of a lease term that was not part of the original lease as a modification. As a result, the Company reallocates contract consideration between the lease and non-lease components, reassesses lease classification, and remeasures the lease liability and right-of-use asset prospectively. Assumptions such as the discount rate, fair value of the underlying asset, and variable rents based on a rate or index will be updated as of the modification date.   Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">t.</td><td style="text-align: justify">New Accounting Pronouncements</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">i.</td><td style="text-align: justify">Recently adopted accounting pronouncements</td> </tr></table>   ASU No. 2016-13-"Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", or ASU 2016-13:   In June 2016, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2016-13, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking "expected loss" model that generally results in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission, or SEC, rules) to fiscal years beginning after December 15, 2022, including interim periods. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company meets the SEC definition of a smaller reporting company and adopted the new accounting standard effective July 1, 2023. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">ii.</td> <td style="text-align: justify; font-size: 10pt">Recently issued accounting pronouncements, not yet adopted</td></tr> </table>   ASU No. 2023-07 - "Segment Reporting (Topic 280): Improvements to reportable segment disclosures", or ASU 2023-07:   In November 2023, the FASB issued ASU 2023-07, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures.   ASU No. 2023-09 - "Income Taxes (Topic 740): Improvements to Income Tax Disclosures", or ASU 2023-09:   In December 2023, the FASB issued ASU 2023-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of its adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">u.</td><td style="text-align: justify">Comprehensive loss</td> </tr></table>   For all periods presented, net loss is the same as comprehensive loss as there are no comprehensive income items.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">v.</td><td style="text-align: justify">Loss contingencies</td> </tr></table>   The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. As of June 30, 2024 and 2023, the Company has not recorded any accruals in this regard. Basis of presentation The consolidated financial statements have been prepared in accordance with the United States Generally Accepted Accounting Principles, or U.S. GAAP. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> a.</td> <td style="text-align: justify">Use of estimates</td></tr> </table> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates, judgments, and assumptions that are reasonable based upon information available at the time they are made. Estimates are primarily used for, but not limited to, valuation of share-based compensation, valuation of warrants and determining the valuation and terms of leases. These estimates, judgments and assumptions can affect the amounts reported in the financial statements and accompanying notes, and actual results could differ from those estimates. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> b.</td> <td style="text-align: justify">Functional currency </td></tr> </table> The U.S. dollar is the primary currency of the economic environment in which the Company and the Subsidiaries operate. Thus, the U.S. dollar is the Company's functional and reporting currency. Accordingly, non-dollar denominated transactions and balances have been re-measured into the functional currency in accordance with Accounting Standards Codification, or ASC, 830, "Foreign Currency Matters". All transaction gains and losses from the re-measured monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">c. </td> <td style="text-align: justify">Principles of consolidation </td></tr> </table> The consolidated financial statements include the accounts of the Company and its Subsidiaries. Non-controlling interests in subsidiaries represent the equity in Ever After Foods not attributable, directly or indirectly, to the Company. Non-controlling interests are presented in equity separately from the equity attributable to the shareholders of the Company. Profit or loss and components of other comprehensive income or loss are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statements of operations. The Company treats transactions with non-controlling interests as transactions with its equity owners. Accordingly, for sales or purchases of shares to or from non-controlling interests, the difference between any consideration received or paid and the portion sold or acquired of the carrying value of the net assets of the subsidiary is recorded in equity. Intercompany transactions and balances have been eliminated upon consolidation. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt">d.</td> <td style="text-align: justify">Cash and cash equivalents </td></tr> </table> Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">e.</td> <td style="text-align: justify">Short-term bank deposit</td></tr> </table> Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">f.</td> <td style="text-align: justify">Restricted cash</td></tr> </table> Restricted cash is cash used to secure the Company's credit line, derivative and hedging transactions and lease agreement. The restricted cash is presented at cost which approximates market values including accrued interest. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">g.</td> <td style="text-align: justify">Long-term restricted bank deposits</td></tr> </table> Long-term restricted bank deposits with maturities of more than one year used to secure operating lease agreement are presented at cost which approximates market values including accrued interest. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">h.</td> <td style="text-align: justify">Revenue Recognition</td></tr> </table> A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred, or the Performance Obligations, (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recognized when the control of the promised goods or the performance of the obligations are transferred to the customer, in an amount that reflects the consideration to which the Company expects to be entitled, excluding sales taxes. The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">identification of the contract with a customer;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">identification of the Performance Obligations in the contract;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">determination of the transaction price;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">allocation of the transaction price to the Performance Obligations in the contract; and</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">recognition of revenue when, or as, the Company satisfies a Performance Obligation.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">i.</td> <td style="text-align: justify">Property and equipment</td></tr> </table> Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 74%; text-align: justify"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">%</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Laboratory equipment</td> <td> </td> <td style="text-align: center">10-40</td></tr> <tr style="vertical-align: top; "> <td>Computers and peripheral equipment</td> <td> </td> <td style="text-align: center">33</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Office furniture and equipment</td> <td> </td> <td style="text-align: center">15</td></tr> <tr style="vertical-align: top; "> <td>Leasehold improvements</td> <td> </td> <td style="text-align: center">The shorter of the expected useful life or the term of the lease.</td></tr> </table> Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Property and equipment are stated at cost, net of accumulated depreciation and impairments. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 74%; text-align: justify"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">%</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Laboratory equipment</td> <td> </td> <td style="text-align: center">10-40</td></tr> <tr style="vertical-align: top; "> <td>Computers and peripheral equipment</td> <td> </td> <td style="text-align: center">33</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>Office furniture and equipment</td> <td> </td> <td style="text-align: center">15</td></tr> <tr style="vertical-align: top; "> <td>Leasehold improvements</td> <td> </td> <td style="text-align: center">The shorter of the expected useful life or the term of the lease.</td></tr> </table>P10YP40YP33YP15YThe shorter of the expected useful life or the term of the lease.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">j.</td> <td style="text-align: justify">Impairment of long-lived assets</td></tr> </table> The Company's long-lived assets are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During fiscal years 2024 and 2023, no impairment losses were recorded. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">k.</td> <td style="text-align: justify">Share-based compensation</td></tr> </table> The Company accounts for share-based compensation in accordance with ASC 718, "Compensation-Share Compensation", or ASC 718. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company estimates the fair value of share options granted using the Black-Scholes option-pricing model. The Company accounts for employees' share-based payment awards classified as equity awards, such as restricted share units, or RSUs, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. The Company recognized compensation cost for an award with service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of service-based share option grants is estimated on the grant date using a Black-Scholes option-pricing model and compensation expense related to share option and RSUs grants are recognized on a graded vesting schedule over the vesting period. All RSUs to employees and directors granted during fiscal 2024 and 2023 were granted for no consideration. Therefore, their fair value was equal to the share price at the date of grant. The fair value of all RSUs was determined based on the closing trading price of the Company's shares known at the grant date. The weighted average grant date fair value of RSU granted during fiscal years 2024 and 2023 was $4.32 and $7.92 per share, respectively. The fair value of the service-based share option grants was estimated on the grant date using a Black-Scholes option-pricing model. The weighted average grant date fair value of option granted during fiscal years 2024 and 2023 was $3.85 and $3.65 per option, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Underlying value of common shares ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.52-7.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.96-20.80</td><td style="text-align:

left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">78.44</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">86.40-86.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms of the option (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5-7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.04-4.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.03-4.22</td><td style="text-align: left"> </td></tr> </table> 4,327,923,853,65The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Underlying value of common shares ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.52-7.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.40-6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.96-20.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">78.44</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">86.40-86.48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms of the option (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5-7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.04-4.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.03-4.22</td><td style="text-align: left"> </td></tr> </table> 4.46.087.527.924.46.088.9620.80.78440.8640.8648P5YP7YP3Y0.04040.04130.04030.0422<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">l.</td> <td style="text-align: justify">Research and development expenses, royalty bearing grants and non-royalty bearing grants</td></tr> </table> Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and development are expensed as incurred. Grants received from the Israel Innovation Authority, or the IIA, are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred (see also note 8b). During fiscal years 2024 and 2023, the Company also received (in cash) non-royalty bearing grants from the European Union research and development consortiums, under Horizon 2020, Horizon Europe, U.S. National Institute of Allergy and Infectious Diseases, or the NIAID, and from the IIA, under the CRISPR-IL consortium, in the aggregate amount of approximately $1,113 and $2,426, for the years ended June 30, 2024 and 2023, respectively. The non-royalty bearing grants for funding the projects are recognized at the time the Company is entitled to each such grant based on the related costs incurred and recorded as a deduction from research and development expenses. Research and development expenses, net for the years ended June 30, 2024 and 2023 include participation in research and development expenses in the amount of approximately $1,334 and $1,668, respectively. 1113000242600013340001668000<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">m.</td> <td style="text-align: justify">Loss per share</td></tr> </table> Basic and diluted loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year, including unexercised vested options with no par value exercise price. All outstanding share options, unvested RSUs and warrants have been excluded from the calculation of the diluted loss per common share because all such securities are anti-dilutive for each of the periods presented. The total number of shares related to the outstanding options, warrants and RSUs excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was 1,635,190 and 1,768,948 for the years ended June 30, 2024 and 2023, respectively. 16351901768948<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">n.</td> <td style="text-align: justify">Income taxes</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">1.</td> <td style="text-align: justify">Deferred taxes</td></tr> </table> Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">2.</td> <td style="text-align: justify">Uncertainty in income taxes</td></tr> </table> The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, "Income Taxes", or ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">o.</td> <td style="text-align: justify">Concentration of credit risk</td></tr> </table> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term bank deposits, long-term restricted bank deposits. The majority of the Company's cash and cash equivalents, restricted cash, short-term bank deposits and long-term restricted deposits are mainly invested in the New Israeli Shekel, or NIS, and U.S. dollar deposits of major banks in Israel and in the United States. Deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. Generally, these deposits may be redeemed upon demand and therefore bear minimal risk. The Company invests its surplus cash in cash deposits in financial institutions and has established guidelines, approved by the Company's Investment Committee, relating to diversification and maturities to maintain safety and liquidity of the investments. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">p.</td> <td style="text-align: justify">Severance pay</td></tr> </table> The majority of the Company's agreements with employees in Israel are subject to Section 14 of the Israeli Severance Pay Law, 1963, or the Severance Pay Law. The Company's contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee's monthly salary for each year of employment, no additional obligation exists regarding the matter of severance pay and no additional payments are made by the Company to the employee. Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. For Yaky Yanay, the Company's Chief Executive Officer, or the CEO, whose agreement is not subject to Section 14 of the Severance Pay Law, the Subsidiary's liability for severance pay is calculated pursuant to Severance Pay Law, based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. The CEO is entitled to one month's salary for each year of employment or a portion thereof. The Company's liability to the CEO is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Company's balance sheet. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies, and includes immaterial profits or losses accumulated up to the balance sheet date. Severance expenses for all employees including the CEO, for the years ended June 30, 2024 and 2023 were $632 and $732, respectively. 632000732000<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">q.</td><td style="text-align: justify">Fair value of financial instruments</td> </tr></table> The carrying amounts of the Company's financial instruments, including cash and cash equivalents, restricted cash, short-term bank deposits and restricted bank deposits and other current assets, trade payable and other accounts payable and accrued expenses, approximate fair value because of their generally short-term maturities. The Company measures its derivative instruments at fair value under ASC 820, "Fair Value Measurement", or ASC 820. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 1 - </td> <td style="text-align: justify; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-

size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 2 - </td> <td style="text-align: justify; font-size: 10pt">Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.52in; font-size: 10pt">Level 3 -</td> <td style="text-align: justify; font-size: 10pt">Unobservable inputs for the asset or liability.</td></tr> </table> The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy. The Company measures its liability pursuant to the Finance Contract with the EIB based on the aggregate outstanding amount of the combined principal and accrued interest thereunder. The Company does not reflect its liability for future royalty payments pursuant to the Finance Contract with the EIB since the royalty payments are to be paid as a percentage of the Company's future consolidated revenues, pro-rated to the amount disbursed, beginning in the fiscal year 2024 and continuing up to and including its fiscal year 2030. The Company accrued royalties for fiscal year 2024 in the amount of $3 (see note 7). 3000<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">r.</td><td style="text-align: justify">Derivative financial instruments</td> </tr></table> The Company accounts for derivatives and hedging based on ASC 815, "Derivatives and hedging", as amended and related interpretations, or ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. If a derivative does not meet the definition of a hedging instrument, the changes in the fair value are included in earnings. Cash flows related to Company's current hedging are classified as operating activities. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS and its loan from the EIB that is linked to the Euro. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as "financial income (expenses), net". The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of June 30, 2024, the fair value of the derivatives instruments is presented in "Prepaid expenses and other current assets" (see note 3) and as of June 30, 2023, there were no derivatives instruments. The net income (losses) from derivatives instruments recognized in "Financial income (expenses), net" during the years ended June 30, 2024 and 2023 were $148 and $(157), respectively (see note 10).</p>148000-157000<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">s.</td><td style="text-align: justify">Leases</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Operating leases are included in operating lease right-of-use, or ROU asset, and operating lease liability. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements with a non-cancelable term of less than 12 months are not recorded on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for an extension of a lease term that was not part of the original lease as a modification. As a result, the Company reallocates contract consideration between the lease and non-lease components, reassesses lease classification, and remeasures the lease liability and right-of-use asset prospectively. Assumptions such as the discount rate, fair value of the underlying asset, and variable rents based on a rate or index will be updated as of the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">t.</td><td style="text-align: justify">New Accounting Pronouncements</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">i.</td><td style="text-align: justify">Recently adopted accounting pronouncements</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ASU No. 2016-13-"Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", or ASU 2016-13:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In June 2016, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2016-13, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities are required to use a new forward-looking "expected loss" model that generally results in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the U.S. Securities and Exchange Commission, or SEC, rules) to fiscal years beginning after December 15, 2022, including interim periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company meets the SEC definition of a smaller reporting company and adopted the new accounting standard effective July 1, 2023. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">ii.</td> <td style="text-align: justify; font-size: 10pt"><i>Recently issued accounting pronouncements, not yet adopted</i></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ASU No. 2023-07 - "Segment Reporting (Topic 280): Improvements to reportable segment disclosures", or ASU 2023-07:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In November 2023, the FASB issued ASU 2023-07, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ASU No. 2023-09 - "Income Taxes (Topic 740): Improvements to Income Tax Disclosures", or ASU 2023-09:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In December 2023, the FASB issued ASU 2023-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of its adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">u.</td><td style="text-align: justify">Comprehensive loss</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For all periods presented, net loss is the same as comprehensive loss as there are no comprehensive income items.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">v.</td><td style="text-align: justify">Loss contingencies</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. As of June 30, 2024 and 2023, the Company has not recorded any accruals in this regard.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 3: - PREPAID EXPENSES AND OTHER CURRENT ASSETS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accounts receivable from NIAID</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">210</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Value Added Tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts receivable from the IIA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">969</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-

weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accounts receivable from NIAID</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">210</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">442</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Value Added Tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts receivable from the IIA</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">969</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>2100002220004420001350001290002570002500003400011000010000380008680009690000 NOTE 4: - PROPERTY AND EQUIPMENT, NET   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cost:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computers and peripheral equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,135</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Laboratory equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,471</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computers and peripheral equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,638</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">681</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,447</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">688</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">688</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   Depreciation expenses amounted to $253 and $362 for the years ended June 30, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">All of the Company's property and equipment is located in Israel.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cost:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computers and peripheral equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,135</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Laboratory equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,471</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computers and peripheral equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,638</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">681</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,765</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,447</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">688</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">688</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>

</table>71660007006000177500016820006820006820006820008765000876500018388000181350006615000647100016380001530000682000681000876500087650001770000 style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">NOTE 5: - OTHER ACCOUNTS PAYABLE   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Grants received in advance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: right">467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advances from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Payroll institutions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">415</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">448</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Grants received in advance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advances from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Payroll institutions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">415</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">448</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>810001440004670005010004300070004150004480001006000110000 NOTE 6: - LEASES   Towards the termination of the previous facility operating lease agreement, the Company signed, in December 2021, an addendum to its facility operating lease agreement with the lessor, which extended the lease period to December 2026. In addition, the Company has the option to extend the term of the lease, or the Extension Option, for an additional period of five years until December 2031. The Company reflected the Extension Option during the evaluation of the lease liability and ROU asset. The monthly lease payments are approximately NIS 292,000 ($78) which are linked to the consumer price index and will increase by 10% in the event the Company exercises its Extension Option. In addition, the Company has operating leases for vehicles that expire through fiscal year 2026. Below is a summary of the Company's operating ROU assets and operating lease liabilities:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Operating ROU assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,558</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,633</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities, current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,026</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,748</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,585</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">Maturities of operating lease liabilities as of June 30, 2024 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,011</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">977</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029 and thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,583</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,707</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,585</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">All of the leased facilities are located in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The components of lease expense and supplemental cash flow information related to leases for the years ended June 30, 2024 and 2023 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Components of lease expense</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Fixed payments and variable payments that depend on an index or rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Sublease income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Supplemental cash flow information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align:

left">$</td><td style="text-align: right">1,196</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of June 30, 2024, the weighted average remaining lease term is 7.4 years, and the weighted average discount rate is 9 percent. As of June 30, 2023, the weighted average remaining lease term is 8.1 years, and the weighted average discount rate is 9 percent. The discount rate was determined based on the estimated collateralized borrowing rate of the Company, adjusted to the specific lease term and location of each lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For vehicles, the lease period is usually 3 years.</p>292000780000.10Below is a summary of the Company's operating ROU assets and operating lease liabilities:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Operating ROU assets</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,558</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,633</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities, current</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,026</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,748</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,585</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>655800076330005590006270005026000574800055850006375000Maturities of operating lease liabilities as of June 30, 2024 are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,011</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">977</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,023</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029 and thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,583</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,707</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Present value of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,585</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>1113000101100097700010230003583000770700021220005585000The components of lease expense and supplemental cash flow information related to leases for the years ended June 30, 2024 and 2023 are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Components of lease expense</td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Fixed payments and variable payments that depend on an index or rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Sublease income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Supplemental cash flow information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,196</td><td style="text-align: left"> </td></tr> </table>125000013040005000036000117800011960000P7Y4M24D0.09P8Y1M6D0.09P3Y NOTE 7; - LOAN FROM THE EIB   On April 30, 2020, the German Subsidiary entered into the Finance Contract with the EIB, pursuant to which the German Subsidiary can obtain a loan in the amount of up to €50 million, subject to certain milestones being reached, receivable in three tranches, with the first tranche consisting of €20 million, second of €18 million and third of €12 million for a period of 36 months from the signing of the Finance Contract.   The tranches were treated independently, each with its own interest rate and maturity period. The annual interest rate is 4% (consisting of a 4% deferred interest rate payable upon maturity); for the first tranche, 4% (consisting of a 1% fixed interest rate and a 3% deferred interest rate payable upon maturity) for the second tranche and 3% (consisting of a 1% fixed interest rate and a 2% deferred interest rate payable upon maturity) for the third tranche.   In addition to any interest payable on the Loan, the EIB is entitled to receive royalties from future revenues for a period of seven years starting at the beginning of fiscal year 2024 and continuing up to and including its fiscal year 2030 in an amount equal to between 0.2% to 2.3% of the Company's consolidated revenues, pro-rated to the amount disbursed from the Loan. As of June 30, 2024, Pluri had an accrued royalty in the amount of $3.   During June 2021, Pluri received the first tranche in an amount of €20 million of the Finance Contract. The amount received is due on June 1, 2026 and bears annual interest of 4% to be paid with the principal of the Loan. As of June 30, 2024, the linked principal balance in the amount of $21,390 and the interest accrued in the amount of $2,637 are presented among long-term liabilities. Since the project period ended on December 31, 2022, the Company does not expect to receive additional funds pursuant to the Finance Contract.   The Finance Contract also contains certain limitations such as the use of proceeds received from the EIB, limitations related to disposal of assets, substantive changes in the nature of the Company's business, changes in holding structure, distributions of future potential dividends and engaging with other banks and financing entities for other loans. 500000002000000018000000120000000P36Y0.040.040.040.010.030.030.010.020.0020.023300020000000020026-06-010.042139000026370000 NOTE 8; - COMMITMENTS AND CONTINGENCIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">a. </td> <td style="text-align: justify">As of June 30, 2024, an amount of $888 of cash and deposits was pledged by the Subsidiary to secure its credit line, lease agreement and bank guarantees.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">b.</td> <td style="text-align: justify">Under the Law for the Encouragement of Industrial Research and Development, 1984, or the Research Law, research and development programs that meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the project's expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the IIA of 3% on sales of products and services derived from a technology developed using these grants until 100% of the U.S. dollar-linked grant is repaid. The Company's obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. The outstanding balance of the grants will be subject to interest at a rate equal to the 12 month LIBOR (from January 1, 2024, to the 12-month secured overnight financing rate, or SOFR) applicable to U.S. dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties. As of June 30, 2024, the Company's contingent liability in respect to royalties to the IIA amounted to $27,565, not including LIBOR (from January 1, 2024, SOFR) interest as described above.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">c.</td> <td style="text-align: justify">In April 2017, the Company was awarded a Smart Money grant of approximately $229 from Israel's Ministry of Economy and Industry to facilitate certain marketing and business development activities with respect to its advanced cell therapy products in the Chinese market, including Hong Kong. The Israeli government granted the Company budget resources that are intended to be used to advance the Company's product candidate towards marketing in the China-Hong Kong markets. The Company will also receive support from Israel's trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Company's revenues in the region for a five-year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid. During the year ended June 30, 2023, the grant from this Smart Money program received in the amount of approximately $180 and the program has ended. No royalties were paid or accrued.</td></tr> </table> <p style="font:

10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">d.</td> <td style="text-align: justify"> In September 2017, the Company signed an agreement with the Tel-Aviv Sourasky Medical Center, or Ichilov Hospital, to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease, or GVHD. As part of the agreement with Ichilov Hospital, the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GVHD, with a maximum aggregate royalty amount of approximately $500. </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">e.</td> <td style="text-align: justify">As to potential royalties to the EIB, see note 7.</td></tr> </table>8880000.500.031275650002290000.05P5Y1800000.01500000 NOTE 9: - SHAREHOLDERS' EQUITY   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="vertical-align: top; width: 0.25in; text-align: left">(1)</td> <td style="vertical-align: top; width: 0.25in; text-align: left">a)</td> <td style="text-align: justify">On May 1, 2023, the Company increased its authorized common shares from 7,500,000 to 37,500,000 with a par value of $0.00001 per share. All shares have equal voting rights and are entitled to one vote per share in all matters to be voted upon by shareholders and may be issued only as fully paid and non-assessable shares. Holders of the common shares are entitled to equal ratable rights to dividends and distributions, as may be declared by the Board out of funds legally available. The Company's authorized preferred shares consist of 1,000,000 preferred shares, par value $0.00001 per share, with series, rights, preferences, privileges and restrictions as may be designated from time to time by the Board. No preferred shares have been issued.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="vertical-align: top; width: 0.25in; text-align: left">b)</td> <td style="text-align: justify">Between December 13, 2022 and December 27, 2022, the Company entered into the December 2022 Private Placement, a series of securities purchase agreements with several purchasers for an aggregate of 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares. On December 13, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.24 per share, up to 697,485 common shares and warrants to purchase up to 697,485 common shares, with an exercise price of $8.24 per share and a term of three years. On December 14, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.40 per share, up to 258,565 common shares and warrants to purchase up to 258,565 common shares, with an exercise price of $8.40 per share and a term of three years. On December 15, 2022, the Company executed securities purchase agreements to sell, at a purchase price of $8.48 per share, up to 29,688 common shares and warrants to purchase up to 29,688 common shares, with an exercise price of $8.48 per share and a term of three years. On December 19, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.72 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.72 per share and a term of three years. On December 27, 2022, the Company executed a securities purchase agreement to sell, at a purchase price of $8.96 per share, up to 16,875 common shares and warrants to purchase up to 16,875 common shares, with an exercise price of $8.96 per share and a term of three years. The warrants sold in the December 2022 Private Placement are exercisable upon the later of six months from their issuance date, or from the date the Company increased its authorized shares. The Company issued 1,019,488 common shares and warrants to purchase up to 1,019,488 common shares that relate to the December 2022 Private Placement and received $8,024 as of that date net of $445 of issuance expenses.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="vertical-align: top; width: 0.25in; text-align: left">c)</td> <td style="text-align: justify">Pursuant to a shelf registration on Form S-3 declared effective by the SEC on September 21, 2023, on February 13, 2024 the Company entered into a Sales Agreement with A.G.P., which provides that, upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $10,000 through A.G.P. acting as sales agent. During April 2024, the Company sold 42,729 common shares under the Sales Agreement at an average price of $5.93 per share.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="vertical-align: top; width: 0.25in; text-align: left">d)</td> <td style="text-align: justify">On August 31, 2023, and as amended and restated as of October 9, 2023, Ever After Foods entered into a Simple Agreement for Future Equity, or the SAFE Agreement, with an investor. Pursuant to the terms of the SAFE Agreement, Ever After Foods will receive an aggregate amount of $2,500, or the SAFE Amount. On December 12, 2023, the SAFE Agreement had been terminated and the SAFE Amount was not received.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="vertical-align: top; width: 0.25in; text-align: left">e)</td> <td style="text-align: justify">On June 12, 2024, Ever After Foods entered into a share purchase agreement with the Subsidiary, Tnuva and other investors (see note 1f).</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">(2)</td> <td style="text-align: justify">Share options and RSUs to employees, directors and consultants:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company adopted the 2016 Equity Compensation Plan, or the 2016 Plan, and the 2019 Equity Compensation Plan, or together, the Plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Under the Plans, share options, restricted shares, or RS, and RSUs may be granted to the Company's officers, directors, employees and consultants or the officers, directors, employees and consultants of the Subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of June 30, 2024, 642,650 common shares are available for future grants under the Plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">a.</td> <td style="text-align: justify">Options to non-employee consultants:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Share options outstanding at beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,281</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.32</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options exercisable at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.69</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom:

1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Share options outstanding at beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 28px">(**)</td> <td style="text-align: justify">See note 1d regarding reverse share split</td></tr> </table> Compensation expenses recorded in general and administrative expenses related to options granted to non-employee consultants by Pluri and its Subsidiary for the years ended June 30, 2024 and 2023 were $9 and $6, respectively.   Unamortized compensation expenses related to options granted to non-employee consultants by Pluri and its Subsidiary are approximately $20 to be recognized by the end of March 2027.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">b.</td> <td style="text-align: justify">Options to CEO and directors:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">A summary of the share options granted to CEO and directors under the Plans by Pluri Inc. and its Subsidiary is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options outstanding at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; padding-bottom: 1.5pt">Share options granted</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">229,353</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">15.20</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3.47</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,353</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,353</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Share options outstanding at the

beginning of the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">229,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15.20</td> <td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Share options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,562</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options vested and exercisable at the end of the period</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right">14.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.42</td><td style="text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%">(**)</td> <td style="width: 96%; padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr> </table>   As of June 30, 2024, the aggregate intrinsic value of these options was $0. On December 14, 2022, Yaky Yanay, the Company's CEO, agreed to forgo, starting January 1, 2023, $375,000 of his annual cash salary for the next twelve months in return for equity grants, issuable under the Company's existing equity compensation plans. In that regard, the Company granted Mr. Yanay (i) 41,853 RSUs, vesting ratably each month (see also item c), and (ii) options to purchase 41,853 common shares, vesting ratably each month, with a term of 3 years, at an exercise price of $8.96 per share. All of these options were granted in December 2022 and will expire three years from the last vesting date.   In addition, the Board also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.80 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023. All options were granted in January 2023 and will expire three years after the last vesting date.   Compensation expenses recorded in general and administrative expenses related to options granted to CEO and directors by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023 were $220 and $568, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">c.</td> <td style="text-align: justify">RSUs to employees and directors:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Unvested at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">207,199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">241,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(132,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,424</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(70,107</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">353,134</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">207,199</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Expected to vest after the end of period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">319,533</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">205,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">(**)</td> <td style="padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr> </table><p style="margin-top: 0; margin-bottom: 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary were recorded as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">316</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,258</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,150</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   Unamortized compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary are approximately $848 to be recognized by the end of January 2027.   General and administrative expenses include compensation expenses for the year ended June 30, 2024 and 2023, in the amount of $58 and $273 were related to 41,853 RSUs granted to the CEO, due each month (see also item b).   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">d.</td> <td style="text-align: justify">RSUs and RS to consultants:</td></tr> </table>   The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color:

rgb(204,238,255)"> <td style="width: 76%; text-align: left">Unvested at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,157</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,968</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,802</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%">(**)</td> <td style="width: 96%; padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr> </table>   Compensation expenses related to RSUs and RS granted to consultants by Pluri Inc. and its Subsidiary were recorded as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   Unamortized compensation expenses related to RSUs and RS granted consultants by Pluri Inc. and its Subsidiary are approximately $21 to be recognized by the end of June 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">e.</td> <td style="text-align: justify">Summary of the Company's warrants and options:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrants / Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise
 price per
 share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options and
 warrants
 for common
 shares (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options and
 warrants
 exercisable
 for common
 shares (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Warrants:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">697,485</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">697,485</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.55</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,875</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,875</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,019,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,019,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Options:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.73</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">257,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid;

text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total warrants and options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,277,254</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,267,879</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   This summary does not include 357,936 RSUs and RS that are not vested as of June 30, 2024.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%">(**)</td> <td style="width: 96%; padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">(3)</td> <td style="text-align: justify"> Nasdaq Deficiency Letter:</td></tr> </table>   On May 28, 2024, the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500 in shareholders' equity for continued listing on The Nasdaq Capital Market, or the Shareholders' Equity Requirement, nor was it in compliance with either of the alternative listing standards, market value of listed securities of at least $35,000 or net income of $500 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Pursuant to the Nasdaq Letter, on July 11, 2024, and subsequent to the balance sheet date, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq granted the Company an extension of time to regain compliance with the Shareholders' Equity Requirement until November 24, 2024. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff's determination to a Hearings Panel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Neither the Nasdaq Letter nor the Company's noncompliance have an immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol "PLUR". </p>750000037500000.000011000000.000011019488101948888.2469748569748958.24P3Y8.425856525856558.4P3Y8.48296882968888.48P3Y8.721687516875 8.72P3Y8.96 summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Share options outstanding at beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,281</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.32</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"></div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options exercisable at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.69</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
 intrinsic
 value price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Share options outstanding at beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Share options granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.24</td><td style="text-align: left"> </td><td> </td> <td

style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,375</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.87</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 28px">(**)</td> <td style="text-align: justify">See note 1d regarding reverse share split</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options outstanding at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; padding-bottom: 1.5pt">Share options granted</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">229,353</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">15.20</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3.47</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,353</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share options exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">114,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options unvested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options vested and expected to vest at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,353</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.47</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number
 (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Share options outstanding at the beginning of the period</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">229,353</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Share options granted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Share options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,562</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Share options outstanding at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share options vested and exercisable at the end of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">240,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.42</td><td style="text-align: left"> </td></tr>
</table>1138110.56P7Y18D44328118.3281007.44P6Y2M26D2974756.69P6Y21D2962516P8Y5M8D81007.44P6Y2M26D2981007.44P6Y2M26D2993754.4P4Y6M21D131747addition, the Board also agreed to grant Mr. Yanay options to purchase 187,500 common shares, with a term of 3 years, with the following terms: (i) options to purchase 62,500 common shares at an exercise price of $12.48 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, (ii) options to purchase 62,500 common shares at an exercise price of $16.64 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023, and (iii) options to purchase 62,500 common shares at an exercise price of $20.80 per share, 50% vesting on June 30, 2023 and 50% vesting on December 31, 2023.2200005680000The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2024 and 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Unvested at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">207,199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">241,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">395,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(132,400</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,424</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(70,107</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">353,134</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">207,199</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Expected to vest after

*the end of period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">319,533</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">205,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2024 and 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Unvested at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,157</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,968</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Unvested at the end of the period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,802</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%">(**)</td> <td style="width: 96%; padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr>
</table>20719924187739532741853132400642411699270107353134207199319533205072Compensation expenses related to RSUs granted to employees and directors by Pluri Inc. and its Subsidiary were recorded as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">316</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,258</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,150</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>Compensation expenses related to RSUs and RS granted to consultants by Pluri Inc. and its Subsidiary were recorded as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"></div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>31600055000125800021500001574000220500084800058000273000418532500515727270249682657480225001000170000204000170000205000210000Summary of the Company's warrants and options: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrants / Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise
 price per
 share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options and
 warrants
 for common
 shares (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options and
 warrants
 exercisable
 for common
 shares (**)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 average
 remaining
 contractual
 terms
 (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-weight: bold">Warrants:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">697,485</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">697,485</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.55</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.40</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,565</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.48</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,688</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,688</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.72</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,875</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,875</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,875</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,875</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,019,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,019,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Options:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align:*

left"> </td><td style="text-align: right">41,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.73</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">257,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total warrants and options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,277,254</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,267,879</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 4%">(**)</td> <td style="width: 96%; padding-left: 2.95pt; text-align: justify; text-indent: -2.95pt">See note 1d regarding reverse share split</td></tr>
</table>8.246974856974851Y6M18D8.4258565258565P1Y9M25D8.4829688829688P1Y5M19D8.721687516875P1Y5M26D8.961687516875P1Y6M1019488810194885.81745
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 10: - FINANCIAL INCOME (EXPENSES), NET   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Foreign currency translation differences, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,709</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Bank and broker commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest income on deposits and restricted bank deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Income (loss) from hedging derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial income (expenses), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,680</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">EIB loan interest expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(866</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(843</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">814</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Foreign currency translation differences, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,709</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Bank and broker commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest income on deposits and restricted bank deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Income (loss) from hedging derivatives</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial income (expenses), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,680</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">EIB loan interest expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(866</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(843</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">814</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>126000-1709000-92000160001314000108400014800-1570001680000-79800086600084300081400 0-1641000 NOTE 11: - TAXES ON INCOME   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">a.</td><td style="text-align: justify">Tax rates applicable to the Company:</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">1.</td> <td style="text-align: justify">Pluri:</td></tr> </table>   The U.S. corporate federal tax rate applicable to Pluri is 21%, which is the result of the Tax Cuts and Jobs Act of 2017, or the Tax Act. Such corporate tax rate excludes state tax and local tax, if any, which rates depend on the state and city in which Pluri conducts its business.   The Tax Act provided for a one-time transition tax on certain foreign earnings for the tax year 2017, and taxation of Global Intangible Low-Taxed Income, or GILTI, earned by foreign subsidiaries beginning after December 31, 2017. The GILTI tax imposes a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Tax Act also made certain changes to the depreciation rules and implemented new limits on the deductibility of certain executive compensation paid by Pluri All losses generated after December 31, 2017 can only be used to offset 80% of net income in the year they will be utilized.   There was no one-time transition tax for the Company under the Tax Act, nor will there be GILTI tax due for the current year, since the Subsidiary had losses for every year to date.   In January 2018, Pluri Inc. registered as an Israeli resident with the Israel Tax Authority, or the ITA, and the Israeli Value Added Tax Authorities (the VAT registration agreed to be canceled by the VAT authorities). As a result, as of such date, Pluri Inc. is classified as a dual tax resident for tax purposes both in Israel and the United States. <p style="font: 10pt Times New Roman,

Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> In June 2018, Pluri Inc. and the Subsidiary submitted an election notice to the ITA to file a consolidated tax return in Israel commencing with the 2018 tax year. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">2.</td> <td style="text-align: justify">The Subsidiary:</td></tr> </table>   Consolidated taxable income of Pluri and the Subsidiary, or the consolidated tax unit, is subject to tax at the rate of 23% for the years ended June 30, 2024 and 2023.   The consolidated tax unit is filing its consolidated tax reports in U.S. dollars based on specific regulations of the ITA which allow, in specific circumstances, filing tax reports in U.S. dollars, or Dollar Regulations. Under the Dollar Regulations, the tax liability is calculated in U.S. dollars according to certain orders. The tax liability, as calculated in dollars, is translated into NIS according to the exchange rate as of June 30 of each year (the fiscal tax year end of the Subsidiary).   The Subsidiary has not received final tax assessments since its incorporation; however the assessments of the Subsidiary are deemed final through 2019.   The Law for the Encouragement of Capital Investments, 1959, or the Law (amendment No. 73):   In December 2016, the Knesset (Israeli Parliament) issued the Law for Changing National Priorities (Legislative Amendments for Achieving Budget Targets for 2017 and 2018), 2017, which consists of amendment No. 73 to the Law, or Amendment No. 73. According to Amendment No. 73, the tax rate on preferred income from a preferred enterprise in 2017 and thereafter will be 16% (in development area A it will be 7.5%).   According to Amendment No. 73, special tax benefits were established for Technological Preferred Enterprise, starting in 2017, will be as follow: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">6% rate would apply to qualifying Israeli companies that are part of a group with global consolidated revenue of over NIS 10 billion (approximately $2,900,000). </td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td> <td style="width: 0.25in">●</td><td style="text-align: justify">Other qualifying companies with global consolidated revenue below NIS 10 billion would be subject to a 12% tax rate (in development area A it will be 7.5%).</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Withholding tax on dividends paid to foreign entity investors (i.e., not to a private person) would be subject to a reduced rate of 4% for all qualifying companies (unless further reduced by a treaty), subject that at least 90% of the company is held by foreign entities (one or more). </td></tr></table>   Taxable income which is not produced as part of Preferred Technological Enterprise income will be taxed at the regular tax rate (23% in 2024).   As of June 30, 2024, the Subsidiary's management believes that the Subsidiary meets the conditions mentioned above to be considered as a Technological Enterprise.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">3.</td> <td style="text-align: justify">Pluristem GmbH:</td></tr> </table>   The corporate tax rate applicable to the German Subsidiary is 15%, which is derived from the German Corporation Tax Act and Solidarity surcharge of 5.5% from the 15% corporate tax rate. This corporate tax rate excludes trade tax, which rate depends on the municipality in which the German Subsidiary conducts its business. Trade tax rate applicable to the German Subsidiary is 15.93%, which is calculated by determining the Trade Tax Base with 3.5% of the trade income and applying the tax factor which differs according to the specific municipality in Germany and equals 455% for the municipality of Potsdam.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">4.</td> <td style="text-align: justify">Ever After Foods:</td></tr> </table>   Ever After Foods is an Israeli tax resident and is subject to corporate income tax at the rate of 23%. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">b.</td> <td style="text-align: justify">Carryforward losses for tax purposes</td></tr> </table>   As of June 30, 2024, Pluri had a U.S. federal net operating loss carryforward for income tax purposes in the amount of $31,414. Net operating loss carryforwards arising in taxable years prior to 2018, can be carried forward and offset against taxable income for 20 years and thus will expire between 2022 and 2037. Net operating losses generated in tax years 2002, 2003 and 2004 have expired and were reduced from the total net operating loss carryforward available.   Utilization of U.S. net operating losses may be subject to substantial annual limitations due to the "change in ownership" provisions of the U.S. Internal Revenue Code of 1986, Section 382 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.   The Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $129,286, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period.   In January 2018, Pluri Inc. registered as an Israeli resident with the ITA.   As of June 30, 2024, Pluri Inc. and the Subsidiaries consolidated accumulated losses, for tax purposes, are approximately $144,906, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period.   The German Subsidiary has accumulated losses, for tax purposes, as of June 30, 2024, in the amount of approximately $601, which may be carried forward and offset against taxable business income and business capital gain in the future for an indefinite period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">c. </td> <td style="text-align: justify">Loss before income taxes</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The components of loss before income taxes are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Consolidated loss of Pluri Inc. and the Israeli Subsidiaries</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Pluristem GmbH</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,344</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,887</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">d.</td> <td style="text-align: justify">Deferred income taxes:</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td> <td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt">Operating loss carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,534</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td

style="text-align: left; padding-left: 9pt">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,057</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Allowances and reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom;"> <td style="text-align: left">Total deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,896</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,830</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,896</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   As of June 30, 2024 and 2023, the Company has provided full valuation allowances with respect to the deferred tax assets resulting from tax loss carryforwards and other temporary differences, since it has a history of operating losses and due to current uncertainty concerning its ability to realize these deferred tax assets in the future.   The Company accounts for its income tax uncertainties in accordance with ASC 740 which clarifies the accounting for uncertainties in income taxes recognized in a Company's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.   As of June 30, 2024 and 2023, there were no unrecognized tax benefits that if recognized would affect the annual effective tax rate.   Reconciliation of taxes at the federal statutory rate to Company's provision for income taxes: In 2024 and 2023, the main reconciling item of the statutory tax rate of the Company (21% to 23%) to the effective tax rate (0%) is tax loss carryforward and R&D credit carryforward for which a full valuation allowance was provided.

0.210.800.230.230.160.0750.061000000000002900000001000000000000.120.0750.040.900.230.150.0550.150.15930.0354.550.233141400012928600014490600060100components of loss before income taxes are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Consolidated loss of Pluri Inc. and the Israeli Subsidiaries</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Pluristem GmbH</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,344</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,887</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> -21339000-28878000-5000-9000-21344000-28887000Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt">Operating loss carryforwards</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,534</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,057</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Allowances and reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,896</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,896</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>6985200080534000378000040570002500068000173000237000738300000848960007383000084896000.210.210.230.230falsefalsefalsefalse74-7108600011-972-3.99-6.2445815035240249 falseFY0001158780 Less than $1 See note 1d regarding reverse share split See note 1d regarding reverse share split Less than $1 See note 1d regarding reverse share split See note 1d regarding reverse share split See note 1d regarding reverse share split See note 1d regarding reverse share split